<SEC-DOCUMENT>0001493152-25-023400.txt : 20251114
<SEC-HEADER>0001493152-25-023400.hdr.sgml : 20251114
<ACCEPTANCE-DATETIME>20251114160058
ACCESSION NUMBER:		0001493152-25-023400
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		69
CONFORMED PERIOD OF REPORT:	20250930
FILED AS OF DATE:		20251114
DATE AS OF CHANGE:		20251114

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GT Biopharma, Inc.
		CENTRAL INDEX KEY:			0000109657
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				941620407
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40023
		FILM NUMBER:		251485498

	BUSINESS ADDRESS:	
		STREET 1:		505 MONTGOMERY STREET
		STREET 2:		10TH FLOOR
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94111
		BUSINESS PHONE:		(800) 304-9888

	MAIL ADDRESS:	
		STREET 1:		505 MONTGOMERY STREET
		STREET 2:		10TH FLOOR
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94111

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	OXIS INTERNATIONAL INC
		DATE OF NAME CHANGE:	19940916

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DDI PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19920703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DIAGNOSTIC DATA INC /DE/
		DATE OF NAME CHANGE:	19850312
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>form10-q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:GTBP="http://gtbiopharma.com/20250930">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_020_US%2DGAAP%2D2025%2D(with%2DECD) -->
<!-- Field: Set; Name: xdx; ID: xdx_034_GTBP_gtbiopharma.com_20250930 -->
<!-- Field: Set; Name: xdx; ID: xdx_042_20250101_20250930 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0xMi0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DDocumentFiscalPeriodFocus_Q3 -->
<!-- Field: Set; Name: xdx; ID: xdx_05D_edei%2D%2DEntityCentralIndexKey_0000109657 -->
<!-- Field: Set; Name: xdx; ID: xdx_070_XDX_form10%2Dq.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_072_SO_form10%2Dq.xdxs -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_Segment_0_Segment -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2025-01-01to2025-09-30" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2025-01-01to2025-09-30" id="Fact000004" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2025-01-01to2025-09-30" id="Fact000005" name="dei:DocumentFiscalPeriodFocus">Q3</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2025-01-01to2025-09-30" id="Fact000006" name="dei:EntityCentralIndexKey">0000109657</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="AsOf2024-12-31" id="xdx2ixbrl0054" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DividendsPayableCurrent" contextRef="AsOf2024-12-31" id="xdx2ixbrl0075" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2025-09-30_custom_SeriesLPreferredStockMember" id="xdx2ixbrl0105" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2024-12-31_custom_SeriesLPreferredStockMember" id="xdx2ixbrl0106" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2025-09-30" id="xdx2ixbrl0116" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2024-12-31" id="xdx2ixbrl0117" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2025-07-012025-09-30" id="xdx2ixbrl0150" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-07-012024-09-30" id="xdx2ixbrl0151" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2025-01-01to2025-09-30" id="xdx2ixbrl0152" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-01-012024-09-30" id="xdx2ixbrl0153" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2025-07-012025-09-30" id="xdx2ixbrl0198" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2024-07-012024-09-30" id="xdx2ixbrl0199" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2024-01-012024-09-30" id="xdx2ixbrl0201" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2025-07-012025-09-30" id="xdx2ixbrl0203" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2024-07-012024-09-30" id="xdx2ixbrl0204" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2024-01-012024-09-30" id="xdx2ixbrl0206" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" contextRef="From2025-07-012025-09-30" id="xdx2ixbrl0208" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" contextRef="From2025-01-01to2025-09-30" id="xdx2ixbrl0210" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockDividendsIncomeStatementImpact" contextRef="From2024-07-012024-09-30" id="xdx2ixbrl0224" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockDividendsIncomeStatementImpact" contextRef="From2024-01-012024-09-30" id="xdx2ixbrl0226" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-06-30_us-gaap_PreferredStockMember_custom_SeriesLPreferredStockMember" id="xdx2ixbrl0266" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-06-30_us-gaap_PreferredStockMember_custom_SeriesLPreferredStockMember" id="xdx2ixbrl0274" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueMezzanineEquityReclassification" contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0282" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueMezzanineEquityReclassification" contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesLPreferredStockMember" id="xdx2ixbrl0283" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueMezzanineEquityReclassification" contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0284" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueMezzanineEquityReclassification" contextRef="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0286" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0295" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesLPreferredStockMember" id="xdx2ixbrl0296" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0297" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0299" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0304" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesLPreferredStockMember" id="xdx2ixbrl0305" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0308" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2025-07-012025-09-30" id="xdx2ixbrl0309" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0315" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesLPreferredStockMember" id="xdx2ixbrl0316" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0317" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0318" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0322" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesLPreferredStockMember" id="xdx2ixbrl0323" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0324" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0326" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0329" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesLPreferredStockMember" id="xdx2ixbrl0330" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0331" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0332" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-09-30_us-gaap_PreferredStockMember_custom_SeriesLPreferredStockMember" id="xdx2ixbrl0337" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="AsOf2025-09-30_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember" id="xdx2ixbrl0349" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="AsOf2025-09-30_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember" id="xdx2ixbrl0351" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_SeriesLPreferredStockMember" id="xdx2ixbrl0354" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_SeriesLPreferredStockMember" id="xdx2ixbrl0362" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="AsOf2024-12-31_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember" id="xdx2ixbrl0366" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="AsOf2024-12-31_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember" id="xdx2ixbrl0368" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet" contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0370" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet" contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesLPreferredStockMember" id="xdx2ixbrl0371" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet" contextRef="From2025-01-012025-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0374" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0379" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesLPreferredStockMember" id="xdx2ixbrl0380" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0381" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2025-01-012025-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0383" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0388" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesLPreferredStockMember" id="xdx2ixbrl0389" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2025-01-012025-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0392" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2025-01-01to2025-09-30" id="xdx2ixbrl0393" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable" contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0399" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable" contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesLPreferredStockMember" id="xdx2ixbrl0400" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable" contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0401" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable" contextRef="From2025-01-012025-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0403" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee" contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0406" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee" contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesLPreferredStockMember" id="xdx2ixbrl0407" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee" contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0408" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee" contextRef="From2025-01-012025-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0410" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0415" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesLPreferredStockMember" id="xdx2ixbrl0416" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0417" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2025-01-012025-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0419" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0424" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesLPreferredStockMember" id="xdx2ixbrl0425" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0426" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2025-01-012025-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0428" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0431" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesLPreferredStockMember" id="xdx2ixbrl0432" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0433" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2025-01-012025-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0434" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0438" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesLPreferredStockMember" id="xdx2ixbrl0439" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0440" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2025-01-012025-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0442" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0445" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesLPreferredStockMember" id="xdx2ixbrl0446" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0447" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0448" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-09-30_us-gaap_PreferredStockMember_custom_SeriesLPreferredStockMember" id="xdx2ixbrl0453" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="AsOf2025-09-30_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember" id="xdx2ixbrl0465" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="AsOf2025-09-30_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember" id="xdx2ixbrl0467" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="AsOf2024-06-30_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember" id="xdx2ixbrl0479" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="AsOf2024-06-30_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember" id="xdx2ixbrl0481" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash" contextRef="From2024-07-012024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0483" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash" contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0484" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash" contextRef="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0485" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash" contextRef="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0486" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash" contextRef="From2024-07-012024-09-30" id="xdx2ixbrl0487" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" contextRef="From2024-07-012024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0489" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0490" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" contextRef="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0491" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" contextRef="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0492" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" contextRef="From2024-07-012024-09-30" id="xdx2ixbrl0493" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable" contextRef="From2024-07-012024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0495" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable" contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0496" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable" contextRef="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0497" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable" contextRef="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0498" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable" contextRef="From2024-07-012024-09-30" id="xdx2ixbrl0499" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2024-07-012024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0501" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0502" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0503" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0504" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2024-07-012024-09-30" id="xdx2ixbrl0505" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-07-012024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0507" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0508" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0509" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="AsOf2024-09-30_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember" id="xdx2ixbrl0523" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="AsOf2024-09-30_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember" id="xdx2ixbrl0525" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="AsOf2023-12-31_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember" id="xdx2ixbrl0537" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="AsOf2023-12-31_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember" id="xdx2ixbrl0539" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="AsOf2023-12-31_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember" id="xdx2ixbrl0551" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="AsOf2023-12-31_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember" id="xdx2ixbrl0553" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash" contextRef="From2024-01-012024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0555" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash" contextRef="From2024-01-012024-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0558" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" contextRef="From2024-01-012024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0563" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" contextRef="From2024-01-012024-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0564" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" contextRef="From2024-01-012024-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0565" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" contextRef="From2024-01-012024-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0566" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" contextRef="From2024-01-012024-09-30" id="xdx2ixbrl0567" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable" contextRef="From2024-01-012024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0571" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable" contextRef="From2024-01-012024-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0572" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable" contextRef="From2024-01-012024-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0574" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2024-01-012024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0579" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2024-01-012024-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0580" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2024-01-012024-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0582" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0585" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0586" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0587" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="AsOf2024-09-30_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember" id="xdx2ixbrl0601" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="AsOf2024-09-30_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember" id="xdx2ixbrl0603" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="AsOf2024-09-30_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember" id="xdx2ixbrl0615" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="AsOf2024-09-30_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember" id="xdx2ixbrl0617" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:IssuanceOfWarrantsForVrtWaiver" contextRef="From2024-01-012024-09-30" id="xdx2ixbrl0632" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2024-01-012024-09-30" id="xdx2ixbrl0638" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:GainOnSettlementOfDebt" contextRef="From2024-01-012024-09-30" id="xdx2ixbrl0641" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DebtSecuritiesUnrealizedGainLoss" contextRef="From2025-01-01to2025-09-30" id="xdx2ixbrl0643" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2025-01-01to2025-09-30" id="xdx2ixbrl0658" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsForProceedsFromInvestments" contextRef="From2025-01-01to2025-09-30" id="xdx2ixbrl0667" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2025-01-01to2025-09-30" id="xdx2ixbrl0670" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2024-01-012024-09-30" id="xdx2ixbrl0677" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2025-01-01to2025-09-30" id="xdx2ixbrl0679" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsOfDividends" contextRef="From2024-01-012024-09-30" id="xdx2ixbrl0686" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestPaid" contextRef="From2025-01-01to2025-09-30" id="xdx2ixbrl0706" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestPaid" contextRef="From2024-01-012024-09-30" id="xdx2ixbrl0707" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2025-01-01to2025-09-30" id="xdx2ixbrl0709" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2024-01-012024-09-30" id="xdx2ixbrl0710" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:FairValueOfSeriesLConvertiblePreferredStockVestedWarrants" contextRef="From2024-01-012024-09-30" id="xdx2ixbrl0716" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:FairValueOfPrefundedWarrantsIssuedForElocFee" contextRef="From2024-01-012024-09-30" id="xdx2ixbrl0719" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssued1" contextRef="From2024-01-012024-09-30" id="xdx2ixbrl0722" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:DividendDeclaredOnSeriesLConvertiblePreferredStock" contextRef="From2024-01-012024-09-30" id="xdx2ixbrl0728" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-09-30_custom_SeriesLConvertiblePreferredStockMember" id="xdx2ixbrl0773" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AccountsPayableTradeCurrent" contextRef="AsOf2025-09-30_custom_LegalServicesFirmMember" id="xdx2ixbrl0813" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AccountsPayableInterestBearingInterestRate" contextRef="AsOf2025-09-30_custom_LegalServicesFirmMember" id="xdx2ixbrl0816" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AccountsPayableTradeCurrent" contextRef="AsOf2025-09-30_custom_LegalServicesFirmMember" id="xdx2ixbrl0820" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="From2025-01-012025-09-30_custom_CytovanceBiologicsIncMember" id="xdx2ixbrl0849" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:RepaymentsOfPrefundedWarrantsAtFairValue" contextRef="From2024-01-012024-09-30_custom_CytovanceBiologicsIncMember" id="xdx2ixbrl0853" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2025-09-30_us-gaap_MeasurementInputExpectedDividendRateMember_custom_TwoThousandTwentyThreeWarrantsMember" id="xdx2ixbrl0914" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-31_us-gaap_MeasurementInputExpectedDividendRateMember_custom_TwoThousandTwentyThreeWarrantsMember" id="xdx2ixbrl0916" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="From2025-01-01to2025-09-30" id="xdx2ixbrl0931" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="From2024-01-012024-09-30" id="xdx2ixbrl0932" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:ExtinguishmentOfWarrant" contextRef="From2025-01-01to2025-09-30" id="xdx2ixbrl0937" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="GTBP:ExtinguishmentOfWarrant" contextRef="From2024-01-012024-09-30" id="xdx2ixbrl0938" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2025-01-01to2025-09-30" id="xdx2ixbrl1289" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2025-01-01to2025-09-30" id="xdx2ixbrl1291" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-07-012024-09-30_custom_SegmentsMember" id="xdx2ixbrl1523" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="gtbp-20250930.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2025-01-01to2025-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-11-06">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-11-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_custom_SeriesLPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_SeriesLPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_us-gaap_SellingGeneralAndAdministrativeExpensesMember_custom_OfficersEmployeesAndDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:OfficersEmployeesAndDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_us-gaap_SellingGeneralAndAdministrativeExpensesMember_custom_OfficersEmployeesAndDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:OfficersEmployeesAndDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_us-gaap_SellingGeneralAndAdministrativeExpensesMember_custom_OfficersEmployeesAndDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:OfficersEmployeesAndDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_us-gaap_SellingGeneralAndAdministrativeExpensesMember_custom_OfficersEmployeesAndDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:OfficersEmployeesAndDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_PreferredStockMember_custom_SeriesLPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:MezzanineEquityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_SeriesLPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:MezzanineEquityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:MezzanineEquityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:MezzanineEquityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesLPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:MezzanineEquityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesLPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_PreferredStockMember_custom_SeriesLPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:MezzanineEquityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:MezzanineEquityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_SeriesLConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">GTBP:SeriesLConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_custom_SeriesLConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">GTBP:SeriesLConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_custom_CytovanceBiologicsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:CytovanceBiologicsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_CytovanceBiologicsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:CytovanceBiologicsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_custom_UniversityOfMinnesotaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:UniversityOfMinnesotaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_UniversityOfMinnesotaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:UniversityOfMinnesotaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_custom_LegalServicesFirmMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:LegalServicesFirmMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_LegalServicesFirmMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:LegalServicesFirmMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_custom_OtherAccountsPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:OtherAccountsPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_OtherAccountsPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:OtherAccountsPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_CytovanceBiologicsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:CytovanceBiologicsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_CytovanceBiologicsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:CytovanceBiologicsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_custom_CytovanceBiologicsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:CytovanceBiologicsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_custom_CytovanceBiologicsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:CytovanceBiologicsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-04-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-06-012024-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-06-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_CytovanceBiologicsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:CytovanceBiologicsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-03-012025-03-31_custom_CytovanceBiologicsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:CytovanceBiologicsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-03-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-03-012025-03-31_custom_LegalServicesFirmMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:LegalServicesFirmMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-03-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-06-012025-06-30_custom_AdvisoryAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:AdvisoryAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-06-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_AdvisoryAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:AdvisoryAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-04_custom_TwoThousandTwentyThreeCommonWarrantsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:TwoThousandTwentyThreeCommonWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-04_custom_TwoThousandTwentyThreePlacementAgentsWarrantsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:TwoThousandTwentyThreePlacementAgentsWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-042023-01-04_custom_TwoThousandTwentyThreeWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-04</xbrli:startDate>
        <xbrli:endDate>2023-01-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-04_custom_TwoThousandTwentyThreeWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_TwoThousandTwentyThreeWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_MeasurementInputSharePriceMember_custom_TwoThousandTwentyThreeWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_MeasurementInputSharePriceMember_custom_TwoThousandTwentyThreeWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_TwoThousandTwentyThreeWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_TwoThousandTwentyThreeWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_MeasurementInputPriceVolatilityMember_custom_TwoThousandTwentyThreeWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_TwoThousandTwentyThreeWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_MeasurementInputExpectedTermMember_custom_TwoThousandTwentyThreeWarrantsMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_MeasurementInputExpectedTermMember_custom_TwoThousandTwentyThreeWarrantsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_MeasurementInputExpectedTermMember_custom_TwoThousandTwentyThreeWarrantsMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_MeasurementInputExpectedTermMember_custom_TwoThousandTwentyThreeWarrantsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_MeasurementInputExpectedDividendRateMember_custom_TwoThousandTwentyThreeWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_MeasurementInputExpectedDividendRateMember_custom_TwoThousandTwentyThreeWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_TwoThousandTwentyThreeWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-142025-05-14_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-14</xbrli:startDate>
        <xbrli:endDate>2025-05-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-05-14_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-05-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-02-262025-02-26">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-02-26</xbrli:startDate>
        <xbrli:endDate>2025-02-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-02-26">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-02-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-02-26_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-02-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-02-26_custom_InducementWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:InducementWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-02-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-02-26_custom_SeriesAInducementWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:SeriesAInducementWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-02-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-02-26_custom_SeriesBInducementWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:SeriesBInducementWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-02-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-122025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_SeriesLTenPercentConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLTenPercentConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-12</xbrli:startDate>
        <xbrli:endDate>2025-05-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_SeriesLTenPercentConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLTenPercentConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-05-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-122025-05-12_custom_SeriesLPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-12</xbrli:startDate>
        <xbrli:endDate>2025-05-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-122025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_GreenshoeRightsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:GreenshoeRightsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-12</xbrli:startDate>
        <xbrli:endDate>2025-05-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-222025-05-22_custom_SeriesLTenPercentConvertiblePreferredStockMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLTenPercentConvertiblePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-22</xbrli:startDate>
        <xbrli:endDate>2025-05-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-222025-05-22_custom_SeriesLTenPercentConvertiblePreferredStockMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLTenPercentConvertiblePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-22</xbrli:startDate>
        <xbrli:endDate>2025-05-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-112025-05-11_custom_SecuritiesPurchaseAgreementMember_custom_SeriesLTenPercentConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLTenPercentConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-11</xbrli:startDate>
        <xbrli:endDate>2025-05-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-122025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_SeriesLTenPercentConvertiblePreferredStockMember_custom_CommonWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLTenPercentConvertiblePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:CommonWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-12</xbrli:startDate>
        <xbrli:endDate>2025-05-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_CommonWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:CommonWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-05-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_VestingWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:VestingWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-05-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_GreenshoeRightsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:GreenshoeRightsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-05-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-122025-05-12_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-12</xbrli:startDate>
        <xbrli:endDate>2025-05-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_custom_SeriesL10PercentageConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesL10PercentageConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-29_custom_SeriesL10PercentageConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesL10PercentageConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_custom_SeriesL10PercentageConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesL10PercentageConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_SeriesLConvertiblePreferredStockMember16969765">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_custom_SeriesLConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-012025-05-31_custom_SeriesLPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-01</xbrli:startDate>
        <xbrli:endDate>2025-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-012025-05-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-01</xbrli:startDate>
        <xbrli:endDate>2025-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-012025-05-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-01</xbrli:startDate>
        <xbrli:endDate>2025-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-012025-05-31_custom_MezzanineEquityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:MezzanineEquityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-01</xbrli:startDate>
        <xbrli:endDate>2025-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-012025-05-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-01</xbrli:startDate>
        <xbrli:endDate>2025-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-312025-05-31_custom_SeriesLPreferredStockMember_custom_CommonWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:CommonWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-31</xbrli:startDate>
        <xbrli:endDate>2025-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-05-31_custom_CommonWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:CommonWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-05-31_custom_VestingWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:VestingWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-05-31_custom_GreenshoeRightsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:GreenshoeRightsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_custom_CommonWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:CommonWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-05-31_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-05-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-06-012025-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-06-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-012025-05-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-01</xbrli:startDate>
        <xbrli:endDate>2025-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-05-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-06-012025-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-06-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-05-31_custom_PrefundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:PrefundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-04-30_custom_OmnibusIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">GTBP:OmnibusIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-04-30_custom_OmnibusIncentivePlanMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">GTBP:OmnibusIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_custom_OmnibusIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">GTBP:OmnibusIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_RangeOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_RangeTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_RangeThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_RangeFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_RangeFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_RangeSixMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeSixMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeSixMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeSixMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_RangeSevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeSevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeSevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeSevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_RangeEightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeEightMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeEightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeEightMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_RangeNineMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeNineMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeNineMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeNineMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_RangeTenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeTenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeTenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeTenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_RangeElevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeElevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeElevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeElevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_RangeTwelveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeTwelveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeTwelveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeTwelveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_RangeThirteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeThirteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeThirteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeThirteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_us-gaap_WarrantMember16970921">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_RangeOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_custom_RangeOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_RangeTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_custom_RangeTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_RangeThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_custom_RangeThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_RangeFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_custom_RangeFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_RangeFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_custom_RangeFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-02-172025-02-17_custom_ZOneLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">GTBP:ZOneLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-02-17</xbrli:startDate>
        <xbrli:endDate>2025-02-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-082025-07-08_custom_CobySilberfeinMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">GTBP:CobySilberfeinMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-08</xbrli:startDate>
        <xbrli:endDate>2025-07-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-092025-07-09_custom_CobySilberfeinMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">GTBP:CobySilberfeinMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-09</xbrli:startDate>
        <xbrli:endDate>2025-07-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-09-022025-09-02_custom_CobySilberfeinMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">GTBP:CobySilberfeinMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-09-02</xbrli:startDate>
        <xbrli:endDate>2025-09-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-08-24_custom_CytovanceBiologicsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">GTBP:CytovanceBiologicsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-08-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-04-25_custom_CytovanceBiologicsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">GTBP:CytovanceBiologicsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-04-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_CytovanceBiologicsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">GTBP:CytovanceBiologicsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_CytovanceBiologicsIncMember_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:CytovanceBiologicsIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_custom_CytovanceBiologicsIncMember_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:CytovanceBiologicsIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-202024-05-20_custom_TwoThousandTwentyThreeSponsoredResearchAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandTwentyThreeSponsoredResearchAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-20</xbrli:startDate>
        <xbrli:endDate>2024-05-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-06-182025-06-18_custom_TwoThousandTwentyThreeSponsoredResearchAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandTwentyThreeSponsoredResearchAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-06-18</xbrli:startDate>
        <xbrli:endDate>2025-06-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_TwoThousandTwentyThreeSponsoredResearchAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandTwentyThreeSponsoredResearchAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_custom_TwoThousandTwentyThreeSponsoredResearchAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandTwentyThreeSponsoredResearchAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_custom_TwoThousandTwentyThreeSponsoredResearchAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandTwentyThreeSponsoredResearchAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-07-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember_custom_TwoThousandSeventeenThroughTwoThousandTwentyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">GTBP:TwoThousandSeventeenThroughTwoThousandTwentyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-07-18</xbrli:startDate>
        <xbrli:endDate>2016-07-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-07-18</xbrli:startDate>
        <xbrli:endDate>2016-07-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-07-18</xbrli:startDate>
        <xbrli:endDate>2016-07-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-07-18</xbrli:startDate>
        <xbrli:endDate>2016-07-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember_custom_TwoThousandTwentyTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">GTBP:TwoThousandTwentyTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-07-18</xbrli:startDate>
        <xbrli:endDate>2016-07-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember_custom_TwoThousandTwentyFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">GTBP:TwoThousandTwentyFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-07-18</xbrli:startDate>
        <xbrli:endDate>2016-07-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember_custom_TwoThousandTwentySevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">GTBP:TwoThousandTwentySevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-07-18</xbrli:startDate>
        <xbrli:endDate>2016-07-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-05-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember_custom_TwoThousandTwentyFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">GTBP:TwoThousandTwentyFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-13</xbrli:startDate>
        <xbrli:endDate>2024-05-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-13</xbrli:startDate>
        <xbrli:endDate>2024-05-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-13</xbrli:startDate>
        <xbrli:endDate>2024-05-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-13</xbrli:startDate>
        <xbrli:endDate>2024-05-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_TwoThousandSixteenPatentLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_custom_TwoThousandSixteenPatentLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-03-262021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandAndTwentyOnePatentLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-03-26</xbrli:startDate>
        <xbrli:endDate>2021-03-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-03-262021-03-26_srt_MinimumMember_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandAndTwentyOnePatentLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-03-26</xbrli:startDate>
        <xbrli:endDate>2021-03-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-03-262021-03-26_srt_MaximumMember_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandAndTwentyOnePatentLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-03-26</xbrli:startDate>
        <xbrli:endDate>2021-03-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-11-182024-11-18_custom_TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-18</xbrli:startDate>
        <xbrli:endDate>2024-11-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_custom_TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-21">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-21</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-09-30_custom_SegmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">GTBP:SegmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_custom_SegmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">GTBP:SegmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-09-30_custom_SegmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">GTBP:SegmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_custom_SegmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">GTBP:SegmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-10-012025-10-31_custom_SeriesL10PercentageConvertiblePreferredStockMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesL10PercentageConvertiblePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-10-01</xbrli:startDate>
        <xbrli:endDate>2025-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-10-30_custom_SeriesL10PercentageConvertiblePreferredStockMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesL10PercentageConvertiblePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-10-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-10-31_custom_SeriesL10PercentageConvertiblePreferredStockMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesL10PercentageConvertiblePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-10-31_custom_SeriesLConvertiblePreferredStockMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLConvertiblePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Segment">
      <xbrli:measure>GTBP:Segment</xbrli:measure>
    </xbrli:unit>
  <ix:relationship fromRefs="Fact000772" toRefs="Footnote000783"/>
  <ix:relationship fromRefs="xdx2ixbrl0773" toRefs="Footnote000783"/>
  <ix:relationship fromRefs="Fact000799" toRefs="Footnote000836"/>
  <ix:relationship fromRefs="Fact000800" toRefs="Footnote000836"/>
  <ix:relationship fromRefs="Fact000802" toRefs="Footnote000836"/>
  <ix:relationship fromRefs="Fact000804" toRefs="Footnote000836"/>
  <ix:relationship fromRefs="Fact000898" toRefs="Footnote000921"/>
  <ix:relationship fromRefs="Fact000900" toRefs="Footnote000921"/>
  <ix:relationship fromRefs="Fact000902" toRefs="Footnote000922"/>
  <ix:relationship fromRefs="Fact000904" toRefs="Footnote000922"/>
  <ix:relationship fromRefs="Fact000906" toRefs="Footnote000923"/>
  <ix:relationship fromRefs="Fact000908" toRefs="Footnote000923"/>
  <ix:relationship fromRefs="Fact000910" toRefs="Footnote000923"/>
  <ix:relationship fromRefs="Fact000912" toRefs="Footnote000923"/>
  <ix:relationship fromRefs="xdx2ixbrl0914" toRefs="Footnote000924"/>
  <ix:relationship fromRefs="xdx2ixbrl0916" toRefs="Footnote000924"/>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_908_edei--DocumentType_c20250101__20250930_zouz7ks6bC02"><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" id="Fact000014" name="dei:DocumentType">10-Q</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--DocumentQuarterlyReport_c20250101__20250930_zsc3CLUbhFel"><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" format="ixt:booleantrue" id="Fact000015" name="dei:DocumentQuarterlyReport">&#9746;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Quarterly
    report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
    the quarterly period ended <span id="xdx_909_edei--DocumentPeriodEndDate_c20250101__20250930_zrC2yzshn6m8"><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" format="ixt:datemonthdayyearen" id="Fact000016" name="dei:DocumentPeriodEndDate">September 30, <span id="xdx_90D_edei--DocumentFiscalYearFocus_c20250101__20250930_zCE36JwNYaqj"><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" id="Fact000017" name="dei:DocumentFiscalYearFocus">2025</ix:nonNumeric></span></ix:nonNumeric></span>.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_edei--DocumentTransitionReport_c20250101__20250930_zsoJVsVm6Ojj"><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" format="ixt:booleanfalse" id="Fact000018" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Transition
    report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
    the transition period from __________ to ____________.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Commission
File Number <span id="xdx_906_edei--EntityFileNumber_c20250101__20250930_zBKkGaAeFj4c"><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" id="Fact000019" name="dei:EntityFileNumber">001-40023</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span style="text-decoration: underline"><span id="xdx_90C_edei--EntityRegistrantName_c20250101__20250930_zeAz4znYMYg8"><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" id="Fact000020" name="dei:EntityRegistrantName">GT
BIOPHARMA, INC.</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Exact
name of registrant as specified in its charter)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90C_edei--EntityIncorporationStateCountryCode_c20250101__20250930_zdzQyqTaX3Fd"><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" format="ixt-sec:stateprovnameen" id="Fact000021" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_900_edei--EntityTaxIdentificationNumber_c20250101__20250930_zUtzkY4Rphte"><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" id="Fact000022" name="dei:EntityTaxIdentificationNumber">94-1620407</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
    or other jurisdiction of incorporation or organization)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
    Employer Identification Number)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 2.9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 2.9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>N/A<sup>1</sup></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of principal executive offices)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_909_edei--CityAreaCode_c20250101__20250930_z3SmQALukx09"><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" id="Fact000023" name="dei:CityAreaCode">415</ix:nonNumeric></span>-<span id="xdx_903_edei--LocalPhoneNumber_c20250101__20250930_zAiu7D7EWal9"><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" id="Fact000024" name="dei:LocalPhoneNumber">919-4040</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant&#8217;s
telephone number, including area code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 38%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title
    of Each Class</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading
    Symbol</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 38%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of exchange on which registered</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_edei--Security12bTitle_c20250101__20250930_zO6BDSS5Xp3g"><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" id="Fact000025" name="dei:Security12bTitle">Common
    Stock, $0.001 par value per share</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_edei--TradingSymbol_c20250101__20250930_zmB934n5eZaa"><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" id="Fact000026" name="dei:TradingSymbol">GTBP</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_edei--SecurityExchangeName_c20250101__20250930_z7hIrOZ9Li5e"><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" format="ixt-sec:exchnameen" id="Fact000027" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span>
    Capital Market</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. <span id="xdx_90F_edei--EntityCurrentReportingStatus_c20250101__20250930_zeYl0ySnk8jb"><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" id="Fact000028" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span> &#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
<span id="xdx_901_edei--EntityInteractiveDataCurrent_c20250101__20250930_zT08mQqgauJc"><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" id="Fact000029" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span> &#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221;
&#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer &#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer &#9744;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_edei--EntityFilerCategory_c20250101__20250930_zbcYIbX2Uum9"><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" format="ixt-sec:entityfilercategoryen" id="Fact000030" name="dei:EntityFilerCategory">Non-accelerated
    filer</ix:nonNumeric></span> &#9746;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    reporting company <span id="xdx_90A_edei--EntitySmallBusiness_c20250101__20250930_zOY0Xz5Ktv83"><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" format="ixt:booleantrue" id="Fact000031" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    growth company <span id="xdx_900_edei--EntityEmergingGrowthCompany_c20250101__20250930_zcxqOIRozVdi"><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" format="ixt:booleanfalse" id="Fact000032" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes &#9744; No <span id="xdx_90B_edei--EntityShellCompany_dbF_c20250101__20250930_zrURYp9VdHXj"><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" format="ixt:booleanfalse" id="Fact000033" name="dei:EntityShellCompany">&#9746;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of November 6, 2025, the registrant had <span id="xdx_901_edei--EntityCommonStockSharesOutstanding_iI_pid_c20251106_z4q7DYtYOLv4"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2025-11-06" id="Fact000034" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,636,135</ix:nonFraction></span> shares of common stock outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><sup>1</sup></b></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective as of July 1, 2024, the Company became a fully remote
company. We do not maintain a principal executive office. For purposes of compliance with applicable requirements of the Securities Act
of 1933, as amended, and the Securities Exchange Act of 1934, as amended, any stockholder communication required to be sent to the Company&#8217;s
principal executive offices may be directed to <span id="xdx_901_edei--EntityAddressAddressLine1_c20250101__20250930_zjFiTuvM6JZ6"><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" id="Fact000035" name="dei:EntityAddressAddressLine1">505 Montgomery Street</ix:nonNumeric></span>, <span id="xdx_908_edei--EntityAddressAddressLine2_c20250101__20250930_z09SMGqBguNb"><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" id="Fact000036" name="dei:EntityAddressAddressLine2">10th Floor</ix:nonNumeric></span>, <span id="xdx_901_edei--EntityAddressCityOrTown_c20250101__20250930_zdT0ABRobZVl"><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" id="Fact000037" name="dei:EntityAddressCityOrTown">San Francisco</ix:nonNumeric></span>, <span id="xdx_908_edei--EntityAddressStateOrProvince_c20250101__20250930_zhBRy3oxG0h9"><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" format="ixt-sec:stateprovnameen" id="Fact000038" name="dei:EntityAddressStateOrProvince">California</ix:nonNumeric></span> <span id="xdx_906_edei--EntityAddressPostalZipCode_c20250101__20250930_zBEMLKo3md4c"><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" id="Fact000039" name="dei:EntityAddressPostalZipCode">94111</ix:nonNumeric></span>, or by email to auditcommittee@gtbiopharma.com.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt; border-bottom: Black 4pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GT
BIOPHARMA, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FORM
10-Q</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the Nine Months Ended September 30, 2025</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Table
of Contents</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART
    I FINANCIAL INFORMATION</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
    Statements</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_001">Condensed Balance Sheets as of September 30, 2025 (Unaudited) and December 31, 2024</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_002">Condensed Statements of Operations for the three and nine months ended September 30, 2025 and 2024 (Unaudited)</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_003">Condensed Statements of Stockholders&#8217; Equity (Deficit) and Mezzanine Equity for the three and nine months ended September 30, 2025 and 2024 (Unaudited)</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_004">Condensed Statements of Cash Flows for the nine months ended September 30, 2025 and 2024 (Unaudited)</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_005">Notes to Unaudited Condensed Financial Statements</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_001">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_002">Quantitative and Qualitative Disclosures About Market Risk</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_003">Controls and Procedures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_004">PART II OTHER INFORMATION</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_005">Legal Proceedings</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_006">Risk Factors</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;32</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_007">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span>32</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_008">Defaults Upon Senior Securities</a> </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span>32</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_009">Mine Safety Disclosures</a> </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span>32</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    5.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_010">Other Information</a> </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span>32</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    6.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_011">Exhibits</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_012">SIGNATURES</a></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">35</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GT
BIOPHARMA, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_001"></span>Condensed
Balance Sheets</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_303_111_z0JaGIuvMTL7" summary="xdx: Statement - Condensed Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20250930_zR2kbiKHleUg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20241231_zGIxCvfwCHf6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AssetsAbstract_iB_zAOToF6czHq2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center">ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AssetsCurrentAbstract_i01B_zf8FcVjH9jB1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maCzFeu_zIqJzNLlksu7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2025-09-30" id="Fact000047" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,528,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2024-12-31" id="Fact000048" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,951,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--RestrictedCashCurrent_i02I_maCzFeu_z8GMIyGeTOZ9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Restricted cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RestrictedCashCurrent" contextRef="AsOf2025-09-30" id="Fact000050" format="ixt:numdotdecimal" decimals="0" unitRef="USD">93,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RestrictedCashCurrent" contextRef="AsOf2024-12-31" id="Fact000051" format="ixt:numdotdecimal" decimals="0" unitRef="USD">93,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredOfferingCosts_i02I_maCzFeu_znZWNhzmI89f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Deferred offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="AsOf2025-09-30" id="Fact000053" format="ixt:numdotdecimal" decimals="0" unitRef="USD">760,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0054">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_maCzFeu_zyqFyEDhiLzk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Prepaid expenses and other current assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2025-09-30" id="Fact000056" format="ixt:numdotdecimal" decimals="0" unitRef="USD">940,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2024-12-31" id="Fact000057" format="ixt:numdotdecimal" decimals="0" unitRef="USD">188,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AssetsCurrent_i02TI_mtCzFeu_zC71dGrpeIrc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">TOTAL ASSETS</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2025-09-30" id="Fact000059" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,321,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2024-12-31" id="Fact000060" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,232,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zgdBhpqPk0Q5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center">LIABILITIES AND STOCKHOLDERS&#8217; DEFICIT</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LiabilitiesCurrentAbstract_i01B_zVr01mBlOq53" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AccountsPayableCurrent_i02I_maCz1PN_z8Lnc0eCMGV7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2025-09-30" id="Fact000068" format="ixt:numdotdecimal" decimals="0" unitRef="USD">769,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2024-12-31" id="Fact000069" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,853,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AccruedLiabilitiesCurrent_i02I_maCz1PN_z7yeyxAcKqNc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2025-09-30" id="Fact000071" format="ixt:numdotdecimal" decimals="0" unitRef="USD">400,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000072" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,797,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DividendsPayableCurrent_i02I_maCz1PN_z87i3KbGchr2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Dividend payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DividendsPayableCurrent" contextRef="AsOf2025-09-30" id="Fact000074" format="ixt:numdotdecimal" decimals="0" unitRef="USD">144,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0075">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--WarrantLiabilityCurrent_i02I_maCz1PN_zry58rnrPny6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Warrant liability</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="GTBP:WarrantLiabilityCurrent" contextRef="AsOf2025-09-30" id="Fact000077" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="GTBP:WarrantLiabilityCurrent" contextRef="AsOf2024-12-31" id="Fact000078" format="ixt:numdotdecimal" decimals="0" unitRef="USD">252,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LiabilitiesCurrent_i01TI_mtCz1PN_maLASEz75V_zB60pKWR0hkg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left">Total Current Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2025-09-30" id="Fact000080" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,321,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000081" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,902,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--StockholdersEquityAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stockholders&#8217; Equity (Deficit)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PreferredStockValue_i02I_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_maSEzD3S_zvLDwXYT1nsh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Convertible Preferred stock, par value $<span id="xdx_90D_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20250930_zHPJFozgJIjf" title="Preferred stock, par value"><span id="xdx_909_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20241231_ztgzsy55zIRa" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2025-09-30" id="Fact000089" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31" id="Fact000091" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></ix:nonFraction></span></span>, <span id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20250930_zjrFXR1VVPNl" title="Preferred stock, shares authorized"><span id="xdx_90F_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20241231_zVeEV4WfJ9b8" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2025-09-30" id="Fact000093" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact000095" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized:
    Series C - <span id="xdx_90C_eus-gaap--PreferredStockSharesIssued_iI_pid_c20250930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zuXrd6jyY3n7" title="Preferred stock, shares issued"><span id="xdx_907_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20250930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zw7jas2MkFs8" title="Preferred stock, shares outstanding"><span id="xdx_908_eus-gaap--PreferredStockSharesIssued_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zhLtGEWBqDp2" title="Preferred stock, shares issued"><span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zkMPw7rexiXe" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2025-09-30_us-gaap_SeriesCPreferredStockMember" id="Fact000097" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2025-09-30_us-gaap_SeriesCPreferredStockMember" id="Fact000099" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember" id="Fact000101" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember" id="Fact000103" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">96,230</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2025-09-30_us-gaap_SeriesCPreferredStockMember" id="Fact000086" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember" id="Fact000087" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PreferredStockValue_i02I_hus-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_maSEzD3S_zumyJRDIo3J" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Series L - <span id="xdx_901_eus-gaap--PreferredStockSharesIssued_iI_pid_c20250930__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_zJJcTfNGFzqk" title="Preferred stock, shares issued"><span id="xdx_907_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20250930__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_zYOWLfKWOye7" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2025-09-30_custom_SeriesLPreferredStockMember" id="Fact000108" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2025-09-30_custom_SeriesLPreferredStockMember" id="Fact000110" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,912</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_902_eus-gaap--PreferredStockSharesIssued_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_zpzJvT7ah5dl" title="Preferred stock, shares issued"><span id="xdx_90A_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_zPeJVPrFcrYj" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2024-12-31_custom_SeriesLPreferredStockMember" id="Fact000112" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-12-31_custom_SeriesLPreferredStockMember" id="Fact000114" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0105">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0106">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--PreferredStockValue_i02I_maSEzD3S_zYRUCrjUr2p9" style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Preferred stock value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0116">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0117">-</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--CommonStockValue_i02I_maSEzD3S_z5SaaoMlaGi5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Common stock, par value $<span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20250930_zZ4nm1MGwcx6" title="Common stock, par value"><span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20241231_zZAyFiOGSF74" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2025-09-30" id="Fact000122" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31" id="Fact000124" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span>, <span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20250930_zXAlbvPcRcx7" title="Common stock, shares authorized"><span id="xdx_90B_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20241231_zsxUUeoCDgvh" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2025-09-30" id="Fact000126" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact000128" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">250,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized, <span id="xdx_905_eus-gaap--CommonStockSharesIssued_iI_pid_c20250930_ztseoxCogor3" title="Common stock, shares issued"><span id="xdx_900_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20250930_zotuRgNFkR13" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2025-09-30" id="Fact000130" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2025-09-30" id="Fact000132" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,051,874</ix:nonFraction></ix:nonFraction> </span></span>and <span id="xdx_906_eus-gaap--CommonStockSharesIssued_iI_pid_c20241231_zatb8pjGcK0a" title="Common stock, shares issued"><span id="xdx_90C_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20241231_z9Wyvll9jgRh" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-12-31" id="Fact000134" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-12-31" id="Fact000136" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,234,328</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2025-09-30" id="Fact000119" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2024-12-31" id="Fact000120" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AdditionalPaidInCapital_i02I_maSEzD3S_za4MbnIPnMRa" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Additional paid in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2025-09-30" id="Fact000138" format="ixt:numdotdecimal" decimals="0" unitRef="USD">703,772,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2024-12-31" id="Fact000139" format="ixt:numdotdecimal" decimals="0" unitRef="USD">693,554,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_maSEzD3S_zpKMk6pOW6Ik" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Accumulated deficit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2025-09-30" id="Fact000141" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">700,779,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-12-31" id="Fact000142" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">695,227,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--StockholdersEquity_i02TI_mtSEzD3S_maLASEz75V_zjBXc2qexzT2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Total Stockholders&#8217; Equity (Deficit)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-09-30" id="Fact000144" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,000,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000145" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,670,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_mtLASEz75V_zgHOWXhFohUb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; (EQUITY) DEFICIT</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2025-09-30" id="Fact000147" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,321,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000148" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,232,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
accompanying notes are an integral part of these unaudited condensed financial statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GT
BIOPHARMA, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_002"></span>Condensed
Statements of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30B_113_zS0E7ZCZn2g7" summary="xdx: Statement - Condensed Statements of Operations (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20250701__20250930_z3tYCIeqGBmk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20240701__20240930_zivD6kHJzaTc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20250101__20250930_zIr1DqaPIiH2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20240101__20240930_zlRoAZJm52J7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">The Three Months</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Nine Months</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_maCziGa_za5b2QOaKldj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Revenues</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0150">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0151">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0152">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0153">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingExpensesAbstract_iB_zdU0thpbx94d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating Expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ResearchAndDevelopmentExpense_i01_msCziGa_z3KwecAI1Cre" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 36%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-07-012025-09-30" id="Fact000160" format="ixt:numdotdecimal" decimals="0" unitRef="USD">634,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-07-012024-09-30" id="Fact000161" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,307,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-01-01to2025-09-30" id="Fact000162" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,096,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-09-30" id="Fact000163" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,868,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--SellingGeneralAndAdministrativeExpense_i01_msCziGa_z7ooqvV5hZl9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Selling, general and administrative (including $<span id="xdx_90F_eus-gaap--AllocatedShareBasedCompensationExpense_c20250701__20250930__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember__srt--TitleOfIndividualAxis__custom--OfficersEmployeesAndDirectorsMember_zpGDfgEbBui1" title="Share-based payment arrangement, expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2025-07-012025-09-30_us-gaap_SellingGeneralAndAdministrativeExpensesMember_custom_OfficersEmployeesAndDirectorsMember" id="Fact000170" format="ixt:numdotdecimal" decimals="0" unitRef="USD">379,000</ix:nonFraction></span> and $<span id="xdx_901_eus-gaap--AllocatedShareBasedCompensationExpense_c20240701__20240930__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember__srt--TitleOfIndividualAxis__custom--OfficersEmployeesAndDirectorsMember_zOT1lHzLe9re" title="Share-based payment arrangement, expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-07-012024-09-30_us-gaap_SellingGeneralAndAdministrativeExpensesMember_custom_OfficersEmployeesAndDirectorsMember" id="Fact000172" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> of stock compensation for the three months ended September 30, 2025 and 2024, respectively, and $<span id="xdx_909_eus-gaap--AllocatedShareBasedCompensationExpense_c20250101__20250930__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember__srt--TitleOfIndividualAxis__custom--OfficersEmployeesAndDirectorsMember_z4DFe4Tzkrfg" title="Share-based payment arrangement, expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2025-01-012025-09-30_us-gaap_SellingGeneralAndAdministrativeExpensesMember_custom_OfficersEmployeesAndDirectorsMember" id="Fact000174" format="ixt:numdotdecimal" decimals="0" unitRef="USD">386,000</ix:nonFraction></span> and $<span id="xdx_90B_eus-gaap--AllocatedShareBasedCompensationExpense_c20240101__20240930__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember__srt--TitleOfIndividualAxis__custom--OfficersEmployeesAndDirectorsMember_z128kCYrwY2j" title="Share-based payment arrangement, expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-09-30_us-gaap_SellingGeneralAndAdministrativeExpensesMember_custom_OfficersEmployeesAndDirectorsMember" id="Fact000176" format="ixt:numdotdecimal" decimals="0" unitRef="USD">222,000</ix:nonFraction></span> of stock compensation for the nine months ended September 30, 2025 and 2024, respectively)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2025-07-012025-09-30" id="Fact000165" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,748,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2024-07-012024-09-30" id="Fact000166" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,297,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2025-01-01to2025-09-30" id="Fact000167" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,731,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2024-01-012024-09-30" id="Fact000168" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,733,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OperatingIncomeLoss_iT_mtCziGa_maNILzSIF_zBN6QppzaTB1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Loss from Operations</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2025-07-012025-09-30" id="Fact000178" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,382,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-07-012024-09-30" id="Fact000179" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,604,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2025-01-01to2025-09-30" id="Fact000180" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,827,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-01-012024-09-30" id="Fact000181" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,601,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zbiEdv6w4ITh" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Other Income (Expense)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--InterestIncomeOther_i01_maNIEzVlj_z6y34fsy29G9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeOther" contextRef="From2025-07-012025-09-30" id="Fact000188" format="ixt:numdotdecimal" decimals="0" unitRef="USD">36,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeOther" contextRef="From2024-07-012024-09-30" id="Fact000189" format="ixt:numdotdecimal" decimals="0" unitRef="USD">96,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeOther" contextRef="From2025-01-01to2025-09-30" id="Fact000190" format="ixt:numdotdecimal" decimals="0" unitRef="USD">106,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeOther" contextRef="From2024-01-012024-09-30" id="Fact000191" format="ixt:numdotdecimal" decimals="0" unitRef="USD">343,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--FairValueAdjustmentOfWarrants_i01N_di_msNIEzVlj_ztqBX0QgO3R7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Change in fair value of warrant liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2025-07-012025-09-30" id="Fact000193" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">232,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-07-012024-09-30" id="Fact000194" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">95,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2025-01-01to2025-09-30" id="Fact000195" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">244,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-01-012024-09-30" id="Fact000196" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">870,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i01_maNIEzVlj_zZUr04dfTa91" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Gain on settlement of vendor payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0198">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0199">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2025-01-01to2025-09-30" id="Fact000200" format="ixt:numdotdecimal" decimals="0" unitRef="USD">998,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0201">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OtherNonoperatingIncomeExpense_i01_maNIEzVlj_z0Y0NyioRds3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Other income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0203">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0204">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2025-01-01to2025-09-30" id="Fact000205" format="ixt:numdotdecimal" decimals="0" unitRef="USD">156,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0206">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_i01_maNIEzVlj_zZwp0SdHU9Di" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Unrealized gain on short-term investments</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0208">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" contextRef="From2024-07-012024-09-30" id="Fact000209" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0210">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" contextRef="From2024-01-012024-09-30" id="Fact000211" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NonoperatingIncomeExpense_i01T_maNILzSIF_mtNIEzVlj_z77J9Bbiwx48" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Total Other Income (Expense), Net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2025-07-012025-09-30" id="Fact000213" format="ixt:numdotdecimal" decimals="0" unitRef="USD">268,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2024-07-012024-09-30" id="Fact000214" format="ixt:numdotdecimal" decimals="0" unitRef="USD">193,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2025-01-01to2025-09-30" id="Fact000215" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,504,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2024-01-012024-09-30" id="Fact000216" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,214,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NetIncomeLoss_iT_mtNILzSIF_maNILATzw02_zcWdD0QvEEM1" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Net Loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-07-012025-09-30" id="Fact000218" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,114,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-07-012024-09-30" id="Fact000219" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,411,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-01to2025-09-30" id="Fact000220" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,323,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-09-30" id="Fact000221" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">9,387,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--PreferredStockDividendsIncomeStatementImpact_iN_di_msNILATzw02_z9qQTWqK3Qp4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividends on preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PreferredStockDividendsIncomeStatementImpact" contextRef="From2025-07-012025-09-30" id="Fact000223" format="ixt:numdotdecimal" decimals="0" unitRef="USD">144,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0224">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PreferredStockDividendsIncomeStatementImpact" contextRef="From2025-01-01to2025-09-30" id="Fact000225" format="ixt:numdotdecimal" decimals="0" unitRef="USD">229,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0226">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_iT_mtNILATzw02_z9FvdQLpzX95" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net Loss attributable to common stockholders&#8217;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2025-07-012025-09-30" id="Fact000228" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,258,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2024-07-012024-09-30" id="Fact000229" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,411,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2025-01-01to2025-09-30" id="Fact000230" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,552,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2024-01-012024-09-30" id="Fact000231" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">9,387,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net Loss Per Share - Basic and Diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--EarningsPerShareBasic_pid_c20250701__20250930_z1g6ByetYIKl" title="Net Loss Per Share - Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_"><span id="xdx_902_eus-gaap--EarningsPerShareDiluted_pid_c20250701__20250930_zAD7u4cPQZPh" title="Net Loss Per Share - Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2025-07-012025-09-30" id="Fact000233" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2025-07-012025-09-30" id="Fact000235" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.83</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--EarningsPerShareBasic_pid_c20240701__20240930_zk81ejkcxyJ1" title="Net Loss Per Share - Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_"><span id="xdx_901_eus-gaap--EarningsPerShareDiluted_pid_c20240701__20240930_zZDDB3ra0Dj1" title="Net Loss Per Share - Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-07-012024-09-30" id="Fact000237" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-07-012024-09-30" id="Fact000239" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1.53</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_eus-gaap--EarningsPerShareBasic_pid_c20250101__20250930_zoEGvkwf0J9k" title="Net Loss Per Share - Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_"><span id="xdx_905_eus-gaap--EarningsPerShareDiluted_pid_c20250101__20250930_zYq3dGWc4st6" title="Net Loss Per Share - Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2025-01-01to2025-09-30" id="Fact000241" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2025-01-01to2025-09-30" id="Fact000243" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1.84</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--EarningsPerShareBasic_pid_c20240101__20240930_zI4Rrc8M6R9k" title="Net Loss Per Share - Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_"><span id="xdx_909_eus-gaap--EarningsPerShareDiluted_pid_c20240101__20240930_zJ5najekHeDg" title="Net Loss Per Share - Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-01-012024-09-30" id="Fact000245" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-01-012024-09-30" id="Fact000247" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">5.28</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Weighted average common shares outstanding - basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20250701__20250930_zQnwMu0YrKLk" title="Weighted average common shares outstanding - basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20250701__20250930_zt3bWFyrgmIa" title="Weighted average common shares outstanding - diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2025-07-012025-09-30" id="Fact000249" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2025-07-012025-09-30" id="Fact000251" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,940,714</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240701__20240930_zegpA2jNTGA4" title="Weighted average common shares outstanding - basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240701__20240930_zGBjRjvotGCa" title="Weighted average common shares outstanding - diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-07-012024-09-30" id="Fact000253" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-07-012024-09-30" id="Fact000255" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,234,328</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20250101__20250930_zXRMo4rZBjsk" title="Weighted average common shares outstanding - basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_"><span id="xdx_905_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20250101__20250930_zGhWYqCqPnp8" title="Weighted average common shares outstanding - diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2025-01-01to2025-09-30" id="Fact000257" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2025-01-01to2025-09-30" id="Fact000259" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,025,033</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240101__20240930_z6n1dsdTLF2c" title="Weighted average common shares outstanding - basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240101__20240930_zopRsWY7kqw9" title="Weighted average common shares outstanding - diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyAoVW5hdWRpdGVkKQA_"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-01-012024-09-30" id="Fact000261" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-01-012024-09-30" id="Fact000263" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,777,313</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
accompanying notes are an integral part of these unaudited condensed financial statements.</i></span></p>
<!-- Field: Split-Segment; Name: 001 -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GT
BIOPHARMA, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_003"></span>CONDENSED
STATEMENTS OF STOCKHOLDERS&#8217; EQUITY (DEFICIT) and MEZZANINE EQUITY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
The Three and Nine Months Ended September 30, 2025 and 2024 (Unaudited):</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30A_114_z33cnmrdZOAk" summary="xdx: Statement - Condensed Statements of Stockholders' Equity (Deficit) and Mezzanine Equity  (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B4_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_us-gaap--StatementClassOfStockAxis_us-gaap--SeriesCPreferredStockMember_zcOHbVeqbuc" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B9_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_us-gaap--StatementClassOfStockAxis_custom--SeriesLPreferredStockMember_z71mhvUEIjQ4" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B3_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_z8f8lAU8Z3y8" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zRQrU29zrz03" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zKfXQjbdavm1" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4BD_za3cO0Azolyh" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series C</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preferred Shares</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series L</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preferred Shares</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Additional</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Paid in</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Accumulated</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shareholders&#8217;</b></span></p>
                                                                                                                                                                                                                                                                     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Equity</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Mezzanine Equity</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series L</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preferred Shares</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Capital</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Deficit</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> (Deficit)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_431_c20250701__20250930_eus-gaap--StockholdersEquity_iS_zDMWZrgBoGNf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 12%">Balance, June 30, 2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharesOutstanding_iS_pid_c20250701__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zGQ0DL4jjTgc" title="Balance, shares" style="width: 4%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="Fact000272" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">96,230</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="Fact000265" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharesOutstanding_iS_pid_c20250701__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_zkKz6vxBdX7a" title="Balance, shares" style="width: 4%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0274">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0266">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharesOutstanding_iS_pid_c20250701__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwSbvbsnLGXj" title="Balance, shares" style="width: 4%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-06-30_us-gaap_CommonStockMember" id="Fact000276" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,272,995</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-06-30_us-gaap_CommonStockMember" id="Fact000267" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000268" format="ixt:numdotdecimal" decimals="0" unitRef="USD">700,378,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-06-30_us-gaap_RetainedEarningsMember" id="Fact000269" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">697,521,000</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right">&#160;&#160;<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-06-30" id="Fact000270" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,861,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--TemporaryEquitySharesOutstanding_iS_pid_c20250701__20250930__us-gaap--StatementEquityComponentsAxis__custom--MezzanineEquityMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_zICNu04N4az2" title="Mezzanine equity balance, shares" style="width: 4%; text-align: right"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="AsOf2025-06-30_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember" id="Fact000278" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,301</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iS_pid_c20250701__20250930__us-gaap--StatementEquityComponentsAxis__custom--MezzanineEquityMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_zeRaLLdLOOHh" title="Mezzanine equity balance" style="width: 4%; text-align: right"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="AsOf2025-06-30_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember" id="Fact000280" format="ixt:numdotdecimal" decimals="INF" unitRef="USD">1,956,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--StockIssuedDuringPeriodValueMezzanineEquityReclassification_zbCKw76rEHXc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Mezzanine equity reclassification</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0282">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--StockIssuedDuringPeriodSharesMezzanineEquityReclassification_pid_c20250701__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_ziOq7DivHDx2" title="Mezzanine equity reclassification, shares" style="text-align: right"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodSharesMezzanineEquityReclassification" contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesLPreferredStockMember" id="Fact000289" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,301</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0283">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0284">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueMezzanineEquityReclassification" contextRef="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000285" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,956,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0286">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueMezzanineEquityReclassification" contextRef="From2025-07-012025-09-30" id="Fact000287" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,956,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--StockIssuedDuringPeriodSharesMezzanineEquityReclassification_pid_c20250701__20250930__us-gaap--StatementEquityComponentsAxis__custom--MezzanineEquityMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_zfidkmu1Jlxa" title="Mezzanine equity reclassification, shares" style="text-align: right">(<ix:nonFraction name="GTBP:StockIssuedDuringPeriodSharesMezzanineEquityReclassification" contextRef="From2025-07-012025-09-30_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember" id="Fact000291" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">6,301</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--StockIssuedDuringPeriodValueMezzanineEquityReclassification_c20250701__20250930__us-gaap--StatementEquityComponentsAxis__custom--MezzanineEquityMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_zVCxy1MdABe4" title="Mezzanine equity reclassification" style="text-align: right">(<ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueMezzanineEquityReclassification" contextRef="From2025-07-012025-09-30_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember" id="Fact000293" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,956,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--StockIssuedDuringPeriodValueConversionOfUnits_zPAVCNZuFKz8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Series L convertible preferred stock <br/>issued for cash, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0295">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_pid_c20250701__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_zknM6v5GOW4c" title="Series L convertible preferred stock issued for cash, net, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesLPreferredStockMember" id="Fact000302" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,222</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0296">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0297">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000298" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,062,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0299">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2025-07-012025-09-30" id="Fact000300" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,062,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_zLBTB8G6Tij3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Conversion of Series L convertible <br/>preferred stock into common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0304">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_c20250701__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_z3bIbVvW0Ej2" title="Conversion of Series L convertible preferred stock into common stock, shares" style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesLPreferredStockMember" id="Fact000311" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">2,611</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0305">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_c20250701__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zobdfgpGuHO3" title="Conversion of Series L convertible preferred stock into common stock, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember" id="Fact000313" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,778,852</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember" id="Fact000306" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000307" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0308">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0309">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DividendsPreferredStock_iN_di_zf1gkmAcdQdi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Dividend on Series L convertible <br/>preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0315">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0316">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0317">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0318">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember" id="Fact000319" format="ixt:numdotdecimal" decimals="0" unitRef="USD">144,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2025-07-012025-09-30" id="Fact000320" format="ixt:numdotdecimal" decimals="0" unitRef="USD">144,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_zifqCrJZyHD2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Fair value of vested stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0322">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0323">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0324">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000325" format="ixt:numdotdecimal" decimals="0" unitRef="USD">379,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0326">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2025-07-012025-09-30" id="Fact000327" format="ixt:numdotdecimal" decimals="0" unitRef="USD">379,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NetIncomeLoss_zRvdm3c7hcOi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0329">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0330">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0331">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0332">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember" id="Fact000333" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,114,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-07-012025-09-30" id="Fact000334" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,114,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_432_c20250701__20250930_eus-gaap--StockholdersEquity_iE_zTxcLdDO1ICf" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Balance, September 30, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharesOutstanding_iE_pid_c20250701__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_znHAed6AP48f" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="Fact000343" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">96,230</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="Fact000336" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharesOutstanding_iE_pid_c20250701__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_zaA10UxYLbb4" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-09-30_us-gaap_PreferredStockMember_custom_SeriesLPreferredStockMember" id="Fact000345" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,912</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0337">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharesOutstanding_iE_pid_c20250701__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zIalJh0CeEs3" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-09-30_us-gaap_CommonStockMember" id="Fact000347" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,051,847</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-09-30_us-gaap_CommonStockMember" id="Fact000338" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000339" format="ixt:numdotdecimal" decimals="0" unitRef="USD">703,772,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-09-30_us-gaap_RetainedEarningsMember" id="Fact000340" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">700,779,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-09-30" id="Fact000341" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,000,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--TemporaryEquitySharesOutstanding_iE_pid_c20250701__20250930__us-gaap--StatementEquityComponentsAxis__custom--MezzanineEquityMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_zQeoZl5t1ZCi" title="Mezzanine equity balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0349">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iE_pid_c20250701__20250930__us-gaap--StatementEquityComponentsAxis__custom--MezzanineEquityMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_zm15gZUk1Li" title="Mezzanine equity balance" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0351">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" summary="xdx: Statement - Condensed Statements of Stockholders' Equity (Deficit) and Mezzanine Equity  (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series C</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preferred Shares</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series L</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preferred Shares</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Additional</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Paid in</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Accumulated</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shareholders&#8217; Equity</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>Mezzanine Equity<br/>
 Series L<br/>
 Preferred Shares</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Capital</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Deficit</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> (Deficit)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Shares</b></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid"><b>Amount</b></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_43D_c20250101__20250930_eus-gaap--StockholdersEquity_iS_zWabZd1hibl2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 12%">Balance, December 31, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharesOutstanding_iS_pid_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_z4YIgLKn6pU4" title="Balance, shares" style="width: 4%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="Fact000360" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">96,230</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="Fact000353" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharesOutstanding_iS_pid_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_z2zl8s8V0g8i" title="Balance, shares" style="width: 4%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0362">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0354">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharesOutstanding_iS_pid_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBAtSBZ0Ad3d" title="Balance, shares" style="width: 4%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000364" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,234,328</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000355" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000356" format="ixt:numdotdecimal" decimals="0" unitRef="USD">693,554,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember" id="Fact000357" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">695,227,000</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000358" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,670,000</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_989_eus-gaap--TemporaryEquitySharesOutstanding_iS_pid_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--MezzanineEquityMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_zXmjmmwf8ipj" title="Mezzanine equity balance, shares" style="text-align: right; width: 4%">&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0366">-</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_98A_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iS_pid_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--MezzanineEquityMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_zpKswpAHCrhd" title="Mezzanine equity balance" style="text-align: right; width: 4%">&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0368">-</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr id="xdx_407_ecustom--StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet_zTDA1Afnc5u5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Exercise of warrants for cash and inducement warrants, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Balance, shares" style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0370">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Balance, shares" style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0371">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Exercise of warrants for cash and inducement warrants, net, shares" id="xdx_987_ecustom--StockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet_pid_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zNnXf5XL9yO6" style="text-align: right"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet" contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember" id="Fact000377" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">537,069</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet" contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember" id="Fact000372" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet" contextRef="From2025-01-012025-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000373" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,051,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0374">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet" contextRef="From2025-01-01to2025-09-30" id="Fact000375" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,052,000</ix:nonFraction></td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">-</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">-</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--StockIssuedDuringPeriodValueConversionOfUnits_zSj2HhaXME9c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Series L convertible preferred stock and warrants issued for cash, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Balance, shares" style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0379">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Series L convertible preferred stock and warrants issued for cash, net, shares" id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_pid_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_zH9hF96Vostc" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesLPreferredStockMember" id="Fact000386" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,833</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0380">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Balance, shares" style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0381">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2025-01-012025-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000382" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,503,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0383">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2025-01-01to2025-09-30" id="Fact000384" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,503,000</ix:nonFraction></td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">-</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">-</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_zavd1XmfvGDa" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Conversion of Series L convertible preferred stock into common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Balance, shares" style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0388">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Conversion of Series L convertible preferred stock into common stock, shares" id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_zPTXNwpeB9sj" style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesLPreferredStockMember" id="Fact000395" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">2,921</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0389">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Conversion of Series L convertible preferred stock into common stock, shares" id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zi1B80MuuDOa" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember" id="Fact000397" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,930,450</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember" id="Fact000390" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2025-01-012025-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000391" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0392">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0393">-</span></td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">-</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">-</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40E_ecustom--StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable_zXVCPbMDtNMi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Issuance of prefunded warrants in settlement of vendor payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Balance, shares" style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0399">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Balance, shares" style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0400">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Balance, shares" style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0401">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable" contextRef="From2025-01-012025-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000402" format="ixt:numdotdecimal" decimals="0" unitRef="USD">847,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0403">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable" contextRef="From2025-01-01to2025-09-30" id="Fact000404" format="ixt:numdotdecimal" decimals="0" unitRef="USD">847,000</ix:nonFraction></td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">-</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">-</td>
    <td>&#160;</td></tr>
  <tr id="xdx_405_ecustom--StockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee_zjLGUrHw54Cl" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Issuance and exercise of prefunded warrants for ELOC fee</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Balance, shares" style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0406">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Balance, shares" style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0407">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Issuance and exercise of prefunded warrants for ELOC fee, shares" id="xdx_984_ecustom--StockIssuedDuringPeriodSharesIssuanceAndExerciseOfPrefundedWarrantsForElocFee_pid_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8IfZnHX7aQ2" style="text-align: right"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodSharesIssuanceAndExerciseOfPrefundedWarrantsForElocFee" contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember" id="Fact000413" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">300,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0408">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee" contextRef="From2025-01-012025-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000409" format="ixt:numdotdecimal" decimals="0" unitRef="USD">672,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0410">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee" contextRef="From2025-01-01to2025-09-30" id="Fact000411" format="ixt:numdotdecimal" decimals="0" unitRef="USD">672,000</ix:nonFraction></td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">-</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">-</td>
    <td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_zP7DKt7KOAFj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Issuance of common stock and warrants for services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Balance, shares" style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0415">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Balance, shares" style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0416">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Issuance of common stock and warrants for services, shares" id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zhps8FoRXOA6" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember" id="Fact000422" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0417">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2025-01-012025-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000418" format="ixt:numdotdecimal" decimals="0" unitRef="USD">718,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0419">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2025-01-01to2025-09-30" id="Fact000420" format="ixt:numdotdecimal" decimals="0" unitRef="USD">718,000</ix:nonFraction></td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">-</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">-</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--StockIssuedDuringPeriodValueOther_zt2uoXWm1lRe" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Issuance of warrants for VRT waiver</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Balance, shares" style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0424">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Balance, shares" style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0425">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Balance, shares" style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0426">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2025-01-012025-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000427" format="ixt:numdotdecimal" decimals="0" unitRef="USD">44,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0428">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2025-01-01to2025-09-30" id="Fact000429" format="ixt:numdotdecimal" decimals="0" unitRef="USD">44,000</ix:nonFraction></td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">-</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">-</td>
    <td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DividendsPreferredStock_iN_di_zfMffWCmwSAf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Dividend on Series L convertible preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Balance, shares" style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0431">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Balance, shares" style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0432">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Balance, shares" style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0433">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0434">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2025-01-012025-09-30_us-gaap_RetainedEarningsMember" id="Fact000435" format="ixt:numdotdecimal" decimals="0" unitRef="USD">229,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2025-01-01to2025-09-30" id="Fact000436" format="ixt:numdotdecimal" decimals="0" unitRef="USD">229,000</ix:nonFraction></td><td style="text-align: left">)</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">-</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">-</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_zsQmhaA551A2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Fair value of vested stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Balance, shares" style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0438">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Balance, shares" style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0439">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Balance, shares" style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0440">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2025-01-012025-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000441" format="ixt:numdotdecimal" decimals="0" unitRef="USD">386,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0442">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2025-01-01to2025-09-30" id="Fact000443" format="ixt:numdotdecimal" decimals="0" unitRef="USD">386,000</ix:nonFraction></td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">-</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">-</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--NetIncomeLoss_zK8f7gCeyAtc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td title="Balance, shares" style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0445">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td title="Balance, shares" style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0446">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td title="Balance, shares" style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0447">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0448">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-09-30_us-gaap_RetainedEarningsMember" id="Fact000449" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,323,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-01to2025-09-30" id="Fact000450" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,323,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">-</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">-</td>
    <td>&#160;</td></tr>
  <tr id="xdx_435_c20250101__20250930_eus-gaap--StockholdersEquity_iE_zvlSrggeb6mg" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Balance, September 30, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharesOutstanding_iE_pid_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zBIOOsy4lyu7" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="Fact000459" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">96,230</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="Fact000452" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharesOutstanding_iE_pid_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_zNhTobwJPLrk" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-09-30_us-gaap_PreferredStockMember_custom_SeriesLPreferredStockMember" id="Fact000461" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,912</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0453">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharesOutstanding_iE_pid_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmM2ETDC1Ybb" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-09-30_us-gaap_CommonStockMember" id="Fact000463" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,051,847</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-09-30_us-gaap_CommonStockMember" id="Fact000454" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000455" format="ixt:numdotdecimal" decimals="0" unitRef="USD">703,772,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-09-30_us-gaap_RetainedEarningsMember" id="Fact000456" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">700,779,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-09-30" id="Fact000457" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,000,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td id="xdx_98C_eus-gaap--TemporaryEquitySharesOutstanding_iE_pid_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--MezzanineEquityMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_zUxWV8gwXxVi" title="Mezzanine equity balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0465">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td id="xdx_980_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iE_pid_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__custom--MezzanineEquityMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_zlhGycSUzDQ5" title="Mezzanine equity balance" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0467">-</span></td>
    <td>&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
accompanying notes are an integral part of these unaudited condensed financial statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GT
BIOPHARMA, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONDENSED
STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
The Three and Nine Months Ended September 30, 2025 and 2024 (Unaudited):</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B4_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_us-gaap--StatementClassOfStockAxis_us-gaap--SeriesCPreferredStockMember_zqlwxA9qIAD2" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B6_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zwCAqRnVakje" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zLzBXxGwvDuk" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zAq0prRhwhP8" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4BD_zS77KZqw72mj" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series C</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preferred Shares</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Additional</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Paid in</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Accumulated</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shareholders&#8217;</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>Mezzanine Equity<br/>
 Series L<br/>
 Preferred Shares</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Capital</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Deficit</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Equity</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Shares</b></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid"><b>Amount</b></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_433_c20240701__20240930_eus-gaap--StockholdersEquity_iS_z3hulms3VTlk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 31%">Balance, June 30, 2024</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharesOutstanding_iS_pid_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zLq5X0Y5bCm3" title="Balance, shares" style="width: 4%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="Fact000475" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">96,230</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="Fact000469" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharesOutstanding_iS_pid_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5uGZ0NxvJmd" title="Balance, shares" style="width: 4%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-06-30_us-gaap_CommonStockMember" id="Fact000477" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,234,348</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_CommonStockMember" id="Fact000470" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000471" format="ixt:numdotdecimal" decimals="0" unitRef="USD">693,546,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_RetainedEarningsMember" id="Fact000472" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">688,041,000</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right">&#160;&#160;<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30" id="Fact000473" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,508,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 7%">&#160;</td>
    <td id="xdx_987_eus-gaap--TemporaryEquitySharesOutstanding_iS_pid_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__custom--MezzanineEquityMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_zMicWFRifIr8" title="Mezzanine equity balance, shares" style="text-align: right; width: 4%"><span style="-sec-ix-hidden: xdx2ixbrl0479">-</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_985_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iS_pid_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__custom--MezzanineEquityMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_zdYD1nruL50b" title="Mezzanine equity balance" style="text-align: right; width: 4%"><span style="-sec-ix-hidden: xdx2ixbrl0481">-</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash_z1WuWCLCHdth" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Issuance of common stock and warrants for cash, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0483">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0484">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0485">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0486">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0487">-</span></td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">-</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">-</td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensationForfeited_iN_di_zmetsWD8QRda" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Cancellation of common stock previously issued to prior CFO</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0489">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0490">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0491">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0492">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0493">-</span></td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">-</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">-</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_ecustom--StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable_zSLbK92ShG12" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Issuance of common stock in settlement of vendor payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0495">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0496">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0497">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0498">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0499">-</span></td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">-</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">-</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_zrCr3kb2Huba" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Fair value of vested stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0501">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0502">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0503">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0504">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0505">-</span></td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">-</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">-</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetIncomeLoss_z8Sh5dqnuKIe" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0507">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0508">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0509">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember" id="Fact000510" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,411,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-07-012024-09-30" id="Fact000511" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,411,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">-</td>
    <td>&#160;</td></tr>
  <tr id="xdx_433_c20240701__20240930_eus-gaap--StockholdersEquity_iE_zc4urghSSacb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance, September 30, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharesOutstanding_iE_pid_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zH4KLcFsHNkd" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="Fact000519" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">96,230</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="Fact000513" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharesOutstanding_iE_pid_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zutrbDavQQZh" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-09-30_us-gaap_CommonStockMember" id="Fact000521" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,234,348</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_CommonStockMember" id="Fact000514" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000515" format="ixt:numdotdecimal" decimals="0" unitRef="USD">693,546,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_RetainedEarningsMember" id="Fact000516" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">691,452,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30" id="Fact000517" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,097,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td id="xdx_987_eus-gaap--TemporaryEquitySharesOutstanding_iE_pid_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__custom--MezzanineEquityMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_zcIItPbHAlc4" title="Mezzanine equity balance, shares" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0523">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td id="xdx_98A_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iE_pid_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__custom--MezzanineEquityMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_zDFBzwdRvWM6" title="Mezzanine equity balance" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0525">-</span></td>
    <td>&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.3pt; text-align: center; text-indent: -3.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series C</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.3pt; text-align: center; text-indent: -3.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preferred Shares</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.3pt; text-align: center; text-indent: -3.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Additional</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.3pt; text-align: center; text-indent: -3.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Paid in</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Accumulated</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.3pt; text-align: center; text-indent: -3.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.3pt; text-align: center; text-indent: -3.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shareholders&#8217;</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>Mezzanine Equity<br/>
 Series L<br/>
 Preferred Shares</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Capital</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Deficit</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Equity</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Shares</b></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Amount</b></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_433_c20240101__20240930_eus-gaap--StockholdersEquity_iS_zSriZJobjr21" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 31%">Balance, December 31, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharesOutstanding_iS_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zGCIN4HdRmhj" title="Balance, shares" style="width: 4%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="Fact000533" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">96,230</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="Fact000527" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharesOutstanding_iS_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zEOsXb2gjmz3" title="Balance, shares" style="width: 4%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000535" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,380,653</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000528" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000529" format="ixt:numdotdecimal" decimals="0" unitRef="USD">689,539,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000530" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">682,065,000</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right">&#160;&#160;<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000531" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,476,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 7%">&#160;</td>
    <td id="xdx_98D_eus-gaap--TemporaryEquitySharesOutstanding_iS_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--MezzanineEquityMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_z87t8Ws56Ktl" title="Mezzanine equity balance, shares" style="text-align: right; width: 4%">&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0537">-</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_98A_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iS_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--MezzanineEquityMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_ztbNNrp1DCxl" title="Mezzanine equity balance" style="text-align: right; width: 4%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0539">-</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr id="xdx_436_c20240101__20240930_eus-gaap--StockholdersEquity_iS_zorIs534DLok" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharesOutstanding_iS_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zlfYeoLcHlLc" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="Fact000547" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">96,230</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="Fact000541" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharesOutstanding_iS_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zvzmRD3YFmr8" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000549" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,380,653</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000542" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000543" format="ixt:numdotdecimal" decimals="0" unitRef="USD">689,539,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000544" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">682,065,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#160;&#160;<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000545" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,476,000</ix:nonFraction></td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_981_eus-gaap--TemporaryEquitySharesOutstanding_iS_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--MezzanineEquityMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_zLgmyfWu07rj" title="Mezzanine equity balance, shares" style="text-align: right">&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0551">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98B_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iS_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--MezzanineEquityMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_zWobKcbkesbg" title="Mezzanine equity balance" style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0553">-</span></td>
    <td>&#160;</td></tr>
<tr id="xdx_40F_ecustom--StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash_zgA3VYZw2zSk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Issuance of common stock and warrants for cash, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0555">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--StockIssuedDuringPeriodShareIssuanceOfCommonStockAndWarrantsForCash_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zAJJXqSsNNRk" title="Issuance of common stock and warrants for cash, net, shares" style="text-align: right"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodShareIssuanceOfCommonStockAndWarrantsForCash" contextRef="From2024-01-012024-09-30_us-gaap_CommonStockMember" id="Fact000561" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">740,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash" contextRef="From2024-01-012024-09-30_us-gaap_CommonStockMember" id="Fact000556" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash" contextRef="From2024-01-012024-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000557" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,975,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0558">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash" contextRef="From2024-01-012024-09-30" id="Fact000559" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,976,000</ix:nonFraction></td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">-</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">-</td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensationForfeited_iN_di_zbZ3hHvGTb7g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Cancellation of common stock previously issued to prior CFO</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0563">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_iN_pid_di_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zlfIrwBwfmUb" title="Cancellation of common stock previously issued to prior CFO, shares" style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" contextRef="From2024-01-012024-09-30_us-gaap_CommonStockMember" id="Fact000569" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,902</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0564">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0565">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0566">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0567">-</span></td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">-</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">-</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_ecustom--StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable_zKa6RIwgmxed" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Issuance of common stock in settlement of vendor payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0571">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBvWx8noT2b3" title="Issuance of common stock in settlement of vendor payable, shares" style="text-align: right"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable" contextRef="From2024-01-012024-09-30_us-gaap_CommonStockMember" id="Fact000577" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">127,597</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0572">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable" contextRef="From2024-01-012024-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000573" format="ixt:numdotdecimal" decimals="0" unitRef="USD">810,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0574">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable" contextRef="From2024-01-012024-09-30" id="Fact000575" format="ixt:numdotdecimal" decimals="0" unitRef="USD">810,000</ix:nonFraction></td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">-</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">-</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_z1q1EG4tlAS1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Fair value of vested stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0579">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0580">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2024-01-012024-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000581" format="ixt:numdotdecimal" decimals="0" unitRef="USD">222,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0582">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2024-01-012024-09-30" id="Fact000583" format="ixt:numdotdecimal" decimals="0" unitRef="USD">222,000</ix:nonFraction></td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">-</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">-</td>
    <td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetIncomeLoss_zLiUREqMDpyh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0585">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0586">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0587">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-09-30_us-gaap_RetainedEarningsMember" id="Fact000588" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">9,387,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-09-30" id="Fact000589" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">9,387,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">-</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">-</td>
    <td>&#160;</td></tr>
  <tr id="xdx_434_c20240101__20240930_eus-gaap--StockholdersEquity_iE_z8ropO0nKf4c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance, September 30, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharesOutstanding_iE_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zmrOy6fseO21" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="Fact000597" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">96,230</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="Fact000591" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharesOutstanding_iE_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z4qkQXpMmPU5" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-09-30_us-gaap_CommonStockMember" id="Fact000599" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,234,348</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_CommonStockMember" id="Fact000592" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000593" format="ixt:numdotdecimal" decimals="0" unitRef="USD">693,546,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_RetainedEarningsMember" id="Fact000594" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">691,452,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30" id="Fact000595" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,097,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td id="xdx_98E_eus-gaap--TemporaryEquitySharesOutstanding_iE_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--MezzanineEquityMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_zkrXwqp0OnRf" title="Mezzanine equity balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0601">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td id="xdx_981_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iE_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--MezzanineEquityMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_zjaOpT5zdytj" title="Mezzanine equity balance" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0603">-</span></td>
    <td>&#160;</td></tr>
  <tr id="xdx_43B_c20240101__20240930_eus-gaap--StockholdersEquity_iE_zGWwVIaCZdFf" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharesOutstanding_iE_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zwFso5bDVZkk" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="Fact000611" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">96,230</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="Fact000605" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharesOutstanding_iE_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ztg4gbuCl5mk" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-09-30_us-gaap_CommonStockMember" id="Fact000613" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,234,348</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_CommonStockMember" id="Fact000606" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000607" format="ixt:numdotdecimal" decimals="0" unitRef="USD">693,546,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_RetainedEarningsMember" id="Fact000608" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">691,452,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30" id="Fact000609" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,097,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td id="xdx_98E_eus-gaap--TemporaryEquitySharesOutstanding_iE_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--MezzanineEquityMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_zfqTlhn4XAx4" title="Mezzanine equity balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0615">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td id="xdx_986_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iE_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--MezzanineEquityMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_zBnw5a0HprSc" title="Mezzanine equity balance" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0617">-</span></td>
    <td>&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
accompanying notes are an integral part of these unaudited condensed financial statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GT
BIOPHARMA, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_004"></span>Condensed
Statements of Cash Flows</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30B_112_z2HcMetNQlJi" summary="xdx: Statement - Condensed Statements of Cash Flows" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_492_20250101__20250930_z50B2qJlulMk" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49C_20240101__20240930_zjqRjV0kxH52" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For The Nine Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zCOMeYDK5y0c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">CASH FLOWS FROM OPERATING ACTIVITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetIncomeLoss_i01_maCzuBM_zAIJIGUNU4Jc" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-01to2025-09-30" id="Fact000622" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,323,000</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-09-30" id="Fact000623" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">9,387,000</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zyQtXyLmts0c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ShareBasedCompensation_i02_maCzuBM_ziAwsKFIbVAk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Stock based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-01-01to2025-09-30" id="Fact000628" format="ixt:numdotdecimal" decimals="0" unitRef="USD">386,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-09-30" id="Fact000629" format="ixt:numdotdecimal" decimals="0" unitRef="USD">222,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--IssuanceOfWarrantsForVrtWaiver_i02_maCzuBM_zUjeCoRUM5W" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Issuance of warrants for VRT waiver</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GTBP:IssuanceOfWarrantsForVrtWaiver" contextRef="From2025-01-01to2025-09-30" id="Fact000631" format="ixt:numdotdecimal" decimals="0" unitRef="USD">44,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0632">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FairValueAdjustmentOfWarrants_i02_maCzuBM_zp4s0x6JnE21" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Change in fair value of warrant liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2025-01-01to2025-09-30" id="Fact000634" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">244,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-01-012024-09-30" id="Fact000635" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">870,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i02N_di_msCzuBM_zC1H2Vsnux09" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Gain on settlement of debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2025-01-01to2025-09-30" id="Fact000637" format="ixt:numdotdecimal" decimals="0" unitRef="USD">998,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0638">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--GainOnSettlementOfDebt_i02N_di_msCzuBM_zMTm99U5kMY2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Gain on extinguishment of debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="GTBP:GainOnSettlementOfDebt" contextRef="From2025-01-01to2025-09-30" id="Fact000640" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0641">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DebtSecuritiesUnrealizedGainLoss_i02N_di_msCzuBM_zuXN3hSB2mC7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Unrealized gain on short-term investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0643">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DebtSecuritiesUnrealizedGainLoss" contextRef="From2024-01-012024-09-30" id="Fact000644" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B_zys9G4LtGdR3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--IncreaseDecreaseInPrepaidExpense_i03N_di_msCzuBM_zI4uFHDfszRa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">(Increase) Decrease in prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2025-01-01to2025-09-30" id="Fact000649" format="ixt:numdotdecimal" decimals="0" unitRef="USD">122,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2024-01-012024-09-30" id="Fact000650" format="ixt:numdotdecimal" decimals="0" unitRef="USD">164,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_i03_maCzuBM_zaEcoVSUcljd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Decrease in accounts payable and accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" contextRef="From2025-01-01to2025-09-30" id="Fact000652" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,436,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" contextRef="From2024-01-012024-09-30" id="Fact000653" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">233,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_ecustom--IncreaseDecreaseInOperatingLeaseRightofuseAssets_i03N_di_msCzuBM_zpAXRW2ojkXa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Decrease in operating lease right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="GTBP:IncreaseDecreaseInOperatingLeaseRightofuseAssets" contextRef="From2024-01-012024-09-30" id="Fact000656" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">53,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--IncreaseDecreaseInOperatingLeaseLiability_i03_maCzuBM_zjMsZtDpww9d" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">(Increase) in operating lease liability</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0658">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2024-01-012024-09-30" id="Fact000659" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">58,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_mtCzuBM_maCzQO5_zqWhFxP01kOh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: left; padding-bottom: 1pt">Net Cash Used in Operating Activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2025-01-01to2025-09-30" id="Fact000661" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,893,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-01-012024-09-30" id="Fact000662" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,436,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_z29MZ3KTVbWl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">CASH FLOWS FROM INVESTING ACTIVITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--PaymentsForProceedsFromInvestments_i01N_di_msCzo0O_z70EUQ9xQig8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1pt">Sale of investments</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0667">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PaymentsForProceedsFromInvestments" contextRef="From2024-01-012024-09-30" id="Fact000668" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,892,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_mtCzo0O_maCzQO5_zqlpG2ZemJOe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Net Cash Provided by Investing Activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0670">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2024-01-012024-09-30" id="Fact000671" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,892,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zPGpRXHMmXGk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--ProceedsFromWarrantExercises_i01_maCzJCT_zSu0ZuFIDKo8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Exercise of warrants and issuance of inducement warrants for cash, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2025-01-01to2025-09-30" id="Fact000676" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,052,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0677">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_i01_maCzJCT_zcTj3gjMv973" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Proceeds from issuance of common stock and warrants, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0679">-</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2024-01-012024-09-30" id="Fact000680" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,976,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_i01_maCzJCT_z4rELuht6aah" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Proceeds from issuance of Series L convertible preferred stock and warrants, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" contextRef="From2025-01-01to2025-09-30" id="Fact000682" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,503,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PaymentsOfDividends_i01N_di_msCzJCT_zQ15H9LVeMJ3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Payment of dividend on Series L convertible preferred stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsOfDividends" contextRef="From2025-01-01to2025-09-30" id="Fact000685" format="ixt:numdotdecimal" decimals="0" unitRef="USD">85,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0686">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_mtCzJCT_maCzQO5_zVC1hN9TG41f" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Net Cash Provided by Financing Activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2025-01-01to2025-09-30" id="Fact000688" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,470,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2024-01-012024-09-30" id="Fact000689" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,976,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_mtCzQO5_zqGqMx2xUJuf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net Increase (Decrease) in Cash and Cash Equivalents and Restricted Cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2025-01-01to2025-09-30" id="Fact000691" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,423,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2024-01-012024-09-30" id="Fact000692" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,432,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iS_zOv8IXRTstAi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Cash and Cash Equivalents and Restricted Cash at Beginning of Period</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2024-12-31" id="Fact000694" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,044,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2023-12-31" id="Fact000695" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,079,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iE_z2i54pWCTs3f" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Cash and Cash Equivalents and Restricted Cash at End of Period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2025-09-30" id="Fact000697" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,621,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2024-09-30" id="Fact000698" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,511,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zFgUypkCR08f" style="vertical-align: bottom; background-color: White">
    <td style="text-decoration: underline; text-align: left">SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--CashPaidDuringYearFor_i01B_z90hM0mAAAsl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash paid during the period for:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--InterestPaid_i02_z248oH23wxZ8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt">Interest</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0706">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0707">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--IncomeTaxesPaidNet_i02_zP8pqYnJ0VHb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Income taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0709">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0710">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NoncashInvestingAndFinancingItemsAbstract_iB_zce5nhQ9jTT4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: left">SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--FairValueOfSeriesLConvertiblePreferredStockVestedWarrants_i01_zpdDbyjm43gj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Fair value of Series L convertible preferred stock vested warrants</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="GTBP:FairValueOfSeriesLConvertiblePreferredStockVestedWarrants" contextRef="From2025-01-01to2025-09-30" id="Fact000715" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,389,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0716">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--FairValueOfPrefundedWarrantsIssuedForElocFee_i01_zmXkHmI3Gaed" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Fair value of prefunded warrants issued for ELOC fee</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="GTBP:FairValueOfPrefundedWarrantsIssuedForElocFee" contextRef="From2025-01-01to2025-09-30" id="Fact000718" format="ixt:numdotdecimal" decimals="0" unitRef="USD">672,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0719">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--StockIssued1_i01_zgkXwvem0zsl" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Fair value of common stock and warrants issued for services</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockIssued1" contextRef="From2025-01-01to2025-09-30" id="Fact000721" format="ixt:numdotdecimal" decimals="0" unitRef="USD">718,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0722">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--FairValueOfPrefundedWarrantAndCommonStockToSettleVendorPayable_i01_zB5aGJ9zDrNb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Fair value of prefunded warrant and common stock to settle vendor payable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="GTBP:FairValueOfPrefundedWarrantAndCommonStockToSettleVendorPayable" contextRef="From2025-01-01to2025-09-30" id="Fact000724" format="ixt:numdotdecimal" decimals="0" unitRef="USD">847,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="GTBP:FairValueOfPrefundedWarrantAndCommonStockToSettleVendorPayable" contextRef="From2024-01-012024-09-30" id="Fact000725" format="ixt:numdotdecimal" decimals="0" unitRef="USD">810,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--DividendDeclaredOnSeriesLConvertiblePreferredStock_i01_zePJmnG65PJ6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Dividend declared on Series L convertible preferred stock</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="GTBP:DividendDeclaredOnSeriesLConvertiblePreferredStock" contextRef="From2025-01-01to2025-09-30" id="Fact000727" format="ixt:numdotdecimal" decimals="0" unitRef="USD">229,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0728">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
accompanying notes are an integral part of these unaudited condensed financial statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GT
BIOPHARMA, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_005"></span>NOTES
TO UNAUDITED CONDENSED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three
and Nine Months Ended September 30, 2025 and 2024 (Unaudited)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact000730" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"><p id="xdx_802_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_z6UOkzaHNIz3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
1 &#8211; <span id="xdx_828_zJh9mWsOY2ak">Organization and Going Concern Analysis</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Organization</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GT
Biopharma, Inc. (the &#8220;Company&#8221;) is a clinical stage biopharmaceutical company focused on the development and commercialization
of novel immune-oncology products based on our proprietary Tri-specific Killer Engager (TriKE&#174;), and Tetra-specific Killer Engager
(Dual Targeting TriKE&#174;) platforms. The Company&#8217;s TriKE&#174; and Dual Targeting TriKE&#174; platforms generate proprietary therapeutics
designed to harness and enhance the cancer killing abilities of a patient&#8217;s own natural killer cells (NK cells).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
corporate predecessor of GT Biopharma, Inc, Diagnostic Data, Inc., was incorporated in the state of California in 1965. Diagnostic Data,
Inc. changed its incorporation to the state of Delaware on December 21, 1972 and changed its name to DDI Pharmaceuticals, Inc. on March
11, 1985. On September 7, 1994, DDI Pharmaceuticals, Inc. merged with International BioClinical, Inc. and Bioxytech S.A. and changed
its name to OXIS International, Inc. On July 17, 2017, OXIS International, Inc. changed its name to GT Biopharma, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Throughout
this Quarterly Report on Form 10-Q, the terms &#8220;GTBP,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;the Company&#8221;
and &#8220;our Company&#8221; refer to GT Biopharma, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
GT Biopharma logo, TriKE&#174;, and other trademarks or service marks of GT Biopharma, Inc. appearing in this quarterly report are the
property of the Company. This quarterly report on Form 10-Q also contains registered marks, trademarks and trade names of other companies.
All other trademarks, registered marks and trade names appearing herein are the property of their respective holders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Going
Concern Analysis</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying unaudited condensed financial statements have been prepared assuming that the Company will continue as a going concern.
The Company does not have any product candidates approved for sale and has not generated any revenue from its product sales. The Company
has sustained operating losses since inception, and expects such losses to continue into the foreseeable future. Historically, the Company
has financed its operations through public and private sales of common stock, the issuance of preferred and common stock, the issuance
of convertible debt instruments, and strategic collaborations. For the nine months ended September 30, 2025, the Company recorded a net
loss of approximately $<span id="xdx_90E_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20250101__20250930_zun01o9mOjah" title="Net loss"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-01to2025-09-30" id="Fact000732" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">5.3</ix:nonFraction> </span>million and used cash in operations of approximately $<span id="xdx_906_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20250101__20250930_zznkrDP2vplk" title="Net cash used in operating activities"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2025-01-01to2025-09-30" id="Fact000734" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">8.9</ix:nonFraction></span> million. These factors raise substantial doubt about
the Company&#8217;s ability to continue as a going concern within one year of the date that the financial statements are issued. In addition,
the Company&#8217;s independent registered public accounting firm, in its report on the Company&#8217;s December 31, 2024, financial
statements, raised substantial doubt about the Company&#8217;s ability to continue as a going concern. The financial statements do not
include any adjustments that might be necessary if the Company is unable to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited condensed financial statements do not include any adjustments that might be necessary if the Company is unable to continue
as a going concern. Accordingly, the unaudited condensed financial statements have been prepared on a basis that assumes the Company
will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in
the ordinary course of business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has evaluated the significance of the uncertainty regarding the Company&#8217;s financial condition in relation to its ability
to meet its obligations, which has raised substantial doubt about the Company&#8217;s ability to continue as a going concern. While it
is very difficult to estimate the Company&#8217;s future liquidity requirements, the Company believes if it is unable to obtain additional
financing, existing cash resources will not be sufficient to enable it to fund the anticipated level of operations through one year from
the date the accompanying unaudited condensed financial statements are issued. There can be no assurances that the Company will be able
to secure additional financing on acceptable terms. In the event the Company does not secure additional financing, the Company will be
forced to delay, reduce, or eliminate some or all of its discretionary spending, which could adversely affect the Company&#8217;s business
prospects, ability to meet long-term liquidity needs and the ability to continue operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact000736" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_806_eus-gaap--SignificantAccountingPoliciesTextBlock_z7Y1Wv9DazT7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2 &#8211; <span id="xdx_82C_zV4FNhZdgQ07">Summary of Significant Accounting Policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact000738" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"><p id="xdx_84E_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zPeugrX0lqi1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zSt4fb2hQaS2">Basis
of Presentation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying condensed financial statements are unaudited. These unaudited interim condensed financial statements have been prepared
in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and applicable rules
and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) regarding interim financial reporting. Certain information
and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant
to such rules and regulations. Accordingly, these unaudited interim condensed financial statements should be read in conjunction with
the financial statements and notes thereto contained in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December
31, 2024 filed with the SEC on February 21, 2025 (the &#8220;2024 Annual Report&#8221;). The balance sheet as of December 31, 2024 included
herein, was derived from the audited financial statements as of that date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 8; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the opinion of management, the accompanying unaudited condensed financial statements contain all adjustments necessary to fairly present
the Company&#8217;s financial position and results of operations for the interim periods reflected. Except as noted, all adjustments
contained herein are of a normal recurring nature. Results of operations for the fiscal periods presented herein are not necessarily
indicative of fiscal year-end results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact000740" name="us-gaap:UseOfEstimates"><p id="xdx_844_eus-gaap--UseOfEstimates_z84eS2DzZUXb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zWlIGXew19m2">Accounting
Estimates</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the
reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant
estimates include management&#8217;s estimates for continued liquidity, accruals for potential liabilities, assumptions used in deriving
the fair value of derivative liabilities, valuation of equity instruments issued for debt and services and realization of deferred tax
assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact000742" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_841_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z7N3ZxDPJEr7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zWGzA7w0aSbc">Cash
Equivalents</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers highly liquid investments with maturities of three months or less at the date of acquisition as cash equivalents in
the accompanying unaudited condensed financial statements. At September 30, 2025 and December 31, 2024, total cash equivalents which
consist of money market funds and treasuries with maturities of three months or less, amounted to approximately $<span id="xdx_904_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20250930_zDF63ap45bsk" title="Cash equivalents"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="AsOf2025-09-30" id="Fact000744" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.1</ix:nonFraction></span> million and $<span id="xdx_907_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20241231_zEEPQ0grDaFd" title="Cash equivalents"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="AsOf2024-12-31" id="Fact000746" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.8</ix:nonFraction></span>
million, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact000748" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"><p id="xdx_84F_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zWX34GyVZ4j6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_zBhI8qlmcvga">Restricted
Cash</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2025, the Company has classified certain cash balances as restricted cash in its unaudited condensed balance sheets.
The Company&#8217;s restricted cash is deposited in a financial institution and held as a collateral for a credit card agreement with
the same financial institution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact000750" name="us-gaap:CapitalizationOfDeferredPolicyAcquisitionCostsPolicy"><p id="xdx_847_eus-gaap--CapitalizationOfDeferredPolicyAcquisitionCostsPolicy_zZgZRRYsVcHl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zPe8nQBYIsx">Deferred
Offering Costs</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company capitalizes the fair value of equity instruments granted and certain legal, accounting and other third-party fees that are directly
related to the Company&#8217;s in-process equity financings until such financings are consummated. After consummation of an equity financing,
these costs are recorded in stockholders&#8217; equity as a reduction of additional paid-in capital generated as a result of the offering.
Should a planned equity financing be abandoned, terminated or significantly delayed, the deferred offering costs are immediately written
off to operating expenses. As of September 30, 2025, there was $<span id="xdx_906_eus-gaap--DeferredOfferingCosts_iI_pn5n6_c20250930_zwAfZucwXoA6" title="Deferred offering costs"><ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="AsOf2025-09-30" id="Fact000752" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.8</ix:nonFraction></span> million of deferred offering costs on the balance sheet.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact000754" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_846_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zKb9KjlPCAhh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zAAueikD6DXd">Fair
Value of Financial Instruments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 820-10 requires entities to disclose
the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet for which it
is practicable to estimate fair value. ASC 820-10 defines the fair value of a financial instrument as the amount at which the instrument
could be exchanged in a current transaction between willing parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
three levels of the fair value hierarchy are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1 Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the entity has the ability
to access.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2 Valuations based on quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs
that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3 Valuations based on inputs that are unobservable, supported by little or no market activity and that are significant to the fair value
of the assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts of the Company&#8217;s other financial assets and liabilities, such as cash and cash equivalents, prepaid expenses and
other current assets, accounts payable, and accrued expenses, approximate their fair values because of the short maturity of these instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amount of the Company&#8217;s warrant liability of $<span id="xdx_90E_ecustom--WarrantLiabilityCurrent_iI_c20250930_zh2mNBhcsWLd" title="Warrant liability"><ix:nonFraction name="GTBP:WarrantLiabilityCurrent" contextRef="AsOf2025-09-30" id="Fact000756" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,000</ix:nonFraction></span> and $<span id="xdx_90F_ecustom--WarrantLiabilityCurrent_iI_c20241231_z3q1o6RZKlY3" title="Warrant liability"><ix:nonFraction name="GTBP:WarrantLiabilityCurrent" contextRef="AsOf2024-12-31" id="Fact000758" format="ixt:numdotdecimal" decimals="0" unitRef="USD">252,000</ix:nonFraction></span> at September 30, 2025 and December 31, 2024, respectively,
was based on Level 3 measurements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 9; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact000760" name="GTBP:WarrantLiabilityPolicyTextBlock"><p id="xdx_84C_ecustom--WarrantLiabilityPolicyTextBlock_znv80nG0J326" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zvDShclBMqPf">Warrant
Liability</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded
derivatives in accordance with ASC Topic 815, &#8220;<i>Derivatives and Hedging</i>&#8221; (&#8220;ASC 815&#8221;). For derivative financial
instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued
at each reporting date, with changes in the fair value reported in the statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s use of derivative financial instruments is generally limited to warrants issued by the Company that do not meet the criteria
for equity treatment and are recorded as liabilities. We do not use financial instruments or derivatives for any trading purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact000762" name="GTBP:MezzanineEquityPolicyTextBlock"><p id="xdx_844_ecustom--MezzanineEquityPolicyTextBlock_z6RzHTez9cs" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_znPncSPyFdul">Mezzanine
Equity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where
ordinary or preferred shares are determined to be conditionally redeemable upon the occurrence of certain events that are not solely
within the control of the issuer, and upon such event, the shares would become redeemable at the option of the holders, they are classified
as &#8216;mezzanine equity&#8217; (temporary equity). The purpose of this classification is to convey that such a security may not be
permanently part of equity and could result in a demand for cash, securities or other assets of the entity in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity
instruments accounted as Mezzanine Equity upon issuance were reclassified to permanent equity as of September 30, 2025 as a result of
subsequent amendments to its terms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact000764" name="us-gaap:CompensationRelatedCostsPolicyTextBlock"><p id="xdx_84F_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zjXU3pwOpSWb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_z2zm6rYqIux5">Stock-Based
Compensation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically issues stock-based compensation to officers, directors, employees, and consultants for services rendered. Such issuances
vest and expire according to terms established at the issuance date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Stock-based
payments to officers, directors, employees, and consultants in exchange for goods and services, which include grants of employee stock
options, are recognized in the financial statements based on their grant date fair values in accordance with ASC 718, <i>Compensation-Stock
Compensation</i>. Stock based payments to officers, directors, employees, and consultants, which are generally time vested, are measured
at the grant date fair value and depending on the conditions associated with the vesting of the award, compensation cost is recognized
on a straight-line or graded basis over the vesting period. Recognition of compensation expense for non-employees is in the same period
and manner as if the Company had paid cash for the services. The fair value of stock options granted is estimated using the Black-Scholes
option-pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life, and future
dividends. The assumptions used in the Black-Scholes option pricing model could materially affect compensation expense recorded in future
periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact000766" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_84F_eus-gaap--ResearchAndDevelopmentExpensePolicy_zoaWReyyh736" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_ze9ZkJBcwOOj">Research
and Development Expenses</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
incurred for research and development are expensed as incurred. The salaries, benefits, and overhead costs of personnel conducting research
and development of the Company&#8217;s products are included in research and development expenses. Purchased materials that do not have
an alternative future use are also expensed. Purchased materials that have an alternative future are classified as a prepaid expense
and periodically reviewed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact000768" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_848_eus-gaap--EarningsPerSharePolicyTextBlock_zzBCiYRJkMD3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zF6xJODp9xh2">Net
Loss Per Share</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
earnings (loss) per share is computed using the weighted-average number of common shares outstanding during the period. Diluted earnings
(loss) per share is computed using the weighted-average number of common shares and the dilutive effect of contingent shares outstanding
during the period. Potentially dilutive contingent shares, which primarily consist of stock issuable upon exercise of stock options and
warrants, and the conversion of Series L convertible preferred stock, have been excluded from the diluted loss per share calculation
because their effect is anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact000770" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"><p id="xdx_895_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zQRDqxVjqmd1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following common stock equivalents were excluded in the computation of the net loss per share because their effect is anti-dilutive:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BC_zFCVDVlwp5S3" style="display: none">Schedule of Anti-dilutive Securities</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 75%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20250101__20250930_zXjs4YBnnFy1" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30, 2025</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20240101__20240930_zZTByQvbDlKb" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30, 2024</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesLConvertiblePreferredStockMember_z5lmL1gNdT8i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series L convertible preferred stock <b><sup id="xdx_F44_zukfJ2qB72Ld">1</sup></b></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-01-012025-09-30_custom_SeriesLConvertiblePreferredStockMember" id="Fact000772" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,649,792</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0773">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zkneGfjaH1oa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Options to purchase common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-01-012025-09-30_us-gaap_EmployeeStockOptionMember" id="Fact000775" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">597,550</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-09-30_us-gaap_EmployeeStockOptionMember" id="Fact000776" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">101,264</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zGwF1cKvFTk4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Warrants to purchase common stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-01-012025-09-30_us-gaap_WarrantMember" id="Fact000778" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">49,459,390</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-09-30_us-gaap_WarrantMember" id="Fact000779" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,133,762</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zbBEwqK4Rv6g" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total anti-dilutive securities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-01-01to2025-09-30" id="Fact000781" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">57,706,732</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-09-30" id="Fact000782" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,235,026</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b id="xdx_F0C_zQQiiyKcALwd"><sup>1</sup></b></span></td><td style="width: 5pt"/><td style="text-align: justify"><span id="xdx_F11_zV80lUlQoPQ9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000783" xml:lang="en-US">Converted into
common stock using a conversion price of $<span id="xdx_904_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20250930_zYB0aw7k7YA3" title="Conversion price per share" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEFudGktZGlsdXRpdmUgU2VjdXJpdGllcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__"><ix:nonFraction name="us-gaap:PreferredStockConvertibleConversionPrice" contextRef="AsOf2025-09-30" id="Fact000785" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.6421</ix:nonFraction></span> per share, as of September 30, 2025</ix:footnote></span></td>
</tr></table>

</ix:nonNumeric><p id="xdx_8AB_zYjDfXlXDxZb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 10; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact000787" name="us-gaap:ConcentrationRiskCreditRisk"><p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_zVcOgvqOXL45" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zI8KcYfr4PP4">Concentration</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
is deposited in one financial institution. The balances held at this financial institution at times may be in excess of Federal Deposit
Insurance Corporation (&#8220;FDIC&#8221;) insurance limits of up to $<span id="xdx_901_eus-gaap--CashFDICInsuredAmount_iI_c20250930_zazTR64ciLQ9" title="Cash, FDIC insured amount"><ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2025-09-30" id="Fact000789" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span>. <span style="background-color: white">Management believes
that the financial institutions that hold the Company&#8217;s cash are financially sound and, accordingly, minimal credit risk exists.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has a significant concentration of expenses incurred from and accounts payable to Cytovance Biologics, Inc. (&#8220;Cytovance&#8221;),
a related party, and the University of Minnesota, see Note 3 &#8211; Accounts Payable and Related Party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact000791" name="us-gaap:SegmentReportingPolicyPolicyTextBlock"><p id="xdx_84D_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zpOSaP5GOIGl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zEwLDVzX81k">Segment
Information</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s Chief Executive Officer and President (&#8220;CEO&#8221;) is our chief operating decision maker (&#8220;CODM&#8221;)
and evaluates performance and makes operating decisions about allocating resources based on financial data presented on a consolidated
basis. Because our CODM evaluates financial performance on a consolidated basis, the Company has determined that it operates as a single
reportable segment composed of the financial results of GT Biopharma, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact000793" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_84E_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zaTm6E90uhy" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_z7v0R6ZiqRR1">Recent
Accounting Pronouncements</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, the FASB issued ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic
220-40): Disaggregation of Income Statement Expenses, requiring public entities to disclose additional information about specific expense
categories in the notes to the financial statements on an interim and annual basis. ASU 2024-03 is effective for fiscal years beginning
after December 15, 2026, and for interim periods beginning after December 15, 2027, with early adoption permitted. The Company is currently
evaluating the impact of adopting ASU 2024-03.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s management has evaluated all the recently issued, but not yet effective, accounting standards and guidance that have
been issued or proposed by the FASB or other standards-setting bodies through the filing date of these financial statements and does
not believe the future adoption of any such pronouncements will have a material effect on the Company&#8217;s financial position and
results of operations.</span></p>

<p id="xdx_8A6_zBDZqEdgdO44" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact000795" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"><p id="xdx_808_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zJtD3LYhH6Jk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
3 &#8211; <span id="xdx_821_zkvjK0VSfOQ">Accounts Payable and Related Party</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact000797" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"><p id="xdx_897_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zVHMOQDwABa6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
payable consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B5_zsdbA4ezRKUa" style="display: none">Schedule of Accounts Payable</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.65in; border-collapse: collapse; width: 85%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49F_20250930_zPkCBJt4ATR4" style="font-weight: bold; text-align: center">As of</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_495_20241231_zbODJkCKqcsk" style="font-weight: bold; text-align: center">As of</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AccountsPayableTradeCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_za2mDomThWP7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts payable to Cytovance, a related party <b><sup id="xdx_F47_zmzpK4rGHVp4">1</sup></b></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableTradeCurrent" contextRef="AsOf2025-09-30_custom_CytovanceBiologicsIncMember" id="Fact000799" format="ixt:numdotdecimal" decimals="0" unitRef="USD">60,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_90D_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_pid_dp_uPure_c20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_fKDEp_zKjUDVBwg857" title="Accounts payable interest rate"><ix:nonFraction name="us-gaap:AccountsPayableInterestBearingInterestRate" contextRef="AsOf2025-09-30_custom_CytovanceBiologicsIncMember" id="Fact000802" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8</ix:nonFraction></span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableTradeCurrent" contextRef="AsOf2024-12-31_custom_CytovanceBiologicsIncMember" id="Fact000800" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,183,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_904_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_pid_dp_uPure_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_fKDEp_zcYtEMPQr9A4" title="Accounts payable interest rate"><ix:nonFraction name="us-gaap:AccountsPayableInterestBearingInterestRate" contextRef="AsOf2024-12-31_custom_CytovanceBiologicsIncMember" id="Fact000804" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">31</ix:nonFraction></span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_408_eus-gaap--AccountsPayableTradeCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UniversityOfMinnesotaMember_zXH5o1fGLKGa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accounts payable to University of Minnesota</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableTradeCurrent" contextRef="AsOf2025-09-30_custom_UniversityOfMinnesotaMember" id="Fact000806" format="ixt:numdotdecimal" decimals="0" unitRef="USD">463,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UniversityOfMinnesotaMember_z8HArOXnGgq" title="Accounts payable interest rate"><ix:nonFraction name="us-gaap:AccountsPayableInterestBearingInterestRate" contextRef="AsOf2025-09-30_custom_UniversityOfMinnesotaMember" id="Fact000809" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">60</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableTradeCurrent" contextRef="AsOf2024-12-31_custom_UniversityOfMinnesotaMember" id="Fact000807" format="ixt:numdotdecimal" decimals="0" unitRef="USD">712,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UniversityOfMinnesotaMember_zq8NtfZAYo26" title="Accounts payable interest rate"><ix:nonFraction name="us-gaap:AccountsPayableInterestBearingInterestRate" contextRef="AsOf2024-12-31_custom_UniversityOfMinnesotaMember" id="Fact000811" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">18</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr id="xdx_40C_eus-gaap--AccountsPayableTradeCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_zPYwIo9J9Peb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Legal services firm</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0813">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_zyWZGSlLRgC7" title="Accounts payable interest rate"><span style="-sec-ix-hidden: xdx2ixbrl0816">&#8212;</span></span>%</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableTradeCurrent" contextRef="AsOf2024-12-31_custom_LegalServicesFirmMember" id="Fact000814" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,505,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_zcGnnI9Zf6p7" title="Accounts payable interest rate"><ix:nonFraction name="us-gaap:AccountsPayableInterestBearingInterestRate" contextRef="AsOf2024-12-31_custom_LegalServicesFirmMember" id="Fact000818" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">39</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr id="xdx_40B_eus-gaap--AccountsPayableTradeCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_zGU3dht5cBp4" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0820">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;%</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableTradeCurrent" contextRef="AsOf2024-12-31_custom_LegalServicesFirmMember" id="Fact000821" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,505,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">39</td><td style="text-align: left">%</td></tr>
<tr id="xdx_404_eus-gaap--AccountsPayableOtherCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OtherAccountsPayableMember_z9rI6JugfKXi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Other accounts payable</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableOtherCurrent" contextRef="AsOf2025-09-30_custom_OtherAccountsPayableMember" id="Fact000823" format="ixt:numdotdecimal" decimals="0" unitRef="USD">246,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_907_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OtherAccountsPayableMember_zJZsPOzbZ5n6" title="Accounts payable interest rate"><ix:nonFraction name="us-gaap:AccountsPayableInterestBearingInterestRate" contextRef="AsOf2025-09-30_custom_OtherAccountsPayableMember" id="Fact000826" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">32</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left">%</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableOtherCurrent" contextRef="AsOf2024-12-31_custom_OtherAccountsPayableMember" id="Fact000824" format="ixt:numdotdecimal" decimals="0" unitRef="USD">453,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90F_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OtherAccountsPayableMember_zNl4LJWXBdlb" title="Accounts payable interest rate"><ix:nonFraction name="us-gaap:AccountsPayableInterestBearingInterestRate" contextRef="AsOf2024-12-31_custom_OtherAccountsPayableMember" id="Fact000828" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr id="xdx_40C_eus-gaap--AccountsPayableCurrent_iI_ztC94l3ZrcDk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total accounts payable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2025-09-30" id="Fact000830" format="ixt:numdotdecimal" decimals="0" unitRef="USD">769,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20250930_zbXyvJNRAWX3" title="Accounts payable interest rate"><ix:nonFraction name="us-gaap:AccountsPayableInterestBearingInterestRate" contextRef="AsOf2025-09-30" id="Fact000833" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2024-12-31" id="Fact000831" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,853,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20241231_zsFtxp3u4Rp9" title="Accounts payable interest rate"><ix:nonFraction name="us-gaap:AccountsPayableInterestBearingInterestRate" contextRef="AsOf2024-12-31" id="Fact000835" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span id="xdx_F0C_zauD72gr0fR1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><sup>1</sup></b></span></td><td style="width: 5pt"/><td style="text-align: justify"><span id="xdx_F1A_zuycTXv7bPnk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000836" xml:lang="en-US">Accounts Payable
to Cytovance, a related party, since Cytovance owns greater than 5% of the Company&#8217;s issued and outstanding common stock. See Note
7 &#8211; Commitments and Contingencies, Significant Agreements.</ix:footnote></span></td>
</tr></table>



</ix:nonNumeric><p id="xdx_8AF_z7qpSzEqnGU5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cytovance,
a Related Party</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact000838" name="GTBP:ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock"><p id="xdx_89C_ecustom--ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock_zRP0PaRVjNGc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
details of the Company&#8217;s accounts payable to Cytovance were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="display: none"><span id="xdx_8B6_zMcldOtFeIHd">Schedule of Accounts Payable to Related Party</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 75%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center"/><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_492_20250101__20250930_zV7l9V0nwTS6" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49D_20240101__20240930_zZqcGinV4shb" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine Months Ending</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AccountsPayableTradeCurrent_iS_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zmDQqzj4sENi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Beginning balance</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableTradeCurrent" contextRef="AsOf2024-12-31_custom_CytovanceBiologicsIncMember" id="Fact000840" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,183,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableTradeCurrent" contextRef="AsOf2023-12-31_custom_CytovanceBiologicsIncMember" id="Fact000841" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,515,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ProceedsFromRelatedPartyDebt_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zatWKkVN8o2f" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Invoices, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="From2025-01-012025-09-30_custom_CytovanceBiologicsIncMember" id="Fact000843" format="ixt:numdotdecimal" decimals="0" unitRef="USD">686,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="From2024-01-012024-09-30_custom_CytovanceBiologicsIncMember" id="Fact000844" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,365,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--RepaymentsOfRelatedPartyDebt_iN_di_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zkfc1ri0A3gb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Payments in cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="From2025-01-012025-09-30_custom_CytovanceBiologicsIncMember" id="Fact000846" format="ixt:numdotdecimal" decimals="0" unitRef="USD">962,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="From2024-01-012024-09-30_custom_CytovanceBiologicsIncMember" id="Fact000847" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,432,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--PaymentsForRepurchaseOfCommonStock_iN_di_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_znsAUxadALma" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Payments in common stock, at fair value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0849">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="From2024-01-012024-09-30_custom_CytovanceBiologicsIncMember" id="Fact000850" format="ixt:numdotdecimal" decimals="0" unitRef="USD">810,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_ecustom--RepaymentsOfPrefundedWarrantsAtFairValue_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zF8Hdx51h8Aj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Payments in pre-funded warrants, at fair value</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="GTBP:RepaymentsOfPrefundedWarrantsAtFairValue" contextRef="From2025-01-012025-09-30_custom_CytovanceBiologicsIncMember" id="Fact000852" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">847,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0853">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AccountsPayableTradeCurrent_iE_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zeSPOiiFsmI9" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Ending balance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableTradeCurrent" contextRef="AsOf2025-09-30_custom_CytovanceBiologicsIncMember" id="Fact000855" format="ixt:numdotdecimal" decimals="0" unitRef="USD">60,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableTradeCurrent" contextRef="AsOf2024-09-30_custom_CytovanceBiologicsIncMember" id="Fact000856" format="ixt:numdotdecimal" decimals="0" unitRef="USD">638,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_zfCeHtMx9Ih5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<ix:exclude><!-- Field: Page; Sequence: 11; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April and June 2024, the Company issued an aggregate of <span id="xdx_90F_ecustom--StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable_c20240401__20240430__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ze0OMsLkTEzh" title="Issuance of prefunded warrant to settle vendor payable, shares"><span id="xdx_90B_ecustom--StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable_c20240601__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwprfxvYjuE5" title="Issuance of prefunded warrant to settle vendor payable, shares"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable" contextRef="From2024-04-012024-04-30_us-gaap_CommonStockMember" id="Fact000858" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable" contextRef="From2024-06-012024-06-30_us-gaap_CommonStockMember" id="Fact000860" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">127,597</ix:nonFraction></ix:nonFraction></span></span> shares of common stock with a fair value of approximately $<span id="xdx_907_ecustom--StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable_c20240401__20240430__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zP2aeUDMMqp2" title="Issuance of prefunded warrant to settle vendor payable, value"><span id="xdx_90D_ecustom--StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable_c20240601__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zx1Ot95Rhm9i" title="Issuance of prefunded warrant to settle vendor payable, value"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable" contextRef="From2024-04-012024-04-30_us-gaap_CommonStockMember" id="Fact000862" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable" contextRef="From2024-06-012024-06-30_us-gaap_CommonStockMember" id="Fact000864" format="ixt:numdotdecimal" decimals="0" unitRef="USD">810,000</ix:nonFraction></ix:nonFraction></span></span> to
Cytovance as partial payment of accounts payable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2025, the Company issued pre-funded warrants to purchase up to <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zjvze5nLz6ie" title="Issuance of pre-funded warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-03-31_custom_CytovanceBiologicsIncMember" id="Fact000866" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">326,251</ix:nonFraction></span> shares of common stock exercisable at $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zKAPC1NI3lX9" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-03-31_custom_CytovanceBiologicsIncMember" id="Fact000868" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> per share
with a fair value of approximately $<span id="xdx_90D_ecustom--RepaymentsOfPrefundedWarrantsAtFairValue_iN_di_c20250301__20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zvvbUNDfQTW3" title="Payments in pre-funded warrants, at fair value"><ix:nonFraction name="GTBP:RepaymentsOfPrefundedWarrantsAtFairValue" contextRef="From2025-03-012025-03-31_custom_CytovanceBiologicsIncMember" id="Fact000870" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">847,000</ix:nonFraction></span> to Cytovance as partial payment of accounts payable. The pre-funded warrants were valued
at the market price on the last day of the month during the respective month that the invoices are due.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2025, a legal services firm currently engaged by the Company agreed to reduce the Company&#8217;s prior year unpaid fees by approximately
$<span id="xdx_902_eus-gaap--PaymentsForFees_pn6n6_c20250301__20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_z7PKbwX4b6O3" title="Prior year unpaid fees"><ix:nonFraction name="us-gaap:PaymentsForFees" contextRef="From2025-03-012025-03-31_custom_LegalServicesFirmMember" id="Fact000872" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">1</ix:nonFraction></span> million. The Company classified this transaction as other income.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>University
of Minnesota</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 7 &#8211; Commitments and Contingencies, Significant Agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PDPC
Advisors Inc., a Related Party</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 30, 2025, the Company entered into an Advisory Agreement (the &#8220;Agreement&#8221;) with PDPC Advisors Inc. (&#8220;PDPC&#8221;),
to perform certain advisory services. Under the Agreement cash payments amounting to $<span id="xdx_907_eus-gaap--RepaymentsOfOtherDebt_c20250601__20250630__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember_zsLGIWeNcQ4a" title="Cash payment"><ix:nonFraction name="us-gaap:RepaymentsOfOtherDebt" contextRef="From2025-06-012025-06-30_custom_AdvisoryAgreementMember" id="Fact000874" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span> are to be paid in six equal installments
beginning on July 1, 2025 and ending on December 31, 2025. In addition, upon execution of the Agreement, the Company issued to PDPC a
pre-funded warrant to purchase <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstanding_iI_c20250630__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember_zw2K4P0C7hM5" title="Warrants outstanding"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="AsOf2025-06-30_custom_AdvisoryAgreementMember" id="Fact000876" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,000</ix:nonFraction></span> shares of common stock of the Company, which had a fair value of $<span id="xdx_905_eus-gaap--PaymentsOfStockIssuanceCosts_c20250601__20250630__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember_zZRCwR7Suz3c" title="Stock issuance"><ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2025-06-012025-06-30_custom_AdvisoryAgreementMember" id="Fact000878" format="ixt:numdotdecimal" decimals="0" unitRef="USD">537,000</ix:nonFraction></span> at the time of issuance.
<span id="xdx_905_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20250601__20250630__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember_zdHcRNTtrRlc" title="Related party transaction description"><ix:nonNumeric contextRef="From2025-06-012025-06-30_custom_AdvisoryAgreementMember" id="Fact000880" name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction">The Agreement begins on July 1, 2025 and terminates on June 30, 2026. PDPC is considered a related party as its CEO is an individual
who has voting and investment control over an entity whose beneficial ownership exceeded 5% of the issued and outstanding shares of the
Company&#8217;s common stock.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact000882" name="GTBP:WarrantLiabilityTextBlock"><p id="xdx_80C_ecustom--WarrantLiabilityTextBlock_z9XQ8r7o1ui4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
4 &#8211; <span id="xdx_823_z1Hv2m00lTj2">Warrant Liability</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023
Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 4, 2023, as part of the private placement offering, the Company issued warrants to purchase up to an aggregate of <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230104__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentyThreeCommonWarrantsMember__srt--RangeAxis__srt--MaximumMember_z0jYKakzILe2" title="Warrants to purchase"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-01-04_custom_TwoThousandTwentyThreeCommonWarrantsMember_srt_MaximumMember" id="Fact000884" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">216,667</ix:nonFraction></span> shares
of the Company&#8217;s common stock (the &#8220;2023 Common Warrants&#8221;), and placement agent warrants to purchase up to <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230104__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentyThreePlacementAgentsWarrantsMember__srt--RangeAxis__srt--MaximumMember_zkjK6gi1nXR" title="Warrants to purchase"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-01-04_custom_TwoThousandTwentyThreePlacementAgentsWarrantsMember_srt_MaximumMember" id="Fact000886" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,000</ix:nonFraction></span> shares
of the Company&#8217;s common stock (the &#8220;2023 Placement Agents Warrants&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2023 Common Warrants and the 2023 Placement Agents Warrants (collectively the &#8220;2023 Warrants&#8221;), provide for a value calculation
for the warrants using the Black Scholes model in the event of certain fundamental transactions. The fair value calculation provides
for a floor on the volatility amount utilized in the value calculation at <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230104__20230104__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentyThreeWarrantsMember_zbesnlHgVKw2" title="Volatility amount utilized in the value calculation percentage"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2023-01-042023-01-04_custom_TwoThousandTwentyThreeWarrantsMember" id="Fact000888" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span>% or greater. The Company has determined this provision
introduces leverage to the holders that could result in a value that would be greater than the settlement amount of a fixed-for-fixed
option on the Company&#8217;s own equity shares. Therefore, pursuant to ASC 815, the Company has classified the 2023 Warrants as a liability
in its balance sheet. The classification of the 2023 Warrants, including whether they should be recorded as liability or as equity, is
evaluated at the end of each reporting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2023 Warrants were initially recorded at a fair value at $<span id="xdx_900_eus-gaap--WarrantsAndRightsOutstanding_iI_pn5n6_c20230104__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentyThreeWarrantsMember_zU121x20o7o4" title="Warrant  fair value"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="AsOf2023-01-04_custom_TwoThousandTwentyThreeWarrantsMember" id="Fact000890" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.8</ix:nonFraction></span> million at the grant date, and upon the closing of placement, was recorded
as a cost of capital. The fair value of the 2023 Warrants classified as a liability in the Company&#8217;s unaudited condensed balance
sheets and will be re-measured at the end of every reporting period with the change in value reported in the unaudited condensed statements
of operations until they are either exercised or expired.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-012025-09-30_custom_TwoThousandTwentyThreeWarrantsMember" escape="true" id="Fact000892" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"><p id="xdx_891_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hus-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_zNBFfx9SPuOi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2023 Warrant liability is valued using a Black Scholes Option pricing model with the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B8_zWjZ7Hx5lTx9" style="display: none">Schedule of Warrant Liability Assumptions</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 75%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023 Warrants</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Stock price</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_zLJNysyStj71" title="Warrants measurement input" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2025-09-30_us-gaap_MeasurementInputSharePriceMember_custom_TwoThousandTwentyThreeWarrantsMember" id="Fact000894" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.59</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_zGijmKtKrnD" title="Warrants measurement input" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-31_us-gaap_MeasurementInputSharePriceMember_custom_TwoThousandTwentyThreeWarrantsMember" id="Fact000896" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.05</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free interest rate <b><sup>1</sup></b></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fMQ_____zULjtQhhpXck" title="Warrants measurement input" style="text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2025-09-30_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_TwoThousandTwentyThreeWarrantsMember" id="Fact000898" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">3.61</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fMQ_____zq4NwV2DTbR9" title="Warrants measurement input" style="text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_TwoThousandTwentyThreeWarrantsMember" id="Fact000900" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">4.27</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected volatility <b><sup>2</sup></b></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fMg_____zc00RU4JLLt7" title="Warrants measurement input" style="text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2025-09-30_us-gaap_MeasurementInputPriceVolatilityMember_custom_TwoThousandTwentyThreeWarrantsMember" id="Fact000902" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">110</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fMg_____zNZTlpAwVrz" title="Warrants measurement input" style="text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_TwoThousandTwentyThreeWarrantsMember" id="Fact000904" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">114</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected life (in years) <b><sup>3</sup></b></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember__srt--RangeAxis__srt--MinimumMember_fMw_____zInI89XGEZB5" title="Expected life (in years)"><ix:nonNumeric contextRef="AsOf2025-09-30_us-gaap_MeasurementInputExpectedTermMember_custom_TwoThousandTwentyThreeWarrantsMember_srt_MinimumMember" format="ixt-sec:duryear" id="Fact000906" name="us-gaap:WarrantsAndRightsOutstandingTerm">2.25</ix:nonNumeric></span> &#8211; <span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember__srt--RangeAxis__srt--MaximumMember_fMw_____zvxxIyKx9oHk" title="Expected life (in years)"><ix:nonNumeric contextRef="AsOf2025-09-30_us-gaap_MeasurementInputExpectedTermMember_custom_TwoThousandTwentyThreeWarrantsMember_srt_MaximumMember" format="ixt-sec:duryear" id="Fact000908" name="us-gaap:WarrantsAndRightsOutstandingTerm">2.76</ix:nonNumeric></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember__srt--RangeAxis__srt--MinimumMember_fMw_____ziFUP3rBV05k" title="Expected life (in years)"><ix:nonNumeric contextRef="AsOf2024-12-31_us-gaap_MeasurementInputExpectedTermMember_custom_TwoThousandTwentyThreeWarrantsMember_srt_MinimumMember" format="ixt-sec:duryear" id="Fact000910" name="us-gaap:WarrantsAndRightsOutstandingTerm">3.0</ix:nonNumeric></span> &#8211; <span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember__srt--RangeAxis__srt--MaximumMember_fMw_____z1srIpYXvahf" title="Expected life (in years)"><ix:nonNumeric contextRef="AsOf2024-12-31_us-gaap_MeasurementInputExpectedTermMember_custom_TwoThousandTwentyThreeWarrantsMember_srt_MaximumMember" format="ixt-sec:duryear" id="Fact000912" name="us-gaap:WarrantsAndRightsOutstandingTerm">3.50</ix:nonNumeric></span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected dividend yield <b><sup>4</sup></b></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fNA_____z5JzdFvXs74h" title="Warrants measurement input" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0914">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fNA_____zCh0lwsjSzVc" title="Warrants measurement input" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0916">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Fair value of warrants</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--FairValueAdjustmentOfWarrants_c20250101__20250930__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_znWjiU7lWKzi" title="Fair value of warrants" style="text-align: right"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2025-01-012025-09-30_custom_TwoThousandTwentyThreeWarrantsMember" id="Fact000918" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_z6ZUOUOr0Yle" title="Fair value of warrants" style="text-align: right"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-01-012024-12-31_custom_TwoThousandTwentyThreeWarrantsMember" id="Fact000920" format="ixt:numdotdecimal" decimals="0" unitRef="USD">252,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><sup>&#160;</sup></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b id="xdx_F0D_zYErwEVo5Yh2"><sup>1</sup></b></span></td><td style="width: 5pt"/><td style="text-align: justify"><span id="xdx_F12_zWAhoOiEQ2p4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000921" xml:lang="en-US">Based on rates
established by the Federal Reserve Bank</ix:footnote></span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b id="xdx_F04_zuzIqXJv6Heg"><sup>2</sup></b></span></td><td style="width: 5pt"/><td style="text-align: justify"><span id="xdx_F18_znCoxutDAss8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000922" xml:lang="en-US">Historical volatility
of the Company&#8217;s common stock is used to estimate the future volatility of its common stock</ix:footnote></span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span id="xdx_F03_z7LK8N3afFF3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><sup>3</sup></b></span></td><td style="width: 5pt"/><td style="text-align: justify"><span id="xdx_F19_zHgePmiMPZt5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000923" xml:lang="en-US">Determined by the
remaining contractual life of the derivative instrument</ix:footnote></span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b id="xdx_F0D_zaBKs5VLDYW9"><sup>4</sup></b></span></td><td style="width: 5pt"/><td style="text-align: justify"><span id="xdx_F1A_zabJbDUIuca3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000924" xml:lang="en-US">Based on no dividends
paid or expected to be paid</ix:footnote></span></td>
</tr></table>

</ix:nonNumeric><p id="xdx_8A6_zVTirCa3aaY8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 12; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact000926" name="us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"><p id="xdx_89B_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zS1ssbT5Gvm6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
details of warrant liability transactions were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BF_zd2V521KWH91" style="display: none">Schedule of Warrant Liability Transactions</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 75%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49C_20250101__20250930_znewNSHF8QP9" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49C_20240101__20240930_z831OcIKrEY7" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine Months Ending</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_ecustom--WarrantLiabilityCurrent_iS_zcqzMKyIIuj1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Beginning balance</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="GTBP:WarrantLiabilityCurrent" contextRef="AsOf2024-12-31" id="Fact000928" format="ixt:numdotdecimal" decimals="0" unitRef="USD">252,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="GTBP:WarrantLiabilityCurrent" contextRef="AsOf2023-12-31" id="Fact000929" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,052,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IssuanceOfStockAndWarrantsForServicesOrClaims_zLXpDWrQTXu8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Issuance of warrants at fair value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0931">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0932">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_zY8WYsozPh3f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Change in fair value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" contextRef="From2025-01-01to2025-09-30" id="Fact000934" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">244,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" contextRef="From2024-01-012024-09-30" id="Fact000935" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">870,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_ecustom--ExtinguishmentOfWarrant_zZhKbNjqBTJh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1pt">Extinguishment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0937">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0938">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--WarrantLiabilityCurrent_iE_zSyhNnzQCCA8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Ending balance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="GTBP:WarrantLiabilityCurrent" contextRef="AsOf2025-09-30" id="Fact000940" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="GTBP:WarrantLiabilityCurrent" contextRef="AsOf2024-09-30" id="Fact000941" format="ixt:numdotdecimal" decimals="0" unitRef="USD">182,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AC_z3ojhHHCiXmf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact000943" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_804_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zM4aRlEgIoDe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
5 &#8211; <span id="xdx_826_zSs3qfoGQvm9">Stockholders&#8217; Equity (Deficit)</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s authorized capital as of September 30, 2025 was <span id="xdx_905_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20250930_zotYYF0QbOD" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2025-09-30" id="Fact000945" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">250,000,000</ix:nonFraction></span> shares of common stock, par value $<span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20250930_z5F4QeLkQ093" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2025-09-30" id="Fact000947" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span> per share, and <span id="xdx_90D_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20250930_zbweAxEGc3pa" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2025-09-30" id="Fact000949" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,000,000</ix:nonFraction></span>
shares of preferred stock, par value $<span id="xdx_908_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20250930_zZvnJTZWc9ra" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2025-09-30" id="Fact000951" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></span> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2025
Private Placement of Equity Facility</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 14, 2025, and as amended on June 10, 2025, the Company entered into a common shares purchase agreement (the &#8220;Purchase Agreement&#8221;)
with investors (collectively, the &#8220;Investors&#8221;) relating to a committed equity facility (the &#8220;Facility&#8221;). Pursuant
to the Purchase Agreement, the Company has the right from time to time at its option to sell to the Investors up to $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_pn6n6_c20250514__20250514__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zDVzuO1CXkJ5" title="Warrants to purcahse"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2025-05-142025-05-14_custom_PurchaseAgreementMember" id="Fact000953" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">20</ix:nonFraction></span> million of its
common stock subject to certain conditions and limitations set forth in the Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of the shares of common stock to the Investors under the Purchase Agreement, and the timing of any sales, will be determined by the Company
from time to time in its sole discretion and will depend on a variety of factors, including, among other things, market conditions, the
trading price of the common stock and determinations by the Company regarding the use of proceeds from the sale of such shares of common
stock. The net proceeds from any sales under the Purchase Agreement will depend on the frequency with, and prices at, which the shares
of common stock are sold to the Investors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
purchase price of the shares of common stock that the Company elects to sell to the Investors pursuant to the Purchase Agreement will
be <span id="xdx_90F_ecustom--WeightedAverageVolumePriceOfCommonStockPercentage_pid_dp_uPure_c20250514__20250514__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_z3wAuLvWfJag" title="Weighted average volume price of common stock percentage"><ix:nonFraction name="GTBP:WeightedAverageVolumePriceOfCommonStockPercentage" contextRef="From2025-05-142025-05-14_custom_PurchaseAgreementMember" id="Fact000955" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">93</ix:nonFraction></span>% of the volume weighted average price of the shares of common stock during the applicable purchase date on which the Company has
timely delivered written notice to the Investors directing it to purchase shares of common stock under the Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the execution of the Purchase Agreement, the Company agreed to issue to the Investors pre-funded warrants to purchase
an aggregate of <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250514__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zj2V9IhH8Vkf" title="Warrants to purcahse"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-05-14_custom_PurchaseAgreementMember" id="Fact000957" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">300,000</ix:nonFraction></span> shares of common stock as consideration for their irrevocable commitment to purchase the shares of common stock
upon the terms and subject to the satisfaction of the conditions set forth in the Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2025
Warrant Inducement Transaction</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 26, 2025, the Company received gross proceeds of $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_c20250226__20250226_zEs2IHD2nizg" title="Proceeds from private placement"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="From2025-02-262025-02-26" id="Fact000959" format="ixt:numdotdecimal" decimals="0" unitRef="USD">686,000</ix:nonFraction></span> before deducting placement agent fees and other offering expenses
of $<span id="xdx_908_eus-gaap--NoninterestExpenseOfferingCost_c20250226__20250226_zADJLQR8FZp2" title="Other offering expenses"><ix:nonFraction name="us-gaap:NoninterestExpenseOfferingCost" contextRef="From2025-02-262025-02-26" id="Fact000961" format="ixt:numdotdecimal" decimals="0" unitRef="USD">70,000</ix:nonFraction></span> in relation to a warrant exercise inducement agreement with certain holders of existing warrants. The existing warrants were
exercisable into <span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_iI_c20250226_zhToVOKHakR8" title="Issuance of warrants, exercisable"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" contextRef="AsOf2025-02-26" id="Fact000963" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">302,069</ix:nonFraction></span> shares of the Company&#8217;s common stock at $<span id="xdx_908_eus-gaap--SharePrice_iI_c20250226__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z3IzXbvFzyid" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2025-02-26_us-gaap_CommonStockMember" id="Fact000965" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.35</ix:nonFraction></span> per share. The holders agreed to exercise these existing
warrants at a reduced exercise price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250226__us-gaap--StatementEquityComponentsAxis__custom--InducementWarrantsMember_zO5DN5VS6rYh" title="Share price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-02-26_custom_InducementWarrantsMember" id="Fact000967" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.27</ix:nonFraction></span> per share in exchange for the Company&#8217;s agreement to issue the holders new warrants
(the &#8220;Inducement Warrants&#8221;) exercisable for an aggregate of up to <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250226__us-gaap--StatementEquityComponentsAxis__custom--InducementWarrantsMember_z7uBOwRJOfCl" title="Issuance of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-02-26_custom_InducementWarrantsMember" id="Fact000969" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">604,138</ix:nonFraction></span> shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Inducement Warrants consist of (i) new Series A Inducement Warrants, representing warrants to purchase up to <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250226__us-gaap--StatementEquityComponentsAxis__custom--SeriesAInducementWarrantsMember_zf5ihwX5oo5e" title="Issuance of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-02-26_custom_SeriesAInducementWarrantsMember" id="Fact000971" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">302,069</ix:nonFraction></span> shares of Common
Stock at $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250226__us-gaap--StatementEquityComponentsAxis__custom--SeriesAInducementWarrantsMember_zmYrpu6rGlp5" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-02-26_custom_SeriesAInducementWarrantsMember" id="Fact000973" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.02</ix:nonFraction></span> per share exercisable immediately upon issuance with a term of <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_c20250226__us-gaap--StatementEquityComponentsAxis__custom--SeriesAInducementWarrantsMember_zpqpCetQluIh" title="Warrant term"><ix:nonNumeric contextRef="AsOf2025-02-26_custom_SeriesAInducementWarrantsMember" format="ixt-sec:durwordsen" id="Fact000975" name="us-gaap:WarrantsAndRightsOutstandingTerm">five years</ix:nonNumeric></span> from the date of issuance, and (ii) new Series
B Inducement Warrants, representing warrants to purchase up to <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250226__us-gaap--StatementEquityComponentsAxis__custom--SeriesBInducementWarrantsMember_zivr0O9X0lnf" title="Issuance of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-02-26_custom_SeriesBInducementWarrantsMember" id="Fact000977" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">302,069</ix:nonFraction></span> shares of common stock at $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250226__us-gaap--StatementEquityComponentsAxis__custom--SeriesBInducementWarrantsMember_zfzJnpckr2x1" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-02-26_custom_SeriesBInducementWarrantsMember" id="Fact000979" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.02</ix:nonFraction></span> per share exercisable immediately
upon issuance with a term of <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20250226__us-gaap--StatementEquityComponentsAxis__custom--SeriesBInducementWarrantsMember_zyrBitJRRTVi" title="Warrant term"><ix:nonNumeric contextRef="AsOf2025-02-26_custom_SeriesBInducementWarrantsMember" format="ixt-sec:durwordsen" id="Fact000981" name="us-gaap:WarrantsAndRightsOutstandingTerm">eighteen months</ix:nonNumeric></span> from the date of issuance. In addition, the Company issued warrants to the placement agent
to purchase <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250226_zSV3RSIy3w45" title="Placement agents"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-02-26" id="Fact000983" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">21,145</ix:nonFraction></span> shares of common stock at $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250226_zTnR3WTxnmt1" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-02-26" id="Fact000985" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.8375</ix:nonFraction></span> per share exercisable immediately upon issuance with a term of <span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_c20250226_zxqj6rLc5lK4" title="Warrant term"><ix:nonNumeric contextRef="AsOf2025-02-26" format="ixt-sec:durwordsen" id="Fact000987" name="us-gaap:WarrantsAndRightsOutstandingTerm">five years</ix:nonNumeric></span> from the
date of issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 13; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determined that under ASC 815, the 2025 inducement and placement agent warrants are considered indexed to the Company&#8217;s
own stock and eligible for an exception from derivative accounting. Accordingly, the fair value of the 2025 inducement and placement
agent warrants are classified as equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognized the aggregate effect of the modification of warrants and grant of inducement warrants of $<span id="xdx_90B_eus-gaap--PaymentsOfStockIssuanceCosts_pn5n6_c20250101__20250930_zvIZsfTHl78g" title="Equity issuance cost"><ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2025-01-01to2025-09-30" id="Fact000989" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.1</ix:nonFraction> </span>million as an equity
issuance cost and the accounting effect is recognized in the Statement of Stockholders&#8217; Equity (Deficit).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preferred
Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series
C Preferred Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2025, there were <span id="xdx_907_eus-gaap--PreferredStockSharesIssued_iI_pid_c20250930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zkTpTyCFB2Fd" title="Preferred stock, shares issued"><span id="xdx_908_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20250930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_z7RVvDQTJ5ca" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2025-09-30_us-gaap_SeriesCPreferredStockMember" id="Fact000991" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2025-09-30_us-gaap_SeriesCPreferredStockMember" id="Fact000993" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">96,230</ix:nonFraction></ix:nonFraction></span></span> shares of series C preferred stock, par value $<span id="xdx_904_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20250930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zpJbpcyPk0V" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2025-09-30_us-gaap_SeriesCPreferredStockMember" id="Fact000995" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></span> per share (the &#8220;Series C Preferred
Stock&#8221;) issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of numerous reverse stock-splits in previous years and the agreement terms for adjusting the rights of the related shares, the
<span id="xdx_90A_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20250930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zMVJ1oEI7zh8" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2025-09-30_us-gaap_SeriesCPreferredStockMember" id="Fact000997" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">96,230</ix:nonFraction></span> shares of Series C Preferred Stock are convertible into an infinitesimal amount of common stock, have no voting rights, and in
the event of liquidation, the holders of the Series C Preferred Stock would not participate in any distribution of the assets or surplus
funds of the Company. The holders of Series C Preferred Stock also are not currently entitled to any dividends if and when declared by
the Board. No dividends to holders of the Series C Preferred Stock were declared or unpaid through September 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series
L Convertible Preferred Stock and Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 12, 2025 (as amended May 21, 2025), the Company entered into a securities purchase agreement (the &#8220;Securities Purchase
Agreement&#8221;) with certain purchasers (the &#8220;Purchasers&#8221;) providing for the issuance and sale of (i) <span id="xdx_90F_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pp2d_c20250512__20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember_ztx6S0x1T4Kk" title="Issuance of shares"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2025-05-122025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_SeriesLTenPercentConvertiblePreferredStockMember" id="Fact000999" format="ixt:numdotdecimal" decimals="2" unitRef="Shares">6,611.11</ix:nonFraction></span>
shares of the Company&#8217;s Series L 10% Convertible Preferred Stock (the &#8220;Series L Convertible Preferred Stock&#8221;) with
an aggregate stated value of $<span id="xdx_908_ecustom--AggregateStatedValue_c20250512__20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember_z7DyNRduahDi" title="Aggregate stated value"><ix:nonFraction name="GTBP:AggregateStatedValue" contextRef="From2025-05-122025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_SeriesLTenPercentConvertiblePreferredStockMember" id="Fact001001" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,611,111</ix:nonFraction></span>,
(ii) warrants to purchase up to <span id="xdx_90E_ecustom--ClassOfWarrantsPurchaseUpPercentage_iI_pid_c20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember_zKaSxg7t3qf7" title="Warrants purchase up percentage"><ix:nonFraction name="GTBP:ClassOfWarrantsPurchaseUpPercentage" contextRef="AsOf2025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_SeriesLTenPercentConvertiblePreferredStockMember" id="Fact001003" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">100</ix:nonFraction></span>%
of the shares of the Company&#8217;s common stock issuable upon conversion of the shares of Series L Convertible Preferred Stock
(the &#8220;Common Warrants&#8221;), and (iii) warrants to purchase up to the number of Greenshoe Conversion Shares (as defined in
the Securities Purchase Agreement) issuable upon exercise of the Greenshoe Right (as defined below) (the &#8220;Vesting
Warrants&#8221;, and together with the Common Warrants, the &#8220;Warrants&#8221;). The aggregate purchase price of the Series L
Convertible Preferred Stock and Warrants was $<span id="xdx_900_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20250512__20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember_zYHvRursQSS" title="Issuance of shares, value"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2025-05-122025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_SeriesLTenPercentConvertiblePreferredStockMember" id="Fact001005" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,950,000</ix:nonFraction></span>,
and net proceeds was $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_c20250512__20250512__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_zWaz6954aBbe" title="Proceeds from issuance of preferred stock and warrants, net"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" contextRef="From2025-05-122025-05-12_custom_SeriesLPreferredStockMember" id="Fact001007" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,441,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Securities Purchase Agreement, each Purchaser may elect to purchase shares of Series L Convertible Preferred Stock with an aggregate
stated value of up to $<span id="xdx_904_ecustom--AggregateStatedValue_c20250512__20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--GreenshoeRightsMember_zE5QoHpFxzFk" title="Aggregate stated value"><ix:nonFraction name="GTBP:AggregateStatedValue" contextRef="From2025-05-122025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_GreenshoeRightsMember" id="Fact001009" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,018,349</ix:nonFraction></span> (the &#8220;Greenshoe Rights&#8221;) for an aggregate purchase price of $<span id="xdx_90D_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20250512__20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--GreenshoeRightsMember_zjptJeHHx12a" title="Issuance of shares, value"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2025-05-122025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_GreenshoeRightsMember" id="Fact001011" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,616,514</ix:nonFraction></span>, subject to adjustments.
Each Purchaser is entitled to exercise its respective Greenshoe Rights in the ratio of such Purchaser&#8217;s original subscription amount
to the original aggregate subscription amounts of all Purchasers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 12, 2025, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series L 10% Convertible Preferred
Stock (the &#8220;Certificate of Designation&#8221;) with the Secretary of State of the State of Delaware. On May 22, 2025, the Company
increased the shares of Series L Convertible Preferred Stock from <span id="xdx_904_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250522__20250522__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember__srt--RangeAxis__srt--MinimumMember_zpZQME2P54qd" title="Issuance of shares"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2025-05-222025-05-22_custom_SeriesLTenPercentConvertiblePreferredStockMember_srt_MinimumMember" id="Fact001013" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">28,056</ix:nonFraction></span> shares to<span id="xdx_905_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250522__20250522__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember__srt--RangeAxis__srt--MaximumMember_zvktF17NJYZ3" title="Issuance of shares"> <ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2025-05-222025-05-22_custom_SeriesLTenPercentConvertiblePreferredStockMember_srt_MaximumMember" id="Fact001015" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">30,630</ix:nonFraction></span> shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Certificate of Designation and subject to certain ownership limitations, the Series L Convertible Preferred Stock may be converted
at any time at the option of the Purchasers into shares of the Company&#8217;s common stock at an initial conversion price of $<span id="xdx_909_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember_z5PwysY2uhSf" title="Conversion price per share"><ix:nonFraction name="us-gaap:PreferredStockConvertibleConversionPrice" contextRef="AsOf2025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_SeriesLTenPercentConvertiblePreferredStockMember" id="Fact001017" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.043</ix:nonFraction></span>,
subject to certain conditions. In addition, the holders of the Series L Convertible Preferred Stock are entitled to receive cumulative
dividends at the rate of <span id="xdx_909_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_c20250511__20250511__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember_znLwgML2v0L5" title="Percentage of dividend"><ix:nonFraction name="us-gaap:PreferredStockDividendRatePercentage" contextRef="From2025-05-112025-05-11_custom_SecuritiesPurchaseAgreementMember_custom_SeriesLTenPercentConvertiblePreferredStockMember" id="Fact001019" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span>% per annum until May 11, 2026, increasing to <span id="xdx_903_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_c20250512__20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember_z2WK8sCAKFfj" title="Percentage of dividend"><ix:nonFraction name="us-gaap:PreferredStockDividendRatePercentage" contextRef="From2025-05-122025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_SeriesLTenPercentConvertiblePreferredStockMember" id="Fact001021" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12</ix:nonFraction></span>% per annum thereafter. The dividends are payable quarterly
in cash, shares of the Company&#8217;s common stock, or a combination thereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Securities Purchase Agreement, each Purchaser was issued (i) a Common Warrant and (ii) a Vesting Warrant. An aggregate of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pp2d_c20250512__20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonWarrantsMember_za6m4cSDSyic" title="Number of shares issued"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2025-05-122025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_SeriesLTenPercentConvertiblePreferredStockMember_custom_CommonWarrantsMember" id="Fact001023" format="ixt:numdotdecimal" decimals="2" unitRef="Shares">3,235,978</ix:nonFraction></span>
Common Warrants were issued with an initial exercise price of $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonWarrantsMember_zxyOdy8sH6g1" title="Exercise price per share"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_CommonWarrantsMember" id="Fact001025" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.043</ix:nonFraction></span> per share, are exercisable immediately subject to certain ownership
limitations, and have a term of <span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonWarrantsMember_zAenxlZYBXU9" title="Warrants term"><ix:nonNumeric contextRef="AsOf2025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_CommonWarrantsMember" format="ixt-sec:durwordsen" id="Fact001027" name="us-gaap:WarrantsAndRightsOutstandingTerm">five years</ix:nonNumeric></span>. An aggregate of <span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pp2d_c20250512__20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonWarrantsMember_zn3lRSHIIg6j" title="Aggregate number of shares vested"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2025-05-122025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_SeriesLTenPercentConvertiblePreferredStockMember_custom_CommonWarrantsMember" id="Fact001029" format="ixt:numdotdecimal" decimals="2" unitRef="Shares">11,576,406</ix:nonFraction></span> Vesting Warrants were issued with an initial exercise price of
$<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--VestingWarrantsMember_zcR0fgUyrS35" title="Exercise price per share"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_VestingWarrantsMember" id="Fact001031" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.043</ix:nonFraction></span> per share, are exercisable immediately subject to certain vesting and ownership limitations, and have a term of <span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonWarrantsMember_z3xGkqNl52L1" title="Warrants term"><ix:nonNumeric contextRef="AsOf2025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_CommonWarrantsMember" format="ixt-sec:durwordsen" id="Fact001033" name="us-gaap:WarrantsAndRightsOutstandingTerm">five years</ix:nonNumeric></span> from
the date that the applicable warrant shares vest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Preferred Shares and Warrants both have full-ratchet price and anti-dilution protections and are subject to other adjustments, as
further described in the Certificate of Designation or the Warrants, as applicable, subject, solely with respect to adjustments in
connection with the exercise of Greenshoe Rights, a floor price of $<span id="xdx_90A_eus-gaap--DerivativeFloorPrice_iI_pid_uUSDPShares_c20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--GreenshoeRightsMember_zPcYycTzBZZ3" title="Floor price"><ix:nonFraction name="us-gaap:DerivativeFloorPrice" contextRef="AsOf2025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_GreenshoeRightsMember" id="Fact001035" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.454</ix:nonFraction></span>
per share (subject to adjustment for reverse and forward splits, recapitalizations and similar transactions).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company and the Purchasers entered into a registration rights agreement pursuant to which the Company agreed to file a registration statement
with the Securities and Exchange Commission covering the public resale of the common stock issuable upon conversion of the Series L Convertible
Preferred Stock and upon exercise of the Warrants. The Company agreed to file a registration statement within 30 days after the initial
closing and after each closing of the exercise of a Greenshoe Right in accordance with the Securities Purchase Agreement, to become effective
no later than 90 days after filing. If these deadlines are not met,<span id="xdx_904_ecustom--LiableOfLiquidatedDamagePercentageDescription_c20250512__20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zd3819ibNCHa" title="Liable of liquidated damage percentage, description"> <ix:nonNumeric contextRef="From2025-05-122025-05-12_custom_SecuritiesPurchaseAgreementMember" id="Fact001037" name="GTBP:LiableOfLiquidatedDamagePercentageDescription">the Company will be liable for liquidated damages of 1.5% of the
subscription amount paid by each Purchaser. Further, if the Company fails to pay such liquidated damages within 7 days from the date
payable, the Company will pay interest thereon at the prime rate plus 12% to each holder of the registrable securities.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 14; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Securities Purchase Agreement, the Company agreed to hold a meeting of its stockholders at the earliest practical date after the
execution of the Securities Purchase Agreement for the purpose of obtaining stockholder approval for the issuance, in the aggregate,
of more than <span id="xdx_90E_ecustom--CommonStockSharesOutstandingPercentage_pid_dp_c20250512__20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z5HNrNTGJ4Ei" title="Common stock shares outstanding percentage"><ix:nonFraction name="GTBP:CommonStockSharesOutstandingPercentage" contextRef="From2025-05-122025-05-12_custom_SecuritiesPurchaseAgreementMember" id="Fact001039" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">19.99</ix:nonFraction></span>% of the number of shares of the Company&#8217;s common stock outstanding on the date of the initial closing (&#8220;Shareholder
Approval&#8221;). Shareholder Approval was obtained on July 24, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended September 30, 2025, Purchasers of the Company&#8217;s Series L 10% Convertible Preferred Stock elected to
exercise their Greenshoe Rights and purchased <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250701__20250930__us-gaap--StatementClassOfStockAxis__custom--SeriesL10PercentageConvertiblePreferredStockMember_z78FKOCsAIEb" title="Shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-07-012025-09-30_custom_SeriesL10PercentageConvertiblePreferredStockMember" id="Fact001041" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,222.22</ix:nonFraction></span>
shares of the Company&#8217;s Series L 10% Convertible Preferred Stock with a stated value of $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pid_c20250701__20250930__us-gaap--StatementClassOfStockAxis__custom--SeriesL10PercentageConvertiblePreferredStockMember_zoTvKkAKtP6g" title="Shares issued value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-07-012025-09-30_custom_SeriesL10PercentageConvertiblePreferredStockMember" id="Fact001043" format="ixt:numdotdecimal" decimals="INF" unitRef="USD">1,222,222</ix:nonFraction></span>
for a purchase price of $<span id="xdx_90B_ecustom--PreferredStockPurchasePrice_c20250701__20250930__us-gaap--StatementClassOfStockAxis__custom--SeriesL10PercentageConvertiblePreferredStockMember_z5BxqfcEo2Kd" title="Purchase price"><ix:nonFraction name="GTBP:PreferredStockPurchasePrice" contextRef="From2025-07-012025-09-30_custom_SeriesL10PercentageConvertiblePreferredStockMember" id="Fact001045" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,100,000</ix:nonFraction></span>.
As a result of the transactions, the conversion price of the Series L 10% Convertible Preferred Stock was decreased from $<span id="xdx_90C_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20250929__us-gaap--StatementClassOfStockAxis__custom--SeriesL10PercentageConvertiblePreferredStockMember_z5p2cekScWQl" title="Exercise price"><ix:nonFraction name="us-gaap:PreferredStockConvertibleConversionPrice" contextRef="AsOf2025-09-29_custom_SeriesL10PercentageConvertiblePreferredStockMember" id="Fact001047" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.043</ix:nonFraction></span>
to $<span id="xdx_902_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20250930__us-gaap--StatementClassOfStockAxis__custom--SeriesL10PercentageConvertiblePreferredStockMember_zqeHfw1J9l0i" title="Exercise price"><ix:nonFraction name="us-gaap:PreferredStockConvertibleConversionPrice" contextRef="AsOf2025-09-30_custom_SeriesL10PercentageConvertiblePreferredStockMember" id="Fact001049" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.6421</ix:nonFraction></span>.
The conversion price adjustment constitutes a Dilutive Issuance (as defined in each of the Common Warrants and Vesting Warrants) and
as a result, the exercise price of the Warrants have been decreased, and the number of warrant shares have been increased, such that
the aggregate exercise price of the Warrants, after taking into account the decrease in the exercise price, shall be equal to the
aggregate exercise price prior to such adjustment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends
to holders of the Series L Convertible Preferred Stock in the amount of $<span id="xdx_901_eus-gaap--PaymentsForRepurchaseOfConvertiblePreferredStock_c20250101__20250930__us-gaap--StatementClassOfStockAxis__custom--SeriesLConvertiblePreferredStockMember_zjV54006XzIk" title="Dividends to holders unpaid"><ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfConvertiblePreferredStock" contextRef="From2025-01-012025-09-30_custom_SeriesLConvertiblePreferredStockMember16969765" id="Fact001051" format="ixt:numdotdecimal" decimals="0" unitRef="USD">229,000</ix:nonFraction></span> were declared and $<span id="xdx_909_eus-gaap--DividendsPayableCurrent_iI_c20250930__us-gaap--StatementClassOfStockAxis__custom--SeriesLConvertiblePreferredStockMember_zR3r37g1Af9e" title="Dividends unpaid"><ix:nonFraction name="us-gaap:DividendsPayableCurrent" contextRef="AsOf2025-09-30_custom_SeriesLConvertiblePreferredStockMember" id="Fact001053" format="ixt:numdotdecimal" decimals="0" unitRef="USD">144,000</ix:nonFraction></span> was unpaid as of September
30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Series
L Convertible Preferred Stock initially classified as Mezzanine Equity</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
May 2025 private placement of Series L Convertible Preferred Stock and Warrants described above was allocated to mezzanine equity and
additional paid in capital based on the relative fair value of the Series L Convertible Preferred Stock and Warrants at issuance, respectively.
Initially, upon the occurrence of certain triggering events, each holder had the right to require the Company to redeem the Preferred
Shares at a premium, in accordance with and subject to certain conditions as further described in the Certificate of Designation. Accordingly,
the relative fair value of the Series L Convertible Preferred Stock was initially recorded as mezzanine equity. The relative fair value
of the Warrants was recorded in additional paid in capital. The relative fair values and allocation of net proceeds is below:</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact001055" name="us-gaap:ScheduleOfConversionsOfStockTextBlock"><p id="xdx_893_eus-gaap--ScheduleOfConversionsOfStockTextBlock_zwlEtNrdjBIj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BE_zQD8KHdsgYI3" style="display: none">Schedule of fair values and allocation of net proceeds</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.85in; border-collapse: collapse; width: 65%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20250501__20250531_zUQwYfvYORY1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Relative Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Percentage</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_hus-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_zFqcvEw9WdC7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Series L Convertible Preferred Stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" contextRef="From2025-05-012025-05-31_custom_SeriesLPreferredStockMember" id="Fact001057" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,688,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_ecustom--ConvertiblePreferredStockAndWarrantsFairValuePercentage_pid_dp_uPure_c20250501__20250531__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_zlzQG7EOTMcj" title="Convertible preferred stock and warrants fair value percentage" style="width: 16%; text-align: right"><ix:nonFraction name="GTBP:ConvertiblePreferredStockAndWarrantsFairValuePercentage" contextRef="From2025-05-012025-05-31_custom_SeriesLPreferredStockMember" id="Fact001059" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">37.7</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_404_eus-gaap--StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_hus-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPCubDqq44Af" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Warrants</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" contextRef="From2025-05-012025-05-31_us-gaap_WarrantMember" id="Fact001061" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,089,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98C_ecustom--ConvertiblePreferredStockAndWarrantsFairValuePercentage_pid_dp_uPure_c20250501__20250531__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z0cmsSWGOh0g" title="Convertible preferred stock and warrants fair value percentage" style="padding-bottom: 1pt; text-align: right"><ix:nonFraction name="GTBP:ConvertiblePreferredStockAndWarrantsFairValuePercentage" contextRef="From2025-05-012025-05-31_us-gaap_WarrantMember" id="Fact001063" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">62.3</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr id="xdx_406_eus-gaap--StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_zhGmkVgz1ka4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" contextRef="From2025-05-012025-05-31" id="Fact001065" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,777,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_98C_ecustom--ConvertiblePreferredStockAndWarrantsFairValuePercentage_pid_dp_uPure_c20250501__20250531_z4QTbDtFRz6" title="Convertible preferred stock and warrants fair value percentage" style="padding-bottom: 2.5pt; text-align: right"><ix:nonFraction name="GTBP:ConvertiblePreferredStockAndWarrantsFairValuePercentage" contextRef="From2025-05-012025-05-31" id="Fact001067" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100.0</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.85in; border-collapse: collapse; width: 65%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20250501__20250531_zSfL5Pa7z8J" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Allocation of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net Proceeds</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Percentage</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_hus-gaap--StatementClassOfStockAxis__custom--MezzanineEquityMember_z6B8H5k5PQNh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Mezzanine equity</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" contextRef="From2025-05-012025-05-31_custom_MezzanineEquityMember" id="Fact001069" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,052,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_ecustom--ConvertiblePreferredStockAndWarrantsNetProceedsPercentage_pid_dp_uPure_c20250501__20250531__us-gaap--StatementClassOfStockAxis__custom--MezzanineEquityMember_zD8Ra4yZrJh9" title="Convertible preferred stock and warrants net proceeds percentage" style="width: 16%; text-align: right"><ix:nonFraction name="GTBP:ConvertiblePreferredStockAndWarrantsNetProceedsPercentage" contextRef="From2025-05-012025-05-31_custom_MezzanineEquityMember" id="Fact001071" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">37.7</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_40B_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_hus-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zbl8wWapqWZ7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Additional paid in capital</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" contextRef="From2025-05-012025-05-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact001073" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,389,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_985_ecustom--ConvertiblePreferredStockAndWarrantsNetProceedsPercentage_pid_dp_uPure_c20250501__20250531__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zjsO5UCWw2jl" title="Convertible preferred stock and warrants net proceeds percentage" style="padding-bottom: 1pt; text-align: right"><ix:nonFraction name="GTBP:ConvertiblePreferredStockAndWarrantsNetProceedsPercentage" contextRef="From2025-05-012025-05-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact001075" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">62.3</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr id="xdx_40E_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_zIX6QabUbDC6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" contextRef="From2025-05-012025-05-31" id="Fact001077" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,441,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_981_ecustom--ConvertiblePreferredStockAndWarrantsNetProceedsPercentage_pid_dp_uPure_c20250501__20250531_zAnr0VDobY3g" title="Convertible preferred stock and warrants net proceeds percentage" style="padding-bottom: 2.5pt; text-align: right"><ix:nonFraction name="GTBP:ConvertiblePreferredStockAndWarrantsNetProceedsPercentage" contextRef="From2025-05-012025-05-31" id="Fact001079" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100.0</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_zqglQf5Ut4De" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2025, all the holders of GT Biopharma, Inc.&#8217;s Series L 10% Convertible Preferred Stock provided waivers and agreed to
waive the rights to redemption set forth in the Certificate of Designation. Accordingly, as of September 30, 2025 the Preferred Stock
has been reclassified from mezzanine equity to shareholders&#8217; equity as it is no longer conditionally redeemable upon the occurrence
of certain events that were not solely within the control of the Company,</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact001081" name="GTBP:CommonStockWarrantsAndOptionsTextBlock"><p id="xdx_809_ecustom--CommonStockWarrantsAndOptionsTextBlock_zNrj7GekWaY" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
6 &#8211; <span id="xdx_82C_z3h5xfFF7ev5">Common Stock Warrants and Options</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
Stock Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact001083" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><p id="xdx_89F_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zojafDrERnad" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
warrant transactions for the nine months ended September 30, 2025 were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B0_zmIuocYy0Jvj" style="display: none">Schedule of Warrant Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 75%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine Months Ended September 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted Average</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%">Warrants outstanding at December 31, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20250101__20250930_zDMi81wrfrC8" title="Warrants outstanding, beginning balance" style="width: 18%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2024-12-31" id="Fact001085" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,120,429</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20250930_zD5R47lSsiu2" title="Weighted average exercise price, beginning balance" style="width: 18%; text-align: right"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-12-31" id="Fact001087" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">18.85</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20250101__20250930_z0wqIIccBgEc" title="Number of warrants, granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2025-01-01to2025-09-30" id="Fact001089" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,468,308</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice_pid_c20250101__20250930_zmvI925Vzm15" title="Weighted average exercise price, granted" style="text-align: right"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice" contextRef="From2025-01-01to2025-09-30" id="Fact001091" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.04</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Granted pursuant to full-ratchet price and anti-dilution protections</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedPursuantToFullRatchetPriceProtection_pid_c20250101__20250930_z8gbwwRzu8B9" title="Number of warrants, granted pursuant to full ratchet price and anti-dilution protections" style="text-align: right"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedPursuantToFullRatchetPriceProtection" contextRef="From2025-01-01to2025-09-30" id="Fact001093" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">32,709,588</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedPursuantToFullRatchetPriceProtectionWeightedAverageExercisePrice_pid_c20250101__20250930_zyRMRaQV3zRl" title="Weighted average exercise price, granted pursuant to full ratchet price and anti-dilution protections" style="text-align: right"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedPursuantToFullRatchetPriceProtectionWeightedAverageExercisePrice" contextRef="From2025-01-01to2025-09-30" id="Fact001095" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.64</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Forfeited/cancelled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20250101__20250930_zCUCfhiXx9zl" title="Number of warrants, forfeited/cancelled" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" contextRef="From2025-01-01to2025-09-30" id="Fact001097" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,866</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice_pid_c20250101__20250930_zdYoRgK4SmH2" title="Weighted average exercise price, forfeited/cancelled" style="text-align: right"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice" contextRef="From2025-01-01to2025-09-30" id="Fact001099" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">102.00</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1pt">Exercised</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20250101__20250930_ziKRaAnaZiQ" title="Number of warrants, exercised" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2025-01-01to2025-09-30" id="Fact001101" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">837,069</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice_pid_c20250101__20250930_z9CDiYG0FdPa" title="Weighted average exercise price, exercised" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice" contextRef="From2025-01-01to2025-09-30" id="Fact001103" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.11</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Warrants outstanding at September 30, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20250101__20250930_zQEAWPH7U4u" title="Warrants outstanding, ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2025-09-30" id="Fact001105" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">49,459,390</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20250930_zBUzbvpGWmhf" title="Weighted average exercise price, ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-09-30" id="Fact001107" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.04</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Warrants exercisable at September 30, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_iI_pid_c20250930_zeOz6m1p7MEa" title="Warrants exercisable, ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" contextRef="AsOf2025-09-30" id="Fact001109" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,956,955</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20250930_zRozTTnSJ334" title="Weighted average exercise price, exercisable, ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2025-09-30" id="Fact001111" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.04</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zIwQ0dxgDORg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 15; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate intrinsic value of all warrants outstanding and all warrants vested and exercisable as of September 30, 2025 was approximately
$<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20250930_zTb9aWQiLZJl" title="Options outstanding vested intrinsic value"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2025-09-30" id="Fact001113" format="ixt:numdotdecimal" decimals="0" unitRef="USD">281,000</ix:nonFraction></span>, in each case based on the fair value of the Company&#8217;s common stock on September 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the May 2025 Private Placement of Series L Convertible Preferred Stock and Warrants the Company issued an aggregate of <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pp2d_c20250531__20250531__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonWarrantsMember_zCSUyqlm2cHd" title="Aggregate number of shares issued"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2025-05-312025-05-31_custom_SeriesLPreferredStockMember_custom_CommonWarrantsMember" id="Fact001115" format="ixt:numdotdecimal" decimals="2" unitRef="Shares">3,235,978</ix:nonFraction></span>
Common Warrants with an initial exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250531__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonWarrantsMember_zDcPfglbFdF6" title="Exercise price per share"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-05-31_custom_CommonWarrantsMember" id="Fact001117" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.043</ix:nonFraction></span>
per share, they are exercisable, subject to certain ownership limitations, immediately upon issuance and have a term of exercise
equal to five years. An aggregate of <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pp2d_c20250531__20250531__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonWarrantsMember_zQi7HBcM70jk" title="Aggregate number of shares vested"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2025-05-312025-05-31_custom_SeriesLPreferredStockMember_custom_CommonWarrantsMember" id="Fact001119" format="ixt:numdotdecimal" decimals="2" unitRef="Shares">11,756,406</ix:nonFraction></span>
Vesting Warrants were issued with an initial exercise price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250531__us-gaap--ClassOfWarrantOrRightAxis__custom--VestingWarrantsMember_zkFZpB3GJbm5" title="Exercise price per share"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-05-31_custom_VestingWarrantsMember" id="Fact001121" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.043</ix:nonFraction></span>
per share, they are exercisable subject to certain vesting and ownership limitations, and have a term of exercise equal to five
years from the date that the applicable warrant shares vest. The Common and Vesting Warrants both have full-ratchet price and
anti-dilition protections and are subject to other adjustments, as further described in the Certificate of Designation or the
Warrants, as applicable, subject, solely with respect to adjustments in connection with the exercise of Greenshoe Rights, a floor
price of $<span id="xdx_902_eus-gaap--DerivativeFloorPrice_iI_pid_uUSDPShares_c20250531__us-gaap--StatementEquityComponentsAxis__custom--GreenshoeRightsMember_zHbNpj77xgTk" title="Floor price per share"><ix:nonFraction name="us-gaap:DerivativeFloorPrice" contextRef="AsOf2025-05-31_custom_GreenshoeRightsMember" id="Fact001123" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.454</ix:nonFraction></span>
per share (subject to adjustment for reverse and forward splits, recapitalizations and similar transactions). As of September 30,
2025 pursuant to full-ratchet price and anti-dilution protections the exercise price of the Common and Vesting Warrants has been
reduced to $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonWarrantsMember_zzpU0TD1JD33" title="Exercise price per share"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-09-30_custom_CommonWarrantsMember" id="Fact001125" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.6421</ix:nonFraction></span>
and an additional <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250930__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonWarrantsMember_z2AT9QXbDLAj" title="Class of warrant or right outstanding"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-09-30_custom_CommonWarrantsMember" id="Fact001127" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">32,709,588</ix:nonFraction></span>
Common and Vesting Warrants have been issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the May 2025 Private Placement of Equity Facility the Company issued pre-funded warrants to purchase an aggregate of <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250531__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zPdSLkFaatBe" title="Issuance of pre-funded warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-05-31_us-gaap_PrivatePlacementMember" id="Fact001129" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">300,000</ix:nonFraction></span> shares
of common stock as consideration for its irrevocable commitment to purchase the shares of common stock upon the terms and subject to
the satisfaction of the conditions set forth in the Purchase Agreement. The pre-funded warrants may be exercise at any time after issuance
and until exercised in full.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2025 the Company issued warrants underlying <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250531_zS0KkOPMJ4K" title="Number of warrant issued"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-05-31" id="Fact001131" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">24,390</ix:nonFraction></span> shares of common stock exercisable immediately upon issuance with a term of five
years from the date of issuance at $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250531_zTGi2zrQVaF6" title="Exercise price per share"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-05-31" id="Fact001133" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.46</ix:nonFraction></span> per share with a fair value of approximately $<span id="xdx_901_eus-gaap--WarrantsAndRightsOutstanding_iI_c20250531_zFF0dfWJalwc" title="Fair value of warrant"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="AsOf2025-05-31" id="Fact001135" format="ixt:numdotdecimal" decimals="0" unitRef="USD">44,000</ix:nonFraction></span> in exchange for the waiver of a variable
rate transaction (&#8220;VRT&#8221;). In addition, in May and June 2025, the Company issued <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250601__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmYKWEzdQW87" title="Number of new shares issued"><span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250501__20250531__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ze8F9Bicvl9i" title="Number of new shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-06-012025-06-30_us-gaap_CommonStockMember" id="Fact001137" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-05-012025-05-31_us-gaap_CommonStockMember" id="Fact001139" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000</ix:nonFraction></ix:nonFraction></span></span> shares of common stock and warrants
underlying <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250531__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zrX3ygy0wad2" title="Number of warrant issued"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ztbmfnSf0WWl" title="Number of warrant issued"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-05-31_us-gaap_CommonStockMember" id="Fact001141" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-06-30_us-gaap_CommonStockMember" id="Fact001143" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">200,000</ix:nonFraction></ix:nonFraction></span></span> shares of common stock with an aggregate fair value of approximately $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20250501__20250531_zvcpnhAqmNdb" title="Number shares issued for service, value"><span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20250601__20250630_z3Zi4w9DOaDk" title="Number shares issued for service, value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2025-05-012025-05-31" id="Fact001145" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2025-06-012025-06-30" id="Fact001147" format="ixt:numdotdecimal" decimals="0" unitRef="USD">718,000</ix:nonFraction></ix:nonFraction></span></span> to vendors as compensation for services.
The warrants underlying <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250531__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5lfFA3HHcl7" title="Number of warrant issued"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-05-31_us-gaap_CommonStockMember" id="Fact001149" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">200,000</ix:nonFraction></span> shares of common stock consist of warrants underlying <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250531__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_z9TgMDXP9eRb" title="Number of warrant issued"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-05-31_custom_PrefundedWarrantsMember" id="Fact001151" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000</ix:nonFraction></span> shares of common stock that are exercisable
immediately upon issuance with a term of five years from the date of issuance at $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250531__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zeMrACZ3YOPk" title="Exercise price per share"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-05-31_custom_PrefundedWarrantsMember" id="Fact001153" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.50</ix:nonFraction></span> per share, and warrants underlying <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightUnissued_iI_c20250531__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zbQozpLu8xm7" title="Issuance of pre-funded warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightUnissued" contextRef="AsOf2025-05-31_custom_PrefundedWarrantsMember" id="Fact001155" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">150,000</ix:nonFraction></span> shares
of common stock that are pre-funded warrants exercisable at any time after issuance and until exercised in full.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-012025-09-30_custom_WarrantsMember" escape="true" id="Fact001157" name="GTBP:ScheduleOfWarrantsOustandingAndExercisableTableTextBlock"><p id="xdx_89D_ecustom--ScheduleOfWarrantsOustandingAndExercisableTableTextBlock_hus-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zHWlacB2NAk9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
outstanding as of September 30, 2025 are exercisable as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B4_z7RvbhSWOw3f" style="display: none">Schedule of Warrants Outstanding and Exercisable</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants Outstanding and Exercisable as of September 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Range of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining Contractual Life (Years)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Price</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td style="width: 22%; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zUT6l6jEKntk" title="Range of exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_RangeOneMember" id="Fact001159" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_ziHQqR1L4Zu9" title="Number of outstanding" style="width: 22%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeOneMember" id="Fact001161" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">476,251</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 21%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 21%; text-align: right"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zlvanojrrKPb" title="Warrants weighted average exercise price"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeOneMember" id="Fact001163" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zXi70y0pXUBb" title="Range of exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_RangeTwoMember" id="Fact001165" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.6421</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_ziHdbHHQIde7" title="Number of outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeTwoMember" id="Fact001167" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,296,061</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zSYduWdmwKB4" title="Warrants outstanding, weighted average remaining contractual life (years)"><ix:nonNumeric contextRef="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_RangeTwoMember" format="ixt-sec:duryear" id="Fact001169" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">4.6</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z1BDBE5FhwH4" title="Warrants weighted average exercise price"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeTwoMember" id="Fact001171" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.6421</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zmAGy9fK2cNa" title="Range of exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_RangeThreeMember" id="Fact001173" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.6421</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_z9wH87jvtpC7" title="Number of outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeThreeMember" id="Fact001175" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">37,405,912</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zhbZKUXx3eVf" title="Warrants weighted average exercise price"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeThreeMember" id="Fact001177" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.6421</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zUgmU8Um88wi" title="Range of exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_RangeFourMember" id="Fact001179" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.02</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_z0cqNmFeX6S2" title="Number of outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeFourMember" id="Fact001181" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">369,138</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zgyaDsI6O1ph" title="Warrants outstanding, weighted average remaining contractual life (years)"><ix:nonNumeric contextRef="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_RangeFourMember" format="ixt-sec:duryear" id="Fact001183" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">2.7</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zfC14Nv9cbnc" title="Warrants weighted average exercise price"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeFourMember" id="Fact001185" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.02</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zs2RZdjqL7wa" title="Range of exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_RangeFiveMember" id="Fact001187" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.46</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zEb5IIygSNy7" title="Number of outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeFiveMember" id="Fact001189" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">24,390</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_z2y1Y41ZnAl1" title="Warrants outstanding, weighted average remaining contractual life (years)"><ix:nonNumeric contextRef="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_RangeFiveMember" format="ixt-sec:duryear" id="Fact001191" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">4.6</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zrbKcHFfFGIk" title="Warrants weighted average exercise price"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeFiveMember" id="Fact001193" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.46</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zeWeRJMU1rSh" title="Range of exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_RangeSixMember" id="Fact001195" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.50</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zss7EjAJGnd2" title="Number of outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeSixMember" id="Fact001197" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_z6vfFtikprAl" title="Warrants outstanding, weighted average remaining contractual life (years)"><ix:nonNumeric contextRef="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_RangeSixMember" format="ixt-sec:duryear" id="Fact001199" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">2.6</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_z0QEfBc2ITei" title="Warrants weighted average exercise price"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeSixMember" id="Fact001201" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.50</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zzkSwPZhUuKa" title="Range of exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_RangeSevenMember" id="Fact001203" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.8375</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zuq6OtqvRWj" title="Number of outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeSevenMember" id="Fact001205" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">21,145</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zqo2FRONefMi" title="Warrants outstanding, weighted average remaining contractual life (years)"><ix:nonNumeric contextRef="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_RangeSevenMember" format="ixt-sec:duryear" id="Fact001207" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">4.6</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zW5gd8jtwPg6" title="Warrants weighted average exercise price"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeSevenMember" id="Fact001209" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.8375</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zkBpwOf5vpT3" title="Range of exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_RangeEightMember" id="Fact001211" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.35</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_z5IfCHLtsme5" title="Number of outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeEightMember" id="Fact001213" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">437,931</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zl282ScRvmz" title="Warrants outstanding, weighted average remaining contractual life (years)"><ix:nonNumeric contextRef="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_RangeEightMember" format="ixt-sec:duryear" id="Fact001215" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">3.6</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zf8NbEcZDPH5" title="Warrants weighted average exercise price"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeEightMember" id="Fact001217" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.35</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zDJLO9B31ut4" title="Range of exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_RangeNineMember" id="Fact001219" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.4375</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zV7sR378lp05" title="Number of outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeNineMember" id="Fact001221" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">88,800</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_z50UlTboaJS" title="Warrants outstanding, weighted average remaining contractual life (years)"><ix:nonNumeric contextRef="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_RangeNineMember" format="ixt-sec:duryear" id="Fact001223" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">3.6</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zYHcMNW7OeBg" title="Warrants weighted average exercise price"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeNineMember" id="Fact001225" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.4375</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_znnXzdKRhTql" title="Range of exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_RangeTenMember" id="Fact001227" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">30.00</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zarnJJL9S6O5" title="Number of outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeTenMember" id="Fact001229" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">216,666</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zQhwh4r1G8u7" title="Warrants outstanding, weighted average remaining contractual life (years)"><ix:nonNumeric contextRef="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_RangeTenMember" format="ixt-sec:duryear" id="Fact001231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">2.8</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zOASU6c886" title="Warrants weighted average exercise price"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeTenMember" id="Fact001233" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">30.00</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeElevenMember_zUbRjEgZB0m7" title="Range of exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_RangeElevenMember" id="Fact001235" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">37.50</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeElevenMember_zyho79WSLx8b" title="Number of outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeElevenMember" id="Fact001237" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeElevenMember_z8J5A8vfjn3b" title="Warrants outstanding, weighted average remaining contractual life (years)"><ix:nonNumeric contextRef="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_RangeElevenMember" format="ixt-sec:duryear" id="Fact001239" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">2.3</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeElevenMember_zucetDw1K5zg" title="Warrants weighted average exercise price"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeElevenMember" id="Fact001241" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">37.50</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwelveMember_zUN460lJhTZ5" title="Range of exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_RangeTwelveMember" id="Fact001243" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">165.00</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwelveMember_zLFwzeWGv932" title="Number of outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeTwelveMember" id="Fact001245" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">52,316</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwelveMember_zQ515VieNZ95" title="Warrants outstanding, weighted average remaining contractual life (years)"><ix:nonNumeric contextRef="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_RangeTwelveMember" format="ixt-sec:duryear" id="Fact001247" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">0.4</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwelveMember_zULwM9EVitxc" title="Warrants weighted average exercise price"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeTwelveMember" id="Fact001249" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">165.00</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThirteenMember_zD6FzkOCevq1" title="Range of exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_RangeThirteenMember" id="Fact001251" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">206.25</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThirteenMember_z6z8QGOxFjF6" title="Number of outstanding" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeThirteenMember" id="Fact001253" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,780</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThirteenMember_zBtbV2FGmGK2" title="Warrants outstanding, weighted average remaining contractual life (years)"><ix:nonNumeric contextRef="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_RangeThirteenMember" format="ixt-sec:duryear" id="Fact001255" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">0.4</ix:nonNumeric></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThirteenMember_zf2jmpvYapTk" title="Warrants weighted average exercise price"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeThirteenMember" id="Fact001257" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">206.25</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zr5DMGgWwvi4" title="Number of outstanding" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2025-09-30_us-gaap_WarrantMember" id="Fact001259" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">49,459,390</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zbQ0KpRWj123" title="Warrants outstanding, weighted average remaining contractual life (years)"><ix:nonNumeric contextRef="From2025-01-012025-09-30_us-gaap_WarrantMember16970921" format="ixt-sec:duryear" id="Fact001261" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">4.5</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zFZSoYIVudOd" title="Warrants weighted average exercise price"><ix:nonFraction name="GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-09-30_us-gaap_WarrantMember" id="Fact001263" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.04</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_zHPoc0x7mo3k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 16; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
Stock Options</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2022 the Company established the 2022 Omnibus Incentive Plan (the &#8220;Plan&#8221;). The Plan was approved by our Board and stockholders.
The purpose of the Plan is to grant stock and options to purchase our common stock, and other incentive awards, to our employees, directors,
and key consultants. On July 24, 2025 shareholders voted to increase the maximum number of shares of common stock that may be issued
pursuant to awards granted under the Plan by <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220401__20220430__us-gaap--AwardTypeAxis__custom--OmnibusIncentivePlanMember_z2F9mVB3ZSh8" title="Common stock awards granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2022-04-012022-04-30_custom_OmnibusIncentivePlanMember" id="Fact001265" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">583,334</ix:nonFraction></span>. Pursuant to the increase, the maximum number of shares of common stock that may
be issued pursuant to awards granted under the Plan is <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220401__20220430__us-gaap--AwardTypeAxis__custom--OmnibusIncentivePlanMember__srt--RangeAxis__srt--MaximumMember_zuu4XF7xh6o4" title="Common stock awards granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2022-04-012022-04-30_custom_OmnibusIncentivePlanMember_srt_MaximumMember" id="Fact001267" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">750,000</ix:nonFraction></span>. The shares of our common stock underlying cancelled and forfeited awards
issued under the Plan may again become available for grant under the Plan. As of September 30, 2025, there were <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250930_zGDZ7L3FJ3Ec" title="Stock option outstanding"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2025-09-30" id="Fact001269" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">597,550</ix:nonFraction></span> stock options
outstanding and <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20250101__20250930_zedJ8fhwYUF1" title="Rstricted stock granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2025-01-01to2025-09-30" id="Fact001271" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,935</ix:nonFraction></span> shares of restricted stock granted in prior years under the Plan, which left <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20250930__us-gaap--AwardTypeAxis__custom--OmnibusIncentivePlanMember_z34bHj57XFP6" title="Available for grant"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2025-09-30_custom_OmnibusIncentivePlanMember" id="Fact001273" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">126,515</ix:nonFraction></span> shares available for grant
under the Plan. The following table summarizes stock option transactions for the nine months ended September 30, 2025:</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact001275" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z58qRwcj4efd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_zVD5FfCQp6Ol" style="display: none">Schedule of Options Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 75%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine Months Ended September, 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted Average</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%">Options outstanding at December 31, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20250101__20250930_zlCpHCqAJDz5" title="Number of options outstanding, beginning" style="width: 18%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-12-31" id="Fact001277" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">124,600</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20250930_zTb4DgWPqfB1" title="Weighted-Average Exercise Price, beginning" style="width: 18%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-12-31" id="Fact001279" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">32.69</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20250101__20250930_z4z6r8NWelW5" title="Number of options, granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2025-01-01to2025-09-30" id="Fact001281" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">525,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250101__20250930_zx5pwK3pMYOi" title="Weighted-Average Exercise Price, granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2025-01-01to2025-09-30" id="Fact001283" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.33</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Forfeited/cancelled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20250101__20250930_zw8dICJoUuEg" title="Number of options, forfeited/cancelled" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="From2025-01-01to2025-09-30" id="Fact001285" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">52,050</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20250101__20250930_zzysbtEhWNF1" title="Weighted-Average Exercise Price, forfeited/cancelled" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2025-01-01to2025-09-30" id="Fact001287" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">43.08</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1pt">Exercised</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20250101__20250930_z3Y07HEMPkHk" title="Number of options, exercised" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1289">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20250101__20250930_zQVMUgoguQN7" title="Weighted-Average Exercise Price, exercised" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1291">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Options outstanding at September 30, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20250101__20250930_ztu8a4f904Id" title="Number of options outstanding, ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2025-09-30" id="Fact001293" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">597,550</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20250930_ziUdv9555Hrk" title="Weighted-Average Exercise Price, ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-09-30" id="Fact001295" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.23</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Options exercisable at September 30, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20250930_zbVv8HUHubmc" title="Number of options outstanding exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2025-09-30" id="Fact001297" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">396,439</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20250930_z6ymFUoUBJil" title="Weighted-Average Exercise Price,exercisable, ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2025-09-30" id="Fact001299" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.68</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_zWwYbfLCiwnh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average remaining contractual life of all options outstanding, and all options vested and exercisable as of September 30, 2025
was approximately <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20250930_zpMaxqfj9EMk" title="Share-based compensation weighted average remaining contractual term"><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" format="ixt-sec:duryear" id="Fact001301" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">9.6</ix:nonNumeric></span> years. Furthermore, the aggregate intrinsic value of all options outstanding and all options vested and exercisable
as of September 30, 2025 was $<span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20250101__20250930_zdBGXeAA89Gl" title="Options outstanding intrinsic value"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="From2025-01-01to2025-09-30" id="Fact001303" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span>, in each case based on the fair value of the Company&#8217;s common stock on September 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
total fair value of options that vested during the nine months ended September 30, 2025 and 2024, was $<span id="xdx_909_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_c20250101__20250930_z2uHj3u5pRah" title="Fair value of vested stock options"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2025-01-01to2025-09-30" id="Fact001305" format="ixt:numdotdecimal" decimals="0" unitRef="USD">386,000</ix:nonFraction></span> and $<span id="xdx_90D_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_c20240101__20240930_zZFDFXG9r483" title="Fair value of vested stock options"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2024-01-012024-09-30" id="Fact001307" format="ixt:numdotdecimal" decimals="0" unitRef="USD">222,000</ix:nonFraction></span>, respectively,
and is included in selling, general and administrative expense in the accompanying unaudited condensed statements of operations. As of
September 30, 2025, <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20250930_zZjKAxYknOm8" title="Stock option, exercisable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2025-09-30" id="Fact001309" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">396,439</ix:nonFraction></span> stock options were vested and exercisable and unvested compensation expense amounted to approximately $<span id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1_c20250101__20250930_zzjFdcqVZVdg" title="Stock option, unvested compensation"><ix:nonFraction name="GTBP:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1" contextRef="From2025-01-01to2025-09-30" id="Fact001311" format="ixt:numdotdecimal" decimals="0" unitRef="USD">236,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact001313" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"><p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zQxhkOstx6f2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
outstanding as of September 30, 2025 are exercisable as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_ziaOabyQCHsk" style="display: none">Schedule of Options Outstanding and Options Exercisable</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Stock Options Exercisable as of September 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Range of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining Contractual Life (Years)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Price</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td style="width: 22%; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zf3an5PIZ5Cf" title="Range of excercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2025-01-012025-09-30_custom_RangeOneMember" id="Fact001315" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.33</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_z2rH9xN7Lf5e" title="Options outstanding" style="width: 22%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2025-09-30_custom_RangeOneMember" id="Fact001317" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">337,500</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 21%; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zIAMyDui7Wk9" title="Options outstanding, weighted average remaining contractual life (years)"><ix:nonNumeric contextRef="From2025-01-012025-09-30_custom_RangeOneMember" format="ixt-sec:duryear" id="Fact001319" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">9.9</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 21%; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zEGktHgLOcUa" title="Options outstanding, weighted average exercise price"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="AsOf2025-09-30_custom_RangeOneMember" id="Fact001321" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.33</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zKBOZuDHs8C7" title="Range of excercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2025-01-012025-09-30_custom_RangeTwoMember" id="Fact001323" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.11</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zjGSanyWE235" title="Options outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2025-09-30_custom_RangeTwoMember" id="Fact001325" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,723</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z467DOdJnBM3" title="Options outstanding, weighted average remaining contractual life (years)"><ix:nonNumeric contextRef="From2025-01-012025-09-30_custom_RangeTwoMember" format="ixt-sec:duryear" id="Fact001327" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">7.7</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z6PAHYRchmTf" title="Options outstanding, weighted average exercise price"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="AsOf2025-09-30_custom_RangeTwoMember" id="Fact001329" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.11</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zJQF9JaqeCfj" title="Range of excercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2025-01-012025-09-30_custom_RangeThreeMember" id="Fact001331" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.50</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zqa0EH8A9zP4" title="Options outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2025-09-30_custom_RangeThreeMember" id="Fact001333" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,667</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zrGTW5p5sR09" title="Options outstanding, weighted average remaining contractual life (years)"><ix:nonNumeric contextRef="From2025-01-012025-09-30_custom_RangeThreeMember" format="ixt-sec:duryear" id="Fact001335" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">7.6</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zpvtAqCOUnB7" title="Options outstanding, weighted average exercise price"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="AsOf2025-09-30_custom_RangeThreeMember" id="Fact001337" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.50</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zuNrXfu4ilVh" title="Range of excercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2025-01-012025-09-30_custom_RangeFourMember" id="Fact001339" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">25.50</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_z4wZzY6gaPkh" title="Options outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2025-09-30_custom_RangeFourMember" id="Fact001341" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,667</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zNTlFwlRbljl" title="Options outstanding, weighted average remaining contractual life (years)"><ix:nonNumeric contextRef="From2025-01-012025-09-30_custom_RangeFourMember" format="ixt-sec:duryear" id="Fact001343" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">7.3</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_z7cZQdT707Uj" title="Options outstanding, weighted average exercise price"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="AsOf2025-09-30_custom_RangeFourMember" id="Fact001345" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">25.50</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zK7rXtkb54Bk" title="Range of excercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2025-01-012025-09-30_custom_RangeFiveMember" id="Fact001347" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">74.40</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zErabDuoLU19" title="Options outstanding" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2025-09-30_custom_RangeFiveMember" id="Fact001349" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,882</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zGQxVdCMPUPa" title="Options outstanding, weighted average remaining contractual life (years)"><ix:nonNumeric contextRef="From2025-01-012025-09-30_custom_RangeFiveMember" format="ixt-sec:duryear" id="Fact001351" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">6.8</ix:nonNumeric></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zW7MkwNXEat6" title="Options outstanding, weighted average exercise price"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="AsOf2025-09-30_custom_RangeFiveMember" id="Fact001353" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">74.40</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250930_z7jQCwmR4Tqe" title="Options outstanding" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2025-09-30" id="Fact001355" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">396,439</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_zFRbcgUZkXRj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact001357" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_80E_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zhurUA49gX87" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
7 &#8211; <span id="xdx_827_zPH1yKHKxpUb">Commitments and Contingencies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Litigation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is involved in certain legal proceedings that arise from time to time in the ordinary course of our business. Except for income
tax contingencies, we record accruals for contingencies to the extent that our management concludes that the occurrence is probable and
that the related amounts of loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred.
There is no current or pending litigation of any significance with the exception of the matters identified below that have arisen under,
and are being handled in, the normal course of business:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ohri
Matter</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 22, 2024, the Company filed an AAA Arbitration Demand against Manu Ohri, its former Chief Financial Officer. In the demand, the
Company asserts claims against Mr. Ohri for breach of his fiduciary duties and breach of contract and seeks a declaratory judgment providing
that the Company may characterize Mr. Ohri&#8217;s termination as &#8220;for cause&#8221; under his employment agreement, and that the
Company may revoke the separation agreement entered into between the Company and Mr. Ohri prior to the Company learning of Mr. Ohri&#8217;s
breaches. In addition to the declaratory judgment, the Company seeks damages arising from Mr. Ohri&#8217;s violations, and attorneys&#8217;
fees and any forum and arbitration fees. On September 3, 2024, Mr. Ohri filed both a general denial of the Company&#8217;s claims against
him and counterclaims for breach of his employment agreement and Separation Agreement. The final hearing date, originally scheduled for
June 10, 2025, has been postponed indefinitely in order to allow the parties to mediate the dispute. At this time, mediation has not
been scheduled. There is a status conference scheduled for December 11, 2025 before the AAA. At this stage in the proceedings the Company
is not able to determine the probability of the outcome of this matter or a range of reasonably expected losses, if any. The Company
believes it has recorded an appropriate accrual for the matter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 17; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TWF
Global Matter</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 24, 2023, TWF Global, LLC (&#8220;TWF&#8221;) filed a Complaint in the California Superior Court for the County of Los Angeles naming
the Company as defendant. The complaint alleges that TWF is the holder of two Convertible Promissory Notes (&#8220;Notes&#8221;) and
that the Company did not deliver shares of common stock due on conversion in February 2021. TWF was seeking per diem liquidated damages
based on the terms of alleged Notes. On July 14, 2023, the Company filed a motion to dismiss for improper forum because the terms of
the Notes, as alleged, require disputes to be filed in New York state and federal courts. TWF voluntarily dismissed its complaint before
the California Superior Court of Los Angeles without prejudice. The Company subsequently filed a summons and complaint for interpleader
against TWF and Z-One, LLC before the Supreme Court of the State of New York County of New York, asking the Supreme Court to determine
if the Company&#8217;s shares of common stock should be registered to TWF or Z-One LLC, as both of these entities have made conflicting
demands for the shares. On February 5, 2024, the Company filed a motion for entry of default against TWF, seeking an order directing
the Company to register the shares of common stock in the name of Z-One, LLC and that the Company be released from all associated liability
and claims. The Court denied the motion without prejudice and agreed to reconsider the motion without further briefing upon the filing
of a supplemental party affidavit. On May 9, 2024, Z-One, LLC filed a motion for summary judgement seeking dismissal of the action, representing
that Z-One, LLC and TWF have settled their dispute over the entitlement to the Company&#8217;s shares of common stock and there is no
remaining dispute before the Court. On May 21, 2024, the Company filed a supplemental affidavit in support of its motion for entry of
default. On November 14, 2024, the Court held a hearing on the parties&#8217; motions, at which the Court found that the motion for entry
of default was mooted by the settlement agreement between Z-One, LLC and TWF. The Court ordered that the case be dismissed. On February
17, 2025, Z-One, LLC filed a Summons with Notice in the Supreme Court of the State of New York, County of New York. The Company then
filed a demand that Z-One, LLC serve a complaint, and on June 25, 2025, Z-One, LLC filed a Complaint alleging that it is the holder,
either originally or by assignment, of a Convertible Note in the principal amount of $<span id="xdx_905_eus-gaap--LossContingencyDamagesPaidValue_c20250217__20250217__srt--LitigationCaseAxis__custom--ZOneLLCMember_z5zo3RDdTZk6" title="Principal amount"><ix:nonFraction name="us-gaap:LossContingencyDamagesPaidValue" contextRef="From2025-02-172025-02-17_custom_ZOneLLCMember" id="Fact001359" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,000</ix:nonFraction></span>, that the Company breached the Convertible
Note by failing to deliver conversion shares to Z-One, LLC, and that the Company owes it damages in excess of $<span id="xdx_904_eus-gaap--LossContingencyDamagesSoughtValue_c20250217__20250217__srt--LitigationCaseAxis__custom--ZOneLLCMember_zKbHcI6bAt81" title="Damages sought value"><ix:nonFraction name="us-gaap:LossContingencyDamagesSoughtValue" contextRef="From2025-02-172025-02-17_custom_ZOneLLCMember" id="Fact001361" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500,000</ix:nonFraction></span>. On August 26,
2025, the Company filed a motion to dismiss the Complaint in its entirety for lack of standing and failure to state a cause of action.
The Company believes that the claims related to the Notes are without merit, and will continue to vigorously defend against these claims.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Silberfein,
DiPietro, and Werthman Trust Matters</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 8, 2025, Coby Silberfein filed a summons with notice in the State of New York Supreme Court for the County of New York naming the
Company as defendant seeking damages for breach of a securities purchase agreement and convertible note in the principal amount of $<span id="xdx_901_eus-gaap--LossContingencyDamagesPaidValue_c20250708__20250708__srt--LitigationCaseAxis__custom--CobySilberfeinMember_zR3V9lwZs5ag" title="Principal amount"><ix:nonFraction name="us-gaap:LossContingencyDamagesPaidValue" contextRef="From2025-07-082025-07-08_custom_CobySilberfeinMember" id="Fact001363" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span>.
On July 8, 2025, Justin DiPietro filed a summons with notice in the State of New York Supreme Court for the County of New York naming
the Company as defendant seeking damages for breach of a securities purchase agreement and convertible note in the principal amount of
$<span id="xdx_908_eus-gaap--LossContingencyDamagesPaidValue_c20250708__20250708__srt--LitigationCaseAxis__custom--CobySilberfeinMember_zMLS7M2rrQli" title="Principal amount"><ix:nonFraction name="us-gaap:LossContingencyDamagesPaidValue" contextRef="From2025-07-082025-07-08_custom_CobySilberfeinMember" id="Fact001365" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span>. On July 9, 2025, Phillip Werthman Trust filed a summons with notice in the State of New York Supreme Court for the County of
New York naming the Company as defendant seeking damages for breach of a securities purchase agreement and convertible note in the principal
amount of $<span id="xdx_901_eus-gaap--LossContingencyDamagesPaidValue_c20250709__20250709__srt--LitigationCaseAxis__custom--CobySilberfeinMember_zfZNVgRWRC23" title="Damages paid"><ix:nonFraction name="us-gaap:LossContingencyDamagesPaidValue" contextRef="From2025-07-092025-07-09_custom_CobySilberfeinMember" id="Fact001367" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span>. The three summons with notice are identical and allege that the plaintiffs are holders of convertible notes and that
the Company breached the convertible notes by failing to deliver shares of common stock due on conversion in in 2021. Plaintiffs are
seeking specific performance and damages. On August 12, 2025, the Company filed demands that the plaintiffs serve complaints. On September
2, 2025, each plaintiff served a Complaint similar in substance to the summons, except that Plaintiff Silberfein now alleges breach of
a convertible note with a principal amount of $<span id="xdx_906_eus-gaap--LossContingencyDamagesPaidValue_c20250902__20250902__srt--LitigationCaseAxis__custom--CobySilberfeinMember_zU643R2p4TY5" title="Principal amount"><ix:nonFraction name="us-gaap:LossContingencyDamagesPaidValue" contextRef="From2025-09-022025-09-02_custom_CobySilberfeinMember" id="Fact001369" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,000</ix:nonFraction></span>, rather than $<span id="xdx_909_eus-gaap--LossContingencyDamagesSoughtValue_c20250902__20250902__srt--LitigationCaseAxis__custom--CobySilberfeinMember_zocpXuXyMZ4b" title="Damages sought value"><ix:nonFraction name="us-gaap:LossContingencyDamagesSoughtValue" contextRef="From2025-09-022025-09-02_custom_CobySilberfeinMember" id="Fact001371" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span>. Each plaintiff alleges that the Company breached a convertible
note by failing to deliver conversion shares to the plaintiff holder, and that the Company owes damages in excess of $<span id="xdx_90F_eus-gaap--LossContingencyDamagesSought_c20250902__20250902__srt--LitigationCaseAxis__custom--CobySilberfeinMember_zdBbxEl87YU8" title="Owes damages excess value"><ix:nonNumeric contextRef="From2025-09-022025-09-02_custom_CobySilberfeinMember" id="Fact001373" name="us-gaap:LossContingencyDamagesSought">500,000</ix:nonNumeric></span>. The Company
intends to seek dismissal of the complaints. The Company believes that the claims are without merit, and intends to vigorously defend
against these claims.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Significant
Agreements</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cytovance
Biologics, Inc., a Related Party</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2020, the Company entered into a Master Services Agreement with Cytovance, to perform biologic development and manufacturing
services, and to produce and test compounds used in the Company&#8217;s potential product candidates. The Company subsequently executed
numerous Statements of Work (&#8220;SOWs&#8221;) for the research and development of products for use in clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 24, 2022, the Company entered into a Settlement and Investment Agreement with Cytovance that amended existing SOWs and allowed
for future invoices to be settled in in a combination of cash and issuance of the Company&#8217;s common stock. The Settlement and Investment
Agreement also set Cytovance&#8217;s beneficial ownership limitation at <span id="xdx_905_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20220824__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--CytovanceBiologicsIncMember_znf6Z4AxyKEf" title="Equity method investment, ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2022-08-24_custom_CytovanceBiologicsIncMember" id="Fact001375" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.9</ix:nonFraction></span>% of the issued and outstanding shares of the Company&#8217;s
common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 18; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 25, 2024, the Company entered into an Amendment to the Settlement and Investment Agreement with Cytovance that increased Cytovance&#8217;s
beneficial ownership limitation to <span id="xdx_907_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20240425__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--CytovanceBiologicsIncMember_zohVwgGfZU51" title="Equity method investment, ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2024-04-25_custom_CytovanceBiologicsIncMember" id="Fact001377" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">9.9</ix:nonFraction></span>% of the issued and outstanding shares of the Company&#8217;s common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 30, 2024, Cytovance became a related party as their beneficial ownership exceeded <span id="xdx_903_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20240630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--CytovanceBiologicsIncMember_zh5CelRi7wJg" title="Equity method investment, ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2024-06-30_custom_CytovanceBiologicsIncMember" id="Fact001379" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>% of the issued and outstanding shares of the
Company&#8217;s common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the nine months ended September 30, 2025 and 2024, the Company recognized research and development expenses of approximately $<span id="xdx_906_eus-gaap--ProceedsFromRelatedPartyDebt_c20250101__20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zEnuRAjrxg4" title="Research and development expenses"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="From2025-01-012025-09-30_custom_CytovanceBiologicsIncMember_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact001381" format="ixt:numdotdecimal" decimals="0" unitRef="USD">686,000</ix:nonFraction></span>
and $<span id="xdx_908_eus-gaap--ProceedsFromRelatedPartyDebt_pn5n6_c20240101__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z6nlxR7lCn65" title="Research and development expenses"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="From2024-01-012024-09-30_custom_CytovanceBiologicsIncMember_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact001383" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.4</ix:nonFraction></span> million, respectively and made cash payments amounting to approximately $<span id="xdx_90A_eus-gaap--RepaymentsOfRelatedPartyDebt_pn6n6_c20250101__20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_z9uaPyKlY69b" title="Cash payments"><ix:nonFraction name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="From2025-01-012025-09-30_custom_CytovanceBiologicsIncMember" id="Fact001385" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">1</ix:nonFraction></span> million and $<span id="xdx_904_eus-gaap--RepaymentsOfRelatedPartyDebt_pn5n6_c20240101__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zi6YarCf6Ir3" title="Cash payments"><ix:nonFraction name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="From2024-01-012024-09-30_custom_CytovanceBiologicsIncMember" id="Fact001387" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.4</ix:nonFraction></span> million, respectively to Cytovance.
In addition, during the nine months ended September 30, 2025, the Company issued pre-funded warrants to purchase up to <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zoZ9qtczA3qe" title="Issuance of pre-funded warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-09-30_custom_CytovanceBiologicsIncMember" id="Fact001389" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">326,251</ix:nonFraction></span> shares
of common stock exercisable at $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_z9vEMOpzkEQh" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-09-30_custom_CytovanceBiologicsIncMember" id="Fact001391" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> per share to settle accounts payable valued at approximately $<span id="xdx_905_eus-gaap--FairValueAdjustmentOfWarrants_c20250101__20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zXGv2cqMrSik" title="Fair value"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2025-01-012025-09-30_custom_CytovanceBiologicsIncMember" id="Fact001393" format="ixt:numdotdecimal" decimals="0" unitRef="USD">847,000</ix:nonFraction></span>; and during the nine months
ended September 30, 2024, the Company issued <span id="xdx_90C_ecustom--StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable_pid_c20240101__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zIOHfkM9SfB8" title="Issuance of common stock in settlement of vendor payable, shares"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable" contextRef="From2024-01-012024-09-30_custom_CytovanceBiologicsIncMember" id="Fact001395" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">127,597</ix:nonFraction></span> shares of common stock to settle accounts payable valued at approximately $<span id="xdx_90F_ecustom--StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable_c20240101__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zgGYE3L0TU4a" title="Issuance of common stock in settlement of vendor payable"><ix:nonFraction name="GTBP:StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable" contextRef="From2024-01-012024-09-30_custom_CytovanceBiologicsIncMember" id="Fact001397" format="ixt:numdotdecimal" decimals="0" unitRef="USD">810,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2025, the Company&#8217;s commitments in relation to unbilled and unaccrued SOWs and any related Change Orders from
Cytovance for services that have not yet been rendered as of September 30, 2025, amounted to approximately $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20250101__20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zayxE9SGETo8" title="Stock issued during period, value, issued for services"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2025-01-012025-09-30_custom_CytovanceBiologicsIncMember" id="Fact001399" format="ixt:numdotdecimal" decimals="0" unitRef="USD">273,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>University
of Minnesota</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023
Sponsored Research Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 20, 2024, the Company entered into a sponsored research agreement with the Regents of the University of Minnesota (the &#8220;2023
Sponsored Research Agreement&#8221;), effective July 1, 2023, and expiring on July 1, 2025. Payments totaling approximately $<span id="xdx_907_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_pn5n6_c20240520__20240520__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeSponsoredResearchAgreementMember_zqvAqnH26Nsa" title="Aggregate research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="From2024-05-202024-05-20_custom_TwoThousandTwentyThreeSponsoredResearchAgreementMember" id="Fact001401" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.7</ix:nonFraction></span> million
are due over the life of the agreement. The purpose of the agreement is for the Regents of the University of Minnesota to continue work
with the Company with three major goals in mind: (1) support the Company&#8217;s TriKE<sup>&#174;</sup> product development and commercial
GMP manufacturing efforts; (2) TriKE<sup>&#174;</sup> pharmacokinetics optimization in humans and investigation of effects of altering
the route of administration; and (3) research and development of TriKE<sup>&#174;</sup> platform. The major deliverables proposed are:
(1) creation of IND enabling data for TriKE<sup>&#174;</sup> constructs in support of the Company&#8217;s product development and commercial
GMP manufacturing efforts outside of the University of Minnesota; (2) TriKE<sup>&#174;</sup> platform drug delivery changes to allow transition
from intravenous (IV) continuous infusion to alternative drug delivery administration (IV bolus, intraperitoneal [IP], subcutaneous [SQ])
and extended PK in humans and gain an increased understanding of changes in the patient&#8217;s native NK cell population as a result
of alteration of TriKE<sup>&#174;</sup> administration; and (3) research and development of TriKE<sup>&#174;</sup> platform combination
with other FDA approved (or soon to be approved) therapeutics and alterations to TriKE<sup>&#174;</sup> platform through formation of
immune complexes. Most studies will use TriKE<sup>&#174;</sup> DNA/amino acid sequences created by the Company under existing licensing
terms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 18, 2025, the 2023 Sponsored Research Agreement was amended to expire on December 31, 2025. In addition, payments amounting to $<span id="xdx_904_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20250618__20250618__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeSponsoredResearchAgreementMember_zqvANflg3Obf" title="Payments of research and development"><ix:nonFraction name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" contextRef="From2025-06-182025-06-18_custom_TwoThousandTwentyThreeSponsoredResearchAgreementMember" id="Fact001403" format="ixt:numdotdecimal" decimals="0" unitRef="USD">216,000</ix:nonFraction></span>
were added bringing the total payments due over the life of the agreement to approximately $<span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_pn5n6_c20250618__20250618__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeSponsoredResearchAgreementMember_z7udLjmFHPwh" title="Aggregate research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="From2025-06-182025-06-18_custom_TwoThousandTwentyThreeSponsoredResearchAgreementMember" id="Fact001405" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.9</ix:nonFraction></span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded an expense classified as research and development of approximately $<span id="xdx_900_eus-gaap--ResearchAndDevelopmentExpense_c20250101__20250930__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeSponsoredResearchAgreementMember_zomvjXZuuC4d" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-01-012025-09-30_custom_TwoThousandTwentyThreeSponsoredResearchAgreementMember" id="Fact001407" format="ixt:numdotdecimal" decimals="0" unitRef="USD">647,000</ix:nonFraction></span> and $<span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20240930__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeSponsoredResearchAgreementMember_z0lEyhPEXhI3" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-09-30_custom_TwoThousandTwentyThreeSponsoredResearchAgreementMember" id="Fact001409" format="ixt:numdotdecimal" decimals="0" unitRef="USD">863,000</ix:nonFraction></span>, pursuant to the 2023 Sponsored
Research Agreement, for the nine months ended September 30, 2025 and 2024, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2025 the Company&#8217;s commitments in relation to unbilled and unaccrued amounts from the University of Minnesota
pursuant to the 2023 Sponsored Research Agreement for services that have not yet been rendered as of September 30, 2025, amounted to
approximately $<span id="xdx_90F_eus-gaap--UnbilledReceivablesCurrent_iI_c20250930__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeSponsoredResearchAgreementMember_zd6OojdXTQ94" title="Unbilled and unaccrued amounts"><ix:nonFraction name="us-gaap:UnbilledReceivablesCurrent" contextRef="AsOf2025-09-30_custom_TwoThousandTwentyThreeSponsoredResearchAgreementMember" id="Fact001411" format="ixt:numdotdecimal" decimals="0" unitRef="USD">216,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2016
Exclusive Patent License Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
July 18, 2016, the Company entered into an exclusive patent license agreement with the Regents of the University of Minnesota (as amended,
the &#8220;2016 Exclusive Patent License Agreement&#8221;), to further develop and commercialize cancer therapies using TriKE<sup>&#174;</sup>
technology developed by researchers at the University of Minnesota to target NK cells to cancer. Under the terms of the agreement, the
Company receives exclusive rights to conduct research and to develop, make, use, sell, and import TriKE<sup>&#174;</sup> technology worldwide
for the treatment of any disease, state, or condition in humans. The Company is responsible for obtaining all permits, licenses, authorizations,
registrations, and regulatory approvals required or granted by any governmental authority anywhere in the world that is responsible for
the regulation of products such as the TriKE<sup>&#174;</sup> technology, including without limitation the FDA and the European Agency
for the Evaluation of Medicinal Products in the European Union. The agreement requires an upfront payment of $<span id="xdx_907_ecustom--ProceedsFromUpfrontAmount_iI_c20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zf0pyul1aoWi" title="Proceeds from upfront amount"><ix:nonFraction name="GTBP:ProceedsFromUpfrontAmount" contextRef="AsOf2016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember" id="Fact001413" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,000</ix:nonFraction></span>, and license maintenance
fees of $<span id="xdx_903_eus-gaap--CostMaintenance_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__us-gaap--AwardDateAxis__custom--TwoThousandSeventeenThroughTwoThousandTwentyMember_zGjUu5lOWnOl" title="License maintenance fees"><ix:nonFraction name="us-gaap:CostMaintenance" contextRef="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember_custom_TwoThousandSeventeenThroughTwoThousandTwentyMember" id="Fact001415" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,000</ix:nonFraction></span> for years 2017 through 2020, and $<span id="xdx_907_eus-gaap--CostMaintenance_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zx490uHUSach" title="License maintenance fees"><ix:nonFraction name="us-gaap:CostMaintenance" contextRef="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember" id="Fact001417" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span> per year beginning in year 2021 and each year thereafter. The agreement also
includes <span id="xdx_902_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__srt--RangeAxis__srt--MinimumMember_zbdhHp5gUWa9" title="Royalty fee percentage"><ix:nonFraction name="GTBP:RoyaltyFeePercentage" contextRef="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember_srt_MinimumMember" id="Fact001419" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4</ix:nonFraction></span>% royalty fees on the net sales of licensed products, not to exceed <span id="xdx_905_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__srt--RangeAxis__srt--MaximumMember_zUS5s4pLTWbc" title="Royalty fee percentage"><ix:nonFraction name="GTBP:RoyaltyFeePercentage" contextRef="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember_srt_MaximumMember" id="Fact001421" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6</ix:nonFraction></span>% under subsequent license agreements or amendments to
this agreement, and minimum royalty payments due upon the commencement of commercial sales of licensed product is $<span id="xdx_90B_eus-gaap--RoyaltyExpense_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentyTwoMember_zX2S8o3vomq5" title="Annual royalty payments"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember_custom_TwoThousandTwentyTwoMember" id="Fact001423" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span> beginning
in 2022, $<span id="xdx_908_eus-gaap--RoyaltyExpense_pn6n6_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentyFiveMember_zngAHCHtDbS3" title="Annual royalty payments"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember_custom_TwoThousandTwentyFiveMember" id="Fact001425" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">2</ix:nonFraction></span> million beginning in 2025, and $<span id="xdx_909_eus-gaap--RoyaltyExpense_pn6n6_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentySevenMember_zBOkncMom0Vk" title="Annual royalty payments"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember_custom_TwoThousandTwentySevenMember" id="Fact001427" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">5</ix:nonFraction></span> million beginning in 2027 throughout the remainder of the term. The agreement also includes
numerous performance milestone payments including clinical development milestone payments totaling $<span id="xdx_909_ecustom--PerformanceMilestonePayments_pn5n6_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zis3bcFsYVMg" title="Performance milestone payments"><ix:nonFraction name="GTBP:PerformanceMilestonePayments" contextRef="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember" id="Fact001429" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.1</ix:nonFraction></span> million, and one-time sales milestone
payments of $<span id="xdx_90A_ecustom--SalesMilestonePayments_pn6n6_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zJEf8dRDGWNe" title="One-time sales milestone payments"><ix:nonFraction name="GTBP:SalesMilestonePayments" contextRef="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember" id="Fact001431" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">1</ix:nonFraction></span> million upon reaching $<span id="xdx_904_ecustom--GrossSales_pn6n6_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zEDLAGJ4CYej" title="Sales"><ix:nonFraction name="GTBP:GrossSales" contextRef="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember" id="Fact001433" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">250</ix:nonFraction></span> million in cumulative gross sales, and $<span id="xdx_90D_ecustom--SalesRevenue_pn6n6_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zkEPcC0bzm59" title="Sales revenue"><ix:nonFraction name="GTBP:SalesRevenue" contextRef="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember" id="Fact001435" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">5</ix:nonFraction></span> million upon reaching $<span id="xdx_907_ecustom--CummulativeGrossSales_pn6n6_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zquDabCUEJx7" title="Cumulative gross sales"><ix:nonFraction name="GTBP:CummulativeGrossSales" contextRef="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember" id="Fact001437" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">500</ix:nonFraction></span> million in cumulative
gross sales of licensed products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 19; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
May 13, 2024, the Company entered into an amended and restated exclusive patent license agreement with the Regents of the University
of Minnesota. The amendment requires an upfront payment of $<span id="xdx_90C_ecustom--ProceedsFromUpfrontAmount_iI_c20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zmRprPPH7tAb" title="Proceeds from upfront amount"><ix:nonFraction name="GTBP:ProceedsFromUpfrontAmount" contextRef="AsOf2024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember" id="Fact001439" format="ixt:numdotdecimal" decimals="0" unitRef="USD">145,000</ix:nonFraction></span> and amends the license maintenance fees to $<span id="xdx_901_eus-gaap--CostMaintenance_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentyFiveMember_ztugY6kUm1yf" title="License maintenance fees"><ix:nonFraction name="us-gaap:CostMaintenance" contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember_custom_TwoThousandTwentyFiveMember" id="Fact001441" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></span> in 2025, and $<span id="xdx_902_eus-gaap--CostMaintenance_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_z4NvcZnzR9mb" title="License maintenance fees"><ix:nonFraction name="us-gaap:CostMaintenance" contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember" id="Fact001443" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span>
per year beginning in year 2026 and each year thereafter. The amendment also includes <span id="xdx_908_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__srt--RangeAxis__srt--MinimumMember_zSP0YAHGTUV6" title="Royalty fee percentage"><ix:nonFraction name="GTBP:RoyaltyFeePercentage" contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember_srt_MinimumMember" id="Fact001445" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1</ix:nonFraction></span>% to <span id="xdx_90C_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__srt--RangeAxis__srt--MaximumMember_zDYpi4vlZVti" title="Royalty fee percentage"><ix:nonFraction name="GTBP:RoyaltyFeePercentage" contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember_srt_MaximumMember" id="Fact001447" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>% royalty fees on the net sales of licensed
products, not to exceed <span id="xdx_90E_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zSjFYSbWbLj4" title="Royalty fee percentage"><ix:nonFraction name="GTBP:RoyaltyFeePercentage" contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember" id="Fact001449" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6</ix:nonFraction></span>% under subsequent license agreements or amendments, and minimum royalty payments due upon the commencement
of commercial sales of licensed product is $<span id="xdx_906_ecustom--RoyaltyExpenseYearOne_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_ziTht2PQwnch" title="Royalty expense year one"><ix:nonFraction name="GTBP:RoyaltyExpenseYearOne" contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember" id="Fact001451" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span> in year one, $<span id="xdx_903_ecustom--RoyaltyExpenseYearTwoThroughFive_pn6n6_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zSyiVIqkU7Kf" title="Royalty expense years two through five"><ix:nonFraction name="GTBP:RoyaltyExpenseYearTwoThroughFive" contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember" id="Fact001453" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">2</ix:nonFraction></span> million in years two through five, and $<span id="xdx_900_ecustom--RoyaltyExpenseYearAfterSix_pn6n6_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_z58oVH3LQ0B" title="Royalty expense year six and thereafter"><ix:nonFraction name="GTBP:RoyaltyExpenseYearAfterSix" contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember" id="Fact001455" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">5</ix:nonFraction></span> million in year six throughout
the remainder of the term. The amendment also includes numerous performance milestone payments including clinical development milestone
payments totaling $<span id="xdx_90B_ecustom--PerformanceMilestonePayments_pn5n6_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zPNX5BSyMDY4" title="Performance milestone payments"><ix:nonFraction name="GTBP:PerformanceMilestonePayments" contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember" id="Fact001457" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.1</ix:nonFraction></span> million, and one-time sales milestone, and one-time sales milestone payments of $<span id="xdx_90B_ecustom--SalesMilestonePayments_pn6n6_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zFwGgmt9iHr" title="One-time sales milestone payments"><ix:nonFraction name="GTBP:SalesMilestonePayments" contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember" id="Fact001459" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">1</ix:nonFraction></span> million upon reaching $<span id="xdx_902_ecustom--GrossSales_pn6n6_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_z7FCwVdFrZGl" title="Gross sales"><ix:nonFraction name="GTBP:GrossSales" contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember" id="Fact001461" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">250</ix:nonFraction></span>
million in cumulative gross sales, and $<span id="xdx_904_ecustom--SalesRevenue_pn6n6_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zzXVHVZczmR5" title="Sales revenue"><ix:nonFraction name="GTBP:SalesRevenue" contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember" id="Fact001463" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">5</ix:nonFraction></span> million upon reaching $<span id="xdx_90B_ecustom--CummulativeGrossSales_pn6n6_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zOKiZFDtJy" title="Cumulative gross sales"><ix:nonFraction name="GTBP:CummulativeGrossSales" contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember" id="Fact001465" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">500</ix:nonFraction></span> million in cumulative gross sales of licensed products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded an expense classified as research and development of approximately $<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_c20250101__20250930__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_z5ZW4qbnP2nd" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-01-012025-09-30_custom_TwoThousandSixteenPatentLicenseAgreementMember" id="Fact001467" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_90C_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20240930__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_ztw8F1oZGO53" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-09-30_custom_TwoThousandSixteenPatentLicenseAgreementMember" id="Fact001469" format="ixt:numdotdecimal" decimals="0" unitRef="USD">145,000</ix:nonFraction></span>, pursuant to the 2016 Exclusive Patent
License Agreement, for the nine months ended September 30, 2025 and 2024, respectively</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021
Exclusive License Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
March 26, 2021, the Company entered into an exclusive license agreement with the Regents of the University of Minnesota (the &#8220;2021
Exclusive Patent License Agreement&#8221;), specific to the B7H3 targeted TriKE<sup>&#174;</sup>. The agreement requires an upfront payment
of $<span id="xdx_902_ecustom--UpfrontLicenseFee_pp0p0_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zE7MI2Bgi1oe" title="Upfront license fee"><ix:nonFraction name="GTBP:UpfrontLicenseFee" contextRef="From2021-03-262021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember" id="Fact001471" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">20,000</ix:nonFraction></span>, and license maintenance fees of $<span id="xdx_900_eus-gaap--CostMaintenance_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_z8YeHZQGU2S1" title="License maintenance fees"><ix:nonFraction name="us-gaap:CostMaintenance" contextRef="From2021-03-262021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember" id="Fact001473" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000</ix:nonFraction></span> per year beginning in year 2022 and each year thereafter. The agreement also includes<span id="xdx_90D_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20210326__20210326__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zvM6SmSQ2MJa" title="Royalty fee percentage">
<ix:nonFraction name="GTBP:RoyaltyFeePercentage" contextRef="From2021-03-262021-03-26_srt_MinimumMember_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember" id="Fact001475" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.5</ix:nonFraction></span>% to <span id="xdx_904_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20210326__20210326__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zD71w4I0FsO2" title="Royalty fee percentage"><ix:nonFraction name="GTBP:RoyaltyFeePercentage" contextRef="From2021-03-262021-03-26_srt_MaximumMember_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember" id="Fact001477" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>% royalty fees on the net sales of licensed products, and minimum royalty payments due upon the commencement of commercial sales
of licensed product is $<span id="xdx_90D_ecustom--RoyaltyExpenseYearOneThoughFour_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zJ0wury3GQ4l" title="Royalty expense year one though four"><ix:nonFraction name="GTBP:RoyaltyExpenseYearOneThoughFour" contextRef="From2021-03-262021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember" id="Fact001479" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span> in year one though four, and $<span id="xdx_904_ecustom--RoyaltyExpenseYearAfterFive_pn6n6_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_z0M2x9OnoQUi" title="Royalty expense year five and thereafter"><ix:nonFraction name="GTBP:RoyaltyExpenseYearAfterFive" contextRef="From2021-03-262021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember" id="Fact001481" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">2</ix:nonFraction></span> million beginning in year five and throughout the remainder of the term.
The agreement also includes numerous performance milestone payments including clinical development milestone payments totaling $<span id="xdx_907_ecustom--PerformanceMilestonePayments_pn5n6_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zPqwCW0BN4C6" title="Performance milestone payments"><ix:nonFraction name="GTBP:PerformanceMilestonePayments" contextRef="From2021-03-262021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember" id="Fact001483" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.1</ix:nonFraction></span> million,
and one-time sales milestone payments of $<span id="xdx_90E_ecustom--SalesMilestonePayments_pn6n6_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_z9QGgGlQiU8i" title="One-time sales milestone payments"><ix:nonFraction name="GTBP:SalesMilestonePayments" contextRef="From2021-03-262021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember" id="Fact001485" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">1</ix:nonFraction></span> million upon reaching $<span id="xdx_905_ecustom--GrossSales_pn6n6_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zeN0wqMTsCLc" title="Gross sales"><ix:nonFraction name="GTBP:GrossSales" contextRef="From2021-03-262021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember" id="Fact001487" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">250</ix:nonFraction></span> million in cumulative gross sales, and $<span id="xdx_906_ecustom--SalesRevenue_pn6n6_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_z4JldzGVp4cf" title="Sales revenue"><ix:nonFraction name="GTBP:SalesRevenue" contextRef="From2021-03-262021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember" id="Fact001489" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">5</ix:nonFraction></span> million upon reaching
$<span id="xdx_90D_ecustom--CummulativeGrossSales_pn6n6_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zdfoVX3DJ2i3" title="Cumulative gross sales"><ix:nonFraction name="GTBP:CummulativeGrossSales" contextRef="From2021-03-262021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember" id="Fact001491" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">500</ix:nonFraction></span> million in cumulative gross sales of licensed products. There is no double payment intended; if one of the milestone payments has
been paid under the 2016 restated exclusive patent license agreement no further payment is due for the corresponding milestone.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company did not record any expense classified as research and development, pursuant to the 2021 Exclusive License Agreement, for the
nine months ended September 30, 2025 and 2024, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024
GTB-3650 Clinical Trial Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 18, 2024, the Registrant entered into an Investigator Initiated Clinical Trial Agreement (the &#8220;Agreement&#8221;) with
the Regents of the University of Minnesota (the &#8220;University&#8221;), pursuant to which, the University shall sponsor an Investigational
New Drug (&#8220;IND&#8221;) application for IND 165546 GTB-3650 (the &#8220;Research Program&#8221;) and shall serve as a sponsor investigator
for a phase 1 clinical trial entitled, &#8220;GTB-3650 (CD16/IL-15/CD33) Tri-Specific Killer Engager (TriKE) for the Treatment of High
Risk Myelodysplastic Syndromes (MDS), Refractory/Relapsed Acute Myeloid Leukemia (AML), and Minimal Residual Disease in AML,&#8221; designed
by the University (the &#8220;Study&#8221;). The Research Program is being conducted for clinical research use. The budget for the Study,
including without limitations, funding and resources, provides for up to approximately $<span id="xdx_901_eus-gaap--RoyaltyExpense_pn5n6_c20241118__20241118__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember_zJnyRpgd63Ga" title="Annual royalty payments"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="From2024-11-182024-11-18_custom_TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember" id="Fact001493" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.1</ix:nonFraction></span> million over the course of three years borne
by the Company. The Study data will be owned by the University, however, the Company may use the Study data subject to any applicable
signed informed consent documents and authorization forms, applicable law and terms of the Agreement. The University and the Company
will each have the right to publish the Study results. The Agreement may be terminated by the Company or the University at any time upon
thirty days&#8217; written notice to the other party, by the University immediately for health, welfare and safety reasons, or by either
party if the other party materially breaches the Agreement, provided that the breaching party fails to cure such breach within thirty
days.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company did not record any expense classified as research and development, pursuant to the 2024 Clinical Trial Agreement, for the nine
months ended September 30, 2025 and 2024, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2025 the Company&#8217;s commitments in relation to unbilled and unaccrued amounts from the University of Minnesota
pursuant to the 2024 Clinical Trial Agreement for services that have not yet been rendered as of September 30, 2025, amounted to approximately
$<span id="xdx_900_eus-gaap--UnbilledReceivablesCurrent_iI_pn5n6_c20250930__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember_zcDeSXmGJ9Ad" title="Unbilled and unaccrued amounts"><ix:nonFraction name="us-gaap:UnbilledReceivablesCurrent" contextRef="AsOf2025-09-30_custom_TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember" id="Fact001495" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.9</ix:nonFraction></span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Contingency
&#8211; NASDAQ Matters</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 21, 2024, we received a letter (the &#8220;Notification Letter&#8221;) from the Nasdaq Listing Qualifications Staff (the &#8220;Staff&#8221;)
notifying us that the amount of our stockholders&#8217; equity had fallen below the $<span id="xdx_908_ecustom--ContigencyMinimumRequired_iI_c20241121_zpaVEXkKVLf8" title="Contigency minimum required"><ix:nonFraction name="GTBP:ContigencyMinimumRequired" contextRef="AsOf2024-11-21" id="Fact001497" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,500,000</ix:nonFraction></span> required minimum for continued listing
set forth in Nasdaq Listing Rule 5550(b)(1) (the &#8220;Minimum Stockholders&#8217; Equity Requirement&#8221;). Nasdaq&#8217;s determination
was based upon our stockholders&#8217; equity as reported in our Quarterly Report on Form 10-Q for the period ended September 30, 2024.
The Notification Letter also noted that we did not meet the alternatives of market value of listed securities or net income from continuing
operations, and therefore, we no longer complied with Nasdaq&#8217;s Listing Rules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 20; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Notification Letter indicated that we had 45 days (i.e., until January 6, 2025) to submit a plan to regain compliance with the Minimum
Stockholders&#8217; Equity Requirement, noting that if such plan is accepted, the Staff can grant us an extension of up to 180 days from
the date of the Notification Letter to evidence compliance. In determining whether to accept our plan, the Staff will consider such things
as the likelihood that the plan will result in compliance with Nasdaq&#8217;s continued listing criteria, our past compliance history,
the reasons for our current non-compliance, other corporate events that may occur within the review period, our overall financial condition
and our public disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
submitted a plan of compliance to the Staff on December 31, 2024, outlining our plan to conduct periodic public and private securities
offerings to regain compliance. The Staff also requested additional information regarding our financing plans and financial projection,
which we provided to them. On June 13, 2025, we received a letter from the Staff notifying us that we have regained compliance with the
Minimum Stockholders&#8217; Equity Requirement set forth in Nasdaq Listing Rule 5550(b)(1). Nasdaq will continue to monitor the Company
to ensure its ongoing compliance with the Minimum Stockholders&#8217; Equity Requirement, so if at the time of the filing of the Company&#8217;s
next periodic financial statements the Company does not evidence compliance with the Minimum Stockholders&#8217; Equity Requirement,
the Company may be subject to delisting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our common stock is delisted from Nasdaq, our ability to raise capital through public offerings of our securities and to finance our
operations could be adversely affected. We also believe that delisting would likely result in decreased liquidity and/or increased volatility
in our common stock and could harm our business and future prospects. In addition, we believe that, if our common stock is delisted,
our stockholders would likely find it more difficult to obtain accurate quotations as to the price of our common stock and it may be
more difficult for stockholders to buy or sell our common stock at competitive market prices, or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact001499" name="us-gaap:SegmentReportingDisclosureTextBlock"><p id="xdx_809_eus-gaap--SegmentReportingDisclosureTextBlock_zue1yziCvkia" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
8 &#8211; <span id="xdx_828_zwO53ogHG65a">Segment Information</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company operates and manages its business as <span id="xdx_90B_eus-gaap--NumberOfReportableSegments_dc_uSegment_c20250101__20250930_znmpa1ZCCgY" title="Number of reportable segments"><span id="xdx_901_eus-gaap--NumberOfOperatingSegments_dc_uSegment_c20250101__20250930_zLKiXK4kkIXa" title="Number of operating segments"><ix:nonFraction name="us-gaap:NumberOfReportableSegments" contextRef="From2025-01-01to2025-09-30" id="Fact001501" format="ixt-sec:numwordsen" decimals="INF" unitRef="Segment"><ix:nonFraction name="us-gaap:NumberOfOperatingSegments" contextRef="From2025-01-01to2025-09-30" id="Fact001503" format="ixt-sec:numwordsen" decimals="INF" unitRef="Segment">one</ix:nonFraction></ix:nonFraction></span></span> reportable and operating as a clinical stage biopharmaceutical company focused on the
development and commercialization of novel immune-oncology products based on our proprietary Tri-specific Killer Engager (TriKE&#174;),
and Tetra-specific Killer Engager (Dual Targeting TriKE&#174;) platforms. The measure of segment assets is reported on the balance sheet
as total assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s CODM reviews financial information presented and decides how to allocate resources based on net income (loss). Net income
(loss) is used for evaluating financial performance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
segment expenses include research and development, salaries, insurance, and stock-based compensation. Operating expenses include all
remaining costs necessary to operate our business, which primarily include external professional services and other administrative expenses.
The following table presents the significant segment expenses and other segment items regularly reviewed by our CODM:</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact001505" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock"><p id="xdx_898_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zYUjP5kVJlN9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B6_z0MNCmWZBUfc" style="display: none">Schedule of Segment Information</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20250701__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentsMember_zlHe3GHsSYwk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20240701__20240930__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentsMember_z5gnyLMkjvjk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20250101__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentsMember_z3RPZOqW7rb6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20240101__20240930__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentsMember_zo9Z7Dj7q5Ba" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three Months Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nine Months Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OtherResearchAndDevelopmentExpense_z0188yUA6f1k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 20%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="From2025-07-012025-09-30_custom_SegmentsMember" id="Fact001507" format="ixt:numdotdecimal" decimals="0" unitRef="USD">634,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="From2024-07-012024-09-30_custom_SegmentsMember" id="Fact001508" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,307,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="From2025-01-012025-09-30_custom_SegmentsMember" id="Fact001509" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,096,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="From2024-01-012024-09-30_custom_SegmentsMember" id="Fact001510" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,868,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--SalariesAndWages_zFNlmjpWubMa" style="vertical-align: bottom; background-color: White">
    <td>Salaries</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:SalariesAndWages" contextRef="From2025-07-012025-09-30_custom_SegmentsMember" id="Fact001512" format="ixt:numdotdecimal" decimals="0" unitRef="USD">373,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:SalariesAndWages" contextRef="From2024-07-012024-09-30_custom_SegmentsMember" id="Fact001513" format="ixt:numdotdecimal" decimals="0" unitRef="USD">340,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:SalariesAndWages" contextRef="From2025-01-012025-09-30_custom_SegmentsMember" id="Fact001514" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,006,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:SalariesAndWages" contextRef="From2024-01-012024-09-30_custom_SegmentsMember" id="Fact001515" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,106,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--InsuranceCommissions_zdhHkdntQvxd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InsuranceCommissions" contextRef="From2025-07-012025-09-30_custom_SegmentsMember" id="Fact001517" format="ixt:numdotdecimal" decimals="0" unitRef="USD">54,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InsuranceCommissions" contextRef="From2024-07-012024-09-30_custom_SegmentsMember" id="Fact001518" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InsuranceCommissions" contextRef="From2025-01-012025-09-30_custom_SegmentsMember" id="Fact001519" format="ixt:numdotdecimal" decimals="0" unitRef="USD">175,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InsuranceCommissions" contextRef="From2024-01-012024-09-30_custom_SegmentsMember" id="Fact001520" format="ixt:numdotdecimal" decimals="0" unitRef="USD">194,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ShareBasedCompensation_zbAxehkzxAn8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-07-012025-09-30_custom_SegmentsMember" id="Fact001522" format="ixt:numdotdecimal" decimals="0" unitRef="USD">379,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1523">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-01-012025-09-30_custom_SegmentsMember" id="Fact001524" format="ixt:numdotdecimal" decimals="0" unitRef="USD">386,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-09-30_custom_SegmentsMember" id="Fact001525" format="ixt:numdotdecimal" decimals="0" unitRef="USD">222,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingExpenses_z56JyVmBIh79" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2025-07-012025-09-30_custom_SegmentsMember" id="Fact001527" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,942,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2024-07-012024-09-30_custom_SegmentsMember" id="Fact001528" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,915,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2025-01-012025-09-30_custom_SegmentsMember" id="Fact001529" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,164,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2024-01-012024-09-30_custom_SegmentsMember" id="Fact001530" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,211,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--NonoperatingIncomeExpense_zWuKoT7EHPj1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Other income</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2025-07-012025-09-30_custom_SegmentsMember" id="Fact001532" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">268,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2024-07-012024-09-30_custom_SegmentsMember" id="Fact001533" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">193,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2025-01-012025-09-30_custom_SegmentsMember" id="Fact001534" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,504,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2024-01-012024-09-30_custom_SegmentsMember" id="Fact001535" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,214,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--NetIncomeLoss_zqz2pyh33BXd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-07-012025-09-30_custom_SegmentsMember" id="Fact001537" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,114,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-07-012024-09-30_custom_SegmentsMember" id="Fact001538" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,411,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-09-30_custom_SegmentsMember" id="Fact001539" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,323,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-09-30_custom_SegmentsMember" id="Fact001540" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,387,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_zqj5a1ll4YFf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" escape="true" id="Fact001542" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_80B_eus-gaap--SubsequentEventsTextBlock_zuFckF18x079" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
9 &#8211; <span id="xdx_823_zk5l3Imrk4O">Subsequent Events</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise
of Series L 10% Convertible Preferred Stock Greenshoe Rights</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
October 2025, Purchasers of the Company&#8217;s Series L 10% Convertible Preferred Stock (the &#8220;Preferred Stock&#8221;) elected
to exercise their Greenshoe Rights and purchased <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20251001__20251031__us-gaap--StatementClassOfStockAxis__custom--SeriesL10PercentageConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zx7wB4P8NCvc" title="Shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-10-012025-10-31_custom_SeriesL10PercentageConvertiblePreferredStockMember_us-gaap_SubsequentEventMember" id="Fact001544" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,055.55</ix:nonFraction></span> shares of the Company&#8217;s Preferred Stock with a stated value of $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20251001__20251031__us-gaap--StatementClassOfStockAxis__custom--SeriesL10PercentageConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zBm1jURi5wt8" title="Shares issued value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-10-012025-10-31_custom_SeriesL10PercentageConvertiblePreferredStockMember_us-gaap_SubsequentEventMember" id="Fact001546" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,055,556</ix:nonFraction></span>
for a purchase price of $<span id="xdx_901_ecustom--PreferredStockPurchasePrice_c20251001__20251031__us-gaap--StatementClassOfStockAxis__custom--SeriesL10PercentageConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zsvLfPMdyRsk" title="Purchase price"><ix:nonFraction name="GTBP:PreferredStockPurchasePrice" contextRef="From2025-10-012025-10-31_custom_SeriesL10PercentageConvertiblePreferredStockMember_us-gaap_SubsequentEventMember" id="Fact001548" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,850,000</ix:nonFraction></span>. As a result of the transaction the conversion price of the Preferred Stock was decreased from $<span id="xdx_909_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20251030__us-gaap--StatementClassOfStockAxis__custom--SeriesL10PercentageConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zK2xyp1rnce7" title="Exercise price"><ix:nonFraction name="us-gaap:PreferredStockConvertibleConversionPrice" contextRef="AsOf2025-10-30_custom_SeriesL10PercentageConvertiblePreferredStockMember_us-gaap_SubsequentEventMember" id="Fact001550" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.6421</ix:nonFraction></span>
to $<span id="xdx_90A_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20251031__us-gaap--StatementClassOfStockAxis__custom--SeriesL10PercentageConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zWYI0C1yjuji" title="Exercise price"><ix:nonFraction name="us-gaap:PreferredStockConvertibleConversionPrice" contextRef="AsOf2025-10-31_custom_SeriesL10PercentageConvertiblePreferredStockMember_us-gaap_SubsequentEventMember" id="Fact001552" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.5319</ix:nonFraction></span>. The conversion price adjustment constitutes a dilutive issuance and as a result, the exercise price of the Common Warrants
and Vesting Warrants issued in the Series L 10% Convertible Preferred Stock transaction have been decreased, and the number of warrant
shares have been increased, such that the aggregate exercise price of the warrants, after taking into account the decrease in the exercise
price, shall be equal to the aggregate exercise price prior to such adjustment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Conversion
of Series L 10% Convertible Preferred Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
October 2025, the holders of the Company&#8217;s Series L Convertible Preferred Stock have converted <span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_c20251031__us-gaap--StatementClassOfStockAxis__custom--SeriesLConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zON0FDn918l7" title="Shares converted"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2025-10-31_custom_SeriesLConvertiblePreferredStockMember_us-gaap_SubsequentEventMember" id="Fact001554" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,556.48</ix:nonFraction></span> shares of Series L Convertible
Preferred Stock into <span id="xdx_90A_eus-gaap--CommonStockSharesOutstanding_iI_c20251031__us-gaap--StatementClassOfStockAxis__custom--SeriesLConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z0kVyr8VBbT4" title="Number of shares converted"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2025-10-31_custom_SeriesLConvertiblePreferredStockMember_us-gaap_SubsequentEventMember" id="Fact001556" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,309,288</ix:nonFraction></span> shares of common stock.</span></p>

</ix:nonNumeric><p id="xdx_819_zjh7NDebONi3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="a_001"></span>Item
2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations. </span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CAUTIONARY
NOTICE REGARDING FORWARD-LOOKING STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
of the statements in this Quarterly Report on Form 10-Q are &#8220;forward-looking statements&#8221; within the meaning of the safe harbor
from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding
our current beliefs, goals and expectations about matters such as our expected financial position and operating results, our business
strategy and our financing plans. The forward-looking statements in this report are not based on historical facts, but rather reflect
the current expectations of our management concerning future results and events. The forward-looking statements generally can be identified
by the use of terms such as &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221;
&#8220;foresee,&#8221; &#8220;may,&#8221; &#8220;guidance,&#8221; &#8220;estimate,&#8221; &#8220;potential,&#8221; &#8220;outlook,&#8221;
&#8220;target,&#8221; &#8220;forecast,&#8221; &#8220;likely&#8221; or other similar words or phrases. Similarly, statements that describe
our objectives, plans or goals are, or may be, forward-looking statements. Forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause our actual results, performance or achievements to be different from any future results,
performance and achievements expressed or implied by these statements. We cannot guarantee that our forward-looking statements will turn
out to be correct or that our beliefs and goals will not change. Our actual results could be very different from and worse than our expectations
for various reasons. You should carefully review all information, including the discussion of risk factors under &#8220;Part I. Item
1A: Risk Factors&#8221; and &#8220;Part II. Item 7: Management&#8217;s Discussion and Analysis of Financial Condition and Results of
Operations&#8221; of the Form 10-K for the year ended December 31, 2024. Any forward-looking statements in the Form 10-Q are made only
as of the date hereof and, except as may be required by law, we do not have any obligation to publicly update any forward-looking statements
contained in this Form 10-Q to reflect subsequent events or circumstances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Organization
</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
corporate predecessor of GT Biopharma, Inc, Diagnostic Data, Inc., was incorporated in the state of California in 1965. Diagnostic Data,
Inc. changed its incorporation to the state of Delaware on December 21, 1972 and changed its name to DDI Pharmaceuticals, Inc. on March
11, 1985. On September 7, 1994, DDI Pharmaceuticals, Inc. merged with International BioClinical, Inc. and Bioxytech S.A. and changed
its name to OXIS International, Inc. On July 17, 2017, OXIS International, Inc. changed its name to GT Biopharma, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products based
on our proprietary Tri-specific Killer Engager (TriKE&#174;), and Tetra-specific Killer Engager (Dual Targeting TriKE&#174;) fusion protein
immune cell engager technology platforms. Our TriKE&#174; and Dual Targeting TriKE&#174; platforms generate proprietary therapeutics designed
to harness and enhance the cancer killing abilities of a patient&#8217;s own natural killer cells, or NK cells. Once bound to an NK cell,
our moieties are designed to activate the NK cell to direct it to one or more specifically targeted proteins expressed on a specific
type of cancer cell or virus infected cell, resulting in the targeted cell&#8217;s death. TriKE&#174;s can be designed to target any number
of tumor antigens, including B7-H3, HER2, CD33 and PDL1, on hematologic malignancies or solid tumors and do not require patient-specific
customization. We believe our TriKE&#174; and Dual Targeting TriKE&#174; platforms that activate endogenous NK cells are potentially safer
than T-cell immunotherapy because there is less cytokine release syndrome (CRS) and fewer neurological complications. Our preclinical
data suggests that this is explained by the TriKE&#174; dependent CD16 directed IL-15 proliferation of NK cells but little effect endogenous
T cells.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are using our TriKE&#174; platform with the intent to bring to market immuno-oncology products that can treat a range of hematologic malignancies,
solid tumors, and potentially autoimmune disorders. The platform is scalable, and we are implementing processes to produce investigational
new drug (IND) ready moieties in a timely manner after a specific TriKE&#174; conceptual design. Specific drug candidates can then be
advanced into the clinic on our own or through potential collaborations with partnering companies. We believe our TriKE&#174;s may have
the ability, if approved for marketing, to be used as both monotherapy and in combination with other standard-of-care therapies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
initial work was conducted in collaboration with the Masonic Cancer Center at the University of Minnesota under a program led by Dr.
Jeffrey Miller, Professor of Medicine, and the Interim Director at the Center. Dr. Miller, who also serves as our Consulting Senior Medical
Director, is a recognized key opinion leader in the field of NK cell and IL-15 biology and their therapeutic potential. We have exclusive
rights to the TriKE&#174; platform and are generating additional intellectual property for specific moieties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 22 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
current product candidate pipeline is summarized in the table below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-q_001.jpg" alt=""/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GTB-3550</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GTB-3550
was our first TriKE&#174; product candidate and its clinical development was suspended so that we could focus resources on second-generation
TriKEs&#174;. GTB-3550 is a tri-specific killer engager (TriKE) comprised of two single-chain variable fragments (&#8220;scFv&#8221;)
composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. We
studied this anti-CD16-IL-15-anti-CD33 TriKE&#174; in CD33 positive leukemias, a marker expressed on tumor cells in acute myelogenous
leukemia, or AML, and myelodysplastic syndrome, or MDS. The anti-CD33 antibody fragment in GTB-3550 was derived from the M195 humanized
anti-CD33 scFv. We believe the approval of the antibody-drug conjugate gemtuzumab validates the targeting of CD33.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
previously announced the interim clinical trial results for GTB-3550, which showed significantly reduced CD 33+ bone marrow blast levels
by 33.3%, 61.7%, 63.6%, 50% in Patient 5 (25 &#181;g/kg/day), Patient 7 (50 &#181;g/kg/day), Patient 9 (100 &#181;g/kg/day), and Patient
11 (150 &#181;g/kg/day), respectively. After the end of infusion, GTB-3550 and IL-15 concentrations declined rapidly with overall geometric
mean terminal phase elimination half-life (T1/2) of 2.2 and 2.52 hours, respectively. There was minimal CRS resulting from hyperactivation
of patient&#8217;s T-cell population at doses 5&#8211;150 &#181;g/kg/day.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Despite
the positive interim clinical trial results, GTB-3550 was replaced by a more potent next-generation camelid nanobody TriKE&#174;, GTB-3650,
that similarly targets CD33 on relapsed/refractory AML and high-risk MDS. A key difference between GTB-3550 and GTB-3650 is the incorporation
of camelid antibody technology instead of a scFv; our preclinical experience showed markedly enhanced potency of TriKEs&#174; comprised
of camelid components. This is illustrated below by better tumor control of AML bearing animals with GTB-3650 (purple dots) compared
to GTB-3550 (blue dots). This provided the rationale for pausing further development of GTB-3550 and moving over to solely develop the
second-generation, camelid-based TriKE&#174; platform.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 2; Value: 22 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-q_002.jpg" alt=""/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Second
Generation TriKE<sup>&#174;</sup>s Utilize Camelid Nanobody Technology</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
goal is to be a leader in immuno-oncology therapies targeting a broad range of indications including hematological malignancies and solid
tumors. A key element of our strategy includes introducing a next-generation camelid nanobody platform. Camelid antibodies (often referred
as nanobodies) are smaller than human immunoglobulin, consisting of two heavy chains instead of two heavy and two light chains. These
nanobodies have the potential to have greater affinity to target antigens, potentially resulting in greater potency. We are utilizing
this camelid antibody structure for all of our new TriKE&#174; product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<!-- Field: Page; Sequence: 3; Value: 22 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
develop second generation TriKE&#174;s, we designed a new humanized CD16 engager derived from a single-domain antibody. While scFvs consist
of a heavy and a light variable chain joined by a linker, single-domain antibodies consist of a single variable heavy chain capable of
engaging without the need of a light chain counterpart (see figure below).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img src="form10-q_003.jpg" alt=""/><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
single-domain antibodies are thought to have certain attractive features for antibody engineering, including physical stability, ability
to bind deep grooves, and increased production yields, amongst others. Pre-clinical studies demonstrated increased NK cell activation
against CD33+ targets including enhanced NK cell degranulation (% CD107a+) and IFN&#947; with the single-domain CD16 TriKE&#174; (cam
16-wt15-33; GTB-3650) compared to the original TriKE&#174; (scFv16-m 15-33; GTB-3550) (see figure below). This data was published by Dr.
Felices M et al (2020) in Cancer Immunol Res.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>CD33+
HL60 Targets in Killing Assays</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
purple line represents the GTB-3650 and the blue line represents GTB-3550.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><img src="form10-q_004.jpg" alt=""/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GTB-3650</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GTB-3650
is a TriKE&#174; which targets CD33 on the surface of myeloid leukemias and an agonistic camelid engager to the potent activating receptor
on NK cells, CD16. Use of this engager enhances the activity of wild type IL-15 included in GTB-3650. The TriKE&#174; approach provides
a novel way to specifically target these tumors by leveraging NK cells, which have been shown to mediate relapse protection in this setting,
in an anti-CD33-targeted fashion. We are advancing GTB-3650 to clinical studies based on pre-clinical data showing a marked increase
in potency compared to GTB-3550, which we anticipate could lead to an enhanced efficacy signal in AML and MDS. We advanced GTB-3650 through
requisite preclinical studies and filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA)
in December 2023. In late June 2024, the FDA cleared our IND Application for GTB-3650. We started study enrollment targeting patients
with relapsed/refractory AML and high grade MDS on January 21, 2025. This initial study is testing GTB-3650 as monotherapy testing administration
2 weeks on and two weeks off (to prevent NK cell exhaustion) for at least 2 cycles of therapy, as agreed on with the FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 4; Value: 22 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-q_005.jpg" alt=""/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GTB-5550</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GTB-5550
is a B7-H3 targeted TriKE&#174; which targets B7-H3 on the surface of advanced solid tumors (figure above). GTB-5550 is our first dual
camelid TriKE&#174;. B7-H3 is expressed on a broad spectrum of solid tumor malignancies, allowing our team to target these malignancies
through GTB-5550. Pre-clinical work has shown that this molecule has NK-cell targeted activity against a variety of solid tumors, including
head and neck cancer squamous cell carcinoma (figure below), prostate cancer, breast cancer, ovarian cancer, glioblastoma, and lung cancer
(amongst others). We are advancing GTB-5550 through preclinical studies and initiated a GMP manufacturing campaign in anticipation of
filing an IND. A pre-IND packet was submitted to the FDA in October 2023 with a written response from the FDA in December 2023. The main
question from the FDA was regarding pre-clinical toxicology and a pivot to subcutaneous dosing. The initial trial is designed as a basket
trial for patients with B7-H3+ solid tumors using Monday through Friday dosing (2 weeks on and 2 weeks off to prevent immune exhaustion),
and is dependent on manufacturing of clinical materials. We anticipate submission of an IND application for GTB-5550 in late December 2025 or in January 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><img src="form10-q_006.jpg" alt=""/></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GTB-7550</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GTB-7550
TriKE&#174; is a product candidate in development for the treatment of lupus and other autoimmune disorders. GTB-7550 TriKE&#174; is a
tri-specific molecule composed of a camelid nanobody that binds the CD16 receptor on NK cells, a scFv engager against CD19 on malignant
and normal B cells, and a human IL-15 sequence between them.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published
data shows that GTB-7550 effectively targets CD19+ malignant cell lines and primary chronic lymphocytic leukemia (CLL). Preliminary data
shows that GTB-7550 can target and eliminate normal B cells, which we are continuing to test in mice. We are currently exploring and
assessing potential manufacturers of GTB-7550.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Accounting Policies and Estimates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of our financial statements in conformity with accounting principles generally accepted in the United States, or GAAP, requires
us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure
of contingent assets and liabilities. When making these estimates and assumptions, we consider our historical experience, our knowledge
of economic and market factors and various other factors that we believe to be reasonable under the circumstances. Actual results may
differ under different estimates and assumptions. The accounting estimates and assumptions discussed in this section are those that we
consider to be the most critical to gain an understanding of our financial statements because they inherently involve significant judgments
and uncertainties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 5; Value: 22 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use
of Estimates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the
reported amounts of revenues and expenses during the reporting period. Significant estimates include accruals for potential liabilities,
assumptions used in deriving the fair value of warrant liabilities, valuation of equity instruments issued for services, and valuation
of deferred tax assets. Actual results could differ from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrant
Liability</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
evaluate our financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives
in accordance with ASC Topic 815, &#8220;<i>Derivatives and Hedging.</i>&#8221; For derivative financial instruments that are accounted
for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with
changes in the fair value reported in the statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
use of derivative financial instruments is generally limited to warrants issued by us that do not meet the criteria for equity treatment
and are recorded as liabilities. We do not use financial instruments or derivatives for any trading purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock-Based
Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
periodically issue stock-based compensation to officers, directors, employees, and consultants for services rendered. Such issuances
vest and expire according to terms established at the issuance date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Stock-based
payments made to officers, directors, employees, and consultants in exchange for goods and services, including grants of employee stock
options, are recognized in the financial statements based on their grant date fair values in accordance with ASC 718, <i>Compensation-Stock
Compensation</i>. Stock based payments to officers, directors, employees, and consultants, which are generally time vested, are measured
at the grant date fair value and depending on the conditions associated with the vesting of the award, compensation cost is recognized
on a straight-line or graded basis over the vesting period. Recognition of compensation expense for non-employees is in the same period
and manner as if we had paid cash for the services. The fair value of stock options granted is estimated using the Black-Scholes option-pricing
model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life, and future dividends.
The assumptions used in the Black-Scholes option pricing model could materially affect compensation expense recorded in future periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Results
of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Comparison
of the Three and Nine Months Ended September 30, 2025 and 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Operating
Expenses</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">$&#160;Change</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">%&#160;Change</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Operating Expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 44%; text-align: justify">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">634,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">1,307,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(673,000</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">(51</td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Selling, general and administrative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,369,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,297,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">72,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Stock compensation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">379,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">379,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total Operating Expenses</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,382,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,604,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(222,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(6</td><td style="padding-bottom: 2.5pt; text-align: left">)%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine Months Ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">$&#160;Change</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">%&#160;Change</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Operating Expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 44%; text-align: justify">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">2,096,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">3,868,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(1,772,000</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">(46</td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Selling, general and administrative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,345,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,511,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,166,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(33</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Stock compensation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">386,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">222,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">164,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">74</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total Operating Expenses</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,827,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,601,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(3,774,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(36</td><td style="padding-bottom: 2.5pt; text-align: left">)%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Research
and Development Expenses</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses decreased by approximately $0.7 and $1.8 million for the three and nine months ended September 30, 2025, respectively,
compared to the same prior year periods, primarily due to a decrease in production and material costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 6; Value: 22 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses relate to our continued licensing, development and production of our most advanced TriKE&#174; product candidates
GTB-3650 and GTB-5550 along with the progression on other promising candidates. In late June 2024, we received clearance from the FDA
with respect to our IND Application in relation to our next generation GTB-3650 camelid nanobody product. Study enrollment began in early
2025 and we have advanced into the clinic, enrolling patients, and performing tests for data collection throughout the year. Following
our May 2025 financing we have restarted the final phase of product development of GTB-5550 and anticipate submission of an IND application
for GTB-5550 in late December 2025 or in January 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Selling,
General, and Administrative Expenses</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selling,
general, and administrative expenses remained relatively flat, increasing by approximately $72,000 for the three months ended September
30, 2025, compared to the same prior year period. Selling, general, and administrative expenses decreased by approximately $2.2 million
for the nine months ended September 30, 2025, compared to the same prior year period, and was primarily due to a significant reduction
in legal fees and other cost reduction measures, and partially offset by increased marketing expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
Income (Expense)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">$&#160;Change</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">%&#160;Change</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Other Income (Expense):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 44%; text-align: justify">Interest income</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">36,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">96,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(60,000</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">(63</td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Change in fair value of warrant liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">232,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">95,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">137,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">144</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Unrealized gain (loss) on marketable securities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(2,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(100</td><td style="padding-bottom: 1pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total Other Income (Expense)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">268,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">193,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">75,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">39</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine Months Ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">$&#160;Change</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">%&#160;Change</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Other Income (Expense):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 44%; text-align: justify">Interest income</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">106,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">343,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(237,000</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">(69</td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Change in fair value of warrant liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">244,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">870,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(626,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(72</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Unrealized gain (loss) on marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(100</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Gain on settlement of vendor payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">998,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">998,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">156,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">156,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total Other Income (Expense)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,504,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,214,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">290,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">24</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Interest
Income</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
income decreased by $60,000 and $237,000 for the three and nine months ended September 30, 2025, respectively, compared to the same prior
year periods, due to lower money market fund and short term investment balances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Change
in Fair Value of Warrant Liability</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
change in fair value of warrant liability increased by approximately $137,000 for the three months ended September 30, 2025, compared
to the same prior year period, resulting from a reduction in our warrant liability primarily due to the relative decline in the Company&#8217;s
stock price at September 30, 2025 as compared to the prior comparable period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
change in fair value of warrant liability decreased by approximately $626,000 for the nine months ended September 30, 2025, compared
to the same prior year period, resulting from a lesser reduction in our warrant liability primarily due to the relative decline in the
Company&#8217;s stock price at September 30, 2025 as compared to the prior comparable period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Gain
on Settlement of Vendor Payable</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2025, a legal services firm currently engaged by the Company agreed to reduce the Company&#8217;s prior year unpaid fees by approximately
$1 million. The Company classified this transaction as other income in June 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2025 the Company issued warrants underlying 24,390 shares of common stock exercisable at $2.24 per share with a fair value of approximately
$44,000 in exchange for the waiver of a variable rate transaction (&#8220;VRT&#8221;). The Company classified this transaction as other
income in June 30, 2025. The Company also recorded other income of $200,000 in June 2025 due to the extinguishment of an accrual of consulting
fees recorded in prior years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 7; Value: 22 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net
Loss</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 85%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">$&#160;Change</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">%&#160;Change</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Net Loss</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 10%; text-align: right">(3,114,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 10%; text-align: right">(3,411,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 10%; text-align: right">297,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; width: 10%; text-align: right">9</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 85%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine Months Ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">$&#160;Change</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">%&#160;Change</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Net Loss</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 10%; text-align: right">(5,323,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 10%; text-align: right">(9,387,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 10%; text-align: right">4,064,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; width: 10%; text-align: right">43</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
loss decreased by approximately $300,00 and $4.1 million for the&#160;three and nine months ended September 30, 2025, respectively, compared
to the same prior year periods, primarily due to a decrease research and development expenses and legal fees, as described above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity
and Going Concern Analysis</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying unaudited condensed financial statements have been prepared assuming that we will continue as a going concern.&#160;We do
not have any product candidates approved for sale and have not generated any revenue from our product sales. We have sustained operating
losses since inception, and we expect such losses to continue into the foreseeable future. Historically, we have financed our operations
through public and private sales of common stock, the issuance of preferred and common stock, the issuance of convertible debt instruments,
and strategic collaborations. For the nine months ended September 30, 2025, we recorded a net loss of approximately $5.3 million and
used cash in operations of approximately $8.9 million. These factors raise substantial doubt about our ability to continue as a going
concern within one year of the date that the financial statements are issued. In addition, the Company&#8217;s independent registered
public accounting firm, in its report on the Company&#8217;s December 31, 2024, financial statements, raised substantial doubt about
the Company&#8217;s ability to continue as a going concern. The financial statements do not include any adjustments that might be necessary
if the Company is unable to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited condensed financial statements do not include any adjustments that might be necessary if we are unable to continue as a going
concern. Accordingly, the unaudited condensed financial statements have been prepared on a basis that assumes we will continue as a going
concern, and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have evaluated the significance of the uncertainty regarding our financial condition in relation to our ability to meet our obligations,
which has raised substantial doubt about our ability to continue as a going concern. While it is very difficult to estimate our future
liquidity requirements we believe if we are unable to obtain additional financing, existing cash resources will not be sufficient to
enable us to fund the anticipated level of operations through one year from the date the accompanying unaudited condensed financial statements
are issued. There can be no assurances that we will be able to secure additional financing on acceptable terms. In the event that we
do not secure additional financing, we will be forced to delay, reduce, or eliminate some or all of our discretionary spending, which
could adversely affect our business prospects, ability to meet long-term liquidity needs and the ability to continue operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash
Flows</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.45in; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nine Months Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Statements of Cash Flow Data:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 62%; text-align: left">Net cash used in operating activities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">(8,893,000</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">(10,436,000</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net cash provided by investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,892,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Net cash provided by financing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">7,470,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,976,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;Net increase (decrease) in cash and cash equivalents and restricted cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,423,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,432,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Cash and cash equivalents and restricted cash, beginning of period</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,044,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,079,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;Cash and cash equivalents and restricted cash, end of period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,621,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,511,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Operating
Activities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in operating activities was approximately $8.9 million for the nine months ended September 30, 2025 and was primarily due to
a decrease in accounts payable and accrued expenses of $2.4 million and a net loss of $5.3 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in operating activities was approximately $ 10.4 million for the nine months ended September 30, 2024 and was primarily due
to a net loss of $9.4 million and a decrease in warrant liability of $0.9 million</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 8; Value: 22 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Investing
Activities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by financing activities was approximately $12.9 million for the nine months ended September 30, 2024, resulted from proceeds
of the sale of short-term investments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financing
Activities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by financing activities was approximately $7.5 million for the nine months ended September 30, 2025 and resulted from net
proceeds from issuance of Series L Convertible Preferred Stock and warrants, and net proceeds from the exercise of warrants for cash
and inducement warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by financing activities approximately $3.0 million for the nine months ended September 30, 2024 and resulted from net proceeds
from issuance of common stock and warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Working
Capital (Deficit)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes total current assets, liabilities, and working capital (deficit) for the periods ended September 30, 2025
and December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.35in; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30, </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2025</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,<br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Increase/(Decrease)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Current assets</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">4,321,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">4,232,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">89,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current liabilities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,321,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5,902,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(4,581,000</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Working capital (deficit)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(1,670,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4,670,000</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Off-Balance
Sheet Arrangements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have no off-balance sheet arrangements as of September 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="a_002"></span>Item
3. Quantitative and Qualitative Disclosures About Market Risk</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Company qualifies as a smaller reporting company, as defined in 17 C.F.R. &#167;229.10(f)(1) and is not required to provide information
for this Item.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="a_003"></span>Item
4. Controls and Procedures</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Evaluation
of Disclosure Controls and Procedures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer evaluated the effectiveness of our &#8220;disclosure
controls and procedures&#8221; (as such term is defined in Rules 13a-15(e) and 15d-15(e) of the United States Securities Exchange Act
of 1934, as amended), as of September 30, 2025. Based on that evaluation, we have concluded that our disclosure controls and procedures
were effective as of September 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Management&#8217;s
Report on Internal Control Over Financial Reporting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting
is defined in Rule 13a-15(f) or 15d-15(f) promulgated under the Securities Exchange Act of 1934, as amended, as a process designed by,
or under the supervision of, a company&#8217;s principal executive and principal accounting officers and effected by a company&#8217;s
board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting
and the preparation of financial statements for external purposes in accordance with GAAP and includes those policies and procedures
that:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pertain
    to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provide
    reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with
    GAAP, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors;
    and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provide
    reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that
    could have a material effect on the financial statements.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 9; Value: 22 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Inherent
Limitations on the Effectiveness of Controls</b>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all
errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance
that the objectives of the control systems are met. Further, the design of a control system must reflect the fact that there are resource
constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in a cost-effective
control system, no evaluation of internal control over financial reporting can provide absolute assurance that misstatements due to error
or fraud will not occur or that all control issues and instances of fraud, if any, have been or will be detected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of a
simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people,
or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood
of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future
conditions. Projections of any evaluation of controls effectiveness to future periods are subject to risks. Over time, controls may become
inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Changes
in Internal Control Over Financial Reporting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
changes in our internal controls over financial reporting were made during our most recent fiscal quarter that has materially affected,
or is reasonably likely to materially affect, our internal control over financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_004"></span>PART
II. OTHER INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="a_005"></span>Item
1. Legal Proceedings</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ohri
Matter</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 22, 2024, the Company filed an AAA Arbitration demand against Manu Ohri, its former Chief Financial Officer.&#160;In the Demand,
the Company asserts claims against Mr. Ohri for breach of his fiduciary duties and breach of contract and seeks a declaratory judgment
providing that the Company may characterize Mr. Ohri&#8217;s termination as &#8220;for cause&#8221; under his employment agreement, and
that the Company may revoke the separation agreement entered into between the Company and Mr. Ohri prior to the Company learning of Mr.
Ohri&#8217;s breaches.&#160;In addition to the declaratory judgment, the Company seeks damages arising from Mr. Ohri&#8217;s violations,
and attorneys&#8217; fees and any forum and arbitration fees. On September 3, 2024, Mr. Ohri filed both a general denial of the Company&#8217;s
claims against him and counterclaims for breach of his employment agreement and separation agreement. The final hearing date, originally
scheduled for June 10, 2025, has been postponed indefinitely in order to allow the parties to mediate the dispute. At this time, mediation
has not been scheduled. There is a status conference scheduled for December 11, 2025 before the AAA. At this stage in the proceedings
the Company is not able to determine the probability of the outcome of this matter or a range of reasonably expected losses, if any.
The Company believes it has recorded an appropriate accrual for the matter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TWF
Global Matter</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 24, 2023, TWF Global, LLC (&#8220;TWF&#8221;) filed a complaint in the California Superior Court for the County of Los Angeles naming
the Company as defendant. The Complaint alleges that TWF is the holder of two Convertible Promissory Notes (&#8220;Notes&#8221;) and
that the Company did not deliver shares of common stock due on conversion in February 2021. TWF was seeking per diem liquidated damages
based on the terms of alleged Notes. On July 14, 2023, the Company filed a motion to dismiss for improper forum because the terms of
the Notes, as alleged, require disputes to be filed in New York state and federal courts. TWF voluntarily dismissed its complaint before
the California Superior Court of Los Angeles without prejudice. The Company subsequently filed a Summons and complaint for interpleader
against TWF and Z-One, LLC before the Supreme Court of the State of New York County of New York, asking the Supreme Court to determine
if the Company&#8217;s shares of common stock should be registered to TWF or Z-One, LLC, as both of these entities have made conflicting
demands for the shares. On February 5, 2024, the Company filed a motion for entry of default against TWF, seeking an order directing
the Company to register the shares of common stock in the name of Z-One, LLC and that the Company be released from all associated liability
and claims. The Court denied the motion without prejudice and agreed to reconsider the motion without further briefing upon the filing
of a supplemental party affidavit. On May 9, 2024, Z-One filed a motion for summary judgement seeking dismissal of the action, representing
that Z-One, LLC and TWF have settled their dispute over the entitlement to the Company&#8217;s shares of common stock and there is no
remaining dispute before the Court. On May 21, 2024, the Company filed a supplemental affidavit in support of its motion for entry of
default. On November 14, 2024, the Court held a hearing on the parties&#8217; motions, at which the Court found that the motion for entry
of default was mooted by the settlement agreement between Z-One, LLC and TWF. The Court ordered that the case be dismissed.&#160;On February
17, 2025, Z-One, LLC filed a Summons with Notice in the Supreme Court of the State of New York, County of New York.&#160;The Company
then filed a demand that Z-One, LLC serve a complaint, and on June 25, 2025, Z-One, LLC filed a Complaint alleging that it is the holder,
either originally or by assignment, of a Convertible Note in the principal amount of $150,000, that the Company breached the Convertible
Note by failing to deliver conversion shares to Z-One, LLC, and that the Company owes it damages in excess of $500,000. On August 26,
2025, the Company filed a motion to dismiss the Complaint in its entirety for lack of standing and failure to state a cause of action.
The Company believes that the claims related to the Notes are without merit, and will continue to vigorously defend against these claims.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 10; Value: 22 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Silberfein,
DiPietro, and Werthman Trust Matters</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 8, 2025, Coby Silberfein filed a summons with notice in the State of New York Supreme Court for the County of New York naming the
Company as defendant seeking damages for breach of a securities purchase agreement and convertible note in the principal amount of $100,000.&#160;On
July 8, 2025, Justin DiPietro filed a summons with notice in the State of New York Supreme Court for the County of New York naming the
Company as defendant seeking damages for breach of a securities purchase agreement and convertible note in the principal amount of $100,000.&#160;On
July 9, 2025, Phillip Werthman Trust filed a summons with notice in the State of New York Supreme Court for the County of New York naming
the Company as defendant seeking damages for breach of a securities purchase agreement and convertible note in the principal amount of
$100,000.&#160;The three summons with notice are identical and allege that the plaintiffs are holders of convertible notes and that the
Company breached the convertible notes by failing to deliver shares of common stock due on conversion in in 2021. Plaintiffs are seeking
specific performance and damages. On August 12, 2025, the Company filed demands that the plaintiffs serve complaints. On September 2,
2025, each plaintiff served a Complaint similar in substance to the summons, except that Plaintiff Silberfein now alleges breach of a
convertible note with a principal amount of $150,000, rather than $100,000. Each plaintiff alleges that the Company breached a convertible
note by failing to deliver conversion shares to the plaintiff holder, and that the Company owes damages in excess of $500,000. The Company
intends to seek dismissal of the complaints.&#160;The Company believes that the claims are without merit, and intends to vigorously defend
against these claims.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="a_006"></span>Item
1A. Risk Factors</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than as set forth below, there have been no material changes from the risk factors disclosed in Part I, Item 1A &#8220;Risk
Factors&#8221; in our Annual Report on Form 10-K for the year ended December&#160;31, 2024&#160;and Part II, Item 1A &#8220;Risk
Factors&#8221; in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><b><i>We are subject to state
and federal securities laws, the terms of the Company&#8217;s Restated Certificate of Incorporation (the &#8220;Charter&#8221;), Amended and Restated
Bylaws (the &#8220;Bylaws&#8221;) and the terms of complex contracts; a failure to comply with current and future laws, regulations or standards,
or the terms of our Charter, Bylaws or contractual arrangements, could have an adverse effect on our business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">We are subject to state and federal securities laws, including the information and reporting requirements of the
Securities Exchange Act of 1934, as amended, and other federal securities laws, as well as the provisions of the Delaware General Corporation
Law.&#160; Failure or noncompliance with such laws, and any regulations or standards could have an adverse effect on our business. In
addition, we operate pursuant to our Charter, Bylaws and complex contractual arrangements, including any amendments or waivers thereunder.
Our failure to comply with the terms of our Charter, Bylaws, or any such contractual arrangements, or if any amendments or waivers thereunder
are deemed unenforceable, we could be exposed to claims or other demands that could divert management&#8217;s attention from other business
concerns and could have an adverse effect on business, financial condition, and results of operation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="a_007"></span>Item
2. Unregistered Sales of Equity Securities and Use of Proceeds</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the second quarter of 2025, the Company issued securities in reliance on the exemption from registration provided by Section 4(a)(2)
of the&#160;Securities Act, in the amounts and for the consideration set forth below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May and June 2025, the Company issued 50,000 shares of common stock and warrants underlying 200,000 shares of common stock with an aggregate
fair value of approximately $718,000 to vendors as compensation for services. The warrants underlying 200,000 shares of common stock
consist of warrants underlying 50,000 shares of common stock that are exercisable immediately upon issuance with a term of five years
from the date of issuance at $2.50 per share, and warrants underlying 150,000 shares of common stock that are pre-funded warrants exercisable
at any time after issuance and until exercised in full.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 14, 2025, pursuant to the May 2025 Private Placement of Equity Facility, the Company issued pre-funded warrants to purchase an aggregate
of 300,000 shares of common stock as consideration for its irrevocable commitment to purchase the shares of common stock upon the terms
and subject to the satisfaction of the conditions set forth in the Purchase Agreement, with a fair market value of $672,000. The pre-funded
warrants may be exercise at any time after issuance and until exercised in full.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 15, 2025, the Company issued warrants underlying 24,390 shares of Common Stock&#160;at an exercise price&#160;equal to $2.46 to investors
in return entering into a Consent and Waiver Agreement dated March 18, 2025, with a fair market value of $44,000. The warrants are exercisable
immediately upon issuance with a term of five years from the date of issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
other issuances of unregistered equity securities during the three months ended September 30, 2025 have previously been disclosed in
filings with the SEC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="a_008"></span>Item
3. Defaults Upon Senior Securities</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="a_009"></span>Item
4. Mine Safety Disclosures</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="a_010"></span>Item
5<i>.</i>&#160;Other Information</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Rule
10b5-1 Trading Plans</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the nine months ended&#160;September 30, 2025,&#160;none of our&#160;directors or officers (as defined in Rule&#160;16a-1(f) under the
Securities Exchange Act of 1934, as amended) <span id="xdx_905_eecd--Rule10b51ArrAdoptedFlag_dbF_c20250101__20250930_z8f6ebzZHWP" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><span id="xdx_906_eecd--NonRule10b51ArrAdoptedFlag_dbF_c20250101__20250930_z4LA4whVO3S8" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" format="ixt:booleanfalse" id="Fact001557" name="ecd:Rule10b51ArrAdoptedFlag"><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" format="ixt:booleanfalse" id="Fact001558" name="ecd:NonRule10b51ArrAdoptedFlag">adopted</ix:nonNumeric></ix:nonNumeric></span></span>, amended, or <span id="xdx_90D_eecd--Rule10b51ArrTrmntdFlag_dbF_c20250101__20250930_zw7RQvsqSjUi" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><span id="xdx_901_eecd--NonRule10b51ArrTrmntdFlag_dbF_c20250101__20250930_zHwBh6F0ACr1" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" format="ixt:booleanfalse" id="Fact001559" name="ecd:Rule10b51ArrTrmntdFlag"><ix:nonNumeric contextRef="From2025-01-01to2025-09-30" format="ixt:booleanfalse" id="Fact001560" name="ecd:NonRule10b51ArrTrmntdFlag">terminated</ix:nonNumeric></ix:nonNumeric></span></span> a &#8220;Rule&#160;10b5-1&#160;trading arrangement&#8221;
or a &#8220;non-Rule&#160;10b5-1&#160;trading arrangement,&#8221; as each term is defined in Item 408 of Regulation S-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><b>Equity Awards</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in">On August 19, 2025, the Compensation
Committee of the Board and the Board approved new stock option awards pursuant to the Plan for management and non-employee members of
the Board. Michael Breen, the Company&#8217;s Executive Chairman and Chief Executive Officer, was awarded (i) 100,000 stock options for
2024, fully vested upon issuance, (ii) 100,000 stock options for 2025, vesting quarterly through 2025, and (iii) 100,000 stock options
for 2026, vesting quarterly through 2026. Alan Urban, the Company&#8217;s Chief Financial Officer, was awarded (i) 50,000 stock options
for 2025, vesting quarterly through 2025, and (ii) 50,000 stock options for 2026, vesting quarterly through 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in">Charles J. Casamento, a non-employee member of our Board, was awarded 31,250 stock options for the 2024-2025 period,
fully vested upon issuance. Each non-employee member of our Board was awarded 31,250 stock options for the 2025-2026 period, fully vested
upon issuance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 11; Value: 22 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="a_011"></span>Item
6. Exhibits</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.65in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit</b></span></td>
    <td style="width: 0.1in">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: justify; font: 10pt Times New Roman, Times, Serif"><b>Description</b></td>
    <td style="width: 0.1in">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif; width: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Filed
    Herewith</b> </span></td>
    <td style="width: 0.1in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Form</b></span></td>
    <td style="width: 0.1in">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b>
    </span></td>
    <td style="width: 0.1in">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif; width: 0.65in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SEC
File No.</b></span></td>
    <td style="width: 0.1in">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Filing
    Date</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/109657/000103221002000530/dex3a.txt" style="-sec-extract: exhibit">Restated Certificate of Incorporation as filed in Delaware September 10, 1996 and as thereafter amended through March 1, 2002</a> </td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-KSB
    &#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.A
    &#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-08092
    &#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/1/2002</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/109657/000151316011000020/ex32.htm" style="-sec-extract: exhibit">Certificate of Amendment to the Restated Certificate of Incorporation of GT Biopharma, Inc., dated February 9, 2011</a> </td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K
    &#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2
    &#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-08092
    &#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/31/2011</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495418002596/gtbp_ex31.htm" style="-sec-extract: exhibit">Certificate of Amendment to the Restated Certificate of Incorporation of GT Biopharma, Inc., effective as of July 19, 2017</a> </td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K/A
    &#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1
    &#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-08092
    &#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/15/2018</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495421001479/gtbp_ex31.htm" style="-sec-extract: exhibit">Certificate of Amendment to the Restated Certificate of Incorporation of GT Biopharma, Inc., effective as of February 10, 2021</a> </td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K
    &#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1
    &#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-40023
    &#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/11/2021</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/109657/000149315223009812/ex3-5.htm" style="-sec-extract: exhibit">Certificate of Amendment to Restated Certificate of Incorporation of the Registrant effective June 13, 2022</a></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K
    &#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5
    &#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-40023
    &#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/30/2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/109657/000149315224004587/ex3-1.htm" style="-sec-extract: exhibit">Certificate of Amendment to Restated Certificate of Incorporation of the Registrant effective February 1, 2024</a> </td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K
    &#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1
    &#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-40023
    &#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/1/2024</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.7</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/109657/000149315222031139/ex3-1.htm" style="-sec-extract: exhibit">Amended and Restated Bylaws of GT Biopharma, Inc. effective November 3, 2022</a></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K
    &#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1
    &#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-40023
    &#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/9/2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/109657/000093979819000017/exhibitthreeone.htm" style="-sec-extract: exhibit">Certificate of Designation of Preferences, Rights and Limitations of Series J-1 Preferred Stock of GT Biopharma, Inc., dated April 3, 2019</a> </td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K
    &#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1
    &#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-08092
    &#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/4/2019</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/109657/000165495421004295/gtbp_ex42.htm" style="-sec-extract: exhibit">Certificate of Designation of Preferences, Rights and Limitations of Series K Preferred Stock of GT Biopharma, Inc. dated April 3, 2019</a></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K
    &#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2
    &#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-40023
    &#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/16/2021</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000164117225009854/ex3-1.htm" style="-sec-extract: exhibit">Certificate of Designation of Preferences, Rights and Limitations of Series L 10% Convertible Preferred Stock of GT Biopharma, Inc., dated May 12, 2025</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-40023</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/13/2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000164117225012481/ex3-1.htm" style="-sec-extract: exhibit">Certificate of Increase to Certificate of Designation of Preferences, Rights and Limitations of Series L 10% Convertible Preferred Stock of GT Biopharma, Inc., dated May 21, 2025</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-40023</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/27/2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/109657/000149315225014684/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Waiver</span></a></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-40023</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/23/2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/109657/000149315225019296/ex4-49.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Pre-Funded Common Stock Purchase Warrant</span></a></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.49</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-291060</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/24/2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/109657/000149315225012479/ex10-1.htm" style="-sec-extract: exhibit">Amendment No. 3 to Employment Agreement with Michael Breen, entered into as of August 26, 2025, with an effective date of April 29, 2025</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-40023</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/29/2025</span></td></tr>

</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 12; Value: 22 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.65in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1</span></td>
    <td style="width: 0.1in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex31-1.htm">Certification of Principal Executive Officer pursuant to Rule 13a-14 and Rule 15d-14(a), promulgated under the Securities and Exchange Act of 1934, as amended.</a></td>
    <td style="width: 0.1in">&#160;</td>
    <td style="width: 0.45in">*</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.1in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.65in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.1in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex31-2.htm">Certification of Principal Executive Officer pursuant to Rule 13a-14 and Rule 15d-14(a), promulgated under the Securities and Exchange Act of 1934, as amended.</a> </td>
    <td>&#160;</td>
    <td>*</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex32-1.htm">Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002*</a></td>
    <td>&#160;</td>
    <td>X</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.2</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex32-2.htm">Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002*</a></td>
    <td>&#160;</td>
    <td>X</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Inline XBRL Instance Document. </td>
    <td>&#160;</td>
    <td>X</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Inline XBRL Taxonomy Extension Schema Document. </td>
    <td>&#160;</td>
    <td>X</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Inline XBRL Taxonomy Extension Calculation Linkbase </td>
    <td>&#160;</td>
    <td>X</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF
    </span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Inline XBRL Taxonomy Extension Definition Linkbase </td>
    <td>&#160;</td>
    <td>X</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB
    </span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Inline XBRL Taxonomy Extension Label Linkbase Document. </td>
    <td>&#160;</td>
    <td>X</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE
    </span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Inline XBRL Taxonomy Extension Presentation Linkbase </td>
    <td>&#160;</td>
    <td>X</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Cover Page Interactive Data File (embedded within the Inline XBRL document) </td>
    <td>&#160;</td>
    <td>X</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
    certification shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act, or otherwise subject to the
    liability of that Section, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act or the
    Exchange Act.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 13; Value: 22 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_012"></span>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GT
    BIOPHARMA, INC.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 47%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    November 14, 2025</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Michael Breen</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
    Breen</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
                                            Executive Officer and</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive
    Chairman of the Board</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    November 14, 2025</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: top; text-align: justify; width: 47%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Alan Urban</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alan
    Urban</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer &amp; Secretary</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial and Accounting Officer)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 14; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>ex31-1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Michael Breen, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have reviewed this report on Form 10-Q of GT Biopharma, Inc.;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
    the period covered by this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
    respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in
    this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and
    15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant
    and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
    within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
    supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
    for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
    the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about
    the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
    in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
    or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors
    and the audit committee of the registrant&rsquo;s Board of Directors (or persons performing the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
    reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
    internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    November 14, 2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 45%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Michael Breen</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
    Breen</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer and </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive
    Chairman of the Board</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>ex31-2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Alan Urban, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have reviewed this report on Form 10-Q of GT Biopharma, Inc.;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
    the period covered by this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
    respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in
    this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and
    15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant
    and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
    within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
    supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
    for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
    the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about
    the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
    in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
    or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors
    and the audit committee of the registrant&rsquo;s Board of Directors (or persons performing the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
    reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
    internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    November 14, 2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 45%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Alan Urban </I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alan
    Urban</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer &amp; Secretary</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>ex32-1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to 18 U.S.C. &sect; 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, I, Michael Breen, Chief Executive Officer of GT
Biopharma, Inc. (the &ldquo;Company&rdquo;), hereby certify that, to the best of my knowledge:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
the Quarterly Report on Form 10-Q of the Company for the fiscal quarter ended September 30, 2025 (the &ldquo;Report&rdquo;) fully complies
with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of
the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    November 14, 2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 45%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Michael Breen</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
    Breen</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer and </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive
    Chairman of the Board</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>ex32-2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to 18 U.S.C. &sect; 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, I, Alan Urbani, Chief Financial Officer and Principal
Accounting Officer of GT Biopharma, Inc. (the &ldquo;Company&rdquo;), hereby certify that, to the best of my knowledge:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
the Quarterly Report on Form 10-Q of the Company for the fiscal quarter ended September 30, 2025 (the &ldquo;Report&rdquo;) fully complies
with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of
the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    November 14, 2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 45%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Alan Urban </I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alan
    Urban</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer &amp; Secretary</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>form10-q_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 form10-q_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $J FL# 2(  A$! Q$!_\0
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M#7K[0]2TNQTS2;6[N+N&20Q&!G9RA0;1M^[G<?F/ Q1H!UO]KZ9_T$;3_O\
MK_C1_:^F?]!&T_[_ *_XUQ9^(FBI"TLFAW2*KS DI$!LA;;(X^;D \8')["H
M&^(>G?V^D*Z8O]EE603%$WO()EBR!N^502<[@#QQ1H!W?]KZ9_T$;3_O^O\
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MU],_Z"-I_P!_U_QJ;[);?\^\7_? H^R6W_/O%_WP*-!D/]KZ9_T$;3_O^O\
MC1_:^F?]!&T_[_K_ (U-]DMO^?>+_O@4?9+;_GWB_P"^!1H!#_:^F?\ 01M/
M^_Z_XT?VOIG_ $$;3_O^O^-3?9+;_GWB_P"^!1]DMO\ GWB_[X%&@$/]KZ9_
MT$;3_O\ K_C1_:^F?]!&T_[_ *_XU-]DMO\ GWB_[X%'V2V_Y]XO^^!1H!#_
M &OIG_01M/\ O^O^-(=8TP#)U&T _P"NZ_XU/]DMO^?>+_O@5G:_:VX\/WY%
MO$#Y#?P#THT$6O[7TS_H(VG_ '_7_&E_M?3/^@C:?]_U_P :F%I;8_X]XO\
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M^O\ C4WV2V_Y]XO^^!1]DMO^?>+_ +X%&@$/]KZ9_P!!&T_[_K_C1_:^F?\
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M2KVYN73?\+FC*GE*"6)R<4S)]:FO/]6G^^/ZU!6B.1BY/K1D^M)13$6_#O\
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M6O\ GG8?]_7_ /B: (MBXQM7KGIW]:=3_P"S-:_YYV'_ ']?_P")H_LS6O\
MGG8?]_7_ /B: &52U?\ Y!DOU7_T(5H?V9K7_/.P_P"_K_\ Q-4=7TW5UTR4
MNECMRO25\_>'^S0!G:CHDUY=7<D<J(EU&(Y5/\2@' _[ZQ^%+_95Q(/)E2$P
MK)YH.[E_E V^P/?VK>_LS6?^>=A_W]?_ .)H_LS6O^>=A_W]?_XFG<+%'3H;
MBWM!'<-D@G8,[BJ]@3WQZU;I_P#9FM?\\[#_ +^O_P#$T?V9K7_/.P_[^O\
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M?V73[O\  \,_X1+7_P#H%7'Y#_&C_A$M?_Z!5Q^0_P :]S_LS6O[EA_W]?\
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M*V/LZX56( #?CBH9/$NG_NA!;M($SM8J L9!"_APPZ54EOM*>]ADGTZ4O #
M$)5DC4,!N'KRP'']*D2YTA3##_8RQ@W#19)78K<<[NASQQZBES/HT:*A%).<
M)-^JMU\^UBPVOZ$TCR>6'9B59Q!G(Z$D]Q5W2Y+*^A:[@L4A(D9<F-0Q*DC.
M1^-3?V3IXW 6<(W9SA>N>M6(;>&W5EAC6,,Q8A1C)/4UHE*^MCAJ5:/):FI7
M\V1WG^K3_?']:@JQ=PW$Z(EJ(C)O!_>L0,<^@-1?V9K7_/.P_P"_K_\ Q-:H
MXF,HI_\ 9FM?\\[#_OZ__P 31_9FM?\ /.P_[^O_ /$TQ%CP[_KM2_Z[C_T$
M5NUA^'HKB&?4DN1$)/.!/E,2/NCU K<I,:"O-X[\0V6E6<5@+R[GB9T0[0%5
M3R<GIU%>D5Y];:7::EI&GM<(WF0IF.2-RC+GK@CL::$Q\WB33+>62&>9TFC*
MJ\8B8G)X &!\W/'%0CQ5H+)]H^T#(P Q@;>002".,D8!_*I$\+Z1'<FX2V(E
M+!\[SU!S_.D;PKH[J@:U^X%5#N.5"YQC\S5:"U*MOXGTYKF:*6".&*-G561=
MY?#JHPH'.21Q6EHU]%JVG)?K;+"9';Y2!G()&2<=:B?PUI4C.QMSN<EB0Y!!
M+!LCT.0*O6-C;Z=:):VJ%(4)(!.>IR>:3L&I+Y,0&/*CQG.-@ZTOE1YSY:9Q
MM^Z.GI]*=12&(%"YPH&>N!BEHHH 99VTUUI<PBC\U4U O)#NQYB@#(YX]#@\
M<58N+?6'=_L<<ELI7]TOF*$1=O*E0?O;LG(XZ<U#8WES8Z7<RVT F9KYD*X)
MQD  \=@<9]J0ZOJUPT<HA-LC8#AD8X&7!^A) (/H10 EYI>LO$R"6>:,SAMI
MF&[8LD;+@GH<!^?I4OV'7'W_ +V2,&-MI$@W9 ;8&/?DKFM'0[B^FMRE\%WH
MD9#@$%LKDYSW%:M*X['+266N7-YNF$JP)-$X6.?&[:W)'/0CG'%-^Q^(1;-&
MCND^Q@KK(NS&TX '][=@Y]._:NKHHN%BGI\5Q!'-'<.S@2MY3.VXE.,9/YT:
MM_R![S_KBW\JN53U;_D#WG_7%OY4#)K3_CS@_P"N:_RJ:H;3_CS@_P"N:_RJ
M:D 451U>6>'3G>WWAMRAF1=S*N>2!W.*P+F>9)W%E?W\K+ C6JD%A*Y=\AOE
MY'"^F!32%<ZVBN5N[F[$>J"*XN>&4P,&/#8.5SM]?X?IS741L6B1B""5!(/4
M46 =6=KO_((F^J?^A"M&L[7?^01-]4_]"%)#)9-3MH7NA,WEK;;=[MT^;IBH
M9M=L8[%KJ.994'0*>IQG'Y<U4O[729Y]1:YNW79&CW,>_"H ,JV,>U59+'0+
MB1H9+F38$(9"2L;?+R>@!.T\XIV0C6?7=+C(#WD:Y4N,GJ!GG]#^5(-=L'W"
M*=796"E3Q@E@O?OR./<53@T+2KR'S8O.:-X_*^?(.W! QN&> >/;%6YM!LIR
MY<29:0RG#D?,2I/_ * *- U+5O?VMU&\D4RE4<HY)QM;T.?J*BU+5K?3+,7,
MN71F"@)@D^I_ 9/X4VRT:SL;:2W5#+'(_F.)L/DX _H*?<:3970B6:W1HXE8
M)'CY1N&"<>N,_F:- *5QXEL[:*_=XY<V;A2H S)GNOJ.OY&M.TN5N[<3("%W
M,N#_ ++%?Z5GGPUIS(%9)&PK*"7.<,,?H.GIDU9MM-6TE#0W,XCW.QB9LJ2Q
MSZ<<DFC0-2]6;X@_Y%Z__P"N#?RK2K-\0?\ (O7_ /UP;^5"&<CKWQ2MM!UR
MZTM]+EF:W8*9%E !R >F/>L[_A=%I_T!I_\ O\/\*X7XA?\ (^ZM_P!=%_\
M0%KF:]BGA:4H)M'S=7'UXU)13V;Z'L'_  NBT_Z T_\ W^'^%'_"Z+3_ * T
M_P#W^'^%>/T5?U.CV,_[1Q'?\$>P?\+HM/\ H#3_ /?X?X4?\+HM/^@-/_W^
M'^%>/T4?4Z/8/[1Q'?\ !'L'_"Z+3_H#3_\ ?X?X4?\ "Z+3_H#3_P#?X?X5
MX_11]3H]@_M'$=_P1[!_PNBT_P"@-/\ ]_A_A3)?C+:20NG]CSC<I&?.'?\
M"O(J*/J='L']H8CO^"/6;/XPVMK8V]N=(F8Q1JA(F'.!CTJ?_A=%I_T!I_\
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M[2I-2&E6P2VM2FSY2T[ D9/;;30F;-%4O,U3_GUL_P#P(;_XBCS-4_Y];/\
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MUK4UM80+"UQY:_\ +RWI_N5)_;FI_P#0/M/_  *;_P"(I6'<Z&BN>_MS4_\
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MU>XT\Z<TI@8+O$N,\ ],>]4?^%I)_P! EO\ O]_]:N6\:_\ (XZE_P!=%_\
M016#7L4\+2<$VCYRKCJ\:DHI[-GH_P#PM)/^@2W_ '^_^M1_PM)/^@2W_?[_
M .M7G%%7]4I=C/\ M#$?S?@CT?\ X6DG_0);_O\ ?_6H_P"%I)_T"6_[_?\
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M_F_!'H__  M)/^@2W_?[_P"M71>&?%=MXC65%B-O<1<F)FSE?4&O%JU?#8U
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MM#G"BBB@ HHHH **** "BBB@"WX=_P!=J7_7<?\ H(K=K"\._P"NU+_KN/\
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M\C_&O2O^$>N/^@O-_P!^8_\ "C_A'KC_ *"\W_?F/_"CZU5_F#ZC0_E/-?\
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M  H_X1ZX_P"@O-_WYC_PH JT5:_X1ZX_Z"\W_?F/_"C_ (1ZX_Z"\W_?F/\
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MCMC;"=VBM9I V Z,I<N%&<%L@'D>M%EW%=GH]%064#6MA;V[OO:*)4+G^(@
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M 2(K ,_4?[9J[]AM?^?>/_OFFP1CR/:R[/,>)MC!URPX/K3_ +1#_P ]H_\
MOH5J_8;7_GWC_P"^:/L-K_S[Q_\ ?-(=S*^T0_\ /:/_ +Z%'VB'_GM'_P!]
M"M7[#:_\^\?_ 'S1]AM?^?>/_OF@1D++;)G;)$N3DX8#)IWVB'_GM'_WT*U?
ML-K_ ,^\?_?-'V&U_P"?>/\ [YH ROM$/_/:/_OH4?:(?^>T?_?0K5^PVO\
MS[Q_]\T?8;7_ )X1_P#?- %71G5XKID8,OVAN0<CH*TJS-$14ANU50%%U)@#
M\*TZ "BBB@ HHHH **** "BBB@#-T_\ Y"6I_P#75?\ T$5I5FZ?_P A+4_^
MNJ_^@BM*FP"LSP]_R+UA_P!<5K3K@])M5;2;5O.N!E,X$S =?K0A,[RBN/\
MLB_\][G_ +_M_C1]D7_GO<_]_P!O\:+!<["BN/\ LB_\][G_ +_M_C1]D7_G
MO<_]_P!O\:+!<["BN/\ LB_\][G_ +_M_C1]D7_GO<_]_P!O\:+!<["BN/\
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M]_V_QH^R+_SWN?\ O^W^-*P7.PHKC_LB_P#/>Y_[_M_C1]D7_GO<_P#?]O\
M&BP7.PHKC_LB_P#/>Y_[_M_C1]D7_GO<_P#?]O\ &BP7.PHKC_LB_P#/>Y_[
M_M_C1]D7_GO<_P#?]O\ &BP7.PK-\0?\B_?_ /7!OY5@_9%_Y[W/_?\ ;_&J
M6L6BC1KP^=<G$3=9F/;ZTT@N=A-I5I<2M+(C%VZX8BF?V)8_\\V_[[-<_P#8
MU_Y[W7_?]O\ &C[&O_/>Z_[_ +?XUG[*#Z"T.@_L2Q_YYM_WV:/[$L?^>;?]
M]FN?^QK_ ,][K_O^W^-'V-?^>]U_W_;_ !H]E#L&G8Z#^Q+'_GFW_?9H_L2Q
M_P">;?\ ?9KG_L:_\][K_O\ M_C1]D7_ )[W7_?]O\:/90[!IV.@_L2Q_P">
M;?\ ?9H_L2Q_YYM_WV:Y_P"R+_SWN?\ O^W^-'V1?^>]S_W_ &_QH]E#L&G8
MZ#^Q+'_GFW_?9J9K>*VT^6.%=J[&_E7,_9%_Y[W/_?\ ;_&HY[1?L\O[^Y^X
M?^6[>GUIJG%.Z0'4:3_R!K'_ *]X_P#T$5<KAM.M%.F6A\ZY&84Z3-_='O5G
M[(O_ #WN?^_[?XU=AW.PHKC_ +(O_/>Y_P"_[?XT?9%_Y[W/_?\ ;_&E8+G8
M45Q_V1?^>]S_ -_V_P :/LB_\][G_O\ M_C18+G845Q_V1?^>]S_ -_V_P :
M/LB_\][G_O\ M_C18+G845Q_V1?^>]S_ -_V_P :/LB_\][G_O\ M_C18+F_
MH7_('A_WG_\ 0S6C7!:3:*=-B/G7(Y;I,W]X^]7?LB_\][G_ +_M_C3:%<["
MBN/^R+_SWN?^_P"W^-'V1?\ GO<_]_V_QI6'<["BN/\ LB_\][G_ +_M_C1]
MD7_GO<_]_P!O\:+!<["BN/\ LB_\][G_ +_M_C1]D7_GO<_]_P!O\:+!<["B
MN/\ LB_\][G_ +_M_C1]D7_GO<_]_P!O\:+!<WM'^Y>?]?4G]*TJX+3;12ES
M^^N1_I#])F]O>KOV1?\ GO<_]_V_QIM!<["BN/\ LB_\][G_ +_M_C1]D7_G
MO<_]_P!O\:5@N=A17'_9%_Y[W/\ W_;_ !H^R+_SWN?^_P"W^-%@N=A17'_9
M%_Y[W/\ W_;_ !H^R+_SWN?^_P"W^-%@N=A17'_9%_Y[W/\ W_;_ !H^R+_S
MWN?^_P"W^-%@N;VG_P#(2U/_ *ZK_P"@BM*L#PS&(WU%0SM^_'+L6/W1W-;]
M#!!7GUMJ=IIVCV N';?*F(XXT+NV.N /2O0:\S?0EU?2+"1;EK>5+=XMP4,"
MC]1C\ <TXB9<E\3:9!--%(UPK0H'DS V IZ'\:N6^J6MW8/>P,[PH65@$.X$
M<$8]:S9O#"36ES ;N0B>TBMBS#)PASD^N:L:9H:Z9:K''=2EU9V4J2J*6_V!
MQ@=LT]!:BV_B+3KN:"*%IFDF9E1?*(.5(!SZ $XII\3Z4+7[29I!#O,88Q'Y
MB,YQZ@8.34)\,Q&/38Q<%5LB&WA!YCL#DG=U&3U'>JS^#D9I9%O6BED=F_=Q
M (JLI4@+TR0>OK3T#4Z5'61%=&#*P#*1T(-+4<$*6]O%!'G9&@1<^@&!4E2,
M**** ,&=+J2VG%FSK*-2#90]0 "0?8]/QJ-+C55DGG9)8Q.P95,>_P H;3A,
M9XYP"?6IWNI;2SO7@ ,SWA1 Q !) [G@?C4D>KR3:/\ :DV!_,6(N<[5)(#,
M1U !S^54(B%YK"J6DB #,056+)B *\]?FX+?E41;5IYX=TCQ[IHBN(> HW@L
M>>_RY'O5V75?LCB)V6XVA2TBL!G<V!M'?'>J<GB*7[(SBV$;%%927!Z@,/TH
M 1+[7)2<PQQ':F 8B<$@9;KZYXILVJZG'>>44:.)I0BNT&2?E<D  \_=!_&K
M+:ZXG2)8-TC97:)!L)R.0V.G-,F\0*\L<<,"/)M$BF1L!#E0P)QP<-0!:TZ[
MO;BZDAN45?*16<@=V (7ZCG-6M1_Y!EU_P!<F_E68FN1Q)(P@!VL?,(8!F.6
M P/XON\FK#WC7FD7K-%Y;)&1C=GJH(_G2 T(/^/:'_KFO\A4E1P?\>T/_7-?
MY"I*0R.>>.VA:65MJ+U-56U6VC;;(LT>%#,7C(" D@%O3)!J>[MA=VYBWE&R
M&5Q_"P.0:IS:9/<O(9KM=LT:Q3!(L;@"3QSQU]Z8$[ZI:)Y@WLQC?RV54).[
M&?Y<U;5E=%=2"K#(([BL^ZTI;K[1EP#,ZMDKG9A=O'/7%7HHUAA2)!A$4*H]
MA0 ^J6K_ /(,E^J_^A"KM4M7_P"09+]5_P#0A2 D^W0?;OL9+"7_ '?E)QG&
M?7%.-Y%]I-N-[.OWRJY5._S'M51]'235VOS)@L ,*N&X!&-V>G-.;3&_TB..
MY98+@?O%(RV=H7(;/H!Z]*>@$W]HVOVA(%E#N^-I3YE.=W<?[IIKZK91I<,T
MV!;RB&7CD.<8'ZBJEIH*6LT4HFRR$$@+PV-WJ3_>_2B;08I[F68S.#)(9&4#
MC=Q@_48(_&C01?DOK>-E4R!F8D80AL$#)!]*>;JV7=NN(1M^]F0#;]>>*R1X
M>!FEDDNW=I#GE?8C^M1P:&[W>9PJP18$>54E^2<G'7ZFC0#;-Q I(,\0( 8Y
M<< ]#]*:]U B@^:C;AE0K EAG&1SR*RCX=5IXW>Z9TC555"O& RG'T^7]:D&
MAJHE19ALE(+ QC*X<L-I[#G&*- -/[1!G'GQ9W;/OC[WI]?:JNL_\@6]_P"N
M+53@\/);F,I.=R2!@Y4EB!GC.<=SVJYK/_(%O?\ KBU R261Q(P#$"F>:_\
M>-$W^M:F5Y$YRYGJ9L?YK_WC1YK_ -XTRBHYY=Q#_-?^\:<DS*P+$D=ZBI54
MNP4=351G.^C'<O@@C(Z44B*$4*.U+7K*]M30*CG_ ./:7_</\JDJ.?\ X]I?
M]P_RI@1:;_R"[/\ ZX)_Z"*LU6TW_D%V?_7!/_015F@ HHHH **** "BBB@
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M1]LMO^?B+_OL5TO]GV7_ #YV_P#WZ7_"C^S[+_GSM_\ OTO^%%PL<U]LMO\
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M1&/[PIW%8ROMEM_S\1?]]BC[9;?\_$7_ 'V*Z7^S[+_GSM_^_2_X4?V?9?\
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M )\[?_OTO^%-L5CFOMEM_P _$7_?8H^V6W_/Q%_WV*Z7^S[+_GSM_P#OTO\
MA1_9]E_SYV__ 'Z7_"E<=CFOMEM_S\1?]]BC[9;?\_$7_?8KI?[/LO\ GSM_
M^_2_X4?V?9?\^=O_ -^E_P *+A8YK[9;?\_$7_?8H^V6W_/Q%_WV*Z7^S[+_
M )\[?_OTO^%']GV7_/G;_P#?I?\ "BX6.:^V6W_/Q%_WV*/MEM_S\1?]]BNE
M_L^R_P"?.W_[]+_A1_9]E_SYV_\ WZ7_  HN%CC=-N[81W.;B(?Z0_\ &/:K
MOVRV_P"?B+_OL5J:186;)=YM(#BZD S&/:M'^S[+_GSM_P#OTO\ A3;%8YK[
M9;?\_$7_ 'V*/MEM_P _$7_?8KI?[/LO^?.W_P"_2_X4?V?9?\^=O_WZ7_"E
M<=CFOMEM_P _$7_?8H^V6W_/Q%_WV*Z7^S[+_GSM_P#OTO\ A1_9]E_SYV__
M 'Z7_"BX6.:^V6W_ #\1?]]BC[9;?\_$7_?8KI?[/LO^?.W_ ._2_P"%']GV
M7_/G;_\ ?I?\*+A8YK[9;?\ /Q%_WV*/MEM_S\1?]]BNE_L^R_Y\[?\ []+_
M (4?V?9?\^=O_P!^E_PHN%C)\-2)))J+(ZLOGCE3G^$5OUEZ7%'#?ZFD4:HO
MFKPHP/NBM2A@@KDX?$,>C:'I4 MVGGFMS(%WJBJB ;F9F. .1^==97,VV@:?
MKGAO3!>(^Z.'"O&Y1@&&&&1V/<4+S!D-WXU>S>\+Z4YAM;=+AI5N$(9'.%Q^
M.:T]'\10:OI7VQ(F1R9%6 NI:0IP=O/(HD\+:5);36_DNL<MO';,%D(Q'&<J
M!Z8]:L:=H>GZ7&%MX SAVD\V7YY"S?>.X\Y-/0-3%B\=6TL=C)]AN EPH>4D
MK^X4R>6"W//S>E1#Q["UJ\BZ?*TPE=/(65=X"*69F!^[P,X/7(K37PAHZFT(
MMW_T7[@\PX8;MX#?W@&Y&:;-X.TBY$IG2>2663>\S3L9#P5V[LYVX)&/2CW1
M:FU;7"75K#<19\N5%=<^A&14M-CC2*)(XU"H@"JHZ #H*=4E!1110!S-QILF
MJ6]S#$=I35!+NSC;M (/YXJ)=(U>,S3ER9KEA),(9MAW;2!@_P!U3CCN!WJ:
MY>Y73]26T,B2O?E?,16.P87)(7G'T]:=#=ZC/X>+LERDJR*DF8R)1&" S#CD
MD9(P.]42-&FZVBLS74DKNS>:HF(W+E<!/[I(W],=:A.@7TUS"\[S',L3LWVD
MY15+\=?O89>1UP>:M-?WEO)'%9)/-#A2IGC=FD);#?,?NX'//6J<^H:^U@V^
M'#-&I_=0L&4E0WKV.1BC4!\>F>('9A<7LHRB+F.3 Q@;AUX;.3D#OUJ.YMM;
MCU!0QN#;2SA5CBN"#@))SN)X'W/3D=*L?VAK#SPK%#PV4\YH6 (W#DKV/7KZ
M4R75]9FF$4=M)"OE*SN8&.U@R9QV((+>_% %W1TO_MTR75P\L4"JNXDX:0@;
MA[@8_6M#5O\ D#WG_7%OY5BC5-7C7:MHQ(W;%:)CYG+<[OX<8'!]:MM->3:%
MJ/VU5#K&=I5"H(* ]#Z$D?A0,U;3_CS@_P"N:_RJ:H;3_CS@_P"N:_RJ:I&%
M%%% !1110 5G:[_R")OJG_H0K1K.UW_D$3?5/_0A0@&7&NVMO?26CY\Y'C4+
M_>W],4RUU^*[\E5@=9970*A(R59=V[Z 9_(U=DT^WEDE=E.Z1D9OF/5>E1P:
M19VUS#<1QD20P>0A+$X3_'W]S3T%J7J***0PHHHH **** "LWQ!_R+U__P!<
M&_E6E6;X@_Y%Z_\ ^N#?RIH#%U4G^TY^3U'?V%5,GU/YU=U2-SJ4Y",1D<@>
MPJIY4G_/-_RKR9I\S,7N-R?4_G1D^I_.G>5)_P \W_*CRI/^>;_E468AN3ZG
M\Z,GU/YT[RI/^>;_ )4>5)_SS?\ *BS ;D^I_.C)]3^=.\J3_GF_Y4>5)_SS
M?\J+,"]I6H&TFV2$^2YYSV/K70W)S9S$=/+;^58.DZ:9YO-F4B)#T(^\:W[G
M_CTF_P"N;?RKT,/S<NIK&]B#2?\ D#6/_7O'_P"@BKE4])_Y UC_ ->\?_H(
MJY704%%%% !1110 4444 %':BCM0!G:%_P @>'_>?_T,UHUG:%_R!X?]Y_\
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MYZ3?^ [_ .%9DUQ';^7YTHC\UQ&FX_>8] />I/F]Z+!<O_\ "3:9_P ])O\
MP'?_  H_X2;3/^>DW_@._P#A6=+(((7EE;9&BEV8] !R321RK-$DD;[D<!E8
M'@@]Z+!<TO\ A)M,_P">DW_@._\ A1_PDVF?\])O_ =_\*H9/J:,GU-%D%PT
MSQ'IJ-?;I)OFNF(_</TPOM5__A)M,_YZ3?\ @._^%<]9W$=O]K::58PUX44L
M<98@8'U-7TG2262)) TD1 =0>5R,C-#07-+_ (2;3/\ GI-_X#O_ (4?\)-I
MG_/2;_P'?_"J'S>]1O/'&RJ\@5F8( 3R6/0?H:+!<T_^$FTS_GI-_P" [_X4
M?\)-IG_/2;_P'?\ PJA\WO1\WO19!<O_ /"3:9_STF_\!W_PJKJGB337TJ[5
M9)LF)@/W#^GTJ+)]35742?[,NN3_ *IOY46"YJ6WB73%M(09)LB-?^6#^GTJ
M7_A)M,_YZ3?^ [_X5F0$_9H>3_JU_D*DR?4T6"Y?_P"$FTS_ )Z3?^ [_P"%
M'_"3:9_STF_\!W_PJAD^IHR?4T607+__  DVF?\ /2;_ ,!W_P */^$FTS_G
MI-_X#O\ X50R?4T9/J:+(+E__A)M,_YZ3?\ @._^%4-9\1Z;)I4JK)-DE?\
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M="OD62;<T+ 9@<=OI1D^IJCK)/\ 8M[R?]2W\J$@N;O_  DVF8_UDW_@._\
MA1_PDVF?\])O_ =_\*S3*JG!?!^M'GI_ST'YU'-'N%S2_P"$FTS_ )Z3?^ [
M_P"%'_"3:9_STF_\!W_PK-\]/^>@_.E60,<*^?QIJ47LPN:/_"3:9_STF_\
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M<-%\1Z;'I42M)-D%_P#E@_\ >/M5_P#X2;3/^>DW_@._^%86D$_V9%R>K_\
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MRPEW%7RI 8C/WAG/I776<!MK&WMV8,8HU0D=\#%8^E-KW]J1KJ&Y[7[-\S;
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M7?)_U+?RH]F@]L^QFP:E +:+Y+C[B_\ +%O2I/[3@_N7'_?EJU+<G[+#R?\
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M?5Y=F'UR'=&A_:<']RX_[\M3)]2@^SR_)<?</_+%O2J7_"Q?#7_/_+_WX?\
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MNC0_M.#^Y<?]^6H_M.#^Y<?]^6K/_P"%B^&O^?\ E_[\/_A1_P +%\-?\_\
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M*74_^05=_P#7%OY5/##';PI#$H6-!M4#L*@U/_D%7?\ UQ;^5 B:W_X]8?\
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M2?\ "L_$?_/.T_\  @4>UI]P]A5_E9Q]%=A_PK/Q'_SSM/\ P(%'_"L_$?\
MSSM/_ @4>UI]P]A5_E9Q]%=A_P *S\1_\\[3_P "!1_PK/Q'_P \[3_P(%'M
M:?</85?Y6<?178?\*S\1_P#/.T_\"!1_PK/Q'_SSM/\ P(%'M:?</85?Y6<?
M178?\*S\1_\ /.T_\"!1_P *S\1_\\[3_P "!1[6GW#V%7^5G'T5U=O\.O$%
MS LT<=KL;.,S@=#C^E2_\*S\1_\ /.T_\"!1[6GW#V%7^5G'T5V'_"L_$?\
MSSM/_ @4?\*S\1_\\[3_ ,"!1[6GW#V%7^5G'T5V'_"L_$?_ #SM/_ @4?\
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M ']*L;=4_P"@6?\ O^G^-3KXMTAM-%^;C;"655###,6"D8'?[PJT^NZ4EQ%
MVH6_F2LZH X.2HRPSVQ[T^>0>R@9VW5/^@6?^_Z?XT;=4_Z!9_[_ *?XULV^
MHV5TZI;W<$K,F\".0,2OKQVJS2]I(/8P.=VZI_T"S_W_ $_QHVZI_P! L_\
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&BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>form10-q_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 form10-q_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *F D # 2(  A$! Q$!_\0
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M*%DN[6%;=5$L<3REI,;#("0 <8/0]2,]JN2^(--@G\E[D!\D# )!PF_.1QC
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M:EIT=R$\MBS(Z9SM=6*L,]^0:1)-8V-MIME%9VD2Q6\*[41>PJS110 4444
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M2,C7#8 7SV\S8 <@+GH,UB_V)XV_Z'&U_P#!2O\ \71_8GC;_H<;7_P4K_\
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M67%$(4(R6=CN=SU=NY-6]:=8[6)W8+&LREB3@ >_XXJI#<0W )AE1\==IZ4
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M9_Y<O#8_[>)O_B:7S?B'_P ^OAH?]MI__B:ZZB@#D=_Q#/\ RP\,C_MK/_\
M$T;OB)_SS\+_ /?=Q_A7744 <AGXC?W?"W_?5Q_A2?\ %Q_3PK^=Q_A7844
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M<*RQ3P$+MSD@YW*1T_/!_"N@FD\J%GV,^!]U>IKAWU6TL-55;BZFM+5%D>-
M T3@_,02,\K@D#N#0!KM91-)--.V2QSNW8VKV%7M!C\JSE56S 96,)QC*\<C
MVSFN8@U6UU#57$-Q->V)9)G# +$I"_*BEL9R?F;TP*[J&3S85?8R9'W6ZB@"
M2BBB@#DO!-I<VDWB;[3;R0B;7+B6+>N-Z%4PP]0<'FNMHHH **** "N7%C=?
M\+0:^\B3[)_8PA\['R[_ #B=N?7'-=110 4444 %%%% !1110 4444 %%%%
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MTQ;UPT*.N?-927+,"%P/X<F@#TZBO/I?&=Z/"WBR^2XM?M>G7$J6@V_P+&C
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M444 %%%% !1110!0U.^:PBA:.W,\DTJQ(@8+R?4GZ5#]OU?_ * H_P# I?\
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M/]XG<3^%='0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_8$7_P!'M0!U-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #'C
M21=KHK+Z,,BHOL=K_P ^\/\ WP*L44 5_L=K_P ^\/\ WP*/L=K_ ,^\/_?
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MC-9<&I+JWA1[Z,+MFMY#A6R 0"",X'<'M5W2/^0+8?\ 7O'_ .@B@"[1110
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M-(A4R(H/S8//<5Z90 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?B_2M9:0:<\UR8]N_P N%OESTS^1K1U?G1[S_KBW\C7G/PA&V?5@< E(<?\
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MUN)9=UQIAU56V\"$#///WL \>U #-#\&3:7J=G>7VLSZ@NG6QM;&-XE00H<
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M@ HHHH **** "BBB@ HKE_'^MWOA_P )7&HZ>R+<QNBJ77<,%@#Q7D)^+?C
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MA<=*\%'Q?\7L0 ]EDDC_ %'_ ->MR7XB^*$\+6NI+-9M<R3M$R>4, #/O[4
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MR'C_ $>UA\,W9C4+,O,A]3VKT&QC"6@5%VG/2L/Q];12>%+Q-N"XP30!Y/\
M"^]CM/$C02H&\^$^7GH&'M7J%CH,MY<_:6F/!.\>HS7D7@G3I+KQ3"58K]G^
M9B/RKZ%TI3': ;2 >OK0!YA\4M%D&GI-;JSM%AF"CJM>6:<GF7MFF?E:901^
M-?1?C*-&T>X*J!MB.2.]>">&;3[7XBLHL#'F!OUH ]WL+*V%O''"I4 9"Y[^
MM4]=TJ&[TBXB:,F?:3OQUKH["T:(Y'S#^5+=@)&X;DD9/% 'R]&KV.HDN,F*
M7:W';->_V5G#>:':K H6,QKG ZY'->2:HD&J>,W2UC5(S-R%'!QQG\37N>E6
MOV.QAA ^5% - ')ZIX=BLM-N(XF+9Y(/?/:O%Y8S%/+&P(*L1@U](:H5^R.,
M?I7SSJYSK-X.WF&@#2\1?\DNT3_L(R_^@FN$/W/H*[KQ"<_"W1?^PC+_ .@F
MN&/W#0!Z1X"M+RXTFV6VE$*[RS, ,MS7J!TP+;L90H'1V'O7#_#"VV>'XW;)
M\PEA[<UZD4\RUQC.1T- 'SC\2-/AL/%(2WX5K?./?)KM_AC+;W_AR2Z C^V[
MA%* ,=,XK%^+]HRZS:2H!M$)#'WIWP>M+D&]N0Y%LS!0GJ1WH ]+_L34':&5
M90L)/S*&ZGMQ7FOQ:T06CVU\L0\S?Y<DB]\^M>Y:=(D\&PCYEZ#->>_%N!7\
M+-O #B7(H XGX22Q/<7L$NT2QKF/"C)SZFO58=!NIKB"42E$W?,JG@UY'\)K
M'[1XDN)R^WRH<8]237T39*4M0C#!SQ0!Y1\7M&<^&9)2F6B*E6Q[\UY%X6E2
MW\3:;)(Y6%Y!'(/8U[]\6V\OPE<(V,$=:^>M&@^T:OI\0ZM.G\Z /I.RT2TN
M+LW+LY<#*Y[^QJKXGT5;VV>)4(4IWZ@^U=-HENWV=3@9QU-)K$&R)G9P1C/!
MH ^4=5TU](U>:UWERKXSCFO<]#\*R77AO3U,CQQJFX<\?3%>67$*ZEXXF63D
M&YV@8]#7TC#MAL;6(* 5C  ]* .3O-)M[>Q>*0XCD!&<<U\_:I@ZU=*I+1I(
M54GT[5] ^-+E;?2I]Q*X0G([5\Z Y+,23N8G)H ^C?A(<?#=?]^3^=;GAN..
M;5KF1E!>."/:?3YGK!^$I_XMH#_M2?SK6\*"275;IUE**L,>Y H.[E^_4?A7
MBXE?\*%)^3.2I.U>$>Z9VU%%%>T=84444 %%%% !1110 4444 9NN:1!KVBW
M>E74DB07<1B=HR P!],@\UA67@*VAO[2\OM8U;5&LF#VT5[,ICB<# <*J@%@
M.A.<5U]% '#1_#73XC#$NJZH+2WOOM\%J)$"1R[MQ_ARPR3U)QFG^'?#T_\
MPG&M^)[[3UL9+E4M[>+S0Y*J!ND.. 6PO'7"\UVU% &1J>AVVK7VF75Q)+G3
MIS<1(A 5GVE1N&.<9)'3FM>BB@#B/BS_ ,D_O/\ KK%_Z&*^?.U?0?Q9_P"2
M?WG_ %UB_P#0Q7S_  !'N8ED.$+@,?0&JA;F7-L-;GIW@*2"73EABR)4^5PP
MQSU_*O0K9-H.3N4'  ]:XK3_  [:Z##;W-M(TMPZ#?,3P_?@=JZ;4TFN] NH
MK.8133(1O;/RD_2NBK&BZW+3?N^8VE>R./\ B7>6E]91QV=U#-)$Q+I&X8KB
MN/\ !>J6NBW;7%^THBEX18TW'/J?2HM<T.?PZJK>M%ELB,1-DMQU]A6U\//#
M^B^)=-NTOUD^T6Q_Y9R[=RGGD5USHX.E5LYN4;=.Y5HIGM&FY:W&,'H35#Q-
M=VUII-T\TRQCRV +G R1P*LZ5Y=K;"%$VHF @S_"!7GGQ,T_6M7N8VM[9WL;
M9-[E6& Q]1[ ?K7+A:$*U=0E+EB^I-KWL<3X%O;6S\8QW=]-Y%OM96D() )Z
M"OH:W7;R'!3;D,/3K7SMX1T&/Q%>W>F_:OLUZN&AW#*,,_,"/6O?M,46=K';
MJ7D\E!&SL>3M&,FGB*5"FDJ<KN[3_0&E:Y;NU61,.0%(W$D]!CK7@>L/;Q^*
MI;I)#]G.TB0C ()P#]*]V>=?M#W$C*L42$D'N*\2N+V*7QE<37\<:QS_ .KC
M8@XYXR.U<T.6_OH2MU/:]'PNEV3!0Q:$9(^E<IXP\>VVB:@--2R:XD"AKA@V
MT(#R /4UN>&]1B2PMH&F4JWRQDGD>U8'C'0M GEN]5U-&66(;<I(5#@=-WK6
M^&E152]9/EU_X!4;7U/-/$2-!XNO;BU42\K*HQD891Z5[3IBL^D6S2(JS+$O
MF(IR%..E>/6GB"#5?%;76!&NQ8TVC&0*]9L]<L;.UM?M-Q'&UVRI$"<F1O05
M$G&453A'6[=^MA;JR0Z\VJ/+*DD+G'85XOXW=#XB"HRLJQCYE8$'\:]JG8W-
MXZYP&1E;'. 017@WB#3$TB^-E]I@N)4;+/"#A1Z'/>B,(.G*3E[RM9=PLK7$
MM<_\(]J7_72#^;5G1)YUQ'#G&]@N?3-:-J?^*=U/_KK!_-JIV<,\][ ENFZ7
M>"HSCIS6!)[SX=M;G2+5K1VB>S*H;8(N'7CY@WKSSGWKI)G$4/S=5'6N#L/%
MEGJ%Y'I\LHBN845FP1ACW ^E;QUF"Y\R(OMPV 2>N!52ES.X/4\\^)TAEE,G
M\/"@U8^%EFWV*XO&7 >7:#]!7*^--=CU6^DCMF)@C)Y/<]*],\ _9YOA] \"
MHLL>4<CKGW_.I [F"+*HP)'.<5F>++6.?0Y58_+GDU>L9\V6'.9%&.1^M<7X
MYDNQ96E]'J+1VL)=)K?'$I(ZU4$I.S=AI7,CX=Z=; ZC?1^8Q9]I?'RISP*]
M:B'EVZYP"<=:\E^&.KV7]E7]LSB*1B"X)[CO^->C&\2YT@M%*KO$P5N>1ZU+
M$<UXW\46+>%;^2U9SM=K=B4*_.#@@9ZUYS\.H(I=41R 98RIS[5T/Q>U*UCT
MRSTJW93(S^9(5/;U-<1X4UU=)U"(SG9#UWCM3=N@'T7:-(;5Y8V"XR<53U2^
M$>BW,KC$PC+ &JNF:W:7,38=8U,2N')X)-<7XO\ &EE'H-_86IWW6W;YV1AL
MGG%(#DO!D"W=\;U_O>:"?SS7O$0"VXDQD%<\U\^^"KV"VU"&-Y=N]E#*QP.O
M!%>YVEX+NSEB5AYD7RLM $'B.]BM=!N;C@E8RPQ7SC)*9YY9F^\[EJ]H\<:G
M#8>&)HGD FG0JJ@UXF@^4T ;_B#_ ));HO\ V$9?_037"L1L(]J[KQ!_R2W1
M#_U$9?\ T$UR.CK%)KNGQSX\IIUW9Z8S0![5\.[66S\*VPN%97=<@$=!7H$+
M8MTW #T]ZYPX66&!/NJ,C'%:CW#"W)R<]<#M0!Y5\84:*6,MSD+@_G6_\+=.
M^Q>&+)SSYX+_ )FL[XN:C;1O C+&9EC5EC89R15WPCK5HWAK3Y;9]L:,1M[C
MN10!ZA;16T$8=@%:09)S7EOQIU"""QM[6-OF<ENM=S-J-M>W5G'#.A5\84=Z
M\7^,EY'-XQM[*!MWD1$N/]H]!0!L_!ZR@33[[46<><9EB(_N@?XU[A+<+;VP
MES\HQ7SSX$OX=!GG@;4+:2"X7$RNQ4QN.A'8^E>J0^*+*[T2:4R QQ .K*<[
ME[T <S\:[Z[?PS&Q7;$S@$?4\5YAX#2)O&NG+,,J&8@'^]CBND^*GCNU\165
MOI=A%\BD-(Y/<=*X_2M7BLKJUD%H%:%U=9HFQ("._/!^E 'TY;WA_L>1HCM>
M-3DCUK(U=9(!9M)*?+E&Y@3[5RFD^-3J OWL6&U5.Y)!@!2/O'\:Y/QG\0+O
M4+2WLK.0)Y(YD0YR: *OA:V_M#QY+,&)CCNV<\=<'@5[L+P7;(81C8"&';-?
M./@/7AI6O!YVRK;F.>Y->X6=S!'8PWLUP(Y)&8QJ&ZD^HH S_&EM)?Z5?PQ@
MO((CP.V*\!7_ %8KW?Q!KMKHGAB[N9)E:[NE*0H>23T_*O!^0!Z]30!]%_";
MCX9'ZR5H>#)+@ZI=^4L1A\J/S"S$,.7Q@8P?Q(K-^%'_ "2]O^VO]:N^!)U3
M4KV-@Y9XHP,(2.K]3T'XUY6(7^VTGY,\G$3MCJ4>Z9Z%1117JGK!1110 444
M4 %%%% !1110 4444 %%%% !1110!Q'Q:_Y)]>?]=8O_ $,5X-%?F&W$*V5J
MPYW-(NXM7T7XWN]%LO#4DFOVSW&GM(BM$@))8GCN.]>9'7OA4O\ S +K_OVW
M_P 50!RL'BS4HKB-VD_<HH7R5^Z /3WKL[GQE-H^@*WRS2SX:(.>Q[_A5;_A
M(?A3_P! &Z_[]-_\55\:W\.=1L&D_L&[>WLH^\9&U<C@?-SR: /._$FM)KKQ
M73O*+A00R-]T#MBIK+Q/J%K&/LD%O;R>5Y2RQ+A@!C\_QKK6UWX3X.?#]T<?
M],F_^*IR^(OA4HPN@78'_7)O_BJ -31_%=Q<Z?'J<L@2*W^6;/ W5EZQX_AU
MFQNM/@?[$TV1YK+G<N/7L35R'Q7\-Y;/^SX]$O/L[OYAC\HXSZGYJIOX@^%6
MXAM NR>G^J;_ .*H\P.'\.WUMI-]-=M).+N(?N&B. Q[Y/I7=:1\1[JZO)+>
M\'EQ7#!8V7DID8P?7GO42^(/A.I&W0+K)_Z9-_\ %58M_$OPO6>-X-!NPZN"
MA$3<'M_%0!C^*?$NHV]S/IMK>.(XUV2-W)ZFN)AO9[:4NC!G?@LXW']:]0O?
M$GPQDNYGNM"NWE9B7;RSR?\ OJJIU[X3Y.?#]U\O_3)O_BJ ,;PMK=S)?>1=
M2LT9W2 CJK =ORK/\1>)+C681&P=(E8MM+D[C[UV5KXL^&%C(9+?0[Q&P1D1
M$\'_ (%4E_J7PPLG2.?0+DF2-9/EC8X!YY^;K0!Y-;L4 9"58'@CK7=^'M31
MM$:ZU##C364Q%ER03T K1&N_"@# \/76.O\ JV_^*JRGBWX81V3VB:)=B"1@
MS((CR1T_BIIM:H%H8S_$:]"RHML55CPRMSM]*Y&]N4NY_-2#RNI/.2?<FO2I
M-5^%\=G#<G0K@K+G $;9')'/S>U5?^$@^%7_ $ +OT_U;?\ Q5(#BK7_ )%W
M4_\ KI!_-JS8V='WJQ5AR"#7IL?B3X7BWD@70KL12$%U\L\D=/XO>HSKOPK'
M_, N_P#OVW_Q5 '!Z/%--K-JL3$2M*#N';GDUH:]K=Q>:D[13,D4+$1&/CVS
M^-=G:>*?AE93>=;:'=I(4(W"(]#U_BJ>_NOAK86]M-<>'KD"Y0R*!&Q(''7Y
MO<4 >6>8;V6.*9XT\QP&F88/U)KL=%\46GA:VN;.PN+F\60YV,@";AW%:+:]
M\)\?-X?NO^_;?_%5)'KWPL.T1^'[LY. !$W_ ,50!TUAXKC^S_VC)*B6;QX)
M/0&N&\4>*E\0Z%/' R0+#,2(VSEUSP?K73_VY\/9/#C.=&N?L$5P%6(H<ER#
MR!NZ<5DOKOPJ&2_AZ[ZX_P!6W7_OJ@#SFREDA9VCD:,LN"5.,BNU;Q-=6?A^
MU>-6\RX!!8\ E>"?<UHKK_PJ7.W0+H8P#^[;O_P*KW_"1?#>ZM$B;0[LPVRE
MD4Q$;03SCYJ /+-1N9KV4SW$C22'J6-5T^Z.*].DU_X5X*OX?NN.<>6W_P 5
M35USX4\ >'[KIG_5M_\ %4 8%]>W4'@_2((YV1;@2%RIP2%. ,UR=X22H)))
MX))KURWU_P"&^I"UL!HET8X]QB5HR N>3_%[51DUCX5^;M?P_=%@<#]VW_Q5
M 'F<6X2Q["0X(VGT/:NZ\0>*;[2Y!86;A9%C7SYOXBQ'(K13Q#\*X721= N@
MP.5/E-_\54\WB;X9:A>F2;1+MYI6&YVC//\ X]0!Y]JVJ3:M.DL^<A<'YB1^
M [50.,<"O3[C5OA=;RM')H%UD#/^K;I_WU4/]N_"O./^$?NN/^F;?_%4 <EX
M@/\ Q:O1>/\ F(R_^@FN5LK2S-G]MN[]H-LF$6%0SY'M7NFI3?#\>#-,GN]'
ME?2I9W:"+:<J^.21GTKGUNO@^Q^?098\?WD;_P"*H YR/XESQ:BC1PE[$(J'
MS%PX(ZMQ767GC./1[,W=P3*;A0\$8QR*:+CX.D'_ (E@ ]U?_&KUW>_"R]@B
MNKG3G>%%$2/Y;[5 Z#K0!XYXF\22^([Q[JXM%64KA7+$D"J.D7=S8F.6WD96
M5]P&?E_*O8)9O@XBG&D;QZ*K_P#Q5$=]\(%52FCL!P<;6X_\>H Y/7?$=YI-
M[##9G%S H+.>@)&>GK7 W]U<7UY/>74C23RMEF)ZU[G<ZK\+-2N9;B71IYY2
M-SL(VZ =?O>@J@UW\'CP="D/_ 6_^*H \BMQB$?7-=1J=Q+I_AG2]-1V1IT:
MXF ZX)^4>WK7;KJ7PA48&A3 #_8;_P"*JU-K/PMU*[5I-$N)IV 50(V)( P
M!NH \,O% D)&1ZTJ\E17M$EW\(78B309LC@Y1O\ XJD%[\'PP T*7IUV-_\
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M.G35-MR]Y-:>065CI[E9&1A&1DK@<5\[>/;DR>(G@8DO#D,??->N^/X-9O\
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MYC&,CM7J/CCPO,_AT7$5OB>VX<X^8H?YUYI$&#%FP"2.!0![C\)$5/ GB$*
M!F3_ - J/X&R,DVKH(797$.7&,+]_K4WPEY\#:__ ,#_ /0*/@G)%#/JT3R(
MKR+#L4GEOO\ 2O7PS_V"LO./ZF$HWJ1EVN>RT445Y!N%%%% !1110 4444 %
M%%% %+4=4L-(LS=ZC=PVEN"%,LSA5!/09-0Z7K^D:UY@TS4[2\,>-X@F5ROU
M Z5S?Q0V?\([IWF;=G]L66[=TQYRYS[5F>)+K2[3Q]H%UI<EO'=0P7<E_);@
M-MMA$3F0+U ?;@'O0!Z517B^B:UK]UXBT>R&L:GY>M65R?.O'A^9A'N26.),
MF( ]FZBNB\&>(]5\3:U9PRSR1KI%D8M50* )+PL4VGZ!&;C^\* .ROO$.C:9
M<Q6U_JEG:SR_<CFF56;G'0GUXJU<WMK:>3]IN(XO.D6*+>P&]VZ*/4GTKS_Q
MC_9USJ>IZ#I5K:R:YJ\"I?75R1Y=I!C:&;/?&=JCJ>:/%OAVSL[CP;?":>XG
MMM2LK2)Y)25"#.6"]-S8&30!+\:CCX=3?]?4/_H5> 6";YVQE& ^7-?0'QK.
M/AS.?^GF'_T*O#=/BVQ"0Q<'@<]!7T&2TO:3]#>DM#>\.PW#W5Y9P./+GMR7
M<X&#G"\GL2<5=0KH%PT=Q8PW%Z.F]LQJIZ=.O>F^'X8[JSUN!U+.8D,>!_$,
MG'Z5#9Z->W<3R+&L(0XQ,2F3^-?,<3.I7S.5.,=DEMOI<]C):V#I4:LL1448
MJ7O*]G?IYV\B;9%>6VKW,4<*QF LMK*P+;^N5SV')K L[>2:[M$@!:08=<=L
M#K^>*U-0CM=.MO(G99=0F.$,3Y6(=\GOD5#HU]%I2W-XT32NDHB1!TVXS7UW
M#6&Q.%P$_:1=Y/W4_2WYGSN?XW#5ISJ85WBTHIV_%=_4Z73]/UJ:YDGU2XBC
MMXE,ABC(5I2HZDCG%5KOR;KPE>:A%%;P7,^?.*GL#G&.V1^=5+?Q?IEM.1'8
M-^]RLDLK;VP>#@FJ.K>39V2VMK.LBW<WF94Y B4?*#[Y/Z5Y%+*\QGFE*KB:
M:C"]TH[*V][=7N<%"IAE@YTJ;:JR<=6K72>J6^GJ:'A/2UG6[O9=HMI%\G:V
M>0OS,3^E-U.XL5D5]*<(7&'*(5V@>F?6M7P:['2FD6-"5,L!+'MN!Z42:1H5
MFP%S(R9SPTQ'!_PKP\TACL5F=:4:;?V59=%_6YZ.!SC+<'7]GBJDFT[\L;VN
M^Z6]C'5I(?"NHRP1KYAF2.1R,G80<U@2C-O*N=P7[J]AQTK?U2PFM?#SP0.)
MO.O%,9C;(90".??D5C74,VG2B*^A$,LB[@ <AOQK[WAJBZ6!5.HK2;>CW^X>
M*Q^&Q&-K5*4DU)JWR2-V"WT]=.GOYY'\PE61%?#9*@D#\R,]A4^LR16/A(0B
MSB1+D*(57)"@\@G/\54M"O-%DL(O[40/+;L8URQ"E>HZ=>M;NK2)XDT;[-:%
M3M^9'*[0N.@_I7R^'R_%X;-(^UBU24F[[+R?F>3FN9X>JH1]Z4[J[:T26EE;
MH]SS^X9(H@O.P8R,8S6Z5D?3K4)OD@M8Q$TI&0&8EL9]*RK812:A8&Z4E#,%
ME7Z'I7HW]GV,%A<P+#)]G<L[[NLA)S^G:O5XQJSJ^QPE-:S;?W'HX7.L+E=?
MZQ6BY/3EMV>[^1Q37,GE>0&"0]651C>?4^IJS>&*WTC3H(1F6YS<3G/) ^Z/
MI3&UK1;2X<0Z7+++'D#SGW+]<5G3ZC=:E=//*H#$!5'0*!T&/2N;(^&\31Q$
M<1BE91V5[Z]#V,?G]/,^2EAX2C"_-)NVO9=>I#,LB^$M;WCK>VY'TPU<MZ5U
MMTDB^#=5+G.;NWQ^35RBCBHS2+CBI(\^I\3+MFT0@=<'S0<@^U=5J>MW^KZ:
M((K8+;@*K,"3O(Z;1VKF=*A603,W4'%;VD7<FD7L4KEY+;G*J,E,]Q7UN!I)
MX&G5<4Y0NXK^NIY./H5)RYX+9&5/I>HG1KB;[,X@QAG88VFJ.AS,9+B-8R2!
MN)8]3Z5UVO>([EM&FM([S[7"XW2RRQ;<#(PH'X=:Y/1H]M_<%OEW1@C\ZY:5
M7$5\53JUH<C=]-W;I?S.O!QG&G)2=UT>J_,T)+>)FA-L3<221YE0C!1\]*T9
M=2O;?17TS4;:8/)M\B21<$(#G'N*SX[:5;G?'(4(Y#@]#5W4+_4=6GM8[N6)
MS"C!'VXSQSG\J][$T?:<L9)2BM==TUM8\F="K%J4_A3WZ[G.Z?\ 9=\C2$%P
MQV#''6M@VKR%HI8;A;N0 6\*#&1W)]JR["-(+T2,H;RG#;>H(S7H]QXHT=8Q
M>VRB2_V[ NP[A_\ 6KQ\+.MAZ2C"GS<S>JZ:Z7\AYMB:T9QITXN2?;OT_P""
M<;+9Z?\ V6L<T<HOHI0'5C\I'I]:YN%LZCYH4("QP!Z9Q712FXGG>YE)\R1]
M["N<5=MPKYZ[OPYI9M'V?LZEO>O=_A^"/2R^G4A3:J7U_"YU%M=75C:31QW<
MD<$F0\2'[P-(+QVTF2T"*UOO$L>>L6.N/K3EMO."DG=P. ,U%/:M%%+&(6CE
M"N&9F.6ST&.V*]JK[/D<[:[_ ($O!Q4DN32^_6_>YRH=S>M-G+%MU:&FF)S,
MX;_22^"6' !]*S@,3$'MD58L5=;MB%8A_EZ=:^$RVI;&<TE>[U^?4ZYJ3A)1
MW.PO=!FA@+Q2KN*"1;=CEBO<YZ>^*Q[NT%S9^4KJ95Y4^F.U=C?Z_9W_ (7>
MV'R7?EK'Y>/FW CI[8[US$=F55B3CBOKL(ZV)I5*>*5O>:6G3H_/U/*P$J[U
M<=5OJ8B$?V1MQAPX)QT/-0UI7J8L.< AL<?6LT5\=F]'V&(]GV2/64N=<QV'
M@B]$FO6\21I$L(&6ZDCWKU>?7!-=I!$@9T.6.WC':O+OAI9)-K+R2 LK90J*
M]NBTR#8@CA579AEL9(%>2,\B^)^E626O]MB --/B(]LL>_OQ7$>$KH1:[#;M
M&&56\S Z\=J]!^+B2V^FVT(&8WN.2?X?2O./"F]/&FGO&A=O-(*CN* /HK[7
M+=16R.WE,Q'E[O7T%><?$G3;F[TB6_NT96M"7C?LP)P17KZ9:($#YI?N^U<O
MXVTF6?P+?6T[H3Y3%=OKF@#YRM(_.O(6!QYA"8^M?2'AVY8Z3#8V]IY:P (A
M9>PZG/O7@GA6S%SXITFTD&0;A0WT%?54=C#;Q(BQA>0N1Z4 <-XTNH;G3)['
MR5+M$65A_> [5X)ITY;5+=V.-\P#\=CUKZ-\9-%IVC7S)$C;4)0XZ''K7S5!
MYC-$\?$OF!A]<TX[@>T>%;N_FTWRHF"V\-R$18DP.15WQMIEQ8Z,MO:QKE5)
M15]3DD?C76>#K&*7PM9!80HV G:,?-ZU)K]M') 5=2SXZGM6U:I&I-R@K+L5
M*2;T/F NYU(.D>QA,ORLO0]#Q7T19V=SIFB0VEFP+L/,8*,@Y['TKP2X G\4
MN(EW;[Q0H'^\*^E-/C9"@=>>,U@2<M</?W=I=&\$L:^5Y:QD?*I'\0^M>):J
MJQZI+&N,H<-CH37TQJD4;6TX9N&4X]/K7S9K\"6^OW4:'(R&S]:;=P/8?A$A
M;P5KJJI9F9\ #))V5>^$%A<VDFJ_:;.X@)6':9H63/WLXR!4/P2;_BF]5)8J
M!-]X=OEZUT7FI#(@3Q>5MU(^1TY+9&?F[\]O>MX8F4*4Z26DK?@,[FBN*DN3
M%%ME\6E9E4AF,..^0<>PR/\ ]5;MMK^G2)%']KS*0HPR%6.>,D=N:YQ&Q111
M0 4444 %%%% !1110!1U+2K#6;)K/4K.&[MF(8Q3(&4D=#@U7TOPWHFB)*FF
MZ5:6BS#$@AA"[QZ'UK6HH P+3P?H6F-YVF:38VETI9HID@&4<@C(]N3Q1X8\
M/'P]9W7G7(NKZ]N&NKNXV!!)(V!PHZ    5OT4 <_J'@KPSJM[+>7^AV%S<R
MX\R66$%FP,#)^E:<FF6,MO;0/:1-%:NCP(5&(F3[I7T([5=HH \\^-'/P]E'
M<W4('_?5>+Q*T=NF1SC!'85[9\8(S)X$95P#]KA/)_VJ\35VDA)VGT&:^QX=
MBN23?<W@[09M^&K^VL#=O-*Z&5UC4H,[<#))]N16?XF341?13W5SY]M*/W,L
M;?*?;ZU%"FV"-LCYUW#'UY_'-;^B62:Q97.E7 9D!$J!1DKV8_R_.O!EQ L/
MFTW72Y+VU6JMUN5C^&H4\%_:5&\INSDMTT]-/-'*Z9H\^I3221R1QPP\RS3-
MA5_QK=\--';S:O:WWE/#%MD:1.<\X&WZ\5#J#QO-Y$42Q6UOF.)0>N#R3ZDU
M!H4EK%J%W;7[&&"Z0)OZ88'(Y[9KHGGF)S15Z>%5E%7C9:Z/]>QS8W(H8;"4
MJN+D^6;3E%?96_K<NS:;I.KN\5DEQ!>."4#@;3CG''3BL*PTJZO&E*LD<=MQ
M++*?E3Z>M=SINFZ=;S-<6^H&>6-6Z$!1D8Y]:S&T&[:Q@-JJRCS':50X!!)X
MX-+"YSF.%P%26(3YDTHW6NO<\Z/]E5<SAA\)4<:;M=RZ/K9LJ^'[U]*OKRVN
M9RMK-%YD4R(?G((!(!^N*IZII?[N;5([E+NTW!6W9#H3['M4DMQF5=-D6,/;
M X9WSELY*H>@^GUI;>Z^Q3&1HE<$%)(F[@]1]:PK9[B\'B:=2K"T9).6F]][
M,]O#\-8:O"KB:$[U$W9:6:6U_7N3^&;^2U@U#YVDMK:$2)&W(5R< BG6B6MY
M9:@NHRCRR%EW$\B0D\CZUM6&CZ99VEZEM.K+-"#-O<'RE(R,^F*YKQ%<V2K%
MIEBBFWCP\DP.3,Q'!SZ55*4\USB-?#-^SC9WV]?G<\>A7PU/"5\)*FU6E);K
M9+K?\NY OAHW]I+=V$L<BID>43\S8ZD4[3M6M4L8+.]CN ]K(3$8"!N8GHV?
M?%3>&X+XW-LUI VV*;RQ)CY>3DACV&#5_4O#'D^)TF\U!:27 <@=1SS^M>U+
M,:>+KU\!B5?D]Z/G8XZ]!9>J4Y5?C3MM>+V:>_0H2Z8UMJ37!GCE:VD^T3Q
M'Y6SG;[C) /I6K9>(KQ+U9+VX>2V<XD3&0H]O3'\JJZK;C2+B0W4D<SSD_NX
MSN.PGYF/OTQ[T^XT"X0P?8]]Y%<(&1PN,9_O>G%?"9O5QV)A#$UXVBKJ+M:V
MI]OED,F4)X:<U+FC;F=K;:I/R9F^(;-K+Q-,B;"+G:T>.GS8Q_.H=0@MM/0"
M"2622,[9I#]USWVCL :[N72()&B^TO#+?V\ "NK9VG'RGTZCBN/U'3;BPMD2
MYDCCN)T.V($,V.Y;'2OH<)Q'7QE3#4</=VMSZ;_\"QX&54,,J=95IV<-(*^_
M9KNK%2[(;P7J1 _Y>K?/Y-7)"NLN3_Q16II@_)=VX.?HU<GU&*O.&GBY6-)7
MOJ;?A^PDO#,HGBMDW!1+-G:S'HHQWK5AS8Z@UKJ,63$Q61% .01P1GCTK-\.
M:M<Z;:RB*."XC=AOBF7=M(Y!'O4]Q?7>L:M).L#/<2( J1C/2OI<JAB/9^^U
M[+ET[I];G!4Q,J-9-W2UO>UO*WZDDMI+J5E<BW@#1IP[_=&>RJ/7VJI9Z7YU
M](SW*6\44"F23!/&<# [DFMJ?Q#ID.@Q6":?)N@&Z0[M@\WN3Z\YK/T3Q)#8
M7):.$3EHPLT9[#/:N>I5Q<I5%""C-?!=ZM+J_P!#2.(]M1<YI[ZI)+2_1]=!
M9H#8M!_I*SP3 E748P1U4@]#2BS&HRLL31P01_ZR>4G8A/8XY)/I4VMZAI]S
M9VD6FV[1+O:5E;D@GBK.C7>G-X?FL[J[%K()=^0NXN1TR*ZIXC,*>6JJX7K;
M6^=KG/#%4IS5*5XTW*UVKM+T.>6U=-:EM(E6XE9@L;QG",>V,^M7KBTOM-E7
M[;;B%7^XP(*D^F1WI+%8;[6);2*1"6?$;N,!F"\=>E;]]IT^FZ!>-?-'Y;@"
M*$/NP^<[AV!KSJ&:8FC7I8>4+J>[[-O7RT/0Q<,/2INK&JKQ:2B]VNZ,1I41
M,MDEON@#)-8>H1QV]NS^7@F7(W<$<=/:NHT2PN;FQGO;96:X$@C4(?FC7J2/
M<UA^+D,95IBQGW*)@QR0^#D?EBNG'9A3G7J851=XJ]^BO8*4Y5:7M(R5KM6O
M[VG7T-J?3;S2+2VOXKCS(\H2Z AHWX(^H]ZAD:>^N5&6EN)VY+<Y]2?H*%UV
M>X\+R:?.))!\GD/UP!VJLEQ<Q207,#F.6+)#8Z<5ZF$A7]@W5:<];/I;I_P3
MSZ%?$<LX-:IZ&'K&G/8:DZEU96&]64$;@>,X/(K9T=8'AM1,C,I&UU0[2><=
M:PM8O[V_O6FN6D?<0N]Q@D#^E=)X=U*+34A-Q:)<6SH/,!&2ISP17R]&G6G.
MK'#O]Y9:[*]];'I1JQIQYZL7)):I;_(DEL_L-[>6TC;GMG\O?TR.U2Q:?J%_
M KHL2AQB)99-K2 ?W1WJ$-)XB\030P.J?:I68LW90/YX%=1J-EID4]NTFH"V
M>T1%96'+*HX(]#7L9ECL7A:5.-*'-4=KK>VWYGET\=0E-4)S<+IN]K^B?Y'G
MUZCI8,) 0?,Q@]CGFLY:W->N8;I[F6W#"%IBZ[NO)SS6#VKYW.IN>)YI*S:7
MY'=2T@CT/X3'SM9GA&<1YD9@.@/%>[P6Z8!5\]*\-^'&AP:SHCE+N:WN8[GS
M&,)P6 Z ^U>UZ?,/LY).23^E>2XQY4T]?R-FM+GGOQ=LT;PZTB ,ROR?>O/O
MAEHCW?B*34G0^3;#:K8_C;_ZU>C_ !.6UET0W$[R*('+* >#[$=ZH_"&ZMKO
M2+VS4!98CO9<<DT-1Y4T]0=K:'I1C++"V,8'(%9/BM99] O-D>$CA).>];=K
M&TD22"0?<S7$^./$FJ6+C3;/3WGMG@)N)3$S Y/ ##ICO54J4JLN6._W!&-V
M>6?#:QEU#XBP;$)6)7=CC@8.*^E&B+.G;!Y&:^=O"4NO0:CJ*Z%N6Y5R\@C5
M2Q7VS7L_@C5]1U304DU2"5;E79&>5=I?!ZX[5K+#M4O:*2MM;J5R:7(O%EHE
MY9SP,A;S05Q^%?.NCV(;7?LKC:(V;\,5]#>(_$%GHZ)-<6MQ<AYA$%@7/7_/
MXU\^RW\5EK=W>1HWE^:^Q#UY)X-8.G)04FM&3;2Y[@)M>D\$6<'AK"W:#?*5
M(#,G/"YX)Z4FK:MJ&E> 6N];91J*1$2<8R3TSCOTS4'P[\56MYX;,@66)8TV
M$OC@CT/?K7G_ ,3O%BZO&FG6DY>$-NE/KCH*IU;PY.5>O4?-I8POAYIO]L^+
M[0RYQ')YQ^N:^DK10 [8'?#$=!7SU\,Y?L'B"&ZF!6"0%%?L"/7T%>ZVFJPM
M931I*&9%S^?2LF2<WK_C71HIKS356X:6#<'E(&PL!D@=Z\&N[IK^_N+HX_>,
M2/I7KWQ!NM)M/#TTB"!KZX&PLBC<P]S7C<(VPC/6MJKIMKV:MIKK?4;MT/>/
M@?@^&-4W+N7SN1G&?EKLTNK!88U_LBW"+R@>>($9Y[G/;-<7\#CGPMJF>!YQ
MY;I]VNDTRT%]*Z7D.DS(0N#'<,S%MG&<GG.1^!QVK$1JC4+9)!&-*@#^6& \
M^+[C$X.<]"<U)%>1W<C/#I,4SC&6CN(B>#D=#ZU0U.%)BC!M/$K6Q1 LC<%#
ME\=@H6J&BL-/CDFM4L8;='1I98-Q9X^XVXSCJ<CVR>#0!V%E>M=-/');M!)"
MX5E9@W4 @Y!]ZO5F:<<ZEJ9'>5/_ $ 5IT %%%% !1110 4444 %%%% !111
M0 4444 >=_&EV3X=S.K;2+F'!_X%7AEC>JQ6&61>5SECSFOJG4M+L-7M#::C
M:175N6#&.5=RY'0XK)_X0'PGC'_"/Z?C_KB*]3+\QEA&]+HTA.RLSP"PO[6%
MKB"XA$L94E,$AE?_ &3TP>^:Z"R@TZ_T:>'2YY8]4<*7$[;2J9Y (XQ7L8\%
M^&@,#0[(?]LA0W@OPTQR=%L\^OEUSYI_9^/;J.FXS=G=-:^J'3Q.*HIJE4:5
M[V>J^X\5O=:TVQ:=M-LUGO @C$S?<!'#,H/?CK7,-<0>099I =^22QSD]R:^
MD/\ A"O#/3^Q+'D8_P!4.E,7P)X56,H- T_:3DCR1C-=V7X["Y?3Y,/3:;W;
M=VR.><Y<U:;F_/\ 3R/FF"2/S_W+NL?<H>1]*E?Q#=HDX%],!+]\=_3\Z^E$
M\#^%XSE-!L%/M"*:W@3PHY);0-/)/)S"*[:N?\\$O9KF\]4<4L%AY2<I1N?-
M=K<PS)\[)L7Y<GUK=L_$MU9VPM_+@G(;Y);@[BGH,=\>M>Z_\(%X4S_R+^GX
MQC_4BG'P-X6(P=!L,=?]4*RKYM0Q4%#$45)'2Z<&DM=-K.WY6/!]8\337MHT
M#VL4&[_72HV3)CHOTKFX-1C65A,R(BKE0!S]*^GCX(\,-'Y9T*Q*>GE#%0O\
M/_"+]?#FG'_M@*QAFL,/RPPL.2"Z>8J-.%*]E>_=W?WL\"MM8O-.1ELKI8XY
M\,4;UQUK4A\2)'HERUY=K<7LB[4C*8*GW]O>O;)/ GA24+YF@6#;1@9A'%2'
MP5X:9=K:)8D8QCRATKHEG&'FW)TO>[JUWZOL<.+RRAB9<S5G>[\_\CYD&I6[
ML\T]^WF@@%9!DN/K5VRU5;&Y$]M=^5*IVJI;*,#VQZ5]#M\/O"#'+>'=./U@
M%*/ 'A#((\.Z=D?],14+/9RBXU8*2]#L]A1<.1QT/GG6/$5_=E([J5?+/+11
M?+D=L^M92ZDIW^:TA'\)W9.!VS7T^_@3PK(<OH%@QQCF$4W_ (0'PG_T+^G?
M]^16/]KNG.^'@HQ[604Z%&G%*,=CYR6Z%QX'U8]-MY;CD^S5S8(]17UHO@KP
MPEK):KH=B()&#O&(1AB.A/YTS_A /"7_ $+NG?\ ?@5Y>(Q$L1/VD]V:GR[H
MX@$EU))<)&T<6] YX<YZ?6M6RO;BWM!K5FRPM&3&<X/)[8/6OHP> /"6,?\
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MH.HZ#!<1ZAX@O=9:5@4:Y4 Q@#H,>M '14453U"VFO-.N;:"ZDM)I8V1+B,
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MRE+J$9E7LQ50,^U=310!P_B#PW9Z/\./$-K:K+</-;RS227+^;)*^W ))[@
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MDRK%+Y;;';HAQP3]*%J[ 6,@FBO&/A]XS71TU)?$6OO=!I5$059)\-SE@P7
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MY-<W^S__ ,DR'_7[+_[+7=^*-O\ PBNJ;Y;B)?LSYDMX_,D7CJJ]S[5Q7P+
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MD91N&>N#VS4]%<IXMU?5+%1;6&D7=U!+$?M,]MGS(U8A/W0 .9!G=@X&%ZT
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MZ5WBJJ*%4!5 P !@"@"-((HWD=(T5Y#N=E4 L<8R?7@5/17FWBB^;5KUM/\
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M>XTMU$D%A<QJ3<P'Y6N(Y<D;U)P8SC@^IH ;#/XF2^70M1O?GU&]<O-:2$W
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M."V2?E'R@_,1D#IQTHT'1H[%Y=02VDL)KY$>YLED#11R@<L .,GH2.N!6]0
M5GZQJUEH.ES:EJ$IBM(=OF/M)VY(4<#W(J\S!1EB /4UY7=>(G\2^+_^))+%
M>):1!GTBZ8QK=A7(9L,/DDC8 C((([\< %FXU#Q%:ZG<VS7\<L.L7:I:2P.6
ME-NX #P 95/+!R2V=V"<CBNWL=!L-/NFNX8W>\>-8GN)I&D=E&.Y/&<9.,9-
M)H6BPZ):R0VXDCAE?S1;F3<D!/WE3T7.3CWK7H **** "BBB@ HHHH ****
M"BBB@ HHHH ***Y77O%T&AZU9Z8RX:2,W$\LN0J0@X(3 S)(20 JY/<]L@%G
MQ'K]KIA@TR2\^QWFI))':7#+F..0#@L>W)&,]3Q7)>'+?6]4O+?1]=MKX6EJ
M&DN(I3(5\U2 H:9B1<1N&9L#&-HR.U:EI::SJGB2\M_$&BQR:7=V7EEA(LD2
ML#T7(#KN!&01U4'-=A8V<>GV$%I$TC1PH$4RN78@=,D\F@"/3=-MM)L(+*T0
MI!"NR-2Q8A1T&3S@4M]J5IIJ1&[N(X3/*((?,;:'D.=JY]3BIYIH[:&2:9UC
MBC4N[L<!0.22?2O.+G7[7QCJJ65QH8OM)#H5AD5DN-CKA;I5SAXOF(R.5Z\4
M 16_BC4/$T+>';Z&WAN[RY:VF\Z%6^S,OSM&82VYAL4[93P3@X%=IH7A?3O#
MYN#9B9C-*TH-Q(96CW  JK'D*=H.,GFI-'T&'288S+)]NO(U,2WT\:^>8L_*
MC.!EL# R>N,FMDG )]/2@!:\UU[Q-<ZQ-#<>'IKJ0:5>/%J%JBL)4PX43>6I
M!F0;7^4'#9]L5<M_&EQXABNX=%MHYI&+^5#YS1S>2I*,[-M*Q/O^ZK8/!)K1
M\-:,]QIVC:EJ]B]IK5DCPLP8*S@D@[]IPP;[^/[QS0!#X;T0:G%;^(-:M[C^
MV/-:2-Y&9/+7!0!$ZHC+R4.>3SG KL@ !@# %+7/>*?$UOX;TXOY4MS>2([6
M]K"A=WVC); YVKP21T% &=XO\7?V3IMQ-ITR2/97*1Z@4C\U[5&4L"4R.IVC
M). &SVK,ATZU^(L]]=:B!;QVVVTC%G+^\1P0Y83J<.IRN!C [C-.\/Z:FO7I
MUGR$L=064227]C^\MM4MW ^7YNHPH!4\HPXZUW5I9VUC;K;V=O#;PK]V.% B
MCZ <4 +;VT-I"(X8UC09.%4#)/4\=R:HZ]KMEX=TMM0OVD%NCHC&--Q&X@9P
M.<#.3CM53Q5XA'AS3(IEB$MS<S+;VZR-LC\QNAD?HBC!)/X#DUB7&H:YJNL:
M->V6G"[T8W/,B. &C*[2[QR $%6&Y67.1GUH QHY_$DVKRZ:TUY<66I7(9;R
MV+LDMJY)\R.8'; 47 VX^;&0<D5Z#I>B6&BK*EA;B".60R,@)(#$ $@'IG S
MCJ>:72M&L]$AEM["-HK>25IO*W$JA;J%'\(SS@<<FM.@"M>WMMIMC->7DJPV
M\*EY)'Z*H[FN"U3Q]=Z7K>H6\\$3VRQI);#Y0'A;:!,K%OWOS$Y10" .I)%/
M\2>+8]0OGT.ST^/4;9MRS"8E4NV0@O!"XX,BCD@\'&/6MW0_#-C9QAUB+V9D
M6YL[.ZA4FP8C)"9Y7GMV[4 0Z#X'L='N%OI&\V\:%4E11MM]X;=O2(Y"$$G&
M/4^M=9110 4444 %%%% !1110 4444 %%%% !1110 445R_B+Q=;^']0LK*0
M*)+@--(\I*I'"A&\CC+N<@*@R23Z4 3^)/$5GH@MK6XNC:3Z@7AM[AES'')C
M@N>PR0,GC)KC]!BU[5+NWT'7;:_%K SO>(QDVEE(VYG8D31R9)V#&.AX%;-J
MFMZIXH=-9T9'T>[L7B+%P\2_-D?*P#H64X92.JCGBNLTZPATO3K>QMS(88$"
M(9'+MM'0$GDT ,TW3+72+&.RLHS';0KM12Q;:,DXR23@9X':K]%<]XH\2P^&
M[#>(9;N]D5C!:PKN=@HRS$#G:HY)_J10!G>+/%QTJW9]/FC?[+=+%J#JGF-:
MAERNY<C 8[1N/ !)YQ6=;Z5;_$*XN]0O\VJV[BUC%G)B5)(V#EO.4XD4Y4@8
MP.>].T'2X]<NSJ_V=;*^\T/+>V9\RVU2!QT^;.5P/NGE"..M=S:VMO96R6]K
M;Q6\*#Y8HD"*OT X% "P6\-M$(X(DB09(5  !DY/ ]ZGHKBW\:O=:U>Z5ID5
MN]U!(;:&*X9U>690&?(524C"D?.1@DC% %/Q?X@FU'[=HNA/.VK:=*DL]HKM
M"]U%LW$1N""<;E) (/&.]/T/23XJ\W4?$,-U*T,R+9M(CVH 0AA(L1.Z-\DJ
M3GD#C@U/X?T:YU.Q(\1:;-;WMEJ#3VLS3*92."IWIUX.P^H49%=M0 T *,
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L@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>form10-q_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 form10-q_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #J =D# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]:]8\L[^BBB@ HHHH **** "BBB@ HHHH **** $KQ#XV_\ (QZ1_P!>S?\
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M56D7!^4-G'\C5J@ HHHH **** "BBB@ KC]3\$VFJWFO75W;V4\NH0+%;/-
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 03PK/;R0/G9(A1L=<$8K"N?"EK<00V_VJ]2U2W2UDACFPLT2]
M%<8^H)&"0<5TE% &-J?AW3M5=7NHVRMN]NFUL; Q4Y7T8%%(/;%4HO!UE'.7
MDO-0G@:X-RUK+,/*:4G.X@ $\\X)QGM7344 <]I'A6QT2[6XMIKERD+01I(Z
?[40L&(  &3D=3D^]=#110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>form10-q_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 form10-q_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #/ D # 2(  A$! Q$!_\0
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M\>_]=X?_ $$T#/2J*** "BDHH 6BC-% !1110 4444 %%%&: "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I*6O'OB1XLU;2/$U]
M86M]+ \VGI#I]LB']_-(^UG!]5%(#V#FN6/@729=;DU&X>ZN%9GD6UEE+0QN
MZ[690>A(K%^&$M[ ==TB?4;G4K?3KI8HKNX.69MH+KGN W%>A@4P.=\.>$=-
M\,M.;5YYI)56/?</N*QK]U!_LC-<QX) 7XL>.@H &ZWZ#_9->E8%>;>"O^2L
M>._]Z#_T$T >DT4E% "T4E+0 44AI P(Z@_2@!U%-Z$<TZ@ HI#3=PSC/(H
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M>@[G/%5=+\23-=W=OK'E64V[-M&_&Y"2%.[)SG%;G]FVGV:"W\E?*@8/&O\
M=(Z&H;70M.LY)WAMEW3'+E_F_ 9Z#K0!SDOB75XK342R6OG6$@,F%8[T(_A'
M<9XW5H7_ (BG@D\JUBB+&.$!W;Y0\IPO_ 1@U9_X131C 8_LORE]^2YS],_W
M?:IKC0[2ZN9'D0&&6 020XX(4Y4^Q':@##?7M7?[*EM<6+2?;OL=P6C<<]B
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MW,-K?7UV)V#$W<Q<KCT]*Z:F 5YMX*_Y*SX[_P!^#_T$UZ37FW@K_DK/CO\
MWX/_ $$T >DT444 %-:-'4JRAE(P01D&G44 5Q8VJ^5MMH1Y6?+P@^3Z>E)]
M@L]AC^RP["V\KY8P6]?K5FB@"M:V4%GYGDH099#(Y)R68]ZLT44 %%%% !11
M10 AH!H(II.!F@!V::Q&,DX%0_:8F8*)48GIAA7$^.M>NKBXA\(Z&W_$UOA^
M^D49%O">K'T/I5*+D[%P@Y.QG732?$GQ6UC$3_PC.DRYN'!XNIA_"/4"MS6D
M6/XA^%410J+%. !V&T5N^'M#M/#NB6VF6:!8HEP3W=N['U)-8FN_\E&\,?\
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MY5LQP8D&-Q/4$_I6+\+-(L]!\<^-=+T]&2UMY85C5F+$#:>YKU<#%>;>!/\
MDJ'CW_KO#_Z":!GI5%%% !36'%.IK4 >$_$/3=&O/B!%-/K!CWR*ETGD%A J
MKD'/?/3\:]HTR.TCT^ V,4:0,@*&-=H(QUKRGQW\0-5\->+SIJ/HY@E ;?)
M6:%3_?\ 7-:T'Q2N;NWBAT?PU?ZE/M"^:D1BA9L<XST%>M4P.)E2A-+W6N__
M  QI/$^T2CV/3.37F?Q9@-O!!J<]E9W-F@$;">Y>-BQ;C '!]:DW_%'7/E6/
M3M"A(^\3YD@_I7%?$7PE<VNGQ-K7B;4=3U5VW0Q"W)B"YPQP.AQ58'"PCB(J
MI->BU_X!BZDHZQ.]\,Z[I'A?P\6U;4=,MC*^]5@NC-D?4\Y]J2X^,&@ES'I=
MIJ&IRCC;;P'!_$]J@\!^"/!,NCPW=KIXO9HP$DN+N)@2PZD*W KT*WL[:T0)
M;6\,*C@"- N*QKRPL*DERN3OZ+]6'O-7/+==\5>/-<T*]72_"SZ= 8B6GN)!
MYFWOA?6LGP%X8\7>(_"\!O/$MYINE@E8;>)0'=/7=U ]*]:U_P /VGB.Q6SO
M9;E(0VXB"4QEO8D=1[55\-^#M,\+&7^SGNBLBA=DT[.J@>@/2MHYA3CAW3IQ
M497OM?\ %W)Y+N[9D:9\*/"MBPEN+.34;GJ9KV0R$GUQTKJ39II]@Z:5:6\<
MBJ?*C"A%)[ XJ_B@BO,J8BK4UG)LM)(\]\,Z7XRTWQ'?WFH0:6+;4IQ+<>5(
MQ:/"X&T=Z] 44;0:4  \4JU5U9<S27H"5A<4$9I:*S&)BEHHH **** "BBB@
M HHHH **** "BBB@ I*6D[T 5KL[;2<J=I$;$$=N#7@F@?$*6TT;P;%+XE"R
M-J<RZD))0S>5DXWYY KW^8$Q2 *&)4X4]&XZ5XG)HFO;WS\)= P2<L9EY'KU
MH ]>TO7M)UU97TK4+>\6(X<P.&VD^N*U*X7X<VMS!97IN/#6FZ&'D7:MA('6
M7CJ2/2NY% D+7FW@K_DK/CO_ 'X/_037I->;>"O^2L^._P#?@_\ 030,])HH
MHH **** "BBB@ HHHH 0]*3-!Z&J]U=V]C;27-U,D,$8RTCG  H06OH97BU+
M)O#UP^H:A<6%LF&>>WDV,/09KR+0[G4=?MO[%T6_O[J\O RZA=SRDQVT(8XV
M_P"TPKJ=>U74OB)87.D^'[01:0W^NU&Z&U9,<XC'?D=:D^#>ARZ7HE[=22QN
MMU-\H7DKL)4Y_*NJ*4:;;W.Z,53HN4M^QW6A:)8^'])@TVPA6.&(=ARQ[D^I
M-:8%(,;L4^N7?4XFVW=B8HS0:0U-Q 3CM4374"-M:>(-Z%P#3R<<G&![UX)\
M0=0\*6?Q!@$=A)?R$%KQ(;A@LLK<(N0>,'T]:[L%A)8J;@K[-Z>1+:B>XZEJ
MEEI5C)>W]S';VT8RTCM@5P)U3Q#\0W>#1/-T?P\25DU!UQ-<#OY8/0>]2Z5X
M'OM>GM]4\:2B;R@/LNE1G]Q;@=-W]YOK7H21K&BH@"*H "J, "CFI8?2/O2[
M]%Z=WY[!JSS7Q;X:TKPSX-L;33+81@ZE;;Y#R\IWCEF[FO2Q]XURGB[P==^*
M9(0NNW%E:Q%7^SQQJ074Y#9/-;FBV%YIVG);WVI2ZC."2;B5 I(/08''%16D
MITHMRO+7OU&E9FD*6D%+7*AA1113 **** (IBX@D,8S(%.WZXXKR;X676AR^
M$-5_MG4D&IWMQ*-52ZN-K Y(Q@G@8/:O6G<1QN[' 4$FO*_&&E> -6T&X\7P
MZ7:ZI(K+N:"0H&8G&9<= .^12 L_!N4G3M<M;2>:?1K;46CTZ60DYC[@$]1F
MO3JX/X<>((]0M[K28K'3;:/3PFQM+D\RW(;L#_>'>N][4V 5YKX$_P"2H>/?
M^N\/_H)KT@-FO-_ G_)4/'O_ %WA_P#030!Z51110 4A&:6B@#S#Q9\-=6\2
M>*(]7%]IJ"!@85>V)) [/_>KT6Q@E@LX8YFC,JH YB7:I;N0.U6<45T5<34J
MPC";TCL)12&[#FD,2MC<JGZBI**YAC%C"#Y0!]!2XIU%,!,48I:* $I:** $
MQ1BEHI6 ****8!1110 4444 %%%% !1110 4444 %%%% !2&EI* &2!BC!6P
MQ'!QT->6>*-7US_A'[_1?$44:QOQ_:FGDO%@'.)D'S("."17J<J%XG0.5+*0
M&'5?<5YAX6^'FK:-XEM[NY%C'#;F3SKN!W::_#9XE!X[YI :'PST-[&.]U-)
M=+CM+P(([72I6D@&W^/+$D,:]"%9&F^&=)T>^NKS3;1+62[QYRQ<(Q]=O0'Z
M5K9P/:F ZO-O!7_)6?'?^_!_Z":]'#>HQ7G'@K_DK'CO_>@_]!- 'I-%%% !
M29H/2FG[M "[O:C?7D/Q,\;^(_#_ (BAM-(F"6[0!V'D;^<^M;%KXG\>WUI"
M]IX6@'R L]S/MW\=0!6WL96YKHZ/J\^52TU/12],DN8X@#*Z(#W9@*X,W'Q.
MN?WB6>D68Z>4S%S^=<KXW\-?$'6;&T-V\%[B4L+:S7;Y7'4GN*(TDY6E)((4
M$Y6E)(]&\0^-=*T*)$\S[7?3<06EO\\DA^@Z#WK"M/"^J^+;I-0\8MLM5.ZW
MTB)L1IZ&0_Q'VZ4_X:^$H]#T..YOM-,6LR$^=)+\S@=@#V'TKNF94&Z1E0=,
ML<4I-1?+$4I*F[0^\H:CH&G:KI0TRYA/V08Q'$QCQCITJGH/@[1O#4\DVEV[
MPM(NQ@9692.O0G&:GU3Q1HNC6DUQ>ZG;(D(^91("V?3'7-<M:_&;PA<VAG:Z
MFB??M$#1$R'W ':M(8;$3BY0@VO0P=2VC9Z#FFO*D<;22,J(HR68X 'K7G3?
M%F.[.-&\-:O?G^\(2B^W6H+KQ+\0;VTG>/PK9V5IL(=KR7)48Y)7N,=JTC@*
MWV[+U:7ZD\R.\B\1Z+<.J0ZM9.[?=59U)/ZUS'B'XH:+I-S]@L5EU;43P+>S
M&_!]R.E>$^%_#5CKGC8VFIW:VULTA(>V0@2,3PJ<<#^5?27A[PCHGAB Q:58
M)"3RTI^9V/NQYKNQF#PN"DE.3FVKVV7WD1E*2.'_ +%\>>.5']M7JZ!I,G)M
M+8_OF7T8]JQKCP4VC>*[";2O!$]S::>[;Y7N03=-@;7YZ8/->V;?FS2E:YHY
ME4@VHI*-FK+1:^FK^97(B.V9Y(8WDC,;,H+1DY*GTJ;%(HP:=7F%B8HQ2T46
M 04M%%, HHHH **** (I9/*@>3!8(I;:!DG Z5X=IUY;>*_$T!LK:TT:\OQ(
M4FTRXWN-HZ7,!&T@]#GO7NN#5*WT?3K2ZDNK;3[6&YE_UDL<2JS?4@4NH&)X
M1M-8TV.YT_4]-TVW2-@T=SIZ"-+C/<I_":U]=U+^R- U#4@F\VMN\P7U*J3B
MK^S\JAO;.'4+&XL[E-\$\;12+ZJ1@TV!PWACQ??1G4E\17,4J6MA#J7GQ1;=
MJ2+DK@=<>M<3X3^)GA;3?'7BW4[F^D2UU"6)K=O)8[@%P> .*]!\':3H&FWF
MHVEEK U2^14@G$KJS1Q(,+'@<8%&CZ'X5T_QGK*PW5K/J5\5DDLG53Y04?PC
M'YT,"I_PNOP-_P!!23_P'?\ PH_X77X%QQJKD^@MWS_*NLMH-"O'G2VM["9H
M'\N4)$IV-Z'CK4%IX1T&RU.]U"#3+<7%Z5,Q9 0<#C / _"@#FO^%V>!<X_M
M63/I]G?_  H_X77X%Y_XFLGO_H[\?I732>$="EUN'6&TV#[;#$T*,$ 7:>N5
MZ$^],3P7H$=[J%VNF0B;4$"7!VC! &.!VZ]J .;_ .%V>!/^@L__ 'X?_"E_
MX79X$QG^UV_[\-_A6O%\.?"UN+<1Z5&!;VSVT>23^[?[P/J>>O6L.?P%\.9]
M:M]*\BW75+>WQ# )CO51T.,\D9SS0!+_ ,+K\"_]!60_2W?_  H_X77X%_Z"
MLG_@._\ A6OHOA[P_P"$M)T[1)#;RL6:.!KF-3)*QRQ XYK;DT;2Y8VB;3K4
MJP*M^Y4<'CTH XW_ (77X%[:K(?<6[G^E'_"[/ O_04DXZ_Z._'Z5U&D^%-$
MT73H[&RTVW6"/.T.@8\G/4\U'8^#M!TY[Y[?2[<&^D,LVY V6(QQGI]!0!S?
M_"[/ O\ T%7QZ^0^/Y4'XV>!!UU9_P#OP_\ A6P?AUX7.AQ:-_9,7V**7SD7
M)W;LY^]UZT7?P[\+7EW/=3Z3$TT\T<SL./F3[N!V_K0!C_\ "[/ G_07;_OR
MW^%'_"Z_ O\ T%)/_ =_\*K^(?A3X':S6YFC&F^5<>=]H63 W,P)!SP<GC%=
MU'I.F[5 L+0@* #Y*]/RH XW_A=G@7_H*R#ZV[_X4O\ PNOP+_T%9!];=_\
M"NFU;PEH6MV)LK[3+=H"ROA$"G(.1R*MOHFF/;M =.M?+*;"/*7IC'I0!QO_
M  NOP+C/]JR8_P"N#_X4?\+L\"X_Y"LGT^SO_A6\O@/PVGAPZ"-+B^P%2NT_
M>Y.?O=>M./@?PZ;ZUO/[+A\ZUMC:Q$#@1D8P1W/OUH Y[_A=O@3_ *"S_P#?
MAO\ "E_X79X%S_R%G/T@8_TK0'PO\'I D']CQ[%@:W W'.QCD_CGO6+!X)\!
M:/KLGBBWN(+>*QW6]RC.&BWX YS_ !#C@4 6O^%U^!?^@I)_X#O_ (4?\+L\
M"YQ_:L@^MN_^%==:6FC7]K'=6MI8S02KN21(E(8>HXJO>^$="U"_L;VXTRW,
M]DQ>$J@ !(P<@<'\: .9_P"%U^!1UU60?6W<?TH_X77X%_Z"L@^MN_/Z5TVK
M>$="URQ-G?:9;M"75\(@0Y!R.1S27O@_0;^\L;NXTR S6+[X"JA0#C'('7\:
M .:_X77X%QG^UG_[\/\ X4?\+L\"?]!9A[>0_P#A6Q-\._"]Q%?12:5$4OKA
M;B< D9=>A'H/851U+P!X&?54>]T^V2\OI"8T+8,C!<':/I0!J>&?'6@>+Y+B
M/1;QKAK< R QE< ].M=)7!>$M#\)^'/$&M3:+J<6]84CN+42 K;*@ZD_SKK]
M-U:PUBS%WIMW'<VY)421MD9'44 7J*!10 4444 %-Q3J* $JAK-^VEZ'?Z@$
M\PVMN\P3^\54G'Z5H57N[6*]M)[2X3?#/&T<B^JD8(H X3PKXOU#??+XAN89
M8HM.BU,311;=B."2F!UQCK7%^&/B9X5T_P"('BO5;B_=;2_,)MW\ECN !SQC
MBO0/".DZ!I=_J-I9ZQ_:E^B+;RK,X9HHE^['@=A18:'X5TCQKJ.;FT?4M45)
M/L,BJ=@4?PC'&: *G_"Z_ O_ $%9/_ =_P#"C_A=?@7G_B:R9';[._\ A761
MPZ%-=3VT-M823V^/.C6)24STR,<5#:^$="L]5O-2ATV 7-YM\XL@(.!Q@'@4
M <S_ ,+L\"]/[4D)]/L[_P"%)_PNKP+_ -!5^G_/N_'Z5T\OA+0YM:M]7?3;
M?[9;Q-%&P0!=IZY7H:C3P9X?CU"_OETR#S[Z,13G;P5 QP.@_"D!XSXY^,#S
MZW:OX6OHFL4C!D:2W^^V>AW#./I4B_&O6-H'V_1!P/\ EFXKU9?AUX62WL+<
M:5'Y5B)! "<_?&&SZ_C6)=^ OAS<7PT&2VM4OS:B)(%E(D" Y!'/7]:])8V"
MI1@J4;KJ^I+3>[.$/Q?UB[X/B#2+(*?O+:R2;ZQ/%/Q$UJ_T<PIXM@N,N,QV
M5M)"[#_>]*]PT7PWX?\ !OA^STN9K9XA)Y44MTB[I'8DA>G)K>.DZ<>/[/M/
M^_*_X40S!PFI*G'3R$XW/GK1_%4$^CVT6K?$K4+9T0;8;>V9RGLS8^8U>6\^
M&<Q_T_QCKM[W*N\@&[UP!Q7M.D^$M#T2U>VL=,MUB>5I6#H'.YNO)YI;3PCH
M=CJE[J,&FP"YO-OG$H"#MZ8'05$\?6E)N+M?LDOT!01Y!#J'P2C@*LSRNRE#
M-*DC,<]\^OO6AX9\5_";PM;-'9W9D=FW-+<6S/)],D<"O0#\.?"ITJ733I,1
MM9+C[2RY.3)G.<]<>W2G7?P\\+WCZ@\^E1$ZAY?VC'&?+^[C'W>G:LI8NO*+
M@YNS\Q\J,-?C1X"0 )JQ51V6W8#^5*?C1X%((.JR$>AMW_PINM?"GP2-(NG>
MW73D".S70?\ U88@L>>.U=AI^CZ5'IMK'%:6LL2Q(J2&%3O  P>G>N8HXM?B
M]\.XR&6]16'(;[&P(_2IE^-/@7@_VK)_X#O_ (5UFI^%]%U?39["[TZW-O,N
MUPD84X]B.14J>'])CLUM%TZU\E4\L Q+G&,=<>E#;>X'(#XU>!?^@J^/7R'Q
M_*D_X77X%QG^UG_[\/S^E;T?@+PW%X=;04TN'^SV!!4_>Y.3\W7K3Y? _AV:
M73I7TN MIR%+?C@ C:<^O'K0!SW_  NSP(/^8L__ 'X?_"E_X79X$_Z"SGV$
M#?X5II\-O"4%O:0C2(O+M1(L623@2?>SZ_CTK!B^'?@33-1CO+.6*U&BS>?=
MQF3>H)7@2;LXX[4 6_\ A=?@7'_(4D_\!W_PH_X79X%_Z"LG_@._^%=7IT>@
MZM8QWEA!87-M(,I)'$I!_2HK[PCH6HWME=W&F0&:R<R0E5"@$^H'7\: .9/Q
ML\"C_F*R8]?L[_X4?\+K\#9YU60?6W<?TKIM7\(Z%K>GO8WVF6[0,P8A$"'(
M.1R*;J?@[0-8CM8[S3(&6UE66(*NW##IG'6@#F_^%V>!>^K/_P!^'_PH_P"%
MV^!/^@L__?AO\*V[GP#X9NI-3DFTN(MJ:!+DCC('3']W\*S[SP'X&BN(X;O3
M[:.6]EC\J,N09'C7  _#K0!I>&?'GA[Q=//#HMZ;AX%#2 QE< _6ND!KS_P?
MX=\(>%O$FN2Z'J48D:,"ZM#*"( O).?\XKLM+U?3]9M/M6FW<5U!N*[XVR 1
MVH OT444 %-D#&-@IPQ! IU% 'BG@MGTO6+*XN+.XB_L>RNUU)Q <EFERHZ?
M.2.1C-/TBSGN/&-I:"UN4NUU>YO)9S&01:R184[_ 'R!CM7LI4G'-&* .#^&
MFE)H\OB6R@AFCMTU-O+,N27&T<Y/7GO7?8I,'/M3J "BBD/2@ ->-M9W*^-_
ML;6D_P!O7Q!_:)F\HX^R"(@MO].V,U[&2"*3!I=0/--<MK35O&7@SQ+917DC
M37;1$R*P6*,(W\)^[D]Z],'6F]QZ4X4P'44F:,T +2$9HR/6C(H \_\ BSHJ
M:EX46Z,<\L]G/&\,41."Q< DJ.N!7>6XQ"F<YV#.?I3B<\ ]Z <4 /HI-U)N
MH =12;J,T 0W5N+JVD@9W19%*%D.& /H>U>+VFDC1M%N42SN?[-T[Q3YLJF-
MI&,( &\CJ_)KVT\_A3<'.1GWQ0!R7PSM)[7P<GGPO )KF>:&-Q@K&TA*\=N.
M<5V IHX)I<XH8#NU%)VI:0"$9KS[Q/HL:_$[POJT:7$EQ*\L3MDLD2",XP.B
MY)ZUZ%36&:8'SX-)U&[T5].M+"Y&H6%G=IJ!\HJ7+3;@-W\9(Y'6O2/AZHGO
MO$&I6T#Q:;=3Q?9@T9C#;8PK$*<8YX_"NZ ;/]:7'M0 HI:0=*6@ HHHH **
M** "FN"5('4@XIU(: /%_"6_3-<LIKFSN8FT:WO3J;^0>=\F4 ./G)ZC&:=>
MP7%SXS:"&TG-Y=ZW:ZC;3>2<"V$?S-OQQCH1FO9,&C:<=: . \$:1'HWC?Q?
M!;QSB%Y()!),2Q=BI+'<>O)KT*F 'T%/H *3%+24 (1BO'+JSNSXY>S^RS?;
MSX@2_6;RC@6JQ8+!^F.V,]Z]C)XS3 21Z4EHP/-?&T%IX@'ACQ#9Q7LKIJD4
M<:,K*$7>=S%.W3J:]-[TF"#ZCWHR,_2F X4M)G%&: %I",BC</6C=0!QGQ/T
M6+5_ FH"59I#;1F:.*)C\[CID#K]*Z/0PPT'3MP*D6L8*D8P=HJ\W2@=1F@!
M]%)FC=0 M%)FC=0 V5=\97)&X8R.HKQ.X\/R:;!XSL]/M+J2UAU2SN&#[G:5
M!AI#D\MWKVTG(IO.<CGZ4 <=\.D9[76[Y(7BL;W5)9[-70IF,X^8*>@)!KM:
M:.O(I<T +12 YI: $89KS[Q5HT:_$CPGJZ1SRSO</$[9)2) AZ#H,GO7H5-(
M[T ?/O\ 96I7FF3Z;::?<#4[*VOEO?W14R;Y=RKN_B)'(KT?X?XNM2U_4[2!
MX=-N7@$ :+RMS)&%<A>W/'X5W6#^M* : 8ZBBB@ HHHH **** "BBB@ J*YE
M6"VEF<$K&A<@>@&:EJ.>)9X)(G&4=2K#V(Q28'CVD#Q[X\TRX\3:=XD_LR,R
MN+"P5 4=5./G/O757OC>]T5=,TBXTF34_$]Q;^;-9V+#:BCJQ8\ 5S-IX?\
MB+X2L+KPUH$5A=:;-(YM;Z28(]LKGG*GJ16C-X7\5>&M>T_Q#IGE:[=C3Q8W
MT=Q,(FD(.0ZL>.O:F!>NOBOIMOX537%L+IV6\6RN;,X$L$A[$=_ZU+9?$VR,
M^K0:SIEWI$NG6PO&2XP3)"> 1COG'%<M>?#SQ%-X<DEEBMY-6U#7(M1N88Y0
M$A1>P)ZD"M+Q9X"U3Q+XQUJ11'%97FC+:Q3EQD3!MP!7KBA :^F?$@7'FRZK
MX>U+2;-;1KR.ZG4%&C'J1T)[ T:)\2X-6U&"SN](NM/:\@>XL&F=2+E5&2.#
M\IQS@UFG3?&_B?0KGPWK&F6.FV!L#;O<)<"5I)0!M90.B\<YJAX,\#W>G:A$
M;SP=864UI;L@U!+\RL\FT@%4SP#GO0!=L_C%!<VUE?2^']0ATRXN?LKWI(V1
MR9P![CWJOIGQ"UM/%/C+^TM*G.G:5&'1 RCR0JDX/J7Z^U5#X$\0?\*CT_0?
MLL9U"'4EN'C\Y<!/,+9STZ'I5O4O"GB0:UXWBM["&:SUZT'DS_:%4HZIM"E3
MZYZT :UI\2;Z^T6#4K;P?JLBWCJMHB[3Y@QDLQZ*H]3UK$\3_%*]N?A]-JF@
MV$]O>Q7HL[I9"";9L_D<] 1ZU9U?PQXJ3PQX2M;.%;F"PC"ZCIJW?DB8X&,N
M.H!SQ6-!\//$H\ >(])>SMHKRXU)+RWB28&-U!!V@]O3F@#I=+\8K'XEU:75
MVOK);/28;JXMIG5HH<]=H'\1JSI7Q.BO+^QAO]"O],M=2R+"[N -DQZ@''W2
M1TS6(W@G7/$6J>(9M2M(]/CU71X;9=LZR>7*G;CMD4^/P[XP\1MH6F:]86=E
M8:+*LLEQ%.':Z9!A-JC[H]<T 31_&2!K07[^'=133DNS:7-WD;(GW8'UKK_&
M/B >'?!VH:U'AGB@)A]W;A?U(KS\^!O$+?"._P!#^RQ?VE-J9N!'YRX*&0-G
M=G'05TWQ/TZ6Z^%>H1)@2V\$<I&>NP@D?I0]@*4/CB\\.C1/#]UI]]K6LW>G
MBZ,D1&68\D'T ]:YKQS\0-5UOP=I%]X8FNM,O9=1>TG@R-ZNHY4UU.G:1?ZE
MX^\.>*88E_LP:+Y;.7 (=AD#;UKG+7P!XB1;(26D(\OQ-)?OB9?]0>A^OMUH
M8(S?'GQ"UR7P=X=FT6^EM;J6U-U>O&>=H(0@_P# LUW>AZ[J%O\ $$Z->W+S
M6NHZ9%?6@?K&X #J/KUKAY?A9KL>F>,H(X4D:ZD6/3%:9<"/S-[=_EZ]#756
MUK+/\8M)A( .DZ$!-S_$QQ@>O2@#TP=*44 <4HH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ IDTJPP22O]U%+'Z 9I],EC66)XW&5<%2/8T >
M/:2?'?CZQNO$FF^)/[+@$SK86*1@HX0X^<GUQ767_C.]\.Z9H]EJFGM?>)KY
M<"QLB#N(^\V3T7WKE[7P_P#$/PA:7GAWP]#876F7$KM:WDLP1[8.<G*]\>U:
M6H^$O$VE7GASQ!I\T>L:KIELUM=QW$@C-PK=2K'@$'UH L7'Q:L+7P_<:A/I
M5Y'>6=VEI=V#8$L3-T/N#VJQ9?$VS:[U2VUC3+O2'L+7[;BXP3)#ZC'?VKE-
M4\!>)M7LM1U:YM;=-5U34K:9K2.8;8((C_>Z,U;/BSP)JGB3QAJ4@$<5C=:+
M]D2<N"1,&W#*]<4 :^B?$%]3N@E]X>U+2[62V:ZANYU!C,2\Y8C[IQV-5]*^
M*5IJ.H6D4VE7-I8Z@SKI]Y*ZE;@J,XP#E<]LU'I=MXUU6R_L#6-+L;'3%L6M
M9KA+@2/*^W:K*!T'L:YOPE\.[O2[ZSM+[PAIY:R#9U87Q+2'!VLL>>#ZYH V
M+;XQ036]M?2^'M0ATN2Z^R37I(*129P/J*KW'Q!UNQ^(^N6L^ES/I.G6'G")
M&484<^:3[] *JMX%\0M\((M!^RQ?VB-3^T-'YRXV>:6SNZ9Q5SQ%X6\1MXKU
MJ[T^PAN;35M&%EYC3JAB=1Z'KS0P->Q^(UUJ'AQM:B\)ZHT,K(EG&F&>X+=3
MQ]U1ZFL#Q+\4]2?P9J<VE:5<6>K6-TEK=QR%6^S[NC9'!STJ_JOAKQ2GPX\.
M:=IJ_O['R_M]FESY7GH!R@D'2N?7X>>))- \7VW]FVMK+J,T%S:P1W 9,(<E
M,GG/N: .GTCQD5\27SZP]]9+;:-%=W-M,ZF*+U(Q_$:LZ;\3X;R]L([_ $2_
MTRRU)MMC>7 &R8]@?[N>V:Q!X*USQ#JNM2ZI:1Z?#J6B168VSK)LE4^W;BG1
M^'?&/B%=!T;7+&SLK#1IDEENHIPYN3&,(%4<K[YH LK\8H/LKWS>'-073[>[
M-K=7>1LB;=@'WKL/%FOKH'@[4-:C^8PVY>(>K$?+^I%>>'P-X@/PGUG0_LL8
MU"ZU)YXX_.7!0R YSG'2NH^(^FS77PHU"V4 2P6J2$9_N8)'Z4 9UOXYO/#D
M.@:%>6%]K6L7UA]J+Q$99SR5/H!GK[5SOC;X@:IK?@W3KOPW+=:5J#ZDUG<0
M$C>KJ/NFNETS2K_5?&WA7Q/!"ATU-&\MW+ %78# V]:P(_ /B)6B!M(L+XG.
MH']\I_<'O]?;K0",SQO\0M=E\">'9]&OI;:_DMFN;V2,C("'80?^!9KN=#U[
M4+;Q]!I-]=--:ZII45Y;!O\ EG(H <#V/6N+F^%FN1VGC:**".479V:6K3#A
M#)O;J?EZ]ZZ6WLY9OBWX>MFX?2="'G\_Q-Q@>M 'IZ]Z=313J "BBB@ HHHH
# __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>form10-q_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 form10-q_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #2 C4# 2(  A$! Q$!_\0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%)THH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBF,RHI9B H&22< "@!U&:X^;6;[5R3I\IL]./W;@*#+./5
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MT-=*ND:(5EBM]I,DLJKM0LV<8 YZ9)H ZZBBB@!:*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH 0FN?\6R$Z3%9@D+?7"6[D?W#EF'XJI7\:
MWG944LQ"J!DDG %>?>(_&.GZNITKP[!<:YJ<,J.#8KNBA93GYY3\HR,CJ>IJ
MHM*2N9U$W!J.Y'XAOM2LQ81:3#')<7$QC",H(VA"W=E Z>O3M47A_5;[4K[4
M4NS J02M&B1[<@J<'G<6/XJ*U[:XAO85GC7E205=<-$XX*D=F'2GQVUO%,\L
M<$22R??=4 9OJ>]>E9WNF?,N247%K4EJ%6-MKNEW2<,TIMG_ -I'4G'X,%/Y
MU-["H]-C.IZ]"T?S6NG,7DD'1IBI4(#WP"2?0D4JS2@[EX2,G6CRG94445YA
M].%%%% !1110 4444 %%%% #6947<S!5'<G J+[5;[MOGQ;M^S&\9W>GU]JC
MU"QAU&R>UN-WE.5)VG!X((_4"L7_ (0W3OM?VGS+G?Y@?&\8P&W;>G3/?KVS
MB@#3UQ&;1+QHYIHG2)G5X7VL" 2.:I:=I(N-,M)I-1U(O)"CL?M3<DJ":@\4
M^'M&OM/OK^]LXI+A;9@LCL1T4X[ULZ1_R!;#_KWC_P#010!!_8:?]!'4O_ I
MJ/[#3_H(ZE_X%-6I10!E_P!AI_T$=2_\"FH_L-/^@CJ7_@4U:E% &7_8:?\
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M(M:O=:U9O"'AJ8PW 4'4M00<6,1_A7_IJPZ#MUKJ-&T>R\/Z3!IVG1"*VA&
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M?_H(JOX@G$'A^^8I*^8'7$2%CRIYP.U6-(_Y MA_U[Q_^@B@"[1110 4444
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MLU2TIMVEVI]8E_E5VO$DK29]O1=Z<7Y+\A:***DU"BBB@ HHHH PF_Y'M/\
ML&'_ -&BMVL)O^1[3_L&'_T:*W: "BBB@ HHHH **** "BBB@ HHHH ****
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MJ,U;L?1Y34E.B^;H_P!!]%%%<A[ 4444 %%%% &$W_(]I_V##_Z-%;M83?\
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M: /5**** "BBB@#*\0B<^'[_ .SO&C>0^3(A88VG/0CFK&D?\@6P_P"O>/\
M]!%5_$$+S:!?A)Y(2('.Z,*21M/'(/%6-'_Y EA_U[Q_^@B@"[1110 4444
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M7) Z UQXF+TD>CEM6*G.GUW_  -&BBBN,]L**** "BBB@#";_D>T_P"P8?\
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MZ'MGTXKJZ* .;\3:#;7MA?7<EQ?)(ML^%ANY(TX4_P (.*U](YT6P_Z]X_\
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M-#6ULYTOHY3=R11QQ1.K2 R=,KGC&>?2KO\ 8MC_ ,3/,;EM3&+IBYRPV[<
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MTP<_-M.!CKDXXQW]*[O[/#R/)CY?>?D'WO7Z^]5K_2;'4;&>RN;:-X)U=9%
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M1%O#F--P& VT9 ]*QT.QJ7<YNRU.SU/QN6LYA,D6GE695. 3(.,UU5-"A>@
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F1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>form10-q_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 form10-q_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ", D # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W\UAIXEM&
M\4/H*QR^<L>[SL?NR^ 3&#_>"D-CTK;/3BN*7P$JI%=KJ,W]KI>_;C<EF\LR
M%OF'EYQ@I\OTH [:H'NK>-]KSQ*PZAG -);+.(<7+1M+DY,:E5QGC@D]L5Y7
M\6;#1[?4M.O9;>V^VW*R12-/ KHR8 W$EE^9>,<GJ>* /6E8, 5((/0BG5D^
M'!"/#.EB%Y'A%I%L:1=K%=HP2.QK6H **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \]\3ZSKL'
MB+4+?3I+XQ6M@DZ);01.H<EN9-Y!Q\HZ>]=GI%Y_:&CV5YYD;F>!)"T>=I)
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M%]%$)[C8R,Q'FGJ,4 :E%5/L"?\ /:X_[_-1]@3_ )[7'_?YJ +=%5/L"?\
M/:X_[_-2?8%_Y[7'_?XT 7**J?8$_P">UQ_W^:C[ G_/:X_[_-0!;HK,M+7S
M5E+SW!*RNH_>GH#Q5C[ G_/:X_[_ #4 6Z*J?8$_Y[7'_?YJ/L"?\]KC_O\
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M7HX4R[?[3M]VR(,/OC[Q_A'O744 %%%% !1110 4444 %%%% !1110 4444
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M>W% '>>']I\.Z;LN?M2_98\3X(\P;1\W///O6I6;HBSQ:'8I<P)!,MO&)(D
M"HVT9  X %:5 '+>,M^S1]HEV_VG;[MCA5^^/O \D?2NIKDO&OE_\23?Y&_^
MU(-GF*2^=X^X1T/U[5UM !3'19%*L 5/!![T^B@#GM2TD"5KFVD6SE8QKYT,
M>7*JV=ISP14,>HR6]VL.HQBVEEFE\IH6+(P SECT!]C73&L^XLQM90JM"P8R
M(V6+9&#4V[%J71B07I$*L_[R/8K>8IR6S]*O*ZL,J0?QZ5S)L+ZQB8Z:Z+$(
MXE2RF7:D>&Y((Y'TJ6#4[22Y$3E[2X-Q(B)*-A<@9RO9A1<;A?5'24C*&&"
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MJQJNLRKIEY+I:K)+# 94ED1C"P'4!AU/M0!I?9[K_G]/_?L4OV>Z_P"?P_\
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MI/8J+2=V<QYAM[W9#<"5!@EJ[S0KAY+;#$D=LUS]GX;D#AG  Z5U=E:+!&$
M/%$4TK,JI)2DVE8O@Y'/6MOPN<WMQ_US'\ZPB=G%;?A0YOKC_KF/YTS,ZNBB
MB@ KCO&NB:EJWV0V?V*:%%DC>WO'V+O<860$*?F7G ]Z[&O+_BW#$W]D3S7$
ML:)(RXB59GYQRL)(+GW'0&@#T/3+>>UTNTM[J?SYXH4224#&]@,$_C5VL[18
MD@T2QBB:9XTMT56G!$A 48W ]#[5HT <MXR+^5HX4RA3J=ON"1AE/SC[Q_A'
MN*ZFN2\:;,:)N$>?[4@V[IMA^^/NK_']/QKK: "BBB@ HHHH **** "DQ2T4
M 5Y;6*;.Y<,1@LO!/XU7-O+&^X,)%WER#P>1C ]:T**!W.7N](LY(W=XWM+@
MVXC,T1V,!NSC(XIXAU6WN 8;J&[B-UG;,NUE79T!'4^YKHRH88(!'H:KO90L
M0P7:P.[*''/K4\I2F]F<V=4FMK827^G7$#+;%VE@_>*IWX !'.?PK1M]9AEG
M:*"]@D*RK&4<X925SCZU>:P.PB.9A\FSYAGC.?K56YTM)YEDGL[:8B82@X (
M.W&>>]&H[Q>Y934" #)"P&TL60[@ #BK"7<+G < C@@\8/I7-'P^D,16V%]:
M$6[QJ8)20"6SP,D9J5H-0CG.W44D0W"$+=6_(4+@@$8YSWHNPY8O9G3YS2UQ
MZW6JP0 BUMY6$$CG[-=;26#<##>W>K0UJ[2;RWL;T#S8HP0BN#N7)((/0>M'
M,+D?0Z:BLW2+B:YLO,G@F@?S'&R9@S8!(!XK1JB&K.PM%%% !1110 4444 %
M%%% !1110!F6UTL3W*F*9OW[<K&2.W>K'VU?^>%S_P!^6HL>MS_UW:K= %3[
M:O\ SPN?^_+4?;5_YX7/_?EJJWNN65A?065P9?.F_P!6%B9@V.3R!C@<TDOB
M'2H2=][#@*6W!LJ0!DX(ZGVH M_;5_YX7/\ WY:C[:O_ #PN?^_+54M=>LKN
M\-K!Y[R*0K'R6"J=H;!., X(K6H R=3NU?2[E1#."8SR8B!7&-'(5 VG\Z[S
M5ANTFZ![QFN+DPJ_+QQ0!2:VD/)7&?>HO);) P3]:E$N78A23C[P/]*:06PV
M[IW- $9MY!U7'XTPVK@C(_*IR2B?,W3OBD6<!/F(49H @FWPJ&$3R9.-J8S]
M>33K*22620?9Y(]H'W\<_D:F?YB>:ELU^>3Z"@!#'(3POZTIAD"Y9>/K5G&T
M]*4R*%YH I?96(.U0?QIODNO\/ZU:$T:?=/6HV?<<@T 0,".U4KBY:)RHMY7
MXSN7&/IR:O.1561210!=T]GELHW,3)N'W6QD<U8$<K' 7CZT6 _T"+\?YU.#
MM- %=X6Z, /QIC6S#'RY![YJS+*A^]BF>>AX!H @\MEXQQ3'.!S4Y;/>J\IS
MTH&5(KQWNHD%I.-SXR=N/KUK:,<G3;^M9ENN;V _[8K=8 $T 51;S-R4_6HO
MLQ<XP,U>\T**KM/$'SG!H$5S:NIYC QTYHV,.U6#.LF,&F,W% %.XE,*9$4D
MG/1,9_4UL>#+AI[^[#02Q;8Q@OCGGV-9,@R>#6WX/&+^Z_ZYC^= '84444 %
M<#XK\,ZSJ&J/?6U_:6UN@!C>6[FB9#C!Y4X ^E=]7G7B;0]9\1>([C3!;S1:
M1(BR--)+NB=U (PO53GCCZT =UI\<D6GV\<LF^18U#.&+!CCKD\GZFF:M?\
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MVW=YOV&7;C\J=)XOTZ%HEDM]24RMLC!L9?F.,X''H#70[1C&!CTHP#U'2@#
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M&]>-.+7([Z%]SNJ)LD&I2,5%(<#WJS U['_D'19'8_SIEQ+L4GIBG6+;M-A
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MHH :RJV-P!P<\BG444 %%%% !1110 5A^(_$EMX8L!?7EK>36^<.]M%O\OD
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M@2)8? NBJN>;17Y]3R?U)KI* $(!ZBD"JOW5 [\"G44 %%%% !1110 4444
M%%%% !1110 4444 %%)0>* *MCUN?^N[5;JF;*'YY0959SN8+*P&?H#2_8(O
M[\__ '^;_&@"W153[!%_?G_[_-_C1]@B_OS_ /?YO\: +=%5/L$7]^?_ +_-
M_C1]@B_OS_\ ?YO\: $U7_D%7/\ US-<9-&)$P/2NR;3;>6/:[3,K#D&9L']
M:B_L:P_Y]_\ QX_XT <2(RF,T[CITQ7:_P!BZ?M_X]Q_WT?\::="TX];8?\
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22Z;:F%Y@%<F5WR!T^\30!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>12
<FILENAME>gtbp-20250930.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaKAKbP9z5Z8+ekhvWB1bbn67y4rNzGsFSW4fP4GsQUG -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:GTBP="http://gtbiopharma.com/20250930" elementFormDefault="qualified" targetNamespace="http://gtbiopharma.com/20250930">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://gtbiopharma.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/BalanceSheets" id="BalanceSheets">
          <link:definition>00000002 - Statement - Condensed Balance Sheets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - Condensed Balance Sheets (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/StatementsOfOperations" id="StatementsOfOperations">
          <link:definition>00000004 - Statement - Condensed Statements of Operations (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/StatementsOfOperationsParenthetical" id="StatementsOfOperationsParenthetical">
          <link:definition>00000005 - Statement - Condensed Statements of Operations (Unaudited) (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity" id="StatementsOfStockholdersEquityDeficitAndMezzanineEquity">
          <link:definition>00000006 - Statement - Condensed Statements of Stockholders' Equity (Deficit) and Mezzanine Equity  (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
          <link:definition>00000007 - Statement - Condensed Statements of Cash Flows</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/OrganizationAndGoingConcernAnalysis" id="OrganizationAndGoingConcernAnalysis">
          <link:definition>999013 - Disclosure - Organization and Going Concern Analysis</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
          <link:definition>999014 - Disclosure - Summary of Significant Accounting Policies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/AccountsPayableAndRelatedParty" id="AccountsPayableAndRelatedParty">
          <link:definition>999015 - Disclosure - Accounts Payable and Related Party</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/WarrantLiability" id="WarrantLiability">
          <link:definition>999016 - Disclosure - Warrant Liability</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/StockholdersEquityDeficit" id="StockholdersEquityDeficit">
          <link:definition>999017 - Disclosure - Stockholders&#8217; Equity (Deficit)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/CommonStockWarrantsAndOptions" id="CommonStockWarrantsAndOptions">
          <link:definition>999018 - Disclosure - Common Stock Warrants and Options</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
          <link:definition>999019 - Disclosure - Commitments and Contingencies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/SegmentInformation" id="SegmentInformation">
          <link:definition>999020 - Disclosure - Segment Information</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/SubsequentEvents" id="SubsequentEvents">
          <link:definition>999021 - Disclosure - Subsequent Events</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
          <link:definition>999022 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
          <link:definition>999023 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyTables" id="AccountsPayableAndRelatedPartyTables">
          <link:definition>999024 - Disclosure - Accounts Payable and Related Party (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/WarrantLiabilityTables" id="WarrantLiabilityTables">
          <link:definition>999025 - Disclosure - Warrant Liability (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/StockholdersEquityDeficitTables" id="StockholdersEquityDeficitTables">
          <link:definition>999026 - Disclosure - Stockholders&#8217; Equity (Deficit) (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsTables" id="CommonStockWarrantsAndOptionsTables">
          <link:definition>999027 - Disclosure - Common Stock Warrants and Options (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/SegmentInformationTables" id="SegmentInformationTables">
          <link:definition>999028 - Disclosure - Segment Information (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/OrganizationAndGoingConcernAnalysisDetailsNarrative" id="OrganizationAndGoingConcernAnalysisDetailsNarrative">
          <link:definition>999029 - Disclosure - Organization and Going Concern Analysis (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails" id="ScheduleOfAnti-dilutiveSecuritiesDetails">
          <link:definition>999030 - Disclosure - Schedule of Anti-dilutive Securities (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetailsParenthetical" id="ScheduleOfAnti-dilutiveSecuritiesDetailsParenthetical">
          <link:definition>999031 - Disclosure - Schedule of Anti-dilutive Securities (Details) (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
          <link:definition>999032 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails" id="ScheduleOfAccountsPayableDetails">
          <link:definition>999033 - Disclosure - Schedule of Accounts Payable (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/ScheduleOfAccountsPayableToRelatedPartyDetails" id="ScheduleOfAccountsPayableToRelatedPartyDetails">
          <link:definition>999034 - Disclosure - Schedule of Accounts Payable to Related Party (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyDetailsNarrative" id="AccountsPayableAndRelatedPartyDetailsNarrative">
          <link:definition>999035 - Disclosure - Accounts Payable and Related Party (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative" id="WarrantLiabilityDetailsNarrative">
          <link:definition>999036 - Disclosure - Warrant Liability (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails" id="ScheduleOfWarrantLiabilityAssumptionsDetails">
          <link:definition>999037 - Disclosure - Schedule of Warrant Liability Assumptions (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityTransactionsDetails" id="ScheduleOfWarrantLiabilityTransactionsDetails">
          <link:definition>999038 - Disclosure - Schedule of Warrant Liability Transactions (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/ScheduleOfFairValuesAndAllocationOfNetProceedsDetails" id="ScheduleOfFairValuesAndAllocationOfNetProceedsDetails">
          <link:definition>999039 - Disclosure - Schedule of fair values and allocation of net proceeds (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative" id="StockholdersEquityDeficitDetailsNarrative">
          <link:definition>999040 - Disclosure - Stockholders&#8217; Equity (Deficit) (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails" id="ScheduleOfWarrantActivityDetails">
          <link:definition>999041 - Disclosure - Schedule of Warrant Activity (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative" id="CommonStockWarrantsAndOptionsDetailsNarrative">
          <link:definition>999042 - Disclosure - Common Stock Warrants and Options (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" id="ScheduleOfWarrantsOutstandingAndExercisableDetails">
          <link:definition>999043 - Disclosure - Schedule of Warrants Outstanding and Exercisable (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails" id="ScheduleOfOptionsActivityDetails">
          <link:definition>999044 - Disclosure - Schedule of Options Activity (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails" id="ScheduleOfOptionsOutstandingAndOptionsExercisableDetails">
          <link:definition>999045 - Disclosure - Schedule of Options Outstanding and Options Exercisable (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
          <link:definition>999046 - Disclosure - Commitments and Contingencies (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/ScheduleOfSegmentInformationDetails" id="ScheduleOfSegmentInformationDetails">
          <link:definition>999047 - Disclosure - Schedule of Segment Information (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/SegmentInformationDetailsNarrative" id="SegmentInformationDetailsNarrative">
          <link:definition>999048 - Disclosure - Segment Information (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
          <link:definition>999049 - Disclosure - Subsequent Events (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="gtbp-20250930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="gtbp-20250930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="gtbp-20250930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="gtbp-20250930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
    <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
    <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
    <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
    <import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
    <element id="GTBP_SeriesLPreferredStockMember" name="SeriesLPreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_OfficersEmployeesAndDirectorsMember" name="OfficersEmployeesAndDirectorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_MezzanineEquityMember" name="MezzanineEquityMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_SeriesLConvertiblePreferredStockMember" name="SeriesLConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_CytovanceBiologicsIncMember" name="CytovanceBiologicsIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_UniversityOfMinnesotaMember" name="UniversityOfMinnesotaMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_LegalServicesFirmMember" name="LegalServicesFirmMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_OtherAccountsPayableMember" name="OtherAccountsPayableMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_AdvisoryAgreementMember" name="AdvisoryAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_TwoThousandTwentyThreeCommonWarrantsMember" name="TwoThousandTwentyThreeCommonWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_TwoThousandTwentyThreePlacementAgentsWarrantsMember" name="TwoThousandTwentyThreePlacementAgentsWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_TwoThousandTwentyThreeWarrantsMember" name="TwoThousandTwentyThreeWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_PurchaseAgreementMember" name="PurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_InducementWarrantsMember" name="InducementWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_SeriesAInducementWarrantsMember" name="SeriesAInducementWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_SeriesBInducementWarrantsMember" name="SeriesBInducementWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_SecuritiesPurchaseAgreementMember" name="SecuritiesPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_SeriesLTenPercentConvertiblePreferredStockMember" name="SeriesLTenPercentConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_GreenshoeRightsMember" name="GreenshoeRightsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_CommonWarrantsMember" name="CommonWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_VestingWarrantsMember" name="VestingWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_SeriesL10PercentageConvertiblePreferredStockMember" name="SeriesL10PercentageConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_WarrantsMember" name="WarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_PrefundedWarrantsMember" name="PrefundedWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_OmnibusIncentivePlanMember" name="OmnibusIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_RangeOneMember" name="RangeOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_RangeTwoMember" name="RangeTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_RangeThreeMember" name="RangeThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_RangeFourMember" name="RangeFourMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_RangeFiveMember" name="RangeFiveMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_RangeSixMember" name="RangeSixMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_RangeSevenMember" name="RangeSevenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_RangeEightMember" name="RangeEightMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_RangeNineMember" name="RangeNineMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_RangeTenMember" name="RangeTenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_RangeElevenMember" name="RangeElevenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_RangeTwelveMember" name="RangeTwelveMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_RangeThirteenMember" name="RangeThirteenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ZOneLLCMember" name="ZOneLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_CobySilberfeinMember" name="CobySilberfeinMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_TwoThousandTwentyThreeSponsoredResearchAgreementMember" name="TwoThousandTwentyThreeSponsoredResearchAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_TwoThousandSixteenPatentLicenseAgreementMember" name="TwoThousandSixteenPatentLicenseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_TwoThousandSeventeenThroughTwoThousandTwentyMember" name="TwoThousandSeventeenThroughTwoThousandTwentyMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_TwoThousandTwentyTwoMember" name="TwoThousandTwentyTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_TwoThousandTwentyFiveMember" name="TwoThousandTwentyFiveMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_TwoThousandTwentySevenMember" name="TwoThousandTwentySevenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember" name="TwoThousandAndTwentyOnePatentLicenseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember" name="TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_SegmentsMember" name="SegmentsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_WarrantLiabilityCurrent" name="WarrantLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_StockIssuedDuringPeriodValueMezzanineEquityReclassification" name="StockIssuedDuringPeriodValueMezzanineEquityReclassification" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_StockIssuedDuringPeriodSharesMezzanineEquityReclassification" name="StockIssuedDuringPeriodSharesMezzanineEquityReclassification" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet" name="StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_StockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet" name="StockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable" name="StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_StockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee" name="StockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_StockIssuedDuringPeriodSharesIssuanceAndExerciseOfPrefundedWarrantsForElocFee" name="StockIssuedDuringPeriodSharesIssuanceAndExerciseOfPrefundedWarrantsForElocFee" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash" name="StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable" name="StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_StockIssuedDuringPeriodShareIssuanceOfCommonStockAndWarrantsForCash" name="StockIssuedDuringPeriodShareIssuanceOfCommonStockAndWarrantsForCash" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable" name="StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_IssuanceOfWarrantsForVrtWaiver" name="IssuanceOfWarrantsForVrtWaiver" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_GainOnSettlementOfDebt" name="GainOnSettlementOfDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_IncreaseDecreaseInOperatingLeaseRightofuseAssets" name="IncreaseDecreaseInOperatingLeaseRightofuseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_CashPaidDuringYearFor" name="CashPaidDuringYearFor" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_FairValueOfSeriesLConvertiblePreferredStockVestedWarrants" name="FairValueOfSeriesLConvertiblePreferredStockVestedWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_FairValueOfPrefundedWarrantsIssuedForElocFee" name="FairValueOfPrefundedWarrantsIssuedForElocFee" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_FairValueOfPrefundedWarrantAndCommonStockToSettleVendorPayable" name="FairValueOfPrefundedWarrantAndCommonStockToSettleVendorPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_DividendDeclaredOnSeriesLConvertiblePreferredStock" name="DividendDeclaredOnSeriesLConvertiblePreferredStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_DisclosureWarrantLiabilityAbstract" name="DisclosureWarrantLiabilityAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_WarrantLiabilityTextBlock" name="WarrantLiabilityTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract" name="DisclosureCommonStockWarrantsAndOptionsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_CommonStockWarrantsAndOptionsTextBlock" name="CommonStockWarrantsAndOptionsTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_WarrantLiabilityPolicyTextBlock" name="WarrantLiabilityPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_MezzanineEquityPolicyTextBlock" name="MezzanineEquityPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock" name="ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ScheduleOfWarrantsOustandingAndExercisableTableTextBlock" name="ScheduleOfWarrantsOustandingAndExercisableTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_RepaymentsOfPrefundedWarrantsAtFairValue" name="RepaymentsOfPrefundedWarrantsAtFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_AccountsPayableAndRelatedPartyAbstract" name="AccountsPayableAndRelatedPartyAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_AccountsPayableAndRelatedPartyTable" name="AccountsPayableAndRelatedPartyTable" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" />
    <element id="GTBP_AccountsPayableAndRelatedPartyLineItems" name="AccountsPayableAndRelatedPartyLineItems" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ExtinguishmentOfWarrant" name="ExtinguishmentOfWarrant" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ConvertiblePreferredStockAndWarrantsFairValuePercentage" name="ConvertiblePreferredStockAndWarrantsFairValuePercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ConvertiblePreferredStockAndWarrantsNetProceedsPercentage" name="ConvertiblePreferredStockAndWarrantsNetProceedsPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_WeightedAverageVolumePriceOfCommonStockPercentage" name="WeightedAverageVolumePriceOfCommonStockPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_AggregateStatedValue" name="AggregateStatedValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ClassOfWarrantsPurchaseUpPercentage" name="ClassOfWarrantsPurchaseUpPercentage" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_LiableOfLiquidatedDamagePercentageDescription" name="LiableOfLiquidatedDamagePercentageDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_CommonStockSharesOutstandingPercentage" name="CommonStockSharesOutstandingPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_PreferredStockPurchasePrice" name="PreferredStockPurchasePrice" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedPursuantToFullRatchetPriceProtection" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedPursuantToFullRatchetPriceProtection" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedPursuantToFullRatchetPriceProtectionWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedPursuantToFullRatchetPriceProtectionWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ProceedsFromUpfrontAmount" name="ProceedsFromUpfrontAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_RoyaltyFeePercentage" name="RoyaltyFeePercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_PerformanceMilestonePayments" name="PerformanceMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_SalesMilestonePayments" name="SalesMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_GrossSales" name="GrossSales" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_SalesRevenue" name="SalesRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_CummulativeGrossSales" name="CummulativeGrossSales" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_RoyaltyExpenseYearOne" name="RoyaltyExpenseYearOne" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_RoyaltyExpenseYearTwoThroughFive" name="RoyaltyExpenseYearTwoThroughFive" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_RoyaltyExpenseYearAfterSix" name="RoyaltyExpenseYearAfterSix" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_UpfrontLicenseFee" name="UpfrontLicenseFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_RoyaltyExpenseYearOneThoughFour" name="RoyaltyExpenseYearOneThoughFour" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_RoyaltyExpenseYearAfterFive" name="RoyaltyExpenseYearAfterFive" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="GTBP_ContigencyMinimumRequired" name="ContigencyMinimumRequired" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>13
<FILENAME>gtbp-20250930_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#Cover" roleURI="http://gtbiopharma.com/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#BalanceSheets" roleURI="http://gtbiopharma.com/role/BalanceSheets" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#BalanceSheetsParenthetical" roleURI="http://gtbiopharma.com/role/BalanceSheetsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#StatementsOfOperations" roleURI="http://gtbiopharma.com/role/StatementsOfOperations" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#StatementsOfOperationsParenthetical" roleURI="http://gtbiopharma.com/role/StatementsOfOperationsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#StatementsOfStockholdersEquityDeficitAndMezzanineEquity" roleURI="http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#StatementsOfCashFlows" roleURI="http://gtbiopharma.com/role/StatementsOfCashFlows" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#OrganizationAndGoingConcernAnalysis" roleURI="http://gtbiopharma.com/role/OrganizationAndGoingConcernAnalysis" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#AccountsPayableAndRelatedParty" roleURI="http://gtbiopharma.com/role/AccountsPayableAndRelatedParty" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#WarrantLiability" roleURI="http://gtbiopharma.com/role/WarrantLiability" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#StockholdersEquityDeficit" roleURI="http://gtbiopharma.com/role/StockholdersEquityDeficit" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#CommonStockWarrantsAndOptions" roleURI="http://gtbiopharma.com/role/CommonStockWarrantsAndOptions" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#CommitmentsAndContingencies" roleURI="http://gtbiopharma.com/role/CommitmentsAndContingencies" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#SegmentInformation" roleURI="http://gtbiopharma.com/role/SegmentInformation" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#SubsequentEvents" roleURI="http://gtbiopharma.com/role/SubsequentEvents" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#AccountsPayableAndRelatedPartyTables" roleURI="http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyTables" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#WarrantLiabilityTables" roleURI="http://gtbiopharma.com/role/WarrantLiabilityTables" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#StockholdersEquityDeficitTables" roleURI="http://gtbiopharma.com/role/StockholdersEquityDeficitTables" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#CommonStockWarrantsAndOptionsTables" roleURI="http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsTables" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#SegmentInformationTables" roleURI="http://gtbiopharma.com/role/SegmentInformationTables" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#OrganizationAndGoingConcernAnalysisDetailsNarrative" roleURI="http://gtbiopharma.com/role/OrganizationAndGoingConcernAnalysisDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#ScheduleOfAnti-dilutiveSecuritiesDetails" roleURI="http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#ScheduleOfAnti-dilutiveSecuritiesDetailsParenthetical" roleURI="http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetailsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#ScheduleOfAccountsPayableDetails" roleURI="http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#ScheduleOfAccountsPayableToRelatedPartyDetails" roleURI="http://gtbiopharma.com/role/ScheduleOfAccountsPayableToRelatedPartyDetails" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#AccountsPayableAndRelatedPartyDetailsNarrative" roleURI="http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#WarrantLiabilityDetailsNarrative" roleURI="http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#ScheduleOfWarrantLiabilityAssumptionsDetails" roleURI="http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#ScheduleOfWarrantLiabilityTransactionsDetails" roleURI="http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityTransactionsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#ScheduleOfFairValuesAndAllocationOfNetProceedsDetails" roleURI="http://gtbiopharma.com/role/ScheduleOfFairValuesAndAllocationOfNetProceedsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#StockholdersEquityDeficitDetailsNarrative" roleURI="http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#ScheduleOfWarrantActivityDetails" roleURI="http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#CommonStockWarrantsAndOptionsDetailsNarrative" roleURI="http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#ScheduleOfWarrantsOutstandingAndExercisableDetails" roleURI="http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#ScheduleOfOptionsActivityDetails" roleURI="http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#ScheduleOfOptionsOutstandingAndOptionsExercisableDetails" roleURI="http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#CommitmentsAndContingenciesDetailsNarrative" roleURI="http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#ScheduleOfSegmentInformationDetails" roleURI="http://gtbiopharma.com/role/ScheduleOfSegmentInformationDetails" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#SegmentInformationDetailsNarrative" roleURI="http://gtbiopharma.com/role/SegmentInformationDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#SubsequentEventsDetailsNarrative" roleURI="http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaapRestrictedCashCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapRestrictedCashCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaapDeferredOfferingCosts" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapDeferredOfferingCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsPayableCurrent" xlink:label="loc_us-gaapDividendsPayableCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDividendsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_WarrantLiabilityCurrent" xlink:label="loc_GTBPWarrantLiabilityCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_GTBPWarrantLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Statements of Operations (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaapInterestIncomeOther" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestIncomeOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaapPreferredStockDividendsIncomeStatementImpact" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapPreferredStockDividendsIncomeStatementImpact" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfOperationsParenthetical" xlink:title="00000005 - Statement - Condensed Statements of Operations (Unaudited) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity" xlink:title="00000006 - Statement - Condensed Statements of Stockholders&apos; Equity (Deficit) and Mezzanine Equity  (Unaudited)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Condensed Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_IssuanceOfWarrantsForVrtWaiver" xlink:label="loc_GTBPIssuanceOfWarrantsForVrtWaiver" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_GTBPIssuanceOfWarrantsForVrtWaiver" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_GainOnSettlementOfDebt" xlink:label="loc_GTBPGainOnSettlementOfDebt" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_GTBPGainOnSettlementOfDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesUnrealizedGainLoss" xlink:label="loc_us-gaapDebtSecuritiesUnrealizedGainLoss" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDebtSecuritiesUnrealizedGainLoss" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_IncreaseDecreaseInOperatingLeaseRightofuseAssets" xlink:label="loc_GTBPIncreaseDecreaseInOperatingLeaseRightofuseAssets" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_GTBPIncreaseDecreaseInOperatingLeaseRightofuseAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForProceedsFromInvestments" xlink:label="loc_us-gaapPaymentsForProceedsFromInvestments" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsForProceedsFromInvestments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfConvertiblePreferredStock" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDividends" xlink:label="loc_us-gaapPaymentsOfDividends" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsOfDividends" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/OrganizationAndGoingConcernAnalysis" xlink:title="999013 - Disclosure - Organization and Going Concern Analysis" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999014 - Disclosure - Summary of Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/AccountsPayableAndRelatedParty" xlink:title="999015 - Disclosure - Accounts Payable and Related Party" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/WarrantLiability" xlink:title="999016 - Disclosure - Warrant Liability" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StockholdersEquityDeficit" xlink:title="999017 - Disclosure - Stockholders&#8217; Equity (Deficit)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/CommonStockWarrantsAndOptions" xlink:title="999018 - Disclosure - Common Stock Warrants and Options" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/CommitmentsAndContingencies" xlink:title="999019 - Disclosure - Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SegmentInformation" xlink:title="999020 - Disclosure - Segment Information" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SubsequentEvents" xlink:title="999021 - Disclosure - Subsequent Events" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999022 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="999023 - Disclosure - Summary of Significant Accounting Policies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyTables" xlink:title="999024 - Disclosure - Accounts Payable and Related Party (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/WarrantLiabilityTables" xlink:title="999025 - Disclosure - Warrant Liability (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StockholdersEquityDeficitTables" xlink:title="999026 - Disclosure - Stockholders&#8217; Equity (Deficit) (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsTables" xlink:title="999027 - Disclosure - Common Stock Warrants and Options (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SegmentInformationTables" xlink:title="999028 - Disclosure - Segment Information (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/OrganizationAndGoingConcernAnalysisDetailsNarrative" xlink:title="999029 - Disclosure - Organization and Going Concern Analysis (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails" xlink:title="999030 - Disclosure - Schedule of Anti-dilutive Securities (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetailsParenthetical" xlink:title="999031 - Disclosure - Schedule of Anti-dilutive Securities (Details) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999032 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails" xlink:title="999033 - Disclosure - Schedule of Accounts Payable (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfAccountsPayableToRelatedPartyDetails" xlink:title="999034 - Disclosure - Schedule of Accounts Payable to Related Party (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyDetailsNarrative" xlink:title="999035 - Disclosure - Accounts Payable and Related Party (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative" xlink:title="999036 - Disclosure - Warrant Liability (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails" xlink:title="999037 - Disclosure - Schedule of Warrant Liability Assumptions (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityTransactionsDetails" xlink:title="999038 - Disclosure - Schedule of Warrant Liability Transactions (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfFairValuesAndAllocationOfNetProceedsDetails" xlink:title="999039 - Disclosure - Schedule of fair values and allocation of net proceeds (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative" xlink:title="999040 - Disclosure - Stockholders&#8217; Equity (Deficit) (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails" xlink:title="999041 - Disclosure - Schedule of Warrant Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative" xlink:title="999042 - Disclosure - Common Stock Warrants and Options (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:title="999043 - Disclosure - Schedule of Warrants Outstanding and Exercisable (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails" xlink:title="999044 - Disclosure - Schedule of Options Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails" xlink:title="999045 - Disclosure - Schedule of Options Outstanding and Options Exercisable (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999046 - Disclosure - Commitments and Contingencies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfSegmentInformationDetails" xlink:title="999047 - Disclosure - Schedule of Segment Information (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SegmentInformationDetailsNarrative" xlink:title="999048 - Disclosure - Segment Information (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative" xlink:title="999049 - Disclosure - Subsequent Events (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>14
<FILENAME>gtbp-20250930_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#Cover" roleURI="http://gtbiopharma.com/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#BalanceSheets" roleURI="http://gtbiopharma.com/role/BalanceSheets" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#BalanceSheetsParenthetical" roleURI="http://gtbiopharma.com/role/BalanceSheetsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#StatementsOfOperations" roleURI="http://gtbiopharma.com/role/StatementsOfOperations" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#StatementsOfOperationsParenthetical" roleURI="http://gtbiopharma.com/role/StatementsOfOperationsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#StatementsOfStockholdersEquityDeficitAndMezzanineEquity" roleURI="http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#StatementsOfCashFlows" roleURI="http://gtbiopharma.com/role/StatementsOfCashFlows" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#OrganizationAndGoingConcernAnalysis" roleURI="http://gtbiopharma.com/role/OrganizationAndGoingConcernAnalysis" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#AccountsPayableAndRelatedParty" roleURI="http://gtbiopharma.com/role/AccountsPayableAndRelatedParty" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#WarrantLiability" roleURI="http://gtbiopharma.com/role/WarrantLiability" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#StockholdersEquityDeficit" roleURI="http://gtbiopharma.com/role/StockholdersEquityDeficit" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#CommonStockWarrantsAndOptions" roleURI="http://gtbiopharma.com/role/CommonStockWarrantsAndOptions" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#CommitmentsAndContingencies" roleURI="http://gtbiopharma.com/role/CommitmentsAndContingencies" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#SegmentInformation" roleURI="http://gtbiopharma.com/role/SegmentInformation" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#SubsequentEvents" roleURI="http://gtbiopharma.com/role/SubsequentEvents" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#AccountsPayableAndRelatedPartyTables" roleURI="http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyTables" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#WarrantLiabilityTables" roleURI="http://gtbiopharma.com/role/WarrantLiabilityTables" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#StockholdersEquityDeficitTables" roleURI="http://gtbiopharma.com/role/StockholdersEquityDeficitTables" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#CommonStockWarrantsAndOptionsTables" roleURI="http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsTables" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#SegmentInformationTables" roleURI="http://gtbiopharma.com/role/SegmentInformationTables" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#OrganizationAndGoingConcernAnalysisDetailsNarrative" roleURI="http://gtbiopharma.com/role/OrganizationAndGoingConcernAnalysisDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#ScheduleOfAnti-dilutiveSecuritiesDetails" roleURI="http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#ScheduleOfAnti-dilutiveSecuritiesDetailsParenthetical" roleURI="http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetailsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#ScheduleOfAccountsPayableDetails" roleURI="http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#ScheduleOfAccountsPayableToRelatedPartyDetails" roleURI="http://gtbiopharma.com/role/ScheduleOfAccountsPayableToRelatedPartyDetails" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#AccountsPayableAndRelatedPartyDetailsNarrative" roleURI="http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#WarrantLiabilityDetailsNarrative" roleURI="http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#ScheduleOfWarrantLiabilityAssumptionsDetails" roleURI="http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#ScheduleOfWarrantLiabilityTransactionsDetails" roleURI="http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityTransactionsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#ScheduleOfFairValuesAndAllocationOfNetProceedsDetails" roleURI="http://gtbiopharma.com/role/ScheduleOfFairValuesAndAllocationOfNetProceedsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#StockholdersEquityDeficitDetailsNarrative" roleURI="http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#ScheduleOfWarrantActivityDetails" roleURI="http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#CommonStockWarrantsAndOptionsDetailsNarrative" roleURI="http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#ScheduleOfWarrantsOutstandingAndExercisableDetails" roleURI="http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#ScheduleOfOptionsActivityDetails" roleURI="http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#ScheduleOfOptionsOutstandingAndOptionsExercisableDetails" roleURI="http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#CommitmentsAndContingenciesDetailsNarrative" roleURI="http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#ScheduleOfSegmentInformationDetails" roleURI="http://gtbiopharma.com/role/ScheduleOfSegmentInformationDetails" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#SegmentInformationDetailsNarrative" roleURI="http://gtbiopharma.com/role/SegmentInformationDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#SubsequentEventsDetailsNarrative" roleURI="http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpDisclosureWithAdditionalMeasures" roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosureWithAdditionalMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpTable" roleURI="http://xbrl.sec.gov/ecd/role/PvpTable" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpAdjustmentsToCompensation" roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsToCompensation" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#TabularListsByExecutiveCategory" roleURI="http://xbrl.sec.gov/ecd/role/TabularListsByExecutiveCategory" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#TabularListMeasures" roleURI="http://xbrl.sec.gov/ecd/role/TabularListMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpMeasures" roleURI="http://xbrl.sec.gov/ecd/role/PvpMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpExecutiveCategoriesOnly" roleURI="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpAdjustmentsOnly" roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#IndividualsOnly" roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardTypeOnly" roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#TradingArrangmentsOnly" roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ForgoneRecoveries" roleURI="http://xbrl.sec.gov/ecd/role/ForgoneRecoveries" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#OutstandingRecoveries" roleURI="http://xbrl.sec.gov/ecd/role/OutstandingRecoveries" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardsCloseToMnpiDisc" roleURI="http://xbrl.sec.gov/ecd/role/AwardsCloseToMnpiDisc" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangemenstByInd" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsByInd" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#Defaults" roleURI="http://xbrl.sec.gov/ecd/role/Defaults" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_SeriesLPreferredStockMember" xlink:label="loc_GTBPSeriesLPreferredStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_GTBPSeriesLPreferredStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsAbstract_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapAssetsCurrentAbstract_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaapRestrictedCashCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapRestrictedCashCurrent_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaapDeferredOfferingCosts_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapDeferredOfferingCosts_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapAssetsCurrent_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapAccountsPayableCurrent_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsPayableCurrent" xlink:label="loc_us-gaapDividendsPayableCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapDividendsPayableCurrent_70" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_WarrantLiabilityCurrent" xlink:label="loc_GTBPWarrantLiabilityCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_GTBPWarrantLiabilityCurrent_70" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapLiabilitiesCurrent_70" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapStockholdersEquityAbstract_70" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapPreferredStockValue_70" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapCommonStockValue_70" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapAdditionalPaidInCapital_70" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_70" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapStockholdersEquity_70" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity_70" xlink:type="arc" order="20" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_SeriesLPreferredStockMember" xlink:label="loc_GTBPSeriesLPreferredStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_GTBPSeriesLPreferredStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_70" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Statements of Operations (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfOperationsParenthetical" xlink:title="00000005 - Statement - Condensed Statements of Operations (Unaudited) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpensesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpensesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_OfficersEmployeesAndDirectorsMember" xlink:label="loc_GTBPOfficersEmployeesAndDirectorsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_GTBPOfficersEmployeesAndDirectorsMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_50" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity" xlink:title="00000006 - Statement - Condensed Statements of Stockholders&apos; Equity (Deficit) and Mezzanine Equity  (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_MezzanineEquityMember" xlink:label="loc_GTBPMezzanineEquityMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GTBPMezzanineEquityMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_SeriesLPreferredStockMember" xlink:label="loc_GTBPSeriesLPreferredStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_GTBPSeriesLPreferredStockMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaapTemporaryEquitySharesOutstanding_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquitySharesOutstanding_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaapTemporaryEquityCarryingAmountAttributableToParent_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquityCarryingAmountAttributableToParent_80" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_StockIssuedDuringPeriodValueMezzanineEquityReclassification" xlink:label="loc_GTBPStockIssuedDuringPeriodValueMezzanineEquityReclassification_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodValueMezzanineEquityReclassification_80" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_StockIssuedDuringPeriodSharesMezzanineEquityReclassification" xlink:label="loc_GTBPStockIssuedDuringPeriodSharesMezzanineEquityReclassification_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodSharesMezzanineEquityReclassification_80" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits_80" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits_80" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_80" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_80" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsPreferredStock" xlink:label="loc_us-gaapDividendsPreferredStock_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDividendsPreferredStock_80" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_80" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_80" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet" xlink:label="loc_GTBPStockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet_80" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_StockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet" xlink:label="loc_GTBPStockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet_80" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable" xlink:label="loc_GTBPStockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable_80" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_StockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee" xlink:label="loc_GTBPStockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee_80" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_StockIssuedDuringPeriodSharesIssuanceAndExerciseOfPrefundedWarrantsForElocFee" xlink:label="loc_GTBPStockIssuedDuringPeriodSharesIssuanceAndExerciseOfPrefundedWarrantsForElocFee_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodSharesIssuanceAndExerciseOfPrefundedWarrantsForElocFee_80" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_80" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_80" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_80" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash" xlink:label="loc_GTBPStockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash_80" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensationForfeited_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensationForfeited_80" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable" xlink:label="loc_GTBPStockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable_80" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_StockIssuedDuringPeriodShareIssuanceOfCommonStockAndWarrantsForCash" xlink:label="loc_GTBPStockIssuedDuringPeriodShareIssuanceOfCommonStockAndWarrantsForCash_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodShareIssuanceOfCommonStockAndWarrantsForCash_80" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensationForfeited_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensationForfeited_80" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable" xlink:label="loc_GTBPStockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable_80" xlink:type="arc" order="27" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Condensed Statements of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/OrganizationAndGoingConcernAnalysis" xlink:title="999013 - Disclosure - Organization and Going Concern Analysis" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999014 - Disclosure - Summary of Significant Accounting Policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/AccountsPayableAndRelatedParty" xlink:title="999015 - Disclosure - Accounts Payable and Related Party" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/WarrantLiability" xlink:title="999016 - Disclosure - Warrant Liability" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StockholdersEquityDeficit" xlink:title="999017 - Disclosure - Stockholders&#8217; Equity (Deficit)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/CommonStockWarrantsAndOptions" xlink:title="999018 - Disclosure - Common Stock Warrants and Options" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/CommitmentsAndContingencies" xlink:title="999019 - Disclosure - Commitments and Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SegmentInformation" xlink:title="999020 - Disclosure - Segment Information" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SubsequentEvents" xlink:title="999021 - Disclosure - Subsequent Events" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999022 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="999023 - Disclosure - Summary of Significant Accounting Policies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyTables" xlink:title="999024 - Disclosure - Accounts Payable and Related Party (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/WarrantLiabilityTables" xlink:title="999025 - Disclosure - Warrant Liability (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_TwoThousandTwentyThreeWarrantsMember" xlink:label="loc_GTBPTwoThousandTwentyThreeWarrantsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_GTBPTwoThousandTwentyThreeWarrantsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="loc_us-gaapScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_30" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StockholdersEquityDeficitTables" xlink:title="999026 - Disclosure - Stockholders&#8217; Equity (Deficit) (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsTables" xlink:title="999027 - Disclosure - Common Stock Warrants and Options (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_WarrantsMember" xlink:label="loc_GTBPWarrantsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_GTBPWarrantsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_ScheduleOfWarrantsOustandingAndExercisableTableTextBlock" xlink:label="loc_GTBPScheduleOfWarrantsOustandingAndExercisableTableTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_GTBPScheduleOfWarrantsOustandingAndExercisableTableTextBlock_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_30" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SegmentInformationTables" xlink:title="999028 - Disclosure - Segment Information (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/OrganizationAndGoingConcernAnalysisDetailsNarrative" xlink:title="999029 - Disclosure - Organization and Going Concern Analysis (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails" xlink:title="999030 - Disclosure - Schedule of Anti-dilutive Securities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_SeriesLConvertiblePreferredStockMember" xlink:label="loc_GTBPSeriesLConvertiblePreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_GTBPSeriesLConvertiblePreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_90" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetailsParenthetical" xlink:title="999031 - Disclosure - Schedule of Anti-dilutive Securities (Details) (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999032 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails" xlink:title="999033 - Disclosure - Schedule of Accounts Payable (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_CytovanceBiologicsIncMember" xlink:label="loc_GTBPCytovanceBiologicsIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_GTBPCytovanceBiologicsIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_UniversityOfMinnesotaMember" xlink:label="loc_GTBPUniversityOfMinnesotaMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_GTBPUniversityOfMinnesotaMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_LegalServicesFirmMember" xlink:label="loc_GTBPLegalServicesFirmMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_GTBPLegalServicesFirmMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_OtherAccountsPayableMember" xlink:label="loc_GTBPOtherAccountsPayableMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_GTBPOtherAccountsPayableMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaapAccountsPayableTradeCurrent_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapAccountsPayableTradeCurrent_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableInterestBearingInterestRate" xlink:label="loc_us-gaapAccountsPayableInterestBearingInterestRate_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapAccountsPayableInterestBearingInterestRate_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="loc_us-gaapAccountsPayableOtherCurrent_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapAccountsPayableOtherCurrent_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapAccountsPayableCurrent_110" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfAccountsPayableToRelatedPartyDetails" xlink:title="999034 - Disclosure - Schedule of Accounts Payable to Related Party (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_CytovanceBiologicsIncMember" xlink:label="loc_GTBPCytovanceBiologicsIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_GTBPCytovanceBiologicsIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaapAccountsPayableTradeCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapAccountsPayableTradeCurrent_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapRepaymentsOfRelatedPartyDebt_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapRepaymentsOfRelatedPartyDebt_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaapPaymentsForRepurchaseOfCommonStock_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapPaymentsForRepurchaseOfCommonStock_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_RepaymentsOfPrefundedWarrantsAtFairValue" xlink:label="loc_GTBPRepaymentsOfPrefundedWarrantsAtFairValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_GTBPRepaymentsOfPrefundedWarrantsAtFairValue_70" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyDetailsNarrative" xlink:title="999035 - Disclosure - Accounts Payable and Related Party (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_AccountsPayableAndRelatedPartyLineItems" xlink:label="loc_GTBPAccountsPayableAndRelatedPartyLineItems" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_AccountsPayableAndRelatedPartyTable" xlink:label="loc_GTBPAccountsPayableAndRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_GTBPAccountsPayableAndRelatedPartyLineItems" xlink:to="loc_GTBPAccountsPayableAndRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_GTBPAccountsPayableAndRelatedPartyTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_GTBPAccountsPayableAndRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_CytovanceBiologicsIncMember" xlink:label="loc_GTBPCytovanceBiologicsIncMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_GTBPCytovanceBiologicsIncMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_LegalServicesFirmMember" xlink:label="loc_GTBPLegalServicesFirmMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_GTBPLegalServicesFirmMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_GTBPAccountsPayableAndRelatedPartyTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_AdvisoryAgreementMember" xlink:label="loc_GTBPAdvisoryAgreementMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPAdvisoryAgreementMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable" xlink:label="loc_GTBPStockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_GTBPAccountsPayableAndRelatedPartyLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable" xlink:label="loc_GTBPStockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_GTBPAccountsPayableAndRelatedPartyLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_GTBPAccountsPayableAndRelatedPartyLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_GTBPAccountsPayableAndRelatedPartyLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_RepaymentsOfPrefundedWarrantsAtFairValue" xlink:label="loc_GTBPRepaymentsOfPrefundedWarrantsAtFairValue_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_GTBPAccountsPayableAndRelatedPartyLineItems" xlink:to="loc_GTBPRepaymentsOfPrefundedWarrantsAtFairValue_80" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForFees" xlink:label="loc_us-gaapPaymentsForFees_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_GTBPAccountsPayableAndRelatedPartyLineItems" xlink:to="loc_us-gaapPaymentsForFees_80" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfOtherDebt" xlink:label="loc_us-gaapRepaymentsOfOtherDebt_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_GTBPAccountsPayableAndRelatedPartyLineItems" xlink:to="loc_us-gaapRepaymentsOfOtherDebt_80" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_GTBPAccountsPayableAndRelatedPartyLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding_80" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_GTBPAccountsPayableAndRelatedPartyLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts_80" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:label="loc_us-gaapRelatedPartyTransactionDescriptionOfTransaction_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_GTBPAccountsPayableAndRelatedPartyLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionDescriptionOfTransaction_80" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative" xlink:title="999036 - Disclosure - Warrant Liability (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_TwoThousandTwentyThreeCommonWarrantsMember" xlink:label="loc_GTBPTwoThousandTwentyThreeCommonWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GTBPTwoThousandTwentyThreeCommonWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_TwoThousandTwentyThreePlacementAgentsWarrantsMember" xlink:label="loc_GTBPTwoThousandTwentyThreePlacementAgentsWarrantsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GTBPTwoThousandTwentyThreePlacementAgentsWarrantsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_TwoThousandTwentyThreeWarrantsMember" xlink:label="loc_GTBPTwoThousandTwentyThreeWarrantsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GTBPTwoThousandTwentyThreeWarrantsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding_50" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails" xlink:title="999037 - Disclosure - Schedule of Warrant Liability Assumptions (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaapBusinessAcquisitionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="loc_us-gaapMeasurementInputSharePriceMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputSharePriceMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaapMeasurementInputExpectedTermMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedTermMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_TwoThousandTwentyThreeWarrantsMember" xlink:label="loc_GTBPTwoThousandTwentyThreeWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_GTBPTwoThousandTwentyThreeWarrantsMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_60" xlink:type="arc" order="63" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_70" xlink:type="arc" order="73" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_150" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_150" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_150" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityTransactionsDetails" xlink:title="999038 - Disclosure - Schedule of Warrant Liability Transactions (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfFairValuesAndAllocationOfNetProceedsDetails" xlink:title="999039 - Disclosure - Schedule of fair values and allocation of net proceeds (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapScheduleOfStockByClassTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_SeriesLPreferredStockMember" xlink:label="loc_GTBPSeriesLPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_GTBPSeriesLPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_MezzanineEquityMember" xlink:label="loc_GTBPMezzanineEquityMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_GTBPMezzanineEquityMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="loc_us-gaapStockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_ConvertiblePreferredStockAndWarrantsFairValuePercentage" xlink:label="loc_GTBPConvertiblePreferredStockAndWarrantsFairValuePercentage_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_GTBPConvertiblePreferredStockAndWarrantsFairValuePercentage_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfConvertiblePreferredStock_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfConvertiblePreferredStock_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_ConvertiblePreferredStockAndWarrantsNetProceedsPercentage" xlink:label="loc_GTBPConvertiblePreferredStockAndWarrantsNetProceedsPercentage_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_GTBPConvertiblePreferredStockAndWarrantsNetProceedsPercentage_60" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative" xlink:title="999040 - Disclosure - Stockholders&#8217; Equity (Deficit) (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_PurchaseAgreementMember" xlink:label="loc_GTBPPurchaseAgreementMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPPurchaseAgreementMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_SecuritiesPurchaseAgreementMember" xlink:label="loc_GTBPSecuritiesPurchaseAgreementMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPSecuritiesPurchaseAgreementMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_InducementWarrantsMember" xlink:label="loc_GTBPInducementWarrantsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GTBPInducementWarrantsMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_SeriesAInducementWarrantsMember" xlink:label="loc_GTBPSeriesAInducementWarrantsMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GTBPSeriesAInducementWarrantsMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_SeriesBInducementWarrantsMember" xlink:label="loc_GTBPSeriesBInducementWarrantsMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GTBPSeriesBInducementWarrantsMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_GreenshoeRightsMember" xlink:label="loc_GTBPGreenshoeRightsMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GTBPGreenshoeRightsMember_140" xlink:type="arc" order="142" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_SeriesLTenPercentConvertiblePreferredStockMember" xlink:label="loc_GTBPSeriesLTenPercentConvertiblePreferredStockMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_GTBPSeriesLTenPercentConvertiblePreferredStockMember_110" xlink:type="arc" order="112" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_SeriesLPreferredStockMember" xlink:label="loc_GTBPSeriesLPreferredStockMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_GTBPSeriesLPreferredStockMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_SeriesL10PercentageConvertiblePreferredStockMember" xlink:label="loc_GTBPSeriesL10PercentageConvertiblePreferredStockMember_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_GTBPSeriesL10PercentageConvertiblePreferredStockMember_230" xlink:type="arc" order="231" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_SeriesLConvertiblePreferredStockMember" xlink:label="loc_GTBPSeriesLConvertiblePreferredStockMember_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_GTBPSeriesLConvertiblePreferredStockMember_260" xlink:type="arc" order="261" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_150" xlink:type="arc" order="152" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_160" xlink:type="arc" order="162" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_CommonWarrantsMember" xlink:label="loc_GTBPCommonWarrantsMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_GTBPCommonWarrantsMember_180" xlink:type="arc" order="183" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_VestingWarrantsMember" xlink:label="loc_GTBPVestingWarrantsMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_GTBPVestingWarrantsMember_200" xlink:type="arc" order="202" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_290" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_290" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_290" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_290" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_290" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_WeightedAverageVolumePriceOfCommonStockPercentage" xlink:label="loc_GTBPWeightedAverageVolumePriceOfCommonStockPercentage_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_GTBPWeightedAverageVolumePriceOfCommonStockPercentage_290" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_290" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement_290" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoninterestExpenseOfferingCost" xlink:label="loc_us-gaapNoninterestExpenseOfferingCost_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapNoninterestExpenseOfferingCost_290" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" xlink:label="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_290" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharePrice_290" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_290" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_290" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts_290" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_290" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_290" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_290" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_AggregateStatedValue" xlink:label="loc_GTBPAggregateStatedValue_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_GTBPAggregateStatedValue_290" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_ClassOfWarrantsPurchaseUpPercentage" xlink:label="loc_GTBPClassOfWarrantsPurchaseUpPercentage_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_GTBPClassOfWarrantsPurchaseUpPercentage_290" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_290" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfConvertiblePreferredStock_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfConvertiblePreferredStock_290" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="loc_us-gaapPreferredStockConvertibleConversionPrice_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockConvertibleConversionPrice_290" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaapPreferredStockDividendRatePercentage_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockDividendRatePercentage_290" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_290" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_290" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeFloorPrice" xlink:label="loc_us-gaapDerivativeFloorPrice_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapDerivativeFloorPrice_290" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_LiableOfLiquidatedDamagePercentageDescription" xlink:label="loc_GTBPLiableOfLiquidatedDamagePercentageDescription_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_GTBPLiableOfLiquidatedDamagePercentageDescription_290" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_CommonStockSharesOutstandingPercentage" xlink:label="loc_GTBPCommonStockSharesOutstandingPercentage_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_GTBPCommonStockSharesOutstandingPercentage_290" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_290" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_290" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_PreferredStockPurchasePrice" xlink:label="loc_GTBPPreferredStockPurchasePrice_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_GTBPPreferredStockPurchasePrice_290" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock" xlink:label="loc_us-gaapPaymentsForRepurchaseOfConvertiblePreferredStock_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPaymentsForRepurchaseOfConvertiblePreferredStock_290" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsPayableCurrent" xlink:label="loc_us-gaapDividendsPayableCurrent_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapDividendsPayableCurrent_290" xlink:type="arc" order="32" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails" xlink:title="999041 - Disclosure - Schedule of Warrant Activity (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative" xlink:title="999042 - Disclosure - Common Stock Warrants and Options (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_SeriesLPreferredStockMember" xlink:label="loc_GTBPSeriesLPreferredStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_GTBPSeriesLPreferredStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_CommonWarrantsMember" xlink:label="loc_GTBPCommonWarrantsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_GTBPCommonWarrantsMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_VestingWarrantsMember" xlink:label="loc_GTBPVestingWarrantsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_GTBPVestingWarrantsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_GreenshoeRightsMember" xlink:label="loc_GTBPGreenshoeRightsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GTBPGreenshoeRightsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_PrefundedWarrantsMember" xlink:label="loc_GTBPPrefundedWarrantsMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GTBPPrefundedWarrantsMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_OmnibusIncentivePlanMember" xlink:label="loc_GTBPOmnibusIncentivePlanMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_GTBPOmnibusIncentivePlanMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_160" xlink:type="arc" order="162" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_210" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_210" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_210" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_210" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeFloorPrice" xlink:label="loc_us-gaapDerivativeFloorPrice_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapDerivativeFloorPrice_210" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_210" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding_210" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_210" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_210" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightUnissued" xlink:label="loc_us-gaapClassOfWarrantOrRightUnissued_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightUnissued_210" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_210" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_210" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_210" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_210" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_210" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_210" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_210" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_210" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1" xlink:label="loc_GTBPSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_GTBPSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1_210" xlink:type="arc" order="18" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:title="999043 - Disclosure - Schedule of Warrants Outstanding and Exercisable (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_RangeOneMember" xlink:label="loc_GTBPRangeOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeOneMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_RangeTwoMember" xlink:label="loc_GTBPRangeTwoMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeTwoMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_RangeThreeMember" xlink:label="loc_GTBPRangeThreeMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeThreeMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_RangeFourMember" xlink:label="loc_GTBPRangeFourMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeFourMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_RangeFiveMember" xlink:label="loc_GTBPRangeFiveMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeFiveMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_RangeSixMember" xlink:label="loc_GTBPRangeSixMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeSixMember_100" xlink:type="arc" order="102" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_RangeSevenMember" xlink:label="loc_GTBPRangeSevenMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeSevenMember_120" xlink:type="arc" order="122" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_RangeEightMember" xlink:label="loc_GTBPRangeEightMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeEightMember_140" xlink:type="arc" order="142" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_RangeNineMember" xlink:label="loc_GTBPRangeNineMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeNineMember_160" xlink:type="arc" order="162" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_RangeTenMember" xlink:label="loc_GTBPRangeTenMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeTenMember_180" xlink:type="arc" order="182" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_RangeElevenMember" xlink:label="loc_GTBPRangeElevenMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeElevenMember_200" xlink:type="arc" order="202" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_RangeTwelveMember" xlink:label="loc_GTBPRangeTwelveMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeTwelveMember_220" xlink:type="arc" order="222" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_RangeThirteenMember" xlink:label="loc_GTBPRangeThirteenMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeThirteenMember_240" xlink:type="arc" order="242" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_290" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_290" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_290" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_290" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails" xlink:title="999044 - Disclosure - Schedule of Options Activity (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails" xlink:title="999045 - Disclosure - Schedule of Options Outstanding and Options Exercisable (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_RangeOneMember" xlink:label="loc_GTBPRangeOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeOneMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_RangeTwoMember" xlink:label="loc_GTBPRangeTwoMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeTwoMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_RangeThreeMember" xlink:label="loc_GTBPRangeThreeMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeThreeMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_RangeFourMember" xlink:label="loc_GTBPRangeFourMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeFourMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_RangeFiveMember" xlink:label="loc_GTBPRangeFiveMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeFiveMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_120" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_120" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_120" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_120" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999046 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLossContingenciesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_LitigationCaseAxis" xlink:label="loc_srtLitigationCaseAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtLitigationCaseAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srtLitigationCaseTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtLitigationCaseAxis" xlink:to="loc_srtLitigationCaseTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srtLitigationCaseTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtLitigationCaseAxis" xlink:to="loc_srtLitigationCaseTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_ZOneLLCMember" xlink:label="loc_GTBPZOneLLCMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtLitigationCaseTypeDomain" xlink:to="loc_GTBPZOneLLCMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_CobySilberfeinMember" xlink:label="loc_GTBPCobySilberfeinMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtLitigationCaseTypeDomain" xlink:to="loc_GTBPCobySilberfeinMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_CytovanceBiologicsIncMember" xlink:label="loc_GTBPCytovanceBiologicsIncMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_GTBPCytovanceBiologicsIncMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_CytovanceBiologicsIncMember" xlink:label="loc_GTBPCytovanceBiologicsIncMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_GTBPCytovanceBiologicsIncMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_TwoThousandTwentyThreeSponsoredResearchAgreementMember" xlink:label="loc_GTBPTwoThousandTwentyThreeSponsoredResearchAgreementMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPTwoThousandTwentyThreeSponsoredResearchAgreementMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_TwoThousandSixteenPatentLicenseAgreementMember" xlink:label="loc_GTBPTwoThousandSixteenPatentLicenseAgreementMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPTwoThousandSixteenPatentLicenseAgreementMember_170" xlink:type="arc" order="171" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember" xlink:label="loc_GTBPTwoThousandAndTwentyOnePatentLicenseAgreementMember_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPTwoThousandAndTwentyOnePatentLicenseAgreementMember_320" xlink:type="arc" order="321" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember" xlink:label="loc_GTBPTwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPTwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember_350" xlink:type="arc" order="351" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapAwardDateAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_TwoThousandSeventeenThroughTwoThousandTwentyMember" xlink:label="loc_GTBPTwoThousandSeventeenThroughTwoThousandTwentyMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_GTBPTwoThousandSeventeenThroughTwoThousandTwentyMember_180" xlink:type="arc" order="182" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_TwoThousandTwentyTwoMember" xlink:label="loc_GTBPTwoThousandTwentyTwoMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_GTBPTwoThousandTwentyTwoMember_220" xlink:type="arc" order="222" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_TwoThousandTwentyFiveMember" xlink:label="loc_GTBPTwoThousandTwentyFiveMember_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_GTBPTwoThousandTwentyFiveMember_230" xlink:type="arc" order="232" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_TwoThousandTwentySevenMember" xlink:label="loc_GTBPTwoThousandTwentySevenMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_GTBPTwoThousandTwentySevenMember_240" xlink:type="arc" order="242" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_200" xlink:type="arc" order="202" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_210" xlink:type="arc" order="212" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyDamagesPaidValue" xlink:label="loc_us-gaapLossContingencyDamagesPaidValue_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLossContingencyDamagesPaidValue_390" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="loc_us-gaapLossContingencyDamagesSoughtValue_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLossContingencyDamagesSoughtValue_390" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyDamagesSought" xlink:label="loc_us-gaapLossContingencyDamagesSought_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLossContingencyDamagesSought_390" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_390" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt_390" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapRepaymentsOfRelatedPartyDebt_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapRepaymentsOfRelatedPartyDebt_390" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_390" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_390" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_390" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable" xlink:label="loc_GTBPStockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable_390" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable" xlink:label="loc_GTBPStockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable_390" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_390" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_390" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="loc_us-gaapPaymentsToAcquireInProcessResearchAndDevelopment_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapPaymentsToAcquireInProcessResearchAndDevelopment_390" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_390" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnbilledReceivablesCurrent" xlink:label="loc_us-gaapUnbilledReceivablesCurrent_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapUnbilledReceivablesCurrent_390" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_ProceedsFromUpfrontAmount" xlink:label="loc_GTBPProceedsFromUpfrontAmount_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPProceedsFromUpfrontAmount_390" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostMaintenance" xlink:label="loc_us-gaapCostMaintenance_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapCostMaintenance_390" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_RoyaltyFeePercentage" xlink:label="loc_GTBPRoyaltyFeePercentage_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPRoyaltyFeePercentage_390" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaapRoyaltyExpense_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapRoyaltyExpense_390" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_PerformanceMilestonePayments" xlink:label="loc_GTBPPerformanceMilestonePayments_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPPerformanceMilestonePayments_390" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_SalesMilestonePayments" xlink:label="loc_GTBPSalesMilestonePayments_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPSalesMilestonePayments_390" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_GrossSales" xlink:label="loc_GTBPGrossSales_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPGrossSales_390" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_SalesRevenue" xlink:label="loc_GTBPSalesRevenue_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPSalesRevenue_390" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_CummulativeGrossSales" xlink:label="loc_GTBPCummulativeGrossSales_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPCummulativeGrossSales_390" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_RoyaltyExpenseYearOne" xlink:label="loc_GTBPRoyaltyExpenseYearOne_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPRoyaltyExpenseYearOne_390" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_RoyaltyExpenseYearTwoThroughFive" xlink:label="loc_GTBPRoyaltyExpenseYearTwoThroughFive_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPRoyaltyExpenseYearTwoThroughFive_390" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_RoyaltyExpenseYearAfterSix" xlink:label="loc_GTBPRoyaltyExpenseYearAfterSix_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPRoyaltyExpenseYearAfterSix_390" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_UpfrontLicenseFee" xlink:label="loc_GTBPUpfrontLicenseFee_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPUpfrontLicenseFee_390" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_RoyaltyExpenseYearOneThoughFour" xlink:label="loc_GTBPRoyaltyExpenseYearOneThoughFour_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPRoyaltyExpenseYearOneThoughFour_390" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_RoyaltyExpenseYearAfterFive" xlink:label="loc_GTBPRoyaltyExpenseYearAfterFive_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPRoyaltyExpenseYearAfterFive_390" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_ContigencyMinimumRequired" xlink:label="loc_GTBPContigencyMinimumRequired_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPContigencyMinimumRequired_390" xlink:type="arc" order="31" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfSegmentInformationDetails" xlink:title="999047 - Disclosure - Schedule of Segment Information (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaapSegmentReportingInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_SegmentsMember" xlink:label="loc_GTBPSegmentsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_GTBPSegmentsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaapOtherResearchAndDevelopmentExpense_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapOtherResearchAndDevelopmentExpense_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaapSalariesAndWages_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapSalariesAndWages_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InsuranceCommissions" xlink:label="loc_us-gaapInsuranceCommissions_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapInsuranceCommissions_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapShareBasedCompensation_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapOperatingExpenses_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapNonoperatingIncomeExpense_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapNetIncomeLoss_50" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SegmentInformationDetailsNarrative" xlink:title="999048 - Disclosure - Segment Information (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative" xlink:title="999049 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_SeriesL10PercentageConvertiblePreferredStockMember" xlink:label="loc_GTBPSeriesL10PercentageConvertiblePreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_GTBPSeriesL10PercentageConvertiblePreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_SeriesLConvertiblePreferredStockMember" xlink:label="loc_GTBPSeriesLConvertiblePreferredStockMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_GTBPSeriesLConvertiblePreferredStockMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_PreferredStockPurchasePrice" xlink:label="loc_GTBPPreferredStockPurchasePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_GTBPPreferredStockPurchasePrice_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="loc_us-gaapPreferredStockConvertibleConversionPrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapPreferredStockConvertibleConversionPrice_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_50" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_OmnibusIncentivePlanMember" xlink:label="loc_GTBPOmnibusIncentivePlanMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_GTBPOmnibusIncentivePlanMember" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>15
<FILENAME>gtbp-20250930_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesCPreferredStockMember" xlink:to="us-gaap_SeriesCPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xml:lang="en-US">Series C Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_SeriesLPreferredStockMember" xlink:label="GTBP_SeriesLPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SeriesLPreferredStockMember" xlink:to="GTBP_SeriesLPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_SeriesLPreferredStockMember_lbl" xml:lang="en-US">Series L Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title and Position [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_OfficersEmployeesAndDirectorsMember" xlink:label="GTBP_OfficersEmployeesAndDirectorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_OfficersEmployeesAndDirectorsMember" xlink:to="GTBP_OfficersEmployeesAndDirectorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_OfficersEmployeesAndDirectorsMember_lbl" xml:lang="en-US">Officers, Employees and Directors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_MezzanineEquityMember" xlink:label="GTBP_MezzanineEquityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_MezzanineEquityMember" xlink:to="GTBP_MezzanineEquityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_MezzanineEquityMember_lbl" xml:lang="en-US">Mezzanine Equity [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_SeriesLConvertiblePreferredStockMember" xlink:label="GTBP_SeriesLConvertiblePreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SeriesLConvertiblePreferredStockMember" xlink:to="GTBP_SeriesLConvertiblePreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_SeriesLConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series L Convertible Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_CytovanceBiologicsIncMember" xlink:label="GTBP_CytovanceBiologicsIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CytovanceBiologicsIncMember" xlink:to="GTBP_CytovanceBiologicsIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_CytovanceBiologicsIncMember_lbl" xml:lang="en-US">Cytovance Biologics Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_UniversityOfMinnesotaMember" xlink:label="GTBP_UniversityOfMinnesotaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_UniversityOfMinnesotaMember" xlink:to="GTBP_UniversityOfMinnesotaMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_UniversityOfMinnesotaMember_lbl" xml:lang="en-US">University of Minnesota [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_LegalServicesFirmMember" xlink:label="GTBP_LegalServicesFirmMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_LegalServicesFirmMember" xlink:to="GTBP_LegalServicesFirmMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_LegalServicesFirmMember_lbl" xml:lang="en-US">Legal Services Firm [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_OtherAccountsPayableMember" xlink:label="GTBP_OtherAccountsPayableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_OtherAccountsPayableMember" xlink:to="GTBP_OtherAccountsPayableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_OtherAccountsPayableMember_lbl" xml:lang="en-US">Other Accounts Payable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_AdvisoryAgreementMember" xlink:label="GTBP_AdvisoryAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_AdvisoryAgreementMember" xlink:to="GTBP_AdvisoryAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_AdvisoryAgreementMember_lbl" xml:lang="en-US">Advisory Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_TwoThousandTwentyThreeCommonWarrantsMember" xlink:label="GTBP_TwoThousandTwentyThreeCommonWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandTwentyThreeCommonWarrantsMember" xlink:to="GTBP_TwoThousandTwentyThreeCommonWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_TwoThousandTwentyThreeCommonWarrantsMember_lbl" xml:lang="en-US">2023 Common Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_TwoThousandTwentyThreePlacementAgentsWarrantsMember" xlink:label="GTBP_TwoThousandTwentyThreePlacementAgentsWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandTwentyThreePlacementAgentsWarrantsMember" xlink:to="GTBP_TwoThousandTwentyThreePlacementAgentsWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_TwoThousandTwentyThreePlacementAgentsWarrantsMember_lbl" xml:lang="en-US">2023 Placement Agents Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_TwoThousandTwentyThreeWarrantsMember" xlink:label="GTBP_TwoThousandTwentyThreeWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandTwentyThreeWarrantsMember" xlink:to="GTBP_TwoThousandTwentyThreeWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_TwoThousandTwentyThreeWarrantsMember_lbl" xml:lang="en-US">2023 Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputSharePriceMember" xlink:to="us-gaap_MeasurementInputSharePriceMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xml:lang="en-US">Measurement Input, Share Price [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_PurchaseAgreementMember" xlink:label="GTBP_PurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_PurchaseAgreementMember" xlink:to="GTBP_PurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_PurchaseAgreementMember_lbl" xml:lang="en-US">Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_InducementWarrantsMember" xlink:label="GTBP_InducementWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_InducementWarrantsMember" xlink:to="GTBP_InducementWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_InducementWarrantsMember_lbl" xml:lang="en-US">Inducement Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_SeriesAInducementWarrantsMember" xlink:label="GTBP_SeriesAInducementWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SeriesAInducementWarrantsMember" xlink:to="GTBP_SeriesAInducementWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_SeriesAInducementWarrantsMember_lbl" xml:lang="en-US">Series A Inducement Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_SeriesBInducementWarrantsMember" xlink:label="GTBP_SeriesBInducementWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SeriesBInducementWarrantsMember" xlink:to="GTBP_SeriesBInducementWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_SeriesBInducementWarrantsMember_lbl" xml:lang="en-US">Series B Inducement Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_SecuritiesPurchaseAgreementMember" xlink:label="GTBP_SecuritiesPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SecuritiesPurchaseAgreementMember" xlink:to="GTBP_SecuritiesPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_SecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_SeriesLTenPercentConvertiblePreferredStockMember" xlink:label="GTBP_SeriesLTenPercentConvertiblePreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SeriesLTenPercentConvertiblePreferredStockMember" xlink:to="GTBP_SeriesLTenPercentConvertiblePreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_SeriesLTenPercentConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series L 10% Convertible Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_GreenshoeRightsMember" xlink:label="GTBP_GreenshoeRightsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_GreenshoeRightsMember" xlink:to="GTBP_GreenshoeRightsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_GreenshoeRightsMember_lbl" xml:lang="en-US">Greenshoe Rights [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_CommonWarrantsMember" xlink:label="GTBP_CommonWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CommonWarrantsMember" xlink:to="GTBP_CommonWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_CommonWarrantsMember_lbl" xml:lang="en-US">Common Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_VestingWarrantsMember" xlink:label="GTBP_VestingWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_VestingWarrantsMember" xlink:to="GTBP_VestingWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_VestingWarrantsMember_lbl" xml:lang="en-US">Vesting Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_SeriesL10PercentageConvertiblePreferredStockMember" xlink:label="GTBP_SeriesL10PercentageConvertiblePreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SeriesL10PercentageConvertiblePreferredStockMember" xlink:to="GTBP_SeriesL10PercentageConvertiblePreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="GTBP_SeriesL10PercentageConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series L 10% Convertible Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_WarrantsMember" xlink:label="GTBP_WarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_WarrantsMember" xlink:to="GTBP_WarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_WarrantsMember_lbl" xml:lang="en-US">Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_PrefundedWarrantsMember" xlink:label="GTBP_PrefundedWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_PrefundedWarrantsMember" xlink:to="GTBP_PrefundedWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_PrefundedWarrantsMember_lbl" xml:lang="en-US">Prefunded Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_OmnibusIncentivePlanMember" xlink:label="GTBP_OmnibusIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_OmnibusIncentivePlanMember" xlink:to="GTBP_OmnibusIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_OmnibusIncentivePlanMember_lbl" xml:lang="en-US">2022 Omnibus Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_RangeOneMember" xlink:label="GTBP_RangeOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeOneMember" xlink:to="GTBP_RangeOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_RangeOneMember_lbl" xml:lang="en-US">Range of Exercise Price One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_RangeTwoMember" xlink:label="GTBP_RangeTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeTwoMember" xlink:to="GTBP_RangeTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_RangeTwoMember_lbl" xml:lang="en-US">Range of Exercise Price Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_RangeThreeMember" xlink:label="GTBP_RangeThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeThreeMember" xlink:to="GTBP_RangeThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_RangeThreeMember_lbl" xml:lang="en-US">Range of Exercise Price Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_RangeFourMember" xlink:label="GTBP_RangeFourMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeFourMember" xlink:to="GTBP_RangeFourMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_RangeFourMember_lbl" xml:lang="en-US">Range of Exercise Price Four [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_RangeFiveMember" xlink:label="GTBP_RangeFiveMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeFiveMember" xlink:to="GTBP_RangeFiveMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_RangeFiveMember_lbl" xml:lang="en-US">Range of Exercise Price Five [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_RangeSixMember" xlink:label="GTBP_RangeSixMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeSixMember" xlink:to="GTBP_RangeSixMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_RangeSixMember_lbl" xml:lang="en-US">Range of Exercise Price Six [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_RangeSevenMember" xlink:label="GTBP_RangeSevenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeSevenMember" xlink:to="GTBP_RangeSevenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_RangeSevenMember_lbl" xml:lang="en-US">Range of Exercise Price Seven [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_RangeEightMember" xlink:label="GTBP_RangeEightMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeEightMember" xlink:to="GTBP_RangeEightMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_RangeEightMember_lbl" xml:lang="en-US">Range of Exercise Price Eight [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_RangeNineMember" xlink:label="GTBP_RangeNineMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeNineMember" xlink:to="GTBP_RangeNineMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_RangeNineMember_lbl" xml:lang="en-US">Range of Exercise Price Nine [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_RangeTenMember" xlink:label="GTBP_RangeTenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeTenMember" xlink:to="GTBP_RangeTenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_RangeTenMember_lbl" xml:lang="en-US">Range of Exercise Price Ten [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_RangeElevenMember" xlink:label="GTBP_RangeElevenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeElevenMember" xlink:to="GTBP_RangeElevenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_RangeElevenMember_lbl" xml:lang="en-US">Range of Exercise Price Eleven [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_RangeTwelveMember" xlink:label="GTBP_RangeTwelveMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeTwelveMember" xlink:to="GTBP_RangeTwelveMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_RangeTwelveMember_lbl" xml:lang="en-US">Range of Exercise Price Twelve [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_RangeThirteenMember" xlink:label="GTBP_RangeThirteenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeThirteenMember" xlink:to="GTBP_RangeThirteenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_RangeThirteenMember_lbl" xml:lang="en-US">Range of Exercise Price Thirteen [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_LitigationCaseAxis_lbl" xml:lang="en-US">Litigation Case [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_ZOneLLCMember" xlink:label="GTBP_ZOneLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ZOneLLCMember" xlink:to="GTBP_ZOneLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ZOneLLCMember_lbl" xml:lang="en-US">Z One LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_CobySilberfeinMember" xlink:label="GTBP_CobySilberfeinMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CobySilberfeinMember" xlink:to="GTBP_CobySilberfeinMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_CobySilberfeinMember_lbl" xml:lang="en-US">Coby Silberfein [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xml:lang="en-US">Investment, Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_TwoThousandTwentyThreeSponsoredResearchAgreementMember" xlink:label="GTBP_TwoThousandTwentyThreeSponsoredResearchAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandTwentyThreeSponsoredResearchAgreementMember" xlink:to="GTBP_TwoThousandTwentyThreeSponsoredResearchAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_TwoThousandTwentyThreeSponsoredResearchAgreementMember_lbl" xml:lang="en-US">2023 Sponsored Research Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_TwoThousandSixteenPatentLicenseAgreementMember" xlink:label="GTBP_TwoThousandSixteenPatentLicenseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandSixteenPatentLicenseAgreementMember" xlink:to="GTBP_TwoThousandSixteenPatentLicenseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_TwoThousandSixteenPatentLicenseAgreementMember_lbl" xml:lang="en-US">2016 Exclusive Patent License Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardDateAxis_lbl" xml:lang="en-US">Award Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_TwoThousandSeventeenThroughTwoThousandTwentyMember" xlink:label="GTBP_TwoThousandSeventeenThroughTwoThousandTwentyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandSeventeenThroughTwoThousandTwentyMember" xlink:to="GTBP_TwoThousandSeventeenThroughTwoThousandTwentyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_TwoThousandSeventeenThroughTwoThousandTwentyMember_lbl" xml:lang="en-US">2017 through 2020 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_TwoThousandTwentyTwoMember" xlink:label="GTBP_TwoThousandTwentyTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandTwentyTwoMember" xlink:to="GTBP_TwoThousandTwentyTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_TwoThousandTwentyTwoMember_lbl" xml:lang="en-US">Beginning in 2022 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_TwoThousandTwentyFiveMember" xlink:label="GTBP_TwoThousandTwentyFiveMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandTwentyFiveMember" xlink:to="GTBP_TwoThousandTwentyFiveMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_TwoThousandTwentyFiveMember_lbl" xml:lang="en-US">Beginning in 2025 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_TwoThousandTwentySevenMember" xlink:label="GTBP_TwoThousandTwentySevenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandTwentySevenMember" xlink:to="GTBP_TwoThousandTwentySevenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_TwoThousandTwentySevenMember_lbl" xml:lang="en-US">Beginning in 2027 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember" xlink:label="GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember" xlink:to="GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember_lbl" xml:lang="en-US">2021 Exclusive License Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember" xlink:label="GTBP_TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember" xlink:to="GTBP_TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember_lbl" xml:lang="en-US">2024 GTB-3650 Clinical Trial Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xml:lang="en-US">Segments [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_SegmentsMember" xlink:label="GTBP_SegmentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SegmentsMember" xlink:to="GTBP_SegmentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_SegmentsMember_lbl" xml:lang="en-US">Segments [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xml:lang="en-US">Restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xml:lang="en-US">Deferred offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">TOTAL ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; DEFICIT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsPayableCurrent" xlink:label="us-gaap_DividendsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPayableCurrent" xlink:to="us-gaap_DividendsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPayableCurrent_lbl" xml:lang="en-US">Dividend payable</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_WarrantLiabilityCurrent" xlink:label="GTBP_WarrantLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_WarrantLiabilityCurrent" xlink:to="GTBP_WarrantLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_WarrantLiabilityCurrent_lbl" xml:lang="en-US">Warrant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; Equity (Deficit)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, par value $0.001, 250,000,000 shares authorized, 6,051,874 and 2,234,328 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Stockholders&#8217; Equity (Deficit)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; (EQUITY) DEFICIT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US">Revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating Expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, general and administrative (including $379,000 and $0 of stock compensation for the three months ended September 30, 2025 and 2024, respectively, and $386,000 and $222,000 of stock compensation for the nine months ended September 30, 2025 and 2024, respectively)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from Operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other Income (Expense)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeOther" xlink:label="us-gaap_InterestIncomeOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeOther" xlink:to="us-gaap_InterestIncomeOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeOther_lbl" xml:lang="en-US">Interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Change in fair value of warrant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Gain on settlement of vendor payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl" xml:lang="en-US">Unrealized gain on short-term investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total Other Income (Expense), Net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl" xml:lang="en-US">Dividends on preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net Loss attributable to common stockholders&#8217;</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net Loss Per Share - Basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net Loss Per Share - Diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average common shares outstanding - basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average common shares outstanding - diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Share-based payment arrangement, expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US">Mezzanine equity balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US">Mezzanine equity balance</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_StockIssuedDuringPeriodValueMezzanineEquityReclassification" xlink:label="GTBP_StockIssuedDuringPeriodValueMezzanineEquityReclassification" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodValueMezzanineEquityReclassification" xlink:to="GTBP_StockIssuedDuringPeriodValueMezzanineEquityReclassification_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_StockIssuedDuringPeriodValueMezzanineEquityReclassification_lbl" xml:lang="en-US">Mezzanine equity reclassification</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_StockIssuedDuringPeriodSharesMezzanineEquityReclassification" xlink:label="GTBP_StockIssuedDuringPeriodSharesMezzanineEquityReclassification" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodSharesMezzanineEquityReclassification" xlink:to="GTBP_StockIssuedDuringPeriodSharesMezzanineEquityReclassification_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_StockIssuedDuringPeriodSharesMezzanineEquityReclassification_lbl" xml:lang="en-US">Mezzanine equity reclassification, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl" xml:lang="en-US">Series L convertible preferred stock and warrants issued for cash, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xml:lang="en-US">Series L convertible preferred stock and warrants issued for cash, net, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Conversion of Series L convertible preferred stock into common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Conversion of Series L convertible preferred stock into common stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsPreferredStock" xlink:label="us-gaap_DividendsPreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPreferredStock" xlink:to="us-gaap_DividendsPreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DividendsPreferredStock_lbl" xml:lang="en-US">Dividend on Series L convertible preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Fair value of vested stock options</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet" xlink:label="GTBP_StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet" xlink:to="GTBP_StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet_lbl" xml:lang="en-US">Exercise of warrants for cash and inducement warrants, net</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_StockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet" xlink:label="GTBP_StockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet" xlink:to="GTBP_StockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_StockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet_lbl" xml:lang="en-US">Exercise of warrants for cash and inducement warrants, net, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable" xlink:label="GTBP_StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable" xlink:to="GTBP_StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable_lbl" xml:lang="en-US">Issuance of prefunded warrants in settlement of vendor payable</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_StockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee" xlink:label="GTBP_StockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee" xlink:to="GTBP_StockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_StockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee_lbl" xml:lang="en-US">Issuance and exercise of prefunded warrants for ELOC fee</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_StockIssuedDuringPeriodSharesIssuanceAndExerciseOfPrefundedWarrantsForElocFee" xlink:label="GTBP_StockIssuedDuringPeriodSharesIssuanceAndExerciseOfPrefundedWarrantsForElocFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodSharesIssuanceAndExerciseOfPrefundedWarrantsForElocFee" xlink:to="GTBP_StockIssuedDuringPeriodSharesIssuanceAndExerciseOfPrefundedWarrantsForElocFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_StockIssuedDuringPeriodSharesIssuanceAndExerciseOfPrefundedWarrantsForElocFee_lbl" xml:lang="en-US">Issuance and exercise of prefunded warrants for ELOC fee, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Issuance of common stock and warrants for services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Issuance of common stock and warrants for services, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Issuance of warrants for VRT waiver</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash" xlink:label="GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash" xlink:to="GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash_lbl" xml:lang="en-US">Issuance of common stock and warrants for cash, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited_lbl" xml:lang="en-US">Cancellation of common stock previously issued to prior CFO</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable" xlink:label="GTBP_StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable" xlink:to="GTBP_StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable_lbl" xml:lang="en-US">Issuance of common stock in settlement of vendor payable</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_StockIssuedDuringPeriodShareIssuanceOfCommonStockAndWarrantsForCash" xlink:label="GTBP_StockIssuedDuringPeriodShareIssuanceOfCommonStockAndWarrantsForCash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodShareIssuanceOfCommonStockAndWarrantsForCash" xlink:to="GTBP_StockIssuedDuringPeriodShareIssuanceOfCommonStockAndWarrantsForCash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_StockIssuedDuringPeriodShareIssuanceOfCommonStockAndWarrantsForCash_lbl" xml:lang="en-US">Issuance of common stock and warrants for cash, net, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_lbl" xml:lang="en-US">Cancellation of common stock previously issued to prior CFO, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable" xlink:label="GTBP_StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable" xlink:to="GTBP_StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable_lbl" xml:lang="en-US">Issuance of common stock in settlement of vendor payable, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_2_lbl" xml:lang="en-US">Mezzanine equity balance, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_2_lbl" xml:lang="en-US">Mezzanine equity balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_IssuanceOfWarrantsForVrtWaiver" xlink:label="GTBP_IssuanceOfWarrantsForVrtWaiver" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_IssuanceOfWarrantsForVrtWaiver" xlink:to="GTBP_IssuanceOfWarrantsForVrtWaiver_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="GTBP_IssuanceOfWarrantsForVrtWaiver_lbl" xml:lang="en-US">Issuance of warrants for VRT waiver</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_2_lbl" xml:lang="en-US">Change in fair value of warrant liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xml:lang="en-US">Gain on settlement of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_GainOnSettlementOfDebt" xlink:label="GTBP_GainOnSettlementOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_GainOnSettlementOfDebt" xlink:to="GTBP_GainOnSettlementOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="GTBP_GainOnSettlementOfDebt_lbl" xml:lang="en-US">Gain on extinguishment of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesUnrealizedGainLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesUnrealizedGainLoss" xlink:to="us-gaap_DebtSecuritiesUnrealizedGainLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtSecuritiesUnrealizedGainLoss_lbl" xml:lang="en-US">Unrealized gain on short-term investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">(Increase) Decrease in prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Decrease in accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_IncreaseDecreaseInOperatingLeaseRightofuseAssets" xlink:label="GTBP_IncreaseDecreaseInOperatingLeaseRightofuseAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_IncreaseDecreaseInOperatingLeaseRightofuseAssets" xlink:to="GTBP_IncreaseDecreaseInOperatingLeaseRightofuseAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="GTBP_IncreaseDecreaseInOperatingLeaseRightofuseAssets_lbl" xml:lang="en-US">Decrease in operating lease right-of-use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">(Increase) in operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Used in Operating Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForProceedsFromInvestments" xlink:label="us-gaap_PaymentsForProceedsFromInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromInvestments" xlink:to="us-gaap_PaymentsForProceedsFromInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForProceedsFromInvestments_lbl" xml:lang="en-US">Sale of investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Provided by Investing Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Exercise of warrants and issuance of inducement warrants for cash, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Proceeds from issuance of common stock and warrants, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xml:lang="en-US">Proceeds from issuance of Series L convertible preferred stock and warrants, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDividends" xlink:label="us-gaap_PaymentsOfDividends" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDividends" xlink:to="us-gaap_PaymentsOfDividends_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfDividends_lbl" xml:lang="en-US">Payment of dividend on Series L convertible preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided by Financing Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net Increase (Decrease) in Cash and Cash Equivalents and Restricted Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and Cash Equivalents and Restricted Cash at Beginning of Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xml:lang="en-US">Cash and Cash Equivalents and Restricted Cash at End of Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_CashPaidDuringYearFor" xlink:label="GTBP_CashPaidDuringYearFor" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CashPaidDuringYearFor" xlink:to="GTBP_CashPaidDuringYearFor_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_CashPaidDuringYearFor_lbl" xml:lang="en-US">Cash paid during the period for:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaid_lbl" xml:lang="en-US">Interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_FairValueOfSeriesLConvertiblePreferredStockVestedWarrants" xlink:label="GTBP_FairValueOfSeriesLConvertiblePreferredStockVestedWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_FairValueOfSeriesLConvertiblePreferredStockVestedWarrants" xlink:to="GTBP_FairValueOfSeriesLConvertiblePreferredStockVestedWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_FairValueOfSeriesLConvertiblePreferredStockVestedWarrants_lbl" xml:lang="en-US">Fair value of Series L convertible preferred stock vested warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_FairValueOfPrefundedWarrantsIssuedForElocFee" xlink:label="GTBP_FairValueOfPrefundedWarrantsIssuedForElocFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_FairValueOfPrefundedWarrantsIssuedForElocFee" xlink:to="GTBP_FairValueOfPrefundedWarrantsIssuedForElocFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_FairValueOfPrefundedWarrantsIssuedForElocFee_lbl" xml:lang="en-US">Fair value of prefunded warrants issued for ELOC fee</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssued1_lbl" xml:lang="en-US">Fair value of common stock and warrants issued for services</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_FairValueOfPrefundedWarrantAndCommonStockToSettleVendorPayable" xlink:label="GTBP_FairValueOfPrefundedWarrantAndCommonStockToSettleVendorPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_FairValueOfPrefundedWarrantAndCommonStockToSettleVendorPayable" xlink:to="GTBP_FairValueOfPrefundedWarrantAndCommonStockToSettleVendorPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_FairValueOfPrefundedWarrantAndCommonStockToSettleVendorPayable_lbl" xml:lang="en-US">Fair value of prefunded warrant and common stock to settle vendor payable</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_DividendDeclaredOnSeriesLConvertiblePreferredStock" xlink:label="GTBP_DividendDeclaredOnSeriesLConvertiblePreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_DividendDeclaredOnSeriesLConvertiblePreferredStock" xlink:to="GTBP_DividendDeclaredOnSeriesLConvertiblePreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_DividendDeclaredOnSeriesLConvertiblePreferredStock_lbl" xml:lang="en-US">Dividend declared on Series L convertible preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable" xlink:label="ecd_PvpTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTable" xlink:to="ecd_PvpTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTable_lbl" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis" xlink:label="ecd_ExecutiveCategoryAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ExecutiveCategoryAxis" xlink:to="ecd_ExecutiveCategoryAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ExecutiveCategoryAxis_lbl" xml:lang="en-US">Executive Category [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis" xlink:label="ecd_IndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_IndividualAxis" xlink:to="ecd_IndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_IndividualAxis_lbl" xml:lang="en-US">Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis" xlink:label="ecd_AdjToCompAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAxis" xlink:to="ecd_AdjToCompAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAxis_lbl" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis" xlink:label="ecd_MeasureAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureAxis" xlink:to="ecd_MeasureAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureAxis_lbl" xml:lang="en-US">Measure [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock" xlink:label="ecd_PvpTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTableTextBlock" xlink:to="ecd_PvpTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTableTextBlock_lbl" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName" xlink:label="ecd_CoSelectedMeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureName" xlink:to="ecd_CoSelectedMeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureName_lbl" xml:lang="en-US">Company Selected Measure Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="ecd_PeerGroupIssuersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupIssuersFnTextBlock" xlink:to="ecd_PeerGroupIssuersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupIssuersFnTextBlock_lbl" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="ecd_ChangedPeerGroupFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ChangedPeerGroupFnTextBlock" xlink:to="ecd_ChangedPeerGroupFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ChangedPeerGroupFnTextBlock_lbl" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt" xlink:label="ecd_PeoTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoTotalCompAmt" xlink:to="ecd_PeoTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoTotalCompAmt_lbl" xml:lang="en-US">PEO Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="ecd_PeoActuallyPaidCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoActuallyPaidCompAmt" xlink:to="ecd_PeoActuallyPaidCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoActuallyPaidCompAmt_lbl" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="ecd_AdjToPeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToPeoCompFnTextBlock" xlink:to="ecd_AdjToPeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToPeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock" xlink:label="ecd_TabularListTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TabularListTableTextBlock" xlink:to="ecd_TabularListTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TabularListTableTextBlock_lbl" xml:lang="en-US">Tabular List, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt" xlink:label="ecd_TotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnAmt" xlink:to="ecd_TotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnAmt_lbl" xml:lang="en-US">Total Shareholder Return Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net Income (Loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt" xlink:label="ecd_CoSelectedMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureAmt" xlink:to="ecd_CoSelectedMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureAmt_lbl" xml:lang="en-US">Company Selected Measure Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt" xlink:label="ecd_OtherPerfMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OtherPerfMeasureAmt" xlink:to="ecd_OtherPerfMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OtherPerfMeasureAmt_lbl" xml:lang="en-US">Other Performance Measure, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt" xlink:label="ecd_AdjToCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAmt" xlink:to="ecd_AdjToCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAmt_lbl" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName" xlink:label="ecd_PeoName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoName" xlink:to="ecd_PeoName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoName_lbl" xml:lang="en-US">PEO Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName" xlink:label="ecd_MeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureName" xlink:to="ecd_MeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xml:lang="en-US">Non-GAAP Measure Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="ecd_Additional402vDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Additional402vDisclosureTextBlock" xlink:to="ecd_Additional402vDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Additional402vDisclosureTextBlock_lbl" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="ecd_PnsnBnftsAdjFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PnsnBnftsAdjFnTextBlock" xlink:to="ecd_PnsnBnftsAdjFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PnsnBnftsAdjFnTextBlock_lbl" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock" xlink:label="ecd_EqtyAwrdsAdjFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="ecd_EqtyAwrdsAdjFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_EqtyAwrdsAdjFnTextBlock_lbl" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable" xlink:label="ecd_ErrCompRecoveryTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompRecoveryTable" xlink:to="ecd_ErrCompRecoveryTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompRecoveryTable_lbl" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis" xlink:label="ecd_RestatementDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDateAxis" xlink:to="ecd_RestatementDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDateAxis_lbl" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate" xlink:label="ecd_RestatementDeterminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDeterminationDate" xlink:to="ecd_RestatementDeterminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDeterminationDate_lbl" xml:lang="en-US">Restatement Determination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt" xlink:label="ecd_AggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompAmt" xlink:to="ecd_AggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompAmt_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="ecd_ErrCompAnalysisTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompAnalysisTextBlock" xlink:to="ecd_ErrCompAnalysisTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompAnalysisTextBlock_lbl" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="ecd_OutstandingAggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingAggtErrCompAmt" xlink:to="ecd_OutstandingAggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingAggtErrCompAmt_lbl" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName" xlink:label="ecd_ForgoneRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_ForgoneRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName" xlink:label="ecd_OutstandingRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_OutstandingRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="ecd_OutstandingRecoveryCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryCompAmt" xlink:to="ecd_OutstandingRecoveryCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryCompAmt_lbl" xml:lang="en-US">Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xml:lang="en-US">Restatement does not require Recovery</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="ecd_AwardsCloseToMnpiDiscTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTable" xlink:to="ecd_AwardsCloseToMnpiDiscTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTable_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="ecd_AwardTmgMnpiDiscTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiDiscTextBlock" xlink:to="ecd_AwardTmgMnpiDiscTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiDiscTextBlock_lbl" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="ecd_AwardTmgMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMethodTextBlock" xlink:to="ecd_AwardTmgMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMethodTextBlock_lbl" xml:lang="en-US">Award Timing Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="ecd_AwardTmgPredtrmndFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgPredtrmndFlag" xlink:to="ecd_AwardTmgPredtrmndFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgPredtrmndFlag_lbl" xml:lang="en-US">Award Timing Predetermined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xml:lang="en-US">Award Timing MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="ecd_MnpiDiscTimedForCompValFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MnpiDiscTimedForCompValFlag" xlink:to="ecd_MnpiDiscTimedForCompValFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MnpiDiscTimedForCompValFlag_lbl" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="ecd_AwardsCloseToMnpiDiscIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="ecd_AwardUndrlygSecuritiesAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardUndrlygSecuritiesAmt" xlink:to="ecd_AwardUndrlygSecuritiesAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardUndrlygSecuritiesAmt_lbl" xml:lang="en-US">Underlying Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice" xlink:label="ecd_AwardExrcPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardExrcPrice" xlink:to="ecd_AwardExrcPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardExrcPrice_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue" xlink:label="ecd_AwardGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardGrantDateFairValue" xlink:to="ecd_AwardGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardGrantDateFairValue_lbl" xml:lang="en-US">Fair Value as of Grant Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="ecd_UndrlygSecurityMktPriceChngPct" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_UndrlygSecurityMktPriceChngPct" xlink:to="ecd_UndrlygSecurityMktPriceChngPct_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_UndrlygSecurityMktPriceChngPct_lbl" xml:lang="en-US">Underlying Security Market Price Change</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems" xlink:label="ecd_InsiderTradingArrLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_InsiderTradingArrLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingArrLineItems_lbl" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName" xlink:label="ecd_TrdArrIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_TrdArrIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle" xlink:label="ecd_TrdArrIndTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndTitle" xlink:to="ecd_TrdArrIndTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndTitle_lbl" xml:lang="en-US">Title</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate" xlink:label="ecd_TrdArrAdoptionDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrAdoptionDate" xlink:to="ecd_TrdArrAdoptionDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrAdoptionDate_lbl" xml:lang="en-US">Adoption Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate" xlink:label="ecd_TrdArrTerminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrTerminationDate" xlink:to="ecd_TrdArrTerminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrTerminationDate_lbl" xml:lang="en-US">Termination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate" xlink:label="ecd_TrdArrExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrExpirationDate" xlink:to="ecd_TrdArrExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrExpirationDate_lbl" xml:lang="en-US">Expiration Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration" xlink:label="ecd_TrdArrDuration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrDuration" xlink:to="ecd_TrdArrDuration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrDuration_lbl" xml:lang="en-US">Arrangement Duration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt" xlink:label="ecd_TrdArrSecuritiesAggAvailAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="ecd_TrdArrSecuritiesAggAvailAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrSecuritiesAggAvailAmt_lbl" xml:lang="en-US">Aggregate Available</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="ecd_InsiderTradingPoliciesProcLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingPoliciesProcLineItems" xlink:to="ecd_InsiderTradingPoliciesProcLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingPoliciesProcLineItems_lbl" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Organization and Going Concern Analysis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">Accounts Payable and Related Party</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_DisclosureWarrantLiabilityAbstract" xlink:label="GTBP_DisclosureWarrantLiabilityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_DisclosureWarrantLiabilityAbstract" xlink:to="GTBP_DisclosureWarrantLiabilityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_DisclosureWarrantLiabilityAbstract_lbl" xml:lang="en-US">Warrant Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_WarrantLiabilityTextBlock" xlink:label="GTBP_WarrantLiabilityTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_WarrantLiabilityTextBlock" xlink:to="GTBP_WarrantLiabilityTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="GTBP_WarrantLiabilityTextBlock_lbl" xml:lang="en-US">Warrant Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders&#8217; Equity (Deficit)</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract" xlink:label="GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract_lbl" xml:lang="en-US">Common Stock Warrants And Options</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_CommonStockWarrantsAndOptionsTextBlock" xlink:label="GTBP_CommonStockWarrantsAndOptionsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CommonStockWarrantsAndOptionsTextBlock" xlink:to="GTBP_CommonStockWarrantsAndOptionsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_CommonStockWarrantsAndOptionsTextBlock_lbl" xml:lang="en-US">Common Stock Warrants and Options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">Segment Information</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Accounting Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US">Restricted Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy" xlink:label="us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy" xlink:to="us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy_lbl" xml:lang="en-US">Deferred Offering Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_WarrantLiabilityPolicyTextBlock" xlink:label="GTBP_WarrantLiabilityPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_WarrantLiabilityPolicyTextBlock" xlink:to="GTBP_WarrantLiabilityPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="GTBP_WarrantLiabilityPolicyTextBlock_lbl" xml:lang="en-US">Warrant Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_MezzanineEquityPolicyTextBlock" xlink:label="GTBP_MezzanineEquityPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_MezzanineEquityPolicyTextBlock" xlink:to="GTBP_MezzanineEquityPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_MezzanineEquityPolicyTextBlock_lbl" xml:lang="en-US">Mezzanine Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Loss Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Information</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Anti-dilutive Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Accounts Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock" xlink:label="GTBP_ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock" xlink:to="GTBP_ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock_lbl" xml:lang="en-US">Schedule of Accounts Payable to Related Party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ScheduleOfShortTermDebtTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShortTermDebtTable_lbl" xml:lang="en-US">Short-Term Debt [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermDebtLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xml:lang="en-US">Short-Term Debt [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US">Schedule of Warrant Liability Assumptions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:to="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl" xml:lang="en-US">Schedule of Warrant Liability Transactions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfConversionsOfStockTextBlock" xlink:label="us-gaap_ScheduleOfConversionsOfStockTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfConversionsOfStockTextBlock" xlink:to="us-gaap_ScheduleOfConversionsOfStockTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfConversionsOfStockTextBlock_lbl" xml:lang="en-US">Schedule of fair values and allocation of net proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of Warrant Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_ScheduleOfWarrantsOustandingAndExercisableTableTextBlock" xlink:label="GTBP_ScheduleOfWarrantsOustandingAndExercisableTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ScheduleOfWarrantsOustandingAndExercisableTableTextBlock" xlink:to="GTBP_ScheduleOfWarrantsOustandingAndExercisableTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ScheduleOfWarrantsOustandingAndExercisableTableTextBlock_lbl" xml:lang="en-US">Schedule of Warrants Outstanding and Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Options Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xml:lang="en-US">Schedule of Options Outstanding and Options Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US">Schedule of Segment Information</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetIncomeLoss_4_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Total anti-dilutive securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionPrice" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice_lbl" xml:lang="en-US">Conversion price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US">Cash, FDIC insured amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xml:lang="en-US">Defined Benefit Plan [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableInterestBearingInterestRate" xlink:label="us-gaap_AccountsPayableInterestBearingInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableInterestBearingInterestRate" xlink:to="us-gaap_AccountsPayableInterestBearingInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableInterestBearingInterestRate_lbl" xml:lang="en-US">Accounts payable interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl" xml:lang="en-US">Other accounts payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableCurrent_2_lbl" xml:lang="en-US">Total accounts payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_AccountsPayableTradeCurrent_2_lbl" xml:lang="en-US">Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xml:lang="en-US">Invoices, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_lbl" xml:lang="en-US">Payments in cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xml:lang="en-US">Payments in common stock, at fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_RepaymentsOfPrefundedWarrantsAtFairValue" xlink:label="GTBP_RepaymentsOfPrefundedWarrantsAtFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RepaymentsOfPrefundedWarrantsAtFairValue" xlink:to="GTBP_RepaymentsOfPrefundedWarrantsAtFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_RepaymentsOfPrefundedWarrantsAtFairValue_lbl" xml:lang="en-US">Payments in pre-funded warrants, at fair value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_AccountsPayableTradeCurrent_3_lbl" xml:lang="en-US">Ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_AccountsPayableAndRelatedPartyTable" xlink:label="GTBP_AccountsPayableAndRelatedPartyTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_AccountsPayableAndRelatedPartyTable" xlink:to="GTBP_AccountsPayableAndRelatedPartyTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_AccountsPayableAndRelatedPartyTable_lbl" xml:lang="en-US">AccountsPayableAndRelatedPartyTable [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_AccountsPayableAndRelatedPartyLineItems" xlink:label="GTBP_AccountsPayableAndRelatedPartyLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_AccountsPayableAndRelatedPartyLineItems" xlink:to="GTBP_AccountsPayableAndRelatedPartyLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_AccountsPayableAndRelatedPartyLineItems_lbl" xml:lang="en-US">AccountsPayableAndRelatedPartyLineItems [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable" xlink:to="GTBP_StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="GTBP_StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable_2_lbl" xml:lang="en-US">Issuance of prefunded warrant to settle vendor payable, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable" xlink:to="GTBP_StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="GTBP_StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable_2_lbl" xml:lang="en-US">Issuance of prefunded warrant to settle vendor payable, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Issuance of pre-funded warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RepaymentsOfPrefundedWarrantsAtFairValue" xlink:to="GTBP_RepaymentsOfPrefundedWarrantsAtFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="GTBP_RepaymentsOfPrefundedWarrantsAtFairValue_2_lbl" xml:lang="en-US">Payments in pre-funded warrants, at fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForFees" xlink:label="us-gaap_PaymentsForFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForFees" xlink:to="us-gaap_PaymentsForFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForFees_lbl" xml:lang="en-US">Prior year unpaid fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfOtherDebt" xlink:label="us-gaap_RepaymentsOfOtherDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfOtherDebt" xlink:to="us-gaap_RepaymentsOfOtherDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfOtherDebt_lbl" xml:lang="en-US">Cash payment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US">Warrants outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Stock issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionDescriptionOfTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction_lbl" xml:lang="en-US">Related party transaction description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Warrants to purchase</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Volatility amount utilized in the value calculation percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstanding_2_lbl" xml:lang="en-US">Warrant fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xml:lang="en-US">Business Combination [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xml:lang="en-US">Business Combination [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xml:lang="en-US">Warrants measurement input</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Expected life (in years)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_3_lbl" xml:lang="en-US">Fair value of warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_DisclosureWarrantLiabilityAbstract" xlink:to="GTBP_DisclosureWarrantLiabilityAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="GTBP_DisclosureWarrantLiabilityAbstract_2_lbl" xml:lang="en-US">Schedule Of Warrant Liability Transactions</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_WarrantLiabilityCurrent" xlink:to="GTBP_WarrantLiabilityCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="GTBP_WarrantLiabilityCurrent_2_lbl" xml:lang="en-US">Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US">Issuance of warrants at fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDerivativeLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:to="us-gaap_IncreaseDecreaseInDerivativeLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDerivativeLiabilities_lbl" xml:lang="en-US">Change in fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_ExtinguishmentOfWarrant" xlink:label="GTBP_ExtinguishmentOfWarrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ExtinguishmentOfWarrant" xlink:to="GTBP_ExtinguishmentOfWarrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ExtinguishmentOfWarrant_lbl" xml:lang="en-US">Extinguishment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_WarrantLiabilityCurrent" xlink:to="GTBP_WarrantLiabilityCurrent_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="GTBP_WarrantLiabilityCurrent_3_lbl" xml:lang="en-US">Ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Class of Stock [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_ConvertiblePreferredStockAndWarrantsFairValuePercentage" xlink:label="GTBP_ConvertiblePreferredStockAndWarrantsFairValuePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ConvertiblePreferredStockAndWarrantsFairValuePercentage" xlink:to="GTBP_ConvertiblePreferredStockAndWarrantsFairValuePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ConvertiblePreferredStockAndWarrantsFairValuePercentage_lbl" xml:lang="en-US">Convertible preferred stock and warrants fair value percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_2_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_ConvertiblePreferredStockAndWarrantsNetProceedsPercentage" xlink:label="GTBP_ConvertiblePreferredStockAndWarrantsNetProceedsPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ConvertiblePreferredStockAndWarrantsNetProceedsPercentage" xlink:to="GTBP_ConvertiblePreferredStockAndWarrantsNetProceedsPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ConvertiblePreferredStockAndWarrantsNetProceedsPercentage_lbl" xml:lang="en-US">Convertible preferred stock and warrants net proceeds percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_2_lbl" xml:lang="en-US">Warrants to purcahse</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_WeightedAverageVolumePriceOfCommonStockPercentage" xlink:label="GTBP_WeightedAverageVolumePriceOfCommonStockPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_WeightedAverageVolumePriceOfCommonStockPercentage" xlink:to="GTBP_WeightedAverageVolumePriceOfCommonStockPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_WeightedAverageVolumePriceOfCommonStockPercentage_lbl" xml:lang="en-US">Weighted average volume price of common stock percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xml:lang="en-US">Placement agents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US">Proceeds from private placement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoninterestExpenseOfferingCost" xlink:label="us-gaap_NoninterestExpenseOfferingCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoninterestExpenseOfferingCost" xlink:to="us-gaap_NoninterestExpenseOfferingCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoninterestExpenseOfferingCost_lbl" xml:lang="en-US">Other offering expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_lbl" xml:lang="en-US">Issuance of warrants, exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xml:lang="en-US">Exercise price per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_2_lbl" xml:lang="en-US">Warrants term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_2_lbl" xml:lang="en-US">Equity issuance cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Issuance of shares</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_AggregateStatedValue" xlink:label="GTBP_AggregateStatedValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_AggregateStatedValue" xlink:to="GTBP_AggregateStatedValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_AggregateStatedValue_lbl" xml:lang="en-US">Aggregate stated value</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_ClassOfWarrantsPurchaseUpPercentage" xlink:label="GTBP_ClassOfWarrantsPurchaseUpPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ClassOfWarrantsPurchaseUpPercentage" xlink:to="GTBP_ClassOfWarrantsPurchaseUpPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ClassOfWarrantsPurchaseUpPercentage_lbl" xml:lang="en-US">Warrants purchase up percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Issuance of shares, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_3_lbl" xml:lang="en-US">Proceeds from issuance of preferred stock and warrants, net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionPrice" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice_2_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendRatePercentage" xlink:to="us-gaap_PreferredStockDividendRatePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xml:lang="en-US">Percentage of dividend</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US">Aggregate number of shares vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeFloorPrice" xlink:label="us-gaap_DerivativeFloorPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFloorPrice" xlink:to="us-gaap_DerivativeFloorPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeFloorPrice_lbl" xml:lang="en-US">Floor price</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_LiableOfLiquidatedDamagePercentageDescription" xlink:label="GTBP_LiableOfLiquidatedDamagePercentageDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_LiableOfLiquidatedDamagePercentageDescription" xlink:to="GTBP_LiableOfLiquidatedDamagePercentageDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_LiableOfLiquidatedDamagePercentageDescription_lbl" xml:lang="en-US">Liable of liquidated damage percentage, description</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_CommonStockSharesOutstandingPercentage" xlink:label="GTBP_CommonStockSharesOutstandingPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CommonStockSharesOutstandingPercentage" xlink:to="GTBP_CommonStockSharesOutstandingPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_CommonStockSharesOutstandingPercentage_lbl" xml:lang="en-US">Common stock shares outstanding percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Shares issued value</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_PreferredStockPurchasePrice" xlink:label="GTBP_PreferredStockPurchasePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_PreferredStockPurchasePrice" xlink:to="GTBP_PreferredStockPurchasePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_PreferredStockPurchasePrice_lbl" xml:lang="en-US">Purchase price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock" xlink:label="us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock" xlink:to="us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock_lbl" xml:lang="en-US">Dividends to holders unpaid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPayableCurrent" xlink:to="us-gaap_DividendsPayableCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DividendsPayableCurrent_2_lbl" xml:lang="en-US">Dividends unpaid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract_2_lbl" xml:lang="en-US">Schedule Of Warrant Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US">Warrants outstanding, beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Number of warrants, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedPursuantToFullRatchetPriceProtection" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedPursuantToFullRatchetPriceProtection" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedPursuantToFullRatchetPriceProtection" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedPursuantToFullRatchetPriceProtection_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedPursuantToFullRatchetPriceProtection_lbl" xml:lang="en-US">Number of warrants, granted pursuant to full ratchet price and anti-dilution protections</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedPursuantToFullRatchetPriceProtectionWeightedAverageExercisePrice" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedPursuantToFullRatchetPriceProtectionWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedPursuantToFullRatchetPriceProtectionWeightedAverageExercisePrice" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedPursuantToFullRatchetPriceProtectionWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedPursuantToFullRatchetPriceProtectionWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, granted pursuant to full ratchet price and anti-dilution protections</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_lbl" xml:lang="en-US">Number of warrants, forfeited/cancelled</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, forfeited/cancelled</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Number of warrants, exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xml:lang="en-US">Warrants outstanding, ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price, ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_lbl" xml:lang="en-US">Warrants exercisable, ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, exercisable, ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Options outstanding vested intrinsic value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xml:lang="en-US">Aggregate number of shares issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFloorPrice" xlink:to="us-gaap_DerivativeFloorPrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DerivativeFloorPrice_2_lbl" xml:lang="en-US">Floor price per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_2_lbl" xml:lang="en-US">Number of warrant issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstanding_3_lbl" xml:lang="en-US">Fair value of warrant</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Number of new shares issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_3_lbl" xml:lang="en-US">Number shares issued for service, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightUnissued" xlink:label="us-gaap_ClassOfWarrantOrRightUnissued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightUnissued" xlink:to="us-gaap_ClassOfWarrantOrRightUnissued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightUnissued_lbl" xml:lang="en-US">Issuance of pre-funded warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US">Common stock awards granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Stock option outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Rstricted stock granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Available for grant</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Share-based compensation weighted average remaining contractual term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US">Options outstanding intrinsic value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Stock option, exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1" xlink:label="GTBP_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1" xlink:to="GTBP_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1_lbl" xml:lang="en-US">Stock option, unvested compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US">Range of exercise price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xml:lang="en-US">Number of outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Warrants weighted average exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Warrants outstanding, weighted average remaining contractual life (years)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract_3_lbl" xml:lang="en-US">Schedule Of Options Activity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Number of options outstanding, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-Average Exercise Price, beginning</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_2_lbl" xml:lang="en-US">Number of options, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-Average Exercise Price, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US">Number of options, forfeited/cancelled</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-Average Exercise Price, forfeited/cancelled</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Number of options, exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-Average Exercise Price, exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Number of options outstanding, ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted-Average Exercise Price, ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xml:lang="en-US">Number of options outstanding exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-Average Exercise Price,exercisable, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_2_lbl" xml:lang="en-US">Range of excercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US">Options outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Options outstanding, weighted average remaining contractual life (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" xml:lang="en-US">Options outstanding, weighted average exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesTable_lbl" xml:lang="en-US">Loss Contingencies [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyDamagesPaidValue" xlink:label="us-gaap_LossContingencyDamagesPaidValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyDamagesPaidValue" xlink:to="us-gaap_LossContingencyDamagesPaidValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingencyDamagesPaidValue_lbl" xml:lang="en-US">Principal amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="us-gaap_LossContingencyDamagesSoughtValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyDamagesSoughtValue" xlink:to="us-gaap_LossContingencyDamagesSoughtValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingencyDamagesSoughtValue_lbl" xml:lang="en-US">Damages sought value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyDamagesSought" xlink:label="us-gaap_LossContingencyDamagesSought" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyDamagesSought" xlink:to="us-gaap_LossContingencyDamagesSought_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingencyDamagesSought_lbl" xml:lang="en-US">Owes damages excess value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US">Equity method investment, ownership percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_2_lbl" xml:lang="en-US">Research and development expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_2_lbl" xml:lang="en-US">Cash payments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_4_lbl" xml:lang="en-US">Fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xml:lang="en-US">Aggregate research and development expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:to="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_lbl" xml:lang="en-US">Payments of research and development</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xml:lang="en-US">Research and development expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnbilledReceivablesCurrent" xlink:label="us-gaap_UnbilledReceivablesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnbilledReceivablesCurrent" xlink:to="us-gaap_UnbilledReceivablesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnbilledReceivablesCurrent_lbl" xml:lang="en-US">Unbilled and unaccrued amounts</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_ProceedsFromUpfrontAmount" xlink:label="GTBP_ProceedsFromUpfrontAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ProceedsFromUpfrontAmount" xlink:to="GTBP_ProceedsFromUpfrontAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ProceedsFromUpfrontAmount_lbl" xml:lang="en-US">Proceeds from upfront amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostMaintenance" xlink:label="us-gaap_CostMaintenance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostMaintenance" xlink:to="us-gaap_CostMaintenance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostMaintenance_lbl" xml:lang="en-US">License maintenance fees</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_RoyaltyFeePercentage" xlink:label="GTBP_RoyaltyFeePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RoyaltyFeePercentage" xlink:to="GTBP_RoyaltyFeePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_RoyaltyFeePercentage_lbl" xml:lang="en-US">Royalty fee percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyExpense_lbl" xml:lang="en-US">Annual royalty payments</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_PerformanceMilestonePayments" xlink:label="GTBP_PerformanceMilestonePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_PerformanceMilestonePayments" xlink:to="GTBP_PerformanceMilestonePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_PerformanceMilestonePayments_lbl" xml:lang="en-US">Performance milestone payments</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_SalesMilestonePayments" xlink:label="GTBP_SalesMilestonePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SalesMilestonePayments" xlink:to="GTBP_SalesMilestonePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_SalesMilestonePayments_lbl" xml:lang="en-US">One-time sales milestone payments</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_GrossSales" xlink:label="GTBP_GrossSales" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_GrossSales" xlink:to="GTBP_GrossSales_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_GrossSales_lbl" xml:lang="en-US">Gross sales</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_SalesRevenue" xlink:label="GTBP_SalesRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SalesRevenue" xlink:to="GTBP_SalesRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_SalesRevenue_lbl" xml:lang="en-US">Sales revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_CummulativeGrossSales" xlink:label="GTBP_CummulativeGrossSales" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CummulativeGrossSales" xlink:to="GTBP_CummulativeGrossSales_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_CummulativeGrossSales_lbl" xml:lang="en-US">Cumulative gross sales</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_RoyaltyExpenseYearOne" xlink:label="GTBP_RoyaltyExpenseYearOne" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RoyaltyExpenseYearOne" xlink:to="GTBP_RoyaltyExpenseYearOne_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_RoyaltyExpenseYearOne_lbl" xml:lang="en-US">Royalty expense year one</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_RoyaltyExpenseYearTwoThroughFive" xlink:label="GTBP_RoyaltyExpenseYearTwoThroughFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RoyaltyExpenseYearTwoThroughFive" xlink:to="GTBP_RoyaltyExpenseYearTwoThroughFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_RoyaltyExpenseYearTwoThroughFive_lbl" xml:lang="en-US">Royalty expense years two through five</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_RoyaltyExpenseYearAfterSix" xlink:label="GTBP_RoyaltyExpenseYearAfterSix" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RoyaltyExpenseYearAfterSix" xlink:to="GTBP_RoyaltyExpenseYearAfterSix_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_RoyaltyExpenseYearAfterSix_lbl" xml:lang="en-US">Royalty expense year six and thereafter</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_UpfrontLicenseFee" xlink:label="GTBP_UpfrontLicenseFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_UpfrontLicenseFee" xlink:to="GTBP_UpfrontLicenseFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_UpfrontLicenseFee_lbl" xml:lang="en-US">Upfront license fee</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_RoyaltyExpenseYearOneThoughFour" xlink:label="GTBP_RoyaltyExpenseYearOneThoughFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RoyaltyExpenseYearOneThoughFour" xlink:to="GTBP_RoyaltyExpenseYearOneThoughFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_RoyaltyExpenseYearOneThoughFour_lbl" xml:lang="en-US">Royalty expense year one though four</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_RoyaltyExpenseYearAfterFive" xlink:label="GTBP_RoyaltyExpenseYearAfterFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RoyaltyExpenseYearAfterFive" xlink:to="GTBP_RoyaltyExpenseYearAfterFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_RoyaltyExpenseYearAfterFive_lbl" xml:lang="en-US">Royalty expense year five and thereafter</link:label>
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_ContigencyMinimumRequired" xlink:label="GTBP_ContigencyMinimumRequired" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ContigencyMinimumRequired" xlink:to="GTBP_ContigencyMinimumRequired_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_ContigencyMinimumRequired_lbl" xml:lang="en-US">Contigency minimum required</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalariesAndWages" xlink:label="us-gaap_SalariesAndWages" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalariesAndWages" xlink:to="us-gaap_SalariesAndWages_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalariesAndWages_lbl" xml:lang="en-US">Salaries</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InsuranceCommissions" xlink:label="us-gaap_InsuranceCommissions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InsuranceCommissions" xlink:to="us-gaap_InsuranceCommissions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InsuranceCommissions_lbl" xml:lang="en-US">Insurance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Operating expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Other income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US">Number of reportable segments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US">Number of operating segments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_2_lbl" xml:lang="en-US">Shares converted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_2_lbl" xml:lang="en-US">Number of shares converted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_WarrantLiabilityCurrent" xlink:to="GTBP_WarrantLiabilityCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_WarrantLiabilityCurrent_doc" xml:lang="en-US">Warrant liability current.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SeriesLPreferredStockMember" xlink:to="GTBP_SeriesLPreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_SeriesLPreferredStockMember_doc" xml:lang="en-US">Series L Preferred Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_OfficersEmployeesAndDirectorsMember" xlink:to="GTBP_OfficersEmployeesAndDirectorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_OfficersEmployeesAndDirectorsMember_doc" xml:lang="en-US">Officers, Employees and Directors [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_MezzanineEquityMember" xlink:to="GTBP_MezzanineEquityMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_MezzanineEquityMember_doc" xml:lang="en-US">Mezzanine Equity [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet" xlink:to="GTBP_StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet_doc" xml:lang="en-US">Exercise of warrants for cash and inducement warrants, net, value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable" xlink:to="GTBP_StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable_doc" xml:lang="en-US">Issuance of prefunded warrant to settle vendor payable, value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee" xlink:to="GTBP_StockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_StockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee_doc" xml:lang="en-US">Stock issued during period value issuance and exercise of prefunded warrants for eloc fee</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodValueMezzanineEquityReclassification" xlink:to="GTBP_StockIssuedDuringPeriodValueMezzanineEquityReclassification_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_StockIssuedDuringPeriodValueMezzanineEquityReclassification_doc" xml:lang="en-US">Mezzanine equity reclassification, value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodSharesMezzanineEquityReclassification" xlink:to="GTBP_StockIssuedDuringPeriodSharesMezzanineEquityReclassification_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_StockIssuedDuringPeriodSharesMezzanineEquityReclassification_doc" xml:lang="en-US">Mezzanine equity reclassification, shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet" xlink:to="GTBP_StockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_StockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet_doc" xml:lang="en-US">Exercise of warrants for cash and inducement warrants, net, shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodSharesIssuanceAndExerciseOfPrefundedWarrantsForElocFee" xlink:to="GTBP_StockIssuedDuringPeriodSharesIssuanceAndExerciseOfPrefundedWarrantsForElocFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_StockIssuedDuringPeriodSharesIssuanceAndExerciseOfPrefundedWarrantsForElocFee_doc" xml:lang="en-US">Issuance and exercise of prefunded warrants for ELOC fee, shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash" xlink:to="GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash_doc" xml:lang="en-US">Stock issued during period value issuance of common stock and warrants for cash</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable" xlink:to="GTBP_StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable_doc" xml:lang="en-US">Stock issued during period value common shares to settle vendor payable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodShareIssuanceOfCommonStockAndWarrantsForCash" xlink:to="GTBP_StockIssuedDuringPeriodShareIssuanceOfCommonStockAndWarrantsForCash_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_StockIssuedDuringPeriodShareIssuanceOfCommonStockAndWarrantsForCash_doc" xml:lang="en-US">Stock issued during period share issuance of common stock and warrants for cash</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable" xlink:to="GTBP_StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable_doc" xml:lang="en-US">Stock issued during period shares common shares to settle vendor payable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_IssuanceOfWarrantsForVrtWaiver" xlink:to="GTBP_IssuanceOfWarrantsForVrtWaiver_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_IssuanceOfWarrantsForVrtWaiver_doc" xml:lang="en-US">Issuance of warrants for vrt waiver.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_GainOnSettlementOfDebt" xlink:to="GTBP_GainOnSettlementOfDebt_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_GainOnSettlementOfDebt_doc" xml:lang="en-US">Gain on settlement of debt.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CashPaidDuringYearFor" xlink:to="GTBP_CashPaidDuringYearFor_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_CashPaidDuringYearFor_doc" xml:lang="en-US">Cash paid during year for</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_FairValueOfPrefundedWarrantsIssuedForElocFee" xlink:to="GTBP_FairValueOfPrefundedWarrantsIssuedForElocFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_FairValueOfPrefundedWarrantsIssuedForElocFee_doc" xml:lang="en-US">Fair value of prefunded warrants issued for eloc fee.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_IncreaseDecreaseInOperatingLeaseRightofuseAssets" xlink:to="GTBP_IncreaseDecreaseInOperatingLeaseRightofuseAssets_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_IncreaseDecreaseInOperatingLeaseRightofuseAssets_doc" xml:lang="en-US">Decrease in operating lease right-of-use assets.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_FairValueOfSeriesLConvertiblePreferredStockVestedWarrants" xlink:to="GTBP_FairValueOfSeriesLConvertiblePreferredStockVestedWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_FairValueOfSeriesLConvertiblePreferredStockVestedWarrants_doc" xml:lang="en-US">Fair value of Series L convertible preferred stock vested warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_FairValueOfPrefundedWarrantAndCommonStockToSettleVendorPayable" xlink:to="GTBP_FairValueOfPrefundedWarrantAndCommonStockToSettleVendorPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_FairValueOfPrefundedWarrantAndCommonStockToSettleVendorPayable_doc" xml:lang="en-US">Fair value of prefunded warrant and common stock to settle vendor payable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_DividendDeclaredOnSeriesLConvertiblePreferredStock" xlink:to="GTBP_DividendDeclaredOnSeriesLConvertiblePreferredStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_DividendDeclaredOnSeriesLConvertiblePreferredStock_doc" xml:lang="en-US">Dividend declared on Series L convertible preferred stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_WarrantLiabilityPolicyTextBlock" xlink:to="GTBP_WarrantLiabilityPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_WarrantLiabilityPolicyTextBlock_doc" xml:lang="en-US">Warrant Liability [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_MezzanineEquityPolicyTextBlock" xlink:to="GTBP_MezzanineEquityPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_MezzanineEquityPolicyTextBlock_doc" xml:lang="en-US">Mezzanine Equity [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CytovanceBiologicsIncMember" xlink:to="GTBP_CytovanceBiologicsIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_CytovanceBiologicsIncMember_doc" xml:lang="en-US">Cytovance Biologics Inc [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_UniversityOfMinnesotaMember" xlink:to="GTBP_UniversityOfMinnesotaMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_UniversityOfMinnesotaMember_doc" xml:lang="en-US">University of Minnesota [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_LegalServicesFirmMember" xlink:to="GTBP_LegalServicesFirmMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_LegalServicesFirmMember_doc" xml:lang="en-US">Legal Services Firm [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_OtherAccountsPayableMember" xlink:to="GTBP_OtherAccountsPayableMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_OtherAccountsPayableMember_doc" xml:lang="en-US">Other Accounts Payable [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock" xlink:to="GTBP_ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock_doc" xml:lang="en-US">Schedule of Accounts Payable and Related Party [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RepaymentsOfPrefundedWarrantsAtFairValue" xlink:to="GTBP_RepaymentsOfPrefundedWarrantsAtFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_RepaymentsOfPrefundedWarrantsAtFairValue_doc" xml:lang="en-US">Repayments of prefunded warrants at fair value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_AdvisoryAgreementMember" xlink:to="GTBP_AdvisoryAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_AdvisoryAgreementMember_doc" xml:lang="en-US">Advisory Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_WarrantLiabilityTextBlock" xlink:to="GTBP_WarrantLiabilityTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_WarrantLiabilityTextBlock_doc" xml:lang="en-US">Warrant Liability [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandTwentyThreeCommonWarrantsMember" xlink:to="GTBP_TwoThousandTwentyThreeCommonWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_TwoThousandTwentyThreeCommonWarrantsMember_doc" xml:lang="en-US">2023 Common Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandTwentyThreePlacementAgentsWarrantsMember" xlink:to="GTBP_TwoThousandTwentyThreePlacementAgentsWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_TwoThousandTwentyThreePlacementAgentsWarrantsMember_doc" xml:lang="en-US">2023 Placement Agents Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandTwentyThreeWarrantsMember" xlink:to="GTBP_TwoThousandTwentyThreeWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_TwoThousandTwentyThreeWarrantsMember_doc" xml:lang="en-US">2023 Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ExtinguishmentOfWarrant" xlink:to="GTBP_ExtinguishmentOfWarrant_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ExtinguishmentOfWarrant_doc" xml:lang="en-US">Extinguishment of warrant.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_PurchaseAgreementMember" xlink:to="GTBP_PurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_PurchaseAgreementMember_doc" xml:lang="en-US">Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_WeightedAverageVolumePriceOfCommonStockPercentage" xlink:to="GTBP_WeightedAverageVolumePriceOfCommonStockPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_WeightedAverageVolumePriceOfCommonStockPercentage_doc" xml:lang="en-US">Weighted average volume price of common stock percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non options exercisable number.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_InducementWarrantsMember" xlink:to="GTBP_InducementWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_InducementWarrantsMember_doc" xml:lang="en-US">Inducement Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SeriesAInducementWarrantsMember" xlink:to="GTBP_SeriesAInducementWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_SeriesAInducementWarrantsMember_doc" xml:lang="en-US">Series A Inducement Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SeriesBInducementWarrantsMember" xlink:to="GTBP_SeriesBInducementWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_SeriesBInducementWarrantsMember_doc" xml:lang="en-US">Series B Inducement Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SecuritiesPurchaseAgreementMember" xlink:to="GTBP_SecuritiesPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_SecuritiesPurchaseAgreementMember_doc" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SeriesLTenPercentConvertiblePreferredStockMember" xlink:to="GTBP_SeriesLTenPercentConvertiblePreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_SeriesLTenPercentConvertiblePreferredStockMember_doc" xml:lang="en-US">Series L 10% Convertible Preferred Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_AggregateStatedValue" xlink:to="GTBP_AggregateStatedValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_AggregateStatedValue_doc" xml:lang="en-US">Aggregate stated value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_GreenshoeRightsMember" xlink:to="GTBP_GreenshoeRightsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_GreenshoeRightsMember_doc" xml:lang="en-US">Greenshoe Rights [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CommonWarrantsMember" xlink:to="GTBP_CommonWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_CommonWarrantsMember_doc" xml:lang="en-US">Common Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_VestingWarrantsMember" xlink:to="GTBP_VestingWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_VestingWarrantsMember_doc" xml:lang="en-US">Vesting Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_LiableOfLiquidatedDamagePercentageDescription" xlink:to="GTBP_LiableOfLiquidatedDamagePercentageDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_LiableOfLiquidatedDamagePercentageDescription_doc" xml:lang="en-US">Liable of liquidated damage percentage, description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CommonStockSharesOutstandingPercentage" xlink:to="GTBP_CommonStockSharesOutstandingPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_CommonStockSharesOutstandingPercentage_doc" xml:lang="en-US">Common stock shares outstanding percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SeriesL10PercentageConvertiblePreferredStockMember" xlink:to="GTBP_SeriesL10PercentageConvertiblePreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_SeriesL10PercentageConvertiblePreferredStockMember_doc" xml:lang="en-US">Series L 10% Convertible Preferred Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_PreferredStockPurchasePrice" xlink:to="GTBP_PreferredStockPurchasePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_PreferredStockPurchasePrice_doc" xml:lang="en-US">Preferred stock purchase price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SeriesLConvertiblePreferredStockMember" xlink:to="GTBP_SeriesLConvertiblePreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_SeriesLConvertiblePreferredStockMember_doc" xml:lang="en-US">Series L Convertible Preferred Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ConvertiblePreferredStockAndWarrantsFairValuePercentage" xlink:to="GTBP_ConvertiblePreferredStockAndWarrantsFairValuePercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ConvertiblePreferredStockAndWarrantsFairValuePercentage_doc" xml:lang="en-US">Convertible preferred stock and warrants fair value percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ConvertiblePreferredStockAndWarrantsNetProceedsPercentage" xlink:to="GTBP_ConvertiblePreferredStockAndWarrantsNetProceedsPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ConvertiblePreferredStockAndWarrantsNetProceedsPercentage_doc" xml:lang="en-US">Convertible preferred stock and warrants net proceeds percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CommonStockWarrantsAndOptionsTextBlock" xlink:to="GTBP_CommonStockWarrantsAndOptionsTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_CommonStockWarrantsAndOptionsTextBlock_doc" xml:lang="en-US">Common Stock Warrants and Options [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_doc" xml:lang="en-US">Share Based Compensation Arrangements By Share Based Payment Award Non Options Equity Instruments Exercisable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangements by share based payment award non options outstanding weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non options granted weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non options forfeitures and expirations weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non options exercised weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_doc" xml:lang="en-US">Share Based Compensation Arrangement By ShareBased Payment Award Non Options Exercisable Weighted Average Exercise Price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedPursuantToFullRatchetPriceProtection" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedPursuantToFullRatchetPriceProtection_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedPursuantToFullRatchetPriceProtection_doc" xml:lang="en-US">Granted pursuant to full ratchet price protection, shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedPursuantToFullRatchetPriceProtectionWeightedAverageExercisePrice" xlink:to="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedPursuantToFullRatchetPriceProtectionWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedPursuantToFullRatchetPriceProtectionWeightedAverageExercisePrice_doc" xml:lang="en-US">Granted pursuant to full ratchet price protection, weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_PrefundedWarrantsMember" xlink:to="GTBP_PrefundedWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_PrefundedWarrantsMember_doc" xml:lang="en-US">Prefunded Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_WarrantsMember" xlink:to="GTBP_WarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_WarrantsMember_doc" xml:lang="en-US">Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ScheduleOfWarrantsOustandingAndExercisableTableTextBlock" xlink:to="GTBP_ScheduleOfWarrantsOustandingAndExercisableTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ScheduleOfWarrantsOustandingAndExercisableTableTextBlock_doc" xml:lang="en-US">Schedule of Warrants Oustanding and Exercisable [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeOneMember" xlink:to="GTBP_RangeOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_RangeOneMember_doc" xml:lang="en-US">Range of Exercise Price One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeTwoMember" xlink:to="GTBP_RangeTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_RangeTwoMember_doc" xml:lang="en-US">Range of Exercise Price Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeThreeMember" xlink:to="GTBP_RangeThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_RangeThreeMember_doc" xml:lang="en-US">Range of Exercise Price Three [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeFourMember" xlink:to="GTBP_RangeFourMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_RangeFourMember_doc" xml:lang="en-US">Range of Exercise Price Four [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeFiveMember" xlink:to="GTBP_RangeFiveMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_RangeFiveMember_doc" xml:lang="en-US">Range of Exercise Price Five [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeSixMember" xlink:to="GTBP_RangeSixMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_RangeSixMember_doc" xml:lang="en-US">Range of Exercise Price Six [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeSevenMember" xlink:to="GTBP_RangeSevenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_RangeSevenMember_doc" xml:lang="en-US">Range of Exercise Price Seven [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeEightMember" xlink:to="GTBP_RangeEightMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_RangeEightMember_doc" xml:lang="en-US">Range of Exercise Price Eight [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeNineMember" xlink:to="GTBP_RangeNineMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_RangeNineMember_doc" xml:lang="en-US">Range of Exercise Price Nine [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeTenMember" xlink:to="GTBP_RangeTenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_RangeTenMember_doc" xml:lang="en-US">Range of Exercise Price Ten [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeElevenMember" xlink:to="GTBP_RangeElevenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_RangeElevenMember_doc" xml:lang="en-US">Range of Exercise Price Eleven [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeTwelveMember" xlink:to="GTBP_RangeTwelveMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_RangeTwelveMember_doc" xml:lang="en-US">Range of Exercise Price Twelve [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RangeThirteenMember" xlink:to="GTBP_RangeThirteenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_RangeThirteenMember_doc" xml:lang="en-US">Range of Exercise Price Thirteen [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_OmnibusIncentivePlanMember" xlink:to="GTBP_OmnibusIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_OmnibusIncentivePlanMember_doc" xml:lang="en-US">2022 Omnibus Incentive Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1" xlink:to="GTBP_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award options non vested in period fair value 1.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ZOneLLCMember" xlink:to="GTBP_ZOneLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ZOneLLCMember_doc" xml:lang="en-US">Z One LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CobySilberfeinMember" xlink:to="GTBP_CobySilberfeinMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_CobySilberfeinMember_doc" xml:lang="en-US">Coby Silberfein [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandTwentyThreeSponsoredResearchAgreementMember" xlink:to="GTBP_TwoThousandTwentyThreeSponsoredResearchAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_TwoThousandTwentyThreeSponsoredResearchAgreementMember_doc" xml:lang="en-US">2023 Sponsored Research Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ProceedsFromUpfrontAmount" xlink:to="GTBP_ProceedsFromUpfrontAmount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ProceedsFromUpfrontAmount_doc" xml:lang="en-US">Received upfront payment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandSixteenPatentLicenseAgreementMember" xlink:to="GTBP_TwoThousandSixteenPatentLicenseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_TwoThousandSixteenPatentLicenseAgreementMember_doc" xml:lang="en-US">2016 Patent License Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandSeventeenThroughTwoThousandTwentyMember" xlink:to="GTBP_TwoThousandSeventeenThroughTwoThousandTwentyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_TwoThousandSeventeenThroughTwoThousandTwentyMember_doc" xml:lang="en-US">2017 through 2020 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RoyaltyFeePercentage" xlink:to="GTBP_RoyaltyFeePercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_RoyaltyFeePercentage_doc" xml:lang="en-US">Royalty fee percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandTwentyTwoMember" xlink:to="GTBP_TwoThousandTwentyTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_TwoThousandTwentyTwoMember_doc" xml:lang="en-US">Beginning in 2022 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandTwentyFiveMember" xlink:to="GTBP_TwoThousandTwentyFiveMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_TwoThousandTwentyFiveMember_doc" xml:lang="en-US">Beginning in 2025 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandTwentySevenMember" xlink:to="GTBP_TwoThousandTwentySevenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_TwoThousandTwentySevenMember_doc" xml:lang="en-US">Beginning in 2027 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_PerformanceMilestonePayments" xlink:to="GTBP_PerformanceMilestonePayments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_PerformanceMilestonePayments_doc" xml:lang="en-US">Performance milestone payments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SalesMilestonePayments" xlink:to="GTBP_SalesMilestonePayments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_SalesMilestonePayments_doc" xml:lang="en-US">Sales milestone payments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_GrossSales" xlink:to="GTBP_GrossSales_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_GrossSales_doc" xml:lang="en-US">Gross sales.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SalesRevenue" xlink:to="GTBP_SalesRevenue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_SalesRevenue_doc" xml:lang="en-US">Sales revenue.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_CummulativeGrossSales" xlink:to="GTBP_CummulativeGrossSales_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_CummulativeGrossSales_doc" xml:lang="en-US">Cummulative gross sales.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RoyaltyExpenseYearOne" xlink:to="GTBP_RoyaltyExpenseYearOne_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_RoyaltyExpenseYearOne_doc" xml:lang="en-US">Royalty expense year one.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RoyaltyExpenseYearTwoThroughFive" xlink:to="GTBP_RoyaltyExpenseYearTwoThroughFive_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_RoyaltyExpenseYearTwoThroughFive_doc" xml:lang="en-US">Royalty expense year two through five.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RoyaltyExpenseYearAfterSix" xlink:to="GTBP_RoyaltyExpenseYearAfterSix_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_RoyaltyExpenseYearAfterSix_doc" xml:lang="en-US">Royalty expense year after six.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_UpfrontLicenseFee" xlink:to="GTBP_UpfrontLicenseFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_UpfrontLicenseFee_doc" xml:lang="en-US">Upfront license fee.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember" xlink:to="GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember_doc" xml:lang="en-US">2021 Patent License Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RoyaltyExpenseYearOneThoughFour" xlink:to="GTBP_RoyaltyExpenseYearOneThoughFour_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_RoyaltyExpenseYearOneThoughFour_doc" xml:lang="en-US">Royalty expense year one though four.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_RoyaltyExpenseYearAfterFive" xlink:to="GTBP_RoyaltyExpenseYearAfterFive_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_RoyaltyExpenseYearAfterFive_doc" xml:lang="en-US">Royalty expense year five and thereafter.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember" xlink:to="GTBP_TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember_doc" xml:lang="en-US">2024 GTB-3650 Clinical Trial Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ContigencyMinimumRequired" xlink:to="GTBP_ContigencyMinimumRequired_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ContigencyMinimumRequired_doc" xml:lang="en-US">Contigency minimum required.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SegmentsMember" xlink:to="GTBP_SegmentsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_SegmentsMember_doc" xml:lang="en-US">Segments [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_ClassOfWarrantsPurchaseUpPercentage" xlink:to="GTBP_ClassOfWarrantsPurchaseUpPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="GTBP_ClassOfWarrantsPurchaseUpPercentage_doc" xml:lang="en-US">Warrants purchase up percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_SeriesL10PercentageConvertiblePreferredStockMember" xlink:to="GTBP_SeriesL10PercentageConvertiblePreferredStockMember_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_SeriesL10PercentageConvertiblePreferredStockMember_3_lbl" xml:lang="en-US">Series L 10% Convertible Preferred Stock [Member] [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_3_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact_2_lbl" xml:lang="en-US">Preferred Stock Dividends, Income Statement Impact</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2_lbl" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_3_lbl" xml:lang="en-US">Temporary Equity, Shares Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_3_lbl" xml:lang="en-US">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPreferredStock" xlink:to="us-gaap_DividendsPreferredStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPreferredStock_2_lbl" xml:lang="en-US">Dividends, Preferred Stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited_2_lbl" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_2_lbl" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_IssuanceOfWarrantsForVrtWaiver" xlink:to="GTBP_IssuanceOfWarrantsForVrtWaiver_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_IssuanceOfWarrantsForVrtWaiver_3_lbl" xml:lang="en-US">Issuance of warrants for vrt waiver</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_GainOnSettlementOfDebt" xlink:to="GTBP_GainOnSettlementOfDebt_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_GainOnSettlementOfDebt_3_lbl" xml:lang="en-US">GainOnSettlementOfDebt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesUnrealizedGainLoss" xlink:to="us-gaap_DebtSecuritiesUnrealizedGainLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesUnrealizedGainLoss_2_lbl" xml:lang="en-US">Debt Securities, Unrealized Gain (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_IncreaseDecreaseInOperatingLeaseRightofuseAssets" xlink:to="GTBP_IncreaseDecreaseInOperatingLeaseRightofuseAssets_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_IncreaseDecreaseInOperatingLeaseRightofuseAssets_3_lbl" xml:lang="en-US">IncreaseDecreaseInOperatingLeaseRightofuseAssets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_3_lbl" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromInvestments" xlink:to="us-gaap_PaymentsForProceedsFromInvestments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForProceedsFromInvestments_2_lbl" xml:lang="en-US">Payments for (Proceeds from) Investments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDividends" xlink:to="us-gaap_PaymentsOfDividends_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDividends_2_lbl" xml:lang="en-US">Payments of Dividends</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryIndName_2_lbl" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryIndName_2_lbl" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndName_2_lbl" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_WarrantLiabilityTextBlock" xlink:to="GTBP_WarrantLiabilityTextBlock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_WarrantLiabilityTextBlock_3_lbl" xml:lang="en-US">Warrant Liability [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_2_lbl" xml:lang="en-US">Equity [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GTBP_WarrantLiabilityPolicyTextBlock" xlink:to="GTBP_WarrantLiabilityPolicyTextBlock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="GTBP_WarrantLiabilityPolicyTextBlock_3_lbl" xml:lang="en-US">Warrant Liability [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_2_lbl" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableTradeCurrent_4_lbl" xml:lang="en-US">Accounts Payable, Trade, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_2_lbl" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightUnissued" xlink:to="us-gaap_ClassOfWarrantOrRightUnissued_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightUnissued_2_lbl" xml:lang="en-US">Class of Warrant or Right, Unissued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_2_lbl" xml:lang="en-US">Other Research and Development Expense</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>16
<FILENAME>gtbp-20250930_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#Cover" roleURI="http://gtbiopharma.com/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#BalanceSheets" roleURI="http://gtbiopharma.com/role/BalanceSheets" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#BalanceSheetsParenthetical" roleURI="http://gtbiopharma.com/role/BalanceSheetsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#StatementsOfOperations" roleURI="http://gtbiopharma.com/role/StatementsOfOperations" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#StatementsOfOperationsParenthetical" roleURI="http://gtbiopharma.com/role/StatementsOfOperationsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#StatementsOfStockholdersEquityDeficitAndMezzanineEquity" roleURI="http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#StatementsOfCashFlows" roleURI="http://gtbiopharma.com/role/StatementsOfCashFlows" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#OrganizationAndGoingConcernAnalysis" roleURI="http://gtbiopharma.com/role/OrganizationAndGoingConcernAnalysis" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#AccountsPayableAndRelatedParty" roleURI="http://gtbiopharma.com/role/AccountsPayableAndRelatedParty" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#WarrantLiability" roleURI="http://gtbiopharma.com/role/WarrantLiability" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#StockholdersEquityDeficit" roleURI="http://gtbiopharma.com/role/StockholdersEquityDeficit" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#CommonStockWarrantsAndOptions" roleURI="http://gtbiopharma.com/role/CommonStockWarrantsAndOptions" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#CommitmentsAndContingencies" roleURI="http://gtbiopharma.com/role/CommitmentsAndContingencies" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#SegmentInformation" roleURI="http://gtbiopharma.com/role/SegmentInformation" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#SubsequentEvents" roleURI="http://gtbiopharma.com/role/SubsequentEvents" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#AccountsPayableAndRelatedPartyTables" roleURI="http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyTables" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#WarrantLiabilityTables" roleURI="http://gtbiopharma.com/role/WarrantLiabilityTables" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#StockholdersEquityDeficitTables" roleURI="http://gtbiopharma.com/role/StockholdersEquityDeficitTables" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#CommonStockWarrantsAndOptionsTables" roleURI="http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsTables" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#SegmentInformationTables" roleURI="http://gtbiopharma.com/role/SegmentInformationTables" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#OrganizationAndGoingConcernAnalysisDetailsNarrative" roleURI="http://gtbiopharma.com/role/OrganizationAndGoingConcernAnalysisDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#ScheduleOfAnti-dilutiveSecuritiesDetails" roleURI="http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#ScheduleOfAnti-dilutiveSecuritiesDetailsParenthetical" roleURI="http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetailsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" roleURI="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#ScheduleOfAccountsPayableDetails" roleURI="http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#ScheduleOfAccountsPayableToRelatedPartyDetails" roleURI="http://gtbiopharma.com/role/ScheduleOfAccountsPayableToRelatedPartyDetails" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#AccountsPayableAndRelatedPartyDetailsNarrative" roleURI="http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#WarrantLiabilityDetailsNarrative" roleURI="http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#ScheduleOfWarrantLiabilityAssumptionsDetails" roleURI="http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#ScheduleOfWarrantLiabilityTransactionsDetails" roleURI="http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityTransactionsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#ScheduleOfFairValuesAndAllocationOfNetProceedsDetails" roleURI="http://gtbiopharma.com/role/ScheduleOfFairValuesAndAllocationOfNetProceedsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#StockholdersEquityDeficitDetailsNarrative" roleURI="http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#ScheduleOfWarrantActivityDetails" roleURI="http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#CommonStockWarrantsAndOptionsDetailsNarrative" roleURI="http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#ScheduleOfWarrantsOutstandingAndExercisableDetails" roleURI="http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#ScheduleOfOptionsActivityDetails" roleURI="http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#ScheduleOfOptionsOutstandingAndOptionsExercisableDetails" roleURI="http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#CommitmentsAndContingenciesDetailsNarrative" roleURI="http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#ScheduleOfSegmentInformationDetails" roleURI="http://gtbiopharma.com/role/ScheduleOfSegmentInformationDetails" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#SegmentInformationDetailsNarrative" roleURI="http://gtbiopharma.com/role/SegmentInformationDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="gtbp-20250930.xsd#SubsequentEventsDetailsNarrative" roleURI="http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ErrCompDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardTimingDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangements" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingPoliciesProc" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" />
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_SeriesLPreferredStockMember" xlink:label="loc_GTBPSeriesLPreferredStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_GTBPSeriesLPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaapRestrictedCashCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapRestrictedCashCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaapDeferredOfferingCosts" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapDeferredOfferingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsPayableCurrent" xlink:label="loc_us-gaapDividendsPayableCurrent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDividendsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_WarrantLiabilityCurrent" xlink:label="loc_GTBPWarrantLiabilityCurrent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_GTBPWarrantLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_SeriesLPreferredStockMember" xlink:label="loc_GTBPSeriesLPreferredStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_GTBPSeriesLPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Statements of Operations (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaapInterestIncomeOther" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestIncomeOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaapPreferredStockDividendsIncomeStatementImpact" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapPreferredStockDividendsIncomeStatementImpact" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfOperationsParenthetical" xlink:title="00000005 - Statement - Condensed Statements of Operations (Unaudited) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpensesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_OfficersEmployeesAndDirectorsMember" xlink:label="loc_GTBPOfficersEmployeesAndDirectorsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_GTBPOfficersEmployeesAndDirectorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity" xlink:title="00000006 - Statement - Condensed Statements of Stockholders&apos; Equity (Deficit) and Mezzanine Equity  (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_MezzanineEquityMember" xlink:label="loc_GTBPMezzanineEquityMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_GTBPMezzanineEquityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapSeriesCPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_SeriesLPreferredStockMember" xlink:label="loc_GTBPSeriesLPreferredStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_GTBPSeriesLPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaapTemporaryEquitySharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquitySharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaapTemporaryEquityCarryingAmountAttributableToParent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquityCarryingAmountAttributableToParent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_StockIssuedDuringPeriodValueMezzanineEquityReclassification" xlink:label="loc_GTBPStockIssuedDuringPeriodValueMezzanineEquityReclassification" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodValueMezzanineEquityReclassification" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_StockIssuedDuringPeriodSharesMezzanineEquityReclassification" xlink:label="loc_GTBPStockIssuedDuringPeriodSharesMezzanineEquityReclassification" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodSharesMezzanineEquityReclassification" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsPreferredStock" xlink:label="loc_us-gaapDividendsPreferredStock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDividendsPreferredStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet" xlink:label="loc_GTBPStockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_StockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet" xlink:label="loc_GTBPStockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable" xlink:label="loc_GTBPStockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_StockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee" xlink:label="loc_GTBPStockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_StockIssuedDuringPeriodSharesIssuanceAndExerciseOfPrefundedWarrantsForElocFee" xlink:label="loc_GTBPStockIssuedDuringPeriodSharesIssuanceAndExerciseOfPrefundedWarrantsForElocFee" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodSharesIssuanceAndExerciseOfPrefundedWarrantsForElocFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash" xlink:label="loc_GTBPStockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensationForfeited" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable" xlink:label="loc_GTBPStockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_StockIssuedDuringPeriodShareIssuanceOfCommonStockAndWarrantsForCash" xlink:label="loc_GTBPStockIssuedDuringPeriodShareIssuanceOfCommonStockAndWarrantsForCash" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodShareIssuanceOfCommonStockAndWarrantsForCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensationForfeited" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable" xlink:label="loc_GTBPStockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaapTemporaryEquitySharesOutstanding_2" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquitySharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaapTemporaryEquityCarryingAmountAttributableToParent_2" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquityCarryingAmountAttributableToParent_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Condensed Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_IssuanceOfWarrantsForVrtWaiver" xlink:label="loc_GTBPIssuanceOfWarrantsForVrtWaiver" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_GTBPIssuanceOfWarrantsForVrtWaiver" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_GainOnSettlementOfDebt" xlink:label="loc_GTBPGainOnSettlementOfDebt" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_GTBPGainOnSettlementOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesUnrealizedGainLoss" xlink:label="loc_us-gaapDebtSecuritiesUnrealizedGainLoss" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDebtSecuritiesUnrealizedGainLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_IncreaseDecreaseInOperatingLeaseRightofuseAssets" xlink:label="loc_GTBPIncreaseDecreaseInOperatingLeaseRightofuseAssets" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_GTBPIncreaseDecreaseInOperatingLeaseRightofuseAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForProceedsFromInvestments" xlink:label="loc_us-gaapPaymentsForProceedsFromInvestments" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsForProceedsFromInvestments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfConvertiblePreferredStock" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDividends" xlink:label="loc_us-gaapPaymentsOfDividends" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsOfDividends" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_CashPaidDuringYearFor" xlink:label="loc_GTBPCashPaidDuringYearFor" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_GTBPCashPaidDuringYearFor" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaapInterestPaid" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPCashPaidDuringYearFor" xlink:to="loc_us-gaapInterestPaid" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPCashPaidDuringYearFor" xlink:to="loc_us-gaapIncomeTaxesPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_FairValueOfSeriesLConvertiblePreferredStockVestedWarrants" xlink:label="loc_GTBPFairValueOfSeriesLConvertiblePreferredStockVestedWarrants" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_GTBPFairValueOfSeriesLConvertiblePreferredStockVestedWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_FairValueOfPrefundedWarrantsIssuedForElocFee" xlink:label="loc_GTBPFairValueOfPrefundedWarrantsIssuedForElocFee" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_GTBPFairValueOfPrefundedWarrantsIssuedForElocFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaapStockIssued1" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_us-gaapStockIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_FairValueOfPrefundedWarrantAndCommonStockToSettleVendorPayable" xlink:label="loc_GTBPFairValueOfPrefundedWarrantAndCommonStockToSettleVendorPayable" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_GTBPFairValueOfPrefundedWarrantAndCommonStockToSettleVendorPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_DividendDeclaredOnSeriesLConvertiblePreferredStock" xlink:label="loc_GTBPDividendDeclaredOnSeriesLConvertiblePreferredStock" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_GTBPDividendDeclaredOnSeriesLConvertiblePreferredStock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:title="995410 - Disclosure - Pay vs Performance Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PayVsPerformanceDisclosureLineItems" xlink:label="loc_ecdPayVsPerformanceDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable" xlink:label="loc_ecdPvpTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis" xlink:label="loc_ecdExecutiveCategoryAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdExecutiveCategoryAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllExecutiveCategoriesMember" xlink:label="loc_ecdAllExecutiveCategoriesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdExecutiveCategoryAxis" xlink:to="loc_ecdAllExecutiveCategoriesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis" xlink:label="loc_ecdAdjToCompAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdAdjToCompAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllAdjToCompMember" xlink:label="loc_ecdAllAdjToCompMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAdjToCompAxis" xlink:to="loc_ecdAllAdjToCompMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis" xlink:label="loc_ecdMeasureAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdMeasureAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock" xlink:label="loc_ecdPvpTableTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName" xlink:label="loc_ecdCoSelectedMeasureName" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdCoSelectedMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="loc_ecdNamedExecutiveOfficersFnTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdNamedExecutiveOfficersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="loc_ecdPeerGroupIssuersFnTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeerGroupIssuersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="loc_ecdChangedPeerGroupFnTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdChangedPeerGroupFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt" xlink:label="loc_ecdPeoTotalCompAmt" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="loc_ecdPeoActuallyPaidCompAmt" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoActuallyPaidCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="loc_ecdAdjToPeoCompFnTextBlock" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdAdjToPeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="loc_ecdNonPeoNeoAvgTotalCompAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="loc_ecdAdjToNonPeoNeoCompFnTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdAdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:presentationArc order="2140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" />
      <link:presentationArc order="2150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" />
      <link:presentationArc order="2160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock" xlink:label="loc_ecdTabularListTableTextBlock" />
      <link:presentationArc order="2170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTabularListTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt" xlink:label="loc_ecdTotalShareholderRtnAmt" />
      <link:presentationArc order="2180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="loc_ecdPeerGroupTotalShareholderRtnAmt" />
      <link:presentationArc order="2190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdPeerGroupTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="2200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt" xlink:label="loc_ecdCoSelectedMeasureAmt" />
      <link:presentationArc order="2210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdCoSelectedMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt" xlink:label="loc_ecdOtherPerfMeasureAmt" />
      <link:presentationArc order="2220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdOtherPerfMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt" xlink:label="loc_ecdAdjToCompAmt" />
      <link:presentationArc order="2230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdAdjToCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName" xlink:label="loc_ecdPeoName" />
      <link:presentationArc order="2240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdPeoName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName" xlink:label="loc_ecdMeasureName" />
      <link:presentationArc order="2250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="loc_ecdNonGaapMeasureDescriptionTextBlock" />
      <link:presentationArc order="2260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdMeasureName" xlink:to="loc_ecdNonGaapMeasureDescriptionTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="loc_ecdAdditional402vDisclosureTextBlock" />
      <link:presentationArc order="2270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdAdditional402vDisclosureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="loc_ecdPnsnBnftsAdjFnTextBlock" />
      <link:presentationArc order="2280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPnsnBnftsAdjFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock" xlink:label="loc_ecdEqtyAwrdsAdjFnTextBlock" />
      <link:presentationArc order="2290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdEqtyAwrdsAdjFnTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:title="995440 - Disclosure - Recovery of Erroneously Awarded Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RecoveryOfErrCompDisclosureLineItems" xlink:label="loc_ecdRecoveryOfErrCompDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable" xlink:label="loc_ecdErrCompRecoveryTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdErrCompRecoveryTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis" xlink:label="loc_ecdRestatementDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdRestatementDateAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate" xlink:label="loc_ecdRestatementDeterminationDate" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdRestatementDeterminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt" xlink:label="loc_ecdAggtErrCompAmt" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="loc_ecdErrCompAnalysisTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdErrCompAnalysisTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="loc_ecdOutstandingAggtErrCompAmt" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdOutstandingAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="loc_ecdAggtErrCompNotYetDeterminedTextBlock" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdAggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName" xlink:label="loc_ecdForgoneRecoveryIndName" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName" xlink:label="loc_ecdOutstandingRecoveryIndName" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="loc_ecdOutstandingRecoveryCompAmt" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:title="995443 - Disclosure - Award Timing Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems" xlink:label="loc_ecdAwardTmgDiscLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="loc_ecdAwardsCloseToMnpiDiscTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_ecdIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="loc_ecdAwardTmgMnpiDiscTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiDiscTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="loc_ecdAwardTmgMethodTextBlock" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="loc_ecdAwardTmgPredtrmndFlag" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgPredtrmndFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="loc_ecdAwardTmgMnpiCnsdrdFlag" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiCnsdrdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="loc_ecdMnpiDiscTimedForCompValFlag" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdMnpiDiscTimedForCompValFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="loc_ecdAwardsCloseToMnpiDiscIndName" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="loc_ecdAwardUndrlygSecuritiesAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardUndrlygSecuritiesAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice" xlink:label="loc_ecdAwardExrcPrice" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardExrcPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue" xlink:label="loc_ecdAwardGrantDateFairValue" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="loc_ecdUndrlygSecurityMktPriceChngPct" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdUndrlygSecurityMktPriceChngPct" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="995445 - Disclosure - Insider Trading Arrangements">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems" xlink:label="loc_ecdInsiderTradingArrLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="loc_ecdMtrlTermsOfTrdArrTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdMtrlTermsOfTrdArrTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName" xlink:label="loc_ecdTrdArrIndName" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle" xlink:label="loc_ecdTrdArrIndTitle" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="loc_ecdRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="loc_ecdNonRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate" xlink:label="loc_ecdTrdArrAdoptionDate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrAdoptionDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="loc_ecdRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="loc_ecdNonRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate" xlink:label="loc_ecdTrdArrTerminationDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrTerminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate" xlink:label="loc_ecdTrdArrExpirationDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrExpirationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration" xlink:label="loc_ecdTrdArrDuration" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrDuration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt" xlink:label="loc_ecdTrdArrSecuritiesAggAvailAmt" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrSecuritiesAggAvailAmt" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:title="995447 - Disclosure - Insider Trading Policies and Procedures">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="loc_ecdInsiderTradingPoliciesProcLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/OrganizationAndGoingConcernAnalysis" xlink:title="999013 - Disclosure - Organization and Going Concern Analysis">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999014 - Disclosure - Summary of Significant Accounting Policies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/AccountsPayableAndRelatedParty" xlink:title="999015 - Disclosure - Accounts Payable and Related Party">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/WarrantLiability" xlink:title="999016 - Disclosure - Warrant Liability">
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_DisclosureWarrantLiabilityAbstract" xlink:label="loc_GTBPDisclosureWarrantLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_WarrantLiabilityTextBlock" xlink:label="loc_GTBPWarrantLiabilityTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureWarrantLiabilityAbstract" xlink:to="loc_GTBPWarrantLiabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StockholdersEquityDeficit" xlink:title="999017 - Disclosure - Stockholders&#8217; Equity (Deficit)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/CommonStockWarrantsAndOptions" xlink:title="999018 - Disclosure - Common Stock Warrants and Options">
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract" xlink:label="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_CommonStockWarrantsAndOptionsTextBlock" xlink:label="loc_GTBPCommonStockWarrantsAndOptionsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_GTBPCommonStockWarrantsAndOptionsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/CommitmentsAndContingencies" xlink:title="999019 - Disclosure - Commitments and Contingencies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SegmentInformation" xlink:title="999020 - Disclosure - Segment Information">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaapSegmentReportingDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapSegmentReportingDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SubsequentEvents" xlink:title="999021 - Disclosure - Subsequent Events">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999022 - Disclosure - Summary of Significant Accounting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaapCashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy" xlink:label="loc_us-gaapCapitalizationOfDeferredPolicyAcquisitionCostsPolicy" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCapitalizationOfDeferredPolicyAcquisitionCostsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_WarrantLiabilityPolicyTextBlock" xlink:label="loc_GTBPWarrantLiabilityPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_GTBPWarrantLiabilityPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_MezzanineEquityPolicyTextBlock" xlink:label="loc_GTBPMezzanineEquityPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_GTBPMezzanineEquityPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="999023 - Disclosure - Summary of Significant Accounting Policies (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyTables" xlink:title="999024 - Disclosure - Accounts Payable and Related Party (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock" xlink:label="loc_GTBPScheduleOfAccountsPayableAndRelatedPartyTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_GTBPScheduleOfAccountsPayableAndRelatedPartyTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/WarrantLiabilityTables" xlink:title="999025 - Disclosure - Warrant Liability (Tables)">
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_DisclosureWarrantLiabilityAbstract" xlink:label="loc_GTBPDisclosureWarrantLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureWarrantLiabilityAbstract" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_TwoThousandTwentyThreeWarrantsMember" xlink:label="loc_GTBPTwoThousandTwentyThreeWarrantsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_GTBPTwoThousandTwentyThreeWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="loc_us-gaapScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StockholdersEquityDeficitTables" xlink:title="999026 - Disclosure - Stockholders&#8217; Equity (Deficit) (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfConversionsOfStockTextBlock" xlink:label="loc_us-gaapScheduleOfConversionsOfStockTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfConversionsOfStockTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsTables" xlink:title="999027 - Disclosure - Common Stock Warrants and Options (Tables)">
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract" xlink:label="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_WarrantsMember" xlink:label="loc_GTBPWarrantsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_GTBPWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_ScheduleOfWarrantsOustandingAndExercisableTableTextBlock" xlink:label="loc_GTBPScheduleOfWarrantsOustandingAndExercisableTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_GTBPScheduleOfWarrantsOustandingAndExercisableTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SegmentInformationTables" xlink:title="999028 - Disclosure - Segment Information (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/OrganizationAndGoingConcernAnalysisDetailsNarrative" xlink:title="999029 - Disclosure - Organization and Going Concern Analysis (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails" xlink:title="999030 - Disclosure - Schedule of Anti-dilutive Securities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_SeriesLConvertiblePreferredStockMember" xlink:label="loc_GTBPSeriesLConvertiblePreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_GTBPSeriesLConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetailsParenthetical" xlink:title="999031 - Disclosure - Schedule of Anti-dilutive Securities (Details) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="loc_us-gaapPreferredStockConvertibleConversionPrice" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPreferredStockConvertibleConversionPrice" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999032 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaapDeferredOfferingCosts" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDeferredOfferingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_WarrantLiabilityCurrent" xlink:label="loc_GTBPWarrantLiabilityCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_GTBPWarrantLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashFDICInsuredAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails" xlink:title="999033 - Disclosure - Schedule of Accounts Payable (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_CytovanceBiologicsIncMember" xlink:label="loc_GTBPCytovanceBiologicsIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_GTBPCytovanceBiologicsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_UniversityOfMinnesotaMember" xlink:label="loc_GTBPUniversityOfMinnesotaMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_GTBPUniversityOfMinnesotaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_LegalServicesFirmMember" xlink:label="loc_GTBPLegalServicesFirmMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_GTBPLegalServicesFirmMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_OtherAccountsPayableMember" xlink:label="loc_GTBPOtherAccountsPayableMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_GTBPOtherAccountsPayableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaapAccountsPayableTradeCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapAccountsPayableTradeCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableInterestBearingInterestRate" xlink:label="loc_us-gaapAccountsPayableInterestBearingInterestRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapAccountsPayableInterestBearingInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="loc_us-gaapAccountsPayableOtherCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapAccountsPayableOtherCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfAccountsPayableToRelatedPartyDetails" xlink:title="999034 - Disclosure - Schedule of Accounts Payable to Related Party (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_CytovanceBiologicsIncMember" xlink:label="loc_GTBPCytovanceBiologicsIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_GTBPCytovanceBiologicsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaapAccountsPayableTradeCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapAccountsPayableTradeCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapRepaymentsOfRelatedPartyDebt" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapRepaymentsOfRelatedPartyDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaapPaymentsForRepurchaseOfCommonStock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapPaymentsForRepurchaseOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_RepaymentsOfPrefundedWarrantsAtFairValue" xlink:label="loc_GTBPRepaymentsOfPrefundedWarrantsAtFairValue" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_GTBPRepaymentsOfPrefundedWarrantsAtFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaapAccountsPayableTradeCurrent_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapAccountsPayableTradeCurrent_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyDetailsNarrative" xlink:title="999035 - Disclosure - Accounts Payable and Related Party (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_AccountsPayableAndRelatedPartyAbstract" xlink:label="loc_GTBPAccountsPayableAndRelatedPartyAbstract" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_AccountsPayableAndRelatedPartyTable" xlink:label="loc_GTBPAccountsPayableAndRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPAccountsPayableAndRelatedPartyAbstract" xlink:to="loc_GTBPAccountsPayableAndRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_AccountsPayableAndRelatedPartyLineItems" xlink:label="loc_GTBPAccountsPayableAndRelatedPartyLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPAccountsPayableAndRelatedPartyTable" xlink:to="loc_GTBPAccountsPayableAndRelatedPartyLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPAccountsPayableAndRelatedPartyTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPAccountsPayableAndRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_CytovanceBiologicsIncMember" xlink:label="loc_GTBPCytovanceBiologicsIncMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_GTBPCytovanceBiologicsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_LegalServicesFirmMember" xlink:label="loc_GTBPLegalServicesFirmMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_GTBPLegalServicesFirmMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPAccountsPayableAndRelatedPartyTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_AdvisoryAgreementMember" xlink:label="loc_GTBPAdvisoryAgreementMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPAdvisoryAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable" xlink:label="loc_GTBPStockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPAccountsPayableAndRelatedPartyLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable" xlink:label="loc_GTBPStockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPAccountsPayableAndRelatedPartyLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPAccountsPayableAndRelatedPartyLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPAccountsPayableAndRelatedPartyLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_RepaymentsOfPrefundedWarrantsAtFairValue" xlink:label="loc_GTBPRepaymentsOfPrefundedWarrantsAtFairValue" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPAccountsPayableAndRelatedPartyLineItems" xlink:to="loc_GTBPRepaymentsOfPrefundedWarrantsAtFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForFees" xlink:label="loc_us-gaapPaymentsForFees" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPAccountsPayableAndRelatedPartyLineItems" xlink:to="loc_us-gaapPaymentsForFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfOtherDebt" xlink:label="loc_us-gaapRepaymentsOfOtherDebt" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPAccountsPayableAndRelatedPartyLineItems" xlink:to="loc_us-gaapRepaymentsOfOtherDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPAccountsPayableAndRelatedPartyLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPAccountsPayableAndRelatedPartyLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:label="loc_us-gaapRelatedPartyTransactionDescriptionOfTransaction" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPAccountsPayableAndRelatedPartyLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionDescriptionOfTransaction" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative" xlink:title="999036 - Disclosure - Warrant Liability (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaapWarrantsAndRightsNoteDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWarrantsAndRightsNoteDisclosureAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_TwoThousandTwentyThreeCommonWarrantsMember" xlink:label="loc_GTBPTwoThousandTwentyThreeCommonWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GTBPTwoThousandTwentyThreeCommonWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_TwoThousandTwentyThreePlacementAgentsWarrantsMember" xlink:label="loc_GTBPTwoThousandTwentyThreePlacementAgentsWarrantsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GTBPTwoThousandTwentyThreePlacementAgentsWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_TwoThousandTwentyThreeWarrantsMember" xlink:label="loc_GTBPTwoThousandTwentyThreeWarrantsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GTBPTwoThousandTwentyThreeWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails" xlink:title="999037 - Disclosure - Schedule of Warrant Liability Assumptions (Details)">
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_DisclosureWarrantLiabilityAbstract" xlink:label="loc_GTBPDisclosureWarrantLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureWarrantLiabilityAbstract" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaapBusinessAcquisitionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="loc_us-gaapMeasurementInputSharePriceMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputSharePriceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaapMeasurementInputExpectedTermMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedTermMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_TwoThousandTwentyThreeWarrantsMember" xlink:label="loc_GTBPTwoThousandTwentyThreeWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_GTBPTwoThousandTwentyThreeWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_srtRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityTransactionsDetails" xlink:title="999038 - Disclosure - Schedule of Warrant Liability Transactions (Details)">
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_DisclosureWarrantLiabilityAbstract" xlink:label="loc_GTBPDisclosureWarrantLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_WarrantLiabilityCurrent" xlink:label="loc_GTBPWarrantLiabilityCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureWarrantLiabilityAbstract" xlink:to="loc_GTBPWarrantLiabilityCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureWarrantLiabilityAbstract" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInDerivativeLiabilities" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureWarrantLiabilityAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInDerivativeLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_ExtinguishmentOfWarrant" xlink:label="loc_GTBPExtinguishmentOfWarrant" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureWarrantLiabilityAbstract" xlink:to="loc_GTBPExtinguishmentOfWarrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_WarrantLiabilityCurrent" xlink:label="loc_GTBPWarrantLiabilityCurrent_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureWarrantLiabilityAbstract" xlink:to="loc_GTBPWarrantLiabilityCurrent_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfFairValuesAndAllocationOfNetProceedsDetails" xlink:title="999039 - Disclosure - Schedule of fair values and allocation of net proceeds (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockByClassTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_SeriesLPreferredStockMember" xlink:label="loc_GTBPSeriesLPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_GTBPSeriesLPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_MezzanineEquityMember" xlink:label="loc_GTBPMezzanineEquityMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_GTBPMezzanineEquityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="loc_us-gaapStockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_ConvertiblePreferredStockAndWarrantsFairValuePercentage" xlink:label="loc_GTBPConvertiblePreferredStockAndWarrantsFairValuePercentage" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_GTBPConvertiblePreferredStockAndWarrantsFairValuePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfConvertiblePreferredStock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_ConvertiblePreferredStockAndWarrantsNetProceedsPercentage" xlink:label="loc_GTBPConvertiblePreferredStockAndWarrantsNetProceedsPercentage" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_GTBPConvertiblePreferredStockAndWarrantsNetProceedsPercentage" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative" xlink:title="999040 - Disclosure - Stockholders&#8217; Equity (Deficit) (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_PurchaseAgreementMember" xlink:label="loc_GTBPPurchaseAgreementMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_SecuritiesPurchaseAgreementMember" xlink:label="loc_GTBPSecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPSecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_InducementWarrantsMember" xlink:label="loc_GTBPInducementWarrantsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GTBPInducementWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_SeriesAInducementWarrantsMember" xlink:label="loc_GTBPSeriesAInducementWarrantsMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GTBPSeriesAInducementWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_SeriesBInducementWarrantsMember" xlink:label="loc_GTBPSeriesBInducementWarrantsMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GTBPSeriesBInducementWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_GreenshoeRightsMember" xlink:label="loc_GTBPGreenshoeRightsMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GTBPGreenshoeRightsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_SeriesLTenPercentConvertiblePreferredStockMember" xlink:label="loc_GTBPSeriesLTenPercentConvertiblePreferredStockMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_GTBPSeriesLTenPercentConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_SeriesLPreferredStockMember" xlink:label="loc_GTBPSeriesLPreferredStockMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_GTBPSeriesLPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_SeriesL10PercentageConvertiblePreferredStockMember" xlink:label="loc_GTBPSeriesL10PercentageConvertiblePreferredStockMember" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_GTBPSeriesL10PercentageConvertiblePreferredStockMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_SeriesLConvertiblePreferredStockMember" xlink:label="loc_GTBPSeriesLConvertiblePreferredStockMember" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_GTBPSeriesLConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtRangeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_CommonWarrantsMember" xlink:label="loc_GTBPCommonWarrantsMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_GTBPCommonWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_VestingWarrantsMember" xlink:label="loc_GTBPVestingWarrantsMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_GTBPVestingWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_WeightedAverageVolumePriceOfCommonStockPercentage" xlink:label="loc_GTBPWeightedAverageVolumePriceOfCommonStockPercentage" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_GTBPWeightedAverageVolumePriceOfCommonStockPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoninterestExpenseOfferingCost" xlink:label="loc_us-gaapNoninterestExpenseOfferingCost" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapNoninterestExpenseOfferingCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" xlink:label="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_AggregateStatedValue" xlink:label="loc_GTBPAggregateStatedValue" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_GTBPAggregateStatedValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_ClassOfWarrantsPurchaseUpPercentage" xlink:label="loc_GTBPClassOfWarrantsPurchaseUpPercentage" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_GTBPClassOfWarrantsPurchaseUpPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfConvertiblePreferredStock" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="loc_us-gaapPreferredStockConvertibleConversionPrice" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockConvertibleConversionPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaapPreferredStockDividendRatePercentage" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockDividendRatePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeFloorPrice" xlink:label="loc_us-gaapDerivativeFloorPrice" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapDerivativeFloorPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_LiableOfLiquidatedDamagePercentageDescription" xlink:label="loc_GTBPLiableOfLiquidatedDamagePercentageDescription" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_GTBPLiableOfLiquidatedDamagePercentageDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_CommonStockSharesOutstandingPercentage" xlink:label="loc_GTBPCommonStockSharesOutstandingPercentage" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_GTBPCommonStockSharesOutstandingPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_PreferredStockPurchasePrice" xlink:label="loc_GTBPPreferredStockPurchasePrice" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_GTBPPreferredStockPurchasePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock" xlink:label="loc_us-gaapPaymentsForRepurchaseOfConvertiblePreferredStock" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPaymentsForRepurchaseOfConvertiblePreferredStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsPayableCurrent" xlink:label="loc_us-gaapDividendsPayableCurrent" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapDividendsPayableCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails" xlink:title="999041 - Disclosure - Schedule of Warrant Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract" xlink:label="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice" xlink:label="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedPursuantToFullRatchetPriceProtection" xlink:label="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedPursuantToFullRatchetPriceProtection" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedPursuantToFullRatchetPriceProtection" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedPursuantToFullRatchetPriceProtectionWeightedAverageExercisePrice" xlink:label="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedPursuantToFullRatchetPriceProtectionWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedPursuantToFullRatchetPriceProtectionWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice" xlink:label="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice" xlink:label="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" xlink:label="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative" xlink:title="999042 - Disclosure - Common Stock Warrants and Options (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_SeriesLPreferredStockMember" xlink:label="loc_GTBPSeriesLPreferredStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_GTBPSeriesLPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_CommonWarrantsMember" xlink:label="loc_GTBPCommonWarrantsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_GTBPCommonWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_VestingWarrantsMember" xlink:label="loc_GTBPVestingWarrantsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_GTBPVestingWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_GreenshoeRightsMember" xlink:label="loc_GTBPGreenshoeRightsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GTBPGreenshoeRightsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_PrefundedWarrantsMember" xlink:label="loc_GTBPPrefundedWarrantsMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_GTBPPrefundedWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_OmnibusIncentivePlanMember" xlink:label="loc_GTBPOmnibusIncentivePlanMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_GTBPOmnibusIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeFloorPrice" xlink:label="loc_us-gaapDerivativeFloorPrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapDerivativeFloorPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightUnissued" xlink:label="loc_us-gaapClassOfWarrantOrRightUnissued" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightUnissued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1" xlink:label="loc_GTBPSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_GTBPSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:title="999043 - Disclosure - Schedule of Warrants Outstanding and Exercisable (Details)">
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract" xlink:label="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_RangeOneMember" xlink:label="loc_GTBPRangeOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_RangeTwoMember" xlink:label="loc_GTBPRangeTwoMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_RangeThreeMember" xlink:label="loc_GTBPRangeThreeMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_RangeFourMember" xlink:label="loc_GTBPRangeFourMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeFourMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_RangeFiveMember" xlink:label="loc_GTBPRangeFiveMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeFiveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_RangeSixMember" xlink:label="loc_GTBPRangeSixMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeSixMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_RangeSevenMember" xlink:label="loc_GTBPRangeSevenMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeSevenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_RangeEightMember" xlink:label="loc_GTBPRangeEightMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeEightMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_RangeNineMember" xlink:label="loc_GTBPRangeNineMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeNineMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_RangeTenMember" xlink:label="loc_GTBPRangeTenMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeTenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_RangeElevenMember" xlink:label="loc_GTBPRangeElevenMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeElevenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_RangeTwelveMember" xlink:label="loc_GTBPRangeTwelveMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeTwelveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_RangeThirteenMember" xlink:label="loc_GTBPRangeThirteenMember" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeThirteenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_GTBPShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails" xlink:title="999044 - Disclosure - Schedule of Options Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract" xlink:label="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails" xlink:title="999045 - Disclosure - Schedule of Options Outstanding and Options Exercisable (Details)">
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract" xlink:label="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_GTBPDisclosureCommonStockWarrantsAndOptionsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_RangeOneMember" xlink:label="loc_GTBPRangeOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_RangeTwoMember" xlink:label="loc_GTBPRangeTwoMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_RangeThreeMember" xlink:label="loc_GTBPRangeThreeMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_RangeFourMember" xlink:label="loc_GTBPRangeFourMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeFourMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_RangeFiveMember" xlink:label="loc_GTBPRangeFiveMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_GTBPRangeFiveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999046 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLossContingenciesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapLossContingenciesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_LitigationCaseAxis" xlink:label="loc_srtLitigationCaseAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtLitigationCaseAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srtLitigationCaseTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtLitigationCaseAxis" xlink:to="loc_srtLitigationCaseTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_ZOneLLCMember" xlink:label="loc_GTBPZOneLLCMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtLitigationCaseTypeDomain" xlink:to="loc_GTBPZOneLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_CobySilberfeinMember" xlink:label="loc_GTBPCobySilberfeinMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtLitigationCaseTypeDomain" xlink:to="loc_GTBPCobySilberfeinMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_CytovanceBiologicsIncMember" xlink:label="loc_GTBPCytovanceBiologicsIncMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_GTBPCytovanceBiologicsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_CytovanceBiologicsIncMember" xlink:label="loc_GTBPCytovanceBiologicsIncMember_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_GTBPCytovanceBiologicsIncMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_TwoThousandTwentyThreeSponsoredResearchAgreementMember" xlink:label="loc_GTBPTwoThousandTwentyThreeSponsoredResearchAgreementMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPTwoThousandTwentyThreeSponsoredResearchAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_TwoThousandSixteenPatentLicenseAgreementMember" xlink:label="loc_GTBPTwoThousandSixteenPatentLicenseAgreementMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPTwoThousandSixteenPatentLicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember" xlink:label="loc_GTBPTwoThousandAndTwentyOnePatentLicenseAgreementMember" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPTwoThousandAndTwentyOnePatentLicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember" xlink:label="loc_GTBPTwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_GTBPTwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapAwardDateAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_TwoThousandSeventeenThroughTwoThousandTwentyMember" xlink:label="loc_GTBPTwoThousandSeventeenThroughTwoThousandTwentyMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_GTBPTwoThousandSeventeenThroughTwoThousandTwentyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_TwoThousandTwentyTwoMember" xlink:label="loc_GTBPTwoThousandTwentyTwoMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_GTBPTwoThousandTwentyTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_TwoThousandTwentyFiveMember" xlink:label="loc_GTBPTwoThousandTwentyFiveMember" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_GTBPTwoThousandTwentyFiveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_TwoThousandTwentySevenMember" xlink:label="loc_GTBPTwoThousandTwentySevenMember" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_GTBPTwoThousandTwentySevenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtRangeAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyDamagesPaidValue" xlink:label="loc_us-gaapLossContingencyDamagesPaidValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLossContingencyDamagesPaidValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="loc_us-gaapLossContingencyDamagesSoughtValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLossContingencyDamagesSoughtValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyDamagesSought" xlink:label="loc_us-gaapLossContingencyDamagesSought" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLossContingencyDamagesSought" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapRepaymentsOfRelatedPartyDebt" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapRepaymentsOfRelatedPartyDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable" xlink:label="loc_GTBPStockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable" xlink:label="loc_GTBPStockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPStockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="loc_us-gaapPaymentsToAcquireInProcessResearchAndDevelopment" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapPaymentsToAcquireInProcessResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnbilledReceivablesCurrent" xlink:label="loc_us-gaapUnbilledReceivablesCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapUnbilledReceivablesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_ProceedsFromUpfrontAmount" xlink:label="loc_GTBPProceedsFromUpfrontAmount" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPProceedsFromUpfrontAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostMaintenance" xlink:label="loc_us-gaapCostMaintenance" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapCostMaintenance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_RoyaltyFeePercentage" xlink:label="loc_GTBPRoyaltyFeePercentage" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPRoyaltyFeePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaapRoyaltyExpense" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapRoyaltyExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_PerformanceMilestonePayments" xlink:label="loc_GTBPPerformanceMilestonePayments" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPPerformanceMilestonePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_SalesMilestonePayments" xlink:label="loc_GTBPSalesMilestonePayments" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPSalesMilestonePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_GrossSales" xlink:label="loc_GTBPGrossSales" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPGrossSales" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_SalesRevenue" xlink:label="loc_GTBPSalesRevenue" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPSalesRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_CummulativeGrossSales" xlink:label="loc_GTBPCummulativeGrossSales" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPCummulativeGrossSales" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_RoyaltyExpenseYearOne" xlink:label="loc_GTBPRoyaltyExpenseYearOne" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPRoyaltyExpenseYearOne" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_RoyaltyExpenseYearTwoThroughFive" xlink:label="loc_GTBPRoyaltyExpenseYearTwoThroughFive" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPRoyaltyExpenseYearTwoThroughFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_RoyaltyExpenseYearAfterSix" xlink:label="loc_GTBPRoyaltyExpenseYearAfterSix" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPRoyaltyExpenseYearAfterSix" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_UpfrontLicenseFee" xlink:label="loc_GTBPUpfrontLicenseFee" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPUpfrontLicenseFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_RoyaltyExpenseYearOneThoughFour" xlink:label="loc_GTBPRoyaltyExpenseYearOneThoughFour" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPRoyaltyExpenseYearOneThoughFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_RoyaltyExpenseYearAfterFive" xlink:label="loc_GTBPRoyaltyExpenseYearAfterFive" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPRoyaltyExpenseYearAfterFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_ContigencyMinimumRequired" xlink:label="loc_GTBPContigencyMinimumRequired" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_GTBPContigencyMinimumRequired" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/ScheduleOfSegmentInformationDetails" xlink:title="999047 - Disclosure - Schedule of Segment Information (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaapSegmentReportingInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapSegmentReportingInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_SegmentsMember" xlink:label="loc_GTBPSegmentsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_GTBPSegmentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaapOtherResearchAndDevelopmentExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapOtherResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaapSalariesAndWages" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapSalariesAndWages" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InsuranceCommissions" xlink:label="loc_us-gaapInsuranceCommissions" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapInsuranceCommissions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SegmentInformationDetailsNarrative" xlink:title="999048 - Disclosure - Segment Information (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaapNumberOfReportableSegments" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapNumberOfReportableSegments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaapNumberOfOperatingSegments" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapNumberOfOperatingSegments" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative" xlink:title="999049 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_SeriesL10PercentageConvertiblePreferredStockMember" xlink:label="loc_GTBPSeriesL10PercentageConvertiblePreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_GTBPSeriesL10PercentageConvertiblePreferredStockMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_SeriesLConvertiblePreferredStockMember" xlink:label="loc_GTBPSeriesLConvertiblePreferredStockMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_GTBPSeriesLConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="gtbp-20250930.xsd#GTBP_PreferredStockPurchasePrice" xlink:label="loc_GTBPPreferredStockPurchasePrice" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_GTBPPreferredStockPurchasePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="loc_us-gaapPreferredStockConvertibleConversionPrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapPreferredStockConvertibleConversionPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Nov. 06, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">GT
BIOPHARMA, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000109657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">94-1620407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">505 Montgomery Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">10th Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Francisco<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">919-4040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, $0.001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GTBP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,636,135<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 2,528,000<span></span>
</td>
<td class="nump">$ 3,951,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">93,000<span></span>
</td>
<td class="nump">93,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="nump">760,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">940,000<span></span>
</td>
<td class="nump">188,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">TOTAL ASSETS</a></td>
<td class="nump">4,321,000<span></span>
</td>
<td class="nump">4,232,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">769,000<span></span>
</td>
<td class="nump">3,853,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">1,797,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrent', window );">Dividend payable</a></td>
<td class="nump">144,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_WarrantLiabilityCurrent', window );">Warrant liability</a></td>
<td class="nump">8,000<span></span>
</td>
<td class="nump">252,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">1,321,000<span></span>
</td>
<td class="nump">5,902,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity (Deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.001, 250,000,000 shares authorized, 6,051,874 and 2,234,328 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively</a></td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid in capital</a></td>
<td class="nump">703,772,000<span></span>
</td>
<td class="nump">693,554,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(700,779,000)<span></span>
</td>
<td class="num">(695,227,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders&#8217; Equity (Deficit)</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="num">(1,670,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; (EQUITY) DEFICIT</a></td>
<td class="nump">4,321,000<span></span>
</td>
<td class="nump">4,232,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity (Deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock value</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=GTBP_SeriesLPreferredStockMember', window );">Series L Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity (Deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_WarrantLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant liability current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_WarrantLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480341/340-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=GTBP_SeriesLPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=GTBP_SeriesLPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">15,000,000<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">6,051,874<span></span>
</td>
<td class="nump">2,234,328<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">6,051,874<span></span>
</td>
<td class="nump">2,234,328<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">96,230<span></span>
</td>
<td class="nump">96,230<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">96,230<span></span>
</td>
<td class="nump">96,230<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=GTBP_SeriesLPreferredStockMember', window );">Series L Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">4,912<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">4,912<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=GTBP_SeriesLPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=GTBP_SeriesLPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Operations (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">634,000<span></span>
</td>
<td class="nump">1,307,000<span></span>
</td>
<td class="nump">2,096,000<span></span>
</td>
<td class="nump">3,868,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative (including $379,000 and $0 of stock compensation for the three months ended September 30, 2025 and 2024, respectively, and $386,000 and $222,000 of stock compensation for the nine months ended September 30, 2025 and 2024, respectively)</a></td>
<td class="nump">2,748,000<span></span>
</td>
<td class="nump">2,297,000<span></span>
</td>
<td class="nump">4,731,000<span></span>
</td>
<td class="nump">6,733,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from Operations</a></td>
<td class="num">(3,382,000)<span></span>
</td>
<td class="num">(3,604,000)<span></span>
</td>
<td class="num">(6,827,000)<span></span>
</td>
<td class="num">(10,601,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other Income (Expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest income</a></td>
<td class="nump">36,000<span></span>
</td>
<td class="nump">96,000<span></span>
</td>
<td class="nump">106,000<span></span>
</td>
<td class="nump">343,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="nump">232,000<span></span>
</td>
<td class="nump">95,000<span></span>
</td>
<td class="nump">244,000<span></span>
</td>
<td class="nump">870,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on settlement of vendor payable</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">998,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">156,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized gain on short-term investments</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total Other Income (Expense), Net</a></td>
<td class="nump">268,000<span></span>
</td>
<td class="nump">193,000<span></span>
</td>
<td class="nump">1,504,000<span></span>
</td>
<td class="nump">1,214,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">(3,114,000)<span></span>
</td>
<td class="num">(3,411,000)<span></span>
</td>
<td class="num">(5,323,000)<span></span>
</td>
<td class="num">(9,387,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Dividends on preferred stock</a></td>
<td class="num">(144,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(229,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net Loss attributable to common stockholders&#8217;</a></td>
<td class="num">$ (3,258,000)<span></span>
</td>
<td class="num">$ (3,411,000)<span></span>
</td>
<td class="num">$ (5,552,000)<span></span>
</td>
<td class="num">$ (9,387,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net Loss Per Share - Basic</a></td>
<td class="num">$ (0.83)<span></span>
</td>
<td class="num">$ (1.53)<span></span>
</td>
<td class="num">$ (1.84)<span></span>
</td>
<td class="num">$ (5.28)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net Loss Per Share - Diluted</a></td>
<td class="num">$ (0.83)<span></span>
</td>
<td class="num">$ (1.53)<span></span>
</td>
<td class="num">$ (1.84)<span></span>
</td>
<td class="num">$ (5.28)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding - basic</a></td>
<td class="nump">3,940,714<span></span>
</td>
<td class="nump">2,234,328<span></span>
</td>
<td class="nump">3,025,033<span></span>
</td>
<td class="nump">1,777,313<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding - diluted</a></td>
<td class="nump">3,940,714<span></span>
</td>
<td class="nump">2,234,328<span></span>
</td>
<td class="nump">3,025,033<span></span>
</td>
<td class="nump">1,777,313<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsIncomeStatementImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsIncomeStatementImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Operations (Unaudited) (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative Expenses [Member] | Officers, Employees and Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment arrangement, expense</a></td>
<td class="nump">$ 379,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 386,000<span></span>
</td>
<td class="nump">$ 222,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=GTBP_OfficersEmployeesAndDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=GTBP_OfficersEmployeesAndDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Statements of Stockholders' Equity (Deficit) and Mezzanine Equity  (Unaudited) - USD ($)<br></strong></div></th>
<th class="th">
<div>Preferred Stock [Member] </div>
<div>Series C Preferred Stock [Member]</div>
</th>
<th class="th">
<div>Preferred Stock [Member] </div>
<div>Series L Preferred Stock [Member]</div>
</th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
<th class="th">
<div>Mezzanine Equity [Member] </div>
<div>Series L Preferred Stock [Member]</div>
</th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 689,539,000<span></span>
</td>
<td class="num">$ (682,065,000)<span></span>
</td>
<td class="nump">$ 7,476,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2023</a></td>
<td class="nump">96,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,380,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Mezzanine equity balance, shares at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Mezzanine equity balance at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Fair value of vested stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">222,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">222,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(9,387,000)<span></span>
</td>
<td class="num">(9,387,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash', window );">Issuance of common stock and warrants for cash, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">2,975,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,976,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited', window );">Cancellation of common stock previously issued to prior CFO</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable', window );">Issuance of common stock in settlement of vendor payable</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">810,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">810,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodShareIssuanceOfCommonStockAndWarrantsForCash', window );">Issuance of common stock and warrants for cash, net, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">740,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited', window );">Cancellation of common stock previously issued to prior CFO, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,902)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable', window );">Issuance of common stock in settlement of vendor payable, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2024</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">693,546,000<span></span>
</td>
<td class="num">(691,452,000)<span></span>
</td>
<td class="nump">2,097,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Sep. 30, 2024</a></td>
<td class="nump">96,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,234,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Mezzanine equity balance, shares at Sep. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Mezzanine equity balance at Sep. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2024</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">693,546,000<span></span>
</td>
<td class="num">(688,041,000)<span></span>
</td>
<td class="nump">5,508,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Jun. 30, 2024</a></td>
<td class="nump">96,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,234,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Mezzanine equity balance, shares at Jun. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Mezzanine equity balance at Jun. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Fair value of vested stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,411,000)<span></span>
</td>
<td class="num">(3,411,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash', window );">Issuance of common stock and warrants for cash, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited', window );">Cancellation of common stock previously issued to prior CFO</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable', window );">Issuance of common stock in settlement of vendor payable</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2024</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">693,546,000<span></span>
</td>
<td class="num">(691,452,000)<span></span>
</td>
<td class="nump">2,097,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Sep. 30, 2024</a></td>
<td class="nump">96,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,234,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Mezzanine equity balance, shares at Sep. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Mezzanine equity balance at Sep. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2024</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">693,554,000<span></span>
</td>
<td class="num">(695,227,000)<span></span>
</td>
<td class="num">(1,670,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2024</a></td>
<td class="nump">96,230<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,234,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Mezzanine equity balance, shares at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Mezzanine equity balance at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Series L convertible preferred stock and warrants issued for cash, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,503,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,503,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Series L convertible preferred stock and warrants issued for cash, net, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of Series L convertible preferred stock into common stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="num">(3,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of Series L convertible preferred stock into common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,921)<span></span>
</td>
<td class="nump">2,930,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Dividend on Series L convertible preferred stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(229,000)<span></span>
</td>
<td class="num">(229,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Fair value of vested stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">386,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">386,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5,323,000)<span></span>
</td>
<td class="num">(5,323,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet', window );">Exercise of warrants for cash and inducement warrants, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">1,051,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,052,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet', window );">Exercise of warrants for cash and inducement warrants, net, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">537,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable', window );">Issuance of prefunded warrants in settlement of vendor payable</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">847,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">847,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee', window );">Issuance and exercise of prefunded warrants for ELOC fee</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">672,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">672,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodSharesIssuanceAndExerciseOfPrefundedWarrantsForElocFee', window );">Issuance and exercise of prefunded warrants for ELOC fee, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock and warrants for services</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">718,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">718,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock and warrants for services, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of warrants for VRT waiver</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">44,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">44,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2025</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="nump">703,772,000<span></span>
</td>
<td class="num">(700,779,000)<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Sep. 30, 2025</a></td>
<td class="nump">96,230<span></span>
</td>
<td class="nump">4,912<span></span>
</td>
<td class="nump">6,051,847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Mezzanine equity balance, shares at Sep. 30, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Mezzanine equity balance at Sep. 30, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2025</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="nump">700,378,000<span></span>
</td>
<td class="num">(697,521,000)<span></span>
</td>
<td class="nump">2,861,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Jun. 30, 2025</a></td>
<td class="nump">96,230<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,272,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Mezzanine equity balance, shares at Jun. 30, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,301<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Mezzanine equity balance at Jun. 30, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,956,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodValueMezzanineEquityReclassification', window );">Mezzanine equity reclassification</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,956,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,956,000<span></span>
</td>
<td class="num">$ (1,956,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodSharesMezzanineEquityReclassification', window );">Mezzanine equity reclassification, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,301)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Series L convertible preferred stock and warrants issued for cash, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,062,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,062,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Series L convertible preferred stock and warrants issued for cash, net, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of Series L convertible preferred stock into common stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="num">(3,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of Series L convertible preferred stock into common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,611)<span></span>
</td>
<td class="nump">2,778,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Dividend on Series L convertible preferred stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(144,000)<span></span>
</td>
<td class="num">(144,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Fair value of vested stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">379,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">379,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,114,000)<span></span>
</td>
<td class="num">(3,114,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2025</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="nump">$ 703,772,000<span></span>
</td>
<td class="num">$ (700,779,000)<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Sep. 30, 2025</a></td>
<td class="nump">96,230<span></span>
</td>
<td class="nump">4,912<span></span>
</td>
<td class="nump">6,051,847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Mezzanine equity balance, shares at Sep. 30, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Mezzanine equity balance at Sep. 30, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_StockIssuedDuringPeriodShareIssuanceOfCommonStockAndWarrantsForCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period share issuance of common stock and warrants for cash</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_StockIssuedDuringPeriodShareIssuanceOfCommonStockAndWarrantsForCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares common shares to settle vendor payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_StockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise of warrants for cash and inducement warrants, net, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_StockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_StockIssuedDuringPeriodSharesIssuanceAndExerciseOfPrefundedWarrantsForElocFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance and exercise of prefunded warrants for ELOC fee, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_StockIssuedDuringPeriodSharesIssuanceAndExerciseOfPrefundedWarrantsForElocFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_StockIssuedDuringPeriodSharesMezzanineEquityReclassification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Mezzanine equity reclassification, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_StockIssuedDuringPeriodSharesMezzanineEquityReclassification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value common shares to settle vendor payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise of warrants for cash and inducement warrants, net, value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_StockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value issuance and exercise of prefunded warrants for eloc fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_StockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value issuance of common stock and warrants for cash</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of prefunded warrant to settle vendor payable, value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_StockIssuedDuringPeriodValueMezzanineEquityReclassification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Mezzanine equity reclassification, value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_StockIssuedDuringPeriodValueMezzanineEquityReclassification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -SubTopic 405<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477787/942-405-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares (or other type of equity) forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of forfeited shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section S55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479772/718-30-S55-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (3,114,000)<span></span>
</td>
<td class="num">$ (3,411,000)<span></span>
</td>
<td class="num">$ (5,323,000)<span></span>
</td>
<td class="num">$ (9,387,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">386,000<span></span>
</td>
<td class="nump">222,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_IssuanceOfWarrantsForVrtWaiver', window );">Issuance of warrants for VRT waiver</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="num">(232,000)<span></span>
</td>
<td class="num">(95,000)<span></span>
</td>
<td class="num">(244,000)<span></span>
</td>
<td class="num">(870,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on settlement of debt</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(998,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_GainOnSettlementOfDebt', window );">Gain on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(200,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesUnrealizedGainLoss', window );">Unrealized gain on short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">(Increase) Decrease in prepaid expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(122,000)<span></span>
</td>
<td class="num">(164,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities', window );">Decrease in accounts payable and accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,436,000)<span></span>
</td>
<td class="num">(233,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_IncreaseDecreaseInOperatingLeaseRightofuseAssets', window );">Decrease in operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">(Increase) in operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(58,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Used in Operating Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,893,000)<span></span>
</td>
<td class="num">(10,436,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromInvestments', window );">Sale of investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">12,892,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net Cash Provided by Investing Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">12,892,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Exercise of warrants and issuance of inducement warrants for cash, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,052,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from issuance of common stock and warrants, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,976,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of Series L convertible preferred stock and warrants, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,503,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDividends', window );">Payment of dividend on Series L convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(85,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net Cash Provided by Financing Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,470,000<span></span>
</td>
<td class="nump">2,976,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net Increase (Decrease) in Cash and Cash Equivalents and Restricted Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,423,000)<span></span>
</td>
<td class="nump">5,432,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and Cash Equivalents and Restricted Cash at Beginning of Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,044,000<span></span>
</td>
<td class="nump">1,079,000<span></span>
</td>
<td class="nump">$ 1,079,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and Cash Equivalents and Restricted Cash at End of Period</a></td>
<td class="nump">$ 2,621,000<span></span>
</td>
<td class="nump">$ 6,511,000<span></span>
</td>
<td class="nump">2,621,000<span></span>
</td>
<td class="nump">6,511,000<span></span>
</td>
<td class="nump">$ 4,044,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_FairValueOfSeriesLConvertiblePreferredStockVestedWarrants', window );">Fair value of Series L convertible preferred stock vested warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,389,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_FairValueOfPrefundedWarrantsIssuedForElocFee', window );">Fair value of prefunded warrants issued for ELOC fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">672,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Fair value of common stock and warrants issued for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">718,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_FairValueOfPrefundedWarrantAndCommonStockToSettleVendorPayable', window );">Fair value of prefunded warrant and common stock to settle vendor payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">847,000<span></span>
</td>
<td class="nump">810,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_DividendDeclaredOnSeriesLConvertiblePreferredStock', window );">Dividend declared on Series L convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 229,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_DividendDeclaredOnSeriesLConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dividend declared on Series L convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_DividendDeclaredOnSeriesLConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_FairValueOfPrefundedWarrantAndCommonStockToSettleVendorPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of prefunded warrant and common stock to settle vendor payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_FairValueOfPrefundedWarrantAndCommonStockToSettleVendorPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_FairValueOfPrefundedWarrantsIssuedForElocFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of prefunded warrants issued for eloc fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_FairValueOfPrefundedWarrantsIssuedForElocFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_FairValueOfSeriesLConvertiblePreferredStockVestedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of Series L convertible preferred stock vested warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_FairValueOfSeriesLConvertiblePreferredStockVestedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_GainOnSettlementOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain on settlement of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_GainOnSettlementOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_IncreaseDecreaseInOperatingLeaseRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in operating lease right-of-use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_IncreaseDecreaseInOperatingLeaseRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_IssuanceOfWarrantsForVrtWaiver">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of warrants for vrt waiver.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_IssuanceOfWarrantsForVrtWaiver</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in net income (trading).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net cash paid (received) associated with the acquisition or disposal of all investments, including securities and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (3,114,000)<span></span>
</td>
<td class="num">$ (3,411,000)<span></span>
</td>
<td class="num">$ (5,323,000)<span></span>
</td>
<td class="num">$ (9,387,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingArrLineItems', window );"><strong>Insider Trading Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingArrLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingArrLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Going Concern Analysis<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Organization and Going Concern Analysis</a></td>
<td class="text"><p id="xdx_802_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_z6UOkzaHNIz3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
1 &#8211; <span id="xdx_828_zJh9mWsOY2ak">Organization and Going Concern Analysis</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Organization</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GT
Biopharma, Inc. (the &#8220;Company&#8221;) is a clinical stage biopharmaceutical company focused on the development and commercialization
of novel immune-oncology products based on our proprietary Tri-specific Killer Engager (TriKE&#174;), and Tetra-specific Killer Engager
(Dual Targeting TriKE&#174;) platforms. The Company&#8217;s TriKE&#174; and Dual Targeting TriKE&#174; platforms generate proprietary therapeutics
designed to harness and enhance the cancer killing abilities of a patient&#8217;s own natural killer cells (NK cells).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
corporate predecessor of GT Biopharma, Inc, Diagnostic Data, Inc., was incorporated in the state of California in 1965. Diagnostic Data,
Inc. changed its incorporation to the state of Delaware on December 21, 1972 and changed its name to DDI Pharmaceuticals, Inc. on March
11, 1985. On September 7, 1994, DDI Pharmaceuticals, Inc. merged with International BioClinical, Inc. and Bioxytech S.A. and changed
its name to OXIS International, Inc. On July 17, 2017, OXIS International, Inc. changed its name to GT Biopharma, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Throughout
this Quarterly Report on Form 10-Q, the terms &#8220;GTBP,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;the Company&#8221;
and &#8220;our Company&#8221; refer to GT Biopharma, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
GT Biopharma logo, TriKE&#174;, and other trademarks or service marks of GT Biopharma, Inc. appearing in this quarterly report are the
property of the Company. This quarterly report on Form 10-Q also contains registered marks, trademarks and trade names of other companies.
All other trademarks, registered marks and trade names appearing herein are the property of their respective holders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Going
Concern Analysis</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying unaudited condensed financial statements have been prepared assuming that the Company will continue as a going concern.
The Company does not have any product candidates approved for sale and has not generated any revenue from its product sales. The Company
has sustained operating losses since inception, and expects such losses to continue into the foreseeable future. Historically, the Company
has financed its operations through public and private sales of common stock, the issuance of preferred and common stock, the issuance
of convertible debt instruments, and strategic collaborations. For the nine months ended September 30, 2025, the Company recorded a net
loss of approximately $<span id="xdx_90E_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20250101__20250930_zun01o9mOjah" title="Net loss">5.3 </span>million and used cash in operations of approximately $<span id="xdx_906_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20250101__20250930_zznkrDP2vplk" title="Net cash used in operating activities">8.9</span> million. These factors raise substantial doubt about
the Company&#8217;s ability to continue as a going concern within one year of the date that the financial statements are issued. In addition,
the Company&#8217;s independent registered public accounting firm, in its report on the Company&#8217;s December 31, 2024, financial
statements, raised substantial doubt about the Company&#8217;s ability to continue as a going concern. The financial statements do not
include any adjustments that might be necessary if the Company is unable to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited condensed financial statements do not include any adjustments that might be necessary if the Company is unable to continue
as a going concern. Accordingly, the unaudited condensed financial statements have been prepared on a basis that assumes the Company
will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in
the ordinary course of business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has evaluated the significance of the uncertainty regarding the Company&#8217;s financial condition in relation to its ability
to meet its obligations, which has raised substantial doubt about the Company&#8217;s ability to continue as a going concern. While it
is very difficult to estimate the Company&#8217;s future liquidity requirements, the Company believes if it is unable to obtain additional
financing, existing cash resources will not be sufficient to enable it to fund the anticipated level of operations through one year from
the date the accompanying unaudited condensed financial statements are issued. There can be no assurances that the Company will be able
to secure additional financing on acceptable terms. In the event the Company does not secure additional financing, the Company will be
forced to delay, reduce, or eliminate some or all of its discretionary spending, which could adversely affect the Company&#8217;s business
prospects, ability to meet long-term liquidity needs and the ability to continue operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p id="xdx_806_eus-gaap--SignificantAccountingPoliciesTextBlock_z7Y1Wv9DazT7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2 &#8211; <span id="xdx_82C_zV4FNhZdgQ07">Summary of Significant Accounting Policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84E_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zPeugrX0lqi1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zSt4fb2hQaS2">Basis
of Presentation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying condensed financial statements are unaudited. These unaudited interim condensed financial statements have been prepared
in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and applicable rules
and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) regarding interim financial reporting. Certain information
and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant
to such rules and regulations. Accordingly, these unaudited interim condensed financial statements should be read in conjunction with
the financial statements and notes thereto contained in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December
31, 2024 filed with the SEC on February 21, 2025 (the &#8220;2024 Annual Report&#8221;). The balance sheet as of December 31, 2024 included
herein, was derived from the audited financial statements as of that date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the opinion of management, the accompanying unaudited condensed financial statements contain all adjustments necessary to fairly present
the Company&#8217;s financial position and results of operations for the interim periods reflected. Except as noted, all adjustments
contained herein are of a normal recurring nature. Results of operations for the fiscal periods presented herein are not necessarily
indicative of fiscal year-end results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_844_eus-gaap--UseOfEstimates_z84eS2DzZUXb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zWlIGXew19m2">Accounting
Estimates</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the
reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant
estimates include management&#8217;s estimates for continued liquidity, accruals for potential liabilities, assumptions used in deriving
the fair value of derivative liabilities, valuation of equity instruments issued for debt and services and realization of deferred tax
assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z7N3ZxDPJEr7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zWGzA7w0aSbc">Cash
Equivalents</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers highly liquid investments with maturities of three months or less at the date of acquisition as cash equivalents in
the accompanying unaudited condensed financial statements. At September 30, 2025 and December 31, 2024, total cash equivalents which
consist of money market funds and treasuries with maturities of three months or less, amounted to approximately $<span id="xdx_904_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20250930_zDF63ap45bsk" title="Cash equivalents">2.1</span> million and $<span id="xdx_907_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20241231_zEEPQ0grDaFd" title="Cash equivalents">3.8</span>
million, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84F_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zWX34GyVZ4j6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_zBhI8qlmcvga">Restricted
Cash</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2025, the Company has classified certain cash balances as restricted cash in its unaudited condensed balance sheets.
The Company&#8217;s restricted cash is deposited in a financial institution and held as a collateral for a credit card agreement with
the same financial institution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_847_eus-gaap--CapitalizationOfDeferredPolicyAcquisitionCostsPolicy_zZgZRRYsVcHl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zPe8nQBYIsx">Deferred
Offering Costs</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company capitalizes the fair value of equity instruments granted and certain legal, accounting and other third-party fees that are directly
related to the Company&#8217;s in-process equity financings until such financings are consummated. After consummation of an equity financing,
these costs are recorded in stockholders&#8217; equity as a reduction of additional paid-in capital generated as a result of the offering.
Should a planned equity financing be abandoned, terminated or significantly delayed, the deferred offering costs are immediately written
off to operating expenses. As of September 30, 2025, there was $<span id="xdx_906_eus-gaap--DeferredOfferingCosts_iI_pn5n6_c20250930_zwAfZucwXoA6" title="Deferred offering costs">0.8</span> million of deferred offering costs on the balance sheet.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_846_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zKb9KjlPCAhh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zAAueikD6DXd">Fair
Value of Financial Instruments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 820-10 requires entities to disclose
the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet for which it
is practicable to estimate fair value. ASC 820-10 defines the fair value of a financial instrument as the amount at which the instrument
could be exchanged in a current transaction between willing parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
three levels of the fair value hierarchy are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1 Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the entity has the ability
to access.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2 Valuations based on quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs
that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3 Valuations based on inputs that are unobservable, supported by little or no market activity and that are significant to the fair value
of the assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts of the Company&#8217;s other financial assets and liabilities, such as cash and cash equivalents, prepaid expenses and
other current assets, accounts payable, and accrued expenses, approximate their fair values because of the short maturity of these instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amount of the Company&#8217;s warrant liability of $<span id="xdx_90E_ecustom--WarrantLiabilityCurrent_iI_c20250930_zh2mNBhcsWLd" title="Warrant liability">8,000</span> and $<span id="xdx_90F_ecustom--WarrantLiabilityCurrent_iI_c20241231_z3q1o6RZKlY3" title="Warrant liability">252,000</span> at September 30, 2025 and December 31, 2024, respectively,
was based on Level 3 measurements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84C_ecustom--WarrantLiabilityPolicyTextBlock_znv80nG0J326" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zvDShclBMqPf">Warrant
Liability</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded
derivatives in accordance with ASC Topic 815, &#8220;<i>Derivatives and Hedging</i>&#8221; (&#8220;ASC 815&#8221;). For derivative financial
instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued
at each reporting date, with changes in the fair value reported in the statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s use of derivative financial instruments is generally limited to warrants issued by the Company that do not meet the criteria
for equity treatment and are recorded as liabilities. We do not use financial instruments or derivatives for any trading purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_844_ecustom--MezzanineEquityPolicyTextBlock_z6RzHTez9cs" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_znPncSPyFdul">Mezzanine
Equity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where
ordinary or preferred shares are determined to be conditionally redeemable upon the occurrence of certain events that are not solely
within the control of the issuer, and upon such event, the shares would become redeemable at the option of the holders, they are classified
as &#8216;mezzanine equity&#8217; (temporary equity). The purpose of this classification is to convey that such a security may not be
permanently part of equity and could result in a demand for cash, securities or other assets of the entity in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity
instruments accounted as Mezzanine Equity upon issuance were reclassified to permanent equity as of September 30, 2025 as a result of
subsequent amendments to its terms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_84F_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zjXU3pwOpSWb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_z2zm6rYqIux5">Stock-Based
Compensation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically issues stock-based compensation to officers, directors, employees, and consultants for services rendered. Such issuances
vest and expire according to terms established at the issuance date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Stock-based
payments to officers, directors, employees, and consultants in exchange for goods and services, which include grants of employee stock
options, are recognized in the financial statements based on their grant date fair values in accordance with ASC 718, <i>Compensation-Stock
Compensation</i>. Stock based payments to officers, directors, employees, and consultants, which are generally time vested, are measured
at the grant date fair value and depending on the conditions associated with the vesting of the award, compensation cost is recognized
on a straight-line or graded basis over the vesting period. Recognition of compensation expense for non-employees is in the same period
and manner as if the Company had paid cash for the services. The fair value of stock options granted is estimated using the Black-Scholes
option-pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life, and future
dividends. The assumptions used in the Black-Scholes option pricing model could materially affect compensation expense recorded in future
periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84F_eus-gaap--ResearchAndDevelopmentExpensePolicy_zoaWReyyh736" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_ze9ZkJBcwOOj">Research
and Development Expenses</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
incurred for research and development are expensed as incurred. The salaries, benefits, and overhead costs of personnel conducting research
and development of the Company&#8217;s products are included in research and development expenses. Purchased materials that do not have
an alternative future use are also expensed. Purchased materials that have an alternative future are classified as a prepaid expense
and periodically reviewed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_848_eus-gaap--EarningsPerSharePolicyTextBlock_zzBCiYRJkMD3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zF6xJODp9xh2">Net
Loss Per Share</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
earnings (loss) per share is computed using the weighted-average number of common shares outstanding during the period. Diluted earnings
(loss) per share is computed using the weighted-average number of common shares and the dilutive effect of contingent shares outstanding
during the period. Potentially dilutive contingent shares, which primarily consist of stock issuable upon exercise of stock options and
warrants, and the conversion of Series L convertible preferred stock, have been excluded from the diluted loss per share calculation
because their effect is anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_895_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zQRDqxVjqmd1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following common stock equivalents were excluded in the computation of the net loss per share because their effect is anti-dilutive:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BC_zFCVDVlwp5S3" style="display: none">Schedule of Anti-dilutive Securities</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 75%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20250101__20250930_zXjs4YBnnFy1" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30, 2025</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20240101__20240930_zZTByQvbDlKb" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30, 2024</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesLConvertiblePreferredStockMember_z5lmL1gNdT8i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series L convertible preferred stock <b><sup id="xdx_F44_zukfJ2qB72Ld">1</sup></b></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right">7,649,792</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0773">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zkneGfjaH1oa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Options to purchase common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">597,550</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">101,264</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zGwF1cKvFTk4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Warrants to purchase common stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">49,459,390</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,133,762</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zbBEwqK4Rv6g" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total anti-dilutive securities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">57,706,732</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,235,026</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b id="xdx_F0C_zQQiiyKcALwd"><sup>1</sup></b></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F11_zV80lUlQoPQ9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Converted into
common stock using a conversion price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEFudGktZGlsdXRpdmUgU2VjdXJpdGllcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_904_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20250930_zYB0aw7k7YA3" title="Conversion price per share">0.6421</span> per share, as of September 30, 2025</span></td>
</tr></table>

<p id="xdx_8AB_zYjDfXlXDxZb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_zVcOgvqOXL45" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zI8KcYfr4PP4">Concentration</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
is deposited in one financial institution. The balances held at this financial institution at times may be in excess of Federal Deposit
Insurance Corporation (&#8220;FDIC&#8221;) insurance limits of up to $<span id="xdx_901_eus-gaap--CashFDICInsuredAmount_iI_c20250930_zazTR64ciLQ9" title="Cash, FDIC insured amount">250,000</span>. <span style="background-color: white">Management believes
that the financial institutions that hold the Company&#8217;s cash are financially sound and, accordingly, minimal credit risk exists.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has a significant concentration of expenses incurred from and accounts payable to Cytovance Biologics, Inc. (&#8220;Cytovance&#8221;),
a related party, and the University of Minnesota, see Note 3 &#8211; Accounts Payable and Related Party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84D_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zpOSaP5GOIGl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zEwLDVzX81k">Segment
Information</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s Chief Executive Officer and President (&#8220;CEO&#8221;) is our chief operating decision maker (&#8220;CODM&#8221;)
and evaluates performance and makes operating decisions about allocating resources based on financial data presented on a consolidated
basis. Because our CODM evaluates financial performance on a consolidated basis, the Company has determined that it operates as a single
reportable segment composed of the financial results of GT Biopharma, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84E_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zaTm6E90uhy" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_z7v0R6ZiqRR1">Recent
Accounting Pronouncements</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, the FASB issued ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic
220-40): Disaggregation of Income Statement Expenses, requiring public entities to disclose additional information about specific expense
categories in the notes to the financial statements on an interim and annual basis. ASU 2024-03 is effective for fiscal years beginning
after December 15, 2026, and for interim periods beginning after December 15, 2027, with early adoption permitted. The Company is currently
evaluating the impact of adopting ASU 2024-03.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s management has evaluated all the recently issued, but not yet effective, accounting standards and guidance that have
been issued or proposed by the FASB or other standards-setting bodies through the filing date of these financial statements and does
not believe the future adoption of any such pronouncements will have a material effect on the Company&#8217;s financial position and
results of operations.</span></p>

<p id="xdx_8A6_zBDZqEdgdO44" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Related Party<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accounts Payable and Related Party</a></td>
<td class="text"><p id="xdx_808_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zJtD3LYhH6Jk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
3 &#8211; <span id="xdx_821_zkvjK0VSfOQ">Accounts Payable and Related Party</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_897_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zVHMOQDwABa6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
payable consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B5_zsdbA4ezRKUa" style="display: none">Schedule of Accounts Payable</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.65in; border-collapse: collapse; width: 85%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49F_20250930_zPkCBJt4ATR4" style="font-weight: bold; text-align: center">As of</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_495_20241231_zbODJkCKqcsk" style="font-weight: bold; text-align: center">As of</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AccountsPayableTradeCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_za2mDomThWP7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts payable to Cytovance, a related party <b><sup id="xdx_F47_zmzpK4rGHVp4">1</sup></b></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">60,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_90D_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_pid_dp_uPure_c20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_fKDEp_zKjUDVBwg857" title="Accounts payable interest rate">8</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,183,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_904_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_pid_dp_uPure_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_fKDEp_zcYtEMPQr9A4" title="Accounts payable interest rate">31</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_408_eus-gaap--AccountsPayableTradeCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UniversityOfMinnesotaMember_zXH5o1fGLKGa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accounts payable to University of Minnesota</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">463,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UniversityOfMinnesotaMember_z8HArOXnGgq" title="Accounts payable interest rate">60</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">712,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UniversityOfMinnesotaMember_zq8NtfZAYo26" title="Accounts payable interest rate">18</span></td><td style="text-align: left">%</td></tr>
  <tr id="xdx_40C_eus-gaap--AccountsPayableTradeCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_zPYwIo9J9Peb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Legal services firm</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0813">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_zyWZGSlLRgC7" title="Accounts payable interest rate"><span style="-sec-ix-hidden: xdx2ixbrl0816">&#8212;</span></span>%</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,505,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_zcGnnI9Zf6p7" title="Accounts payable interest rate">39</span></td><td style="text-align: left">%</td></tr>
  <tr id="xdx_40B_eus-gaap--AccountsPayableTradeCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_zGU3dht5cBp4" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0820">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;%</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,505,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">39</td><td style="text-align: left">%</td></tr>
<tr id="xdx_404_eus-gaap--AccountsPayableOtherCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OtherAccountsPayableMember_z9rI6JugfKXi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Other accounts payable</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">246,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_907_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OtherAccountsPayableMember_zJZsPOzbZ5n6" title="Accounts payable interest rate">32</span></td><td style="padding-bottom: 1pt; text-align: left">%</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">453,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90F_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OtherAccountsPayableMember_zNl4LJWXBdlb" title="Accounts payable interest rate">12</span></td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr id="xdx_40C_eus-gaap--AccountsPayableCurrent_iI_ztC94l3ZrcDk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total accounts payable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">769,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20250930_zbXyvJNRAWX3" title="Accounts payable interest rate">100</span></td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,853,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20241231_zsFtxp3u4Rp9" title="Accounts payable interest rate">100</span></td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span id="xdx_F0C_zauD72gr0fR1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><sup>1</sup></b></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F1A_zuycTXv7bPnk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts Payable
to Cytovance, a related party, since Cytovance owns greater than 5% of the Company&#8217;s issued and outstanding common stock. See Note
7 &#8211; Commitments and Contingencies, Significant Agreements.</span></td>
</tr></table>



<p id="xdx_8AF_z7qpSzEqnGU5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cytovance,
a Related Party</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89C_ecustom--ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock_zRP0PaRVjNGc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
details of the Company&#8217;s accounts payable to Cytovance were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="display: none"><span id="xdx_8B6_zMcldOtFeIHd">Schedule of Accounts Payable to Related Party</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 75%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center"></td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_492_20250101__20250930_zV7l9V0nwTS6" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49D_20240101__20240930_zZqcGinV4shb" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine Months Ending</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AccountsPayableTradeCurrent_iS_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zmDQqzj4sENi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Beginning balance</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,183,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,515,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ProceedsFromRelatedPartyDebt_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zatWKkVN8o2f" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Invoices, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">686,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,365,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--RepaymentsOfRelatedPartyDebt_iN_di_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zkfc1ri0A3gb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Payments in cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(962,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,432,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--PaymentsForRepurchaseOfCommonStock_iN_di_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_znsAUxadALma" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Payments in common stock, at fair value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0849">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(810,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_ecustom--RepaymentsOfPrefundedWarrantsAtFairValue_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zF8Hdx51h8Aj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Payments in pre-funded warrants, at fair value</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(847,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0853">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AccountsPayableTradeCurrent_iE_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zeSPOiiFsmI9" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Ending balance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">60,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">638,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A5_zfCeHtMx9Ih5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April and June 2024, the Company issued an aggregate of <span id="xdx_90F_ecustom--StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable_c20240401__20240430__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ze0OMsLkTEzh" title="Issuance of prefunded warrant to settle vendor payable, shares"><span id="xdx_90B_ecustom--StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable_c20240601__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwprfxvYjuE5" title="Issuance of prefunded warrant to settle vendor payable, shares">127,597</span></span> shares of common stock with a fair value of approximately $<span id="xdx_907_ecustom--StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable_c20240401__20240430__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zP2aeUDMMqp2" title="Issuance of prefunded warrant to settle vendor payable, value"><span id="xdx_90D_ecustom--StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable_c20240601__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zx1Ot95Rhm9i" title="Issuance of prefunded warrant to settle vendor payable, value">810,000</span></span> to
Cytovance as partial payment of accounts payable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2025, the Company issued pre-funded warrants to purchase up to <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zjvze5nLz6ie" title="Issuance of pre-funded warrants">326,251</span> shares of common stock exercisable at $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zKAPC1NI3lX9" title="Exercise price">0.0001</span> per share
with a fair value of approximately $<span id="xdx_90D_ecustom--RepaymentsOfPrefundedWarrantsAtFairValue_iN_di_c20250301__20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zvvbUNDfQTW3" title="Payments in pre-funded warrants, at fair value">847,000</span> to Cytovance as partial payment of accounts payable. The pre-funded warrants were valued
at the market price on the last day of the month during the respective month that the invoices are due.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2025, a legal services firm currently engaged by the Company agreed to reduce the Company&#8217;s prior year unpaid fees by approximately
$<span id="xdx_902_eus-gaap--PaymentsForFees_pn6n6_c20250301__20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_z7PKbwX4b6O3" title="Prior year unpaid fees">1</span> million. The Company classified this transaction as other income.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>University
of Minnesota</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 7 &#8211; Commitments and Contingencies, Significant Agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PDPC
Advisors Inc., a Related Party</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 30, 2025, the Company entered into an Advisory Agreement (the &#8220;Agreement&#8221;) with PDPC Advisors Inc. (&#8220;PDPC&#8221;),
to perform certain advisory services. Under the Agreement cash payments amounting to $<span id="xdx_907_eus-gaap--RepaymentsOfOtherDebt_c20250601__20250630__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember_zsLGIWeNcQ4a" title="Cash payment">100,000</span> are to be paid in six equal installments
beginning on July 1, 2025 and ending on December 31, 2025. In addition, upon execution of the Agreement, the Company issued to PDPC a
pre-funded warrant to purchase <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstanding_iI_c20250630__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember_zw2K4P0C7hM5" title="Warrants outstanding">150,000</span> shares of common stock of the Company, which had a fair value of $<span id="xdx_905_eus-gaap--PaymentsOfStockIssuanceCosts_c20250601__20250630__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember_zZRCwR7Suz3c" title="Stock issuance">537,000</span> at the time of issuance.
<span id="xdx_905_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20250601__20250630__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember_zdHcRNTtrRlc" title="Related party transaction description">The Agreement begins on July 1, 2025 and terminates on June 30, 2026. PDPC is considered a related party as its CEO is an individual
who has voting and investment control over an entity whose beneficial ownership exceeded 5% of the issued and outstanding shares of the
Company&#8217;s common stock.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrant Liability<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_DisclosureWarrantLiabilityAbstract', window );"><strong>Warrant Liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_WarrantLiabilityTextBlock', window );">Warrant Liability</a></td>
<td class="text"><p id="xdx_80C_ecustom--WarrantLiabilityTextBlock_z9XQ8r7o1ui4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
4 &#8211; <span id="xdx_823_z1Hv2m00lTj2">Warrant Liability</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023
Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 4, 2023, as part of the private placement offering, the Company issued warrants to purchase up to an aggregate of <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230104__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentyThreeCommonWarrantsMember__srt--RangeAxis__srt--MaximumMember_z0jYKakzILe2" title="Warrants to purchase">216,667</span> shares
of the Company&#8217;s common stock (the &#8220;2023 Common Warrants&#8221;), and placement agent warrants to purchase up to <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230104__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentyThreePlacementAgentsWarrantsMember__srt--RangeAxis__srt--MaximumMember_zkjK6gi1nXR" title="Warrants to purchase">13,000</span> shares
of the Company&#8217;s common stock (the &#8220;2023 Placement Agents Warrants&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2023 Common Warrants and the 2023 Placement Agents Warrants (collectively the &#8220;2023 Warrants&#8221;), provide for a value calculation
for the warrants using the Black Scholes model in the event of certain fundamental transactions. The fair value calculation provides
for a floor on the volatility amount utilized in the value calculation at <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230104__20230104__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentyThreeWarrantsMember_zbesnlHgVKw2" title="Volatility amount utilized in the value calculation percentage">100</span>% or greater. The Company has determined this provision
introduces leverage to the holders that could result in a value that would be greater than the settlement amount of a fixed-for-fixed
option on the Company&#8217;s own equity shares. Therefore, pursuant to ASC 815, the Company has classified the 2023 Warrants as a liability
in its balance sheet. The classification of the 2023 Warrants, including whether they should be recorded as liability or as equity, is
evaluated at the end of each reporting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2023 Warrants were initially recorded at a fair value at $<span id="xdx_900_eus-gaap--WarrantsAndRightsOutstanding_iI_pn5n6_c20230104__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentyThreeWarrantsMember_zU121x20o7o4" title="Warrant  fair value">5.8</span> million at the grant date, and upon the closing of placement, was recorded
as a cost of capital. The fair value of the 2023 Warrants classified as a liability in the Company&#8217;s unaudited condensed balance
sheets and will be re-measured at the end of every reporting period with the change in value reported in the unaudited condensed statements
of operations until they are either exercised or expired.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_891_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hus-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_zNBFfx9SPuOi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2023 Warrant liability is valued using a Black Scholes Option pricing model with the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B8_zWjZ7Hx5lTx9" style="display: none">Schedule of Warrant Liability Assumptions</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 75%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023 Warrants</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Stock price</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_zLJNysyStj71" style="width: 16%; text-align: right" title="Warrants measurement input">0.59</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_zGijmKtKrnD" style="width: 16%; text-align: right" title="Warrants measurement input">3.05</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free interest rate <b><sup>1</sup></b></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fMQ_____zULjtQhhpXck" style="text-align: right" title="Warrants measurement input">3.61</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fMQ_____zq4NwV2DTbR9" style="text-align: right" title="Warrants measurement input">4.27</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected volatility <b><sup>2</sup></b></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fMg_____zc00RU4JLLt7" style="text-align: right" title="Warrants measurement input">110</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fMg_____zNZTlpAwVrz" style="text-align: right" title="Warrants measurement input">114</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected life (in years) <b><sup>3</sup></b></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember__srt--RangeAxis__srt--MinimumMember_fMw_____zInI89XGEZB5" title="Expected life (in years)">2.25</span> &#8211; <span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember__srt--RangeAxis__srt--MaximumMember_fMw_____zvxxIyKx9oHk" title="Expected life (in years)">2.76</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember__srt--RangeAxis__srt--MinimumMember_fMw_____ziFUP3rBV05k" title="Expected life (in years)">3.0</span> &#8211; <span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember__srt--RangeAxis__srt--MaximumMember_fMw_____z1srIpYXvahf" title="Expected life (in years)">3.50</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected dividend yield <b><sup>4</sup></b></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fNA_____z5JzdFvXs74h" style="text-align: right" title="Warrants measurement input"><span style="-sec-ix-hidden: xdx2ixbrl0914">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fNA_____zCh0lwsjSzVc" style="text-align: right" title="Warrants measurement input"><span style="-sec-ix-hidden: xdx2ixbrl0916">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Fair value of warrants</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--FairValueAdjustmentOfWarrants_c20250101__20250930__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_znWjiU7lWKzi" style="text-align: right" title="Fair value of warrants">8,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_z6ZUOUOr0Yle" style="text-align: right" title="Fair value of warrants">252,000</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><sup>&#160;</sup></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b id="xdx_F0D_zYErwEVo5Yh2"><sup>1</sup></b></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F12_zWAhoOiEQ2p4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on rates
established by the Federal Reserve Bank</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b id="xdx_F04_zuzIqXJv6Heg"><sup>2</sup></b></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F18_znCoxutDAss8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Historical volatility
of the Company&#8217;s common stock is used to estimate the future volatility of its common stock</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span id="xdx_F03_z7LK8N3afFF3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><sup>3</sup></b></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F19_zHgePmiMPZt5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Determined by the
remaining contractual life of the derivative instrument</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b id="xdx_F0D_zaBKs5VLDYW9"><sup>4</sup></b></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F1A_zabJbDUIuca3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on no dividends
paid or expected to be paid</span></td>
</tr></table>

<p id="xdx_8A6_zVTirCa3aaY8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89B_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zS1ssbT5Gvm6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
details of warrant liability transactions were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BF_zd2V521KWH91" style="display: none">Schedule of Warrant Liability Transactions</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 75%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49C_20250101__20250930_znewNSHF8QP9" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49C_20240101__20240930_z831OcIKrEY7" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine Months Ending</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_ecustom--WarrantLiabilityCurrent_iS_zcqzMKyIIuj1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Beginning balance</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">252,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,052,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IssuanceOfStockAndWarrantsForServicesOrClaims_zLXpDWrQTXu8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Issuance of warrants at fair value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0931">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0932">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_zY8WYsozPh3f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Change in fair value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(244,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(870,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_ecustom--ExtinguishmentOfWarrant_zZhKbNjqBTJh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1pt">Extinguishment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0937">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0938">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--WarrantLiabilityCurrent_iE_zSyhNnzQCCA8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Ending balance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">182,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AC_z3ojhHHCiXmf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_DisclosureWarrantLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_DisclosureWarrantLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_WarrantLiabilityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Liability [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_WarrantLiabilityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Deficit)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders&#8217; Equity (Deficit)</a></td>
<td class="text"><p id="xdx_804_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zM4aRlEgIoDe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
5 &#8211; <span id="xdx_826_zSs3qfoGQvm9">Stockholders&#8217; Equity (Deficit)</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s authorized capital as of September 30, 2025 was <span id="xdx_905_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20250930_zotYYF0QbOD" title="Common stock, shares authorized">250,000,000</span> shares of common stock, par value $<span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20250930_z5F4QeLkQ093" title="Common stock, par value">0.001</span> per share, and <span id="xdx_90D_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20250930_zbweAxEGc3pa" title="Preferred stock, shares authorized">15,000,000</span>
shares of preferred stock, par value $<span id="xdx_908_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20250930_zZvnJTZWc9ra" title="Preferred stock, par value">0.01</span> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2025
Private Placement of Equity Facility</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 14, 2025, and as amended on June 10, 2025, the Company entered into a common shares purchase agreement (the &#8220;Purchase Agreement&#8221;)
with investors (collectively, the &#8220;Investors&#8221;) relating to a committed equity facility (the &#8220;Facility&#8221;). Pursuant
to the Purchase Agreement, the Company has the right from time to time at its option to sell to the Investors up to $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_pn6n6_c20250514__20250514__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zDVzuO1CXkJ5" title="Warrants to purcahse">20</span> million of its
common stock subject to certain conditions and limitations set forth in the Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of the shares of common stock to the Investors under the Purchase Agreement, and the timing of any sales, will be determined by the Company
from time to time in its sole discretion and will depend on a variety of factors, including, among other things, market conditions, the
trading price of the common stock and determinations by the Company regarding the use of proceeds from the sale of such shares of common
stock. The net proceeds from any sales under the Purchase Agreement will depend on the frequency with, and prices at, which the shares
of common stock are sold to the Investors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
purchase price of the shares of common stock that the Company elects to sell to the Investors pursuant to the Purchase Agreement will
be <span id="xdx_90F_ecustom--WeightedAverageVolumePriceOfCommonStockPercentage_pid_dp_uPure_c20250514__20250514__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_z3wAuLvWfJag" title="Weighted average volume price of common stock percentage">93</span>% of the volume weighted average price of the shares of common stock during the applicable purchase date on which the Company has
timely delivered written notice to the Investors directing it to purchase shares of common stock under the Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the execution of the Purchase Agreement, the Company agreed to issue to the Investors pre-funded warrants to purchase
an aggregate of <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250514__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zj2V9IhH8Vkf" title="Warrants to purcahse">300,000</span> shares of common stock as consideration for their irrevocable commitment to purchase the shares of common stock
upon the terms and subject to the satisfaction of the conditions set forth in the Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2025
Warrant Inducement Transaction</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 26, 2025, the Company received gross proceeds of $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_c20250226__20250226_zEs2IHD2nizg" title="Proceeds from private placement">686,000</span> before deducting placement agent fees and other offering expenses
of $<span id="xdx_908_eus-gaap--NoninterestExpenseOfferingCost_c20250226__20250226_zADJLQR8FZp2" title="Other offering expenses">70,000</span> in relation to a warrant exercise inducement agreement with certain holders of existing warrants. The existing warrants were
exercisable into <span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_iI_c20250226_zhToVOKHakR8" title="Issuance of warrants, exercisable">302,069</span> shares of the Company&#8217;s common stock at $<span id="xdx_908_eus-gaap--SharePrice_iI_c20250226__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z3IzXbvFzyid" title="Share price">4.35</span> per share. The holders agreed to exercise these existing
warrants at a reduced exercise price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250226__us-gaap--StatementEquityComponentsAxis__custom--InducementWarrantsMember_zO5DN5VS6rYh" title="Share price">2.27</span> per share in exchange for the Company&#8217;s agreement to issue the holders new warrants
(the &#8220;Inducement Warrants&#8221;) exercisable for an aggregate of up to <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250226__us-gaap--StatementEquityComponentsAxis__custom--InducementWarrantsMember_z7uBOwRJOfCl" title="Issuance of warrants">604,138</span> shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Inducement Warrants consist of (i) new Series A Inducement Warrants, representing warrants to purchase up to <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250226__us-gaap--StatementEquityComponentsAxis__custom--SeriesAInducementWarrantsMember_zf5ihwX5oo5e" title="Issuance of warrants">302,069</span> shares of Common
Stock at $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250226__us-gaap--StatementEquityComponentsAxis__custom--SeriesAInducementWarrantsMember_zmYrpu6rGlp5" title="Exercise price">2.02</span> per share exercisable immediately upon issuance with a term of <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_c20250226__us-gaap--StatementEquityComponentsAxis__custom--SeriesAInducementWarrantsMember_zpqpCetQluIh" title="Warrant term">five years</span> from the date of issuance, and (ii) new Series
B Inducement Warrants, representing warrants to purchase up to <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250226__us-gaap--StatementEquityComponentsAxis__custom--SeriesBInducementWarrantsMember_zivr0O9X0lnf" title="Issuance of warrants">302,069</span> shares of common stock at $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250226__us-gaap--StatementEquityComponentsAxis__custom--SeriesBInducementWarrantsMember_zfzJnpckr2x1" title="Exercise price">2.02</span> per share exercisable immediately
upon issuance with a term of <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20250226__us-gaap--StatementEquityComponentsAxis__custom--SeriesBInducementWarrantsMember_zyrBitJRRTVi" title="Warrant term">eighteen months</span> from the date of issuance. In addition, the Company issued warrants to the placement agent
to purchase <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250226_zSV3RSIy3w45" title="Placement agents">21,145</span> shares of common stock at $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250226_zTnR3WTxnmt1" title="Exercise price">2.8375</span> per share exercisable immediately upon issuance with a term of <span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_c20250226_zxqj6rLc5lK4" title="Warrant term">five years</span> from the
date of issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determined that under ASC 815, the 2025 inducement and placement agent warrants are considered indexed to the Company&#8217;s
own stock and eligible for an exception from derivative accounting. Accordingly, the fair value of the 2025 inducement and placement
agent warrants are classified as equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognized the aggregate effect of the modification of warrants and grant of inducement warrants of $<span id="xdx_90B_eus-gaap--PaymentsOfStockIssuanceCosts_pn5n6_c20250101__20250930_zvIZsfTHl78g" title="Equity issuance cost">1.1 </span>million as an equity
issuance cost and the accounting effect is recognized in the Statement of Stockholders&#8217; Equity (Deficit).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preferred
Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series
C Preferred Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2025, there were <span id="xdx_907_eus-gaap--PreferredStockSharesIssued_iI_pid_c20250930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zkTpTyCFB2Fd" title="Preferred stock, shares issued"><span id="xdx_908_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20250930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_z7RVvDQTJ5ca" title="Preferred stock, shares outstanding">96,230</span></span> shares of series C preferred stock, par value $<span id="xdx_904_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20250930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zpJbpcyPk0V" title="Preferred stock, par value">0.01</span> per share (the &#8220;Series C Preferred
Stock&#8221;) issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of numerous reverse stock-splits in previous years and the agreement terms for adjusting the rights of the related shares, the
<span id="xdx_90A_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20250930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zMVJ1oEI7zh8" title="Preferred stock, shares outstanding">96,230</span> shares of Series C Preferred Stock are convertible into an infinitesimal amount of common stock, have no voting rights, and in
the event of liquidation, the holders of the Series C Preferred Stock would not participate in any distribution of the assets or surplus
funds of the Company. The holders of Series C Preferred Stock also are not currently entitled to any dividends if and when declared by
the Board. No dividends to holders of the Series C Preferred Stock were declared or unpaid through September 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series
L Convertible Preferred Stock and Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 12, 2025 (as amended May 21, 2025), the Company entered into a securities purchase agreement (the &#8220;Securities Purchase
Agreement&#8221;) with certain purchasers (the &#8220;Purchasers&#8221;) providing for the issuance and sale of (i) <span id="xdx_90F_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pp2d_c20250512__20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember_ztx6S0x1T4Kk" title="Issuance of shares">6,611.11</span>
shares of the Company&#8217;s Series L 10% Convertible Preferred Stock (the &#8220;Series L Convertible Preferred Stock&#8221;) with
an aggregate stated value of $<span id="xdx_908_ecustom--AggregateStatedValue_c20250512__20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember_z7DyNRduahDi" title="Aggregate stated value">6,611,111</span>,
(ii) warrants to purchase up to <span id="xdx_90E_ecustom--ClassOfWarrantsPurchaseUpPercentage_iI_pid_c20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember_zKaSxg7t3qf7" title="Warrants purchase up percentage">100</span>%
of the shares of the Company&#8217;s common stock issuable upon conversion of the shares of Series L Convertible Preferred Stock
(the &#8220;Common Warrants&#8221;), and (iii) warrants to purchase up to the number of Greenshoe Conversion Shares (as defined in
the Securities Purchase Agreement) issuable upon exercise of the Greenshoe Right (as defined below) (the &#8220;Vesting
Warrants&#8221;, and together with the Common Warrants, the &#8220;Warrants&#8221;). The aggregate purchase price of the Series L
Convertible Preferred Stock and Warrants was $<span id="xdx_900_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20250512__20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember_zYHvRursQSS" title="Issuance of shares, value">5,950,000</span>,
and net proceeds was $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_c20250512__20250512__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_zWaz6954aBbe" title="Proceeds from issuance of preferred stock and warrants, net">5,441,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Securities Purchase Agreement, each Purchaser may elect to purchase shares of Series L Convertible Preferred Stock with an aggregate
stated value of up to $<span id="xdx_904_ecustom--AggregateStatedValue_c20250512__20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--GreenshoeRightsMember_zE5QoHpFxzFk" title="Aggregate stated value">24,018,349</span> (the &#8220;Greenshoe Rights&#8221;) for an aggregate purchase price of $<span id="xdx_90D_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20250512__20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--GreenshoeRightsMember_zjptJeHHx12a" title="Issuance of shares, value">21,616,514</span>, subject to adjustments.
Each Purchaser is entitled to exercise its respective Greenshoe Rights in the ratio of such Purchaser&#8217;s original subscription amount
to the original aggregate subscription amounts of all Purchasers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 12, 2025, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series L 10% Convertible Preferred
Stock (the &#8220;Certificate of Designation&#8221;) with the Secretary of State of the State of Delaware. On May 22, 2025, the Company
increased the shares of Series L Convertible Preferred Stock from <span id="xdx_904_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250522__20250522__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember__srt--RangeAxis__srt--MinimumMember_zpZQME2P54qd" title="Issuance of shares">28,056</span> shares to<span id="xdx_905_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250522__20250522__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember__srt--RangeAxis__srt--MaximumMember_zvktF17NJYZ3" title="Issuance of shares"> 30,630</span> shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Certificate of Designation and subject to certain ownership limitations, the Series L Convertible Preferred Stock may be converted
at any time at the option of the Purchasers into shares of the Company&#8217;s common stock at an initial conversion price of $<span id="xdx_909_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember_z5PwysY2uhSf" title="Conversion price per share">2.043</span>,
subject to certain conditions. In addition, the holders of the Series L Convertible Preferred Stock are entitled to receive cumulative
dividends at the rate of <span id="xdx_909_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_c20250511__20250511__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember_znLwgML2v0L5" title="Percentage of dividend">10</span>% per annum until May 11, 2026, increasing to <span id="xdx_903_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_c20250512__20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember_z2WK8sCAKFfj" title="Percentage of dividend">12</span>% per annum thereafter. The dividends are payable quarterly
in cash, shares of the Company&#8217;s common stock, or a combination thereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Securities Purchase Agreement, each Purchaser was issued (i) a Common Warrant and (ii) a Vesting Warrant. An aggregate of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pp2d_c20250512__20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonWarrantsMember_za6m4cSDSyic" title="Number of shares issued">3,235,978</span>
Common Warrants were issued with an initial exercise price of $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonWarrantsMember_zxyOdy8sH6g1" title="Exercise price per share">2.043</span> per share, are exercisable immediately subject to certain ownership
limitations, and have a term of <span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonWarrantsMember_zAenxlZYBXU9" title="Warrants term">five years</span>. An aggregate of <span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pp2d_c20250512__20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonWarrantsMember_zn3lRSHIIg6j" title="Aggregate number of shares vested">11,576,406</span> Vesting Warrants were issued with an initial exercise price of
$<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--VestingWarrantsMember_zcR0fgUyrS35" title="Exercise price per share">2.043</span> per share, are exercisable immediately subject to certain vesting and ownership limitations, and have a term of <span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonWarrantsMember_z3xGkqNl52L1" title="Warrants term">five years</span> from
the date that the applicable warrant shares vest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Preferred Shares and Warrants both have full-ratchet price and anti-dilution protections and are subject to other adjustments, as
further described in the Certificate of Designation or the Warrants, as applicable, subject, solely with respect to adjustments in
connection with the exercise of Greenshoe Rights, a floor price of $<span id="xdx_90A_eus-gaap--DerivativeFloorPrice_iI_pid_uUSDPShares_c20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--GreenshoeRightsMember_zPcYycTzBZZ3" title="Floor price">0.454</span>
per share (subject to adjustment for reverse and forward splits, recapitalizations and similar transactions).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company and the Purchasers entered into a registration rights agreement pursuant to which the Company agreed to file a registration statement
with the Securities and Exchange Commission covering the public resale of the common stock issuable upon conversion of the Series L Convertible
Preferred Stock and upon exercise of the Warrants. The Company agreed to file a registration statement within 30 days after the initial
closing and after each closing of the exercise of a Greenshoe Right in accordance with the Securities Purchase Agreement, to become effective
no later than 90 days after filing. If these deadlines are not met,<span id="xdx_904_ecustom--LiableOfLiquidatedDamagePercentageDescription_c20250512__20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zd3819ibNCHa" title="Liable of liquidated damage percentage, description"> the Company will be liable for liquidated damages of 1.5% of the
subscription amount paid by each Purchaser. Further, if the Company fails to pay such liquidated damages within 7 days from the date
payable, the Company will pay interest thereon at the prime rate plus 12% to each holder of the registrable securities.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Securities Purchase Agreement, the Company agreed to hold a meeting of its stockholders at the earliest practical date after the
execution of the Securities Purchase Agreement for the purpose of obtaining stockholder approval for the issuance, in the aggregate,
of more than <span id="xdx_90E_ecustom--CommonStockSharesOutstandingPercentage_pid_dp_c20250512__20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z5HNrNTGJ4Ei" title="Common stock shares outstanding percentage">19.99</span>% of the number of shares of the Company&#8217;s common stock outstanding on the date of the initial closing (&#8220;Shareholder
Approval&#8221;). Shareholder Approval was obtained on July 24, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended September 30, 2025, Purchasers of the Company&#8217;s Series L 10% Convertible Preferred Stock elected to
exercise their Greenshoe Rights and purchased <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250701__20250930__us-gaap--StatementClassOfStockAxis__custom--SeriesL10PercentageConvertiblePreferredStockMember_z78FKOCsAIEb" title="Shares issued">1,222.22</span>
shares of the Company&#8217;s Series L 10% Convertible Preferred Stock with a stated value of $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pid_c20250701__20250930__us-gaap--StatementClassOfStockAxis__custom--SeriesL10PercentageConvertiblePreferredStockMember_zoTvKkAKtP6g" title="Shares issued value">1,222,222</span>
for a purchase price of $<span id="xdx_90B_ecustom--PreferredStockPurchasePrice_c20250701__20250930__us-gaap--StatementClassOfStockAxis__custom--SeriesL10PercentageConvertiblePreferredStockMember_z5BxqfcEo2Kd" title="Purchase price">1,100,000</span>.
As a result of the transactions, the conversion price of the Series L 10% Convertible Preferred Stock was decreased from $<span id="xdx_90C_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20250929__us-gaap--StatementClassOfStockAxis__custom--SeriesL10PercentageConvertiblePreferredStockMember_z5p2cekScWQl" title="Exercise price">2.043</span>
to $<span id="xdx_902_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20250930__us-gaap--StatementClassOfStockAxis__custom--SeriesL10PercentageConvertiblePreferredStockMember_zqeHfw1J9l0i" title="Exercise price">0.6421</span>.
The conversion price adjustment constitutes a Dilutive Issuance (as defined in each of the Common Warrants and Vesting Warrants) and
as a result, the exercise price of the Warrants have been decreased, and the number of warrant shares have been increased, such that
the aggregate exercise price of the Warrants, after taking into account the decrease in the exercise price, shall be equal to the
aggregate exercise price prior to such adjustment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends
to holders of the Series L Convertible Preferred Stock in the amount of $<span id="xdx_901_eus-gaap--PaymentsForRepurchaseOfConvertiblePreferredStock_c20250101__20250930__us-gaap--StatementClassOfStockAxis__custom--SeriesLConvertiblePreferredStockMember_zjV54006XzIk" title="Dividends to holders unpaid">229,000</span> were declared and $<span id="xdx_909_eus-gaap--DividendsPayableCurrent_iI_c20250930__us-gaap--StatementClassOfStockAxis__custom--SeriesLConvertiblePreferredStockMember_zR3r37g1Af9e" title="Dividends unpaid">144,000</span> was unpaid as of September
30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Series
L Convertible Preferred Stock initially classified as Mezzanine Equity</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
May 2025 private placement of Series L Convertible Preferred Stock and Warrants described above was allocated to mezzanine equity and
additional paid in capital based on the relative fair value of the Series L Convertible Preferred Stock and Warrants at issuance, respectively.
Initially, upon the occurrence of certain triggering events, each holder had the right to require the Company to redeem the Preferred
Shares at a premium, in accordance with and subject to certain conditions as further described in the Certificate of Designation. Accordingly,
the relative fair value of the Series L Convertible Preferred Stock was initially recorded as mezzanine equity. The relative fair value
of the Warrants was recorded in additional paid in capital. The relative fair values and allocation of net proceeds is below:</span></p>

<p id="xdx_893_eus-gaap--ScheduleOfConversionsOfStockTextBlock_zwlEtNrdjBIj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BE_zQD8KHdsgYI3" style="display: none">Schedule of fair values and allocation of net proceeds</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.85in; border-collapse: collapse; width: 65%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20250501__20250531_zUQwYfvYORY1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Relative Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Percentage</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_hus-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_zFqcvEw9WdC7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Series L Convertible Preferred Stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">3,688,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_ecustom--ConvertiblePreferredStockAndWarrantsFairValuePercentage_pid_dp_uPure_c20250501__20250531__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_zlzQG7EOTMcj" style="width: 16%; text-align: right" title="Convertible preferred stock and warrants fair value percentage">37.7</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_404_eus-gaap--StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_hus-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPCubDqq44Af" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Warrants</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">6,089,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98C_ecustom--ConvertiblePreferredStockAndWarrantsFairValuePercentage_pid_dp_uPure_c20250501__20250531__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z0cmsSWGOh0g" style="padding-bottom: 1pt; text-align: right" title="Convertible preferred stock and warrants fair value percentage">62.3</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr id="xdx_406_eus-gaap--StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_zhGmkVgz1ka4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,777,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_98C_ecustom--ConvertiblePreferredStockAndWarrantsFairValuePercentage_pid_dp_uPure_c20250501__20250531_z4QTbDtFRz6" style="padding-bottom: 2.5pt; text-align: right" title="Convertible preferred stock and warrants fair value percentage">100.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.85in; border-collapse: collapse; width: 65%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20250501__20250531_zSfL5Pa7z8J" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Allocation of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net Proceeds</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Percentage</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_hus-gaap--StatementClassOfStockAxis__custom--MezzanineEquityMember_z6B8H5k5PQNh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Mezzanine equity</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">2,052,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_ecustom--ConvertiblePreferredStockAndWarrantsNetProceedsPercentage_pid_dp_uPure_c20250501__20250531__us-gaap--StatementClassOfStockAxis__custom--MezzanineEquityMember_zD8Ra4yZrJh9" style="width: 16%; text-align: right" title="Convertible preferred stock and warrants net proceeds percentage">37.7</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_40B_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_hus-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zbl8wWapqWZ7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Additional paid in capital</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,389,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_985_ecustom--ConvertiblePreferredStockAndWarrantsNetProceedsPercentage_pid_dp_uPure_c20250501__20250531__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zjsO5UCWw2jl" style="padding-bottom: 1pt; text-align: right" title="Convertible preferred stock and warrants net proceeds percentage">62.3</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr id="xdx_40E_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_zIX6QabUbDC6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,441,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_981_ecustom--ConvertiblePreferredStockAndWarrantsNetProceedsPercentage_pid_dp_uPure_c20250501__20250531_zAnr0VDobY3g" style="padding-bottom: 2.5pt; text-align: right" title="Convertible preferred stock and warrants net proceeds percentage">100.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

<p id="xdx_8AB_zqglQf5Ut4De" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2025, all the holders of GT Biopharma, Inc.&#8217;s Series L 10% Convertible Preferred Stock provided waivers and agreed to
waive the rights to redemption set forth in the Certificate of Designation. Accordingly, as of September 30, 2025 the Preferred Stock
has been reclassified from mezzanine equity to shareholders&#8217; equity as it is no longer conditionally redeemable upon the occurrence
of certain events that were not solely within the control of the Company,</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Warrants and Options<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract', window );"><strong>Common Stock Warrants And Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_CommonStockWarrantsAndOptionsTextBlock', window );">Common Stock Warrants and Options</a></td>
<td class="text"><p id="xdx_809_ecustom--CommonStockWarrantsAndOptionsTextBlock_zNrj7GekWaY" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
6 &#8211; <span id="xdx_82C_z3h5xfFF7ev5">Common Stock Warrants and Options</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
Stock Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89F_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zojafDrERnad" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
warrant transactions for the nine months ended September 30, 2025 were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B0_zmIuocYy0Jvj" style="display: none">Schedule of Warrant Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 75%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine Months Ended September 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted Average</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%">Warrants outstanding at December 31, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20250101__20250930_zDMi81wrfrC8" style="width: 18%; text-align: right" title="Warrants outstanding, beginning balance">1,120,429</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20250930_zD5R47lSsiu2" style="width: 18%; text-align: right" title="Weighted average exercise price, beginning balance">18.85</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20250101__20250930_z0wqIIccBgEc" style="text-align: right" title="Number of warrants, granted">16,468,308</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice_pid_c20250101__20250930_zmvI925Vzm15" style="text-align: right" title="Weighted average exercise price, granted">2.04</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Granted pursuant to full-ratchet price and anti-dilution protections</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedPursuantToFullRatchetPriceProtection_pid_c20250101__20250930_z8gbwwRzu8B9" style="text-align: right" title="Number of warrants, granted pursuant to full ratchet price and anti-dilution protections">32,709,588</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedPursuantToFullRatchetPriceProtectionWeightedAverageExercisePrice_pid_c20250101__20250930_zyRMRaQV3zRl" style="text-align: right" title="Weighted average exercise price, granted pursuant to full ratchet price and anti-dilution protections">0.64</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Forfeited/cancelled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20250101__20250930_zCUCfhiXx9zl" style="text-align: right" title="Number of warrants, forfeited/cancelled">(1,866</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice_pid_c20250101__20250930_zdYoRgK4SmH2" style="text-align: right" title="Weighted average exercise price, forfeited/cancelled">102.00</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1pt">Exercised</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20250101__20250930_ziKRaAnaZiQ" style="border-bottom: Black 1pt solid; text-align: right" title="Number of warrants, exercised">(837,069</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice_pid_c20250101__20250930_z9CDiYG0FdPa" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, exercised">2.11</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Warrants outstanding at September 30, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20250101__20250930_zQEAWPH7U4u" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants outstanding, ending balance">49,459,390</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20250930_zBUzbvpGWmhf" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, ending balance">1.04</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Warrants exercisable at September 30, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_iI_pid_c20250930_zeOz6m1p7MEa" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants exercisable, ending balance">13,956,955</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20250930_zRozTTnSJ334" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable, ending balance">2.04</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A1_zIwQ0dxgDORg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate intrinsic value of all warrants outstanding and all warrants vested and exercisable as of September 30, 2025 was approximately
$<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20250930_zTb9aWQiLZJl" title="Options outstanding vested intrinsic value">281,000</span>, in each case based on the fair value of the Company&#8217;s common stock on September 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the May 2025 Private Placement of Series L Convertible Preferred Stock and Warrants the Company issued an aggregate of <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pp2d_c20250531__20250531__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonWarrantsMember_zCSUyqlm2cHd" title="Aggregate number of shares issued">3,235,978</span>
Common Warrants with an initial exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250531__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonWarrantsMember_zDcPfglbFdF6" title="Exercise price per share">2.043</span>
per share, they are exercisable, subject to certain ownership limitations, immediately upon issuance and have a term of exercise
equal to five years. An aggregate of <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pp2d_c20250531__20250531__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonWarrantsMember_zQi7HBcM70jk" title="Aggregate number of shares vested">11,756,406</span>
Vesting Warrants were issued with an initial exercise price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250531__us-gaap--ClassOfWarrantOrRightAxis__custom--VestingWarrantsMember_zkFZpB3GJbm5" title="Exercise price per share">2.043</span>
per share, they are exercisable subject to certain vesting and ownership limitations, and have a term of exercise equal to five
years from the date that the applicable warrant shares vest. The Common and Vesting Warrants both have full-ratchet price and
anti-dilition protections and are subject to other adjustments, as further described in the Certificate of Designation or the
Warrants, as applicable, subject, solely with respect to adjustments in connection with the exercise of Greenshoe Rights, a floor
price of $<span id="xdx_902_eus-gaap--DerivativeFloorPrice_iI_pid_uUSDPShares_c20250531__us-gaap--StatementEquityComponentsAxis__custom--GreenshoeRightsMember_zHbNpj77xgTk" title="Floor price per share">0.454</span>
per share (subject to adjustment for reverse and forward splits, recapitalizations and similar transactions). As of September 30,
2025 pursuant to full-ratchet price and anti-dilution protections the exercise price of the Common and Vesting Warrants has been
reduced to $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonWarrantsMember_zzpU0TD1JD33" title="Exercise price per share">0.6421</span>
and an additional <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250930__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonWarrantsMember_z2AT9QXbDLAj" title="Class of warrant or right outstanding">32,709,588</span>
Common and Vesting Warrants have been issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the May 2025 Private Placement of Equity Facility the Company issued pre-funded warrants to purchase an aggregate of <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250531__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zPdSLkFaatBe" title="Issuance of pre-funded warrants">300,000</span> shares
of common stock as consideration for its irrevocable commitment to purchase the shares of common stock upon the terms and subject to
the satisfaction of the conditions set forth in the Purchase Agreement. The pre-funded warrants may be exercise at any time after issuance
and until exercised in full.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2025 the Company issued warrants underlying <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250531_zS0KkOPMJ4K" title="Number of warrant issued">24,390</span> shares of common stock exercisable immediately upon issuance with a term of five
years from the date of issuance at $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250531_zTGi2zrQVaF6" title="Exercise price per share">2.46</span> per share with a fair value of approximately $<span id="xdx_901_eus-gaap--WarrantsAndRightsOutstanding_iI_c20250531_zFF0dfWJalwc" title="Fair value of warrant">44,000</span> in exchange for the waiver of a variable
rate transaction (&#8220;VRT&#8221;). In addition, in May and June 2025, the Company issued <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250601__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmYKWEzdQW87" title="Number of new shares issued"><span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250501__20250531__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ze8F9Bicvl9i" title="Number of new shares issued">50,000</span></span> shares of common stock and warrants
underlying <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250531__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zrX3ygy0wad2" title="Number of warrant issued"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ztbmfnSf0WWl" title="Number of warrant issued">200,000</span></span> shares of common stock with an aggregate fair value of approximately $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20250501__20250531_zvcpnhAqmNdb" title="Number shares issued for service, value"><span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20250601__20250630_z3Zi4w9DOaDk" title="Number shares issued for service, value">718,000</span></span> to vendors as compensation for services.
The warrants underlying <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250531__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5lfFA3HHcl7" title="Number of warrant issued">200,000</span> shares of common stock consist of warrants underlying <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250531__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_z9TgMDXP9eRb" title="Number of warrant issued">50,000</span> shares of common stock that are exercisable
immediately upon issuance with a term of five years from the date of issuance at $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250531__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zeMrACZ3YOPk" title="Exercise price per share">2.50</span> per share, and warrants underlying <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightUnissued_iI_c20250531__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zbQozpLu8xm7" title="Issuance of pre-funded warrants">150,000</span> shares
of common stock that are pre-funded warrants exercisable at any time after issuance and until exercised in full.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89D_ecustom--ScheduleOfWarrantsOustandingAndExercisableTableTextBlock_hus-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zHWlacB2NAk9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
outstanding as of September 30, 2025 are exercisable as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B4_z7RvbhSWOw3f" style="display: none">Schedule of Warrants Outstanding and Exercisable</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants Outstanding and Exercisable as of September 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Range of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining Contractual Life (Years)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Price</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td style="width: 22%; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zUT6l6jEKntk" title="Range of exercise price">0.0001</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_ziHQqR1L4Zu9" style="width: 22%; text-align: right" title="Number of outstanding">476,251</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 21%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 21%; text-align: right"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zlvanojrrKPb" title="Warrants weighted average exercise price">0.0001</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zXi70y0pXUBb" title="Range of exercise price">0.6421</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_ziHdbHHQIde7" style="text-align: right" title="Number of outstanding">10,296,061</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zSYduWdmwKB4" title="Warrants outstanding, weighted average remaining contractual life (years)">4.6</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z1BDBE5FhwH4" title="Warrants weighted average exercise price">0.6421</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zmAGy9fK2cNa" title="Range of exercise price">0.6421</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_z9wH87jvtpC7" style="text-align: right" title="Number of outstanding">37,405,912</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zhbZKUXx3eVf" title="Warrants weighted average exercise price">0.6421</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zUgmU8Um88wi" title="Range of exercise price">2.02</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_z0cqNmFeX6S2" style="text-align: right" title="Number of outstanding">369,138</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zgyaDsI6O1ph" title="Warrants outstanding, weighted average remaining contractual life (years)">2.7</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zfC14Nv9cbnc" title="Warrants weighted average exercise price">2.02</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zs2RZdjqL7wa" title="Range of exercise price">2.46</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zEb5IIygSNy7" style="text-align: right" title="Number of outstanding">24,390</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_z2y1Y41ZnAl1" title="Warrants outstanding, weighted average remaining contractual life (years)">4.6</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zrbKcHFfFGIk" title="Warrants weighted average exercise price">2.46</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zeWeRJMU1rSh" title="Range of exercise price">2.50</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zss7EjAJGnd2" style="text-align: right" title="Number of outstanding">50,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_z6vfFtikprAl" title="Warrants outstanding, weighted average remaining contractual life (years)">2.6</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_z0QEfBc2ITei" title="Warrants weighted average exercise price">2.50</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zzkSwPZhUuKa" title="Range of exercise price">2.8375</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zuq6OtqvRWj" style="text-align: right" title="Number of outstanding">21,145</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zqo2FRONefMi" title="Warrants outstanding, weighted average remaining contractual life (years)">4.6</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zW5gd8jtwPg6" title="Warrants weighted average exercise price">2.8375</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zkBpwOf5vpT3" title="Range of exercise price">4.35</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_z5IfCHLtsme5" style="text-align: right" title="Number of outstanding">437,931</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zl282ScRvmz" title="Warrants outstanding, weighted average remaining contractual life (years)">3.6</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zf8NbEcZDPH5" title="Warrants weighted average exercise price">4.35</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zDJLO9B31ut4" title="Range of exercise price">5.4375</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zV7sR378lp05" style="text-align: right" title="Number of outstanding">88,800</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_z50UlTboaJS" title="Warrants outstanding, weighted average remaining contractual life (years)">3.6</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zYHcMNW7OeBg" title="Warrants weighted average exercise price">5.4375</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_znnXzdKRhTql" title="Range of exercise price">30.00</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zarnJJL9S6O5" style="text-align: right" title="Number of outstanding">216,666</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zQhwh4r1G8u7" title="Warrants outstanding, weighted average remaining contractual life (years)">2.8</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zOASU6c886" title="Warrants weighted average exercise price">30.00</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeElevenMember_zUbRjEgZB0m7" title="Range of exercise price">37.50</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeElevenMember_zyho79WSLx8b" style="text-align: right" title="Number of outstanding">13,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeElevenMember_z8J5A8vfjn3b" title="Warrants outstanding, weighted average remaining contractual life (years)">2.3</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeElevenMember_zucetDw1K5zg" title="Warrants weighted average exercise price">37.50</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwelveMember_zUN460lJhTZ5" title="Range of exercise price">165.00</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwelveMember_zLFwzeWGv932" style="text-align: right" title="Number of outstanding">52,316</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwelveMember_zQ515VieNZ95" title="Warrants outstanding, weighted average remaining contractual life (years)">0.4</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwelveMember_zULwM9EVitxc" title="Warrants weighted average exercise price">165.00</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThirteenMember_zD6FzkOCevq1" title="Range of exercise price">206.25</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThirteenMember_z6z8QGOxFjF6" style="border-bottom: Black 1pt solid; text-align: right" title="Number of outstanding">7,780</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThirteenMember_zBtbV2FGmGK2" title="Warrants outstanding, weighted average remaining contractual life (years)">0.4</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThirteenMember_zf2jmpvYapTk" title="Warrants weighted average exercise price">206.25</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zr5DMGgWwvi4" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of outstanding">49,459,390</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zbQ0KpRWj123" title="Warrants outstanding, weighted average remaining contractual life (years)">4.5</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zFZSoYIVudOd" title="Warrants weighted average exercise price">1.04</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A5_zHPoc0x7mo3k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
Stock Options</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2022 the Company established the 2022 Omnibus Incentive Plan (the &#8220;Plan&#8221;). The Plan was approved by our Board and stockholders.
The purpose of the Plan is to grant stock and options to purchase our common stock, and other incentive awards, to our employees, directors,
and key consultants. On July 24, 2025 shareholders voted to increase the maximum number of shares of common stock that may be issued
pursuant to awards granted under the Plan by <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220401__20220430__us-gaap--AwardTypeAxis__custom--OmnibusIncentivePlanMember_z2F9mVB3ZSh8" title="Common stock awards granted">583,334</span>. Pursuant to the increase, the maximum number of shares of common stock that may
be issued pursuant to awards granted under the Plan is <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220401__20220430__us-gaap--AwardTypeAxis__custom--OmnibusIncentivePlanMember__srt--RangeAxis__srt--MaximumMember_zuu4XF7xh6o4" title="Common stock awards granted">750,000</span>. The shares of our common stock underlying cancelled and forfeited awards
issued under the Plan may again become available for grant under the Plan. As of September 30, 2025, there were <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250930_zGDZ7L3FJ3Ec" title="Stock option outstanding">597,550</span> stock options
outstanding and <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20250101__20250930_zedJ8fhwYUF1" title="Rstricted stock granted">25,935</span> shares of restricted stock granted in prior years under the Plan, which left <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20250930__us-gaap--AwardTypeAxis__custom--OmnibusIncentivePlanMember_z34bHj57XFP6" title="Available for grant">126,515</span> shares available for grant
under the Plan. The following table summarizes stock option transactions for the nine months ended September 30, 2025:</span></p>

<p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z58qRwcj4efd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_zVD5FfCQp6Ol" style="display: none">Schedule of Options Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 75%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine Months Ended September, 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted Average</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%">Options outstanding at December 31, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20250101__20250930_zlCpHCqAJDz5" style="width: 18%; text-align: right" title="Number of options outstanding, beginning">124,600</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20250930_zTb4DgWPqfB1" style="width: 18%; text-align: right" title="Weighted-Average Exercise Price, beginning">32.69</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20250101__20250930_z4z6r8NWelW5" style="text-align: right" title="Number of options, granted">525,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250101__20250930_zx5pwK3pMYOi" style="text-align: right" title="Weighted-Average Exercise Price, granted">1.33</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Forfeited/cancelled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20250101__20250930_zw8dICJoUuEg" style="text-align: right" title="Number of options, forfeited/cancelled">(52,050</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20250101__20250930_zzysbtEhWNF1" style="text-align: right" title="Weighted-Average Exercise Price, forfeited/cancelled">43.08</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1pt">Exercised</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20250101__20250930_z3Y07HEMPkHk" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1289">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20250101__20250930_zQVMUgoguQN7" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-Average Exercise Price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1291">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Options outstanding at September 30, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20250101__20250930_ztu8a4f904Id" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options outstanding, ending">597,550</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20250930_ziUdv9555Hrk" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-Average Exercise Price, ending">4.23</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Options exercisable at September 30, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20250930_zbVv8HUHubmc" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options outstanding exercisable">396,439</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20250930_z6ymFUoUBJil" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-Average Exercise Price,exercisable, ending">5.68</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AB_zWwYbfLCiwnh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average remaining contractual life of all options outstanding, and all options vested and exercisable as of September 30, 2025
was approximately <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20250930_zpMaxqfj9EMk" title="Share-based compensation weighted average remaining contractual term">9.6</span> years. Furthermore, the aggregate intrinsic value of all options outstanding and all options vested and exercisable
as of September 30, 2025 was $<span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20250101__20250930_zdBGXeAA89Gl" title="Options outstanding intrinsic value">0</span>, in each case based on the fair value of the Company&#8217;s common stock on September 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
total fair value of options that vested during the nine months ended September 30, 2025 and 2024, was $<span id="xdx_909_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_c20250101__20250930_z2uHj3u5pRah" title="Fair value of vested stock options">386,000</span> and $<span id="xdx_90D_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_c20240101__20240930_zZFDFXG9r483" title="Fair value of vested stock options">222,000</span>, respectively,
and is included in selling, general and administrative expense in the accompanying unaudited condensed statements of operations. As of
September 30, 2025, <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20250930_zZjKAxYknOm8" title="Stock option, exercisable">396,439</span> stock options were vested and exercisable and unvested compensation expense amounted to approximately $<span id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1_c20250101__20250930_zzjFdcqVZVdg" title="Stock option, unvested compensation">236,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zQxhkOstx6f2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
outstanding as of September 30, 2025 are exercisable as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_ziaOabyQCHsk" style="display: none">Schedule of Options Outstanding and Options Exercisable</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Stock Options Exercisable as of September 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Range of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining Contractual Life (Years)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Price</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td style="width: 22%; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zf3an5PIZ5Cf" title="Range of excercise price">1.33</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_z2rH9xN7Lf5e" style="width: 22%; text-align: right" title="Options outstanding">337,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 21%; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zIAMyDui7Wk9" title="Options outstanding, weighted average remaining contractual life (years)">9.9</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 21%; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zEGktHgLOcUa" title="Options outstanding, weighted average exercise price">1.33</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zKBOZuDHs8C7" title="Range of excercise price">2.11</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zjGSanyWE235" style="text-align: right" title="Options outstanding">9,723</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z467DOdJnBM3" title="Options outstanding, weighted average remaining contractual life (years)">7.7</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z6PAHYRchmTf" title="Options outstanding, weighted average exercise price">2.11</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zJQF9JaqeCfj" title="Range of excercise price">10.50</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zqa0EH8A9zP4" style="text-align: right" title="Options outstanding">16,667</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zrGTW5p5sR09" title="Options outstanding, weighted average remaining contractual life (years)">7.6</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zpvtAqCOUnB7" title="Options outstanding, weighted average exercise price">10.50</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zuNrXfu4ilVh" title="Range of excercise price">25.50</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_z4wZzY6gaPkh" style="text-align: right" title="Options outstanding">16,667</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zNTlFwlRbljl" title="Options outstanding, weighted average remaining contractual life (years)">7.3</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_z7cZQdT707Uj" title="Options outstanding, weighted average exercise price">25.50</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zK7rXtkb54Bk" title="Range of excercise price">74.40</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zErabDuoLU19" style="border-bottom: Black 1pt solid; text-align: right" title="Options outstanding">15,882</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zGQxVdCMPUPa" title="Options outstanding, weighted average remaining contractual life (years)">6.8</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zW7MkwNXEat6" title="Options outstanding, weighted average exercise price">74.40</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250930_z7jQCwmR4Tqe" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding">396,439</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A5_zFRbcgUZkXRj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_CommonStockWarrantsAndOptionsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock Warrants and Options [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_CommonStockWarrantsAndOptionsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zhurUA49gX87" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
7 &#8211; <span id="xdx_827_zPH1yKHKxpUb">Commitments and Contingencies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Litigation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is involved in certain legal proceedings that arise from time to time in the ordinary course of our business. Except for income
tax contingencies, we record accruals for contingencies to the extent that our management concludes that the occurrence is probable and
that the related amounts of loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred.
There is no current or pending litigation of any significance with the exception of the matters identified below that have arisen under,
and are being handled in, the normal course of business:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ohri
Matter</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 22, 2024, the Company filed an AAA Arbitration Demand against Manu Ohri, its former Chief Financial Officer. In the demand, the
Company asserts claims against Mr. Ohri for breach of his fiduciary duties and breach of contract and seeks a declaratory judgment providing
that the Company may characterize Mr. Ohri&#8217;s termination as &#8220;for cause&#8221; under his employment agreement, and that the
Company may revoke the separation agreement entered into between the Company and Mr. Ohri prior to the Company learning of Mr. Ohri&#8217;s
breaches. In addition to the declaratory judgment, the Company seeks damages arising from Mr. Ohri&#8217;s violations, and attorneys&#8217;
fees and any forum and arbitration fees. On September 3, 2024, Mr. Ohri filed both a general denial of the Company&#8217;s claims against
him and counterclaims for breach of his employment agreement and Separation Agreement. The final hearing date, originally scheduled for
June 10, 2025, has been postponed indefinitely in order to allow the parties to mediate the dispute. At this time, mediation has not
been scheduled. There is a status conference scheduled for December 11, 2025 before the AAA. At this stage in the proceedings the Company
is not able to determine the probability of the outcome of this matter or a range of reasonably expected losses, if any. The Company
believes it has recorded an appropriate accrual for the matter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TWF
Global Matter</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 24, 2023, TWF Global, LLC (&#8220;TWF&#8221;) filed a Complaint in the California Superior Court for the County of Los Angeles naming
the Company as defendant. The complaint alleges that TWF is the holder of two Convertible Promissory Notes (&#8220;Notes&#8221;) and
that the Company did not deliver shares of common stock due on conversion in February 2021. TWF was seeking per diem liquidated damages
based on the terms of alleged Notes. On July 14, 2023, the Company filed a motion to dismiss for improper forum because the terms of
the Notes, as alleged, require disputes to be filed in New York state and federal courts. TWF voluntarily dismissed its complaint before
the California Superior Court of Los Angeles without prejudice. The Company subsequently filed a summons and complaint for interpleader
against TWF and Z-One, LLC before the Supreme Court of the State of New York County of New York, asking the Supreme Court to determine
if the Company&#8217;s shares of common stock should be registered to TWF or Z-One LLC, as both of these entities have made conflicting
demands for the shares. On February 5, 2024, the Company filed a motion for entry of default against TWF, seeking an order directing
the Company to register the shares of common stock in the name of Z-One, LLC and that the Company be released from all associated liability
and claims. The Court denied the motion without prejudice and agreed to reconsider the motion without further briefing upon the filing
of a supplemental party affidavit. On May 9, 2024, Z-One, LLC filed a motion for summary judgement seeking dismissal of the action, representing
that Z-One, LLC and TWF have settled their dispute over the entitlement to the Company&#8217;s shares of common stock and there is no
remaining dispute before the Court. On May 21, 2024, the Company filed a supplemental affidavit in support of its motion for entry of
default. On November 14, 2024, the Court held a hearing on the parties&#8217; motions, at which the Court found that the motion for entry
of default was mooted by the settlement agreement between Z-One, LLC and TWF. The Court ordered that the case be dismissed. On February
17, 2025, Z-One, LLC filed a Summons with Notice in the Supreme Court of the State of New York, County of New York. The Company then
filed a demand that Z-One, LLC serve a complaint, and on June 25, 2025, Z-One, LLC filed a Complaint alleging that it is the holder,
either originally or by assignment, of a Convertible Note in the principal amount of $<span id="xdx_905_eus-gaap--LossContingencyDamagesPaidValue_c20250217__20250217__srt--LitigationCaseAxis__custom--ZOneLLCMember_z5zo3RDdTZk6" title="Principal amount">150,000</span>, that the Company breached the Convertible
Note by failing to deliver conversion shares to Z-One, LLC, and that the Company owes it damages in excess of $<span id="xdx_904_eus-gaap--LossContingencyDamagesSoughtValue_c20250217__20250217__srt--LitigationCaseAxis__custom--ZOneLLCMember_zKbHcI6bAt81" title="Damages sought value">500,000</span>. On August 26,
2025, the Company filed a motion to dismiss the Complaint in its entirety for lack of standing and failure to state a cause of action.
The Company believes that the claims related to the Notes are without merit, and will continue to vigorously defend against these claims.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Silberfein,
DiPietro, and Werthman Trust Matters</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 8, 2025, Coby Silberfein filed a summons with notice in the State of New York Supreme Court for the County of New York naming the
Company as defendant seeking damages for breach of a securities purchase agreement and convertible note in the principal amount of $<span id="xdx_901_eus-gaap--LossContingencyDamagesPaidValue_c20250708__20250708__srt--LitigationCaseAxis__custom--CobySilberfeinMember_zR3V9lwZs5ag" title="Principal amount">100,000</span>.
On July 8, 2025, Justin DiPietro filed a summons with notice in the State of New York Supreme Court for the County of New York naming
the Company as defendant seeking damages for breach of a securities purchase agreement and convertible note in the principal amount of
$<span id="xdx_908_eus-gaap--LossContingencyDamagesPaidValue_c20250708__20250708__srt--LitigationCaseAxis__custom--CobySilberfeinMember_zMLS7M2rrQli" title="Principal amount">100,000</span>. On July 9, 2025, Phillip Werthman Trust filed a summons with notice in the State of New York Supreme Court for the County of
New York naming the Company as defendant seeking damages for breach of a securities purchase agreement and convertible note in the principal
amount of $<span id="xdx_901_eus-gaap--LossContingencyDamagesPaidValue_c20250709__20250709__srt--LitigationCaseAxis__custom--CobySilberfeinMember_zfZNVgRWRC23" title="Damages paid">100,000</span>. The three summons with notice are identical and allege that the plaintiffs are holders of convertible notes and that
the Company breached the convertible notes by failing to deliver shares of common stock due on conversion in in 2021. Plaintiffs are
seeking specific performance and damages. On August 12, 2025, the Company filed demands that the plaintiffs serve complaints. On September
2, 2025, each plaintiff served a Complaint similar in substance to the summons, except that Plaintiff Silberfein now alleges breach of
a convertible note with a principal amount of $<span id="xdx_906_eus-gaap--LossContingencyDamagesPaidValue_c20250902__20250902__srt--LitigationCaseAxis__custom--CobySilberfeinMember_zU643R2p4TY5" title="Principal amount">150,000</span>, rather than $<span id="xdx_909_eus-gaap--LossContingencyDamagesSoughtValue_c20250902__20250902__srt--LitigationCaseAxis__custom--CobySilberfeinMember_zocpXuXyMZ4b" title="Damages sought value">100,000</span>. Each plaintiff alleges that the Company breached a convertible
note by failing to deliver conversion shares to the plaintiff holder, and that the Company owes damages in excess of $<span id="xdx_90F_eus-gaap--LossContingencyDamagesSought_c20250902__20250902__srt--LitigationCaseAxis__custom--CobySilberfeinMember_zdBbxEl87YU8" title="Owes damages excess value">500,000</span>. The Company
intends to seek dismissal of the complaints. The Company believes that the claims are without merit, and intends to vigorously defend
against these claims.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Significant
Agreements</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cytovance
Biologics, Inc., a Related Party</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2020, the Company entered into a Master Services Agreement with Cytovance, to perform biologic development and manufacturing
services, and to produce and test compounds used in the Company&#8217;s potential product candidates. The Company subsequently executed
numerous Statements of Work (&#8220;SOWs&#8221;) for the research and development of products for use in clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 24, 2022, the Company entered into a Settlement and Investment Agreement with Cytovance that amended existing SOWs and allowed
for future invoices to be settled in in a combination of cash and issuance of the Company&#8217;s common stock. The Settlement and Investment
Agreement also set Cytovance&#8217;s beneficial ownership limitation at <span id="xdx_905_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20220824__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--CytovanceBiologicsIncMember_znf6Z4AxyKEf" title="Equity method investment, ownership percentage">4.9</span>% of the issued and outstanding shares of the Company&#8217;s
common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 25, 2024, the Company entered into an Amendment to the Settlement and Investment Agreement with Cytovance that increased Cytovance&#8217;s
beneficial ownership limitation to <span id="xdx_907_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20240425__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--CytovanceBiologicsIncMember_zohVwgGfZU51" title="Equity method investment, ownership percentage">9.9</span>% of the issued and outstanding shares of the Company&#8217;s common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 30, 2024, Cytovance became a related party as their beneficial ownership exceeded <span id="xdx_903_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20240630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--CytovanceBiologicsIncMember_zh5CelRi7wJg" title="Equity method investment, ownership percentage">5</span>% of the issued and outstanding shares of the
Company&#8217;s common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the nine months ended September 30, 2025 and 2024, the Company recognized research and development expenses of approximately $<span id="xdx_906_eus-gaap--ProceedsFromRelatedPartyDebt_c20250101__20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zEnuRAjrxg4" title="Research and development expenses">686,000</span>
and $<span id="xdx_908_eus-gaap--ProceedsFromRelatedPartyDebt_pn5n6_c20240101__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z6nlxR7lCn65" title="Research and development expenses">1.4</span> million, respectively and made cash payments amounting to approximately $<span id="xdx_90A_eus-gaap--RepaymentsOfRelatedPartyDebt_pn6n6_c20250101__20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_z9uaPyKlY69b" title="Cash payments">1</span> million and $<span id="xdx_904_eus-gaap--RepaymentsOfRelatedPartyDebt_pn5n6_c20240101__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zi6YarCf6Ir3" title="Cash payments">3.4</span> million, respectively to Cytovance.
In addition, during the nine months ended September 30, 2025, the Company issued pre-funded warrants to purchase up to <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zoZ9qtczA3qe" title="Issuance of pre-funded warrants">326,251</span> shares
of common stock exercisable at $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_z9vEMOpzkEQh" title="Exercise price">0.0001</span> per share to settle accounts payable valued at approximately $<span id="xdx_905_eus-gaap--FairValueAdjustmentOfWarrants_c20250101__20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zXGv2cqMrSik" title="Fair value">847,000</span>; and during the nine months
ended September 30, 2024, the Company issued <span id="xdx_90C_ecustom--StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable_pid_c20240101__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zIOHfkM9SfB8" title="Issuance of common stock in settlement of vendor payable, shares">127,597</span> shares of common stock to settle accounts payable valued at approximately $<span id="xdx_90F_ecustom--StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable_c20240101__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zgGYE3L0TU4a" title="Issuance of common stock in settlement of vendor payable">810,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2025, the Company&#8217;s commitments in relation to unbilled and unaccrued SOWs and any related Change Orders from
Cytovance for services that have not yet been rendered as of September 30, 2025, amounted to approximately $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20250101__20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zayxE9SGETo8" title="Stock issued during period, value, issued for services">273,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>University
of Minnesota</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023
Sponsored Research Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 20, 2024, the Company entered into a sponsored research agreement with the Regents of the University of Minnesota (the &#8220;2023
Sponsored Research Agreement&#8221;), effective July 1, 2023, and expiring on July 1, 2025. Payments totaling approximately $<span id="xdx_907_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_pn5n6_c20240520__20240520__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeSponsoredResearchAgreementMember_zqvAqnH26Nsa" title="Aggregate research and development expense">1.7</span> million
are due over the life of the agreement. The purpose of the agreement is for the Regents of the University of Minnesota to continue work
with the Company with three major goals in mind: (1) support the Company&#8217;s TriKE<sup>&#174;</sup> product development and commercial
GMP manufacturing efforts; (2) TriKE<sup>&#174;</sup> pharmacokinetics optimization in humans and investigation of effects of altering
the route of administration; and (3) research and development of TriKE<sup>&#174;</sup> platform. The major deliverables proposed are:
(1) creation of IND enabling data for TriKE<sup>&#174;</sup> constructs in support of the Company&#8217;s product development and commercial
GMP manufacturing efforts outside of the University of Minnesota; (2) TriKE<sup>&#174;</sup> platform drug delivery changes to allow transition
from intravenous (IV) continuous infusion to alternative drug delivery administration (IV bolus, intraperitoneal [IP], subcutaneous [SQ])
and extended PK in humans and gain an increased understanding of changes in the patient&#8217;s native NK cell population as a result
of alteration of TriKE<sup>&#174;</sup> administration; and (3) research and development of TriKE<sup>&#174;</sup> platform combination
with other FDA approved (or soon to be approved) therapeutics and alterations to TriKE<sup>&#174;</sup> platform through formation of
immune complexes. Most studies will use TriKE<sup>&#174;</sup> DNA/amino acid sequences created by the Company under existing licensing
terms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 18, 2025, the 2023 Sponsored Research Agreement was amended to expire on December 31, 2025. In addition, payments amounting to $<span id="xdx_904_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20250618__20250618__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeSponsoredResearchAgreementMember_zqvANflg3Obf" title="Payments of research and development">216,000</span>
were added bringing the total payments due over the life of the agreement to approximately $<span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_pn5n6_c20250618__20250618__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeSponsoredResearchAgreementMember_z7udLjmFHPwh" title="Aggregate research and development expense">1.9</span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded an expense classified as research and development of approximately $<span id="xdx_900_eus-gaap--ResearchAndDevelopmentExpense_c20250101__20250930__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeSponsoredResearchAgreementMember_zomvjXZuuC4d" title="Research and development expense">647,000</span> and $<span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20240930__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeSponsoredResearchAgreementMember_z0lEyhPEXhI3" title="Research and development expense">863,000</span>, pursuant to the 2023 Sponsored
Research Agreement, for the nine months ended September 30, 2025 and 2024, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2025 the Company&#8217;s commitments in relation to unbilled and unaccrued amounts from the University of Minnesota
pursuant to the 2023 Sponsored Research Agreement for services that have not yet been rendered as of September 30, 2025, amounted to
approximately $<span id="xdx_90F_eus-gaap--UnbilledReceivablesCurrent_iI_c20250930__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeSponsoredResearchAgreementMember_zd6OojdXTQ94" title="Unbilled and unaccrued amounts">216,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2016
Exclusive Patent License Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
July 18, 2016, the Company entered into an exclusive patent license agreement with the Regents of the University of Minnesota (as amended,
the &#8220;2016 Exclusive Patent License Agreement&#8221;), to further develop and commercialize cancer therapies using TriKE<sup>&#174;</sup>
technology developed by researchers at the University of Minnesota to target NK cells to cancer. Under the terms of the agreement, the
Company receives exclusive rights to conduct research and to develop, make, use, sell, and import TriKE<sup>&#174;</sup> technology worldwide
for the treatment of any disease, state, or condition in humans. The Company is responsible for obtaining all permits, licenses, authorizations,
registrations, and regulatory approvals required or granted by any governmental authority anywhere in the world that is responsible for
the regulation of products such as the TriKE<sup>&#174;</sup> technology, including without limitation the FDA and the European Agency
for the Evaluation of Medicinal Products in the European Union. The agreement requires an upfront payment of $<span id="xdx_907_ecustom--ProceedsFromUpfrontAmount_iI_c20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zf0pyul1aoWi" title="Proceeds from upfront amount">200,000</span>, and license maintenance
fees of $<span id="xdx_903_eus-gaap--CostMaintenance_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__us-gaap--AwardDateAxis__custom--TwoThousandSeventeenThroughTwoThousandTwentyMember_zGjUu5lOWnOl" title="License maintenance fees">200,000</span> for years 2017 through 2020, and $<span id="xdx_907_eus-gaap--CostMaintenance_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zx490uHUSach" title="License maintenance fees">100,000</span> per year beginning in year 2021 and each year thereafter. The agreement also
includes <span id="xdx_902_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__srt--RangeAxis__srt--MinimumMember_zbdhHp5gUWa9" title="Royalty fee percentage">4</span>% royalty fees on the net sales of licensed products, not to exceed <span id="xdx_905_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__srt--RangeAxis__srt--MaximumMember_zUS5s4pLTWbc" title="Royalty fee percentage">6</span>% under subsequent license agreements or amendments to
this agreement, and minimum royalty payments due upon the commencement of commercial sales of licensed product is $<span id="xdx_90B_eus-gaap--RoyaltyExpense_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentyTwoMember_zX2S8o3vomq5" title="Annual royalty payments">250,000</span> beginning
in 2022, $<span id="xdx_908_eus-gaap--RoyaltyExpense_pn6n6_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentyFiveMember_zngAHCHtDbS3" title="Annual royalty payments">2</span> million beginning in 2025, and $<span id="xdx_909_eus-gaap--RoyaltyExpense_pn6n6_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentySevenMember_zBOkncMom0Vk" title="Annual royalty payments">5</span> million beginning in 2027 throughout the remainder of the term. The agreement also includes
numerous performance milestone payments including clinical development milestone payments totaling $<span id="xdx_909_ecustom--PerformanceMilestonePayments_pn5n6_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zis3bcFsYVMg" title="Performance milestone payments">3.1</span> million, and one-time sales milestone
payments of $<span id="xdx_90A_ecustom--SalesMilestonePayments_pn6n6_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zJEf8dRDGWNe" title="One-time sales milestone payments">1</span> million upon reaching $<span id="xdx_904_ecustom--GrossSales_pn6n6_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zEDLAGJ4CYej" title="Sales">250</span> million in cumulative gross sales, and $<span id="xdx_90D_ecustom--SalesRevenue_pn6n6_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zkEPcC0bzm59" title="Sales revenue">5</span> million upon reaching $<span id="xdx_907_ecustom--CummulativeGrossSales_pn6n6_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zquDabCUEJx7" title="Cumulative gross sales">500</span> million in cumulative
gross sales of licensed products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
May 13, 2024, the Company entered into an amended and restated exclusive patent license agreement with the Regents of the University
of Minnesota. The amendment requires an upfront payment of $<span id="xdx_90C_ecustom--ProceedsFromUpfrontAmount_iI_c20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zmRprPPH7tAb" title="Proceeds from upfront amount">145,000</span> and amends the license maintenance fees to $<span id="xdx_901_eus-gaap--CostMaintenance_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentyFiveMember_ztugY6kUm1yf" title="License maintenance fees">50,000</span> in 2025, and $<span id="xdx_902_eus-gaap--CostMaintenance_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_z4NvcZnzR9mb" title="License maintenance fees">100,000</span>
per year beginning in year 2026 and each year thereafter. The amendment also includes <span id="xdx_908_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__srt--RangeAxis__srt--MinimumMember_zSP0YAHGTUV6" title="Royalty fee percentage">1</span>% to <span id="xdx_90C_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__srt--RangeAxis__srt--MaximumMember_zDYpi4vlZVti" title="Royalty fee percentage">5</span>% royalty fees on the net sales of licensed
products, not to exceed <span id="xdx_90E_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zSjFYSbWbLj4" title="Royalty fee percentage">6</span>% under subsequent license agreements or amendments, and minimum royalty payments due upon the commencement
of commercial sales of licensed product is $<span id="xdx_906_ecustom--RoyaltyExpenseYearOne_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_ziTht2PQwnch" title="Royalty expense year one">250,000</span> in year one, $<span id="xdx_903_ecustom--RoyaltyExpenseYearTwoThroughFive_pn6n6_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zSyiVIqkU7Kf" title="Royalty expense years two through five">2</span> million in years two through five, and $<span id="xdx_900_ecustom--RoyaltyExpenseYearAfterSix_pn6n6_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_z58oVH3LQ0B" title="Royalty expense year six and thereafter">5</span> million in year six throughout
the remainder of the term. The amendment also includes numerous performance milestone payments including clinical development milestone
payments totaling $<span id="xdx_90B_ecustom--PerformanceMilestonePayments_pn5n6_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zPNX5BSyMDY4" title="Performance milestone payments">3.1</span> million, and one-time sales milestone, and one-time sales milestone payments of $<span id="xdx_90B_ecustom--SalesMilestonePayments_pn6n6_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zFwGgmt9iHr" title="One-time sales milestone payments">1</span> million upon reaching $<span id="xdx_902_ecustom--GrossSales_pn6n6_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_z7FCwVdFrZGl" title="Gross sales">250</span>
million in cumulative gross sales, and $<span id="xdx_904_ecustom--SalesRevenue_pn6n6_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zzXVHVZczmR5" title="Sales revenue">5</span> million upon reaching $<span id="xdx_90B_ecustom--CummulativeGrossSales_pn6n6_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zOKiZFDtJy" title="Cumulative gross sales">500</span> million in cumulative gross sales of licensed products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded an expense classified as research and development of approximately $<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_c20250101__20250930__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_z5ZW4qbnP2nd" title="Research and development expense">0</span> and $<span id="xdx_90C_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20240930__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_ztw8F1oZGO53" title="Research and development expense">145,000</span>, pursuant to the 2016 Exclusive Patent
License Agreement, for the nine months ended September 30, 2025 and 2024, respectively</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021
Exclusive License Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
March 26, 2021, the Company entered into an exclusive license agreement with the Regents of the University of Minnesota (the &#8220;2021
Exclusive Patent License Agreement&#8221;), specific to the B7H3 targeted TriKE<sup>&#174;</sup>. The agreement requires an upfront payment
of $<span id="xdx_902_ecustom--UpfrontLicenseFee_pp0p0_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zE7MI2Bgi1oe" title="Upfront license fee">20,000</span>, and license maintenance fees of $<span id="xdx_900_eus-gaap--CostMaintenance_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_z8YeHZQGU2S1" title="License maintenance fees">5,000</span> per year beginning in year 2022 and each year thereafter. The agreement also includes<span id="xdx_90D_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20210326__20210326__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zvM6SmSQ2MJa" title="Royalty fee percentage">
2.5</span>% to <span id="xdx_904_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20210326__20210326__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zD71w4I0FsO2" title="Royalty fee percentage">5</span>% royalty fees on the net sales of licensed products, and minimum royalty payments due upon the commencement of commercial sales
of licensed product is $<span id="xdx_90D_ecustom--RoyaltyExpenseYearOneThoughFour_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zJ0wury3GQ4l" title="Royalty expense year one though four">250,000</span> in year one though four, and $<span id="xdx_904_ecustom--RoyaltyExpenseYearAfterFive_pn6n6_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_z0M2x9OnoQUi" title="Royalty expense year five and thereafter">2</span> million beginning in year five and throughout the remainder of the term.
The agreement also includes numerous performance milestone payments including clinical development milestone payments totaling $<span id="xdx_907_ecustom--PerformanceMilestonePayments_pn5n6_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zPqwCW0BN4C6" title="Performance milestone payments">3.1</span> million,
and one-time sales milestone payments of $<span id="xdx_90E_ecustom--SalesMilestonePayments_pn6n6_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_z9QGgGlQiU8i" title="One-time sales milestone payments">1</span> million upon reaching $<span id="xdx_905_ecustom--GrossSales_pn6n6_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zeN0wqMTsCLc" title="Gross sales">250</span> million in cumulative gross sales, and $<span id="xdx_906_ecustom--SalesRevenue_pn6n6_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_z4JldzGVp4cf" title="Sales revenue">5</span> million upon reaching
$<span id="xdx_90D_ecustom--CummulativeGrossSales_pn6n6_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zdfoVX3DJ2i3" title="Cumulative gross sales">500</span> million in cumulative gross sales of licensed products. There is no double payment intended; if one of the milestone payments has
been paid under the 2016 restated exclusive patent license agreement no further payment is due for the corresponding milestone.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company did not record any expense classified as research and development, pursuant to the 2021 Exclusive License Agreement, for the
nine months ended September 30, 2025 and 2024, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024
GTB-3650 Clinical Trial Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 18, 2024, the Registrant entered into an Investigator Initiated Clinical Trial Agreement (the &#8220;Agreement&#8221;) with
the Regents of the University of Minnesota (the &#8220;University&#8221;), pursuant to which, the University shall sponsor an Investigational
New Drug (&#8220;IND&#8221;) application for IND 165546 GTB-3650 (the &#8220;Research Program&#8221;) and shall serve as a sponsor investigator
for a phase 1 clinical trial entitled, &#8220;GTB-3650 (CD16/IL-15/CD33) Tri-Specific Killer Engager (TriKE) for the Treatment of High
Risk Myelodysplastic Syndromes (MDS), Refractory/Relapsed Acute Myeloid Leukemia (AML), and Minimal Residual Disease in AML,&#8221; designed
by the University (the &#8220;Study&#8221;). The Research Program is being conducted for clinical research use. The budget for the Study,
including without limitations, funding and resources, provides for up to approximately $<span id="xdx_901_eus-gaap--RoyaltyExpense_pn5n6_c20241118__20241118__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember_zJnyRpgd63Ga" title="Annual royalty payments">2.1</span> million over the course of three years borne
by the Company. The Study data will be owned by the University, however, the Company may use the Study data subject to any applicable
signed informed consent documents and authorization forms, applicable law and terms of the Agreement. The University and the Company
will each have the right to publish the Study results. The Agreement may be terminated by the Company or the University at any time upon
thirty days&#8217; written notice to the other party, by the University immediately for health, welfare and safety reasons, or by either
party if the other party materially breaches the Agreement, provided that the breaching party fails to cure such breach within thirty
days.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company did not record any expense classified as research and development, pursuant to the 2024 Clinical Trial Agreement, for the nine
months ended September 30, 2025 and 2024, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2025 the Company&#8217;s commitments in relation to unbilled and unaccrued amounts from the University of Minnesota
pursuant to the 2024 Clinical Trial Agreement for services that have not yet been rendered as of September 30, 2025, amounted to approximately
$<span id="xdx_900_eus-gaap--UnbilledReceivablesCurrent_iI_pn5n6_c20250930__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember_zcDeSXmGJ9Ad" title="Unbilled and unaccrued amounts">1.9</span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Contingency
&#8211; NASDAQ Matters</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 21, 2024, we received a letter (the &#8220;Notification Letter&#8221;) from the Nasdaq Listing Qualifications Staff (the &#8220;Staff&#8221;)
notifying us that the amount of our stockholders&#8217; equity had fallen below the $<span id="xdx_908_ecustom--ContigencyMinimumRequired_iI_c20241121_zpaVEXkKVLf8" title="Contigency minimum required">2,500,000</span> required minimum for continued listing
set forth in Nasdaq Listing Rule 5550(b)(1) (the &#8220;Minimum Stockholders&#8217; Equity Requirement&#8221;). Nasdaq&#8217;s determination
was based upon our stockholders&#8217; equity as reported in our Quarterly Report on Form 10-Q for the period ended September 30, 2024.
The Notification Letter also noted that we did not meet the alternatives of market value of listed securities or net income from continuing
operations, and therefore, we no longer complied with Nasdaq&#8217;s Listing Rules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Notification Letter indicated that we had 45 days (i.e., until January 6, 2025) to submit a plan to regain compliance with the Minimum
Stockholders&#8217; Equity Requirement, noting that if such plan is accepted, the Staff can grant us an extension of up to 180 days from
the date of the Notification Letter to evidence compliance. In determining whether to accept our plan, the Staff will consider such things
as the likelihood that the plan will result in compliance with Nasdaq&#8217;s continued listing criteria, our past compliance history,
the reasons for our current non-compliance, other corporate events that may occur within the review period, our overall financial condition
and our public disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
submitted a plan of compliance to the Staff on December 31, 2024, outlining our plan to conduct periodic public and private securities
offerings to regain compliance. The Staff also requested additional information regarding our financing plans and financial projection,
which we provided to them. On June 13, 2025, we received a letter from the Staff notifying us that we have regained compliance with the
Minimum Stockholders&#8217; Equity Requirement set forth in Nasdaq Listing Rule 5550(b)(1). Nasdaq will continue to monitor the Company
to ensure its ongoing compliance with the Minimum Stockholders&#8217; Equity Requirement, so if at the time of the filing of the Company&#8217;s
next periodic financial statements the Company does not evidence compliance with the Minimum Stockholders&#8217; Equity Requirement,
the Company may be subject to delisting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our common stock is delisted from Nasdaq, our ability to raise capital through public offerings of our securities and to finance our
operations could be adversely affected. We also believe that delisting would likely result in decreased liquidity and/or increased volatility
in our common stock and could harm our business and future prospects. In addition, we believe that, if our common stock is delisted,
our stockholders would likely find it more difficult to obtain accurate quotations as to the price of our common stock and it may be
more difficult for stockholders to buy or sell our common stock at competitive market prices, or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text"><p id="xdx_809_eus-gaap--SegmentReportingDisclosureTextBlock_zue1yziCvkia" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
8 &#8211; <span id="xdx_828_zwO53ogHG65a">Segment Information</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company operates and manages its business as <span id="xdx_90B_eus-gaap--NumberOfReportableSegments_dc_uSegment_c20250101__20250930_znmpa1ZCCgY" title="Number of reportable segments"><span id="xdx_901_eus-gaap--NumberOfOperatingSegments_dc_uSegment_c20250101__20250930_zLKiXK4kkIXa" title="Number of operating segments">one</span></span> reportable and operating as a clinical stage biopharmaceutical company focused on the
development and commercialization of novel immune-oncology products based on our proprietary Tri-specific Killer Engager (TriKE&#174;),
and Tetra-specific Killer Engager (Dual Targeting TriKE&#174;) platforms. The measure of segment assets is reported on the balance sheet
as total assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s CODM reviews financial information presented and decides how to allocate resources based on net income (loss). Net income
(loss) is used for evaluating financial performance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
segment expenses include research and development, salaries, insurance, and stock-based compensation. Operating expenses include all
remaining costs necessary to operate our business, which primarily include external professional services and other administrative expenses.
The following table presents the significant segment expenses and other segment items regularly reviewed by our CODM:</span></p>

<p id="xdx_898_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zYUjP5kVJlN9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B6_z0MNCmWZBUfc" style="display: none">Schedule of Segment Information</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20250701__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentsMember_zlHe3GHsSYwk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20240701__20240930__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentsMember_z5gnyLMkjvjk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20250101__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentsMember_z3RPZOqW7rb6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20240101__20240930__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentsMember_zo9Z7Dj7q5Ba" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three Months Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nine Months Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OtherResearchAndDevelopmentExpense_z0188yUA6f1k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 20%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">634,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,307,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,096,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,868,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--SalariesAndWages_zFNlmjpWubMa" style="vertical-align: bottom; background-color: White">
    <td>Salaries</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">373,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">340,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,006,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,106,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--InsuranceCommissions_zdhHkdntQvxd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">54,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">175,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">194,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ShareBasedCompensation_zbAxehkzxAn8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">379,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1523">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">386,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">222,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingExpenses_z56JyVmBIh79" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,942,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,915,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,164,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,211,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--NonoperatingIncomeExpense_zWuKoT7EHPj1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Other income</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(268,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(193,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,504,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,214,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--NetIncomeLoss_zqz2pyh33BXd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,114,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,411,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,323,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,387,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A2_zqj5a1ll4YFf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--SubsequentEventsTextBlock_zuFckF18x079" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
9 &#8211; <span id="xdx_823_zk5l3Imrk4O">Subsequent Events</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise
of Series L 10% Convertible Preferred Stock Greenshoe Rights</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
October 2025, Purchasers of the Company&#8217;s Series L 10% Convertible Preferred Stock (the &#8220;Preferred Stock&#8221;) elected
to exercise their Greenshoe Rights and purchased <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20251001__20251031__us-gaap--StatementClassOfStockAxis__custom--SeriesL10PercentageConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zx7wB4P8NCvc" title="Shares issued">2,055.55</span> shares of the Company&#8217;s Preferred Stock with a stated value of $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20251001__20251031__us-gaap--StatementClassOfStockAxis__custom--SeriesL10PercentageConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zBm1jURi5wt8" title="Shares issued value">2,055,556</span>
for a purchase price of $<span id="xdx_901_ecustom--PreferredStockPurchasePrice_c20251001__20251031__us-gaap--StatementClassOfStockAxis__custom--SeriesL10PercentageConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zsvLfPMdyRsk" title="Purchase price">1,850,000</span>. As a result of the transaction the conversion price of the Preferred Stock was decreased from $<span id="xdx_909_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20251030__us-gaap--StatementClassOfStockAxis__custom--SeriesL10PercentageConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zK2xyp1rnce7" title="Exercise price">0.6421</span>
to $<span id="xdx_90A_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20251031__us-gaap--StatementClassOfStockAxis__custom--SeriesL10PercentageConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zWYI0C1yjuji" title="Exercise price">0.5319</span>. The conversion price adjustment constitutes a dilutive issuance and as a result, the exercise price of the Common Warrants
and Vesting Warrants issued in the Series L 10% Convertible Preferred Stock transaction have been decreased, and the number of warrant
shares have been increased, such that the aggregate exercise price of the warrants, after taking into account the decrease in the exercise
price, shall be equal to the aggregate exercise price prior to such adjustment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Conversion
of Series L 10% Convertible Preferred Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
October 2025, the holders of the Company&#8217;s Series L Convertible Preferred Stock have converted <span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_c20251031__us-gaap--StatementClassOfStockAxis__custom--SeriesLConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zON0FDn918l7" title="Shares converted">2,556.48</span> shares of Series L Convertible
Preferred Stock into <span id="xdx_90A_eus-gaap--CommonStockSharesOutstanding_iI_c20251031__us-gaap--StatementClassOfStockAxis__custom--SeriesLConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z0kVyr8VBbT4" title="Number of shares converted">4,309,288</span> shares of common stock.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zPeugrX0lqi1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zSt4fb2hQaS2">Basis
of Presentation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying condensed financial statements are unaudited. These unaudited interim condensed financial statements have been prepared
in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and applicable rules
and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) regarding interim financial reporting. Certain information
and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant
to such rules and regulations. Accordingly, these unaudited interim condensed financial statements should be read in conjunction with
the financial statements and notes thereto contained in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December
31, 2024 filed with the SEC on February 21, 2025 (the &#8220;2024 Annual Report&#8221;). The balance sheet as of December 31, 2024 included
herein, was derived from the audited financial statements as of that date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the opinion of management, the accompanying unaudited condensed financial statements contain all adjustments necessary to fairly present
the Company&#8217;s financial position and results of operations for the interim periods reflected. Except as noted, all adjustments
contained herein are of a normal recurring nature. Results of operations for the fiscal periods presented herein are not necessarily
indicative of fiscal year-end results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Accounting Estimates</a></td>
<td class="text"><p id="xdx_844_eus-gaap--UseOfEstimates_z84eS2DzZUXb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zWlIGXew19m2">Accounting
Estimates</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the
reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant
estimates include management&#8217;s estimates for continued liquidity, accruals for potential liabilities, assumptions used in deriving
the fair value of derivative liabilities, valuation of equity instruments issued for debt and services and realization of deferred tax
assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash Equivalents</a></td>
<td class="text"><p id="xdx_841_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z7N3ZxDPJEr7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zWGzA7w0aSbc">Cash
Equivalents</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers highly liquid investments with maturities of three months or less at the date of acquisition as cash equivalents in
the accompanying unaudited condensed financial statements. At September 30, 2025 and December 31, 2024, total cash equivalents which
consist of money market funds and treasuries with maturities of three months or less, amounted to approximately $<span id="xdx_904_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20250930_zDF63ap45bsk" title="Cash equivalents">2.1</span> million and $<span id="xdx_907_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20241231_zEEPQ0grDaFd" title="Cash equivalents">3.8</span>
million, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zWX34GyVZ4j6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_zBhI8qlmcvga">Restricted
Cash</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2025, the Company has classified certain cash balances as restricted cash in its unaudited condensed balance sheets.
The Company&#8217;s restricted cash is deposited in a financial institution and held as a collateral for a credit card agreement with
the same financial institution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy', window );">Deferred Offering Costs</a></td>
<td class="text"><p id="xdx_847_eus-gaap--CapitalizationOfDeferredPolicyAcquisitionCostsPolicy_zZgZRRYsVcHl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zPe8nQBYIsx">Deferred
Offering Costs</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company capitalizes the fair value of equity instruments granted and certain legal, accounting and other third-party fees that are directly
related to the Company&#8217;s in-process equity financings until such financings are consummated. After consummation of an equity financing,
these costs are recorded in stockholders&#8217; equity as a reduction of additional paid-in capital generated as a result of the offering.
Should a planned equity financing be abandoned, terminated or significantly delayed, the deferred offering costs are immediately written
off to operating expenses. As of September 30, 2025, there was $<span id="xdx_906_eus-gaap--DeferredOfferingCosts_iI_pn5n6_c20250930_zwAfZucwXoA6" title="Deferred offering costs">0.8</span> million of deferred offering costs on the balance sheet.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p id="xdx_846_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zKb9KjlPCAhh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zAAueikD6DXd">Fair
Value of Financial Instruments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 820-10 requires entities to disclose
the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet for which it
is practicable to estimate fair value. ASC 820-10 defines the fair value of a financial instrument as the amount at which the instrument
could be exchanged in a current transaction between willing parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
three levels of the fair value hierarchy are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1 Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the entity has the ability
to access.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2 Valuations based on quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs
that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3 Valuations based on inputs that are unobservable, supported by little or no market activity and that are significant to the fair value
of the assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts of the Company&#8217;s other financial assets and liabilities, such as cash and cash equivalents, prepaid expenses and
other current assets, accounts payable, and accrued expenses, approximate their fair values because of the short maturity of these instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amount of the Company&#8217;s warrant liability of $<span id="xdx_90E_ecustom--WarrantLiabilityCurrent_iI_c20250930_zh2mNBhcsWLd" title="Warrant liability">8,000</span> and $<span id="xdx_90F_ecustom--WarrantLiabilityCurrent_iI_c20241231_z3q1o6RZKlY3" title="Warrant liability">252,000</span> at September 30, 2025 and December 31, 2024, respectively,
was based on Level 3 measurements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_WarrantLiabilityPolicyTextBlock', window );">Warrant Liability</a></td>
<td class="text"><p id="xdx_84C_ecustom--WarrantLiabilityPolicyTextBlock_znv80nG0J326" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zvDShclBMqPf">Warrant
Liability</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded
derivatives in accordance with ASC Topic 815, &#8220;<i>Derivatives and Hedging</i>&#8221; (&#8220;ASC 815&#8221;). For derivative financial
instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued
at each reporting date, with changes in the fair value reported in the statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s use of derivative financial instruments is generally limited to warrants issued by the Company that do not meet the criteria
for equity treatment and are recorded as liabilities. We do not use financial instruments or derivatives for any trading purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_MezzanineEquityPolicyTextBlock', window );">Mezzanine Equity</a></td>
<td class="text"><p id="xdx_844_ecustom--MezzanineEquityPolicyTextBlock_z6RzHTez9cs" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_znPncSPyFdul">Mezzanine
Equity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where
ordinary or preferred shares are determined to be conditionally redeemable upon the occurrence of certain events that are not solely
within the control of the issuer, and upon such event, the shares would become redeemable at the option of the holders, they are classified
as &#8216;mezzanine equity&#8217; (temporary equity). The purpose of this classification is to convey that such a security may not be
permanently part of equity and could result in a demand for cash, securities or other assets of the entity in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity
instruments accounted as Mezzanine Equity upon issuance were reclassified to permanent equity as of September 30, 2025 as a result of
subsequent amendments to its terms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zjXU3pwOpSWb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_z2zm6rYqIux5">Stock-Based
Compensation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically issues stock-based compensation to officers, directors, employees, and consultants for services rendered. Such issuances
vest and expire according to terms established at the issuance date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Stock-based
payments to officers, directors, employees, and consultants in exchange for goods and services, which include grants of employee stock
options, are recognized in the financial statements based on their grant date fair values in accordance with ASC 718, <i>Compensation-Stock
Compensation</i>. Stock based payments to officers, directors, employees, and consultants, which are generally time vested, are measured
at the grant date fair value and depending on the conditions associated with the vesting of the award, compensation cost is recognized
on a straight-line or graded basis over the vesting period. Recognition of compensation expense for non-employees is in the same period
and manner as if the Company had paid cash for the services. The fair value of stock options granted is estimated using the Black-Scholes
option-pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life, and future
dividends. The assumptions used in the Black-Scholes option pricing model could materially affect compensation expense recorded in future
periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--ResearchAndDevelopmentExpensePolicy_zoaWReyyh736" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_ze9ZkJBcwOOj">Research
and Development Expenses</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
incurred for research and development are expensed as incurred. The salaries, benefits, and overhead costs of personnel conducting research
and development of the Company&#8217;s products are included in research and development expenses. Purchased materials that do not have
an alternative future use are also expensed. Purchased materials that have an alternative future are classified as a prepaid expense
and periodically reviewed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p id="xdx_848_eus-gaap--EarningsPerSharePolicyTextBlock_zzBCiYRJkMD3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zF6xJODp9xh2">Net
Loss Per Share</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
earnings (loss) per share is computed using the weighted-average number of common shares outstanding during the period. Diluted earnings
(loss) per share is computed using the weighted-average number of common shares and the dilutive effect of contingent shares outstanding
during the period. Potentially dilutive contingent shares, which primarily consist of stock issuable upon exercise of stock options and
warrants, and the conversion of Series L convertible preferred stock, have been excluded from the diluted loss per share calculation
because their effect is anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_895_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zQRDqxVjqmd1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following common stock equivalents were excluded in the computation of the net loss per share because their effect is anti-dilutive:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BC_zFCVDVlwp5S3" style="display: none">Schedule of Anti-dilutive Securities</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 75%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20250101__20250930_zXjs4YBnnFy1" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30, 2025</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20240101__20240930_zZTByQvbDlKb" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30, 2024</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesLConvertiblePreferredStockMember_z5lmL1gNdT8i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series L convertible preferred stock <b><sup id="xdx_F44_zukfJ2qB72Ld">1</sup></b></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right">7,649,792</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0773">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zkneGfjaH1oa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Options to purchase common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">597,550</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">101,264</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zGwF1cKvFTk4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Warrants to purchase common stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">49,459,390</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,133,762</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zbBEwqK4Rv6g" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total anti-dilutive securities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">57,706,732</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,235,026</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b id="xdx_F0C_zQQiiyKcALwd"><sup>1</sup></b></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F11_zV80lUlQoPQ9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Converted into
common stock using a conversion price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEFudGktZGlsdXRpdmUgU2VjdXJpdGllcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_904_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20250930_zYB0aw7k7YA3" title="Conversion price per share">0.6421</span> per share, as of September 30, 2025</span></td>
</tr></table>

<p id="xdx_8AB_zYjDfXlXDxZb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration</a></td>
<td class="text"><p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_zVcOgvqOXL45" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zI8KcYfr4PP4">Concentration</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
is deposited in one financial institution. The balances held at this financial institution at times may be in excess of Federal Deposit
Insurance Corporation (&#8220;FDIC&#8221;) insurance limits of up to $<span id="xdx_901_eus-gaap--CashFDICInsuredAmount_iI_c20250930_zazTR64ciLQ9" title="Cash, FDIC insured amount">250,000</span>. <span style="background-color: white">Management believes
that the financial institutions that hold the Company&#8217;s cash are financially sound and, accordingly, minimal credit risk exists.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has a significant concentration of expenses incurred from and accounts payable to Cytovance Biologics, Inc. (&#8220;Cytovance&#8221;),
a related party, and the University of Minnesota, see Note 3 &#8211; Accounts Payable and Related Party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zpOSaP5GOIGl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zEwLDVzX81k">Segment
Information</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s Chief Executive Officer and President (&#8220;CEO&#8221;) is our chief operating decision maker (&#8220;CODM&#8221;)
and evaluates performance and makes operating decisions about allocating resources based on financial data presented on a consolidated
basis. Because our CODM evaluates financial performance on a consolidated basis, the Company has determined that it operates as a single
reportable segment composed of the financial results of GT Biopharma, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zaTm6E90uhy" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_z7v0R6ZiqRR1">Recent
Accounting Pronouncements</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, the FASB issued ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic
220-40): Disaggregation of Income Statement Expenses, requiring public entities to disclose additional information about specific expense
categories in the notes to the financial statements on an interim and annual basis. ASU 2024-03 is effective for fiscal years beginning
after December 15, 2026, and for interim periods beginning after December 15, 2027, with early adoption permitted. The Company is currently
evaluating the impact of adopting ASU 2024-03.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s management has evaluated all the recently issued, but not yet effective, accounting standards and guidance that have
been issued or proposed by the FASB or other standards-setting bodies through the filing date of these financial statements and does
not believe the future adoption of any such pronouncements will have a material effect on the Company&#8217;s financial position and
results of operations.</span></p>

<p id="xdx_8A6_zBDZqEdgdO44" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_MezzanineEquityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Mezzanine Equity [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_MezzanineEquityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_WarrantLiabilityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Liability [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_WarrantLiabilityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferred policy acquisition costs, including the nature, type, and amount of capitalized costs incurred to write or acquire insurance contracts, and the basis for and methodologies applied in capitalizing and amortizing such costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 944<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479432/944-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 944<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479432/944-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Anti-dilutive Securities</a></td>
<td class="text"><p id="xdx_895_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zQRDqxVjqmd1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following common stock equivalents were excluded in the computation of the net loss per share because their effect is anti-dilutive:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BC_zFCVDVlwp5S3" style="display: none">Schedule of Anti-dilutive Securities</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 75%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20250101__20250930_zXjs4YBnnFy1" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30, 2025</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20240101__20240930_zZTByQvbDlKb" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30, 2024</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesLConvertiblePreferredStockMember_z5lmL1gNdT8i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series L convertible preferred stock <b><sup id="xdx_F44_zukfJ2qB72Ld">1</sup></b></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right">7,649,792</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0773">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zkneGfjaH1oa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Options to purchase common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">597,550</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">101,264</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zGwF1cKvFTk4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Warrants to purchase common stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">49,459,390</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,133,762</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zbBEwqK4Rv6g" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total anti-dilutive securities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">57,706,732</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,235,026</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b id="xdx_F0C_zQQiiyKcALwd"><sup>1</sup></b></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F11_zV80lUlQoPQ9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Converted into
common stock using a conversion price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEFudGktZGlsdXRpdmUgU2VjdXJpdGllcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_904_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20250930_zYB0aw7k7YA3" title="Conversion price per share">0.6421</span> per share, as of September 30, 2025</span></td>
</tr></table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Related Party (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable</a></td>
<td class="text"><p id="xdx_897_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zVHMOQDwABa6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
payable consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B5_zsdbA4ezRKUa" style="display: none">Schedule of Accounts Payable</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.65in; border-collapse: collapse; width: 85%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49F_20250930_zPkCBJt4ATR4" style="font-weight: bold; text-align: center">As of</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_495_20241231_zbODJkCKqcsk" style="font-weight: bold; text-align: center">As of</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AccountsPayableTradeCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_za2mDomThWP7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts payable to Cytovance, a related party <b><sup id="xdx_F47_zmzpK4rGHVp4">1</sup></b></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">60,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_90D_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_pid_dp_uPure_c20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_fKDEp_zKjUDVBwg857" title="Accounts payable interest rate">8</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,183,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_904_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_pid_dp_uPure_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_fKDEp_zcYtEMPQr9A4" title="Accounts payable interest rate">31</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_408_eus-gaap--AccountsPayableTradeCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UniversityOfMinnesotaMember_zXH5o1fGLKGa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accounts payable to University of Minnesota</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">463,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UniversityOfMinnesotaMember_z8HArOXnGgq" title="Accounts payable interest rate">60</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">712,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UniversityOfMinnesotaMember_zq8NtfZAYo26" title="Accounts payable interest rate">18</span></td><td style="text-align: left">%</td></tr>
  <tr id="xdx_40C_eus-gaap--AccountsPayableTradeCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_zPYwIo9J9Peb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Legal services firm</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0813">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_zyWZGSlLRgC7" title="Accounts payable interest rate"><span style="-sec-ix-hidden: xdx2ixbrl0816">&#8212;</span></span>%</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,505,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_zcGnnI9Zf6p7" title="Accounts payable interest rate">39</span></td><td style="text-align: left">%</td></tr>
  <tr id="xdx_40B_eus-gaap--AccountsPayableTradeCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_zGU3dht5cBp4" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0820">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;%</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,505,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">39</td><td style="text-align: left">%</td></tr>
<tr id="xdx_404_eus-gaap--AccountsPayableOtherCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OtherAccountsPayableMember_z9rI6JugfKXi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Other accounts payable</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">246,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_907_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OtherAccountsPayableMember_zJZsPOzbZ5n6" title="Accounts payable interest rate">32</span></td><td style="padding-bottom: 1pt; text-align: left">%</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">453,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90F_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OtherAccountsPayableMember_zNl4LJWXBdlb" title="Accounts payable interest rate">12</span></td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr id="xdx_40C_eus-gaap--AccountsPayableCurrent_iI_ztC94l3ZrcDk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total accounts payable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">769,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20250930_zbXyvJNRAWX3" title="Accounts payable interest rate">100</span></td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,853,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20241231_zsFtxp3u4Rp9" title="Accounts payable interest rate">100</span></td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span id="xdx_F0C_zauD72gr0fR1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><sup>1</sup></b></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F1A_zuycTXv7bPnk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts Payable
to Cytovance, a related party, since Cytovance owns greater than 5% of the Company&#8217;s issued and outstanding common stock. See Note
7 &#8211; Commitments and Contingencies, Significant Agreements.</span></td>
</tr></table>



<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock', window );">Schedule of Accounts Payable to Related Party</a></td>
<td class="text"><p id="xdx_89C_ecustom--ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock_zRP0PaRVjNGc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
details of the Company&#8217;s accounts payable to Cytovance were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="display: none"><span id="xdx_8B6_zMcldOtFeIHd">Schedule of Accounts Payable to Related Party</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 75%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center"></td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_492_20250101__20250930_zV7l9V0nwTS6" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49D_20240101__20240930_zZqcGinV4shb" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine Months Ending</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AccountsPayableTradeCurrent_iS_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zmDQqzj4sENi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Beginning balance</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,183,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,515,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ProceedsFromRelatedPartyDebt_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zatWKkVN8o2f" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Invoices, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">686,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,365,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--RepaymentsOfRelatedPartyDebt_iN_di_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zkfc1ri0A3gb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Payments in cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(962,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,432,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--PaymentsForRepurchaseOfCommonStock_iN_di_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_znsAUxadALma" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Payments in common stock, at fair value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0849">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(810,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_ecustom--RepaymentsOfPrefundedWarrantsAtFairValue_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zF8Hdx51h8Aj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Payments in pre-funded warrants, at fair value</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(847,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0853">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AccountsPayableTradeCurrent_iE_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zeSPOiiFsmI9" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Ending balance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">60,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">638,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Accounts Payable and Related Party [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrant Liability (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock', window );">Schedule of Warrant Liability Transactions</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zS1ssbT5Gvm6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
details of warrant liability transactions were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BF_zd2V521KWH91" style="display: none">Schedule of Warrant Liability Transactions</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 75%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49C_20250101__20250930_znewNSHF8QP9" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49C_20240101__20240930_z831OcIKrEY7" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine Months Ending</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_ecustom--WarrantLiabilityCurrent_iS_zcqzMKyIIuj1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Beginning balance</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">252,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,052,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IssuanceOfStockAndWarrantsForServicesOrClaims_zLXpDWrQTXu8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Issuance of warrants at fair value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0931">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0932">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_zY8WYsozPh3f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Change in fair value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(244,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(870,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_ecustom--ExtinguishmentOfWarrant_zZhKbNjqBTJh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1pt">Extinguishment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0937">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0938">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--WarrantLiabilityCurrent_iE_zSyhNnzQCCA8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Ending balance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">182,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=GTBP_TwoThousandTwentyThreeWarrantsMember', window );">2023 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Warrant Liability Assumptions</a></td>
<td class="text"><p id="xdx_891_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hus-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_zNBFfx9SPuOi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2023 Warrant liability is valued using a Black Scholes Option pricing model with the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B8_zWjZ7Hx5lTx9" style="display: none">Schedule of Warrant Liability Assumptions</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 75%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023 Warrants</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Stock price</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_zLJNysyStj71" style="width: 16%; text-align: right" title="Warrants measurement input">0.59</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_zGijmKtKrnD" style="width: 16%; text-align: right" title="Warrants measurement input">3.05</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free interest rate <b><sup>1</sup></b></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fMQ_____zULjtQhhpXck" style="text-align: right" title="Warrants measurement input">3.61</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fMQ_____zq4NwV2DTbR9" style="text-align: right" title="Warrants measurement input">4.27</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected volatility <b><sup>2</sup></b></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fMg_____zc00RU4JLLt7" style="text-align: right" title="Warrants measurement input">110</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fMg_____zNZTlpAwVrz" style="text-align: right" title="Warrants measurement input">114</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected life (in years) <b><sup>3</sup></b></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember__srt--RangeAxis__srt--MinimumMember_fMw_____zInI89XGEZB5" title="Expected life (in years)">2.25</span> &#8211; <span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember__srt--RangeAxis__srt--MaximumMember_fMw_____zvxxIyKx9oHk" title="Expected life (in years)">2.76</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember__srt--RangeAxis__srt--MinimumMember_fMw_____ziFUP3rBV05k" title="Expected life (in years)">3.0</span> &#8211; <span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember__srt--RangeAxis__srt--MaximumMember_fMw_____z1srIpYXvahf" title="Expected life (in years)">3.50</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected dividend yield <b><sup>4</sup></b></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fNA_____z5JzdFvXs74h" style="text-align: right" title="Warrants measurement input"><span style="-sec-ix-hidden: xdx2ixbrl0914">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fNA_____zCh0lwsjSzVc" style="text-align: right" title="Warrants measurement input"><span style="-sec-ix-hidden: xdx2ixbrl0916">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Fair value of warrants</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--FairValueAdjustmentOfWarrants_c20250101__20250930__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_znWjiU7lWKzi" style="text-align: right" title="Fair value of warrants">8,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_z6ZUOUOr0Yle" style="text-align: right" title="Fair value of warrants">252,000</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><sup>&#160;</sup></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b id="xdx_F0D_zYErwEVo5Yh2"><sup>1</sup></b></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F12_zWAhoOiEQ2p4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on rates
established by the Federal Reserve Bank</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b id="xdx_F04_zuzIqXJv6Heg"><sup>2</sup></b></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F18_znCoxutDAss8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Historical volatility
of the Company&#8217;s common stock is used to estimate the future volatility of its common stock</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span id="xdx_F03_z7LK8N3afFF3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><sup>3</sup></b></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F19_zHgePmiMPZt5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Determined by the
remaining contractual life of the derivative instrument</span></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b id="xdx_F0D_zaBKs5VLDYW9"><sup>4</sup></b></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F1A_zabJbDUIuca3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on no dividends
paid or expected to be paid</span></td>
</tr></table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative liabilities at fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=GTBP_TwoThousandTwentyThreeWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=GTBP_TwoThousandTwentyThreeWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Deficit) (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfConversionsOfStockTextBlock', window );">Schedule of fair values and allocation of net proceeds</a></td>
<td class="text"><p id="xdx_893_eus-gaap--ScheduleOfConversionsOfStockTextBlock_zwlEtNrdjBIj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BE_zQD8KHdsgYI3" style="display: none">Schedule of fair values and allocation of net proceeds</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.85in; border-collapse: collapse; width: 65%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20250501__20250531_zUQwYfvYORY1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Relative Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Percentage</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_hus-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_zFqcvEw9WdC7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Series L Convertible Preferred Stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">3,688,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_ecustom--ConvertiblePreferredStockAndWarrantsFairValuePercentage_pid_dp_uPure_c20250501__20250531__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_zlzQG7EOTMcj" style="width: 16%; text-align: right" title="Convertible preferred stock and warrants fair value percentage">37.7</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_404_eus-gaap--StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_hus-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPCubDqq44Af" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Warrants</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">6,089,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98C_ecustom--ConvertiblePreferredStockAndWarrantsFairValuePercentage_pid_dp_uPure_c20250501__20250531__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z0cmsSWGOh0g" style="padding-bottom: 1pt; text-align: right" title="Convertible preferred stock and warrants fair value percentage">62.3</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr id="xdx_406_eus-gaap--StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_zhGmkVgz1ka4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,777,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_98C_ecustom--ConvertiblePreferredStockAndWarrantsFairValuePercentage_pid_dp_uPure_c20250501__20250531_z4QTbDtFRz6" style="padding-bottom: 2.5pt; text-align: right" title="Convertible preferred stock and warrants fair value percentage">100.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.85in; border-collapse: collapse; width: 65%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20250501__20250531_zSfL5Pa7z8J" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Allocation of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net Proceeds</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Percentage</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_hus-gaap--StatementClassOfStockAxis__custom--MezzanineEquityMember_z6B8H5k5PQNh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Mezzanine equity</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">2,052,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_ecustom--ConvertiblePreferredStockAndWarrantsNetProceedsPercentage_pid_dp_uPure_c20250501__20250531__us-gaap--StatementClassOfStockAxis__custom--MezzanineEquityMember_zD8Ra4yZrJh9" style="width: 16%; text-align: right" title="Convertible preferred stock and warrants net proceeds percentage">37.7</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_40B_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_hus-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zbl8wWapqWZ7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Additional paid in capital</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,389,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_985_ecustom--ConvertiblePreferredStockAndWarrantsNetProceedsPercentage_pid_dp_uPure_c20250501__20250531__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zjsO5UCWw2jl" style="padding-bottom: 1pt; text-align: right" title="Convertible preferred stock and warrants net proceeds percentage">62.3</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr id="xdx_40E_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_zIX6QabUbDC6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,441,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_981_ecustom--ConvertiblePreferredStockAndWarrantsNetProceedsPercentage_pid_dp_uPure_c20250501__20250531_zAnr0VDobY3g" style="padding-bottom: 2.5pt; text-align: right" title="Convertible preferred stock and warrants net proceeds percentage">100.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfConversionsOfStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to converting stock into another financial instrument(s) in a noncash (or part noncash) transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfConversionsOfStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Warrants and Options (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Warrant Activity</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zojafDrERnad" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
warrant transactions for the nine months ended September 30, 2025 were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B0_zmIuocYy0Jvj" style="display: none">Schedule of Warrant Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 75%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine Months Ended September 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted Average</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%">Warrants outstanding at December 31, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20250101__20250930_zDMi81wrfrC8" style="width: 18%; text-align: right" title="Warrants outstanding, beginning balance">1,120,429</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20250930_zD5R47lSsiu2" style="width: 18%; text-align: right" title="Weighted average exercise price, beginning balance">18.85</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20250101__20250930_z0wqIIccBgEc" style="text-align: right" title="Number of warrants, granted">16,468,308</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice_pid_c20250101__20250930_zmvI925Vzm15" style="text-align: right" title="Weighted average exercise price, granted">2.04</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Granted pursuant to full-ratchet price and anti-dilution protections</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedPursuantToFullRatchetPriceProtection_pid_c20250101__20250930_z8gbwwRzu8B9" style="text-align: right" title="Number of warrants, granted pursuant to full ratchet price and anti-dilution protections">32,709,588</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedPursuantToFullRatchetPriceProtectionWeightedAverageExercisePrice_pid_c20250101__20250930_zyRMRaQV3zRl" style="text-align: right" title="Weighted average exercise price, granted pursuant to full ratchet price and anti-dilution protections">0.64</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Forfeited/cancelled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20250101__20250930_zCUCfhiXx9zl" style="text-align: right" title="Number of warrants, forfeited/cancelled">(1,866</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice_pid_c20250101__20250930_zdYoRgK4SmH2" style="text-align: right" title="Weighted average exercise price, forfeited/cancelled">102.00</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1pt">Exercised</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20250101__20250930_ziKRaAnaZiQ" style="border-bottom: Black 1pt solid; text-align: right" title="Number of warrants, exercised">(837,069</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice_pid_c20250101__20250930_z9CDiYG0FdPa" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, exercised">2.11</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Warrants outstanding at September 30, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20250101__20250930_zQEAWPH7U4u" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants outstanding, ending balance">49,459,390</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20250930_zBUzbvpGWmhf" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, ending balance">1.04</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Warrants exercisable at September 30, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_iI_pid_c20250930_zeOz6m1p7MEa" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants exercisable, ending balance">13,956,955</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20250930_zRozTTnSJ334" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable, ending balance">2.04</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Options Activity</a></td>
<td class="text"><p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z58qRwcj4efd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_zVD5FfCQp6Ol" style="display: none">Schedule of Options Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 75%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine Months Ended September, 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted Average</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%">Options outstanding at December 31, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20250101__20250930_zlCpHCqAJDz5" style="width: 18%; text-align: right" title="Number of options outstanding, beginning">124,600</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20250930_zTb4DgWPqfB1" style="width: 18%; text-align: right" title="Weighted-Average Exercise Price, beginning">32.69</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20250101__20250930_z4z6r8NWelW5" style="text-align: right" title="Number of options, granted">525,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250101__20250930_zx5pwK3pMYOi" style="text-align: right" title="Weighted-Average Exercise Price, granted">1.33</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Forfeited/cancelled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20250101__20250930_zw8dICJoUuEg" style="text-align: right" title="Number of options, forfeited/cancelled">(52,050</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20250101__20250930_zzysbtEhWNF1" style="text-align: right" title="Weighted-Average Exercise Price, forfeited/cancelled">43.08</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1pt">Exercised</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20250101__20250930_z3Y07HEMPkHk" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1289">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20250101__20250930_zQVMUgoguQN7" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-Average Exercise Price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1291">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Options outstanding at September 30, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20250101__20250930_ztu8a4f904Id" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options outstanding, ending">597,550</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20250930_ziUdv9555Hrk" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-Average Exercise Price, ending">4.23</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Options exercisable at September 30, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20250930_zbVv8HUHubmc" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options outstanding exercisable">396,439</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20250930_z6ymFUoUBJil" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-Average Exercise Price,exercisable, ending">5.68</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Schedule of Options Outstanding and Options Exercisable</a></td>
<td class="text"><p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zQxhkOstx6f2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
outstanding as of September 30, 2025 are exercisable as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_ziaOabyQCHsk" style="display: none">Schedule of Options Outstanding and Options Exercisable</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Stock Options Exercisable as of September 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Range of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining Contractual Life (Years)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Price</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td style="width: 22%; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zf3an5PIZ5Cf" title="Range of excercise price">1.33</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_z2rH9xN7Lf5e" style="width: 22%; text-align: right" title="Options outstanding">337,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 21%; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zIAMyDui7Wk9" title="Options outstanding, weighted average remaining contractual life (years)">9.9</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 21%; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zEGktHgLOcUa" title="Options outstanding, weighted average exercise price">1.33</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zKBOZuDHs8C7" title="Range of excercise price">2.11</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zjGSanyWE235" style="text-align: right" title="Options outstanding">9,723</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z467DOdJnBM3" title="Options outstanding, weighted average remaining contractual life (years)">7.7</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z6PAHYRchmTf" title="Options outstanding, weighted average exercise price">2.11</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zJQF9JaqeCfj" title="Range of excercise price">10.50</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zqa0EH8A9zP4" style="text-align: right" title="Options outstanding">16,667</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zrGTW5p5sR09" title="Options outstanding, weighted average remaining contractual life (years)">7.6</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zpvtAqCOUnB7" title="Options outstanding, weighted average exercise price">10.50</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zuNrXfu4ilVh" title="Range of excercise price">25.50</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_z4wZzY6gaPkh" style="text-align: right" title="Options outstanding">16,667</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zNTlFwlRbljl" title="Options outstanding, weighted average remaining contractual life (years)">7.3</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_z7cZQdT707Uj" title="Options outstanding, weighted average exercise price">25.50</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zK7rXtkb54Bk" title="Range of excercise price">74.40</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zErabDuoLU19" style="border-bottom: Black 1pt solid; text-align: right" title="Options outstanding">15,882</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zGQxVdCMPUPa" title="Options outstanding, weighted average remaining contractual life (years)">6.8</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zW7MkwNXEat6" title="Options outstanding, weighted average exercise price">74.40</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250930_z7jQCwmR4Tqe" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding">396,439</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=GTBP_WarrantsMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ScheduleOfWarrantsOustandingAndExercisableTableTextBlock', window );">Schedule of Warrants Outstanding and Exercisable</a></td>
<td class="text"><p id="xdx_89D_ecustom--ScheduleOfWarrantsOustandingAndExercisableTableTextBlock_hus-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zHWlacB2NAk9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
outstanding as of September 30, 2025 are exercisable as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B4_z7RvbhSWOw3f" style="display: none">Schedule of Warrants Outstanding and Exercisable</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants Outstanding and Exercisable as of September 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Range of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining Contractual Life (Years)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Price</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td style="width: 22%; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zUT6l6jEKntk" title="Range of exercise price">0.0001</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_ziHQqR1L4Zu9" style="width: 22%; text-align: right" title="Number of outstanding">476,251</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 21%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 21%; text-align: right"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zlvanojrrKPb" title="Warrants weighted average exercise price">0.0001</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zXi70y0pXUBb" title="Range of exercise price">0.6421</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_ziHdbHHQIde7" style="text-align: right" title="Number of outstanding">10,296,061</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zSYduWdmwKB4" title="Warrants outstanding, weighted average remaining contractual life (years)">4.6</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z1BDBE5FhwH4" title="Warrants weighted average exercise price">0.6421</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zmAGy9fK2cNa" title="Range of exercise price">0.6421</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_z9wH87jvtpC7" style="text-align: right" title="Number of outstanding">37,405,912</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zhbZKUXx3eVf" title="Warrants weighted average exercise price">0.6421</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zUgmU8Um88wi" title="Range of exercise price">2.02</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_z0cqNmFeX6S2" style="text-align: right" title="Number of outstanding">369,138</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zgyaDsI6O1ph" title="Warrants outstanding, weighted average remaining contractual life (years)">2.7</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zfC14Nv9cbnc" title="Warrants weighted average exercise price">2.02</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zs2RZdjqL7wa" title="Range of exercise price">2.46</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zEb5IIygSNy7" style="text-align: right" title="Number of outstanding">24,390</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_z2y1Y41ZnAl1" title="Warrants outstanding, weighted average remaining contractual life (years)">4.6</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zrbKcHFfFGIk" title="Warrants weighted average exercise price">2.46</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zeWeRJMU1rSh" title="Range of exercise price">2.50</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zss7EjAJGnd2" style="text-align: right" title="Number of outstanding">50,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_z6vfFtikprAl" title="Warrants outstanding, weighted average remaining contractual life (years)">2.6</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_z0QEfBc2ITei" title="Warrants weighted average exercise price">2.50</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zzkSwPZhUuKa" title="Range of exercise price">2.8375</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zuq6OtqvRWj" style="text-align: right" title="Number of outstanding">21,145</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zqo2FRONefMi" title="Warrants outstanding, weighted average remaining contractual life (years)">4.6</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zW5gd8jtwPg6" title="Warrants weighted average exercise price">2.8375</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zkBpwOf5vpT3" title="Range of exercise price">4.35</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_z5IfCHLtsme5" style="text-align: right" title="Number of outstanding">437,931</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zl282ScRvmz" title="Warrants outstanding, weighted average remaining contractual life (years)">3.6</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zf8NbEcZDPH5" title="Warrants weighted average exercise price">4.35</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zDJLO9B31ut4" title="Range of exercise price">5.4375</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zV7sR378lp05" style="text-align: right" title="Number of outstanding">88,800</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_z50UlTboaJS" title="Warrants outstanding, weighted average remaining contractual life (years)">3.6</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zYHcMNW7OeBg" title="Warrants weighted average exercise price">5.4375</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_znnXzdKRhTql" title="Range of exercise price">30.00</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zarnJJL9S6O5" style="text-align: right" title="Number of outstanding">216,666</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zQhwh4r1G8u7" title="Warrants outstanding, weighted average remaining contractual life (years)">2.8</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zOASU6c886" title="Warrants weighted average exercise price">30.00</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeElevenMember_zUbRjEgZB0m7" title="Range of exercise price">37.50</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeElevenMember_zyho79WSLx8b" style="text-align: right" title="Number of outstanding">13,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeElevenMember_z8J5A8vfjn3b" title="Warrants outstanding, weighted average remaining contractual life (years)">2.3</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeElevenMember_zucetDw1K5zg" title="Warrants weighted average exercise price">37.50</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwelveMember_zUN460lJhTZ5" title="Range of exercise price">165.00</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwelveMember_zLFwzeWGv932" style="text-align: right" title="Number of outstanding">52,316</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwelveMember_zQ515VieNZ95" title="Warrants outstanding, weighted average remaining contractual life (years)">0.4</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwelveMember_zULwM9EVitxc" title="Warrants weighted average exercise price">165.00</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThirteenMember_zD6FzkOCevq1" title="Range of exercise price">206.25</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThirteenMember_z6z8QGOxFjF6" style="border-bottom: Black 1pt solid; text-align: right" title="Number of outstanding">7,780</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThirteenMember_zBtbV2FGmGK2" title="Warrants outstanding, weighted average remaining contractual life (years)">0.4</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThirteenMember_zf2jmpvYapTk" title="Warrants weighted average exercise price">206.25</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zr5DMGgWwvi4" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of outstanding">49,459,390</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zbQ0KpRWj123" title="Warrants outstanding, weighted average remaining contractual life (years)">4.5</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zFZSoYIVudOd" title="Warrants weighted average exercise price">1.04</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ScheduleOfWarrantsOustandingAndExercisableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Warrants Oustanding and Exercisable [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ScheduleOfWarrantsOustandingAndExercisableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=GTBP_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=GTBP_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Information</a></td>
<td class="text"><p id="xdx_898_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zYUjP5kVJlN9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B6_z0MNCmWZBUfc" style="display: none">Schedule of Segment Information</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20250701__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentsMember_zlHe3GHsSYwk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20240701__20240930__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentsMember_z5gnyLMkjvjk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20250101__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentsMember_z3RPZOqW7rb6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20240101__20240930__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentsMember_zo9Z7Dj7q5Ba" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three Months Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nine Months Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OtherResearchAndDevelopmentExpense_z0188yUA6f1k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 20%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">634,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,307,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,096,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,868,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--SalariesAndWages_zFNlmjpWubMa" style="vertical-align: bottom; background-color: White">
    <td>Salaries</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">373,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">340,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,006,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,106,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--InsuranceCommissions_zdhHkdntQvxd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">54,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">175,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">194,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ShareBasedCompensation_zbAxehkzxAn8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">379,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1523">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">386,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">222,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingExpenses_z56JyVmBIh79" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,942,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,915,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,164,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,211,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--NonoperatingIncomeExpense_zWuKoT7EHPj1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Other income</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(268,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(193,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,504,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,214,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--NetIncomeLoss_zqz2pyh33BXd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,114,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,411,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,323,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,387,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Going Concern Analysis (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 3,114,000<span></span>
</td>
<td class="nump">$ 3,411,000<span></span>
</td>
<td class="nump">$ 5,323,000<span></span>
</td>
<td class="nump">$ 9,387,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,893,000<span></span>
</td>
<td class="nump">$ 10,436,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Schedule of Anti-dilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total anti-dilutive securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">57,706,732<span></span>
</td>
<td class="nump">1,235,026<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=GTBP_SeriesLConvertiblePreferredStockMember', window );">Series L Convertible Preferred Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total anti-dilutive securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">7,649,792<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total anti-dilutive securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">597,550<span></span>
</td>
<td class="nump">101,264<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total anti-dilutive securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">49,459,390<span></span>
</td>
<td class="nump">1,133,762<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Converted into
common stock using a conversion price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEFudGktZGlsdXRpdmUgU2VjdXJpdGllcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_904_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20250930_zYB0aw7k7YA3" title="Conversion price per share">0.6421</span> per share, as of September 30, 2025</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=GTBP_SeriesLConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=GTBP_SeriesLConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Anti-dilutive Securities (Details) (Parenthetical)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Conversion price per share</a></td>
<td class="nump">$ 0.6421<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share conversion price of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="nump">$ 3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="nump">760,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_WarrantLiabilityCurrent', window );">Warrant liability</a></td>
<td class="nump">8,000<span></span>
</td>
<td class="nump">$ 252,000<span></span>
</td>
<td class="nump">$ 182,000<span></span>
</td>
<td class="nump">$ 1,052,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Cash, FDIC insured amount</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_WarrantLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant liability current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_WarrantLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480341/340-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Schedule of Accounts Payable (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2"><div>Sep. 30, 2025</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableInterestBearingInterestRate', window );">Accounts payable interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">100.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">100.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Total accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 769,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 3,853,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_CytovanceBiologicsIncMember', window );">Cytovance Biologics Inc [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 1,183,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 638,000<span></span>
</td>
<td class="nump">$ 3,515,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableInterestBearingInterestRate', window );">Accounts payable interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">8.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">31.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_UniversityOfMinnesotaMember', window );">University of Minnesota [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 463,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 712,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableInterestBearingInterestRate', window );">Accounts payable interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">60.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">18.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_LegalServicesFirmMember', window );">Legal Services Firm [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1,505,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableInterestBearingInterestRate', window );">Accounts payable interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">39.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_OtherAccountsPayableMember', window );">Other Accounts Payable [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableInterestBearingInterestRate', window );">Accounts payable interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">32.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">12.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Other accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 246,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 453,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Accounts Payable
to Cytovance, a related party, since Cytovance owns greater than 5% of the Company&#8217;s issued and outstanding common stock. See Note
7 &#8211; Commitments and Contingencies, Significant Agreements.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableInterestBearingInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the effective interest rate as of the balance sheet date on interest-bearing trade payables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableInterestBearingInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (j)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (j)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (j)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (j)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (q)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (m)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_CytovanceBiologicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_CytovanceBiologicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_UniversityOfMinnesotaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_UniversityOfMinnesotaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_LegalServicesFirmMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_LegalServicesFirmMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_OtherAccountsPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_OtherAccountsPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Accounts Payable to Related Party (Details) - Cytovance Biologics Inc [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th" colspan="2"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,183,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 3,515,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Invoices, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">686,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,365,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Payments in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(962,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(3,432,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments in common stock, at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(810,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_RepaymentsOfPrefundedWarrantsAtFairValue', window );">Payments in pre-funded warrants, at fair value</a></td>
<td class="num">$ (847,000)<span></span>
</td>
<td class="num">(847,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 638,000<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Accounts Payable
to Cytovance, a related party, since Cytovance owns greater than 5% of the Company&#8217;s issued and outstanding common stock. See Note
7 &#8211; Commitments and Contingencies, Significant Agreements.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_RepaymentsOfPrefundedWarrantsAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayments of prefunded warrants at fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_RepaymentsOfPrefundedWarrantsAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (j)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (j)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (j)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (j)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (q)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (m)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_CytovanceBiologicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_CytovanceBiologicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Related Party (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Apr. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>May 31, 2025</div></th>
<th class="th"><div>Feb. 26, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_AccountsPayableAndRelatedPartyLineItems', window );"><strong>AccountsPayableAndRelatedPartyLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable', window );">Issuance of prefunded warrant to settle vendor payable, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 810,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Issuance of pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.46<span></span>
</td>
<td class="nump">$ 2.8375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_AdvisoryAgreementMember', window );">Advisory Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_AccountsPayableAndRelatedPartyLineItems', window );"><strong>AccountsPayableAndRelatedPartyLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfOtherDebt', window );">Cash payment</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants outstanding</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance</a></td>
<td class="nump">$ 537,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">Related party transaction description</a></td>
<td class="text">The Agreement begins on July 1, 2025 and terminates on June 30, 2026. PDPC is considered a related party as its CEO is an individual
who has voting and investment control over an entity whose beneficial ownership exceeded 5% of the issued and outstanding shares of the
Company&#8217;s common stock.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_CytovanceBiologicsIncMember', window );">Cytovance Biologics Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_AccountsPayableAndRelatedPartyLineItems', window );"><strong>AccountsPayableAndRelatedPartyLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable', window );">Issuance of prefunded warrant to settle vendor payable, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable', window );">Issuance of prefunded warrant to settle vendor payable, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 810,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Issuance of pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">326,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">326,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_RepaymentsOfPrefundedWarrantsAtFairValue', window );">Payments in pre-funded warrants, at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 847,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 847,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_LegalServicesFirmMember', window );">Legal Services Firm [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_AccountsPayableAndRelatedPartyLineItems', window );"><strong>AccountsPayableAndRelatedPartyLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Prior year unpaid fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_AccountsPayableAndRelatedPartyLineItems', window );"><strong>AccountsPayableAndRelatedPartyLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable', window );">Issuance of prefunded warrant to settle vendor payable, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,597<span></span>
</td>
<td class="nump">127,597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable', window );">Issuance of prefunded warrant to settle vendor payable, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 810,000<span></span>
</td>
<td class="nump">$ 810,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Issuance of pre-funded warrants</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_AccountsPayableAndRelatedPartyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_AccountsPayableAndRelatedPartyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_RepaymentsOfPrefundedWarrantsAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayments of prefunded warrants at fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_RepaymentsOfPrefundedWarrantsAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares common shares to settle vendor payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value common shares to settle vendor payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for fees classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A description of the related party transaction, including transactions to which no amounts or nominal amounts were ascribed and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements. Examples of common related party transactions are, sales, purchases and transfers of realty and personal property, services received or furnished, loans and leases to and from top management and affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481440/840-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479773/842-30-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479741/842-40-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionDescriptionOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfOtherDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the payment of debt classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfOtherDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=GTBP_AdvisoryAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=GTBP_AdvisoryAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_CytovanceBiologicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_CytovanceBiologicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_LegalServicesFirmMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_LegalServicesFirmMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Warrant Liability (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Jan. 04, 2023</div></th>
<th class="th"><div>May 31, 2025</div></th>
<th class="th"><div>Feb. 26, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,145<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=GTBP_TwoThousandTwentyThreeCommonWarrantsMember', window );">2023 Common Warrants [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase</a></td>
<td class="nump">216,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=GTBP_TwoThousandTwentyThreePlacementAgentsWarrantsMember', window );">2023 Placement Agents Warrants [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase</a></td>
<td class="nump">13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=GTBP_TwoThousandTwentyThreeWarrantsMember', window );">2023 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility amount utilized in the value calculation percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant fair value</a></td>
<td class="nump">$ 5,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=GTBP_TwoThousandTwentyThreeCommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=GTBP_TwoThousandTwentyThreeCommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=GTBP_TwoThousandTwentyThreePlacementAgentsWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=GTBP_TwoThousandTwentyThreePlacementAgentsWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=GTBP_TwoThousandTwentyThreeWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=GTBP_TwoThousandTwentyThreeWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Schedule of Warrant Liability Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th"><div>Feb. 26, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected life (in years)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (232,000)<span></span>
</td>
<td class="num">$ (95,000)<span></span>
</td>
<td class="num">$ (244,000)<span></span>
</td>
<td class="num">$ (870,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=GTBP_TwoThousandTwentyThreeWarrantsMember', window );">2023 Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 252,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Measurement Input, Share Price [Member] | 2023 Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member] | 2023 Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">3.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member] | 2023 Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member] | 2023 Warrants [Member] | Minimum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected life (in years)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">2 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member] | 2023 Warrants [Member] | Maximum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected life (in years)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">2 years 9 months 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 9 months 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Measurement Input, Expected Dividend Rate [Member] | 2023 Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Based on rates
established by the Federal Reserve Bank</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Historical volatility
of the Company&#8217;s common stock is used to estimate the future volatility of its common stock</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Determined by the
remaining contractual life of the derivative instrument</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">Based on no dividends
paid or expected to be paid</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-47<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 37: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=GTBP_TwoThousandTwentyThreeWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=GTBP_TwoThousandTwentyThreeWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Warrant Liability Transactions (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_DisclosureWarrantLiabilityAbstract', window );"><strong>Warrant Liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_WarrantLiabilityCurrent', window );">Beginning balance</a></td>
<td class="nump">$ 252,000<span></span>
</td>
<td class="nump">$ 1,052,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Issuance of warrants at fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities', window );">Change in fair value</a></td>
<td class="num">(244,000)<span></span>
</td>
<td class="num">(870,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ExtinguishmentOfWarrant', window );">Extinguishment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_WarrantLiabilityCurrent', window );">Ending balance</a></td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="nump">$ 182,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_DisclosureWarrantLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_DisclosureWarrantLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ExtinguishmentOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Extinguishment of warrant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ExtinguishmentOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_WarrantLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant liability current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_WarrantLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of fair values and allocation of net proceeds (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 12, 2025</div></th>
<th class="th"><div>May 31, 2025</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,777,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ConvertiblePreferredStockAndWarrantsFairValuePercentage', window );">Convertible preferred stock and warrants fair value percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,441,000<span></span>
</td>
<td class="nump">$ 6,503,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ConvertiblePreferredStockAndWarrantsNetProceedsPercentage', window );">Convertible preferred stock and warrants net proceeds percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,089,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ConvertiblePreferredStockAndWarrantsFairValuePercentage', window );">Convertible preferred stock and warrants fair value percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-in Capital [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,389,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ConvertiblePreferredStockAndWarrantsNetProceedsPercentage', window );">Convertible preferred stock and warrants net proceeds percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=GTBP_SeriesLPreferredStockMember', window );">Series L Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,688,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ConvertiblePreferredStockAndWarrantsFairValuePercentage', window );">Convertible preferred stock and warrants fair value percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Total</a></td>
<td class="nump">$ 5,441,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=GTBP_MezzanineEquityMember', window );">Mezzanine Equity [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,052,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ConvertiblePreferredStockAndWarrantsNetProceedsPercentage', window );">Convertible preferred stock and warrants net proceeds percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ConvertiblePreferredStockAndWarrantsFairValuePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible preferred stock and warrants fair value percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ConvertiblePreferredStockAndWarrantsFairValuePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ConvertiblePreferredStockAndWarrantsNetProceedsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible preferred stock and warrants net proceeds percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ConvertiblePreferredStockAndWarrantsNetProceedsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of preferred stock and warrants for common stock issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=GTBP_SeriesLPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=GTBP_SeriesLPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=GTBP_MezzanineEquityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=GTBP_MezzanineEquityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Deficit) (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2025</div></th>
<th class="th"><div>May 22, 2025</div></th>
<th class="th"><div>May 14, 2025</div></th>
<th class="th"><div>May 12, 2025</div></th>
<th class="th"><div>May 11, 2025</div></th>
<th class="th"><div>Feb. 26, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>May 31, 2025</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 29, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Warrants to purcahse</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 718,000<span></span>
</td>
<td class="nump">$ 718,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 718,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Placement agents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 686,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoninterestExpenseOfferingCost', window );">Other offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber', window );">Issuance of warrants, exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">302,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
<td class="nump">$ 2.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.8375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Equity issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of preferred stock and warrants, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,441,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,503,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.6421<span></span>
</td>
<td class="nump">$ 0.6421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrent', window );">Dividends unpaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 144,000<span></span>
</td>
<td class="nump">$ 144,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=GTBP_CommonWarrantsMember', window );">Common Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
<td class="nump">2.043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.043<span></span>
</td>
<td class="nump">$ 0.6421<span></span>
</td>
<td class="nump">$ 0.6421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=GTBP_VestingWarrantsMember', window );">Vesting Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
<td class="nump">$ 2.043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,230<span></span>
</td>
<td class="nump">96,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,230<span></span>
</td>
<td class="nump">96,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,230<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=GTBP_SeriesLTenPercentConvertiblePreferredStockMember', window );">Series L 10% Convertible Preferred Stock [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Issuance of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=GTBP_SeriesLTenPercentConvertiblePreferredStockMember', window );">Series L 10% Convertible Preferred Stock [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Issuance of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=GTBP_SeriesLPreferredStockMember', window );">Series L Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,912<span></span>
</td>
<td class="nump">4,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,912<span></span>
</td>
<td class="nump">4,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of preferred stock and warrants, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,441,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=GTBP_SeriesLPreferredStockMember', window );">Series L Preferred Stock [Member] | Common Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares issued</a></td>
<td class="nump">3,235,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Aggregate number of shares vested</a></td>
<td class="nump">11,756,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=GTBP_SeriesL10PercentageConvertiblePreferredStockMember', window );">Series L 10% Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.6421<span></span>
</td>
<td class="nump">$ 0.6421<span></span>
</td>
<td class="nump">$ 2.043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,222.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,222,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_PreferredStockPurchasePrice', window );">Purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=GTBP_SeriesLConvertiblePreferredStockMember', window );">Series L Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock', window );">Dividends to holders unpaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 229,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrent', window );">Dividends unpaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 144,000<span></span>
</td>
<td class="nump">144,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Warrants to purcahse</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=GTBP_InducementWarrantsMember', window );">Inducement Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Placement agents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">604,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=GTBP_SeriesAInducementWarrantsMember', window );">Series A Inducement Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Placement agents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">302,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=GTBP_SeriesBInducementWarrantsMember', window );">Series B Inducement Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Placement agents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">302,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=GTBP_GreenshoeRightsMember', window );">Greenshoe Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFloorPrice', window );">Floor price</a></td>
<td class="nump">0.454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_PurchaseAgreementMember', window );">Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Warrants to purcahse</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_WeightedAverageVolumePriceOfCommonStockPercentage', window );">Weighted average volume price of common stock percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Placement agents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_LiableOfLiquidatedDamagePercentageDescription', window );">Liable of liquidated damage percentage, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company will be liable for liquidated damages of 1.5% of the
subscription amount paid by each Purchaser. Further, if the Company fails to pay such liquidated damages within 7 days from the date
payable, the Company will pay interest thereon at the prime rate plus 12% to each holder of the registrable securities.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_CommonStockSharesOutstandingPercentage', window );">Common stock shares outstanding percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | Common Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | Vesting Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | Series L 10% Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Issuance of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,611.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_AggregateStatedValue', window );">Aggregate stated value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,611,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ClassOfWarrantsPurchaseUpPercentage', window );">Warrants purchase up percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10000.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Issuance of shares, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,950,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Percentage of dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | Series L 10% Convertible Preferred Stock [Member] | Common Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,235,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Aggregate number of shares vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,576,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | Greenshoe Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_AggregateStatedValue', window );">Aggregate stated value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,018,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Issuance of shares, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,616,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFloorPrice', window );">Floor price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_AggregateStatedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate stated value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_AggregateStatedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ClassOfWarrantsPurchaseUpPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants purchase up percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ClassOfWarrantsPurchaseUpPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_CommonStockSharesOutstandingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock shares outstanding percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_CommonStockSharesOutstandingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_LiableOfLiquidatedDamagePercentageDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liable of liquidated damage percentage, description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_LiableOfLiquidatedDamagePercentageDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_PreferredStockPurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred stock purchase price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_PreferredStockPurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non options exercisable number.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_WeightedAverageVolumePriceOfCommonStockPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average volume price of common stock percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_WeightedAverageVolumePriceOfCommonStockPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFloorPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Floor rate on a price risk derivative such as a floor or a collar. A payment or receipt is triggered if the market rate falls below the floor rate on the contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFloorPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:perUnitItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoninterestExpenseOfferingCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for cost associated with issuance of security by investment company. Includes, but is not limited to, legal fee pertaining to share offered for sale, registration fee, underwriting, printing prospectus, and initial fee for listing on exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoninterestExpenseOfferingCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire preferred stock originally issued and identified as a security that can be exchanged for another type of financial security. This repurchased stock is held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share conversion price of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=GTBP_CommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=GTBP_CommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=GTBP_VestingWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=GTBP_VestingWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=GTBP_SeriesLTenPercentConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=GTBP_SeriesLTenPercentConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=GTBP_SeriesLPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=GTBP_SeriesLPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=GTBP_SeriesL10PercentageConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=GTBP_SeriesL10PercentageConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=GTBP_SeriesLConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=GTBP_SeriesLConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=GTBP_InducementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=GTBP_InducementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=GTBP_SeriesAInducementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=GTBP_SeriesAInducementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=GTBP_SeriesBInducementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=GTBP_SeriesBInducementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=GTBP_GreenshoeRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=GTBP_GreenshoeRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=GTBP_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=GTBP_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=GTBP_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=GTBP_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Warrant Activity (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract', window );"><strong>Common Stock Warrants And Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants outstanding, beginning balance | shares</a></td>
<td class="nump">1,120,429<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, beginning balance | $ / shares</a></td>
<td class="nump">$ 18.85<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of warrants, granted | shares</a></td>
<td class="nump">16,468,308<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice', window );">Weighted average exercise price, granted | $ / shares</a></td>
<td class="nump">$ 2.04<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedPursuantToFullRatchetPriceProtection', window );">Number of warrants, granted pursuant to full ratchet price and anti-dilution protections | shares</a></td>
<td class="nump">32,709,588<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedPursuantToFullRatchetPriceProtectionWeightedAverageExercisePrice', window );">Weighted average exercise price, granted pursuant to full ratchet price and anti-dilution protections | $ / shares</a></td>
<td class="nump">$ 0.64<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations', window );">Number of warrants, forfeited/cancelled | shares</a></td>
<td class="num">(1,866)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice', window );">Weighted average exercise price, forfeited/cancelled | $ / shares</a></td>
<td class="nump">$ 102.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Number of warrants, exercised | shares</a></td>
<td class="num">(837,069)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice', window );">Weighted average exercise price, exercised | $ / shares</a></td>
<td class="nump">$ 2.11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants outstanding, ending balance | shares</a></td>
<td class="nump">49,459,390<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, ending balance | $ / shares</a></td>
<td class="nump">$ 1.04<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable', window );">Warrants exercisable, ending balance | shares</a></td>
<td class="nump">13,956,955<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, exercisable, ending balance | $ / shares</a></td>
<td class="nump">$ 2.04<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangements By Share Based Payment Award Non Options Equity Instruments Exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedPursuantToFullRatchetPriceProtection">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Granted pursuant to full ratchet price protection, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedPursuantToFullRatchetPriceProtection</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By ShareBased Payment Award Non Options Exercisable Weighted Average Exercise Price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non options exercised weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non options forfeitures and expirations weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedPursuantToFullRatchetPriceProtectionWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Granted pursuant to full ratchet price protection, weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedPursuantToFullRatchetPriceProtectionWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non options granted weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangements by share based payment award non options outstanding weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements that were either cancelled or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Warrants and Options (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>May 31, 2025</div></th>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Feb. 26, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding vested intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 281,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 281,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
<td class="nump">$ 2.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.8375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrant issued</a></td>
<td class="nump">24,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Fair value of warrant</a></td>
<td class="nump">$ 44,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Number shares issued for service, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 718,000<span></span>
</td>
<td class="nump">$ 718,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 718,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Common stock awards granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">525,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock option outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">597,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">597,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Rstricted stock granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Share-based compensation weighted average remaining contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Options outstanding intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Fair value of vested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 379,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 386,000<span></span>
</td>
<td class="nump">$ 222,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Stock option, exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">396,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">396,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1', window );">Stock option, unvested compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 236,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=GTBP_OmnibusIncentivePlanMember', window );">2022 Omnibus Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Common stock awards granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">583,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=GTBP_OmnibusIncentivePlanMember', window );">2022 Omnibus Incentive Plan [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Common stock awards granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrant issued</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=GTBP_GreenshoeRightsMember', window );">Greenshoe Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFloorPrice', window );">Floor price per share</a></td>
<td class="nump">0.454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrant issued</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of new shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Number shares issued for service, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Fair value of vested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=GTBP_PrefundedWarrantsMember', window );">Prefunded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrant issued</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightUnissued', window );">Issuance of pre-funded warrants</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=GTBP_CommonWarrantsMember', window );">Common Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
<td class="nump">$ 2.043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.6421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.6421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrant issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,709,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,709,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=GTBP_VestingWarrantsMember', window );">Vesting Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
<td class="nump">$ 2.043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=GTBP_SeriesLPreferredStockMember', window );">Series L Preferred Stock [Member] | Common Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Aggregate number of shares issued</a></td>
<td class="nump">3,235,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Aggregate number of shares vested</a></td>
<td class="nump">11,756,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options non vested in period fair value 1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightUnissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants or rights which entitle the entity to receive future services in exchange for the unvested, forfeitable warrants or rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightUnissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFloorPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Floor rate on a price risk derivative such as a floor or a collar. A payment or receipt is triggered if the market rate falls below the floor rate on the contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFloorPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:perUnitItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=GTBP_OmnibusIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=GTBP_OmnibusIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=GTBP_GreenshoeRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=GTBP_GreenshoeRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=GTBP_PrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=GTBP_PrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=GTBP_CommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=GTBP_CommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=GTBP_VestingWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=GTBP_VestingWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=GTBP_SeriesLPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=GTBP_SeriesLPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Warrants Outstanding and Exercisable (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of outstanding</a></td>
<td class="nump">49,459,390<span></span>
</td>
<td class="nump">1,120,429<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice', window );">Warrants weighted average exercise price</a></td>
<td class="nump">$ 1.04<span></span>
</td>
<td class="nump">$ 18.85<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeOneMember', window );">Range of Exercise Price One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise price</a></td>
<td class="nump">1.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeTwoMember', window );">Range of Exercise Price Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise price</a></td>
<td class="nump">2.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeThreeMember', window );">Range of Exercise Price Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise price</a></td>
<td class="nump">10.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeFourMember', window );">Range of Exercise Price Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise price</a></td>
<td class="nump">25.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeFiveMember', window );">Range of Exercise Price Five [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise price</a></td>
<td class="nump">$ 74.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of outstanding</a></td>
<td class="nump">49,459,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice', window );">Warrants weighted average exercise price</a></td>
<td class="nump">$ 1.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Warrants outstanding, weighted average remaining contractual life (years)</a></td>
<td class="text">4 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Range of Exercise Price One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise price</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of outstanding</a></td>
<td class="nump">476,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice', window );">Warrants weighted average exercise price</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Range of Exercise Price Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise price</a></td>
<td class="nump">$ 0.6421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of outstanding</a></td>
<td class="nump">10,296,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice', window );">Warrants weighted average exercise price</a></td>
<td class="nump">$ 0.6421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Warrants outstanding, weighted average remaining contractual life (years)</a></td>
<td class="text">4 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Range of Exercise Price Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise price</a></td>
<td class="nump">$ 0.6421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of outstanding</a></td>
<td class="nump">37,405,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice', window );">Warrants weighted average exercise price</a></td>
<td class="nump">$ 0.6421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Range of Exercise Price Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise price</a></td>
<td class="nump">$ 2.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of outstanding</a></td>
<td class="nump">369,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice', window );">Warrants weighted average exercise price</a></td>
<td class="nump">$ 2.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Warrants outstanding, weighted average remaining contractual life (years)</a></td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Range of Exercise Price Five [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise price</a></td>
<td class="nump">$ 2.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of outstanding</a></td>
<td class="nump">24,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice', window );">Warrants weighted average exercise price</a></td>
<td class="nump">$ 2.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Warrants outstanding, weighted average remaining contractual life (years)</a></td>
<td class="text">4 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Range of Exercise Price Six [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise price</a></td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of outstanding</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice', window );">Warrants weighted average exercise price</a></td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Warrants outstanding, weighted average remaining contractual life (years)</a></td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Range of Exercise Price Seven [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise price</a></td>
<td class="nump">$ 2.8375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of outstanding</a></td>
<td class="nump">21,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice', window );">Warrants weighted average exercise price</a></td>
<td class="nump">$ 2.8375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Warrants outstanding, weighted average remaining contractual life (years)</a></td>
<td class="text">4 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Range of Exercise Price Eight [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise price</a></td>
<td class="nump">$ 4.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of outstanding</a></td>
<td class="nump">437,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice', window );">Warrants weighted average exercise price</a></td>
<td class="nump">$ 4.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Warrants outstanding, weighted average remaining contractual life (years)</a></td>
<td class="text">3 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Range of Exercise Price Nine [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise price</a></td>
<td class="nump">$ 5.4375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of outstanding</a></td>
<td class="nump">88,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice', window );">Warrants weighted average exercise price</a></td>
<td class="nump">$ 5.4375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Warrants outstanding, weighted average remaining contractual life (years)</a></td>
<td class="text">3 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Range of Exercise Price Ten [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise price</a></td>
<td class="nump">$ 30.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of outstanding</a></td>
<td class="nump">216,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice', window );">Warrants weighted average exercise price</a></td>
<td class="nump">$ 30.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Warrants outstanding, weighted average remaining contractual life (years)</a></td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Range of Exercise Price Eleven [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise price</a></td>
<td class="nump">$ 37.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of outstanding</a></td>
<td class="nump">13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice', window );">Warrants weighted average exercise price</a></td>
<td class="nump">$ 37.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Warrants outstanding, weighted average remaining contractual life (years)</a></td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Range of Exercise Price Twelve [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise price</a></td>
<td class="nump">$ 165.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of outstanding</a></td>
<td class="nump">52,316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice', window );">Warrants weighted average exercise price</a></td>
<td class="nump">$ 165.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Warrants outstanding, weighted average remaining contractual life (years)</a></td>
<td class="text">4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Range of Exercise Price Thirteen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise price</a></td>
<td class="nump">$ 206.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of outstanding</a></td>
<td class="nump">7,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice', window );">Warrants weighted average exercise price</a></td>
<td class="nump">$ 206.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Warrants outstanding, weighted average remaining contractual life (years)</a></td>
<td class="text">4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangements by share based payment award non options outstanding weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeTenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeTenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeElevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeElevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeTwelveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeTwelveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeThirteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeThirteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Options Activity (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract', window );"><strong>Common Stock Warrants And Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding, beginning | shares</a></td>
<td class="nump">124,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, beginning | $ / shares</a></td>
<td class="nump">$ 32.69<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Number of options, granted | shares</a></td>
<td class="nump">525,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, granted | $ / shares</a></td>
<td class="nump">$ 1.33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Number of options, forfeited/cancelled | shares</a></td>
<td class="num">(52,050)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, forfeited/cancelled | $ / shares</a></td>
<td class="nump">$ 43.08<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of options, exercised | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, exercised | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding, ending | shares</a></td>
<td class="nump">597,550<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, ending | $ / shares</a></td>
<td class="nump">$ 4.23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options outstanding exercisable | shares</a></td>
<td class="nump">396,439<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price,exercisable, ending | $ / shares</a></td>
<td class="nump">$ 5.68<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Options Outstanding and Options Exercisable (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding | shares</a></td>
<td class="nump">396,439<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeOneMember', window );">Range of Exercise Price One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of excercise price</a></td>
<td class="nump">$ 1.33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding | shares</a></td>
<td class="nump">337,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options outstanding, weighted average remaining contractual life (years)</a></td>
<td class="text">9 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options outstanding, weighted average exercise price</a></td>
<td class="nump">$ 1.33<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeTwoMember', window );">Range of Exercise Price Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of excercise price</a></td>
<td class="nump">$ 2.11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding | shares</a></td>
<td class="nump">9,723<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options outstanding, weighted average remaining contractual life (years)</a></td>
<td class="text">7 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options outstanding, weighted average exercise price</a></td>
<td class="nump">$ 2.11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeThreeMember', window );">Range of Exercise Price Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of excercise price</a></td>
<td class="nump">$ 10.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding | shares</a></td>
<td class="nump">16,667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options outstanding, weighted average remaining contractual life (years)</a></td>
<td class="text">7 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options outstanding, weighted average exercise price</a></td>
<td class="nump">$ 10.50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeFourMember', window );">Range of Exercise Price Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of excercise price</a></td>
<td class="nump">$ 25.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding | shares</a></td>
<td class="nump">16,667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options outstanding, weighted average remaining contractual life (years)</a></td>
<td class="text">7 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options outstanding, weighted average exercise price</a></td>
<td class="nump">$ 25.50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeFiveMember', window );">Range of Exercise Price Five [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of excercise price</a></td>
<td class="nump">$ 74.40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding | shares</a></td>
<td class="nump">15,882<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options outstanding, weighted average remaining contractual life (years)</a></td>
<td class="text">6 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options outstanding, weighted average exercise price</a></td>
<td class="nump">$ 74.40<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=GTBP_RangeFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 02, 2025</div></th>
<th class="th"><div>Jul. 09, 2025</div></th>
<th class="th"><div>Jul. 08, 2025</div></th>
<th class="th"><div>Jun. 18, 2025</div></th>
<th class="th"><div>Feb. 17, 2025</div></th>
<th class="th"><div>Nov. 18, 2024</div></th>
<th class="th"><div>May 20, 2024</div></th>
<th class="th"><div>May 13, 2024</div></th>
<th class="th"><div>Mar. 26, 2021</div></th>
<th class="th"><div>Jul. 18, 2016</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>May 31, 2025</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Feb. 26, 2025</div></th>
<th class="th"><div>Nov. 21, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Apr. 25, 2024</div></th>
<th class="th"><div>Aug. 24, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Issuance of pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.8375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (232,000)<span></span>
</td>
<td class="num">$ (95,000)<span></span>
</td>
<td class="num">$ (244,000)<span></span>
</td>
<td class="num">$ (870,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable', window );">Issuance of common stock in settlement of vendor payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">810,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock and warrants for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 718,000<span></span>
</td>
<td class="nump">$ 718,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">718,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">634,000<span></span>
</td>
<td class="nump">$ 1,307,000<span></span>
</td>
<td class="nump">2,096,000<span></span>
</td>
<td class="nump">3,868,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ContigencyMinimumRequired', window );">Contigency minimum required</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandTwentyThreeSponsoredResearchAgreementMember', window );">2023 Sponsored Research Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Aggregate research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment', window );">Payments of research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 216,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">647,000<span></span>
</td>
<td class="nump">863,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnbilledReceivablesCurrent', window );">Unbilled and unaccrued amounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">216,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">216,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandSixteenPatentLicenseAgreementMember', window );">2016 Exclusive Patent License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">145,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_ProceedsFromUpfrontAmount', window );">Proceeds from upfront amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 145,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostMaintenance', window );">License maintenance fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_RoyaltyFeePercentage', window );">Royalty fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_PerformanceMilestonePayments', window );">Performance milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_SalesMilestonePayments', window );">One-time sales milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_GrossSales', window );">Gross sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_SalesRevenue', window );">Sales revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_CummulativeGrossSales', window );">Cumulative gross sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_RoyaltyExpenseYearOne', window );">Royalty expense year one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_RoyaltyExpenseYearTwoThroughFive', window );">Royalty expense years two through five</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_RoyaltyExpenseYearAfterSix', window );">Royalty expense year six and thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandSixteenPatentLicenseAgreementMember', window );">2016 Exclusive Patent License Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_RoyaltyFeePercentage', window );">Royalty fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandSixteenPatentLicenseAgreementMember', window );">2016 Exclusive Patent License Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_RoyaltyFeePercentage', window );">Royalty fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandSixteenPatentLicenseAgreementMember', window );">2016 Exclusive Patent License Agreement [Member] | 2017 through 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostMaintenance', window );">License maintenance fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandSixteenPatentLicenseAgreementMember', window );">2016 Exclusive Patent License Agreement [Member] | Beginning in 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Annual royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandSixteenPatentLicenseAgreementMember', window );">2016 Exclusive Patent License Agreement [Member] | Beginning in 2025 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostMaintenance', window );">License maintenance fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Annual royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandSixteenPatentLicenseAgreementMember', window );">2016 Exclusive Patent License Agreement [Member] | Beginning in 2027 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Annual royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember', window );">2021 Exclusive License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostMaintenance', window );">License maintenance fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_PerformanceMilestonePayments', window );">Performance milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_SalesMilestonePayments', window );">One-time sales milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_GrossSales', window );">Gross sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_SalesRevenue', window );">Sales revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_CummulativeGrossSales', window );">Cumulative gross sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_UpfrontLicenseFee', window );">Upfront license fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_RoyaltyExpenseYearOneThoughFour', window );">Royalty expense year one though four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_RoyaltyExpenseYearAfterFive', window );">Royalty expense year five and thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember', window );">2021 Exclusive License Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_RoyaltyFeePercentage', window );">Royalty fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember', window );">2021 Exclusive License Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_RoyaltyFeePercentage', window );">Royalty fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember', window );">2024 GTB-3650 Clinical Trial Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnbilledReceivablesCurrent', window );">Unbilled and unaccrued amounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Annual royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_CytovanceBiologicsIncMember', window );">Cytovance Biologics Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">686,000<span></span>
</td>
<td class="nump">1,365,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 962,000<span></span>
</td>
<td class="nump">$ 3,432,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Issuance of pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">326,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">326,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">326,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 847,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable', window );">Issuance of common stock in settlement of vendor payable, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable', window );">Issuance of common stock in settlement of vendor payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 810,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock and warrants for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">273,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_CytovanceBiologicsIncMember', window );">Cytovance Biologics Inc [Member] | Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 686,000<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=GTBP_CytovanceBiologicsIncMember', window );">Cytovance Biologics Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">9.90%<span></span>
</td>
<td class="nump">4.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=GTBP_ZOneLLCMember', window );">Z One LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesPaidValue', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Damages sought value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=GTBP_CobySilberfeinMember', window );">Coby Silberfein [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesPaidValue', window );">Principal amount</a></td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Damages sought value</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSought', window );">Owes damages excess value</a></td>
<td class="text">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ContigencyMinimumRequired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contigency minimum required.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ContigencyMinimumRequired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_CummulativeGrossSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cummulative gross sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_CummulativeGrossSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_GrossSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_GrossSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_PerformanceMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Performance milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_PerformanceMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_ProceedsFromUpfrontAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Received upfront payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_ProceedsFromUpfrontAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_RoyaltyExpenseYearAfterFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty expense year five and thereafter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_RoyaltyExpenseYearAfterFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_RoyaltyExpenseYearAfterSix">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty expense year after six.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_RoyaltyExpenseYearAfterSix</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_RoyaltyExpenseYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty expense year one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_RoyaltyExpenseYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_RoyaltyExpenseYearOneThoughFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty expense year one though four.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_RoyaltyExpenseYearOneThoughFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_RoyaltyExpenseYearTwoThroughFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty expense year two through five.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_RoyaltyExpenseYearTwoThroughFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_RoyaltyFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty fee percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_RoyaltyFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_SalesMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_SalesMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_SalesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_SalesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares common shares to settle vendor payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value common shares to settle vendor payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_UpfrontLicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront license fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_UpfrontLicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostMaintenance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of maintenance incurred and directly related to good produced and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostMaintenance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesPaidValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of damages paid to the plaintiff in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesPaidValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSought">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describes the form and magnitude of the award the plaintiff seeks in the legal matter, which may include an unspecified amount of money.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSought</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnbilledReceivablesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount received for services rendered and products shipped, but not yet billed, for non-contractual agreements due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnbilledReceivablesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandTwentyThreeSponsoredResearchAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandTwentyThreeSponsoredResearchAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandSixteenPatentLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandSixteenPatentLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=GTBP_TwoThousandSeventeenThroughTwoThousandTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=GTBP_TwoThousandSeventeenThroughTwoThousandTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=GTBP_TwoThousandTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=GTBP_TwoThousandTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=GTBP_TwoThousandTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=GTBP_TwoThousandTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=GTBP_TwoThousandTwentySevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=GTBP_TwoThousandTwentySevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_CytovanceBiologicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=GTBP_CytovanceBiologicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=GTBP_CytovanceBiologicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=GTBP_CytovanceBiologicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=GTBP_ZOneLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=GTBP_ZOneLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=GTBP_CobySilberfeinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=GTBP_CobySilberfeinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Segment Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 386,000<span></span>
</td>
<td class="nump">$ 222,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income</a></td>
<td class="nump">$ 268,000<span></span>
</td>
<td class="nump">$ 193,000<span></span>
</td>
<td class="nump">1,504,000<span></span>
</td>
<td class="nump">1,214,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(3,114,000)<span></span>
</td>
<td class="num">(3,411,000)<span></span>
</td>
<td class="num">(5,323,000)<span></span>
</td>
<td class="num">(9,387,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=GTBP_SegmentsMember', window );">Segments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">634,000<span></span>
</td>
<td class="nump">1,307,000<span></span>
</td>
<td class="nump">2,096,000<span></span>
</td>
<td class="nump">3,868,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesAndWages', window );">Salaries</a></td>
<td class="nump">373,000<span></span>
</td>
<td class="nump">340,000<span></span>
</td>
<td class="nump">1,006,000<span></span>
</td>
<td class="nump">1,106,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceCommissions', window );">Insurance</a></td>
<td class="nump">54,000<span></span>
</td>
<td class="nump">42,000<span></span>
</td>
<td class="nump">175,000<span></span>
</td>
<td class="nump">194,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">379,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">386,000<span></span>
</td>
<td class="nump">222,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating expenses</a></td>
<td class="nump">1,942,000<span></span>
</td>
<td class="nump">1,915,000<span></span>
</td>
<td class="nump">3,164,000<span></span>
</td>
<td class="nump">5,211,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income</a></td>
<td class="num">(268,000)<span></span>
</td>
<td class="num">(193,000)<span></span>
</td>
<td class="num">(1,504,000)<span></span>
</td>
<td class="num">(1,214,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 3,114,000<span></span>
</td>
<td class="nump">$ 3,411,000<span></span>
</td>
<td class="nump">$ 5,323,000<span></span>
</td>
<td class="nump">$ 9,387,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expense incurred by an insurance company to persons or entities for generating or placing insurance or investment contracts with the company, usually determined as a percentage of policy or contract premiums. Excludes advances or draws to be applied against commissions earned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(7)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesAndWages">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalariesAndWages</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=GTBP_SegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=GTBP_SegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2025 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2025</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Oct. 30, 2025</div></th>
<th class="th"><div>Sep. 29, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.6421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Number of shares converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,051,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,234,328<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=GTBP_SeriesL10PercentageConvertiblePreferredStockMember', window );">Series L 10% Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,222.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,222,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_PreferredStockPurchasePrice', window );">Purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.6421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=GTBP_SeriesL10PercentageConvertiblePreferredStockMember', window );">Series L 10% Convertible Preferred Stock [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="nump">2,055.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued value</a></td>
<td class="nump">$ 2,055,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_GTBP_PreferredStockPurchasePrice', window );">Purchase price</a></td>
<td class="nump">$ 1,850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Exercise price</a></td>
<td class="nump">$ 0.5319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.6421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=GTBP_SeriesLConvertiblePreferredStockMember', window );">Series L Convertible Preferred Stock [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Shares converted</a></td>
<td class="nump">2,556.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Number of shares converted</a></td>
<td class="nump">4,309,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_GTBP_PreferredStockPurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred stock purchase price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">GTBP_PreferredStockPurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>GTBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share conversion price of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=GTBP_SeriesL10PercentageConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=GTBP_SeriesL10PercentageConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=GTBP_SeriesLConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=GTBP_SeriesLConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>241</ContextCount>
  <ElementCount>270</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>73</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Condensed Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/BalanceSheets</Role>
      <ShortName>Condensed Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Condensed Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Condensed Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Condensed Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/StatementsOfOperations</Role>
      <ShortName>Condensed Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Condensed Statements of Operations (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/StatementsOfOperationsParenthetical</Role>
      <ShortName>Condensed Statements of Operations (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Condensed Statements of Stockholders' Equity (Deficit) and Mezzanine Equity  (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity</Role>
      <ShortName>Condensed Statements of Stockholders' Equity (Deficit) and Mezzanine Equity  (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Statement - Condensed Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/StatementsOfCashFlows</Role>
      <ShortName>Condensed Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>999013 - Disclosure - Organization and Going Concern Analysis</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/OrganizationAndGoingConcernAnalysis</Role>
      <ShortName>Organization and Going Concern Analysis</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>999014 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>999015 - Disclosure - Accounts Payable and Related Party</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/AccountsPayableAndRelatedParty</Role>
      <ShortName>Accounts Payable and Related Party</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>999016 - Disclosure - Warrant Liability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/WarrantLiability</Role>
      <ShortName>Warrant Liability</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>999017 - Disclosure - Stockholders??? Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/StockholdersEquityDeficit</Role>
      <ShortName>Stockholders??? Equity (Deficit)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>999018 - Disclosure - Common Stock Warrants and Options</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/CommonStockWarrantsAndOptions</Role>
      <ShortName>Common Stock Warrants and Options</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>999019 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>999020 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>999021 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>999022 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>999023 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>999024 - Disclosure - Accounts Payable and Related Party (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyTables</Role>
      <ShortName>Accounts Payable and Related Party (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/AccountsPayableAndRelatedParty</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>999025 - Disclosure - Warrant Liability (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/WarrantLiabilityTables</Role>
      <ShortName>Warrant Liability (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/WarrantLiability</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>999026 - Disclosure - Stockholders??? Equity (Deficit) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/StockholdersEquityDeficitTables</Role>
      <ShortName>Stockholders??? Equity (Deficit) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/StockholdersEquityDeficit</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>999027 - Disclosure - Common Stock Warrants and Options (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsTables</Role>
      <ShortName>Common Stock Warrants and Options (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/CommonStockWarrantsAndOptions</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>999028 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/SegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/SegmentInformation</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>999029 - Disclosure - Organization and Going Concern Analysis (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/OrganizationAndGoingConcernAnalysisDetailsNarrative</Role>
      <ShortName>Organization and Going Concern Analysis (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/OrganizationAndGoingConcernAnalysis</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>999030 - Disclosure - Schedule of Anti-dilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails</Role>
      <ShortName>Schedule of Anti-dilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>999031 - Disclosure - Schedule of Anti-dilutive Securities (Details) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetailsParenthetical</Role>
      <ShortName>Schedule of Anti-dilutive Securities (Details) (Parenthetical)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>999032 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>Summary of Significant Accounting Policies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>999033 - Disclosure - Schedule of Accounts Payable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails</Role>
      <ShortName>Schedule of Accounts Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>999034 - Disclosure - Schedule of Accounts Payable to Related Party (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/ScheduleOfAccountsPayableToRelatedPartyDetails</Role>
      <ShortName>Schedule of Accounts Payable to Related Party (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>999035 - Disclosure - Accounts Payable and Related Party (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyDetailsNarrative</Role>
      <ShortName>Accounts Payable and Related Party (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>999036 - Disclosure - Warrant Liability (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative</Role>
      <ShortName>Warrant Liability (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/WarrantLiabilityTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>999037 - Disclosure - Schedule of Warrant Liability Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails</Role>
      <ShortName>Schedule of Warrant Liability Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>999038 - Disclosure - Schedule of Warrant Liability Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityTransactionsDetails</Role>
      <ShortName>Schedule of Warrant Liability Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>999039 - Disclosure - Schedule of fair values and allocation of net proceeds (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/ScheduleOfFairValuesAndAllocationOfNetProceedsDetails</Role>
      <ShortName>Schedule of fair values and allocation of net proceeds (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>999040 - Disclosure - Stockholders??? Equity (Deficit) (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative</Role>
      <ShortName>Stockholders??? Equity (Deficit) (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/StockholdersEquityDeficitTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>999041 - Disclosure - Schedule of Warrant Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails</Role>
      <ShortName>Schedule of Warrant Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>999042 - Disclosure - Common Stock Warrants and Options (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative</Role>
      <ShortName>Common Stock Warrants and Options (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>999043 - Disclosure - Schedule of Warrants Outstanding and Exercisable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails</Role>
      <ShortName>Schedule of Warrants Outstanding and Exercisable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>999044 - Disclosure - Schedule of Options Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails</Role>
      <ShortName>Schedule of Options Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>999045 - Disclosure - Schedule of Options Outstanding and Options Exercisable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails</Role>
      <ShortName>Schedule of Options Outstanding and Options Exercisable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>999046 - Disclosure - Commitments and Contingencies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>Commitments and Contingencies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>999047 - Disclosure - Schedule of Segment Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/ScheduleOfSegmentInformationDetails</Role>
      <ShortName>Schedule of Segment Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>999048 - Disclosure - Segment Information (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/SegmentInformationDetailsNarrative</Role>
      <ShortName>Segment Information (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/SegmentInformationTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>999049 - Disclosure - Subsequent Events (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>Subsequent Events (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://gtbiopharma.com/role/SubsequentEvents</ParentRole>
      <Position>46</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="form10-q.htm">form10-q.htm</File>
    <File>gtbp-20250930.xsd</File>
    <File>gtbp-20250930_cal.xml</File>
    <File>gtbp-20250930_def.xml</File>
    <File>gtbp-20250930_lab.xml</File>
    <File>gtbp-20250930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>form10-q_001.jpg</File>
    <File>form10-q_002.jpg</File>
    <File>form10-q_003.jpg</File>
    <File>form10-q_004.jpg</File>
    <File>form10-q_005.jpg</File>
    <File>form10-q_006.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="716">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>69
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form10-q.htm": {
   "nsprefix": "GTBP",
   "nsuri": "http://gtbiopharma.com/20250930",
   "dts": {
    "inline": {
     "local": [
      "form10-q.htm"
     ]
    },
    "schema": {
     "local": [
      "gtbp-20250930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "gtbp-20250930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "gtbp-20250930_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "gtbp-20250930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "gtbp-20250930_pre.xml"
     ]
    }
   },
   "keyStandard": 211,
   "keyCustom": 59,
   "axisStandard": 19,
   "axisCustom": 0,
   "memberStandard": 18,
   "memberCustom": 49,
   "hidden": {
    "total": 183,
    "http://fasb.org/us-gaap/2025": 141,
    "http://gtbiopharma.com/20250930": 38,
    "http://xbrl.sec.gov/dei/2025": 4
   },
   "contextCount": 241,
   "entityCount": 1,
   "segmentCount": 73,
   "elementCount": 544,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 716,
    "http://xbrl.sec.gov/dei/2025": 30,
    "http://xbrl.sec.gov/ecd/2025": 4
   },
   "report": {
    "R1": {
     "role": "http://gtbiopharma.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://gtbiopharma.com/role/BalanceSheets",
     "longName": "00000002 - Statement - Condensed Balance Sheets",
     "shortName": "Condensed Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2025-09-30",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-09-30",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://gtbiopharma.com/role/BalanceSheetsParenthetical",
     "longName": "00000003 - Statement - Condensed Balance Sheets (Parenthetical)",
     "shortName": "Condensed Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2025-09-30",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-09-30",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://gtbiopharma.com/role/StatementsOfOperations",
     "longName": "00000004 - Statement - Condensed Statements of Operations (Unaudited)",
     "shortName": "Condensed Statements of Operations (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2025-07-012025-09-30",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-07-012025-09-30",
      "name": "us-gaap:SellingGeneralAndAdministrativeExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://gtbiopharma.com/role/StatementsOfOperationsParenthetical",
     "longName": "00000005 - Statement - Condensed Statements of Operations (Unaudited) (Parenthetical)",
     "shortName": "Condensed Statements of Operations (Unaudited) (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "From2025-07-012025-09-30_us-gaap_SellingGeneralAndAdministrativeExpensesMember_custom_OfficersEmployeesAndDirectorsMember",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-07-012025-09-30_us-gaap_SellingGeneralAndAdministrativeExpensesMember_custom_OfficersEmployeesAndDirectorsMember",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity",
     "longName": "00000006 - Statement - Condensed Statements of Stockholders' Equity (Deficit) and Mezzanine Equity  (Unaudited)",
     "shortName": "Condensed Statements of Stockholders' Equity (Deficit) and Mezzanine Equity  (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://gtbiopharma.com/role/StatementsOfCashFlows",
     "longName": "00000007 - Statement - Condensed Statements of Cash Flows",
     "shortName": "Condensed Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2025-07-012025-09-30",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "GTBP:IssuanceOfWarrantsForVrtWaiver",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2025-07-012025-09-30",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R9": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://gtbiopharma.com/role/OrganizationAndGoingConcernAnalysis",
     "longName": "999013 - Disclosure - Organization and Going Concern Analysis",
     "shortName": "Organization and Going Concern Analysis",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPolicies",
     "longName": "999014 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://gtbiopharma.com/role/AccountsPayableAndRelatedParty",
     "longName": "999015 - Disclosure - Accounts Payable and Related Party",
     "shortName": "Accounts Payable and Related Party",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://gtbiopharma.com/role/WarrantLiability",
     "longName": "999016 - Disclosure - Warrant Liability",
     "shortName": "Warrant Liability",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "GTBP:WarrantLiabilityTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "GTBP:WarrantLiabilityTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://gtbiopharma.com/role/StockholdersEquityDeficit",
     "longName": "999017 - Disclosure - Stockholders\u2019 Equity (Deficit)",
     "shortName": "Stockholders\u2019 Equity (Deficit)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://gtbiopharma.com/role/CommonStockWarrantsAndOptions",
     "longName": "999018 - Disclosure - Common Stock Warrants and Options",
     "shortName": "Common Stock Warrants and Options",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "GTBP:CommonStockWarrantsAndOptionsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "GTBP:CommonStockWarrantsAndOptionsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://gtbiopharma.com/role/CommitmentsAndContingencies",
     "longName": "999019 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://gtbiopharma.com/role/SegmentInformation",
     "longName": "999020 - Disclosure - Segment Information",
     "shortName": "Segment Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://gtbiopharma.com/role/SubsequentEvents",
     "longName": "999021 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "999022 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "longName": "999023 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyTables",
     "longName": "999024 - Disclosure - Accounts Payable and Related Party (Tables)",
     "shortName": "Accounts Payable and Related Party (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://gtbiopharma.com/role/WarrantLiabilityTables",
     "longName": "999025 - Disclosure - Warrant Liability (Tables)",
     "shortName": "Warrant Liability (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "GTBP:WarrantLiabilityTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "GTBP:WarrantLiabilityTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://gtbiopharma.com/role/StockholdersEquityDeficitTables",
     "longName": "999026 - Disclosure - Stockholders\u2019 Equity (Deficit) (Tables)",
     "shortName": "Stockholders\u2019 Equity (Deficit) (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:ScheduleOfConversionsOfStockTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:ScheduleOfConversionsOfStockTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsTables",
     "longName": "999027 - Disclosure - Common Stock Warrants and Options (Tables)",
     "shortName": "Common Stock Warrants and Options (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "GTBP:CommonStockWarrantsAndOptionsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "GTBP:CommonStockWarrantsAndOptionsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://gtbiopharma.com/role/SegmentInformationTables",
     "longName": "999028 - Disclosure - Segment Information (Tables)",
     "shortName": "Segment Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://gtbiopharma.com/role/OrganizationAndGoingConcernAnalysisDetailsNarrative",
     "longName": "999029 - Disclosure - Organization and Going Concern Analysis (Details Narrative)",
     "shortName": "Organization and Going Concern Analysis (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2025-07-012025-09-30",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R27": {
     "role": "http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails",
     "longName": "999030 - Disclosure - Schedule of Anti-dilutive Securities (Details)",
     "shortName": "Schedule of Anti-dilutive Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetailsParenthetical",
     "longName": "999031 - Disclosure - Schedule of Anti-dilutive Securities (Details) (Parenthetical)",
     "shortName": "Schedule of Anti-dilutive Securities (Details) (Parenthetical)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "AsOf2025-09-30",
      "name": "us-gaap:PreferredStockConvertibleConversionPrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "link:footnote",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R29": {
     "role": "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "longName": "999032 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)",
     "shortName": "Summary of Significant Accounting Policies (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "AsOf2025-09-30",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-09-30",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails",
     "longName": "999033 - Disclosure - Schedule of Accounts Payable (Details)",
     "shortName": "Schedule of Accounts Payable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "AsOf2025-09-30",
      "name": "us-gaap:AccountsPayableInterestBearingInterestRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-09-30",
      "name": "us-gaap:AccountsPayableInterestBearingInterestRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://gtbiopharma.com/role/ScheduleOfAccountsPayableToRelatedPartyDetails",
     "longName": "999034 - Disclosure - Schedule of Accounts Payable to Related Party (Details)",
     "shortName": "Schedule of Accounts Payable to Related Party (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31_custom_CytovanceBiologicsIncMember",
      "name": "us-gaap:AccountsPayableTradeCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-09-30_custom_CytovanceBiologicsIncMember",
      "name": "us-gaap:PaymentsForRepurchaseOfCommonStock",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "GTBP:ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R32": {
     "role": "http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyDetailsNarrative",
     "longName": "999035 - Disclosure - Accounts Payable and Related Party (Details Narrative)",
     "shortName": "Accounts Payable and Related Party (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-09-30",
      "name": "GTBP:StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-06-012025-06-30_custom_AdvisoryAgreementMember",
      "name": "us-gaap:RepaymentsOfOtherDebt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R33": {
     "role": "http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative",
     "longName": "999036 - Disclosure - Warrant Liability (Details Narrative)",
     "shortName": "Warrant Liability (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "AsOf2025-02-26",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-01-04_custom_TwoThousandTwentyThreeCommonWarrantsMember_srt_MaximumMember",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "GTBP:WarrantLiabilityTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R34": {
     "role": "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails",
     "longName": "999037 - Disclosure - Schedule of Warrant Liability Assumptions (Details)",
     "shortName": "Schedule of Warrant Liability Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "AsOf2025-02-26",
      "name": "us-gaap:WarrantsAndRightsOutstandingTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-012025-09-30_custom_TwoThousandTwentyThreeWarrantsMember",
      "name": "us-gaap:FairValueAdjustmentOfWarrants",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "GTBP:WarrantLiabilityTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityTransactionsDetails",
     "longName": "999038 - Disclosure - Schedule of Warrant Liability Transactions (Details)",
     "shortName": "Schedule of Warrant Liability Transactions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "GTBP:WarrantLiabilityCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:IncreaseDecreaseInDerivativeLiabilities",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
       "GTBP:WarrantLiabilityTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://gtbiopharma.com/role/ScheduleOfFairValuesAndAllocationOfNetProceedsDetails",
     "longName": "999039 - Disclosure - Schedule of fair values and allocation of net proceeds (Details)",
     "shortName": "Schedule of fair values and allocation of net proceeds (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "From2025-05-012025-05-31",
      "name": "us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfConversionsOfStockTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-05-012025-05-31",
      "name": "us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfConversionsOfStockTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative",
     "longName": "999040 - Disclosure - Stockholders\u2019 Equity (Deficit) (Details Narrative)",
     "shortName": "Stockholders\u2019 Equity (Deficit) (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "AsOf2025-09-30",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-02-262025-02-26",
      "name": "us-gaap:ProceedsFromIssuanceOfPrivatePlacement",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails",
     "longName": "999041 - Disclosure - Schedule of Warrant Activity (Details)",
     "shortName": "Schedule of Warrant Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "GTBP:CommonStockWarrantsAndOptionsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "GTBP:CommonStockWarrantsAndOptionsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative",
     "longName": "999042 - Disclosure - Common Stock Warrants and Options (Details Narrative)",
     "shortName": "Common Stock Warrants and Options (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "AsOf2025-09-30",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "GTBP:CommonStockWarrantsAndOptionsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "GTBP:CommonStockWarrantsAndOptionsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails",
     "longName": "999043 - Disclosure - Schedule of Warrants Outstanding and Exercisable (Details)",
     "shortName": "Schedule of Warrants Outstanding and Exercisable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "AsOf2025-09-30",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "GTBP:CommonStockWarrantsAndOptionsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-09-30_us-gaap_WarrantMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "GTBP:ScheduleOfWarrantsOustandingAndExercisableTableTextBlock",
       "GTBP:CommonStockWarrantsAndOptionsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails",
     "longName": "999044 - Disclosure - Schedule of Options Activity (Details)",
     "shortName": "Schedule of Options Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "GTBP:CommonStockWarrantsAndOptionsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "GTBP:CommonStockWarrantsAndOptionsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails",
     "longName": "999045 - Disclosure - Schedule of Options Outstanding and Options Exercisable (Details)",
     "shortName": "Schedule of Options Outstanding and Options Exercisable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "AsOf2025-09-30",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "GTBP:CommonStockWarrantsAndOptionsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-09-30",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "GTBP:CommonStockWarrantsAndOptionsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "longName": "999046 - Disclosure - Commitments and Contingencies (Details Narrative)",
     "shortName": "Commitments and Contingencies (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "AsOf2025-05-31",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "GTBP:CommonStockWarrantsAndOptionsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-11-21",
      "name": "GTBP:ContigencyMinimumRequired",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://gtbiopharma.com/role/ScheduleOfSegmentInformationDetails",
     "longName": "999047 - Disclosure - Schedule of Segment Information (Details)",
     "shortName": "Schedule of Segment Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-07-012025-09-30_custom_SegmentsMember",
      "name": "us-gaap:OtherResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://gtbiopharma.com/role/SegmentInformationDetailsNarrative",
     "longName": "999048 - Disclosure - Segment Information (Details Narrative)",
     "shortName": "Segment Information (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-09-30",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative",
     "longName": "999049 - Disclosure - Subsequent Events (Details Narrative)",
     "shortName": "Subsequent Events (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "AsOf2025-09-30",
      "name": "us-gaap:PreferredStockConvertibleConversionPrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "link:footnote",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-10-012025-10-31_custom_SeriesL10PercentageConvertiblePreferredStockMember_us-gaap_SubsequentEventMember",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableAndRelatedParty"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Related Party",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r45",
      "r47",
      "r834"
     ]
    },
    "GTBP_AccountsPayableAndRelatedPartyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "AccountsPayableAndRelatedPartyAbstract",
     "auth_ref": []
    },
    "GTBP_AccountsPayableAndRelatedPartyLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "AccountsPayableAndRelatedPartyLineItems",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AccountsPayableAndRelatedPartyLineItems [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_AccountsPayableAndRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "AccountsPayableAndRelatedPartyTable",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AccountsPayableAndRelatedPartyTable [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets",
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "verboseLabel": "Total accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r644"
     ]
    },
    "us-gaap_AccountsPayableInterestBearingInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableInterestBearingInterestRate",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable interest rate",
        "documentation": "Reflects the effective interest rate as of the balance sheet date on interest-bearing trade payables."
       }
      }
     },
     "auth_ref": [
      "r854"
     ]
    },
    "us-gaap_AccountsPayableOtherCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableOtherCurrent",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other accounts payable",
        "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableTradeCurrent",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails",
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableToRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Accounts Payable, Trade, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r43"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r114",
      "r428",
      "r429",
      "r430",
      "r431",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r114",
      "r428",
      "r429",
      "r430",
      "r431",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r707"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r644",
      "r901"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfFairValuesAndAllocationOfNetProceedsDetails",
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r512",
      "r777",
      "r778",
      "r779",
      "r780",
      "r848",
      "r904"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative",
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of vested stock options",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r804",
      "r806"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_AdvisoryAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "AdvisoryAgreementMember",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advisory Agreement [Member]",
        "documentation": "Advisory Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_AggregateStatedValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "AggregateStatedValue",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate stated value",
        "documentation": "Aggregate stated value."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r678",
      "r689",
      "r699",
      "r725"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r681",
      "r692",
      "r702",
      "r728"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r714"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r721"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r682",
      "r693",
      "r703",
      "r721",
      "r729",
      "r733",
      "r741"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperationsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based payment arrangement, expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r356",
      "r358"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r685"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total anti-dilutive securities",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyDetailsNarrative",
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r412"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL ASSETS",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r110",
      "r123",
      "r124",
      "r125",
      "r211",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r413",
      "r415",
      "r444",
      "r644",
      "r800",
      "r801",
      "r858"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r685"
     ]
    },
    "us-gaap_AwardDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardDateAxis",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Date [Axis]",
        "documentation": "Information by date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "auth_ref": [
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832"
     ]
    },
    "us-gaap_AwardDateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardDateDomain",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "auth_ref": [
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r736"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r737"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "auth_ref": [
      "r732"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r732"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r732"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r732"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r732"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r732"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r733"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r733"
     ]
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r769"
     ]
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r223",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r406",
      "r407",
      "r408",
      "r409",
      "r630",
      "r633",
      "r841",
      "r843",
      "r844"
     ]
    },
    "us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CapitalizationOfDeferredPolicyAcquisitionCostsPolicy",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Offering Costs",
        "documentation": "Disclosure of accounting policy for deferred policy acquisition costs, including the nature, type, and amount of capitalized costs incurred to write or acquire insurance contracts, and the basis for and methodologies applied in capitalizing and amortizing such costs."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r94"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r105",
      "r600"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r82"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and Cash Equivalents and Restricted Cash at Beginning of Period",
        "periodEndLabel": "Cash and Cash Equivalents and Restricted Cash at End of Period",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r64",
      "r120"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Increase (Decrease) in Cash and Cash Equivalents and Restricted Cash",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation",
        "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r64"
     ]
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash equivalents",
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r756",
      "r868"
     ]
    },
    "us-gaap_CashFDICInsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashFDICInsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, FDIC insured amount",
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_CashPaidDuringYearFor": {
     "xbrltype": "stringItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "CashPaidDuringYearFor",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid during the period for:",
        "documentation": "Cash paid during year for"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets",
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical",
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative",
      "http://gtbiopharma.com/role/ScheduleOfFairValuesAndAllocationOfNetProceedsDetails",
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative",
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r107",
      "r108",
      "r109",
      "r123",
      "r125",
      "r148",
      "r149",
      "r152",
      "r154",
      "r160",
      "r161",
      "r211",
      "r240",
      "r242",
      "r243",
      "r244",
      "r247",
      "r248",
      "r267",
      "r268",
      "r270",
      "r271",
      "r273",
      "r277",
      "r280",
      "r281",
      "r285",
      "r288",
      "r295",
      "r444",
      "r507",
      "r508",
      "r509",
      "r510",
      "r512",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r533",
      "r552",
      "r570",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r750",
      "r772",
      "r774",
      "r781"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfFairValuesAndAllocationOfNetProceedsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r108",
      "r109",
      "r160",
      "r270",
      "r280",
      "r281",
      "r283",
      "r285",
      "r288",
      "r293",
      "r295",
      "r421",
      "r507",
      "r508",
      "r509",
      "r510",
      "r628",
      "r750",
      "r770",
      "r772"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative",
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsTables",
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative",
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsTables",
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyDetailsNarrative",
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price",
        "verboseLabel": "Exercise price per share",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r126",
      "r296"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsTables",
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails",
      "http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative",
      "http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants to purchase",
        "verboseLabel": "Placement agents",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r296"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyDetailsNarrative",
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of pre-funded warrants",
        "verboseLabel": "Number of warrant issued",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsTables",
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails",
      "http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Table]",
        "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame."
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightUnissued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightUnissued",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of pre-funded warrants",
        "label": "Class of Warrant or Right, Unissued",
        "documentation": "The number of warrants or rights which entitle the entity to receive future services in exchange for the unvested, forfeitable warrants or rights."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_ClassOfWarrantsPurchaseUpPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "ClassOfWarrantsPurchaseUpPercentage",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants purchase up percentage",
        "documentation": "Warrants purchase up percentage."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r713"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r713"
     ]
    },
    "GTBP_CobySilberfeinMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "CobySilberfeinMember",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Coby Silberfein [Member]",
        "documentation": "Coby Silberfein [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r232",
      "r233",
      "r595",
      "r791",
      "r796"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyDetailsNarrative",
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative",
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r649",
      "r650",
      "r651",
      "r653",
      "r654",
      "r655",
      "r656",
      "r777",
      "r778",
      "r780",
      "r848",
      "r900",
      "r904"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r533"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical",
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares outstanding",
        "verboseLabel": "Number of shares converted",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r50",
      "r533",
      "r550",
      "r904",
      "r905"
     ]
    },
    "GTBP_CommonStockSharesOutstandingPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "CommonStockSharesOutstandingPercentage",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock shares outstanding percentage",
        "documentation": "Common stock shares outstanding percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value $0.001, 250,000,000 shares authorized, 6,051,874 and 2,234,328 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r268",
      "r276",
      "r476",
      "r644"
     ]
    },
    "GTBP_CommonStockWarrantsAndOptionsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "CommonStockWarrantsAndOptionsTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Warrants and Options",
        "documentation": "Common Stock Warrants and Options [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_CommonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "CommonWarrantsMember",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Warrants [Member]",
        "documentation": "Common Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r719"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r79"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration",
        "documentation": "Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r442",
      "r443"
     ]
    },
    "GTBP_ContigencyMinimumRequired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "ContigencyMinimumRequired",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contigency minimum required",
        "documentation": "Contigency minimum required."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_ConvertiblePreferredStockAndWarrantsFairValuePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "ConvertiblePreferredStockAndWarrantsFairValuePercentage",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfFairValuesAndAllocationOfNetProceedsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible preferred stock and warrants fair value percentage",
        "documentation": "Convertible preferred stock and warrants fair value percentage"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_ConvertiblePreferredStockAndWarrantsNetProceedsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "ConvertiblePreferredStockAndWarrantsNetProceedsPercentage",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfFairValuesAndAllocationOfNetProceedsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible preferred stock and warrants net proceeds percentage",
        "documentation": "Convertible preferred stock and warrants net proceeds percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostMaintenance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostMaintenance",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License maintenance fees",
        "documentation": "Cost of maintenance incurred and directly related to good produced and service rendered."
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_CummulativeGrossSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "CummulativeGrossSales",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative gross sales",
        "documentation": "Cummulative gross sales."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_CytovanceBiologicsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "CytovanceBiologicsIncMember",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyDetailsNarrative",
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails",
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableToRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cytovance Biologics Inc [Member]",
        "documentation": "Cytovance Biologics Inc [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails",
      "http://gtbiopharma.com/role/WarrantLiabilityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r44",
      "r45",
      "r83",
      "r84",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r643",
      "r770",
      "r771",
      "r773",
      "r776",
      "r792",
      "r793",
      "r794",
      "r854",
      "r855",
      "r867"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails",
      "http://gtbiopharma.com/role/WarrantLiabilityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r643",
      "r770",
      "r771",
      "r773",
      "r776",
      "r792",
      "r793",
      "r794",
      "r854",
      "r855",
      "r867"
     ]
    },
    "us-gaap_DebtSecuritiesUnrealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesUnrealizedGainLoss",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unrealized gain on short-term investments",
        "label": "Debt Securities, Unrealized Gain (Loss)",
        "documentation": "Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in net income (trading)."
       }
      }
     },
     "auth_ref": [
      "r484",
      "r762",
      "r763"
     ]
    },
    "us-gaap_DeferredOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredOfferingCosts",
     "crdr": "debit",
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets",
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred offering costs",
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails",
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableToRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322"
     ]
    },
    "us-gaap_DerivativeFloorPrice": {
     "xbrltype": "perUnitItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeFloorPrice",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Floor price",
        "verboseLabel": "Floor price per share",
        "documentation": "Floor rate on a price risk derivative such as a floor or a collar. A payment or receipt is triggered if the market rate falls below the floor rate on the contract."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "DisclosureCommonStockWarrantsAndOptionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Warrants And Options",
        "verboseLabel": "Schedule Of Warrant Activity",
        "terseLabel": "Schedule Of Options Activity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "auth_ref": []
    },
    "GTBP_DisclosureWarrantLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "DisclosureWarrantLiabilityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Liability",
        "verboseLabel": "Schedule Of Warrant Liability Transactions"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_DividendDeclaredOnSeriesLConvertiblePreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "DividendDeclaredOnSeriesLConvertiblePreferredStock",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend declared on Series L convertible preferred stock",
        "documentation": "Dividend declared on Series L convertible preferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DividendsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DividendsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend payable",
        "verboseLabel": "Dividends unpaid",
        "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_DividendsPreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DividendsPreferredStock",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Dividend on Series L convertible preferred stock",
        "label": "Dividends, Preferred Stock",
        "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK)."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r72"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r673"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r671",
      "r673",
      "r685"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r672"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r673"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r673"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r706"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r663"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Share - Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r116",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r145",
      "r148",
      "r152",
      "r153",
      "r154",
      "r157",
      "r266",
      "r355",
      "r371",
      "r411",
      "r434",
      "r435",
      "r471",
      "r483",
      "r606"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Share - Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r116",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r148",
      "r152",
      "r153",
      "r154",
      "r157",
      "r266",
      "r355",
      "r371",
      "r411",
      "r434",
      "r435",
      "r471",
      "r483",
      "r606"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r156"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r666"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r685"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r711"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyDetailsNarrative",
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative",
      "http://gtbiopharma.com/role/ScheduleOfFairValuesAndAllocationOfNetProceedsDetails",
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative",
      "http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r98",
      "r99",
      "r100",
      "r113",
      "r114",
      "r115",
      "r129",
      "r130",
      "r131",
      "r133",
      "r140",
      "r142",
      "r144",
      "r159",
      "r212",
      "r213",
      "r225",
      "r265",
      "r297",
      "r355",
      "r365",
      "r366",
      "r368",
      "r369",
      "r370",
      "r372",
      "r410",
      "r411",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r433",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r455",
      "r456",
      "r460",
      "r482",
      "r500",
      "r501",
      "r502",
      "r512",
      "r570"
     ]
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "auth_ref": [
      "r208",
      "r209",
      "r210",
      "r367",
      "r444",
      "r751",
      "r752",
      "r753",
      "r836",
      "r837",
      "r838",
      "r839"
     ]
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity method investment, ownership percentage",
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r444"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r715"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r678",
      "r689",
      "r699",
      "r725"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r675",
      "r686",
      "r696",
      "r722"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r721"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_ExtinguishmentOfWarrant": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "ExtinguishmentOfWarrant",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extinguishment",
        "documentation": "Extinguishment of warrant."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 2.0
      },
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails",
      "http://gtbiopharma.com/role/StatementsOfCashFlows",
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in fair value of warrant liability",
        "label": "Change in fair value of warrant liability",
        "verboseLabel": "Fair value of warrants",
        "terseLabel": "Fair value",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/WarrantLiabilityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Warrant Liability Assumptions",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r436",
      "r437",
      "r638"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r852"
     ]
    },
    "GTBP_FairValueOfPrefundedWarrantAndCommonStockToSettleVendorPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "FairValueOfPrefundedWarrantAndCommonStockToSettleVendorPayable",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of prefunded warrant and common stock to settle vendor payable",
        "documentation": "Fair value of prefunded warrant and common stock to settle vendor payable."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_FairValueOfPrefundedWarrantsIssuedForElocFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "FairValueOfPrefundedWarrantsIssuedForElocFee",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of prefunded warrants issued for ELOC fee",
        "documentation": "Fair value of prefunded warrants issued for eloc fee."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_FairValueOfSeriesLConvertiblePreferredStockVestedWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "FairValueOfSeriesLConvertiblePreferredStockVestedWarrants",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of Series L convertible preferred stock vested warrants",
        "documentation": "Fair value of Series L convertible preferred stock vested warrants."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r682",
      "r693",
      "r703",
      "r729"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r682",
      "r693",
      "r703",
      "r729"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r682",
      "r693",
      "r703",
      "r729"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r682",
      "r693",
      "r703",
      "r729"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r682",
      "r693",
      "r703",
      "r729"
     ]
    },
    "GTBP_GainOnSettlementOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "GainOnSettlementOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gain on extinguishment of debt",
        "documentation": "Gain on settlement of debt.",
        "label": "GainOnSettlementOfDebt"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      },
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows",
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain on settlement of vendor payable",
        "negatedLabel": "Gain on settlement of debt",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r28",
      "r29"
     ]
    },
    "GTBP_GreenshoeRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "GreenshoeRightsMember",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Greenshoe Rights [Member]",
        "documentation": "Greenshoe Rights [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_GrossSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "GrossSales",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross sales",
        "documentation": "Gross sales."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/StatementsOfOperationsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r228",
      "r229",
      "r417",
      "r418",
      "r419",
      "r420",
      "r439",
      "r440",
      "r441",
      "r445",
      "r446",
      "r447",
      "r497",
      "r499",
      "r555",
      "r598",
      "r599",
      "r630",
      "r631",
      "r635",
      "r636",
      "r637",
      "r642",
      "r840",
      "r842",
      "r871"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/StatementsOfOperationsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r228",
      "r229",
      "r417",
      "r418",
      "r419",
      "r420",
      "r439",
      "r440",
      "r441",
      "r445",
      "r446",
      "r447",
      "r497",
      "r499",
      "r555",
      "r598",
      "r599",
      "r630",
      "r631",
      "r635",
      "r636",
      "r637",
      "r642",
      "r840",
      "r842",
      "r871"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income taxes",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r119",
      "r363",
      "r364"
     ]
    },
    "us-gaap_IncreaseDecreaseInDerivativeLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInDerivativeLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value",
        "documentation": "The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer)."
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "(Increase) in operating lease liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r754",
      "r766"
     ]
    },
    "GTBP_IncreaseDecreaseInOperatingLeaseRightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "IncreaseDecreaseInOperatingLeaseRightofuseAssets",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Decrease in operating lease right-of-use assets",
        "documentation": "Decrease in operating lease right-of-use assets.",
        "label": "IncreaseDecreaseInOperatingLeaseRightofuseAssets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Decrease in accounts payable and accrued expenses",
        "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "(Increase) Decrease in prepaid expenses",
        "label": "Increase (Decrease) in Prepaid Expense",
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r682",
      "r693",
      "r703",
      "r721",
      "r729",
      "r733",
      "r741"
     ]
    },
    "GTBP_InducementWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "InducementWarrantsMember",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inducement Warrants [Member]",
        "documentation": "Inducement Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r674",
      "r745"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r674",
      "r745"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r674",
      "r745"
     ]
    },
    "us-gaap_InsuranceCommissions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InsuranceCommissions",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insurance",
        "documentation": "The expense incurred by an insurance company to persons or entities for generating or placing insurance or investment contracts with the company, usually determined as a percentage of policy or contract premiums. Excludes advances or draws to be applied against commissions earned."
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "us-gaap_InterestIncomeOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestIncomeOther",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income",
        "documentation": "Amount of interest income earned from interest bearing assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r604"
     ]
    },
    "us-gaap_InterestPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestPaid",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest",
        "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities."
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of warrants at fair value",
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "GTBP_IssuanceOfWarrantsForVrtWaiver": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "IssuanceOfWarrantsForVrtWaiver",
     "crdr": "debit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of warrants for VRT waiver",
        "documentation": "Issuance of warrants for vrt waiver.",
        "label": "Issuance of warrants for vrt waiver"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_LegalServicesFirmMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "LegalServicesFirmMember",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyDetailsNarrative",
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Services Firm [Member]",
        "documentation": "Legal Services Firm [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 (EQUITY) DEFICIT",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r85",
      "r479",
      "r644",
      "r647",
      "r648",
      "r770",
      "r775",
      "r789",
      "r853"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS\u2019 DEFICIT"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Current Liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r104",
      "r123",
      "r124",
      "r125",
      "r211",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r414",
      "r415",
      "r416",
      "r444",
      "r644",
      "r800",
      "r858",
      "r859"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_LiableOfLiquidatedDamagePercentageDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "LiableOfLiquidatedDamagePercentageDescription",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liable of liquidated damage percentage, description",
        "documentation": "Liable of liquidated damage percentage, description."
       }
      }
     },
     "auth_ref": []
    },
    "srt_LitigationCaseAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "LitigationCaseAxis",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_LitigationCaseTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "LitigationCaseTypeDomain",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r234",
      "r235",
      "r236",
      "r239",
      "r360",
      "r622",
      "r798",
      "r799"
     ]
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingencies [Table]",
        "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r234",
      "r235",
      "r236",
      "r239",
      "r360",
      "r622",
      "r798",
      "r799"
     ]
    },
    "us-gaap_LossContingencyDamagesPaidValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingencyDamagesPaidValue",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principal amount",
        "documentation": "Amount of damages paid to the plaintiff in the legal matter."
       }
      }
     },
     "auth_ref": [
      "r797",
      "r798",
      "r799"
     ]
    },
    "us-gaap_LossContingencyDamagesSought": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingencyDamagesSought",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Owes damages excess value",
        "documentation": "Describes the form and magnitude of the award the plaintiff seeks in the legal matter, which may include an unspecified amount of money."
       }
      }
     },
     "auth_ref": [
      "r797",
      "r798",
      "r799"
     ]
    },
    "us-gaap_LossContingencyDamagesSoughtValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingencyDamagesSoughtValue",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Damages sought value",
        "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter."
       }
      }
     },
     "auth_ref": [
      "r797",
      "r798",
      "r799"
     ]
    },
    "us-gaap_MarketableSecuritiesUnrealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketableSecuritiesUnrealizedGainLoss",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrealized gain on short-term investments",
        "documentation": "Amount of unrealized gain (loss) on investment in marketable security."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative",
      "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative",
      "http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r165",
      "r235",
      "r236",
      "r237",
      "r238",
      "r323",
      "r349",
      "r350",
      "r351",
      "r360",
      "r438",
      "r469",
      "r496",
      "r498",
      "r505",
      "r525",
      "r526",
      "r576",
      "r578",
      "r581",
      "r582",
      "r583",
      "r591",
      "r592",
      "r593",
      "r594",
      "r596",
      "r597",
      "r620",
      "r628",
      "r629",
      "r630",
      "r632",
      "r633",
      "r638",
      "r639",
      "r640",
      "r641",
      "r645",
      "r802",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r713"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name"
       }
      }
     },
     "auth_ref": [
      "r713"
     ]
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputExpectedDividendRateMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year."
       }
      }
     },
     "auth_ref": [
      "r350",
      "r849",
      "r850",
      "r851"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Term [Member]",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r849",
      "r850",
      "r851"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Price Volatility [Member]",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r349",
      "r638",
      "r849",
      "r850",
      "r851"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r351",
      "r849",
      "r850",
      "r851"
     ]
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputSharePriceMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Share Price [Member]",
        "documentation": "Measurement input using share price of saleable stock."
       }
      }
     },
     "auth_ref": [
      "r849",
      "r850",
      "r851"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r436",
      "r437",
      "r438",
      "r630",
      "r632",
      "r633",
      "r638"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r436",
      "r437",
      "r438",
      "r630",
      "r632",
      "r633",
      "r638"
     ]
    },
    "GTBP_MezzanineEquityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "MezzanineEquityMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfFairValuesAndAllocationOfNetProceedsDetails",
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mezzanine Equity [Member]",
        "documentation": "Mezzanine Equity [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_MezzanineEquityPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "MezzanineEquityPolicyTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mezzanine Equity",
        "documentation": "Mezzanine Equity [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r165",
      "r235",
      "r236",
      "r237",
      "r238",
      "r323",
      "r349",
      "r350",
      "r351",
      "r360",
      "r438",
      "r469",
      "r496",
      "r498",
      "r505",
      "r525",
      "r526",
      "r576",
      "r578",
      "r581",
      "r582",
      "r583",
      "r591",
      "r592",
      "r593",
      "r594",
      "r596",
      "r597",
      "r620",
      "r628",
      "r629",
      "r630",
      "r632",
      "r633",
      "r638",
      "r639",
      "r640",
      "r645",
      "r802",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r732"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Cash Provided by Financing Activities",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Cash Provided by Investing Activities",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM INVESTING ACTIVITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/OrganizationAndGoingConcernAnalysisDetailsNarrative",
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Cash Used in Operating Activities",
        "negatedLabel": "Net cash used in operating activities",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r65",
      "r66"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM OPERATING ACTIVITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0,
       "order": 1.0
      },
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/OrganizationAndGoingConcernAnalysisDetailsNarrative",
      "http://gtbiopharma.com/role/ScheduleOfSegmentInformationDetails",
      "http://gtbiopharma.com/role/StatementsOfCashFlows",
      "http://gtbiopharma.com/role/StatementsOfOperations",
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Loss",
        "label": "Net loss",
        "verboseLabel": "Net Income (Loss)",
        "negatedLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r66",
      "r87",
      "r100",
      "r102",
      "r111",
      "r112",
      "r115",
      "r123",
      "r124",
      "r125",
      "r128",
      "r132",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r143",
      "r144",
      "r150",
      "r211",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r266",
      "r269",
      "r272",
      "r278",
      "r355",
      "r371",
      "r411",
      "r435",
      "r444",
      "r481",
      "r551",
      "r568",
      "r569",
      "r602",
      "r604",
      "r605",
      "r657",
      "r800"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Loss attributable to common stockholders\u2019",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r117",
      "r136",
      "r137",
      "r138",
      "r139",
      "r145",
      "r146",
      "r151",
      "r154",
      "r269",
      "r272",
      "r278",
      "r411"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recent Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r713"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r710"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r709"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoninterestExpenseOfferingCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NoninterestExpenseOfferingCost",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other offering expenses",
        "documentation": "Amount of expense for cost associated with issuance of security by investment company. Includes, but is not limited to, legal fee pertaining to share offered for sale, registration fee, underwriting, printing prospectus, and initial fee for listing on exchange."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r903"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfSegmentInformationDetails",
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Other Income (Expense), Net",
        "verboseLabel": "Other income",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income (Expense)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://gtbiopharma.com/role/SegmentInformationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of operating segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r615",
      "r783"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://gtbiopharma.com/role/SegmentInformationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of reportable segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r609",
      "r619",
      "r783"
     ]
    },
    "GTBP_OfficersEmployeesAndDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "OfficersEmployeesAndDirectorsMember",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperationsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Officers, Employees and Directors [Member]",
        "documentation": "Officers, Employees and Directors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_OmnibusIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "OmnibusIncentivePlanMember",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2022 Omnibus Incentive Plan [Member]",
        "documentation": "2022 Omnibus Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r605"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from Operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r602",
      "r605",
      "r608",
      "r782",
      "r784",
      "r785",
      "r786",
      "r787"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/OrganizationAndGoingConcernAnalysis"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Going Concern Analysis",
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r755",
      "r769"
     ]
    },
    "GTBP_OtherAccountsPayableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "OtherAccountsPayableMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accounts Payable [Member]",
        "documentation": "Other Accounts Payable [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r634"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r713"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r673"
     ]
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research and development",
        "label": "Other Research and Development Expense",
        "documentation": "Amount of other research and development expense."
       }
      }
     },
     "auth_ref": [
      "r835"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r680",
      "r691",
      "r701",
      "r727"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r683",
      "r694",
      "r704",
      "r730"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r683",
      "r694",
      "r704",
      "r730"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "auth_ref": [
      "r708"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForFees",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior year unpaid fees",
        "documentation": "Amount of cash outflow for fees classified as other."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_PaymentsForProceedsFromInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForProceedsFromInvestments",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Sale of investments",
        "label": "Payments for (Proceeds from) Investments",
        "documentation": "The net cash paid (received) associated with the acquisition or disposal of all investments, including securities and other assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableToRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments in common stock, at fair value",
        "label": "Payments for Repurchase of Common Stock",
        "documentation": "The cash outflow to reacquire common stock during the period."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForRepurchaseOfConvertiblePreferredStock",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends to holders unpaid",
        "documentation": "The cash outflow to reacquire preferred stock originally issued and identified as a security that can be exchanged for another type of financial security. This repurchased stock is held in treasury."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "us-gaap_PaymentsOfDividends": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsOfDividends",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment of dividend on Series L convertible preferred stock",
        "label": "Payments of Dividends",
        "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyDetailsNarrative",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock issuance",
        "verboseLabel": "Equity issuance cost",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireInProcessResearchAndDevelopment",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of research and development",
        "documentation": "The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r710"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r709"
     ]
    },
    "GTBP_PerformanceMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "PerformanceMilestonePayments",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Performance milestone payments",
        "documentation": "Performance milestone payments."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r710"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r667"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r669"
     ]
    },
    "us-gaap_PreferredStockConvertibleConversionPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockConvertibleConversionPrice",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetailsParenthetical",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative",
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion price per share",
        "verboseLabel": "Exercise price",
        "documentation": "Per share conversion price of preferred stock."
       }
      }
     },
     "auth_ref": [
      "r282"
     ]
    },
    "us-gaap_PreferredStockDividendRatePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockDividendRatePercentage",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of dividend",
        "documentation": "The percentage rate used to calculate dividend payments on preferred stock."
       }
      }
     },
     "auth_ref": [
      "r281",
      "r577",
      "r579",
      "r580",
      "r584"
     ]
    },
    "us-gaap_PreferredStockDividendsIncomeStatementImpact": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockDividendsIncomeStatementImpact",
     "crdr": "debit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Dividends on preferred stock",
        "label": "Preferred Stock Dividends, Income Statement Impact",
        "documentation": "The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r649",
      "r650",
      "r653",
      "r654",
      "r655",
      "r656",
      "r900",
      "r904"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r280"
     ]
    },
    "GTBP_PreferredStockPurchasePrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "PreferredStockPurchasePrice",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative",
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase price",
        "documentation": "Preferred stock purchase price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r533"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r280"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative",
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares outstanding",
        "verboseLabel": "Shares converted",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r533",
      "r550",
      "r904",
      "r905"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock value",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r268",
      "r275",
      "r475",
      "r644"
     ]
    },
    "GTBP_PrefundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "PrefundedWarrantsMember",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prefunded Warrants [Member]",
        "documentation": "Prefunded Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "crdr": "debit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfFairValuesAndAllocationOfNetProceedsDetails",
      "http://gtbiopharma.com/role/StatementsOfCashFlows",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of Series L convertible preferred stock and warrants, net",
        "verboseLabel": "Total",
        "terseLabel": "Proceeds from issuance of preferred stock and warrants, net",
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from private placement",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of common stock and warrants, net",
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r507"
     ]
    },
    "us-gaap_ProceedsFromRelatedPartyDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromRelatedPartyDebt",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableToRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Invoices, net",
        "verboseLabel": "Research and development expenses",
        "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "GTBP_ProceedsFromUpfrontAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "ProceedsFromUpfrontAmount",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from upfront amount",
        "documentation": "Received upfront payment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of warrants and issuance of inducement warrants for cash, net",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "GTBP_PurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "PurchaseAgreementMember",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Agreement [Member]",
        "documentation": "Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative",
      "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative",
      "http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r165",
      "r235",
      "r236",
      "r237",
      "r238",
      "r301",
      "r323",
      "r349",
      "r350",
      "r351",
      "r354",
      "r360",
      "r438",
      "r467",
      "r468",
      "r469",
      "r496",
      "r498",
      "r505",
      "r525",
      "r526",
      "r576",
      "r578",
      "r581",
      "r582",
      "r583",
      "r591",
      "r592",
      "r593",
      "r594",
      "r596",
      "r597",
      "r620",
      "r628",
      "r629",
      "r630",
      "r632",
      "r633",
      "r638",
      "r639",
      "r640",
      "r641",
      "r645",
      "r651",
      "r795",
      "r802",
      "r850",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865"
     ]
    },
    "GTBP_RangeEightMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "RangeEightMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range of Exercise Price Eight [Member]",
        "documentation": "Range of Exercise Price Eight [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_RangeElevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "RangeElevenMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range of Exercise Price Eleven [Member]",
        "documentation": "Range of Exercise Price Eleven [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_RangeFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "RangeFiveMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails",
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range of Exercise Price Five [Member]",
        "documentation": "Range of Exercise Price Five [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_RangeFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "RangeFourMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails",
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range of Exercise Price Four [Member]",
        "documentation": "Range of Exercise Price Four [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative",
      "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative",
      "http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "auth_ref": [
      "r165",
      "r235",
      "r236",
      "r237",
      "r238",
      "r301",
      "r323",
      "r349",
      "r350",
      "r351",
      "r354",
      "r360",
      "r438",
      "r467",
      "r468",
      "r469",
      "r496",
      "r498",
      "r505",
      "r525",
      "r526",
      "r576",
      "r578",
      "r581",
      "r582",
      "r583",
      "r591",
      "r592",
      "r593",
      "r594",
      "r596",
      "r597",
      "r620",
      "r628",
      "r629",
      "r630",
      "r632",
      "r633",
      "r638",
      "r639",
      "r640",
      "r641",
      "r645",
      "r651",
      "r795",
      "r802",
      "r850",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865"
     ]
    },
    "GTBP_RangeNineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "RangeNineMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range of Exercise Price Nine [Member]",
        "documentation": "Range of Exercise Price Nine [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_RangeOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "RangeOneMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails",
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range of Exercise Price One [Member]",
        "documentation": "Range of Exercise Price One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_RangeSevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "RangeSevenMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range of Exercise Price Seven [Member]",
        "documentation": "Range of Exercise Price Seven [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_RangeSixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "RangeSixMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range of Exercise Price Six [Member]",
        "documentation": "Range of Exercise Price Six [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_RangeTenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "RangeTenMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range of Exercise Price Ten [Member]",
        "documentation": "Range of Exercise Price Ten [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_RangeThirteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "RangeThirteenMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range of Exercise Price Thirteen [Member]",
        "documentation": "Range of Exercise Price Thirteen [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_RangeThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "RangeThreeMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails",
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range of Exercise Price Three [Member]",
        "documentation": "Range of Exercise Price Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_RangeTwelveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "RangeTwelveMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range of Exercise Price Twelve [Member]",
        "documentation": "Range of Exercise Price Twelve [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_RangeTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "RangeTwoMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails",
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range of Exercise Price Two [Member]",
        "documentation": "Range of Exercise Price Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "auth_ref": [
      "r675",
      "r686",
      "r696",
      "r722"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyDetailsNarrative",
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails",
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableToRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r127",
      "r128",
      "r207",
      "r302",
      "r319",
      "r462",
      "r463",
      "r474",
      "r480",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r549",
      "r575",
      "r902"
     ]
    },
    "us-gaap_RelatedPartyTransactionDescriptionOfTransaction": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionDescriptionOfTransaction",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related party transaction description",
        "documentation": "A description of the related party transaction, including transactions to which no amounts or nominal amounts were ascribed and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements. Examples of common related party transactions are, sales, purchases and transfers of realty and personal property, services received or furnished, loans and leases to and from top management and affiliates."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r106",
      "r457",
      "r458",
      "r459",
      "r461"
     ]
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyDetailsNarrative",
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails",
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableToRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r127",
      "r128",
      "r207",
      "r302",
      "r319",
      "r462",
      "r463",
      "r474",
      "r480",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r549",
      "r575",
      "r857",
      "r902"
     ]
    },
    "us-gaap_RepaymentsOfOtherDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RepaymentsOfOtherDebt",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash payment",
        "documentation": "Amount of cash outflow for the payment of debt classified as other."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "GTBP_RepaymentsOfPrefundedWarrantsAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "RepaymentsOfPrefundedWarrantsAtFairValue",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyDetailsNarrative",
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableToRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments in pre-funded warrants, at fair value",
        "negatedLabel": "Payments in pre-funded warrants, at fair value",
        "documentation": "Repayments of prefunded warrants at fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RepaymentsOfRelatedPartyDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RepaymentsOfRelatedPartyDebt",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableToRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments in cash",
        "label": "Cash payments",
        "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "verboseLabel": "Research and development expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r362",
      "r598",
      "r602",
      "r603",
      "r614",
      "r866"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate research and development expense",
        "documentation": "Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r835"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expenses",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r361"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r676",
      "r687",
      "r697",
      "r723"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r677",
      "r688",
      "r698",
      "r724"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r684",
      "r695",
      "r705",
      "r731"
     ]
    },
    "us-gaap_RestrictedCashCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashCurrent",
     "crdr": "debit",
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r756",
      "r768"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r72",
      "r478",
      "r503",
      "r504",
      "r511",
      "r534",
      "r644"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r99",
      "r100",
      "r129",
      "r130",
      "r131",
      "r133",
      "r140",
      "r142",
      "r144",
      "r212",
      "r213",
      "r225",
      "r265",
      "r355",
      "r365",
      "r366",
      "r368",
      "r369",
      "r370",
      "r372",
      "r410",
      "r411",
      "r422",
      "r424",
      "r425",
      "r427",
      "r433",
      "r455",
      "r456",
      "r500",
      "r502",
      "r512",
      "r904"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r89",
      "r158",
      "r171",
      "r172",
      "r193",
      "r199",
      "r203",
      "r205",
      "r206",
      "r298",
      "r299",
      "r300",
      "r470",
      "r602",
      "r605"
     ]
    },
    "us-gaap_RoyaltyExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RoyaltyExpense",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual royalty payments",
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "GTBP_RoyaltyExpenseYearAfterFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "RoyaltyExpenseYearAfterFive",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty expense year five and thereafter",
        "documentation": "Royalty expense year five and thereafter."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_RoyaltyExpenseYearAfterSix": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "RoyaltyExpenseYearAfterSix",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty expense year six and thereafter",
        "documentation": "Royalty expense year after six."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_RoyaltyExpenseYearOne": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "RoyaltyExpenseYearOne",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty expense year one",
        "documentation": "Royalty expense year one."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_RoyaltyExpenseYearOneThoughFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "RoyaltyExpenseYearOneThoughFour",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty expense year one though four",
        "documentation": "Royalty expense year one though four."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_RoyaltyExpenseYearTwoThroughFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "RoyaltyExpenseYearTwoThroughFive",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty expense years two through five",
        "documentation": "Royalty expense year two through five."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_RoyaltyFeePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "RoyaltyFeePercentage",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty fee percentage",
        "documentation": "Royalty fee percentage."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "us-gaap_SalariesAndWages": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SalariesAndWages",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Salaries",
        "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold."
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of shares, value",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of shares",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_SalesMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "SalesMilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "One-time sales milestone payments",
        "documentation": "Sales milestone payments."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_SalesRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "SalesRevenue",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales revenue",
        "documentation": "Sales revenue."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accounts Payable",
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accounts Payable to Related Party",
        "documentation": "Schedule of Accounts Payable and Related Party [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Anti-dilutive Securities",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination [Table]",
        "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability."
       }
      }
     },
     "auth_ref": [
      "r223",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r406",
      "r407",
      "r408",
      "r409",
      "r630",
      "r633",
      "r841",
      "r843",
      "r844"
     ]
    },
    "us-gaap_ScheduleOfConversionsOfStockTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfConversionsOfStockTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDeficitTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of fair values and allocation of net proceeds",
        "documentation": "Tabular disclosure of information related to converting stock into another financial instrument(s) in a noncash (or part noncash) transaction."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21",
      "r22"
     ]
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails",
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableToRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan [Table]",
        "documentation": "Disclosure of information about individual defined benefit pension plan or other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r36",
      "r37",
      "r38",
      "r39",
      "r303",
      "r304",
      "r305",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322"
     ]
    },
    "us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/WarrantLiabilityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Warrant Liability Transactions",
        "documentation": "Tabular disclosure of derivative liabilities at fair value."
       }
      }
     },
     "auth_ref": [
      "r845",
      "r846",
      "r847"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r208",
      "r209",
      "r210",
      "r367",
      "r444",
      "r751",
      "r752",
      "r753",
      "r836",
      "r837",
      "r838",
      "r839"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r27"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/SegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Information",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r27"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r354"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement by range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Options Outstanding and Options Exercisable",
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Options Activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r11",
      "r74"
     ]
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShortTermDebtTable",
     "presentation": [
      "http://gtbiopharma.com/role/WarrantLiabilityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt [Table]",
        "documentation": "Disclosure of information about short-term debt arrangement. Includes, but is not limited to, description of arrangement, lender, repayment term, weighted-average interest rate, borrowed amount, and description and amount of refinancing of short-term obligation when obligation is excluded from current liability."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfFairValuesAndAllocationOfNetProceedsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r32",
      "r33",
      "r34",
      "r35",
      "r70",
      "r71",
      "r72",
      "r107",
      "r108",
      "r109",
      "r160",
      "r280",
      "r281",
      "r283",
      "r285",
      "r288",
      "r293",
      "r295",
      "r421",
      "r507",
      "r508",
      "r509",
      "r510",
      "r628",
      "r750",
      "r770",
      "r772"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Warrant Activity",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "GTBP_ScheduleOfWarrantsOustandingAndExercisableTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "ScheduleOfWarrantsOustandingAndExercisableTableTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Warrants Outstanding and Exercisable",
        "documentation": "Schedule of Warrants Oustanding and Exercisable [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_SecuritiesPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "SecuritiesPurchaseAgreementMember",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Purchase Agreement [Member]",
        "documentation": "Securities Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r661"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r665"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r670"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentDomain",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r89",
      "r90",
      "r91",
      "r158",
      "r167",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r183",
      "r184",
      "r185",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r199",
      "r200",
      "r201",
      "r206",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r224",
      "r230",
      "r231",
      "r405",
      "r408",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r611",
      "r614",
      "r615",
      "r621",
      "r646",
      "r870",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/SegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Information",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r158",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r182",
      "r184",
      "r185",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r203",
      "r204",
      "r206",
      "r609",
      "r612",
      "r613",
      "r614",
      "r616",
      "r618",
      "r619"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Segment Information",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r202",
      "r205",
      "r610",
      "r611",
      "r617"
     ]
    },
    "GTBP_SegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "SegmentsMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Member]",
        "documentation": "Segments [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, general and administrative (including $379,000 and $0 of stock compensation for the three months ended September 30, 2025 and 2024, respectively, and $386,000 and $222,000 of stock compensation for the nine months ended September 30, 2025 and 2024, respectively)",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r601",
      "r602",
      "r603",
      "r605",
      "r764"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperationsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, General and Administrative Expenses [Member]",
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r630",
      "r631"
     ]
    },
    "GTBP_SeriesAInducementWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "SeriesAInducementWarrantsMember",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Inducement Warrants [Member]",
        "documentation": "Series A Inducement Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_SeriesBInducementWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "SeriesBInducementWarrantsMember",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Inducement Warrants [Member]",
        "documentation": "Series B Inducement Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesCPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SeriesCPreferredStockMember",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets",
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical",
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series C Preferred Stock [Member]",
        "documentation": "Series C preferred stock."
       }
      }
     },
     "auth_ref": [
      "r757",
      "r758",
      "r803",
      "r804"
     ]
    },
    "GTBP_SeriesL10PercentageConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "SeriesL10PercentageConvertiblePreferredStockMember",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative",
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Series L 10% Convertible Preferred Stock [Member]",
        "documentation": "Series L 10% Convertible Preferred Stock [Member]",
        "label": "Series L 10% Convertible Preferred Stock [Member] [Default Label]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_SeriesLConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "SeriesLConvertiblePreferredStockMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative",
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series L Convertible Preferred Stock [Member]",
        "documentation": "Series L Convertible Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_SeriesLPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "SeriesLPreferredStockMember",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets",
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical",
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative",
      "http://gtbiopharma.com/role/ScheduleOfFairValuesAndAllocationOfNetProceedsDetails",
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series L Preferred Stock [Member]",
        "documentation": "Series L Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_SeriesLTenPercentConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "SeriesLTenPercentConvertiblePreferredStockMember",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series L 10% Convertible Preferred Stock [Member]",
        "documentation": "Series L 10% Convertible Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://gtbiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfSegmentInformationDetails",
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock based compensation",
        "verboseLabel": "Stock-based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rstricted stock granted",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r340"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants outstanding, weighted average remaining contractual life (years)",
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Volatility amount utilized in the value calculation percentage",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r349"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r354"
     ]
    },
    "GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants exercisable, ending balance",
        "documentation": "Share Based Compensation Arrangements By Share Based Payment Award Non Options Equity Instruments Exercisable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of warrants, exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised",
        "documentation": "Number of non-option equity instruments exercised by participants."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of warrants, forfeited/cancelled",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations",
        "documentation": "Number of shares under non-option equity instrument agreements that were either cancelled or expired."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r78"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of warrants, granted",
        "documentation": "Net number of non-option equity instruments granted to participants."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedPursuantToFullRatchetPriceProtection": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedPursuantToFullRatchetPriceProtection",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of warrants, granted pursuant to full ratchet price and anti-dilution protections",
        "documentation": "Granted pursuant to full ratchet price protection, shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails",
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Warrants outstanding, beginning balance",
        "periodEndLabel": "Warrants outstanding, ending balance",
        "label": "Number of outstanding",
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r76"
     ]
    },
    "GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of warrants, exercisable",
        "documentation": "Share based compensation arrangement by share based payment award non options exercisable number."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, exercisable, ending balance",
        "documentation": "Share Based Compensation Arrangement By ShareBased Payment Award Non Options Exercisable Weighted Average Exercise Price."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, exercised",
        "documentation": "Share based compensation arrangement by share based payment award non options exercised weighted average exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, forfeited/cancelled",
        "documentation": "Share based compensation arrangement by share based payment award non options forfeitures and expirations weighted average exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedPursuantToFullRatchetPriceProtectionWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedPursuantToFullRatchetPriceProtectionWeightedAverageExercisePrice",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, granted pursuant to full ratchet price and anti-dilution protections",
        "documentation": "Granted pursuant to full ratchet price protection, weighted average exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, granted",
        "documentation": "Share based compensation arrangement by share based payment award non options granted weighted average exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails",
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average exercise price, beginning balance",
        "periodEndLabel": "Weighted average exercise price, ending balance",
        "label": "Warrants weighted average exercise price",
        "documentation": "Share based compensation arrangements by share based payment award non options outstanding weighted average exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Available for grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative",
      "http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock option, exercisable",
        "verboseLabel": "Number of options outstanding exercisable",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r331"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-Average Exercise Price,exercisable, ending",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r331"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of options, forfeited/cancelled",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-Average Exercise Price, forfeited/cancelled",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative",
      "http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock awards granted",
        "verboseLabel": "Number of options, granted",
        "documentation": "Net number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares issued",
        "verboseLabel": "Aggregate number of shares issued",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r333"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options outstanding vested intrinsic value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative",
      "http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock option outstanding",
        "periodStartLabel": "Number of options outstanding, beginning",
        "periodEndLabel": "Number of options outstanding, ending",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r329",
      "r330"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted-Average Exercise Price, beginning",
        "periodEndLabel": "Weighted-Average Exercise Price, ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r329",
      "r330"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-Average Exercise Price, exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r334"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-Average Exercise Price, granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r333"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails",
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range [Axis]",
        "documentation": "Information by range of option prices pertaining to options granted."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails",
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options outstanding",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r76"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails",
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range of exercise price",
        "verboseLabel": "Range of excercise price",
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharePrice",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based compensation weighted average remaining contractual term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "GTBP_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock option, unvested compensation",
        "documentation": "Share based compensation arrangement by share based payment award options non vested in period fair value 1."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options outstanding intrinsic value",
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock."
       }
      }
     },
     "auth_ref": [
      "r344"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate number of shares vested",
        "documentation": "Number of options vested."
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options outstanding, weighted average exercise price",
        "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r76"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options outstanding, weighted average remaining contractual life (years)",
        "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, shares",
        "periodEndLabel": "Balance, shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermDebtLineItems",
     "presentation": [
      "http://gtbiopharma.com/role/WarrantLiabilityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r122"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r668"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r89",
      "r90",
      "r91",
      "r101",
      "r158",
      "r167",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r183",
      "r184",
      "r185",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r199",
      "r200",
      "r201",
      "r206",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r224",
      "r227",
      "r230",
      "r231",
      "r405",
      "r408",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r611",
      "r614",
      "r615",
      "r621",
      "r646",
      "r870",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets",
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical",
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative",
      "http://gtbiopharma.com/role/ScheduleOfFairValuesAndAllocationOfNetProceedsDetails",
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative",
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r107",
      "r108",
      "r109",
      "r123",
      "r125",
      "r148",
      "r149",
      "r152",
      "r154",
      "r160",
      "r161",
      "r211",
      "r240",
      "r242",
      "r243",
      "r244",
      "r247",
      "r248",
      "r267",
      "r268",
      "r270",
      "r271",
      "r273",
      "r277",
      "r280",
      "r281",
      "r285",
      "r288",
      "r295",
      "r444",
      "r507",
      "r508",
      "r509",
      "r510",
      "r512",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r533",
      "r552",
      "r570",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r750",
      "r772",
      "r774",
      "r781"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyDetailsNarrative",
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative",
      "http://gtbiopharma.com/role/ScheduleOfFairValuesAndAllocationOfNetProceedsDetails",
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative",
      "http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r50",
      "r53",
      "r54",
      "r98",
      "r99",
      "r100",
      "r113",
      "r114",
      "r115",
      "r129",
      "r130",
      "r131",
      "r133",
      "r140",
      "r142",
      "r144",
      "r159",
      "r212",
      "r213",
      "r225",
      "r265",
      "r297",
      "r355",
      "r365",
      "r366",
      "r368",
      "r369",
      "r370",
      "r372",
      "r410",
      "r411",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r433",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r455",
      "r456",
      "r460",
      "r482",
      "r500",
      "r501",
      "r502",
      "r512",
      "r570"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets",
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical",
      "http://gtbiopharma.com/role/StatementsOfOperationsParenthetical",
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r130",
      "r131",
      "r159",
      "r267",
      "r268",
      "r270",
      "r273",
      "r456",
      "r470",
      "r506",
      "r513",
      "r524",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r553",
      "r554",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r570",
      "r604",
      "r605",
      "r652",
      "r902"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets",
      "http://gtbiopharma.com/role/BalanceSheetsParenthetical",
      "http://gtbiopharma.com/role/StatementsOfOperationsParenthetical",
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r130",
      "r131",
      "r159",
      "r207",
      "r267",
      "r268",
      "r270",
      "r273",
      "r456",
      "r470",
      "r506",
      "r513",
      "r524",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r553",
      "r554",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r570",
      "r604",
      "r605",
      "r652",
      "r902"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r679",
      "r690",
      "r700",
      "r726"
     ]
    },
    "us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfFairValuesAndAllocationOfNetProceedsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total",
        "documentation": "Value of preferred stock and warrants for common stock issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssued1",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of common stock and warrants issued for services",
        "documentation": "The fair value of stock issued in noncash financing activities."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21",
      "r22"
     ]
    },
    "GTBP_StockIssuedDuringPeriodShareIssuanceOfCommonStockAndWarrantsForCash": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "StockIssuedDuringPeriodShareIssuanceOfCommonStockAndWarrantsForCash",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock and warrants for cash, net, shares",
        "documentation": "Stock issued during period share issuance of common stock and warrants for cash"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyDetailsNarrative",
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock in settlement of vendor payable, shares",
        "verboseLabel": "Issuance of prefunded warrant to settle vendor payable, shares",
        "documentation": "Stock issued during period shares common shares to settle vendor payable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Series L convertible preferred stock into common stock, shares",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r32",
      "r50",
      "r53",
      "r72",
      "r259"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesConversionOfUnits",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series L convertible preferred stock and warrants issued for cash, net, shares",
        "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r32",
      "r49",
      "r50",
      "r72"
     ]
    },
    "GTBP_StockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "StockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of warrants for cash and inducement warrants, net, shares",
        "documentation": "Exercise of warrants for cash and inducement warrants, net, shares."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_StockIssuedDuringPeriodSharesIssuanceAndExerciseOfPrefundedWarrantsForElocFee": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "StockIssuedDuringPeriodSharesIssuanceAndExerciseOfPrefundedWarrantsForElocFee",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance and exercise of prefunded warrants for ELOC fee, shares",
        "documentation": "Issuance and exercise of prefunded warrants for ELOC fee, shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock and warrants for services, shares",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_StockIssuedDuringPeriodSharesMezzanineEquityReclassification": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "StockIssuedDuringPeriodSharesMezzanineEquityReclassification",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mezzanine equity reclassification, shares",
        "documentation": "Mezzanine equity reclassification, shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative",
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued",
        "verboseLabel": "Number of new shares issued",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r49",
      "r50",
      "r72",
      "r507",
      "r570",
      "r586"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationForfeited",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cancellation of common stock previously issued to prior CFO, shares",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, Forfeited",
        "documentation": "Number of shares (or other type of equity) forfeited during the period."
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of options, exercised",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r49",
      "r50",
      "r72",
      "r334"
     ]
    },
    "GTBP_StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyDetailsNarrative",
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock in settlement of vendor payable",
        "verboseLabel": "Issuance of prefunded warrant to settle vendor payable, value",
        "documentation": "Stock issued during period value common shares to settle vendor payable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Series L convertible preferred stock into common stock",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r50",
      "r53",
      "r54",
      "r72"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueConversionOfUnits",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series L convertible preferred stock and warrants issued for cash, net",
        "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r50",
      "r53",
      "r54",
      "r72"
     ]
    },
    "GTBP_StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of warrants for cash and inducement warrants, net",
        "documentation": "Exercise of warrants for cash and inducement warrants, net, value."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_StockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "StockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance and exercise of prefunded warrants for ELOC fee",
        "documentation": "Stock issued during period value issuance and exercise of prefunded warrants for eloc fee"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock and warrants for cash, net",
        "documentation": "Stock issued during period value issuance of common stock and warrants for cash"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of prefunded warrants in settlement of vendor payable",
        "documentation": "Issuance of prefunded warrant to settle vendor payable, value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative",
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock and warrants for services",
        "verboseLabel": "Warrants to purcahse",
        "terseLabel": "Number shares issued for service, value",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_StockIssuedDuringPeriodValueMezzanineEquityReclassification": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "StockIssuedDuringPeriodValueMezzanineEquityReclassification",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mezzanine equity reclassification",
        "documentation": "Mezzanine equity reclassification, value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative",
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued value",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r49",
      "r50",
      "r72",
      "r512",
      "r570",
      "r586",
      "r658"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueOther",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of warrants for VRT waiver",
        "documentation": "Value of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensationForfeited",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cancellation of common stock previously issued to prior CFO",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, Forfeited",
        "documentation": "Value of forfeited shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets",
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Stockholders\u2019 Equity (Deficit)",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r53",
      "r54",
      "r67",
      "r535",
      "r550",
      "r571",
      "r572",
      "r644",
      "r659",
      "r770",
      "r774",
      "r775",
      "r789",
      "r853",
      "r904"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity (Deficit)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stockholders\u2019 Equity (Deficit)",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r279",
      "r281",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r294",
      "r297",
      "r421",
      "r432",
      "r573",
      "r574",
      "r590"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r454",
      "r465"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r454",
      "r465"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r454",
      "r465"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r454",
      "r465"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r454",
      "r465"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r464",
      "r466"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r720"
     ]
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Mezzanine equity balance",
        "periodEndLabel": "Mezzanine equity balance",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r240",
      "r242",
      "r243",
      "r244",
      "r247",
      "r248",
      "r267",
      "r268",
      "r270",
      "r274",
      "r357",
      "r359",
      "r477"
     ]
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquitySharesOutstanding",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfStockholdersEquityDeficitAndMezzanineEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Mezzanine equity balance, shares",
        "periodEndLabel": "Mezzanine equity balance, shares",
        "label": "Temporary Equity, Shares Outstanding",
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r270"
     ]
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperationsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r788",
      "r856"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperationsParenthetical"
     ],
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r719"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r743"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r743"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title"
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "TwoThousandAndTwentyOnePatentLicenseAgreementMember",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2021 Exclusive License Agreement [Member]",
        "documentation": "2021 Patent License Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_TwoThousandSeventeenThroughTwoThousandTwentyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "TwoThousandSeventeenThroughTwoThousandTwentyMember",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2017 through 2020 [Member]",
        "documentation": "2017 through 2020 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_TwoThousandSixteenPatentLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "TwoThousandSixteenPatentLicenseAgreementMember",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2016 Exclusive Patent License Agreement [Member]",
        "documentation": "2016 Patent License Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_TwoThousandTwentyFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "TwoThousandTwentyFiveMember",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Beginning in 2025 [Member]",
        "documentation": "Beginning in 2025 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2024 GTB-3650 Clinical Trial Agreement [Member]",
        "documentation": "2024 GTB-3650 Clinical Trial Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_TwoThousandTwentySevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "TwoThousandTwentySevenMember",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Beginning in 2027 [Member]",
        "documentation": "Beginning in 2027 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_TwoThousandTwentyThreeCommonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "TwoThousandTwentyThreeCommonWarrantsMember",
     "presentation": [
      "http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2023 Common Warrants [Member]",
        "documentation": "2023 Common Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_TwoThousandTwentyThreePlacementAgentsWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "TwoThousandTwentyThreePlacementAgentsWarrantsMember",
     "presentation": [
      "http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2023 Placement Agents Warrants [Member]",
        "documentation": "2023 Placement Agents Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_TwoThousandTwentyThreeSponsoredResearchAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "TwoThousandTwentyThreeSponsoredResearchAgreementMember",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2023 Sponsored Research Agreement [Member]",
        "documentation": "2023 Sponsored Research Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_TwoThousandTwentyThreeWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "TwoThousandTwentyThreeWarrantsMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails",
      "http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative",
      "http://gtbiopharma.com/role/WarrantLiabilityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2023 Warrants [Member]",
        "documentation": "2023 Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_TwoThousandTwentyTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "TwoThousandTwentyTwoMember",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Beginning in 2022 [Member]",
        "documentation": "Beginning in 2022 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyDetailsNarrative",
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r412"
     ]
    },
    "us-gaap_UnbilledReceivablesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnbilledReceivablesCurrent",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unbilled and unaccrued amounts",
        "documentation": "Amount received for services rendered and products shipped, but not yet billed, for non-contractual agreements due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r738"
     ]
    },
    "GTBP_UniversityOfMinnesotaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "UniversityOfMinnesotaMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "University of Minnesota [Member]",
        "documentation": "University of Minnesota [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_UpfrontLicenseFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "UpfrontLicenseFee",
     "crdr": "debit",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Upfront license fee",
        "documentation": "Upfront license fee."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r96",
      "r162",
      "r163",
      "r164",
      "r165",
      "r472",
      "r473",
      "r607"
     ]
    },
    "GTBP_VestingWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "VestingWarrantsMember",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Warrants [Member]",
        "documentation": "Vesting Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_WarrantLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "WarrantLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://gtbiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://gtbiopharma.com/role/BalanceSheets",
      "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityTransactionsDetails",
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant liability",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "documentation": "Warrant liability current."
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_WarrantLiabilityPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "WarrantLiabilityPolicyTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Warrant Liability",
        "documentation": "Warrant Liability [Policy Text Block]",
        "label": "Warrant Liability [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "GTBP_WarrantLiabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "WarrantLiabilityTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/WarrantLiability"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Warrant Liability",
        "documentation": "Warrant Liability [Text Block]",
        "label": "Warrant Liability [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantMember",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails",
      "http://gtbiopharma.com/role/ScheduleOfFairValuesAndAllocationOfNetProceedsDetails",
      "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r649",
      "r650",
      "r653",
      "r654",
      "r655",
      "r656"
     ]
    },
    "us-gaap_WarrantsAndRightsNoteDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantsAndRightsNoteDisclosureAbstract",
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantsAndRightsOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyDetailsNarrative",
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative",
      "http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants outstanding",
        "verboseLabel": "Warrant fair value",
        "terseLabel": "Fair value of warrant",
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price."
       }
      }
     },
     "auth_ref": [
      "r849",
      "r850",
      "r851"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants measurement input",
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur."
       }
      }
     },
     "auth_ref": [
      "r849",
      "r850",
      "r851"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://gtbiopharma.com/role/ScheduleOfWarrantLiabilityAssumptionsDetails",
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected life (in years)",
        "verboseLabel": "Warrants term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r849",
      "r850",
      "r851"
     ]
    },
    "GTBP_WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "WarrantsMember",
     "presentation": [
      "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants [Member]",
        "documentation": "Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average common shares outstanding - diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r154"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://gtbiopharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average common shares outstanding - basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r154"
     ]
    },
    "GTBP_WeightedAverageVolumePriceOfCommonStockPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "WeightedAverageVolumePriceOfCommonStockPercentage",
     "presentation": [
      "http://gtbiopharma.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average volume price of common stock percentage",
        "documentation": "Weighted average volume price of common stock percentage."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "GTBP_ZOneLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://gtbiopharma.com/20250930",
     "localname": "ZOneLLCMember",
     "presentation": [
      "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Z One LLC [Member]",
        "documentation": "Z One LLC [Member]"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477787/942-405-45-2"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-4"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481440/840-10-50-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-1"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-4"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-7"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(j)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(j)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(j)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(j)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-7"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.E.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "S55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479772/718-30-S55-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-4"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479741/842-40-50-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(d)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "184",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r754": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r755": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r772": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480341/340-10-S99-1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-4"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4E"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(7)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>70
<FILENAME>0001493152-25-023400-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-25-023400-xbrl.zip
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M=]7OG0^OFQ=_G@T_L][)N!Z\GS'?1XVW;WHQ3]DG/:'D@=!61@MFI]RVJ]"
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M&P  "@   &5X,S(M,2YH=&WM66UO(C<0_H[$?Y@B-4HDWA-./=A#XF6Y(''
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M+,3>"H_O:)?5;5U)5/ FN@,@\I"P'D\5PZ(O)OP[>]W)MR5722ND]L%7>AC
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M<_E D'!<TT-@SFA\?'3-]"K%5O0J88J&:'=LUL^W1+UQ2HJ !+8WFJ=^,=U
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M4\KV'YR5R+,Y<?*#.2*C#RYQF;)_-N4UO_E (Y2+/M8ZN!B"CU@N^D1TDE+
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MJ8 ?0)4TW=D(=:A!'%UM0!HE$GP\\W1R/G>\ O&=G/GH2OD/S"J>%>.CVQ.
MS2\,%99AQ";K*)YH*)IX"0XU_/GH"OM3*9(PXS^R?.ZA)8)A )++N<3,*Z8%
MB'Z?A1_/0((\.6N/A_+4^>CK;!)G.\1(CK[Z)DZN_4=K]#4Y<?*#.R(3#9^L
MS7&'&H71ET@DPFJ(D<<F:F_"<.H_VF+:*!8A#Y@CC(T\31.PE"_N<15].42,
M#(883=&73$3#G_\8XB)/E$9#>:"2%9X[MM*VV ?DL97=QCW (_>!TBDO?X/!
M1QZ?I5,2F%,W'[GEQRKTB]L^\)&[AY&S%6(4\X<I^0T_UB(/)_>A-]B4S,>S
M]'BP*E(^^IY*::HBY8NK(SY=]6RQL9R.NF#>:=,1-7NE]-8%Q\5R=+4L 9;+
M5NQX594V"M'P&O=$/X$GV)TC'DGXSXX)=NF(A\5@$VHY,I?L0.QB>M31-2=)
MEL]M1A)=#'"/D" '?0"#(NE@=BC1Q8-HA>!O@BJ)+E9&RUTPZU-)M$HT6DXQ
M#4^R%721L+C-0W+3OC,Z++\2OT(H 9,379NGQ&6 87&2FQVC9BZ@P4FNR"=J
M1G'M37*E/1%QN,W"4:7%X[=-A>A;,Z=38+Z&K$ ?51^3B*Q>(?J>V.F4"IZ)
M+$3?#RY5XMCF]P#++DE8O0.L8^QEFR)?N]B'WH 6)/(I.6Q2.XZ<?6&MG5/J
MDMKQL!RY40BE42Z>K@*%M>XLZ=)H;"RG8XS&Q=Y:=Y;3T&ATB\-Q)ZV9F.?Z
M0F:6*3PD@>F:%A+=6ATR6QBWLHN);K./5@C^;F QT=T T7(7S&DL)KH;(%I.
M,<=K#(>PQ,WB-@\9R(G&;7(2["X4M0S\+4XIN4-EHF8.<QA&WRKIP!F=V/%^
M;"GVT(,C^L9+Z90$YDB*[@"J0$FJN/$>79E3%&QAH/( ->51N7W15RBE*5=8
MI-.;AXB-Y704J<?%'I/>(O786([6YU_F3%:R)#]T\U&07SRV-_O&)<7HM[_&
M=#1R,;I]CY8T$9DMU7:>]Z:-CWZ3-"0FCL-PBWSD9@;.>) Z ]2!_6]3;<U/
M1[Y&OU_+0D]6MO;\!* Y^H0=#)0LWQ&.H#M=$P&0#$1/4WT!CE<9FMCHMZ9
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M:ERQ%,'&XS1QXH 1!\P?UTD>?DP6S;, T#0MFA\2G<2]/R%E$_<\)>[Y(4%
MW.LT[-).3.VD\II47J<-FR2+G@D?.;U!')\T0HF;?$+*)FYR^MSDQ$% W.0T
MN,E)J3V3S8P2&Q,DAB Q1&JPZ5E5OP[$FJ:^ -V4>PHX-DQ6X5,E69F8\@MH
M W&BP]D:&(TW49E(0$+R03"=0,S VUK]N2&_ WI[*.C@8NK^@&T\^<CP8"N3
M::W7WUC0)H \%4"F:ZG<=]]18S16M"D ENA:8Z05 L*=()R_Q%-RQ!;B%?<0
MZ!T/]#)F]1X%78<^*($;%MS6I$6L&YYU(Q#+'L329<7<5V]K4U-[$5017,B:
MH@UDT6BJ8O91=@\4*#;I#DI\VH%0, 01X<FXF*Y^LQ(&[)##\:Z5KC44)TA(
M*Q)B/T9TPR8\J-"TZ@8DM=6_D545&)HIG" 2=LCA1&P"04):D9"T3;@& T%I
M _U%%H%Q*>NC$T2!APQ.Q!80!*0- 4G;@)8Y!'I5%+6):AIWPE3H*> $0> M
MAA.Q! 0'Z<1![/: (Q%C-B+&) Y\<J^1()A(%2:RF/(F2$H]DE*9V2;X23-^
MDJS@@R_@%S:%)[LM4M1SB ]A-OBX)Z#B BQ% I84@:48 BS%N%=/.1(!96".
M<105:P3$+2(@@HG48F(S N)"1$"K2(JEKLP=223CGHJ,>R805%P@J+@2 U6E
M%]G0]&EUH -K\L\^@CK3,6CUJZB^:V"QM (6#W8/"9; +DPA 1>&0.20$%GW
M4HJQKMQP5J*&GRN[\ZIUAMK$$%2I\PIIGG:&4 RVS^_43#J[<KN&;G9OA#=Y
M-#F":0=GKR6^;'S!@D,:E._'>P10FP3TZYJX#[9R8 'FP(B\4P31'KD#I"4"
MS<!"(AC=PY]R7H"+UG7)GR88 Z(O+H]K QI8'M?&/=%[7 1$J0=1DM;%<^W\
MV(%1!SVS"<6I3S:<\K2A(<6KYAZM-V^ 8$QT:]0UU?'$M/9*W>FRZ%0DG0K$
M-N6 0L'U!0X_247B.&4.\8>H)B38)=C-6@6DG]V]EXWG2RB-)KQ3!X9Y#\T^
M0?%N%'O+[.3Q?'!;3/!,\'Q,]MF:+']HBF#*RE:C00)E+'&=/(H/;I4)B@F*
MLV^+&V]C()I ZH!Y54<0"-NK0+)Z'*M P4&]+;T,(3KLXM.JNH_5^"<Q;(YE
M\90,FZRLV1[<9R*S#1DVV9MM8G?2DA@V9+8YJ6&3@MDF-;%-77Y!:)1(WA1_
ML&S++$.#YLB])X)G@N=4VV>7KA)K/6N.'::904,$_236,!3+KJI"GN&7/\TQ
M=#?1Q:%@@!/9,N/![B$+\I V@A;DK=X32T$>@<@A(;+N+:TJ.Y8*7C;/%I<_
M9>>0O\V1A*@/.I)6[XEE)&5+I.O(6Q5.+'$G>@%I49*"TX,34[8SIS15:6)O
M^#H>=Q5GKX@7WR>B=ON NNJI:M^'_9,"P<5I@\"3_:,#P5H$RBY_6L)A?NZ1
MA^>]<4)H!ZAW0!?AUT=\5NBN ,578)&FY# /5<;6RH%#;39$J,TNWQU/J$W&
M AD+B><4V(/8>L\3V+.,T(P</)]B<QB9DW %/U6-H0;NY<'P&%S*%%J_'<ZM
MJ_@)QK<PSK++G\+.Z<=5QY?XW(I#7)HJZ;:1S89 -IL=9!]+J5UFD'VH8K>,
M()MAEC^1@"U;+DL& S873R9PXY[5>]+HK0>>&.9]R5TZ69(1D\D1$X0XAR9'
M[RW="C)6V[2':7!Z&L''GOE&,N#B&G!IQW0B><,]T?D#&*:L#@@\DX>GJ^@)
M/DE2DB0E$\;HWDXY >1INXA+ )5<6_HZKC]#.YZ_, !'G,3 #(0"2..0,"NE
ML^LO6R'@RAZX-C=SLI5872YB@XX#)G&>DNO9A]X1D8]8F&*E6"D5"R< EA0!
M)#NMZ0.!B8#HB*U,86%E"BL[L4E=6YKL2"&$'2G$O_UZ#3CS36].XNR(L+)[
MP]L:OP0D.T&2G6VC&13NW'3?@-E,4&45V+@]HH'H8;1=&28C$<]<5R5)1H<\
M"\J=($M-M2:,95-0C@@UN\WW3OX)B+!"TN-9IO1;'$Q/)4:*0LM5&\,%BR6.
MM1HCSC@C2CP?NA9CV^AQ:3%ZJROD2RP?&U#3#I#-A>:8VX:NJOKH:G R5_F2
MH+*/KJ EDV4D230%)H8\!6,[]D,ZUF+<.UU^@:/A3A'$(ZD.:D]ZABS)@CYM
M"PI8\R_GE[@S?<2C.UL)QD2$LXS,BHO O;C:&9UTJ#MPP%,,$<87XP_C75.%
M!"P'CXY3DQ+TF&D)1(YQCO6:1K(SVZ;8[+K'HR@S.%$E(!U/A((3D7JP?:PC
MBLW3O#VBK)^6T6EKI,J]B=%441&D_(*\>#7["*B^"KJT/)K#TK@WIP>;:1VM
M!+(/CO[B<\M"0.6XFHY$#!Z<5Z>VI4BZ$.J>8",F[ @3;)Z5 *[5?W,H6&.H
MI8+LJW]'EC5</6 @!VHHZ.!",("$?"?XK8 *5ZQ/C>K$'&JZ/ /2 W2?="L:
M:8W1]PB-QL6T\09T43: ==SZBE&S$+RN(%+6L.LP08)P@O!CLLN=5XV@-LVH
M72B(V.5P=ID@G" \@W89G0!)<)MJW"Y51&QS2-M,4$Y0GDG[?*E-= +<- -W
MJ2%BG<-99X)Q@O%,VF;YA3@5Z<;M0D/$-H>TS03C!.,9M,UM^8W -LVP72B(
M6.9PEID@G" \@W89O( C*- Y:MPN541L<TC;3%!.4)Y)^]Q *B;(33-R5U1$
M[',X^TQ03E">3?M\*Y/RSW0#=ZDA8IW#66>"<8+Q+-KF#HGYT@W;#LEK[%E'
M1Q!.$)XYN]Q02#HN[<!=U1&QSB&S&@3G!.<9M=&=5Z"02J-T8W=51\1&A]TE
M2'!.<)Y1&SV4=1,0#R/EZ%W3$K'387<,$JP3K!_85N.@ED SPPH.-ADSQ4J)
MKK ':C]^_"I/\?SE=S;:_=%TACK&YDPI!I9[5T4"IS3#Z;!3T]'U/#K&MD/9
MM#@$3BF%4XHLSG%T\CG.9CH9M3H$4NF%5'HLSW%TJ3G*1C'9M#L$4*D%5(JL
MSE'T7SG*%B@9M3H$4&D%5,)6A\TSI>5/<Y#\;JG@^KJ678B@\W.N95,>6)"H
M08RL:'>-NT,:"R3RH,9B]9Y8UA9*>;J\_&EYAG5OVI85*)D^D#.\(+X3&&Y,
M'A(?2 %!\;%Z3USXJ"Q_(O@X+#XJ(?!1B14?%6BCEC\1?!P0'T@!P9W1Y3W1
M.Z,LM$YYEE^@8FIJ+X(J@@M94[2!+**3S;(-CC:D0IHHH-6WSQZ] = 1E9KJ
M"S!,],3M3P&X%49K,/*6RH$\44=M,7BB#BYX=&(@6R"XR!8N'+7%BHOB2O!*
M<)$97!0/DR_;(8M%/=T],("@B\,JG-[ "U"TL27H-Y1".(*TR#U0X*0MW<'Y
M?MK1!=401.2K&!?3U6\BPD\0PN!3M1%8G,U]K8F6$[5>^(>A')+?6QT*_&(H
M\&0HD*&0T%#@0PP%/H&A4,C#?Q<_S8="YU7K#+6)(:A2YQ7R/+46LMMC" 5-
M!])"T /X*1)3]I&/SHUN]:NHB'I@L;0"\G#2."34D"Z#0FWUGE@2'<4\4U[^
M1*!V!%!S=!ET@E^])\%Z?P*U;$,M0[XD@5J&H98N7\V]+($ +%L 2W#K*U-$
MJU:N'E9;?D,[?^\@-&$0)8LH,#H]B&!(X3#0F&LNMCS@_ 7[@L3M+M2B"=T'
MAYXV&0RWAB2!5P!X!2&K^BKHUFSC00Z>8@XUVVYB'F>VW;PG<L<NJG%"T$Z@
M%9<)-G2S>R.K\F@R(F"+V+2BA<:5&E?TZYJH":)C0[3P1A"=$*)714T0G8R;
M[(2GQ[!G.V4(QW2'-Q1 <)\D[H]C'TV6@7_X75^GB?PC.=PRR]!/P1&M*</^
MLFBTD&<XDN+(1HICO6X4:2ZV?/'\!?N"A#@$J;6*AW<(-E&,7["TO">FVKC]
MD4]@3: 5EU$E&>#3RP"? *))!OBD,L#I1#1.$2F9_M,^_6>V:)1 *^W02E>1
MJ ,M2!&79XO+GUR@59U'?BT5G#B^<$5Q,) Y6@P$LHU[D@#95B!R8K#;.U@@
MV$XWME?]9(+M8&$#P79*L,WG&<;>@NG\Y)V5UR;ZE=FS-U'(;RA%_!OH6DV!
M1DT4E(XN"\H10#O4SI(0LCF@CVKI.:"/NG9/\AN9"/@R"[XDS_>S<'JH8]WV
M7K:U:(]OV=;N6^B2O6K;2C:R/VX6O4 N)H:L L.8L[8R?M:Y/606JI3&+%3)
M-0M%('*8;%)@B,2>3?+,@1.(D%RV3RZ;0(3DI.=6A*'G5@3^Q#%+B.@R,*X9
M^@[H,'HWA0&H:>H+T$VYIX ['?2!K@/).HK 2;W,V["U)ST#_)G FQHO1Q$%
M+$#F'/5K,;T&L*"RBC0OLR%O%+.LMUYS5<@!3:4%N8"FT@)GG'$O>@%-T$_0
M'SGZUP)O"V;Q!=[$BA,<)X;C.'(D.W%,L+L;NP2OB>!UHLHV6!_:]4U4C8!@
M3'1P+AL:SS*EC_"2^:/F7ZT]'SW+_>'VT5]>SW>D9%T3\@60M#OWETCR"T3R
MED#1G;>3$= %4]M&#3[OF^2Y/'/EC76@:B-9]7FGKSPV7^KRV/G7J^S[B_$.
MOF*WEL;PQ[ @L(>!U_-7XUNL-WR6WS[JJ%LT:AP]E,=4'\:!]Z!OP(A0$$UH
MT$HE]HPR-><S33-5S03H\S)W]L'G$6_2&RNC%\*G<*&?,B>D4G%]1)DKXCZB
M3-/[/\)='($>P>_]B$K9]1$5EL%]1,5#%H$>X2Z+"LOB/\)=%H$>4?1X!#:T
M*K27./$?P7B),\ CO,099*15&"^)\H&>XB74^5,^6(\QM ETC@WXB?7!$ @2
MFKT_?X V\_S=NW>?QY1A3A7H-/7AQ/F18NBQ276@]V!0M^"5NM=&@IJS/\A1
MR&OI?Z)&@CZ0U8\4NG3Q]^S\LS$6U-6GY?O"2%:F'_V>9UUKR#-@O_[L_/_^
MPQ3I3Y\_H >>?_XP/H^0SD\4<@_R@B(/X%<H;D">9G2TKU/]/_D\=2D#1?I(
MW4\4D+^#00J5SY]_AN*?O\XF,V]J8XO4.=WYGF9"5]KY[%66S"%Z!_W7V=K=
M/4V'&K7OOE $\9GB(9N&ILC2.G7H*<[%\R?;US/SZY>"1^!P_K_"P8<U%C*D
MDXSBJ6SAJ7?^<-OL-.KOVIUJI]'^_*%WGEE.VHW:PWVSTVRTWU5OZU3C9^U+
M]?:J0=5:-S?-=KO9NLTD>ZS#WJ, [;4Z,#4U]Z[^OO:>8ND"7\DD2\<P;BY;
M]S?O["<BUQQ.GEWH2'2!!.1\OJZ)DY$3!W=%%'+2#,UTN]9/%8[NSK3)K/1L
M%'LUZ$6=HTE9U50K\I%%RHDRX?2[N;YK:LN5PC-[Y<;V'F@T[ZL"RD]  CZN
MOO_L'$:[WZT)>OF.)6:."3ZFT%, ?)>BP$]%.%C^/8-B0K^/!4F:_QZ8O[7I
M$7D_IA[\(58J1A24N43@G.K$<9]-*31-]'NV(*N1NA@^D/X^$72H2F5Z#\::
M;KJCVQ"YVO5#;W@)E-#H[FOZ2##_/9/?S(\]35. H)KZ!&S ON &^PT:$5@J
M);[XR7,0./^84FB-1*J"WOF" XL>W6*#&D]T8P*E +$#[[6.>Z(8CM)TBBG\
M+?U#:7W*' +TU42731F^L_$F#E&Q(E453?0U4^'XM2$/.8;_TV-"M:BA@:C^
M>\8&'G41R_-2TRVJD'S^S&5+V2D^"J@2D*A-X%<V@']G7=RP%QO=8:_7V.G,
M&*K%43D2V$LHSPOO&TK"= H$':@;Z"^ZH7^-T+/S-AB;=MZ6HW-;7-8WN+R4
M#:C.7_!EE_ 3PYW/6H,K?GV]_27\>8IF\BJY\;%!RIF5NO4<PJX?O_<$^P=K
MKCB/:[Y[FABFW)^2"2][$UYQTX=#A^O)R-CNG/&TKS^,'Z-BZRG\D'"9\?J"
M8FQ.>6573V^#2F?.XS,TYRU9()->Y).>N1#N?-9#B3^JN_B#Y-M=^7/LIC,K
M<0[48TT;C60#+;B^NY2AO8=#&4WG7H:K8:V*HBOM"]T-UL6WYRNA"BZ?>#&:
M.;RR:I8V:4#+XTR>IVF6.W D2N"UF<E8>YCU-@F(FFXM$7RD)M YUA59!=LS
M96T-</=@(!O(S)CH#&]WT('JC)^IOVY^#<([R*N@8^EMT*W3@4HBWETT6W=?
MJO<WU1S5O*V]]YL2LYH2@;K\N_$&1?,.R01-??I"%I1@4,88B*@<1:)DJ$;3
MH. \B2*A?[++\F&<XL5:!YSK%6%L0'+F/T7G+]OK*!&XS'SEKP20M]LXH$.A
M];%C5*SZI9HV44U]6M,D#ULAS;Y/_W2$G]RE%(5'G3> B,J+33#6M1<T0#:C
M:9;9-B8[Z3X[KP-%>!50/8?_G+:'H[U0)1N[)C<&5!1$'P9_]!K^.L);TZG&
MLX\CW^4:/9BSYU_\_7B(TB=1S%+L-K \"#H[K_!YILC2/%W"!%6DH<S^1B=>
M1?]MC4&+.A@!:C"RT:%'I\N&)-NA(9STY-4Q:UVF#P15GEF__Q,-M+,S"&/6
M1_/]_?OV>XN\QFBL:%.HD'5@.^'*/X>()6V&G<]D%=$%C>C[RC+O$Y'UF6LL
M23\J ;9N/U0_&Y/Q.0.Y@O]DUT_\NRI).C",=] ^C'5H(>2QH%#@#8@34WY!
MOC*$*S#^R29W&0U O:;N^<I+#<Z351T(WCXBUQY]KUY/GM_H2C0S-;<Z4Z^^
M_^R<9[P6'_*;#' . ]<:G%KOAIJZ,Q-3E2>E>JGQ*"@1,;%6"K!) _0PF$J>
MAP[&T94$_+T,_?_O/V66*7TRWIE  6/$/:5:[.>0>Z!,4!A(0<==@!*6 !GV
MR2?-E@G[=W:6 NA <L_VLW_W%GG^JFA^C(=CDI;8*T+87?UIRR@01UPYB;"Q
M(YN*$T_TJ88@#BEK4U5TD;NCW(5@F)6"VS2$\Y'KC:43T9LN(+%:W+2GHYZF
M$)6E?*BA=/Q\I('Y&BVT[Z]#&0Z[Y21PT@F.35>2=UQ)9[J<,FS/,EGNKF2K
M>%%OMPL_Q]P@&E=RK;QNDX8S:V726:ZW=I;FJ/^EW],T X>03KT(R@2@U6;*
MVH@78R'"X8=D6BCU6A-VS*5M*=VQ,[JH<+Q: +\%(1KLK!6GK1%@[U,F@#@
M(!H;]F1>+..]9EL:-O76[\JU7 B?#=]<AT'FWW4)IN1F;U9I/(/3B"$)?SS
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MBG%]U_]Z/),I;ESNJ,V]";>C@(]8\O?HQ>W2,)$O8?;BIE<Z<3^TZV?G;*[
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M*!M_NWDNCEN/Q6:8+HO1E$)[[.E<(1Z*UZ(^PSL&__;K;NNG.?QAS@?8O61
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M7(-^)90U!$KU33:6EZWW![FQ1J7+0VHH](2A'KIH_0$(!\"HN3YG)K:^]'Z
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M47#T?G6"3(YEV:R'1I7TA4:9,V^EU(DPU,ATGY'C2TQ40M=_,#FZR!X^\(P
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MU,^*4[CKTF/#)^E3*[VT&*8H_*7:BK]4E=#9LM8ACQW-(R"Q8NL+P0 22G<
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M*2#*3NV-5!2$XYWVH'ZI JE8O>/+?=\VV0&%&&W[;/_Z[:#G"W#\?G6FF*=
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MP2NCJ!1/9G.$_X61[]18E'I<\+@^_^[U. R/'Z_"X(_R^E:M_&E6ZSN[TA]
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M8JU!QM,@N#V@P6T4$MSVK!]OFP3W>7B"@&.? ,(2YQ5V_E,9X/=A]?1_O8'
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M:$!6#;<]EK'_0*% 3%YA$R7V()A"+IMFGB5(JVGZ"C:DB 0>0%B<C6$@^W*
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M7$9EB6.#!IO,21HSXSD5))KGNZ9.TDHFQ95QAQ]+,&!'9I#2T>W8G\D[6U+
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M5I'B'GCXW>7+MV@HCDG8N=&=.OS*=5M6UBD"7KM2VE!2E6QO/56KT:3!#:,
M-$J 1GEK9M.?L_ETUHZL2R+$QMXH%^(6[O^]8U1>@32(#8^03>:R2](Y4!!X
M&K(S<ISH!J;-R)#ZHHD:W2JYXB)=RM<O#C2S<O<IRI7+P0JA=V+( ->U7A*:
MJ79%Q1"@[<2VE,WEREM:-C?GU,UGLC6=O7QL#ZF4CH;GN-C).W)NH-R2Z,9
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M48W3ZY?0&@_Q^RN&V%&D7\(U/G*4IM<Z4"^==O_J?_QG\)7#EIPG__T?)G,
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M/&UR1QB!8FI6[,%Y89I3B3C1K:>GD]2?3L/!,ZVZLDR3O-6X,\.Y/27#W[^
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M [[RH*DT^=;[S!<[F9!=&Y"J 8?_]T;F9G0F9!";(Y4X QI$6/41. WOV!]
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MMZ7<Y8O0:V(N-G@4$+DO\/YB<_?GN"&/2^99H1>&:A?=OULIOETLMHW ?JL
MR9OAT#G42@JS@/)F!4\2GN )* A2.A8.I%>-BSVZ??Q80=JG^OQT]'A7#F@\
M&1W9;X7L$PT>$+/6.N !YQL!5;\1T)FO8#HA"@8L$"1[X\][*X $ ++J;?.L
M7N\57@(R332_/?!."!G)'ECQ=NV>0;!,84PZG<P7"\E<*OPBRF=5+V@2)+ZS
M2<!(X^=UZ3;5[=V-C68VK,7$+MD$@8OTLF V'F#*5Q@%[XQ["<Q$\.W*?\M
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MEHJEN<ME:47T_-W)H\II2_.4TR[\\M^3J_?^RX5AOE>[_,;XP"[">D)$V=$
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MX8P*;2#E3.&=,&J'RM&VY73$(!$'4>@6Z'KD =^OR)O[:/::@-ET<_@J.+Y
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M!9?;[\M2EVL!PP6.",1XT04V(.F[W EEQB)9A+S1X?; F(#! S-3!'E@N"^
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MJAE<$Z2> OM58?=$(_9HDJ#(25VP]P5;5^DX;P-M0NK9#@W<L$PE<U]34-]
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M/7&B?6M@W_['TN:K=2"T]^\.?[S7W.:1H9@9>ZVAYUGA_6:B&L:8I*%TF_-
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M! :[W(7*_;!4R9X24XDP 1W3CFYWVD0C[/A-8J<D@:<IOIJ;3^_GYC O;-O
M85R$J^ Q!QK8/DQWM^-3R"I5)%!.QMP&M:?1D'.D)$BXXSR'!21=CO%#$H=B
M'+LKDXH/]J^ \S:G D6X2.5>(LGV8T4CGLB7J&%]"A@.(0P_]=YSP;AC6_+&
M&46)<>@M3_N S9]T<T3":0/ 9VK7DFQ.B5F$A#XI"5!Y!;JW@C>,C$>0,;8D
M#&43$U18HV+&N5P697M67-N26(P:0T<)O_48E!@+5T1$$D'$J &&1@72=T,2
M=[D'B;*T-FQ0(B%@H D'A;@1>9;H$&./LB!*'93I1!L Q!19;/D?DGMC?_6F
M860##Y=CAKL/*KAINK6^ +8[?M^V#&!)!N.0EHF$#YR01+<,HB#9_)9P/^^>
M\R1A-P;R^5S0T> _' !/!"X#;$A'>[\+6AL>%L"JM4V4!P(J'R@W7BV-Y:>@
M<X*)*! J'<F^FJESRG:4/!=8GL1@O'N"Y=H6"9G#12DAJU$M2S)EDNS,_ [D
M[324C:%U1?F3:)_YOLZQS$_NV,XZ]L^8'F2FY@92OG"2 82%IK*.)0\^_USC
M2R!8<R/UD--2[Q*0P8&C*-["J_84N ABM=I>RKIO('V"IW]/+*DXGLC[;R^R
M\&53+N??]G]@STBY.F<'"OS.VCI?_ST9751*6N_XJ%H1OOS'0 &4Z^A&FQ]-
M ##8:+JQ9_#F.5!1P<0(/"STX&_4MUQV/#W%:<^#\$"*H)-?="G&HSN(W;OQ
M6^S\MM@_0KLA3E380_%I?[_WZ+CJZ7+(2W5G0>"&/3OQ+2:SS][)!95^:B_Y
M1DY_RK]^EE]>3GX)(3O1[ 6]&XD-^$8#):YOHI]G>;@4[-<71=@!\8^1A)&F
MBX:D3K6/< ()[*U)MSL%N92[+2VX6TV50H(>X5$0-QCBH NQ])T[(\G!3FJJ
M@=U N+:L#5'Q$#J21;RM1*XB/72UCH7Z"^UZD?/6B%.=Q>YZ8:?E:6AGP8\P
M^PQ,M!U-[6B*UAL[)4<LW,&"'? IR&O)1,<7YA0;L3G%M'?85UJ.?"N9NA#]
MP &FBMZ2_F-X;._S:'J:)'^06K,#T-%0O8*],XP&*($=9Z#.Y 1<6../MJ 0
MQ=+H2Y))'$M8&,\>^)-4C8W9O(=_.RZZ_8N#,^81,SRFJ=<O,<14-9*L0U/5
M.B2)NH^Q5PW51@W]MFZBM8NWGM#5WZ#+&&C'.Q_EZ$>(.81P4*F5,!1&J<_C
MZG#;"&RQY@,V?P,+$W>T:N9LJF<IC79[#"DFF]$ -@","UX@HU.&^FQ)1BV:
M)CL468AUHAH$WW8Y1YQ,OP?0+4>[?5"?C@&\1Y4 ZPQDC&AW4;W$9QGF:54*
M&CP 0@""LQRZYG65^M.Z\$OJE'/RVXA (.YE040'.U;G$ O*WA>-!W<U(((1
MB1$0.<((AGIU#!=\W!3XW!?87\FF-$!>VK, ;,1\1M*DZ=%X)J37;WY,RMBT
MJ10J4Z9-IR^)EB)==(-FBD='WQNS+R/,G4;=:^ZD6_'WY/'N^;+R<O]#.6]L
MC@FT)$;BMZ/VJMA\Z'Q_\/"T=]?M.- 19:P<@I>I9*";#7F:F1EM:7DQ;*Y@
M]KRWL8.!Z6]8M*!]YV9'PNL8"&=/DK(#^N@7C/1ZPN&^4W_G@M%Q&JS_PL+#
MINA %D/4;HB<7,!(HJ]I:XKXG6,0<,+]1>^]P-/VBKASA.'_^<)_<2ZIW&A1
MZZ$6T=[]QG8)[S'>96O4_H15^U,[]50YEDI'Q\;-X^@EF%00F;80<K;IC( O
M$8 )@4+(BE%/+PFL90>LP=;J*<%:Z:GCT[.7Y[?G3PK6@]^QPPA2@K5T??ET
M\?I0T]O5SPG6P]^Q@P!2@E5K/-4.GFNOE3UA?<&*Z3]^3IV2-<]_!<F1+0P$
M2U+8G>6S]#22#'_NC-8"'6(N8\#KR&W2:7QIF(&#S(L56P1*YK''-B%;_ G!
MG\SX5U92)5M&CT)^/:5GYN<L?Y)S;N\SG7KBJ&N^L-4%>FOBISQ-"L5Z?7S7
MK':+KMD0SB7 X(7S]G3-4D4T>C7]&Z?WVG_SA7*>+]7S?*7RU>4D]EK,$N;1
M$I[.\(Z:\10$C[W*7^%WY?]5,?15_Q.Q9K$:^#DQU&=%DV:#-BJL5 L='N;7
MCP,^KM3E-=52.:*X)AP4H8 +)ZT_Y4;*SHV4Y[B1>NJ97OE2H;:]DY0C]F+O
M)'W+]WRA4=W>2<K9>'%W4BRDO9-2OEZM9WLGH>+26[!_PZ(_ )0'3!'Y/6F=
M*X/GX8/5/A-2",>'OFQ*'MW:7M\^01Q")$6ON:\_>,CLQ%213WW9M5*BJYX%
ME/4%:"HI4TP]PJE4CBJJ_5, FDI$%,OIQ7:AD$Q$;"Y(TW'XI%TV0D!:S 2D
MH6R]YF'K)W8H?Q_[TI"X.;!VL7_\(JKFU=N[F*G=\Y_SN@^]\;!#9\CJ4ULD
ME60&R5I246*8IN/VJ6V*,O\)8)J.X:>?O5R+&H/X)P$U%<OG4ROUQ486U!_*
M\,M>/;XOZ-(>YFKM>U*U?D_:S7>I_S)Y;ZKUQ;7YZ+W>1.2*?:P&$ J3["0"
MOX#RWUAK2O-&=S#+>T=^W^G+HBC!;P#W>/F]K2L @!(N6N>+O)L[N1X'R! O
MYN? ?&J5NU3?9(4[.5C3\>#4:C?/9Z$MA/+@BC?T8*?%,I\2:-R5ZH_Q_6#O
MI%]K+"72,+WCZ=S<#T6**9ADR'Y3*^3%?&.3]<=D,$VED/,+./D;Q0U6'Q/C
M:0IQD%HA+^6+U0VV'1/CZ?RRH)1:'Z_D^6)Q6=*@ZJU:U%2G5NV$5-0X\><'
MZZ=V6SL\OGPN+D\ICPC[DU (*_%)G7&5(LLJ#K/F68=AWM\S"A^C@)^=^"G-
MH?UCC0EHTE-Z2<)P3VBBQ#1POV[O<P'15YHC\A!QG\5&LIC.]C[GIL_YQ6YI
M#BLLZC[SE4(R^;N]T;DI-(70G\, C+Q1OKB,&PW5!O:]VH!D4JB<:@;8A:\3
M?CCNETI[O[*-Q 1W3TNW,--V>O/3"@*_6T'\PQI@K/V=!1+V\WG1E3S&1G0F
M2OV8<Y5$NJGO/C)4"E+;I*#KI\1, HGDI/^Y;C&=*I#:"B[ERPFMB^TMSD>+
M*12 U'9W)5_BTVERVUN,I\7YA7XYM:7?R)?JR=).4]VB+?)9J^R0EF:>VOHF
M#S+_N2(4%:7\V.IN3F5\=%>L)3=PJY3YJ2X'5ML@[<K-0])"^%8*;]OF+0>(
M?.;WQ&IU7EK%^GNAMD&="EBSMD9DL[;2[\E+12F=#/27\L67_]SS<Q0 F]^I
M;:.;M< %'KYCHRE#HM/%,$6-.X5O_^+V-978 -C+X5*7NI*.,T!(:)T[TB4P
MIOJ:Q%TC,S:V]_<QFS^PL%UK[J)C:F1T#^G9?&GI'9Q$K!L1'8:3W[-W3DO@
M.V?0CZ20-J^DCS+#)7RIK$]A">V,S78G3K7[:WD9);[BQ# L2:1GO"3]D$E0
MUP#XD*^,WT-9I)WVB@6[YT"Q4"J&%<?OXSC%BRY9.%@8C] X+1;@'5@@)O0D
M#TR<8Y,G6?'\[RB.CM,NZ.I1O[#+[]]KH[WR9?U\_ZWC] *DQ^-D<NZ9 >Y$
M((I08(L%6X&%OP!@CNHS-RC8=GZ''C,@0Y/ZP +]^LB)2)%(I;);J40.*C(H
M^"*0/HC;I#6VP)&NVJ([52=VH& $S,D\&!<K-Q0C]P;%Y[MKN3(RZ^$828&4
M$B_],%HKM*PN4+94J>0KE6H42MJ#X1G/<SLXA\T.MV_??QZ;FU_BHYN*6L;;
M:??R3!Q?&R\.:EWZ@!([("T&(FN%2 ND*]0KL4/8=KDF]A=EW=$9AS-U0348
MM.A <I6,;"5-&!FBX>=3G$\P/-W52;?X*7ST-IOVP\4#L'WGA10[<:BJ*Y'#
MF]2L&VK^Y-_'PZ*N=J2:@YJV3AR/FC;#2PJ>B"&LB*"%U2!H):GWPB^  44O
M;2%<V*V6^6(DOP,E< J5FAF@TD9PN8?'D\)^<?QL/<L?ATHKXG65I/D&<:A4
M*14CA_O2%L)3+$T0T8PB;0AQ(A5 V2)MQ3E15BS2;!-U%=))&*T-P>6:=**5
MY+L/CZZ(XP\>!!SY;!JD#_*]1,=3V!_:2A ;"Y78AO)R:3(5APR]=OBO,XN1
M4YU.X"/ZRAQ3:-VGG,$7>7L,EST0M=?#83MFU '9BCCYL4OF@PDO>#99I9._
MR#15,E>,;<L^I;U:CJR61Q5;47#.!Z 'S@_1XM\._ZOI=. :=IAP[FY3._/^
M"6WYX0PN-YG'Z[/!9_[SG#Q(=O8\EUE>GCCN1'@+Y;)FB$^F&BF[*1>_L$PP
MH%6,5]@#DM.+ZQ6(Z(OS0NM ;13K2BUHXSI F$](3\%A#MF<I3Q>U+<"5NQN
MN9[ MQ*&5KD@6A'!$J<(4HF[P9A4>+D?Z_7[O?9M.626AS$G3L6!XX,0*JE7
M)!RAROE2H9'GZTDPRCM\:C<^K.<)K!4;OR?/_=KY@=2^.)=+&Q,T"QT^'3=P
MNK@=.)WAP.GBI@R<WB05)5(OSNP(&>_6MQ@!#C TC4XS_ ;<#-!=D;'_O2O#
MA-_ %K_8ISL!293C=[DS,LL*A9*C=^$L-HN4?!/3KJD*RMB0":=K.6-*]NV!
MP>0WU\1")3^Y<(8J[G+;Z/A'8_5^\^[VY.*\>?V8.[^X/=D_Y*X/CYK7!R?G
M1USKXOH!_MPYO;CXB?^^N6W>'IX=GM_>;"_L@V;/X* @9@UYIN427P80X)4E
M@"Z&8U+H^! <.M0"%0>>WKGB0!NQ0]W V$>"+NXHFD;<).Y:+.KMG0\^D 35
M,\W7$+HX_5@'F9DCKG5%ML>O2@:*%=GHT_DLU#5/YT3?N(-63^$_/3I*Z1I%
MS(!K=HC+O]AH5'9QPQ%[<\;4>#YRAD3GO#/1R5#3+@"RIX$*1S@0EN=VG)&C
M;<W"::(X[=E@OAN#S).A/Y-\LZ4UPV5D[CPTZG0S\K[1.CDR$D?JC3E[3'I@
M;C7U^D7#W[E+.CZ,7!K./G:&2-&9\&366A<43GA_&XX"+\4Z,U"),5F!##>V
M8>$[.)NM.G"8.JK>'4DG%\R&Q;*#4:B1)*:9F^Y)*AD8/^8Z@.EMB<-!S8#\
MLB3F&")8!O752?K A3A#1S:#-F\C'_N8[CSXJ0 +=^0AO#OX#=ADDBH&/T6P
MVY_E7/R7#&EJ@8$P#G[4LV21S&@*[@UH>Q"RAZ%FXLD%)?@%CE@'P 5W8I)!
M<\$?X_XZ@C'U.1VS:W^HZ?:P)!G8B:!S9#(@?CSLZP*.8^)NZ#?*.,_YIFN3
M^<1&1Y?;$B$<C4R^EM^0^=#YZK *(QY=(C-QZ>S=? P:S*#=-TUYD[@751M1
M4K)4^K<N&R]&/F<A'N*08&<:,ST<8KFFLTWC)CH"P24<^]PQT4GK4*)G-!J9
MXMOI(UJQ,^-X9C(T6")D05@7F53HP_I\SKL(\;![5P&4A!\24M0Y&:>0.ZS.
MD'R@>, AU"J2;@^X,B"MQ.9"$Z80#2<RTAUVI.:01=%=@^*FXV!R,MB=+<%8
M'-DBO2CR)+ZPTQ?4GK3+74R!R!UC#=;*>!H:(J(026\25 \[I,R#Q/K?!%W6
M+&1/@D%4N$?- DN7+-L!5.E:BC.E"Z>3>2?GY1D#)Y/!T!?OZI$XIQ30P+EL
MHJ ZB5D@U;B378ZHI,7F-^X:?]JB/[6) 3?O^SU[@*M]RUR'S;DZK$.+5#C:
MTO8GF=^'GXPE($P)9P9P!U*']=TOYM'+6=Z%]XYG"@,I(,,' HA 357&.$22
MO5=$&0O4(L&_8:]YN+B.-,1QE/9P>QT,05FGV*H((S+[6]0(OA 7*1EB"\*;
M269 /#HS'6[3&I+EA=B]YM"' ]1K!Y  ENZV<2X[%4W ^IT,62I<$*L[LMZQ
M!N@/ZDC+FH6Y*4IDQ@K^A=X#]8T.6<UM]?:/FS0*3'RHD5F,($)$,J-1(Z[4
MHUMNSYZCF^=.U$X>N)/04S781H<[$$SZZ6Z>Y+5@*P&VD!.J)52(2^W#$8!$
M55G KXJ-*NC3P;5RN!:3$2(94>TNR2C?M^:!!.P"^0Y\YW P'CA8L5'CZ3!?
MSUKH]<4E#@Y.N$O?:&"#G@*7.<.^T+DB6:,.6[Q0.7<H20T_;93S,4L,)!W?
M]_^W]Z7-;2-)VM_Q*Q#>[@UIAZ(('CK:/1TARW:W>WR-98_GG2\=(%$DT08!
M-@[)G%__YE%5*)"@1$DD14C8F)VQ2**05965E<>3F01P?!-2R\J46U7"0I[+
M%L7RMT@@?/I]E@K0.2^:9TV39LND^<._WUP4QY-C 'V_9R (G6.4V_C?2W]:
MMA8+&US5Z'"ESR#*PDOL9"JNMBX&<Z=HE5;LJ[#PW-^YZ[=]VZ[?T;*NW]:]
MNG[;]^SZ/<PD/@=L.S^TN$$YA1) L>/G4;B$DO*\1S@JX,9(1,?R%^5/2GN:
MKHI\PF@-N5-:<H0W8LH]9R7 7J#O@0WV<$R6"WD \%^Q_0VF2@W<R4OC<TC*
MM<&"]DV-&$TQ$&89V/'T"#Q)T1(R_M[_@_] 60BC]S$]GMI=A^JK!MF1DPB(
M)?LM%II&^B%:ES@C)$P^@I][/EDV/IDZ44AVVP2L7UOM%'D5V$J&D>0>% RQ
M$$'N\M=6.IO2K27G3J]!L\6/,[SHANS<(8*E4<0P(<:;JM?@]WIA/.&FXZ:Y
M4XER<Y@SY(=)2V:@$SGJL@D:HF#3PI8FI@'TXOC@MT[#_NW5IW;#/G_9Z=#V
M?7SY%FY%=/,(L)F0H8!7)W3$T281I"U3V(N'YDV7>KQ4\=7.:F:W.(8JSQR9
MIM+C0H?J3AQ*=JC>5+!O(I@@&H:*4X@#M#<$]A#]AK%%EN7G ]H7/O/,UFBC
ML&&/?R/(S0Z0IP>S%"T-M%\"PFTEL]"+J87Z^:>+?2)X**Y@JT.1Q;Q@4B"!
M\:+B#!](=@@EQRRP9X!GLM%(),H=0A:+3XP5L!DC'5?F_#TQ15,.Q-GY2^=(
M,B_\],W; Z>'S GJE[0,D0GU6J"+#LY>&L!2#9$'C16S/LNC5=](J]Y(Z&P=
M+?"N8D[6"W'KR"'(3I28G X1TOT-3NG2ZX9X 4]W&@OD<#M&?0XW<]F);%CF
M>>3+QN1[[,8LKPS/3RC0+!VJFF!@NP38$D.R_#S8YCA/=#"1=4WNXSA"FT&0
M*XOIQ1E>HB=R))50*X2E].)L9.^]>?]R'[TTWBP7RCZ*RA26&,B"Y0ZQD3NA
M)7,!6EA1\@U/R8'$DJYI7ZC?T5L&".! YP!+1%AS%(N6ZUVB^/48)4-7$9T\
M6U[C>-60>R2.LM$X7RT.N_>E)9+P1D[=. 5*N;\]JAF^2*Z38>SQ0)\&N<%E
M; )$+UQZ4UBW2W3NDS\3.0&&;4@O&VDN8&'U023!FN62"7<$E@[>WO=9W6?*
MI/,542SH$XF&!^@!D_>TOS%'QJ,ZT2"9+6 -VOVK*.;<#> [/(U"+KO!$_G9
M?H?^1V"I<[[HSPD_84NT\)?0)_QG.L.3^\X'5D\B$/GL5G3Q^(QB=P)7#(GY
MEW'3^AT$<RQF\&-4?1KVQS@::A/]G?#\ 5P*.9:9;#]_ M8U7@&1?C/3T<0A
M]5!78]!_@B2R$S _4#?B4-,YL+C4/RY$B#AB>@V<8C5H R4#PKL'T2B$1?/L
M;T!A-(4%@Z6 ^]"CVH+TXB&B*XQ+ARCE>PGT=1)RDG8_-E7)_/31H2)?H/@.
M6DH"2VC%G-<J3W&IM"4?.;"]U%E)T_38;>H&)((#=/RA$$%M5L0IN1%SB:/$
M4VT5/X157"#[&I26\]S^,"6Q_!,.?R$([)8CMVKHUOVA6^T:NE4?SX7K407R
MI8Z:*UWVU)\*1'&1 IE-@$2Z)+0UB\<(M*3HZJ=[3[^,X4V^:F$%G[G3S,=L
M-S?R6JHWWH3;GXSL)![@,/'$:1W\A="[YI_3T3-0%-*_/WMV>'__Y [LV/:R
MB7RRRN&[9L\/USR%7S^_..CT>JTZ>/8PQ*OUMZZDXCSTXR0M*J,+HI%L-@0\
M*->UZ8O&@9(LF7)8/HG8ZK\2$AY!7FST#L++!NAR@WD(M$D.E(X;A1:]/N'W
M-VU%(ROLJ>F:EKY447!-[Y,M&_ODP!S:Z148!Z#8!.)@,'9!?B/,@L3W,':Y
M6)N])]$-R>#UI:I-8^$HD1H$9+Y^+A8C!?BB3"KA7K(!$*!&;]-;V!$,NO\!
M>;-(D>>_R!N9^OW(4U@<%]1TCP!=E#2!3Y)Q@4:#E:29A]^0#TT/>$ _.,B'
M-'<,YDB?,;@.;(Y 9-_$Q'?1@\*V>5QT\K(KE?UIZ,@89+#-DQELJO2CJ1'(
M87WV[BT;:_0+;Y: O4(Q4.4_I%^]>WG!KIB%><_TRN/+]/9R98'8OU1U!<@4
M=4Y[]CB;N&2C6?E8N%4%5P4Y),@) 1PIMT:]\( ]*E'X9T:9IB,Q2;/_PJA]
M+$LBO2RYEUHB,O$]M9]A)<_A%%%)P"CHDPN!8\A#I=R$:,MK60'GU\!,H;&J
M& "->7\P1L33%8H.()>"%&%*J"?TR7FP)W:G\S>[C^$,F&T<7=E]Y#[@<9!!
M"2(B8=,Z/S;L(Z=YC/_3:1[!__1:/R*S?63WO=VS]]H]&Y;[Q'D^.OPV.O3<
MV7Y#?WUL[P%#+OWZU-X#2V3Q>XHR\&\LQX$?E0T"4Y\R'C"8->TSSJ@>DY\?
MF<X/.236R ]&[FT@IV&8*A^>1UYW6!7TB7FP2NPZNR2\*# Y'$58[H&%*&-"
MA_KH-IA2X10X-1/E<1N[P?  W>L@09W#]C[2T6XR *'=[+7M,4CK9)[TSQ1,
MP%,+ V$^EWW^Z<((_- 9'L\0SL6Q#)DR/!\<DQ&+:33- J8'$901>F-[LC3@
MXD+6YW*%W%_8+C]E5ZV^"ZX_D(VB.(X%B/8!._)<CAVR2\L.D?3\R@;M8"+0
M4Q^Z840BWKB0Y*!'<,0MT@82A9R5\C;A^PJ&B07Y%[S#6 QC B'.\+HA3AS#
M[7I 2$:Z6L[(8:=@EA@X%>D5UCDHG!OU9E0>6!X9>!R+@IE,N+Z;C' S7..I
M<#V.Z>*%\UQ&RG6TBT"<L4_OEW*+[E<\C#)<+",6 W*7FII-KJ:8=)#6$2ID
M.,?-0,O)&/SNL<V)^P'3)='!5S?L?1S1O8?+U1<N.?5=.I?2V:^78F^:Q=,
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M4I1/L%U7K-.B/=/6&$T+5#)# <J"K!R5_)6Y$RQH1&\8N#'H ;#C>JW9#=Q
MFXM+)?)S#1LOQ"35?T849@SUWZ/ CR@;),)B@)21E84C^;6U5W3*[R^QRFAS
M=?F4)>8+:^*T+/:O[SYBQ9<,Z^MF7$O%!?L+]L.6L0LRMKAND06&#R.ST<A
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MB@U+JG:C<W1:MM</)#G;C?9IZ<EY('J.VSM$3.=F.M; RTLNDU+L9*ENR6&
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MR8M:.'RK%H?*$8K2Q2&Q-4"-EW\LXDE"*@H!UB]I.7A42TKE:P9KF"\';7C
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M*;U;UR"=ZAM$Z.M'EL^5GQMU4R.^65A,LEB4E<CGQ[7ZD1M3?IP':CJ5DVW
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MO-$_\1.SEQGWC24>P: 6<4?>>2A"KREIEM0S+,AIH'X_B8S08!^F 6\G#=#
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M,2J]F(,U!"L)WH%-C#/=9#O_"=V=Z!6AWMQ"?$NXOG.  ?T(GE(6H,4>! :
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M7HK+* !ND,U$F#)\'A56O==\:UG7<]<<.Z'+%GWFTUB [@2J<LY I#EE_80
M%&F0K]%%AGN92-U#O9W6"?60*>AS, %+J2E(/O[T/P<?0L$GQ;A?@;P8%(^<
M.OJ0U@+^T*N3'P;U$2[S-Y4U51S%O'4MOU276L::R9B@5WW"?/D)Z[8P'DX"
M)IC/@7:9M#>F&=@!'?ZDPU 0COQWJ',$_H#2MMA^2?3Y9@J(,37O]ZZQB!1O
M4DH7V!:T&G#P,4AD&XO=T&?&59H68W+GY08&#.0D#8(6ED0*+! \M"7&-NK
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MOT&8N\O9/2_=U+5?^X&P]["NNH=IH)@#Y(<4X33EB2=UBOU:8#S>8U@=2I7
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MZ=T1FK)Y] B;9(?]R)L!3Q^.TTGPR_\'4$L#!!0    ( !F ;EL;0IO\G6\
M $F/   0    9F]R;3$P+7%?,# Q+FIP9\2\!5A5V[HW/I&4%.E.:5!*F@4B
M+2!(AR A)2"@I+A !!1I)*6[46DI4;J[0[J[8<5_LL\Y>\/^[M[WGN_\[_,M
MG[58XYECO..-WUMKS"ER%/D+N*$DIR@'H*"@ ";@/P Y <@ 6!@8F!CH6)B8
MF->O8V'C$N/AXN#@4MPD(B"FH:2CI:&DIJ9GYF&E9^1BHJ9F$V+GNL,K("!
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MGC+@Y)%3[(B(&95AE0+F6_[B9>N<9]!J#>A36^/][I\(1#T2()+"S7K7I\!
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MAF[X6@9F!28L97!6BE;+ J2YM@>4"['X!]OGT?^4L+A8[2OK.4^RZPDM!1+
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M# L).-9%A8AJMU&0%QSU,S[E7FKG'Q4$M'.VN.>^5;BQ2NT*_V3?UD8"7^;
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MPOYCSXE\3/=-JFR[\ U9B];'8".T4=8/_2$!ZES:O7Z[$SHK#V,:H3L@^X2
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M6A* 1=6#XHZOQ@P=X(-0?AUOCJ/^$/O]*94+5FA<F!1.!>TAR28BR,(O"57
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M!M0\?](K+\U#YTP;#S=#H)T5"">$KI_D@7[!<OX_QC+_O;$?[11/NFS.SSY
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MU&U:"5HQ#?0<,S1;I\/V5'ET,R5M69OEZC:66J?NNZ+L]TP843(%S5L34C;
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ML_<*#'!-M8I_U%%*^*8IO.F_&)%X[=W1A"/3LB;M='\QD5>;309<>=E;U##
MB]D#T'#%00I%5<WWP8*/_T0K^4.,.4VOR O(W$!](N?##A*5?PN^_#E!X%KR
MY8::<!O:^:59CMCVE]7@?T.\O#]8\P\ A;> 6_VNB#T,<'TP1O[@VQN!%O2W
M9</\H!K K,%<>,,@>\\>-KI=<C@Z5Q+8OL::FW%+#LI&>"% FF$ 1W?5HNL
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M @Y;_C)6YDQ9Z'A*[/J5K #&RIOAX4$<#%&X9C:6.WBCWV*DGJ\W?<!?WNF
M:F3X8I*A4GUX1?1>Y=4@H)D*D5<00M^/HK6%.SN74<MTL' :)D(1@.N-]<!!
MZZ4N.KJV"38&:@!_P-KE/F/+WWR)!/@,*C WDJ66&[Q-0#'T*@98HZNRP&J2
M$O?$,;>%\,$F _1ITDR6!.+=\U9 !K%#=0DZ1V?Y"N805ZFB;BX7W"#12!+
M2W<9Z )4E>9'207A+MQ?4=0 P?-)\(#_H3;<1X7H)$%LY2$W56/_Y>!.1CJH
MG8,-;M9U<;A!J: BH1YPGRKZT,GW>M2/(.%&OR>,=VWO =0E"0/,X<O#?:^Z
M PR@QP9A7+LL#89\>WS35,VX<BS/C'P\4CD&)6X9LE\I"+RG LX8'E7#%JP5
M<DQ^G>/MT"?(MZ'!Z9*D)*6&/^34WMU9;VASB)L8O=5(GF# 1Y,FB,%*ECZ9
M<S.AII2FVZUO8M)T$D*M_>3K"Z6Y.N.U+:]XB'FW?%[+0KEF6L)N-'<KUM,8
MNH!Y6_8Y/C@XIR8+)BO]NUL_T =TW/YD=/^U_CKH0]93Y;&OQ-WY3]VD??J^
MI;\)C@HNZG8]>1AF5[]]1"/WV5_NP<#<RU-/:GE(^>VEM5JV9?'L1C+J)=M&
M@36455).=<>4O/)<V?$$BB<4:>4KZY5-NPXUM'EBA5NF6=U#D<]0[$4?Q5M3
MT!,N!]SP<&AAC@TJKGY"P$12]G7,TLE5UHNP%R_ $#$(6DI;48.WH)B%0LBT
MX5ZT8>EX++<$%6J8I\PS>Q0QFO:PL\OFGF)C*T?GQ/3LF_5'%R-QP6=@^#J#
MMOY!7L6ES*PSOLJHRJ"Y8:N,#;P+/,+5+OME/<DT]J[$9%+TX<HS8A 2?;YX
MEZK ^;AS/1T>W&G:@T;0*L577QHO6>"#2N>A*VV0<W/@C\+$;W'7T$0:N>4%
MX=RD+<A^"7I91OZC8+G\?44GZT$I]PBPV>$%5MG! )Y:P3]+Y?;?XX)@XS=3
M0JT\)_'DTY4P0 .+Q,^2-M_W $/BL\A.DD',T#&ARJP1W>I*,$Y%<E[##S):
M0[=F/#I@@.!,J(SZP?\]>B07<MB[ST!SD;F3OAD(0];",D$OK(LK,APUA3)S
MS0UA ".=[\%OVD3R2=^G..0,0/F'Y<J+#S  L_9@.G3HS444^>E*GM)T4DES
MQ]4&2[M*U3\GGO:C4!#_/7+\C5H@) OEE!6XUZ4JJ*[H5;H!D (7:6A??*E^
MEJ2L\C ,5+*R?*P'057<[G<W&6^NK1C:LR8S0QHWF?>ZU40BV;04VNM9ACX^
M(<47L5)O\!KP(!%9I&U#QV32@%.*(,8O\+&0"X L?H!E6.'+8&W:BX P++.#
M^_"1ED9'J>QQ?1I+A5M ]C)W^3VJ[93D]0ULVQRC4K#VPCMXD;Q0R$]'7J:Z
MM*/TB+2ZZ@^&3+>ROT<T]#G'VFV0YL.!C[&J1<+)W!OH5&]?PGO!1Y$'X%T*
MB@ ,'1UC%\_D&$^3M_-'Q<>3S3 52]U\0[_@EQL_K*X>,O&$IC*J2[1)1"@K
MX]X[P<_;QC" F4CP'PU<*)6O^60P;QHPT%W\H*DO>KP1/NLY,[[*,#_5)$DY
MSMCNAWS>-@*9-4&Z@B\.1F34AY];D7T3E0^_@Z5OO@'/3!5&.Z#-]?#,-,=F
MY;LA7A3]B:44],ZF1 ?W,DIJ:D-9*2D>O8N>7Q(4/LV=V__TZB$, (0[O#D_
M>!#<D-=Q9"Q/A)]FVO\##MD_<0&$WF7S;5B#ZEWL?X\<F?4P07V7#:<+\) P
M:61EPF_L_@PQ^;],*A-X=<O^V"4, $_2/,F_WW[P8:'H' :(@EX"SQ2/79WT
MC]N=Q?W^A&]->%KW*X? A1=G%E 0/"]LP(;B>>CJ1'O8DPZD_$"7,MUP\H5
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MSBH/+T>,/SG5GQ'SQA_N4/SC@PV;^#]02P,$%     @ &8!N6Y._7^$&_@
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M&C_,)/WV3?0&.U7_JNM:NWTN&6=V:-7Q=:$,Y]P8@>/'9/V/D^FN(Y)F:G[
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M<#? HD]3+!7,9.]"C4C58)7,2@X6#;DBRM]<U5.?2SPX<S@YF2;+0=IY:]S
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MM7R7-B5W-^_U3U3:S^?3/&F]F[%"M9_FL@55M;J\/!2YHM35NV:)Z=YW:T(
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M;7A 745KK<YG-V)?X6$@ !(-NY8;8G*N=$<3C=W6YA8./2^BQ1=;T/)V]):
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M8EJE__Y$H3-N($V*@-N3_4C@?"@%5%1YS F?(74<6?S:8JSSP#!PFYT6\='
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MYOYAN0%=S7,_8.M-^O;F8?9LL]X-J>:&^C%5)Z-_G7?;)I$N[?#+:9-, 1^
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M:.@ZQO!Z*GLUB<!,Y/W=1N_ONN+#GZ0LB'>BL)$-?8$K>3.<\RVO.YXM4LM
MB/?9SP*I%&G2"Q+K@0W(YI$.(%"UZ]!^0)Q?PW?DB2?/-%G<LR6N?["H%"H/
MUAPB\4O-&_D+<_,&0K2V+)+SD*(HJ:,>H6"BB^,!VRW+ MX%&D,18<8# RS1
M\R+YB*]]*/2DP3[0=^E3P**%!,$F)TROTK%A>04W[K,S[QUM9M #$L4;6VSZ
M$W136(,LMN65!(X4!O>&"QET"N88/IVWDO^L_0)@R%!%N8W!>#^PJTBUVZD_
M?QIIX2)7^TL?4K%X6+S9RU(E;<P].+;#HFD:X[C^KC5?I\9D2^#88X"5&[D!
MY)T=:E.?35(7V&Y(H8BL/9WTG#G;@BX@\ =OB>P48\HPQ?(TA8N!X.. X$[,
M"N0/+(\*.6P_JM&8+4$(N+J;YC=6EXI$0G2)22A.=?DA#LVSM/'9VH*'CT\X
M=W5U.*4'3M_V*NA=KX*.5WO:L:,W&_K,%7I?9WY#6(JU^"0R0]W2G&[\7CXC
M /RC]N*&>W-?KK=IB'H>LT>6QP"C(C]Z7!XX2?A#YV;H]ER4C.^2UC3B"[-4
MD[(WA&,#BGV<<CM=/UCH_R?BL/V+3HU>_^E 2AK@,7WPXEW.[9@G250!@^:K
M+"YN546.LXFE!LLCT,4D#WK\YTO;T!X><RY4]FM*J%#YI(W)!TM<?*N)'SV7
MT%IE#^5+[HW&+DZ$5^E#/3>IO:028WAWO2FL[_6.;.X(CQ^M(57$RBKVS3E9
M/M>._H>9@N;+GS2:X$6X.=45^*]+(=L20FV U\,D\A\?Y2E3(B\YNXI3/,*@
MF')]K6*Z-&_SM'MMLS=^7#<&4?F24V<H)<3&?%1M'G0AML*0+<8O_]CVWKVN
M>?6$"13<ZMA=*$J(F@VO4]";_MLRS?+9<BC'2N!ROED 53)LQZ?G7GDU(+[1
M3H904!%Y9*I\X8BZ<2A"#S1@ ^E8U.KQ_+M4@8+'0;2/5"G%M9.>)U;F,38]
MSR4]NA),0N*8TPMI.E3O,*D*^2BLJH@.</(J#C6NGK&C"H^T2,#TN07CIW#@
M7/5W!E5(HOM2EN$^4D7Y)5^/5SI7K&&L&>6BLV+Y#[%,B9Q0L<*#@+]%G \8
MFR\_3'2OXO^_LFYRAP[PD@H L;)P9IC5)WUK&>$ L*] 2DB_,K<0?@N<6O"&
M8%YT+UN$;KL-77\P.AWSBE=@AQ",2WT7)>=]DI[9_'<I+>N'"[J.]4D_A1.,
MV/MO#K$$Q)ZV_%8.8)OAK3"(O(UJ'BLH>3?U <WW<!T9Q"+6UH0A4?-5,;O
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MYE@I-9IDFL;/I$/^:W^97@!#(O^?__4Y-1![TGH!)/A[O@#TC%\ DWT^+P"
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M51'JC:8.+351FSF+89PI@,!Q-\IA?L<QCKO_X0$Y/>=-!8"'WW&1_]Q_>8$
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M;9*(ZWY<.'@#X*8N&GY84;YD"AYC0@H] ?H4PL*/(.=RG?6J!#KQMP8N2AC
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M-G#K28ID.W<,73_> &&L_6(2M6S>1&\ #6%UPIX<?)U1# 05B++<I2R/X7*
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MVZKLY-KL(B8B](YU)ZG?L4F"Y7?16O6@),/):LPK-_CY:PFHS;\KKM2_8-'
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M5GV@Q8.C-0$E#(UO .ISC#< >*?[487= 2RRA8)(TAVQRW*"<V3)2I)J]IK
M^4F((=4_P+%1IXC@Z(=!Y7+2N=N7V)@6^"(K,A<;] /K:@XL F,D2AM%N>W&
M'T#?R[9:MB?)3RJC[Z7)]J/5M_GCE90E;>D:0N\2%4E#?\'$/49&QLA,T(/$
M?\*5;N7BV[SBS*G=/LOUR2,Z%RFF6@X%_N!-??TX;54_=X99B,X:P..0]$?+
M86G8P>L1+%3^\"K"WZ86R6YRF>.9Y.N>)5+(\J'0B07.;,KGX@V 9\-N6K4,
M)7+(0Q]$;<KX\Y#'ST-R)M*M</-1QY8H+.]\HL)>;[$I@S^695(5K$AQ19C@
MINMGY,=?PPE%P%NOO[/HF5QYW&JK7M@5QX=E'IYT,23Q!^E'H>F-%2&?$0$"
MSL@C&6OQRS82*(Q!PDHO0]TEADN*CAY_NP^FFD?IM@4I^T.(;GO$CF,^E#'3
M*SRR.]H_GMA@@HR ^3,&-T.M[OMK@_;VF%3QS&HV.WUUXB>U *M8$\Q2/N7]
MH?>DF<@$??)TZ3RN)'7GX6JX=@:)5P2)WJ)8N\%6ND9?MY18>]O2HO9G&^[=
M=B[H!Z [OBV[7LL)XV.7?T@C]]H2[I6T@.GV)XQI9@,H?RGTFF;2]A-^)5[N
MEQ8;B*-,3T4#([M&UQTG3Z&3$TM#IYT\\3>=2 KL;6E01<_#0!K&B>F+>W'2
MU7L]Z->%QC%#?D4T%[3"\Y02P_7>$/[D']RNC]HESWP=TXX=$KQKE+.3F80Y
MGZ<)V*\V7+.NAEAK6IK#SU"H<GA3B?$J"F-#Q)!_-[SPCRDVZ.NC69]N$-,(
M@A'XJNR^L/:V#LVU+5A7.:R.Q)(9)4B-""+F(%5Y3]835+ENCXG)3@WPSQPZ
MGZR%G   $L(_#Y9OW@"HS1<,PX-W'JF!L)BUJ@Y;_5,Y?,^/PTCLS[19"3Z7
MZ6?5N ,$7S-?Z'\R@%/<V)C8P7?F(??#!CY;]<6$;> SD0/)H]FNEX0BFA2&
M*/.HA9EP:>:_$G'R1IJP*]4+O\>#YO;+^& RE=T&/:\FZ4F\&G UZP*(6&9P
M^9<R!\>X'E-!4=#_*,;Q\FI,$'DB%BJV<1^ < ;@L@;;0/<-T#?!21%3K.+L
M8!(-JE*0FD@#<CW(!6BJ:E@\7H)J9QW8GWTWD,T[FS[VED%^9M YMB\HSQTF
M_@A(F3S.6.]+P%Z1$:_];9V6-/ Q@2[W(T4Z.;"V^ER^9>[LNMV[H94FJ?<'
M,@F9'420U!D:#;A@S18?EEQPCV2_42%?@^@;$,QSVCF,#MLIQ(:?T\*%R)TF
M*-R1OH\[8<\@SO"*55#3$N)H(?KFF[S8\J*_>3-Q>EM@YP?T+SV$%*9UUT?A
MA\5JL.*9C3H@O&\7T;>N/*5N#/;H1V6S[HI^_PZ@4]":0'*4T1677[SWBSU\
M>4MW)XVNG#>ZF^6:[NS,ZZY:7?MBK;'$-J-HC+XH-5%LM8,_7%14"5UA2]9N
M)T1^&R&$"6&ZT9LQ0:[#%T3?E?W-C+S^ V)5/%[R,%_/,TFV"8S^^<XZ-9B/
M-2T%#>//1HBLCTF@PG3=1<.C0+A[YHO[9/%+B@>5]_6]K(66A@G4-3CN7O2V
M$BO<HVK+^+O/.$%2$26$$*Q/87T7A@G41#3?>)S3:NOJL\I;NJ^1G*]Z/E;2
MF]E>T690+960#M6\6?\P#,I?4RE:T3,\PA[00T8L5Q28)LLUT/ZY>L][SSVT
MM;@]L$8*&BFP^:8DU8-"&@NHG!H6NUBL??YOQ;UE5!S1MBY:>(*[.XV[6T.
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MXJ[_C3_&1XZ9T) BHT4(QNFL66WU$*"7!1#T(P?0G"D1G'7U\ ]A141F:NW
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M)YXC-*I.-&?U2<M494.9VZL4C//CZ24:L <+R+%_X-(D=)3 M7LA^Q<1=K_
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M\>8+/>NNQT9ZIU[7VG^OE/>_+UW+^E+#/4.5OES/WK>!SHX2&=V+K"BL,89
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MHJ!AX&-BH*-CD.#B8>-3D%)14I"2DU/3L3-2T[#2DI,SO7[)^HJ3AX>'BE%
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MPEST^ _O'H&NS%AI?.V)+!Y\-6G@W\'TYK-:@L)X05.$A\*KDEXG%9(*]+;
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M:W('X.,/ ZJ;Y]F8J:O"$FL9ZL<[!E,\NU-&5<4+#DZ$V]Q8 S1F<U9Q*C+
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M'0W]-0;&:TXJ4BK._\_;<P\ &QDP"2L.!T,-@,6&@<.&>1X 4   , @P?VV
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M23Q$ &U+P,0R>6FG[\1TU&4@@AODWYH*T5?F#6J4!QY@&;6P\C?P0$?LUS,
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MZR$,T8_RY<;0B-ZNU[,X,S+LOVL.1I(.5"'+.K5&0Q^ &71#>[%?K>>B(,\
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MB@ HHHH **** "BBB@ HHHH *9-*L,$DK_=12Q^@&:?3)8UEB>-QE7!4CV-
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MK6:X2X$CROMVJR@=![&N;\)?#N[TN^L[2^\(:>6L@V=6%\2TAP=K+'G@^N:
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M)NV=>V= <(E%L<Z>^9$1RM0C^4R%<YE&R^NUHDAN*.&I6E@B]1[?(-_=$K3
M>LT]#FN2X>[;]P0NZ2_#(1A^?$F"\S$.<I03"(QML"VS^,8G&=7,^7Q/@"ED
M"UGLDAYM^[:RO&]8K@9LC3G3-T-H]E+?( B:]AY.,]OO32T+FK G;W-]B@S#
M)&">W8D)-<&707AS-XV^K^/\ MJ;3WC^*Z6B3Q:1FH:4IGCI1K:IX'M.^NA3
M"1;2X(KR#YQ,8JHDQ_.O8^RN'&1\U,N#9V:0"8WJZX+(@^!Q7GZ$4CH3>U]
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MY8](WO\^2_S_01">YO\74$L#!!0    ( !F ;EON1>&UW2T  #PP   0
M9F]R;3$P+7%?,# V+FIP9YUZ!5A<3;/F&=P)%EP")+CKH ,$=_?@[NX,\@'!
M P0($"0X(1!<@R4P@T-PAZ#!'4(&6?++_>_NO;O[[_9,/<^9/GVJZZVJ4_-V
M/_TP][ &/%&24Y0#0" 08/[X 1X6 1D  PT-'0T5 QT='1,3 PN'&!<'&QN'
MG) (GYB:@I:&FH**BHZ1DXF.GIV!BHI9B(6=FX>?GY^6"2PNS"O&R<?/^T<)
M" ,3$P<;APP7EXSW&=4SWO_G]M -$&  "4@09! ]@$0 0B8 /?0"M   0@7]
MK0'_:" D9!14-'0,3"SLQP&-3P D$#(R$@HR*BH*RN/=D,?[  H!*N$S'BDT
M(DT+='H/8M[PE \8#-*U/21:WT\8^2P](S"QGI*2D5,\?\'$S,+*+R H) P6
MD7DI*R>OH*BDK:.KIV]@:&1E;6-K9^_@Z.7MX^OG'Q 8^5=4=,SKV+C4M+?I
M&9GOLK(+BXI+2LO**S[6U3<T-C6WM+9]_=;;!X/W#PQ.3$Y-S\S.S2_\6-_8
MW-K>^;F[=WIV?G%Y=?WKYO<?7"  &?3/]M_B(GC$A82"@HR"_@<7",GOSP "
M%-1G/&B$4IKH%AY$]+SA&,32*1]J>S 9^+1.2"P]OV,]9>3_\?ST#[2_(?OW
M@$7\?R'[#V#_PK4 X""#'H.'3 !( M?G!@[KQG*G,C_9J#H]X>VC\*.A-2(R
MR14L&:N)IC$UMC@S$&NQOE/YR%UU9I>KT/.<(=ZG-S&9[\W+ABX*\!8*@BK]
M5YW&"&OVR+OY,X:$8T@Y*)73TBC23>R2,,5K7^F?VGZ3;YYJV)]W.>Q<]*R3
M95!':N,UQ^W-,,ORAS-5K(>).QAPHRK07=#G&DI0/4G&V;4D3?GQ-,79@=2)
M9(%;X<#)* R+N?#_6\2N>W^/MJ._;L0.$5'>(*F*4(MU05'[,.!JO2(%'Q0)
MFK4K?@6UM[_2S[-VM0MGY*#Q384PD>^0Z#T WT0D*GU=/SLS9%M&"'HJ+!45
M"(LEJ1MUX"8V-D2M15D])Y%X!>C^!'[R0)[^_/2BKKTE+^BU .9XK&%PIJ55
M]V]/263Y[!DXZ>F*M.3.)R_^E/Q>3TD""&6#+H9Y<TN"(N[4Q+.? V"&F\GL
M7E1&94\%*GSA<PBI?;4T=>B\]1NSO@#+6+9OG<H%\S8P"):BN*Q*L$Q!@)SZ
M(3A=#HU\B=!3'KCLT<Y7H0#V[#_%ZI%.XDXW3ATEA&_XO'LC]=-QKE8:=%XM
M>;Q;@/U65[V&Z?:JY0'H&I&?([H/,H&N;A=@>__ONB5KN/[>#:OL*"?]_I*I
M9:Y_6#X[,$$#K81$^P#S 1!_5'RN>87R .3-TE[?E",M_Z=^K9!PZ$XC_.Z>
M'^095_&O00@DZ)A3,N)V"N0:-]S0>*ZG=;Y$6->6O)(7=JHGT9U_OK!Q_P (
M ,:%'T/")?^FP?'?Z:[G<@G.D4]A:L'!.M_.UV"%_QL0_Z_(LXAMJ96'")7Z
M+3AB/)<V \=1?_])J;/56#]\'Z@;#I]*] 18TGO&2<Q385 P%?,G>-,3-S ]
M0+TO7EC/2?1U'@QS2YZK#25@AZT9($SL1CF?6P\3%>8X7NW6D"+9K'6DG=]#
MV?N0[R_5C][I%->6!GO]6W2AJ81C]LJ2;;$M/7ED8;'8;Q0;N7E+X&<>+2$^
MWFZA5JF4$\UZ$;*HG$?WO6X%A,;EQXB;R<3%+[72YZG85=*B_I(-Q2R>,J@X
M$#B=X$&0?O$LUP;]_:LDXJ%FA-JJ;W\D?J?$Z3W!L:DL0*SY[XA"H 9(UL;X
M 7!^_"YAA]O=Y30&I^9\&5D^7VBYLZ0EDJEP/)_GV.JK&KG\H@PPDKT-L!M)
MOLO_0A;*OU"3)DX1M\GO=/SDE;(?];I*V"(?X<R]69K@.M*S>YX$JO/+[9H?
M7:=O*5[RHK6Z5Q%S;2^$GLH--^1B,OD-3;P94R[\,GJL?YH[]EMD8>GK&$@1
MQ[?7Q8K ?,\#/@)G^DQ6J;G\JV?MW"HC)-R6.=4@;*16V]9KU"3CMAQYO/RS
M6/.,F).7]^F H\OUX,>Y)G8ZK35K0L MDZFB2AU/M6J@VO0!<&P<4*^/2N 7
M9;"L$\F@CB19\#B&4(<0:T+(OX\VS31/MCRG3Y5W]NDF_[0/?3I7F^AFF3VP
ME<@8:V.Z8MFLVNZ5!F=H-#%TH1%==-B&,*9,OVW"P^C3;/KNK1Q@D5)M%/!L
M@2&@;$E7YPEQ4# LC/ ( 4FX*S;CJ*_#%%MTCF:5DWD"0C'WH6\@=)'&F#ZE
MOD!!(I=0Y-E/BKFH#CW^NF#<LS7OZ.9\D*>M8+WTE9V@-@0-U_MD:5X*Q;UJ
MV,9*HXA=!!0'#!MSX&ODZFZPN+]PN*U09H@1'NC9OY978S5.QG;0EPH>\FK%
M9/[1SZK\5%AB*^>\,I/0(5/S(/=P\U7/:^'?@;J2OR[!M=-$=K>G+2[[OX16
M:*L D_8(41?JM5A?.)6%3B!(?_8HN<1K-O# S#J5LN',VJ+1D'(X,0GZ1224
M3N^KF1$)66O,Y'$<T&@"J^?\F+W$YNCJZQ(_:##+T[H2/+)#9>$1]U-BWN4!
MD"2 KDJG'39UG9^3WETQ(V=U=)Y2EQSN&TMS/G-H@B03B*)GE/E*;;J.T5;Y
M<,<^)2:L<1!,'$8#B?\Z5$'X?+Z][7L 0N+4FXV@8\.2UW,%V )*ZC=8/0^
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MZ/"K(&N'Y/"96G8Q>;?0X%:T"7CK>N.F1S,0F?<6A!(G)8;;V+'6APWU"7\
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MM.HKR/I*/M"A1/X4U0*3P< DSQX X?)B<"6/0-7B'1ZG9$RV%<"+OJ_:Z+Q
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ML^W76==V[)(QY%4++,(?EM^O-?=5G+F5F!B_X>WIBE_Y].Y8;V<KCXG6GC:
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M!V3S'7,2NI(Z [!R68W<[KG#9HMM="IPUA 9H)7+=9ALJ3L M]Q;)T$T(30
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M8I=53$S\+Q%&K8 ?357L@G>\)SY518&B&H-A]2RVK0XS)*Z#"0_CSGM':3N
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M,?G:&B;+V<4F1F\A,UF'9XIU'I/D:9T=79H0V<KTG FHWVJVV $T7 'DQT]
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MJ"K_H$=GP&F1_+HET-EXU$1E +T. Y 37ZX8G6Q"2FJA,N$D5FR5 CK8AXS
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MD*]S 8R,CQ$J@\G(Q5L]E(/F->8G\4(G@DU-9T>:S@%%A@(6X1U<E#ZU/><
M-/T[BA,_G NINK'M[%AOO%54UPSFX3E*GP>P347)'ON*QVGRB"/_Q_8F%C/I
MIMII=OQ94RZIFBLR7-$@#$U(EKIQHDF4'>!XZRNWF1!"2$*=]PA1MHC@5*CO
M1G(Y=B8^/-G];,=31#IPHC4#2OEQ*M9_OZ!M-UJUI6=D/ ,U+?)?7^#H#D5+
MWT6\2B"B9&P'O(6PJD/8@+OZ!Z)>'O+&2Q0Y<_K28KK(7T*E=0^V*PJOG( T
M'6LA[2"M'1&6ZY3J;_*PO7)TY@0!\DY7:U^_:"@;/1,G;*UQJ!0?LI:/9E6.
M(6:_)/JZ"9P\ 9>UN(OTMQU[&2DAB$]T07R-0[]X-YF^\AG&A'7BJI 5ZPS'
M#&C9_6R'5$0Z",I/BG,OJ&=XZL3(H[(05IQ<@9OKI*>K;9,;9Y7=Q7YV(GKI
M=/*473+]\D*6)3^FAP3YE 1E:O3P*6LMH5^%0,;S69N33^7('!J&![]I8RVJ
M@"1@A,2L,Y;"F-:.9]6+.))TSWCD;$>Y@]"@06B+F?7XZI;E,(O)!R*J+W26
M+QCKY,.UZT@]#,9&B]7+=B3YLH$H:HN.-45M\PB/7!P[[V,]@AS)0/S4)FIV
MQ*\T@<B!6.JXCTC6Q /AU!;@NG,V#T5LPB\E*[P,2]5W&)ZN!!7;@9:7%42]
M;: *V/J.Y_,(S8E\I;,28.O:U-1:8-@"@=IO&T.",HAVO.=-%:KO3_Q*P_R>
M5F,C+!\(5=L8D<KI\0P3F0D[64SC%KF(*,";2,^/?#+68MU>6!!X;?$=;47@
M+0>_E;A@EH:V<-(NER7V\W_25%E.\$^4@OV R\@)(FU(;M6YOR3S5>C=TJ,H
MUKK=*'US[_U"F"4CB*Z^ C=M3R2*XXBO^0,U89Z.\C4BZN+$^]5^S';;Z4TE
MH*GI2_NB<MSS1;T'1*7IXLC;W5)R;$WQU_;"V'K1"6AMVL)PYRC+ER#ZN0@P
MCCC.2%-KV]&&90+1:AME W;\5SX]IIX\7/E_I;Y'Y3EW%F0QW"Z+YRAV(_\)
MV!Q2(E(TK(6LI:0@D(H#9[6['J7 K< [42*=K89.1D00,VTI6T!N<2[)-7K.
M_B2?B%WI;RW +:0$,=87IV/DC[>'>+?[GB+<)"0(<-MX'/2:R.X]CR(P##DS
MV?L;< ]K\1&2"X)$7QW%=?;!!8YNT5/!<;L8J20E:Y'N)"]H =IB9^M84$P$
MHL[=64I89B6X QULQY,I%@A;*2@V](.9[B/RTF";SC=VR3XJ>S<S>]5RPW3I
MG<RCVCN9!9$1?A@59$9K.IOW,7\NR:A>CI)?6DIJ*W;S(H]_'E>%RBGF;X"N
MI8I'Q-,=%53->?FS=6BM9LT*(YDEVIH<P8UI<V6((2$X3X<J_(32*:_+NZ+J
MC*GJ=*K&HSGIW*!G2/>DIKYZX#H7W-?FYQP*[IMS,G\HN#]TP?UAJH);4,T8
M9!R<L'3/6+;7<^Q[$6I1[-&L$IV'8H^&KD^'8H]R4-I5[-&*^H,@Z^!RI?C=
MD.Z5'O4^0]&MT"/KQ0E](=L]>VQZL%VJW$O4VI+0#B]1&^H6'%ZB%@1O4$>@
M^X.D=KY'RGJ.]+V^36N7U[Y-?H>7R32$@^K'=VGT(J7G:T+^&-#:_ =XF8R#
MGJ\^H[]+[V/?\YUH5;HWQW'&X"[[ZXCQU-3W6U8RD)9NB#L+\L_2?4?>PB_2
M5Y-[QD4 OB?/UH))?EJ_V!GMP2G'U]#W?ZN5)GF^1G/[F:;W%R6&5?4:'R@&
MA)'B!Q@E,,K7 _(!]DI8:;:WJU^C.@PJD]Q>ZJUDH4=,,Z0VS9UG>_F:GE6U
M&5G)2Y0=M&O4VFN]%9F\ONNRM$$#.I-%Z-^G\65([R3Y2[K:A<Q]+MQA^(<Z
MAQCN6%QT<+/\X? N\T#+O]BCS6KKW1\>;395G4:N+G8^VGQX5]@0EXY3_Z-T
MT?@R3"*?&*L+U37LFLK.^^3L6%/>1W_)^?VJ"K)'<S<8QE<#.EB@H)+ N="H
MO,#!'RC8-_OIH ;0_SL4D&I?+&G?[*L_+8&.L,T5I?8-?EA*XPZ=&V="H<+\
MO)[[!ZN8Q,:=LK >;H'A9?7:/VCYT@X319-*R1ZF/M6^02TC-P2Z:47)>GXD
M^F]B BSQ(4O05KJL<3'Z'OJ<-Y&8W?8/:0%Q(63UOA&I++@Q5*1I_VRG#_V
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MJ$<\R[X>7T_,7=+0,]<T<K(2I"4];$=VP0S]SSW1"OG-_P)02P,$%     @
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M<VGE%7Z2S8L&>C8I:&Q&EX9:)3!#FRG2(0^I'J+'(#C/HW+KFK#PA?C[9!4
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MWVTUMA!6W=:]'T$TM0B1/&$_=5"[Z=;=M/Q'[-$)2-+NO5]MM;H 4MWFG9]
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MCOK29.,EO69T>1#[QU0CE#UAD +G2-OY*BNJS3R6;T?)Z+U*LK;]OY^IS;'
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MZ$;FE;<A+EGKG'4>1Q%M?(TLP-INXR3#FGW'4=K.F349\I!O91ETD(J:4E#
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M:O1^A44%$;1AX_V#[<@3*<=W9I]VCV%$/K_"H6Q\%@G!JG %0OYN&^D1K2S
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MUA[UM0\NZ6NB9PMHP8>.4#$Z+VU"X Z\X_F<WT DY:T^?R%Q/H\SUEGJ/=!
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M9D\W7%UFZ_DC\;. 3!9CUB^?!EE*G\@^P\3E\SS(F$9<,3WGF_1L&]Q8WS9
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M33>49(#!!](8^W$$]R1FW[DIG.U2RE1ZNMV*Y]96Y2TUM#+VL0>JL ?78D;
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M2L@F3:.-??W.4 _&4;^'4Y/O.DP)(R<](UZ<!U<5/]XQS09SKVP#>Y'O41<
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M)^OFY*#G*%TGU[P_HVN>Q* U^Q+-'J,L82>/V1?VM<V,%2\M[-LI7'G5:-+
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M*H4<]36U0T4#'*M,D">B3L;5+.:H"YLE-IH V>3CDI\5]7P<%'/4Y\4.'P*
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MV64B5$.FU;70G3',:(9 T#/'\ANQ\B_\_SVP%8+]YO\#4$L! A0#%     @
M&8!N6^&[I^(Y"   3U,   H              ( !     &5X,S$M,2YH=&U0
M2P$"% ,4    "  9@&Y;R^"Z6A,(   040  "@              @ %A"
M97@S,2TR+FAT;5!+ 0(4 Q0    ( !F ;ELD$N1.200  (\;   *
M      "  9P0  !E>#,R+3$N:'1M4$L! A0#%     @ &8!N6_.%T6I-!
M+!H   H              ( !#14  &5X,S(M,BYH=&U02P$"% ,4    "  9
M@&Y;M^M=T'^& 0#TSA  #               @ &"&0  9F]R;3$P+7$N:'1M
M4$L! A0#%     @ &8!N6QM"F_R=;P  28\  !               ( !*Z !
M &9O<FTQ,"UQ7S P,2YJ<&=02P$"% ,4    "  9@&Y;D[]?X0;^  "Y" $
M$               @ 'V#P( 9F]R;3$P+7%?,# R+FIP9U!+ 0(4 Q0    (
M !F ;EL-C60?7S4  -4Z   0              "  2H. P!F;W)M,3 M<5\P
M,#,N:G!G4$L! A0#%     @ &8!N6Z+@? 8U2   $DL  !
M ( !MT,# &9O<FTQ,"UQ7S P-"YJ<&=02P$"% ,4    "  9@&Y;%'I )@$V
M   V.P  $               @ $:C , 9F]R;3$P+7%?,# U+FIP9U!+ 0(4
M Q0    ( !F ;EON1>&UW2T  #PP   0              "  4G" P!F;W)M
M,3 M<5\P,#8N:G!G4$L! A0#%     @ &8!N6\)O/58Z$   @L(  !$
M         ( !5/ # &=T8G M,C R-3 Y,S N>'-D4$L! A0#%     @ &8!N
M6X9"-9S0#   Y)@  !4              ( !O0 $ &=T8G M,C R-3 Y,S!?
M8V%L+GAM;%!+ 0(4 Q0    ( !F ;EO8"U3^@3,  &N3 P 5
M  "  < -! !G=&)P+3(P,C4P.3,P7V1E9BYX;6Q02P$"% ,4    "  9@&Y;
MLJ0\="5P  ##E08 %0              @ %T000 9W1B<"TR,#(U,#DS,%]L
M86(N>&UL4$L! A0#%     @ &8!N6T7I*:LL3@  "5(% !4
M ( !S+$$ &=T8G M,C R-3 Y,S!?<')E+GAM;%!+!08     $  0 -D#   K
%  4    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>form10-q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:GTBP="http://gtbiopharma.com/20250930"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="gtbp-20250930.xsd" xlink:type="simple"/>
    <context id="From2025-01-01to2025-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-11-06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <instant>2025-11-06</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_SeriesLPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SeriesLPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-07-012025-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_SellingGeneralAndAdministrativeExpensesMember_custom_OfficersEmployeesAndDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:OfficersEmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_us-gaap_SellingGeneralAndAdministrativeExpensesMember_custom_OfficersEmployeesAndDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:OfficersEmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_SellingGeneralAndAdministrativeExpensesMember_custom_OfficersEmployeesAndDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:OfficersEmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_us-gaap_SellingGeneralAndAdministrativeExpensesMember_custom_OfficersEmployeesAndDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">GTBP:OfficersEmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_PreferredStockMember_custom_SeriesLPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:MezzanineEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_SeriesLPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:MezzanineEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:MezzanineEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:MezzanineEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesLPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:MezzanineEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesLPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_PreferredStockMember_custom_SeriesLPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:MezzanineEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:MezzanineEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_SeriesLConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">GTBP:SeriesLConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_SeriesLConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">GTBP:SeriesLConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_CytovanceBiologicsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:CytovanceBiologicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_CytovanceBiologicsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:CytovanceBiologicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_UniversityOfMinnesotaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:UniversityOfMinnesotaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_UniversityOfMinnesotaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:UniversityOfMinnesotaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_LegalServicesFirmMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:LegalServicesFirmMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_LegalServicesFirmMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:LegalServicesFirmMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_OtherAccountsPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:OtherAccountsPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_OtherAccountsPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:OtherAccountsPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_CytovanceBiologicsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:CytovanceBiologicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_CytovanceBiologicsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:CytovanceBiologicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_CytovanceBiologicsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:CytovanceBiologicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-30_custom_CytovanceBiologicsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:CytovanceBiologicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="From2024-04-012024-04-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-04-30</endDate>
        </period>
    </context>
    <context id="From2024-06-012024-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_CytovanceBiologicsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:CytovanceBiologicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2025-03-012025-03-31_custom_CytovanceBiologicsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:CytovanceBiologicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-03-012025-03-31_custom_LegalServicesFirmMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:LegalServicesFirmMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-06-012025-06-30_custom_AdvisoryAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:AdvisoryAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_AdvisoryAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:AdvisoryAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-01-04_custom_TwoThousandTwentyThreeCommonWarrantsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:TwoThousandTwentyThreeCommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-04</instant>
        </period>
    </context>
    <context id="AsOf2023-01-04_custom_TwoThousandTwentyThreePlacementAgentsWarrantsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:TwoThousandTwentyThreePlacementAgentsWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-04</instant>
        </period>
    </context>
    <context id="From2023-01-042023-01-04_custom_TwoThousandTwentyThreeWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-04</startDate>
            <endDate>2023-01-04</endDate>
        </period>
    </context>
    <context id="AsOf2023-01-04_custom_TwoThousandTwentyThreeWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-04</instant>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_TwoThousandTwentyThreeWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_MeasurementInputSharePriceMember_custom_TwoThousandTwentyThreeWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_MeasurementInputSharePriceMember_custom_TwoThousandTwentyThreeWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_TwoThousandTwentyThreeWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_TwoThousandTwentyThreeWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_MeasurementInputPriceVolatilityMember_custom_TwoThousandTwentyThreeWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_TwoThousandTwentyThreeWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_MeasurementInputExpectedTermMember_custom_TwoThousandTwentyThreeWarrantsMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_MeasurementInputExpectedTermMember_custom_TwoThousandTwentyThreeWarrantsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_MeasurementInputExpectedTermMember_custom_TwoThousandTwentyThreeWarrantsMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_MeasurementInputExpectedTermMember_custom_TwoThousandTwentyThreeWarrantsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_MeasurementInputExpectedDividendRateMember_custom_TwoThousandTwentyThreeWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_MeasurementInputExpectedDividendRateMember_custom_TwoThousandTwentyThreeWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_TwoThousandTwentyThreeWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">GTBP:TwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-05-142025-05-14_custom_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-14</startDate>
            <endDate>2025-05-14</endDate>
        </period>
    </context>
    <context id="AsOf2025-05-14_custom_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-14</instant>
        </period>
    </context>
    <context id="From2025-02-262025-02-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <startDate>2025-02-26</startDate>
            <endDate>2025-02-26</endDate>
        </period>
    </context>
    <context id="AsOf2025-02-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <instant>2025-02-26</instant>
        </period>
    </context>
    <context id="AsOf2025-02-26_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-26</instant>
        </period>
    </context>
    <context id="AsOf2025-02-26_custom_InducementWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:InducementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-26</instant>
        </period>
    </context>
    <context id="AsOf2025-02-26_custom_SeriesAInducementWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:SeriesAInducementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-26</instant>
        </period>
    </context>
    <context id="AsOf2025-02-26_custom_SeriesBInducementWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:SeriesBInducementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-26</instant>
        </period>
    </context>
    <context id="From2025-05-122025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_SeriesLTenPercentConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLTenPercentConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-12</startDate>
            <endDate>2025-05-12</endDate>
        </period>
    </context>
    <context id="AsOf2025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_SeriesLTenPercentConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLTenPercentConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-12</instant>
        </period>
    </context>
    <context id="From2025-05-122025-05-12_custom_SeriesLPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-12</startDate>
            <endDate>2025-05-12</endDate>
        </period>
    </context>
    <context id="From2025-05-122025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_GreenshoeRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:GreenshoeRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-12</startDate>
            <endDate>2025-05-12</endDate>
        </period>
    </context>
    <context id="From2025-05-222025-05-22_custom_SeriesLTenPercentConvertiblePreferredStockMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLTenPercentConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-22</startDate>
            <endDate>2025-05-22</endDate>
        </period>
    </context>
    <context id="From2025-05-222025-05-22_custom_SeriesLTenPercentConvertiblePreferredStockMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLTenPercentConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-22</startDate>
            <endDate>2025-05-22</endDate>
        </period>
    </context>
    <context id="From2025-05-112025-05-11_custom_SecuritiesPurchaseAgreementMember_custom_SeriesLTenPercentConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLTenPercentConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-11</startDate>
            <endDate>2025-05-11</endDate>
        </period>
    </context>
    <context id="From2025-05-122025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_SeriesLTenPercentConvertiblePreferredStockMember_custom_CommonWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLTenPercentConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-12</startDate>
            <endDate>2025-05-12</endDate>
        </period>
    </context>
    <context id="AsOf2025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_CommonWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-12</instant>
        </period>
    </context>
    <context id="AsOf2025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_VestingWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:VestingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-12</instant>
        </period>
    </context>
    <context id="AsOf2025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_GreenshoeRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:GreenshoeRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-12</instant>
        </period>
    </context>
    <context id="From2025-05-122025-05-12_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-12</startDate>
            <endDate>2025-05-12</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_SeriesL10PercentageConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesL10PercentageConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-29_custom_SeriesL10PercentageConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesL10PercentageConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-29</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_SeriesL10PercentageConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesL10PercentageConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_SeriesLConvertiblePreferredStockMember16969765">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_SeriesLConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2025-05-012025-05-31_custom_SeriesLPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2025-05-31</endDate>
        </period>
    </context>
    <context id="From2025-05-012025-05-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2025-05-31</endDate>
        </period>
    </context>
    <context id="From2025-05-012025-05-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2025-05-31</endDate>
        </period>
    </context>
    <context id="From2025-05-012025-05-31_custom_MezzanineEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:MezzanineEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2025-05-31</endDate>
        </period>
    </context>
    <context id="From2025-05-012025-05-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2025-05-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-05-312025-05-31_custom_SeriesLPreferredStockMember_custom_CommonWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-31</startDate>
            <endDate>2025-05-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-05-31_custom_CommonWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:CommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-31</instant>
        </period>
    </context>
    <context id="AsOf2025-05-31_custom_VestingWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:VestingWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-31</instant>
        </period>
    </context>
    <context id="AsOf2025-05-31_custom_GreenshoeRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:GreenshoeRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-31</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_CommonWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">GTBP:CommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-05-31_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-31</instant>
        </period>
    </context>
    <context id="AsOf2025-05-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <instant>2025-05-31</instant>
        </period>
    </context>
    <context id="From2025-06-012025-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2025-05-012025-05-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2025-05-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-05-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-31</instant>
        </period>
    </context>
    <context id="From2025-06-012025-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <startDate>2025-06-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-05-31_custom_PrefundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">GTBP:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-31</instant>
        </period>
    </context>
    <context id="From2022-04-012022-04-30_custom_OmnibusIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">GTBP:OmnibusIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-04-30_custom_OmnibusIncentivePlanMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">GTBP:OmnibusIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_OmnibusIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">GTBP:OmnibusIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_RangeOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_RangeTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_RangeThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_RangeFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_RangeFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_RangeSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_RangeSevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeSevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_RangeEightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeEightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_RangeNineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeNineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_RangeTenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeTenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_RangeElevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeElevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeElevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeElevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_RangeTwelveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeTwelveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeTwelveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeTwelveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_RangeThirteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeThirteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeThirteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeThirteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_WarrantMember16970921">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_RangeOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_RangeOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_RangeTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_RangeTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_RangeThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_RangeThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_RangeFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_RangeFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_RangeFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_RangeFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">GTBP:RangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2025-02-172025-02-17_custom_ZOneLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">GTBP:ZOneLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-17</startDate>
            <endDate>2025-02-17</endDate>
        </period>
    </context>
    <context id="From2025-07-082025-07-08_custom_CobySilberfeinMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">GTBP:CobySilberfeinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-08</startDate>
            <endDate>2025-07-08</endDate>
        </period>
    </context>
    <context id="From2025-07-092025-07-09_custom_CobySilberfeinMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">GTBP:CobySilberfeinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-09</startDate>
            <endDate>2025-07-09</endDate>
        </period>
    </context>
    <context id="From2025-09-022025-09-02_custom_CobySilberfeinMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">GTBP:CobySilberfeinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-02</startDate>
            <endDate>2025-09-02</endDate>
        </period>
    </context>
    <context id="AsOf2022-08-24_custom_CytovanceBiologicsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">GTBP:CytovanceBiologicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-24</instant>
        </period>
    </context>
    <context id="AsOf2024-04-25_custom_CytovanceBiologicsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">GTBP:CytovanceBiologicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-25</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_CytovanceBiologicsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">GTBP:CytovanceBiologicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_CytovanceBiologicsIncMember_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:CytovanceBiologicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_CytovanceBiologicsIncMember_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">GTBP:CytovanceBiologicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-05-202024-05-20_custom_TwoThousandTwentyThreeSponsoredResearchAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandTwentyThreeSponsoredResearchAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-20</startDate>
            <endDate>2024-05-20</endDate>
        </period>
    </context>
    <context id="From2025-06-182025-06-18_custom_TwoThousandTwentyThreeSponsoredResearchAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandTwentyThreeSponsoredResearchAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-18</startDate>
            <endDate>2025-06-18</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_TwoThousandTwentyThreeSponsoredResearchAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandTwentyThreeSponsoredResearchAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_TwoThousandTwentyThreeSponsoredResearchAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandTwentyThreeSponsoredResearchAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_TwoThousandTwentyThreeSponsoredResearchAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandTwentyThreeSponsoredResearchAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-07-18</instant>
        </period>
    </context>
    <context id="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember_custom_TwoThousandSeventeenThroughTwoThousandTwentyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">GTBP:TwoThousandSeventeenThroughTwoThousandTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-18</startDate>
            <endDate>2016-07-18</endDate>
        </period>
    </context>
    <context id="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-18</startDate>
            <endDate>2016-07-18</endDate>
        </period>
    </context>
    <context id="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-18</startDate>
            <endDate>2016-07-18</endDate>
        </period>
    </context>
    <context id="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-18</startDate>
            <endDate>2016-07-18</endDate>
        </period>
    </context>
    <context id="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember_custom_TwoThousandTwentyTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">GTBP:TwoThousandTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-18</startDate>
            <endDate>2016-07-18</endDate>
        </period>
    </context>
    <context id="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember_custom_TwoThousandTwentyFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">GTBP:TwoThousandTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-18</startDate>
            <endDate>2016-07-18</endDate>
        </period>
    </context>
    <context id="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember_custom_TwoThousandTwentySevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">GTBP:TwoThousandTwentySevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-18</startDate>
            <endDate>2016-07-18</endDate>
        </period>
    </context>
    <context id="AsOf2024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-13</instant>
        </period>
    </context>
    <context id="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember_custom_TwoThousandTwentyFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">GTBP:TwoThousandTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-13</startDate>
            <endDate>2024-05-13</endDate>
        </period>
    </context>
    <context id="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-13</startDate>
            <endDate>2024-05-13</endDate>
        </period>
    </context>
    <context id="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-13</startDate>
            <endDate>2024-05-13</endDate>
        </period>
    </context>
    <context id="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-13</startDate>
            <endDate>2024-05-13</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_TwoThousandSixteenPatentLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_TwoThousandSixteenPatentLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandSixteenPatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2021-03-262021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandAndTwentyOnePatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-26</startDate>
            <endDate>2021-03-26</endDate>
        </period>
    </context>
    <context id="From2021-03-262021-03-26_srt_MinimumMember_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandAndTwentyOnePatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-26</startDate>
            <endDate>2021-03-26</endDate>
        </period>
    </context>
    <context id="From2021-03-262021-03-26_srt_MaximumMember_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandAndTwentyOnePatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-26</startDate>
            <endDate>2021-03-26</endDate>
        </period>
    </context>
    <context id="From2024-11-182024-11-18_custom_TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-18</startDate>
            <endDate>2024-11-18</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">GTBP:TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-11-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <instant>2024-11-21</instant>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_SegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">GTBP:SegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_custom_SegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">GTBP:SegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_SegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">GTBP:SegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_SegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">GTBP:SegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-10-012025-10-31_custom_SeriesL10PercentageConvertiblePreferredStockMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesL10PercentageConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-10-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-10-30_custom_SeriesL10PercentageConvertiblePreferredStockMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesL10PercentageConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-30</instant>
        </period>
    </context>
    <context id="AsOf2025-10-31_custom_SeriesL10PercentageConvertiblePreferredStockMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesL10PercentageConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="AsOf2025-10-31_custom_SeriesLConvertiblePreferredStockMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">GTBP:SeriesLConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Segment">
        <measure>GTBP:Segment</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2025-01-01to2025-09-30" id="Fact000003">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2025-01-01to2025-09-30" id="Fact000004">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="From2025-01-01to2025-09-30" id="Fact000005">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="From2025-01-01to2025-09-30" id="Fact000006">0000109657</dei:EntityCentralIndexKey>
    <us-gaap:DeferredOfferingCosts
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0054"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DividendsPayableCurrent
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0075"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2025-09-30_custom_SeriesLPreferredStockMember"
      id="xdx2ixbrl0105"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-12-31_custom_SeriesLPreferredStockMember"
      id="xdx2ixbrl0106"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2025-09-30"
      id="xdx2ixbrl0116"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0117"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-07-012025-09-30"
      id="xdx2ixbrl0150"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-07-012024-09-30"
      id="xdx2ixbrl0151"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-01-01to2025-09-30"
      id="xdx2ixbrl0152"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-012024-09-30"
      id="xdx2ixbrl0153"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2025-07-012025-09-30"
      id="xdx2ixbrl0198"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2024-07-012024-09-30"
      id="xdx2ixbrl0199"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2024-01-012024-09-30"
      id="xdx2ixbrl0201"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2025-07-012025-09-30"
      id="xdx2ixbrl0203"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2024-07-012024-09-30"
      id="xdx2ixbrl0204"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2024-01-012024-09-30"
      id="xdx2ixbrl0206"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="From2025-07-012025-09-30"
      id="xdx2ixbrl0208"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="From2025-01-01to2025-09-30"
      id="xdx2ixbrl0210"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="From2024-07-012024-09-30"
      id="xdx2ixbrl0224"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="From2024-01-012024-09-30"
      id="xdx2ixbrl0226"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_PreferredStockMember_custom_SeriesLPreferredStockMember"
      id="xdx2ixbrl0266"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-06-30_us-gaap_PreferredStockMember_custom_SeriesLPreferredStockMember"
      id="xdx2ixbrl0274"
      unitRef="Shares"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueMezzanineEquityReclassification
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0282"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueMezzanineEquityReclassification
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesLPreferredStockMember"
      id="xdx2ixbrl0283"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueMezzanineEquityReclassification
      contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0284"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueMezzanineEquityReclassification
      contextRef="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0286"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0295"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesLPreferredStockMember"
      id="xdx2ixbrl0296"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0297"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0299"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0304"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesLPreferredStockMember"
      id="xdx2ixbrl0305"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0308"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2025-07-012025-09-30"
      id="xdx2ixbrl0309"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DividendsPreferredStock
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0315"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DividendsPreferredStock
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesLPreferredStockMember"
      id="xdx2ixbrl0316"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DividendsPreferredStock
      contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0317"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DividendsPreferredStock
      contextRef="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0318"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0322"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesLPreferredStockMember"
      id="xdx2ixbrl0323"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0324"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0326"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0329"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesLPreferredStockMember"
      id="xdx2ixbrl0330"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0331"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0332"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30_us-gaap_PreferredStockMember_custom_SeriesLPreferredStockMember"
      id="xdx2ixbrl0337"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="AsOf2025-09-30_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember"
      id="xdx2ixbrl0349"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="AsOf2025-09-30_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember"
      id="xdx2ixbrl0351"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_SeriesLPreferredStockMember"
      id="xdx2ixbrl0354"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_SeriesLPreferredStockMember"
      id="xdx2ixbrl0362"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="AsOf2024-12-31_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember"
      id="xdx2ixbrl0366"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="AsOf2024-12-31_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember"
      id="xdx2ixbrl0368"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0370"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesLPreferredStockMember"
      id="xdx2ixbrl0371"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet
      contextRef="From2025-01-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0374"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0379"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesLPreferredStockMember"
      id="xdx2ixbrl0380"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0381"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2025-01-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0383"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0388"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesLPreferredStockMember"
      id="xdx2ixbrl0389"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2025-01-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0392"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2025-01-01to2025-09-30"
      id="xdx2ixbrl0393"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0399"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesLPreferredStockMember"
      id="xdx2ixbrl0400"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable
      contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0401"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable
      contextRef="From2025-01-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0403"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0406"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesLPreferredStockMember"
      id="xdx2ixbrl0407"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee
      contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0408"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee
      contextRef="From2025-01-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0410"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0415"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesLPreferredStockMember"
      id="xdx2ixbrl0416"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0417"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-01-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0419"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0424"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesLPreferredStockMember"
      id="xdx2ixbrl0425"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0426"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-01-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0428"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DividendsPreferredStock
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0431"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DividendsPreferredStock
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesLPreferredStockMember"
      id="xdx2ixbrl0432"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DividendsPreferredStock
      contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0433"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DividendsPreferredStock
      contextRef="From2025-01-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0434"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0438"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesLPreferredStockMember"
      id="xdx2ixbrl0439"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0440"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2025-01-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0442"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0445"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesLPreferredStockMember"
      id="xdx2ixbrl0446"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0447"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0448"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30_us-gaap_PreferredStockMember_custom_SeriesLPreferredStockMember"
      id="xdx2ixbrl0453"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="AsOf2025-09-30_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember"
      id="xdx2ixbrl0465"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="AsOf2025-09-30_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember"
      id="xdx2ixbrl0467"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="AsOf2024-06-30_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember"
      id="xdx2ixbrl0479"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="AsOf2024-06-30_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember"
      id="xdx2ixbrl0481"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash
      contextRef="From2024-07-012024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0483"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash
      contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0484"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash
      contextRef="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0485"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash
      contextRef="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0486"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash
      contextRef="From2024-07-012024-09-30"
      id="xdx2ixbrl0487"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="From2024-07-012024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0489"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0490"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0491"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0492"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="From2024-07-012024-09-30"
      id="xdx2ixbrl0493"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable
      contextRef="From2024-07-012024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0495"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable
      contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0496"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable
      contextRef="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0497"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable
      contextRef="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0498"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable
      contextRef="From2024-07-012024-09-30"
      id="xdx2ixbrl0499"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2024-07-012024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0501"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0502"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0503"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0504"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2024-07-012024-09-30"
      id="xdx2ixbrl0505"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0507"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0508"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0509"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="AsOf2024-09-30_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember"
      id="xdx2ixbrl0523"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="AsOf2024-09-30_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember"
      id="xdx2ixbrl0525"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="AsOf2023-12-31_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember"
      id="xdx2ixbrl0537"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="AsOf2023-12-31_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember"
      id="xdx2ixbrl0539"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="AsOf2023-12-31_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember"
      id="xdx2ixbrl0551"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="AsOf2023-12-31_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember"
      id="xdx2ixbrl0553"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash
      contextRef="From2024-01-012024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0555"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash
      contextRef="From2024-01-012024-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0558"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="From2024-01-012024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0563"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="From2024-01-012024-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0564"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="From2024-01-012024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0565"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="From2024-01-012024-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0566"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="From2024-01-012024-09-30"
      id="xdx2ixbrl0567"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable
      contextRef="From2024-01-012024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0571"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable
      contextRef="From2024-01-012024-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0572"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable
      contextRef="From2024-01-012024-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0574"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2024-01-012024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0579"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2024-01-012024-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0580"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2024-01-012024-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0582"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0585"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0586"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0587"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="AsOf2024-09-30_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember"
      id="xdx2ixbrl0601"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="AsOf2024-09-30_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember"
      id="xdx2ixbrl0603"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="AsOf2024-09-30_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember"
      id="xdx2ixbrl0615"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="AsOf2024-09-30_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember"
      id="xdx2ixbrl0617"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:IssuanceOfWarrantsForVrtWaiver
      contextRef="From2024-01-012024-09-30"
      id="xdx2ixbrl0632"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2024-01-012024-09-30"
      id="xdx2ixbrl0638"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:GainOnSettlementOfDebt
      contextRef="From2024-01-012024-09-30"
      id="xdx2ixbrl0641"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DebtSecuritiesUnrealizedGainLoss
      contextRef="From2025-01-01to2025-09-30"
      id="xdx2ixbrl0643"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2025-01-01to2025-09-30"
      id="xdx2ixbrl0658"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsForProceedsFromInvestments
      contextRef="From2025-01-01to2025-09-30"
      id="xdx2ixbrl0667"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2025-01-01to2025-09-30"
      id="xdx2ixbrl0670"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2024-01-012024-09-30"
      id="xdx2ixbrl0677"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2025-01-01to2025-09-30"
      id="xdx2ixbrl0679"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsOfDividends
      contextRef="From2024-01-012024-09-30"
      id="xdx2ixbrl0686"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaid
      contextRef="From2025-01-01to2025-09-30"
      id="xdx2ixbrl0706"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaid
      contextRef="From2024-01-012024-09-30"
      id="xdx2ixbrl0707"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2025-01-01to2025-09-30"
      id="xdx2ixbrl0709"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2024-01-012024-09-30"
      id="xdx2ixbrl0710"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:FairValueOfSeriesLConvertiblePreferredStockVestedWarrants
      contextRef="From2024-01-012024-09-30"
      id="xdx2ixbrl0716"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:FairValueOfPrefundedWarrantsIssuedForElocFee
      contextRef="From2024-01-012024-09-30"
      id="xdx2ixbrl0719"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssued1
      contextRef="From2024-01-012024-09-30"
      id="xdx2ixbrl0722"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:DividendDeclaredOnSeriesLConvertiblePreferredStock
      contextRef="From2024-01-012024-09-30"
      id="xdx2ixbrl0728"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-09-30_custom_SeriesLConvertiblePreferredStockMember"
      id="xdx2ixbrl0773"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="AsOf2025-09-30_custom_LegalServicesFirmMember"
      id="xdx2ixbrl0813"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AccountsPayableInterestBearingInterestRate
      contextRef="AsOf2025-09-30_custom_LegalServicesFirmMember"
      id="xdx2ixbrl0816"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="AsOf2025-09-30_custom_LegalServicesFirmMember"
      id="xdx2ixbrl0820"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="From2025-01-012025-09-30_custom_CytovanceBiologicsIncMember"
      id="xdx2ixbrl0849"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:RepaymentsOfPrefundedWarrantsAtFairValue
      contextRef="From2024-01-012024-09-30_custom_CytovanceBiologicsIncMember"
      id="xdx2ixbrl0853"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2025-09-30_us-gaap_MeasurementInputExpectedDividendRateMember_custom_TwoThousandTwentyThreeWarrantsMember"
      id="xdx2ixbrl0914"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-31_us-gaap_MeasurementInputExpectedDividendRateMember_custom_TwoThousandTwentyThreeWarrantsMember"
      id="xdx2ixbrl0916"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2025-01-01to2025-09-30"
      id="xdx2ixbrl0931"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2024-01-012024-09-30"
      id="xdx2ixbrl0932"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:ExtinguishmentOfWarrant
      contextRef="From2025-01-01to2025-09-30"
      id="xdx2ixbrl0937"
      unitRef="USD"
      xsi:nil="true"/>
    <GTBP:ExtinguishmentOfWarrant
      contextRef="From2024-01-012024-09-30"
      id="xdx2ixbrl0938"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2025-01-01to2025-09-30"
      id="xdx2ixbrl1289"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2025-01-01to2025-09-30"
      id="xdx2ixbrl1291"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-07-012024-09-30_custom_SegmentsMember"
      id="xdx2ixbrl1523"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2025-01-01to2025-09-30" id="Fact000014">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="From2025-01-01to2025-09-30" id="Fact000015">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="From2025-01-01to2025-09-30" id="Fact000016">2025-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2025-01-01to2025-09-30" id="Fact000017">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2025-01-01to2025-09-30" id="Fact000018">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2025-01-01to2025-09-30" id="Fact000019">001-40023</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2025-01-01to2025-09-30" id="Fact000020">GT BIOPHARMA, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2025-01-01to2025-09-30" id="Fact000021">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2025-01-01to2025-09-30" id="Fact000022">94-1620407</dei:EntityTaxIdentificationNumber>
    <dei:CityAreaCode contextRef="From2025-01-01to2025-09-30" id="Fact000023">415</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2025-01-01to2025-09-30" id="Fact000024">919-4040</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2025-01-01to2025-09-30" id="Fact000025">Common     Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2025-01-01to2025-09-30" id="Fact000026">GTBP</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2025-01-01to2025-09-30" id="Fact000027">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="From2025-01-01to2025-09-30" id="Fact000028">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2025-01-01to2025-09-30" id="Fact000029">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2025-01-01to2025-09-30" id="Fact000030">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2025-01-01to2025-09-30" id="Fact000031">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2025-01-01to2025-09-30" id="Fact000032">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2025-01-01to2025-09-30" id="Fact000033">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2025-11-06"
      decimals="INF"
      id="Fact000034"
      unitRef="Shares">10636135</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityAddressAddressLine1 contextRef="From2025-01-01to2025-09-30" id="Fact000035">505 Montgomery Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2025-01-01to2025-09-30" id="Fact000036">10th Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2025-01-01to2025-09-30" id="Fact000037">San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2025-01-01to2025-09-30" id="Fact000038">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2025-01-01to2025-09-30" id="Fact000039">94111</dei:EntityAddressPostalZipCode>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000047"
      unitRef="USD">2528000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000048"
      unitRef="USD">3951000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000050"
      unitRef="USD">93000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000051"
      unitRef="USD">93000</us-gaap:RestrictedCashCurrent>
    <us-gaap:DeferredOfferingCosts
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000053"
      unitRef="USD">760000</us-gaap:DeferredOfferingCosts>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000056"
      unitRef="USD">940000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000057"
      unitRef="USD">188000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000059"
      unitRef="USD">4321000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000060"
      unitRef="USD">4232000</us-gaap:AssetsCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000068"
      unitRef="USD">769000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000069"
      unitRef="USD">3853000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000071"
      unitRef="USD">400000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000072"
      unitRef="USD">1797000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DividendsPayableCurrent
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000074"
      unitRef="USD">144000</us-gaap:DividendsPayableCurrent>
    <GTBP:WarrantLiabilityCurrent
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000077"
      unitRef="USD">8000</GTBP:WarrantLiabilityCurrent>
    <GTBP:WarrantLiabilityCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000078"
      unitRef="USD">252000</GTBP:WarrantLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000080"
      unitRef="USD">1321000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000081"
      unitRef="USD">5902000</us-gaap:LiabilitiesCurrent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000089"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000091"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000093"
      unitRef="Shares">15000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000095"
      unitRef="Shares">15000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2025-09-30_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000097"
      unitRef="Shares">96230</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2025-09-30_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000099"
      unitRef="Shares">96230</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000101"
      unitRef="Shares">96230</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000103"
      unitRef="Shares">96230</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2025-09-30_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact000086"
      unitRef="USD">1000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact000087"
      unitRef="USD">1000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2025-09-30_custom_SeriesLPreferredStockMember"
      decimals="INF"
      id="Fact000108"
      unitRef="Shares">4912</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2025-09-30_custom_SeriesLPreferredStockMember"
      decimals="INF"
      id="Fact000110"
      unitRef="Shares">4912</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-12-31_custom_SeriesLPreferredStockMember"
      decimals="INF"
      id="Fact000112"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-12-31_custom_SeriesLPreferredStockMember"
      decimals="INF"
      id="Fact000114"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000122"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000124"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000126"
      unitRef="Shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000128"
      unitRef="Shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000130"
      unitRef="Shares">6051874</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000132"
      unitRef="Shares">6051874</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000134"
      unitRef="Shares">2234328</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000136"
      unitRef="Shares">2234328</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000119"
      unitRef="USD">6000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000120"
      unitRef="USD">2000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000138"
      unitRef="USD">703772000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000139"
      unitRef="USD">693554000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000141"
      unitRef="USD">-700779000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000142"
      unitRef="USD">-695227000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000144"
      unitRef="USD">3000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000145"
      unitRef="USD">-1670000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000147"
      unitRef="USD">4321000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000148"
      unitRef="USD">4232000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000160"
      unitRef="USD">634000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000161"
      unitRef="USD">1307000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000162"
      unitRef="USD">2096000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000163"
      unitRef="USD">3868000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2025-07-012025-09-30_us-gaap_SellingGeneralAndAdministrativeExpensesMember_custom_OfficersEmployeesAndDirectorsMember"
      decimals="0"
      id="Fact000170"
      unitRef="USD">379000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-07-012024-09-30_us-gaap_SellingGeneralAndAdministrativeExpensesMember_custom_OfficersEmployeesAndDirectorsMember"
      decimals="0"
      id="Fact000172"
      unitRef="USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2025-01-012025-09-30_us-gaap_SellingGeneralAndAdministrativeExpensesMember_custom_OfficersEmployeesAndDirectorsMember"
      decimals="0"
      id="Fact000174"
      unitRef="USD">386000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-09-30_us-gaap_SellingGeneralAndAdministrativeExpensesMember_custom_OfficersEmployeesAndDirectorsMember"
      decimals="0"
      id="Fact000176"
      unitRef="USD">222000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000165"
      unitRef="USD">2748000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000166"
      unitRef="USD">2297000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000167"
      unitRef="USD">4731000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000168"
      unitRef="USD">6733000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000178"
      unitRef="USD">-3382000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000179"
      unitRef="USD">-3604000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000180"
      unitRef="USD">-6827000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000181"
      unitRef="USD">-10601000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOther
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000188"
      unitRef="USD">36000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000189"
      unitRef="USD">96000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000190"
      unitRef="USD">106000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000191"
      unitRef="USD">343000</us-gaap:InterestIncomeOther>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000193"
      unitRef="USD">-232000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000194"
      unitRef="USD">-95000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000195"
      unitRef="USD">-244000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000196"
      unitRef="USD">-870000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000200"
      unitRef="USD">998000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000205"
      unitRef="USD">156000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000209"
      unitRef="USD">2000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000211"
      unitRef="USD">1000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000213"
      unitRef="USD">268000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000214"
      unitRef="USD">193000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000215"
      unitRef="USD">1504000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000216"
      unitRef="USD">1214000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000218"
      unitRef="USD">-3114000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000219"
      unitRef="USD">-3411000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000220"
      unitRef="USD">-5323000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000221"
      unitRef="USD">-9387000</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000223"
      unitRef="USD">144000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000225"
      unitRef="USD">229000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000228"
      unitRef="USD">-3258000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000229"
      unitRef="USD">-3411000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000230"
      unitRef="USD">-5552000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000231"
      unitRef="USD">-9387000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-07-012025-09-30"
      decimals="INF"
      id="Fact000233"
      unitRef="USDPShares">-0.83</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-07-012025-09-30"
      decimals="INF"
      id="Fact000235"
      unitRef="USDPShares">-0.83</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-07-012024-09-30"
      decimals="INF"
      id="Fact000237"
      unitRef="USDPShares">-1.53</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-07-012024-09-30"
      decimals="INF"
      id="Fact000239"
      unitRef="USDPShares">-1.53</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-01-01to2025-09-30"
      decimals="INF"
      id="Fact000241"
      unitRef="USDPShares">-1.84</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-01-01to2025-09-30"
      decimals="INF"
      id="Fact000243"
      unitRef="USDPShares">-1.84</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-01-012024-09-30"
      decimals="INF"
      id="Fact000245"
      unitRef="USDPShares">-5.28</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-01-012024-09-30"
      decimals="INF"
      id="Fact000247"
      unitRef="USDPShares">-5.28</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-07-012025-09-30"
      decimals="INF"
      id="Fact000249"
      unitRef="Shares">3940714</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-07-012025-09-30"
      decimals="INF"
      id="Fact000251"
      unitRef="Shares">3940714</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-07-012024-09-30"
      decimals="INF"
      id="Fact000253"
      unitRef="Shares">2234328</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-07-012024-09-30"
      decimals="INF"
      id="Fact000255"
      unitRef="Shares">2234328</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-01-01to2025-09-30"
      decimals="INF"
      id="Fact000257"
      unitRef="Shares">3025033</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-01-01to2025-09-30"
      decimals="INF"
      id="Fact000259"
      unitRef="Shares">3025033</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-012024-09-30"
      decimals="INF"
      id="Fact000261"
      unitRef="Shares">1777313</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-012024-09-30"
      decimals="INF"
      id="Fact000263"
      unitRef="Shares">1777313</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000272"
      unitRef="Shares">96230</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact000265"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000276"
      unitRef="Shares">3272995</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000267"
      unitRef="USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000268"
      unitRef="USD">700378000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000269"
      unitRef="USD">-697521000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000270"
      unitRef="USD">2861000</us-gaap:StockholdersEquity>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="AsOf2025-06-30_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember"
      decimals="INF"
      id="Fact000278"
      unitRef="Shares">6301</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="AsOf2025-06-30_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember"
      decimals="INF"
      id="Fact000280"
      unitRef="USD">1956000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <GTBP:StockIssuedDuringPeriodSharesMezzanineEquityReclassification
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesLPreferredStockMember"
      decimals="INF"
      id="Fact000289"
      unitRef="Shares">6301</GTBP:StockIssuedDuringPeriodSharesMezzanineEquityReclassification>
    <GTBP:StockIssuedDuringPeriodValueMezzanineEquityReclassification
      contextRef="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000285"
      unitRef="USD">1956000</GTBP:StockIssuedDuringPeriodValueMezzanineEquityReclassification>
    <GTBP:StockIssuedDuringPeriodValueMezzanineEquityReclassification
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000287"
      unitRef="USD">1956000</GTBP:StockIssuedDuringPeriodValueMezzanineEquityReclassification>
    <GTBP:StockIssuedDuringPeriodSharesMezzanineEquityReclassification
      contextRef="From2025-07-012025-09-30_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember"
      decimals="INF"
      id="Fact000291"
      unitRef="Shares">-6301</GTBP:StockIssuedDuringPeriodSharesMezzanineEquityReclassification>
    <GTBP:StockIssuedDuringPeriodValueMezzanineEquityReclassification
      contextRef="From2025-07-012025-09-30_custom_MezzanineEquityMember_custom_SeriesLPreferredStockMember"
      decimals="0"
      id="Fact000293"
      unitRef="USD">-1956000</GTBP:StockIssuedDuringPeriodValueMezzanineEquityReclassification>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesLPreferredStockMember"
      decimals="INF"
      id="Fact000302"
      unitRef="Shares">1222</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000298"
      unitRef="USD">1062000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000300"
      unitRef="USD">1062000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesLPreferredStockMember"
      decimals="INF"
      id="Fact000311"
      unitRef="Shares">-2611</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000313"
      unitRef="Shares">2778852</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000306"
      unitRef="USD">3000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000307"
      unitRef="USD">-3000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:DividendsPreferredStock
      contextRef="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000319"
      unitRef="USD">144000</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000320"
      unitRef="USD">144000</us-gaap:DividendsPreferredStock>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000325"
      unitRef="USD">379000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000327"
      unitRef="USD">379000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000333"
      unitRef="USD">-3114000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012025-09-30"
      decimals="0"
      id="Fact000334"
      unitRef="USD">-3114000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000343"
      unitRef="Shares">96230</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact000336"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-09-30_us-gaap_PreferredStockMember_custom_SeriesLPreferredStockMember"
      decimals="INF"
      id="Fact000345"
      unitRef="Shares">4912</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000347"
      unitRef="Shares">6051847</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000338"
      unitRef="USD">6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000339"
      unitRef="USD">703772000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000340"
      unitRef="USD">-700779000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000341"
      unitRef="USD">3000000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000360"
      unitRef="Shares">96230</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact000353"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000364"
      unitRef="Shares">2234328</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000355"
      unitRef="USD">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000356"
      unitRef="USD">693554000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000357"
      unitRef="USD">-695227000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000358"
      unitRef="USD">-1670000</us-gaap:StockholdersEquity>
    <GTBP:StockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet
      contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000377"
      unitRef="Shares">537069</GTBP:StockIssuedDuringPeriodSharesExerciseOfWarrantsForCashAndInducementWarrantsNet>
    <GTBP:StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet
      contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000372"
      unitRef="USD">1000</GTBP:StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet>
    <GTBP:StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet
      contextRef="From2025-01-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000373"
      unitRef="USD">1051000</GTBP:StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet>
    <GTBP:StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000375"
      unitRef="USD">1052000</GTBP:StockIssuedDuringPeriodValueExerciseOfWarrantsForCashAndInducementWarrantsNet>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesLPreferredStockMember"
      decimals="INF"
      id="Fact000386"
      unitRef="Shares">7833</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2025-01-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000382"
      unitRef="USD">6503000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000384"
      unitRef="USD">6503000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesLPreferredStockMember"
      decimals="INF"
      id="Fact000395"
      unitRef="Shares">-2921</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000397"
      unitRef="Shares">2930450</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000390"
      unitRef="USD">3000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2025-01-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000391"
      unitRef="USD">-3000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <GTBP:StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable
      contextRef="From2025-01-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000402"
      unitRef="USD">847000</GTBP:StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable>
    <GTBP:StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000404"
      unitRef="USD">847000</GTBP:StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantToSettleVendorPayable>
    <GTBP:StockIssuedDuringPeriodSharesIssuanceAndExerciseOfPrefundedWarrantsForElocFee
      contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000413"
      unitRef="Shares">300000</GTBP:StockIssuedDuringPeriodSharesIssuanceAndExerciseOfPrefundedWarrantsForElocFee>
    <GTBP:StockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee
      contextRef="From2025-01-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000409"
      unitRef="USD">672000</GTBP:StockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee>
    <GTBP:StockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000411"
      unitRef="USD">672000</GTBP:StockIssuedDuringPeriodValueIssuanceAndExerciseOfPrefundedWarrantsForElocFee>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000422"
      unitRef="Shares">50000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-01-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000418"
      unitRef="USD">718000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000420"
      unitRef="USD">718000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-01-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000427"
      unitRef="USD">44000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000429"
      unitRef="USD">44000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:DividendsPreferredStock
      contextRef="From2025-01-012025-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000435"
      unitRef="USD">229000</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000436"
      unitRef="USD">229000</us-gaap:DividendsPreferredStock>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2025-01-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000441"
      unitRef="USD">386000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000443"
      unitRef="USD">386000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000449"
      unitRef="USD">-5323000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000450"
      unitRef="USD">-5323000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000459"
      unitRef="Shares">96230</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact000452"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-09-30_us-gaap_PreferredStockMember_custom_SeriesLPreferredStockMember"
      decimals="INF"
      id="Fact000461"
      unitRef="Shares">4912</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000463"
      unitRef="Shares">6051847</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000454"
      unitRef="USD">6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000455"
      unitRef="USD">703772000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000456"
      unitRef="USD">-700779000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000457"
      unitRef="USD">3000000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000475"
      unitRef="Shares">96230</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact000469"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000477"
      unitRef="Shares">2234348</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000470"
      unitRef="USD">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000471"
      unitRef="USD">693546000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000472"
      unitRef="USD">-688041000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000473"
      unitRef="USD">5508000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000510"
      unitRef="USD">-3411000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact000511"
      unitRef="USD">-3411000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000519"
      unitRef="Shares">96230</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact000513"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000521"
      unitRef="Shares">2234348</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000514"
      unitRef="USD">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000515"
      unitRef="USD">693546000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000516"
      unitRef="USD">-691452000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000517"
      unitRef="USD">2097000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000533"
      unitRef="Shares">96230</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact000527"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000535"
      unitRef="Shares">1380653</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000528"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000529"
      unitRef="USD">689539000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000530"
      unitRef="USD">-682065000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000531"
      unitRef="USD">7476000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000547"
      unitRef="Shares">96230</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact000541"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000549"
      unitRef="Shares">1380653</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000542"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000543"
      unitRef="USD">689539000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000544"
      unitRef="USD">-682065000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000545"
      unitRef="USD">7476000</us-gaap:StockholdersEquity>
    <GTBP:StockIssuedDuringPeriodShareIssuanceOfCommonStockAndWarrantsForCash
      contextRef="From2024-01-012024-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000561"
      unitRef="Shares">740000</GTBP:StockIssuedDuringPeriodShareIssuanceOfCommonStockAndWarrantsForCash>
    <GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash
      contextRef="From2024-01-012024-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000556"
      unitRef="USD">1000</GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash>
    <GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash
      contextRef="From2024-01-012024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000557"
      unitRef="USD">2975000</GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash>
    <GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000559"
      unitRef="USD">2976000</GTBP:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited
      contextRef="From2024-01-012024-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000569"
      unitRef="Shares">13902</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited>
    <GTBP:StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable
      contextRef="From2024-01-012024-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000577"
      unitRef="Shares">127597</GTBP:StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable>
    <GTBP:StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable
      contextRef="From2024-01-012024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000573"
      unitRef="USD">810000</GTBP:StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable>
    <GTBP:StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000575"
      unitRef="USD">810000</GTBP:StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2024-01-012024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000581"
      unitRef="USD">222000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000583"
      unitRef="USD">222000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000588"
      unitRef="USD">-9387000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000589"
      unitRef="USD">-9387000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000597"
      unitRef="Shares">96230</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact000591"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000599"
      unitRef="Shares">2234348</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000592"
      unitRef="USD">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000593"
      unitRef="USD">693546000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000594"
      unitRef="USD">-691452000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000595"
      unitRef="USD">2097000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000611"
      unitRef="Shares">96230</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact000605"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000613"
      unitRef="Shares">2234348</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000606"
      unitRef="USD">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000607"
      unitRef="USD">693546000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000608"
      unitRef="USD">-691452000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000609"
      unitRef="USD">2097000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000622"
      unitRef="USD">-5323000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000623"
      unitRef="USD">-9387000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000628"
      unitRef="USD">386000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000629"
      unitRef="USD">222000</us-gaap:ShareBasedCompensation>
    <GTBP:IssuanceOfWarrantsForVrtWaiver
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000631"
      unitRef="USD">44000</GTBP:IssuanceOfWarrantsForVrtWaiver>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000634"
      unitRef="USD">-244000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000635"
      unitRef="USD">-870000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000637"
      unitRef="USD">998000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <GTBP:GainOnSettlementOfDebt
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000640"
      unitRef="USD">200000</GTBP:GainOnSettlementOfDebt>
    <us-gaap:DebtSecuritiesUnrealizedGainLoss
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000644"
      unitRef="USD">-1000</us-gaap:DebtSecuritiesUnrealizedGainLoss>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000649"
      unitRef="USD">122000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000650"
      unitRef="USD">164000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000652"
      unitRef="USD">-2436000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000653"
      unitRef="USD">-233000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <GTBP:IncreaseDecreaseInOperatingLeaseRightofuseAssets
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000656"
      unitRef="USD">-53000</GTBP:IncreaseDecreaseInOperatingLeaseRightofuseAssets>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000659"
      unitRef="USD">-58000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000661"
      unitRef="USD">-8893000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000662"
      unitRef="USD">-10436000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsForProceedsFromInvestments
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000668"
      unitRef="USD">-12892000</us-gaap:PaymentsForProceedsFromInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000671"
      unitRef="USD">12892000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000676"
      unitRef="USD">1052000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000680"
      unitRef="USD">2976000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000682"
      unitRef="USD">6503000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:PaymentsOfDividends
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000685"
      unitRef="USD">85000</us-gaap:PaymentsOfDividends>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000688"
      unitRef="USD">7470000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000689"
      unitRef="USD">2976000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000691"
      unitRef="USD">-1423000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000692"
      unitRef="USD">5432000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000694"
      unitRef="USD">4044000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000695"
      unitRef="USD">1079000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000697"
      unitRef="USD">2621000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000698"
      unitRef="USD">6511000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <GTBP:FairValueOfSeriesLConvertiblePreferredStockVestedWarrants
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000715"
      unitRef="USD">3389000</GTBP:FairValueOfSeriesLConvertiblePreferredStockVestedWarrants>
    <GTBP:FairValueOfPrefundedWarrantsIssuedForElocFee
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000718"
      unitRef="USD">672000</GTBP:FairValueOfPrefundedWarrantsIssuedForElocFee>
    <us-gaap:StockIssued1
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000721"
      unitRef="USD">718000</us-gaap:StockIssued1>
    <GTBP:FairValueOfPrefundedWarrantAndCommonStockToSettleVendorPayable
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000724"
      unitRef="USD">847000</GTBP:FairValueOfPrefundedWarrantAndCommonStockToSettleVendorPayable>
    <GTBP:FairValueOfPrefundedWarrantAndCommonStockToSettleVendorPayable
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000725"
      unitRef="USD">810000</GTBP:FairValueOfPrefundedWarrantAndCommonStockToSettleVendorPayable>
    <GTBP:DividendDeclaredOnSeriesLConvertiblePreferredStock
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000727"
      unitRef="USD">229000</GTBP:DividendDeclaredOnSeriesLConvertiblePreferredStock>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact000730">&lt;p id="xdx_802_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_z6UOkzaHNIz3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
1 &#x2013; &lt;span id="xdx_828_zJh9mWsOY2ak"&gt;Organization and Going Concern Analysis&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Organization&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;GT
Biopharma, Inc. (the &#x201c;Company&#x201d;) is a clinical stage biopharmaceutical company focused on the development and commercialization
of novel immune-oncology products based on our proprietary Tri-specific Killer Engager (TriKE&#xae;), and Tetra-specific Killer Engager
(Dual Targeting TriKE&#xae;) platforms. The Company&#x2019;s TriKE&#xae; and Dual Targeting TriKE&#xae; platforms generate proprietary therapeutics
designed to harness and enhance the cancer killing abilities of a patient&#x2019;s own natural killer cells (NK cells).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
corporate predecessor of GT Biopharma, Inc, Diagnostic Data, Inc., was incorporated in the state of California in 1965. Diagnostic Data,
Inc. changed its incorporation to the state of Delaware on December 21, 1972 and changed its name to DDI Pharmaceuticals, Inc. on March
11, 1985. On September 7, 1994, DDI Pharmaceuticals, Inc. merged with International BioClinical, Inc. and Bioxytech S.A. and changed
its name to OXIS International, Inc. On July 17, 2017, OXIS International, Inc. changed its name to GT Biopharma, Inc.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Throughout
this Quarterly Report on Form 10-Q, the terms &#x201c;GTBP,&#x201d; &#x201c;we,&#x201d; &#x201c;us,&#x201d; &#x201c;our,&#x201d; &#x201c;the Company&#x201d;
and &#x201c;our Company&#x201d; refer to GT Biopharma, Inc.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
GT Biopharma logo, TriKE&#xae;, and other trademarks or service marks of GT Biopharma, Inc. appearing in this quarterly report are the
property of the Company. This quarterly report on Form 10-Q also contains registered marks, trademarks and trade names of other companies.
All other trademarks, registered marks and trade names appearing herein are the property of their respective holders.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Going
Concern Analysis&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying unaudited condensed financial statements have been prepared assuming that the Company will continue as a going concern.
The Company does not have any product candidates approved for sale and has not generated any revenue from its product sales. The Company
has sustained operating losses since inception, and expects such losses to continue into the foreseeable future. Historically, the Company
has financed its operations through public and private sales of common stock, the issuance of preferred and common stock, the issuance
of convertible debt instruments, and strategic collaborations. For the nine months ended September 30, 2025, the Company recorded a net
loss of approximately $&lt;span id="xdx_90E_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20250101__20250930_zun01o9mOjah" title="Net loss"&gt;5.3 &lt;/span&gt;million and used cash in operations of approximately $&lt;span id="xdx_906_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20250101__20250930_zznkrDP2vplk" title="Net cash used in operating activities"&gt;8.9&lt;/span&gt; million. These factors raise substantial doubt about
the Company&#x2019;s ability to continue as a going concern within one year of the date that the financial statements are issued. In addition,
the Company&#x2019;s independent registered public accounting firm, in its report on the Company&#x2019;s December 31, 2024, financial
statements, raised substantial doubt about the Company&#x2019;s ability to continue as a going concern. The financial statements do not
include any adjustments that might be necessary if the Company is unable to continue as a going concern.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
unaudited condensed financial statements do not include any adjustments that might be necessary if the Company is unable to continue
as a going concern. Accordingly, the unaudited condensed financial statements have been prepared on a basis that assumes the Company
will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in
the ordinary course of business.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has evaluated the significance of the uncertainty regarding the Company&#x2019;s financial condition in relation to its ability
to meet its obligations, which has raised substantial doubt about the Company&#x2019;s ability to continue as a going concern. While it
is very difficult to estimate the Company&#x2019;s future liquidity requirements, the Company believes if it is unable to obtain additional
financing, existing cash resources will not be sufficient to enable it to fund the anticipated level of operations through one year from
the date the accompanying unaudited condensed financial statements are issued. There can be no assurances that the Company will be able
to secure additional financing on acceptable terms. In the event the Company does not secure additional financing, the Company will be
forced to delay, reduce, or eliminate some or all of its discretionary spending, which could adversely affect the Company&#x2019;s business
prospects, ability to meet long-term liquidity needs and the ability to continue operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-01to2025-09-30"
      decimals="-5"
      id="Fact000732"
      unitRef="USD">-5300000</us-gaap:NetIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2025-01-01to2025-09-30"
      decimals="-5"
      id="Fact000734"
      unitRef="USD">-8900000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact000736">&lt;p id="xdx_806_eus-gaap--SignificantAccountingPoliciesTextBlock_z7Y1Wv9DazT7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
2 &#x2013; &lt;span id="xdx_82C_zV4FNhZdgQ07"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zPeugrX0lqi1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86B_zSt4fb2hQaS2"&gt;Basis
of Presentation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying condensed financial statements are unaudited. These unaudited interim condensed financial statements have been prepared
in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) and applicable rules
and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) regarding interim financial reporting. Certain information
and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant
to such rules and regulations. Accordingly, these unaudited interim condensed financial statements should be read in conjunction with
the financial statements and notes thereto contained in the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended December
31, 2024 filed with the SEC on February 21, 2025 (the &#x201c;2024 Annual Report&#x201d;). The balance sheet as of December 31, 2024 included
herein, was derived from the audited financial statements as of that date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
the opinion of management, the accompanying unaudited condensed financial statements contain all adjustments necessary to fairly present
the Company&#x2019;s financial position and results of operations for the interim periods reflected. Except as noted, all adjustments
contained herein are of a normal recurring nature. Results of operations for the fiscal periods presented herein are not necessarily
indicative of fiscal year-end results.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--UseOfEstimates_z84eS2DzZUXb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86F_zWlIGXew19m2"&gt;Accounting
Estimates&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the
reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant
estimates include management&#x2019;s estimates for continued liquidity, accruals for potential liabilities, assumptions used in deriving
the fair value of derivative liabilities, valuation of equity instruments issued for debt and services and realization of deferred tax
assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z7N3ZxDPJEr7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86D_zWGzA7w0aSbc"&gt;Cash
Equivalents&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers highly liquid investments with maturities of three months or less at the date of acquisition as cash equivalents in
the accompanying unaudited condensed financial statements. At September 30, 2025 and December 31, 2024, total cash equivalents which
consist of money market funds and treasuries with maturities of three months or less, amounted to approximately $&lt;span id="xdx_904_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20250930_zDF63ap45bsk" title="Cash equivalents"&gt;2.1&lt;/span&gt; million and $&lt;span id="xdx_907_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20241231_zEEPQ0grDaFd" title="Cash equivalents"&gt;3.8&lt;/span&gt;
million, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zWX34GyVZ4j6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_861_zBhI8qlmcvga"&gt;Restricted
Cash&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of September 30, 2025, the Company has classified certain cash balances as restricted cash in its unaudited condensed balance sheets.
The Company&#x2019;s restricted cash is deposited in a financial institution and held as a collateral for a credit card agreement with
the same financial institution.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--CapitalizationOfDeferredPolicyAcquisitionCostsPolicy_zZgZRRYsVcHl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86A_zPe8nQBYIsx"&gt;Deferred
Offering Costs&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company capitalizes the fair value of equity instruments granted and certain legal, accounting and other third-party fees that are directly
related to the Company&#x2019;s in-process equity financings until such financings are consummated. After consummation of an equity financing,
these costs are recorded in stockholders&#x2019; equity as a reduction of additional paid-in capital generated as a result of the offering.
Should a planned equity financing be abandoned, terminated or significantly delayed, the deferred offering costs are immediately written
off to operating expenses. As of September 30, 2025, there was $&lt;span id="xdx_906_eus-gaap--DeferredOfferingCosts_iI_pn5n6_c20250930_zwAfZucwXoA6" title="Deferred offering costs"&gt;0.8&lt;/span&gt; million of deferred offering costs on the balance sheet.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zKb9KjlPCAhh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_867_zAAueikD6DXd"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) 820-10 requires entities to disclose
the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet for which it
is practicable to estimate fair value. ASC 820-10 defines the fair value of a financial instrument as the amount at which the instrument
could be exchanged in a current transaction between willing parties.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
three levels of the fair value hierarchy are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
1 Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the entity has the ability
to access.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
2 Valuations based on quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs
that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
3 Valuations based on inputs that are unobservable, supported by little or no market activity and that are significant to the fair value
of the assets or liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying amounts of the Company&#x2019;s other financial assets and liabilities, such as cash and cash equivalents, prepaid expenses and
other current assets, accounts payable, and accrued expenses, approximate their fair values because of the short maturity of these instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying amount of the Company&#x2019;s warrant liability of $&lt;span id="xdx_90E_ecustom--WarrantLiabilityCurrent_iI_c20250930_zh2mNBhcsWLd" title="Warrant liability"&gt;8,000&lt;/span&gt; and $&lt;span id="xdx_90F_ecustom--WarrantLiabilityCurrent_iI_c20241231_z3q1o6RZKlY3" title="Warrant liability"&gt;252,000&lt;/span&gt; at September 30, 2025 and December 31, 2024, respectively,
was based on Level 3 measurements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_ecustom--WarrantLiabilityPolicyTextBlock_znv80nG0J326" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_862_zvDShclBMqPf"&gt;Warrant
Liability&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded
derivatives in accordance with ASC Topic 815, &#x201c;&lt;i&gt;Derivatives and Hedging&lt;/i&gt;&#x201d; (&#x201c;ASC 815&#x201d;). For derivative financial
instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued
at each reporting date, with changes in the fair value reported in the statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s use of derivative financial instruments is generally limited to warrants issued by the Company that do not meet the criteria
for equity treatment and are recorded as liabilities. We do not use financial instruments or derivatives for any trading purposes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_ecustom--MezzanineEquityPolicyTextBlock_z6RzHTez9cs" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_863_znPncSPyFdul"&gt;Mezzanine
Equity&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Where
ordinary or preferred shares are determined to be conditionally redeemable upon the occurrence of certain events that are not solely
within the control of the issuer, and upon such event, the shares would become redeemable at the option of the holders, they are classified
as &#x2018;mezzanine equity&#x2019; (temporary equity). The purpose of this classification is to convey that such a security may not be
permanently part of equity and could result in a demand for cash, securities or other assets of the entity in the future.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Equity
instruments accounted as Mezzanine Equity upon issuance were reclassified to permanent equity as of September 30, 2025 as a result of
subsequent amendments to its terms.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zjXU3pwOpSWb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86F_z2zm6rYqIux5"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company periodically issues stock-based compensation to officers, directors, employees, and consultants for services rendered. Such issuances
vest and expire according to terms established at the issuance date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Stock-based
payments to officers, directors, employees, and consultants in exchange for goods and services, which include grants of employee stock
options, are recognized in the financial statements based on their grant date fair values in accordance with ASC 718, &lt;i&gt;Compensation-Stock
Compensation&lt;/i&gt;. Stock based payments to officers, directors, employees, and consultants, which are generally time vested, are measured
at the grant date fair value and depending on the conditions associated with the vesting of the award, compensation cost is recognized
on a straight-line or graded basis over the vesting period. Recognition of compensation expense for non-employees is in the same period
and manner as if the Company had paid cash for the services. The fair value of stock options granted is estimated using the Black-Scholes
option-pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life, and future
dividends. The assumptions used in the Black-Scholes option pricing model could materially affect compensation expense recorded in future
periods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--ResearchAndDevelopmentExpensePolicy_zoaWReyyh736" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86A_ze9ZkJBcwOOj"&gt;Research
and Development Expenses&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Costs
incurred for research and development are expensed as incurred. The salaries, benefits, and overhead costs of personnel conducting research
and development of the Company&#x2019;s products are included in research and development expenses. Purchased materials that do not have
an alternative future use are also expensed. Purchased materials that have an alternative future are classified as a prepaid expense
and periodically reviewed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--EarningsPerSharePolicyTextBlock_zzBCiYRJkMD3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_863_zF6xJODp9xh2"&gt;Net
Loss Per Share&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
earnings (loss) per share is computed using the weighted-average number of common shares outstanding during the period. Diluted earnings
(loss) per share is computed using the weighted-average number of common shares and the dilutive effect of contingent shares outstanding
during the period. Potentially dilutive contingent shares, which primarily consist of stock issuable upon exercise of stock options and
warrants, and the conversion of Series L convertible preferred stock, have been excluded from the diluted loss per share calculation
because their effect is anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zQRDqxVjqmd1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following common stock equivalents were excluded in the computation of the net loss per share because their effect is anti-dilutive:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BC_zFCVDVlwp5S3" style="display: none"&gt;Schedule of Anti-dilutive Securities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 75%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20250101__20250930_zXjs4YBnnFy1" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September 30, 2025&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Unaudited)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20240101__20240930_zZTByQvbDlKb" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September 30, 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Unaudited)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesLConvertiblePreferredStockMember_z5lmL1gNdT8i" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Series L convertible preferred stock &lt;b&gt;&lt;sup id="xdx_F44_zukfJ2qB72Ld"&gt;1&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;7,649,792&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0773"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zkneGfjaH1oa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Options to purchase common stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;597,550&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;101,264&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zGwF1cKvFTk4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Warrants to purchase common stock&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;49,459,390&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,133,762&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zbBEwqK4Rv6g" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total anti-dilutive securities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;57,706,732&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,235,026&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b id="xdx_F0C_zQQiiyKcALwd"&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F11_zV80lUlQoPQ9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Converted into
common stock using a conversion price of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEFudGktZGlsdXRpdmUgU2VjdXJpdGllcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_904_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20250930_zYB0aw7k7YA3" title="Conversion price per share"&gt;0.6421&lt;/span&gt; per share, as of September 30, 2025&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p id="xdx_8AB_zYjDfXlXDxZb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_zVcOgvqOXL45" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_868_zI8KcYfr4PP4"&gt;Concentration&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
is deposited in one financial institution. The balances held at this financial institution at times may be in excess of Federal Deposit
Insurance Corporation (&#x201c;FDIC&#x201d;) insurance limits of up to $&lt;span id="xdx_901_eus-gaap--CashFDICInsuredAmount_iI_c20250930_zazTR64ciLQ9" title="Cash, FDIC insured amount"&gt;250,000&lt;/span&gt;. &lt;span style="background-color: white"&gt;Management believes
that the financial institutions that hold the Company&#x2019;s cash are financially sound and, accordingly, minimal credit risk exists.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has a significant concentration of expenses incurred from and accounts payable to Cytovance Biologics, Inc. (&#x201c;Cytovance&#x201d;),
a related party, and the University of Minnesota, see Note 3 &#x2013; Accounts Payable and Related Party.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zpOSaP5GOIGl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86A_zEwLDVzX81k"&gt;Segment
Information&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s Chief Executive Officer and President (&#x201c;CEO&#x201d;) is our chief operating decision maker (&#x201c;CODM&#x201d;)
and evaluates performance and makes operating decisions about allocating resources based on financial data presented on a consolidated
basis. Because our CODM evaluates financial performance on a consolidated basis, the Company has determined that it operates as a single
reportable segment composed of the financial results of GT Biopharma, Inc.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zaTm6E90uhy" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86E_z7v0R6ZiqRR1"&gt;Recent
Accounting Pronouncements&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2024, the FASB issued ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic
220-40): Disaggregation of Income Statement Expenses, requiring public entities to disclose additional information about specific expense
categories in the notes to the financial statements on an interim and annual basis. ASU 2024-03 is effective for fiscal years beginning
after December 15, 2026, and for interim periods beginning after December 15, 2027, with early adoption permitted. The Company is currently
evaluating the impact of adopting ASU 2024-03.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s management has evaluated all the recently issued, but not yet effective, accounting standards and guidance that have
been issued or proposed by the FASB or other standards-setting bodies through the filing date of these financial statements and does
not believe the future adoption of any such pronouncements will have a material effect on the Company&#x2019;s financial position and
results of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_8A6_zBDZqEdgdO44" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact000738">&lt;p id="xdx_84E_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zPeugrX0lqi1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86B_zSt4fb2hQaS2"&gt;Basis
of Presentation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying condensed financial statements are unaudited. These unaudited interim condensed financial statements have been prepared
in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) and applicable rules
and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) regarding interim financial reporting. Certain information
and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant
to such rules and regulations. Accordingly, these unaudited interim condensed financial statements should be read in conjunction with
the financial statements and notes thereto contained in the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended December
31, 2024 filed with the SEC on February 21, 2025 (the &#x201c;2024 Annual Report&#x201d;). The balance sheet as of December 31, 2024 included
herein, was derived from the audited financial statements as of that date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
the opinion of management, the accompanying unaudited condensed financial statements contain all adjustments necessary to fairly present
the Company&#x2019;s financial position and results of operations for the interim periods reflected. Except as noted, all adjustments
contained herein are of a normal recurring nature. Results of operations for the fiscal periods presented herein are not necessarily
indicative of fiscal year-end results.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2025-01-01to2025-09-30" id="Fact000740">&lt;p id="xdx_844_eus-gaap--UseOfEstimates_z84eS2DzZUXb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86F_zWlIGXew19m2"&gt;Accounting
Estimates&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the
reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant
estimates include management&#x2019;s estimates for continued liquidity, accruals for potential liabilities, assumptions used in deriving
the fair value of derivative liabilities, valuation of equity instruments issued for debt and services and realization of deferred tax
assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact000742">&lt;p id="xdx_841_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z7N3ZxDPJEr7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86D_zWGzA7w0aSbc"&gt;Cash
Equivalents&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers highly liquid investments with maturities of three months or less at the date of acquisition as cash equivalents in
the accompanying unaudited condensed financial statements. At September 30, 2025 and December 31, 2024, total cash equivalents which
consist of money market funds and treasuries with maturities of three months or less, amounted to approximately $&lt;span id="xdx_904_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20250930_zDF63ap45bsk" title="Cash equivalents"&gt;2.1&lt;/span&gt; million and $&lt;span id="xdx_907_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20241231_zEEPQ0grDaFd" title="Cash equivalents"&gt;3.8&lt;/span&gt;
million, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="AsOf2025-09-30"
      decimals="-5"
      id="Fact000744"
      unitRef="USD">2100000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact000746"
      unitRef="USD">3800000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="From2025-01-01to2025-09-30" id="Fact000748">&lt;p id="xdx_84F_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zWX34GyVZ4j6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_861_zBhI8qlmcvga"&gt;Restricted
Cash&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of September 30, 2025, the Company has classified certain cash balances as restricted cash in its unaudited condensed balance sheets.
The Company&#x2019;s restricted cash is deposited in a financial institution and held as a collateral for a credit card agreement with
the same financial institution.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:CapitalizationOfDeferredPolicyAcquisitionCostsPolicy contextRef="From2025-01-01to2025-09-30" id="Fact000750">&lt;p id="xdx_847_eus-gaap--CapitalizationOfDeferredPolicyAcquisitionCostsPolicy_zZgZRRYsVcHl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86A_zPe8nQBYIsx"&gt;Deferred
Offering Costs&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company capitalizes the fair value of equity instruments granted and certain legal, accounting and other third-party fees that are directly
related to the Company&#x2019;s in-process equity financings until such financings are consummated. After consummation of an equity financing,
these costs are recorded in stockholders&#x2019; equity as a reduction of additional paid-in capital generated as a result of the offering.
Should a planned equity financing be abandoned, terminated or significantly delayed, the deferred offering costs are immediately written
off to operating expenses. As of September 30, 2025, there was $&lt;span id="xdx_906_eus-gaap--DeferredOfferingCosts_iI_pn5n6_c20250930_zwAfZucwXoA6" title="Deferred offering costs"&gt;0.8&lt;/span&gt; million of deferred offering costs on the balance sheet.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CapitalizationOfDeferredPolicyAcquisitionCostsPolicy>
    <us-gaap:DeferredOfferingCosts
      contextRef="AsOf2025-09-30"
      decimals="-5"
      id="Fact000752"
      unitRef="USD">800000</us-gaap:DeferredOfferingCosts>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2025-01-01to2025-09-30" id="Fact000754">&lt;p id="xdx_846_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zKb9KjlPCAhh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_867_zAAueikD6DXd"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) 820-10 requires entities to disclose
the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet for which it
is practicable to estimate fair value. ASC 820-10 defines the fair value of a financial instrument as the amount at which the instrument
could be exchanged in a current transaction between willing parties.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
three levels of the fair value hierarchy are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
1 Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the entity has the ability
to access.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
2 Valuations based on quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs
that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
3 Valuations based on inputs that are unobservable, supported by little or no market activity and that are significant to the fair value
of the assets or liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying amounts of the Company&#x2019;s other financial assets and liabilities, such as cash and cash equivalents, prepaid expenses and
other current assets, accounts payable, and accrued expenses, approximate their fair values because of the short maturity of these instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying amount of the Company&#x2019;s warrant liability of $&lt;span id="xdx_90E_ecustom--WarrantLiabilityCurrent_iI_c20250930_zh2mNBhcsWLd" title="Warrant liability"&gt;8,000&lt;/span&gt; and $&lt;span id="xdx_90F_ecustom--WarrantLiabilityCurrent_iI_c20241231_z3q1o6RZKlY3" title="Warrant liability"&gt;252,000&lt;/span&gt; at September 30, 2025 and December 31, 2024, respectively,
was based on Level 3 measurements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <GTBP:WarrantLiabilityCurrent
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000756"
      unitRef="USD">8000</GTBP:WarrantLiabilityCurrent>
    <GTBP:WarrantLiabilityCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000758"
      unitRef="USD">252000</GTBP:WarrantLiabilityCurrent>
    <GTBP:WarrantLiabilityPolicyTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact000760">&lt;p id="xdx_84C_ecustom--WarrantLiabilityPolicyTextBlock_znv80nG0J326" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_862_zvDShclBMqPf"&gt;Warrant
Liability&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded
derivatives in accordance with ASC Topic 815, &#x201c;&lt;i&gt;Derivatives and Hedging&lt;/i&gt;&#x201d; (&#x201c;ASC 815&#x201d;). For derivative financial
instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued
at each reporting date, with changes in the fair value reported in the statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s use of derivative financial instruments is generally limited to warrants issued by the Company that do not meet the criteria
for equity treatment and are recorded as liabilities. We do not use financial instruments or derivatives for any trading purposes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</GTBP:WarrantLiabilityPolicyTextBlock>
    <GTBP:MezzanineEquityPolicyTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact000762">&lt;p id="xdx_844_ecustom--MezzanineEquityPolicyTextBlock_z6RzHTez9cs" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_863_znPncSPyFdul"&gt;Mezzanine
Equity&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Where
ordinary or preferred shares are determined to be conditionally redeemable upon the occurrence of certain events that are not solely
within the control of the issuer, and upon such event, the shares would become redeemable at the option of the holders, they are classified
as &#x2018;mezzanine equity&#x2019; (temporary equity). The purpose of this classification is to convey that such a security may not be
permanently part of equity and could result in a demand for cash, securities or other assets of the entity in the future.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Equity
instruments accounted as Mezzanine Equity upon issuance were reclassified to permanent equity as of September 30, 2025 as a result of
subsequent amendments to its terms.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</GTBP:MezzanineEquityPolicyTextBlock>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact000764">&lt;p id="xdx_84F_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zjXU3pwOpSWb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86F_z2zm6rYqIux5"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company periodically issues stock-based compensation to officers, directors, employees, and consultants for services rendered. Such issuances
vest and expire according to terms established at the issuance date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Stock-based
payments to officers, directors, employees, and consultants in exchange for goods and services, which include grants of employee stock
options, are recognized in the financial statements based on their grant date fair values in accordance with ASC 718, &lt;i&gt;Compensation-Stock
Compensation&lt;/i&gt;. Stock based payments to officers, directors, employees, and consultants, which are generally time vested, are measured
at the grant date fair value and depending on the conditions associated with the vesting of the award, compensation cost is recognized
on a straight-line or graded basis over the vesting period. Recognition of compensation expense for non-employees is in the same period
and manner as if the Company had paid cash for the services. The fair value of stock options granted is estimated using the Black-Scholes
option-pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life, and future
dividends. The assumptions used in the Black-Scholes option pricing model could materially affect compensation expense recorded in future
periods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2025-01-01to2025-09-30" id="Fact000766">&lt;p id="xdx_84F_eus-gaap--ResearchAndDevelopmentExpensePolicy_zoaWReyyh736" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86A_ze9ZkJBcwOOj"&gt;Research
and Development Expenses&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Costs
incurred for research and development are expensed as incurred. The salaries, benefits, and overhead costs of personnel conducting research
and development of the Company&#x2019;s products are included in research and development expenses. Purchased materials that do not have
an alternative future use are also expensed. Purchased materials that have an alternative future are classified as a prepaid expense
and periodically reviewed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact000768">&lt;p id="xdx_848_eus-gaap--EarningsPerSharePolicyTextBlock_zzBCiYRJkMD3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_863_zF6xJODp9xh2"&gt;Net
Loss Per Share&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
earnings (loss) per share is computed using the weighted-average number of common shares outstanding during the period. Diluted earnings
(loss) per share is computed using the weighted-average number of common shares and the dilutive effect of contingent shares outstanding
during the period. Potentially dilutive contingent shares, which primarily consist of stock issuable upon exercise of stock options and
warrants, and the conversion of Series L convertible preferred stock, have been excluded from the diluted loss per share calculation
because their effect is anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zQRDqxVjqmd1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following common stock equivalents were excluded in the computation of the net loss per share because their effect is anti-dilutive:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BC_zFCVDVlwp5S3" style="display: none"&gt;Schedule of Anti-dilutive Securities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 75%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20250101__20250930_zXjs4YBnnFy1" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September 30, 2025&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Unaudited)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20240101__20240930_zZTByQvbDlKb" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September 30, 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Unaudited)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesLConvertiblePreferredStockMember_z5lmL1gNdT8i" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Series L convertible preferred stock &lt;b&gt;&lt;sup id="xdx_F44_zukfJ2qB72Ld"&gt;1&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;7,649,792&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0773"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zkneGfjaH1oa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Options to purchase common stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;597,550&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;101,264&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zGwF1cKvFTk4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Warrants to purchase common stock&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;49,459,390&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,133,762&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zbBEwqK4Rv6g" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total anti-dilutive securities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;57,706,732&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,235,026&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b id="xdx_F0C_zQQiiyKcALwd"&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F11_zV80lUlQoPQ9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Converted into
common stock using a conversion price of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEFudGktZGlsdXRpdmUgU2VjdXJpdGllcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_904_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20250930_zYB0aw7k7YA3" title="Conversion price per share"&gt;0.6421&lt;/span&gt; per share, as of September 30, 2025&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p id="xdx_8AB_zYjDfXlXDxZb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact000770">&lt;p id="xdx_895_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zQRDqxVjqmd1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following common stock equivalents were excluded in the computation of the net loss per share because their effect is anti-dilutive:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BC_zFCVDVlwp5S3" style="display: none"&gt;Schedule of Anti-dilutive Securities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 75%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20250101__20250930_zXjs4YBnnFy1" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September 30, 2025&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Unaudited)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20240101__20240930_zZTByQvbDlKb" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September 30, 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Unaudited)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesLConvertiblePreferredStockMember_z5lmL1gNdT8i" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Series L convertible preferred stock &lt;b&gt;&lt;sup id="xdx_F44_zukfJ2qB72Ld"&gt;1&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;7,649,792&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0773"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zkneGfjaH1oa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Options to purchase common stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;597,550&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;101,264&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zGwF1cKvFTk4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Warrants to purchase common stock&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;49,459,390&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,133,762&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zbBEwqK4Rv6g" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total anti-dilutive securities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;57,706,732&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,235,026&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b id="xdx_F0C_zQQiiyKcALwd"&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F11_zV80lUlQoPQ9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Converted into
common stock using a conversion price of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEFudGktZGlsdXRpdmUgU2VjdXJpdGllcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_904_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20250930_zYB0aw7k7YA3" title="Conversion price per share"&gt;0.6421&lt;/span&gt; per share, as of September 30, 2025&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-012025-09-30_custom_SeriesLConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000772"
      unitRef="Shares">7649792</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-012025-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000775"
      unitRef="Shares">597550</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000776"
      unitRef="Shares">101264</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-012025-09-30_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000778"
      unitRef="Shares">49459390</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-09-30_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000779"
      unitRef="Shares">1133762</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-01to2025-09-30"
      decimals="INF"
      id="Fact000781"
      unitRef="Shares">57706732</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-09-30"
      decimals="INF"
      id="Fact000782"
      unitRef="Shares">1235026</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000785"
      unitRef="USDPShares">0.6421</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2025-01-01to2025-09-30" id="Fact000787">&lt;p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_zVcOgvqOXL45" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_868_zI8KcYfr4PP4"&gt;Concentration&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
is deposited in one financial institution. The balances held at this financial institution at times may be in excess of Federal Deposit
Insurance Corporation (&#x201c;FDIC&#x201d;) insurance limits of up to $&lt;span id="xdx_901_eus-gaap--CashFDICInsuredAmount_iI_c20250930_zazTR64ciLQ9" title="Cash, FDIC insured amount"&gt;250,000&lt;/span&gt;. &lt;span style="background-color: white"&gt;Management believes
that the financial institutions that hold the Company&#x2019;s cash are financially sound and, accordingly, minimal credit risk exists.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has a significant concentration of expenses incurred from and accounts payable to Cytovance Biologics, Inc. (&#x201c;Cytovance&#x201d;),
a related party, and the University of Minnesota, see Note 3 &#x2013; Accounts Payable and Related Party.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashFDICInsuredAmount
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000789"
      unitRef="USD">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact000791">&lt;p id="xdx_84D_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zpOSaP5GOIGl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86A_zEwLDVzX81k"&gt;Segment
Information&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s Chief Executive Officer and President (&#x201c;CEO&#x201d;) is our chief operating decision maker (&#x201c;CODM&#x201d;)
and evaluates performance and makes operating decisions about allocating resources based on financial data presented on a consolidated
basis. Because our CODM evaluates financial performance on a consolidated basis, the Company has determined that it operates as a single
reportable segment composed of the financial results of GT Biopharma, Inc.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact000793">&lt;p id="xdx_84E_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zaTm6E90uhy" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86E_z7v0R6ZiqRR1"&gt;Recent
Accounting Pronouncements&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2024, the FASB issued ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic
220-40): Disaggregation of Income Statement Expenses, requiring public entities to disclose additional information about specific expense
categories in the notes to the financial statements on an interim and annual basis. ASU 2024-03 is effective for fiscal years beginning
after December 15, 2026, and for interim periods beginning after December 15, 2027, with early adoption permitted. The Company is currently
evaluating the impact of adopting ASU 2024-03.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s management has evaluated all the recently issued, but not yet effective, accounting standards and guidance that have
been issued or proposed by the FASB or other standards-setting bodies through the filing date of these financial statements and does
not believe the future adoption of any such pronouncements will have a material effect on the Company&#x2019;s financial position and
results of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_8A6_zBDZqEdgdO44" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact000795">&lt;p id="xdx_808_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zJtD3LYhH6Jk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
3 &#x2013; &lt;span id="xdx_821_zkvjK0VSfOQ"&gt;Accounts Payable and Related Party&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zVHMOQDwABa6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounts
payable consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B5_zsdbA4ezRKUa" style="display: none"&gt;Schedule of Accounts Payable&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.65in; border-collapse: collapse; width: 85%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20250930_zPkCBJt4ATR4" style="font-weight: bold; text-align: center"&gt;As of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20241231_zbODJkCKqcsk" style="font-weight: bold; text-align: center"&gt;As of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AccountsPayableTradeCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_za2mDomThWP7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounts payable to Cytovance, a related party &lt;b&gt;&lt;sup id="xdx_F47_zmzpK4rGHVp4"&gt;1&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;60,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_pid_dp_uPure_c20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_fKDEp_zKjUDVBwg857" title="Accounts payable interest rate"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;1,183,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_pid_dp_uPure_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_fKDEp_zcYtEMPQr9A4" title="Accounts payable interest rate"&gt;31&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AccountsPayableTradeCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UniversityOfMinnesotaMember_zXH5o1fGLKGa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accounts payable to University of Minnesota&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;463,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UniversityOfMinnesotaMember_z8HArOXnGgq" title="Accounts payable interest rate"&gt;60&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;712,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UniversityOfMinnesotaMember_zq8NtfZAYo26" title="Accounts payable interest rate"&gt;18&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AccountsPayableTradeCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_zPYwIo9J9Peb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Legal services firm&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0813"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_zyWZGSlLRgC7" title="Accounts payable interest rate"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0816"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,505,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_zcGnnI9Zf6p7" title="Accounts payable interest rate"&gt;39&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AccountsPayableTradeCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_zGU3dht5cBp4" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accounts payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0820"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,505,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;39&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--AccountsPayableOtherCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OtherAccountsPayableMember_z9rI6JugfKXi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Other accounts payable&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;246,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OtherAccountsPayableMember_zJZsPOzbZ5n6" title="Accounts payable interest rate"&gt;32&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;453,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OtherAccountsPayableMember_zNl4LJWXBdlb" title="Accounts payable interest rate"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AccountsPayableCurrent_iI_ztC94l3ZrcDk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total accounts payable&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;769,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20250930_zbXyvJNRAWX3" title="Accounts payable interest rate"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,853,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20241231_zsFtxp3u4Rp9" title="Accounts payable interest rate"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span id="xdx_F0C_zauD72gr0fR1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F1A_zuycTXv7bPnk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounts Payable
to Cytovance, a related party, since Cytovance owns greater than 5% of the Company&#x2019;s issued and outstanding common stock. See Note
7 &#x2013; Commitments and Contingencies, Significant Agreements.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;



&lt;p id="xdx_8AF_z7qpSzEqnGU5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Cytovance,
a Related Party&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_ecustom--ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock_zRP0PaRVjNGc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
details of the Company&#x2019;s accounts payable to Cytovance were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="display: none"&gt;&lt;span id="xdx_8B6_zMcldOtFeIHd"&gt;Schedule of Accounts Payable to Related Party&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 75%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20250101__20250930_zV7l9V0nwTS6" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20240101__20240930_zZqcGinV4shb" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Nine Months Ending&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;(Unaudited)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;(Unaudited)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AccountsPayableTradeCurrent_iS_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zmDQqzj4sENi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Beginning balance&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,183,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;3,515,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--ProceedsFromRelatedPartyDebt_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zatWKkVN8o2f" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Invoices, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;686,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,365,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--RepaymentsOfRelatedPartyDebt_iN_di_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zkfc1ri0A3gb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Payments in cash&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(962,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,432,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--PaymentsForRepurchaseOfCommonStock_iN_di_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_znsAUxadALma" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Payments in common stock, at fair value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0849"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(810,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--RepaymentsOfPrefundedWarrantsAtFairValue_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zF8Hdx51h8Aj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Payments in pre-funded warrants, at fair value&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(847,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0853"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AccountsPayableTradeCurrent_iE_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zeSPOiiFsmI9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Ending balance&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;60,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;638,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zfCeHtMx9Ih5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
April and June 2024, the Company issued an aggregate of &lt;span id="xdx_90F_ecustom--StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable_c20240401__20240430__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ze0OMsLkTEzh" title="Issuance of prefunded warrant to settle vendor payable, shares"&gt;&lt;span id="xdx_90B_ecustom--StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable_c20240601__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwprfxvYjuE5" title="Issuance of prefunded warrant to settle vendor payable, shares"&gt;127,597&lt;/span&gt;&lt;/span&gt; shares of common stock with a fair value of approximately $&lt;span id="xdx_907_ecustom--StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable_c20240401__20240430__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zP2aeUDMMqp2" title="Issuance of prefunded warrant to settle vendor payable, value"&gt;&lt;span id="xdx_90D_ecustom--StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable_c20240601__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zx1Ot95Rhm9i" title="Issuance of prefunded warrant to settle vendor payable, value"&gt;810,000&lt;/span&gt;&lt;/span&gt; to
Cytovance as partial payment of accounts payable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
March 2025, the Company issued pre-funded warrants to purchase up to &lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zjvze5nLz6ie" title="Issuance of pre-funded warrants"&gt;326,251&lt;/span&gt; shares of common stock exercisable at $&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zKAPC1NI3lX9" title="Exercise price"&gt;0.0001&lt;/span&gt; per share
with a fair value of approximately $&lt;span id="xdx_90D_ecustom--RepaymentsOfPrefundedWarrantsAtFairValue_iN_di_c20250301__20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zvvbUNDfQTW3" title="Payments in pre-funded warrants, at fair value"&gt;847,000&lt;/span&gt; to Cytovance as partial payment of accounts payable. The pre-funded warrants were valued
at the market price on the last day of the month during the respective month that the invoices are due.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
March 2025, a legal services firm currently engaged by the Company agreed to reduce the Company&#x2019;s prior year unpaid fees by approximately
$&lt;span id="xdx_902_eus-gaap--PaymentsForFees_pn6n6_c20250301__20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_z7PKbwX4b6O3" title="Prior year unpaid fees"&gt;1&lt;/span&gt; million. The Company classified this transaction as other income.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;University
of Minnesota&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;See
Note 7 &#x2013; Commitments and Contingencies, Significant Agreements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;PDPC
Advisors Inc., a Related Party&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 30, 2025, the Company entered into an Advisory Agreement (the &#x201c;Agreement&#x201d;) with PDPC Advisors Inc. (&#x201c;PDPC&#x201d;),
to perform certain advisory services. Under the Agreement cash payments amounting to $&lt;span id="xdx_907_eus-gaap--RepaymentsOfOtherDebt_c20250601__20250630__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember_zsLGIWeNcQ4a" title="Cash payment"&gt;100,000&lt;/span&gt; are to be paid in six equal installments
beginning on July 1, 2025 and ending on December 31, 2025. In addition, upon execution of the Agreement, the Company issued to PDPC a
pre-funded warrant to purchase &lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstanding_iI_c20250630__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember_zw2K4P0C7hM5" title="Warrants outstanding"&gt;150,000&lt;/span&gt; shares of common stock of the Company, which had a fair value of $&lt;span id="xdx_905_eus-gaap--PaymentsOfStockIssuanceCosts_c20250601__20250630__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember_zZRCwR7Suz3c" title="Stock issuance"&gt;537,000&lt;/span&gt; at the time of issuance.
&lt;span id="xdx_905_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20250601__20250630__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember_zdHcRNTtrRlc" title="Related party transaction description"&gt;The Agreement begins on July 1, 2025 and terminates on June 30, 2026. PDPC is considered a related party as its CEO is an individual
who has voting and investment control over an entity whose beneficial ownership exceeded 5% of the issued and outstanding shares of the
Company&#x2019;s common stock.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact000797">&lt;p id="xdx_897_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zVHMOQDwABa6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounts
payable consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B5_zsdbA4ezRKUa" style="display: none"&gt;Schedule of Accounts Payable&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.65in; border-collapse: collapse; width: 85%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20250930_zPkCBJt4ATR4" style="font-weight: bold; text-align: center"&gt;As of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20241231_zbODJkCKqcsk" style="font-weight: bold; text-align: center"&gt;As of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AccountsPayableTradeCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_za2mDomThWP7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounts payable to Cytovance, a related party &lt;b&gt;&lt;sup id="xdx_F47_zmzpK4rGHVp4"&gt;1&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;60,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_pid_dp_uPure_c20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_fKDEp_zKjUDVBwg857" title="Accounts payable interest rate"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;1,183,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_pid_dp_uPure_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_fKDEp_zcYtEMPQr9A4" title="Accounts payable interest rate"&gt;31&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AccountsPayableTradeCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UniversityOfMinnesotaMember_zXH5o1fGLKGa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accounts payable to University of Minnesota&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;463,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UniversityOfMinnesotaMember_z8HArOXnGgq" title="Accounts payable interest rate"&gt;60&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;712,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UniversityOfMinnesotaMember_zq8NtfZAYo26" title="Accounts payable interest rate"&gt;18&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AccountsPayableTradeCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_zPYwIo9J9Peb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Legal services firm&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0813"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_zyWZGSlLRgC7" title="Accounts payable interest rate"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0816"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,505,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_zcGnnI9Zf6p7" title="Accounts payable interest rate"&gt;39&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AccountsPayableTradeCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalServicesFirmMember_zGU3dht5cBp4" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accounts payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0820"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,505,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;39&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--AccountsPayableOtherCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OtherAccountsPayableMember_z9rI6JugfKXi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Other accounts payable&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;246,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OtherAccountsPayableMember_zJZsPOzbZ5n6" title="Accounts payable interest rate"&gt;32&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;453,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OtherAccountsPayableMember_zNl4LJWXBdlb" title="Accounts payable interest rate"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AccountsPayableCurrent_iI_ztC94l3ZrcDk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total accounts payable&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;769,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20250930_zbXyvJNRAWX3" title="Accounts payable interest rate"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,853,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_uPure_c20241231_zsFtxp3u4Rp9" title="Accounts payable interest rate"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span id="xdx_F0C_zauD72gr0fR1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F1A_zuycTXv7bPnk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounts Payable
to Cytovance, a related party, since Cytovance owns greater than 5% of the Company&#x2019;s issued and outstanding common stock. See Note
7 &#x2013; Commitments and Contingencies, Significant Agreements.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;



</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="AsOf2025-09-30_custom_CytovanceBiologicsIncMember"
      decimals="0"
      id="Fact000799"
      unitRef="USD">60000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableInterestBearingInterestRate
      contextRef="AsOf2025-09-30_custom_CytovanceBiologicsIncMember"
      decimals="INF"
      id="Fact000802"
      unitRef="Pure">0.08</us-gaap:AccountsPayableInterestBearingInterestRate>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="AsOf2024-12-31_custom_CytovanceBiologicsIncMember"
      decimals="0"
      id="Fact000800"
      unitRef="USD">1183000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableInterestBearingInterestRate
      contextRef="AsOf2024-12-31_custom_CytovanceBiologicsIncMember"
      decimals="INF"
      id="Fact000804"
      unitRef="Pure">0.31</us-gaap:AccountsPayableInterestBearingInterestRate>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="AsOf2025-09-30_custom_UniversityOfMinnesotaMember"
      decimals="0"
      id="Fact000806"
      unitRef="USD">463000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableInterestBearingInterestRate
      contextRef="AsOf2025-09-30_custom_UniversityOfMinnesotaMember"
      decimals="INF"
      id="Fact000809"
      unitRef="Pure">0.60</us-gaap:AccountsPayableInterestBearingInterestRate>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="AsOf2024-12-31_custom_UniversityOfMinnesotaMember"
      decimals="0"
      id="Fact000807"
      unitRef="USD">712000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableInterestBearingInterestRate
      contextRef="AsOf2024-12-31_custom_UniversityOfMinnesotaMember"
      decimals="INF"
      id="Fact000811"
      unitRef="Pure">0.18</us-gaap:AccountsPayableInterestBearingInterestRate>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="AsOf2024-12-31_custom_LegalServicesFirmMember"
      decimals="0"
      id="Fact000814"
      unitRef="USD">1505000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableInterestBearingInterestRate
      contextRef="AsOf2024-12-31_custom_LegalServicesFirmMember"
      decimals="INF"
      id="Fact000818"
      unitRef="Pure">0.39</us-gaap:AccountsPayableInterestBearingInterestRate>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="AsOf2024-12-31_custom_LegalServicesFirmMember"
      decimals="0"
      id="Fact000821"
      unitRef="USD">1505000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="AsOf2025-09-30_custom_OtherAccountsPayableMember"
      decimals="0"
      id="Fact000823"
      unitRef="USD">246000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableInterestBearingInterestRate
      contextRef="AsOf2025-09-30_custom_OtherAccountsPayableMember"
      decimals="INF"
      id="Fact000826"
      unitRef="Pure">0.32</us-gaap:AccountsPayableInterestBearingInterestRate>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="AsOf2024-12-31_custom_OtherAccountsPayableMember"
      decimals="0"
      id="Fact000824"
      unitRef="USD">453000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableInterestBearingInterestRate
      contextRef="AsOf2024-12-31_custom_OtherAccountsPayableMember"
      decimals="INF"
      id="Fact000828"
      unitRef="Pure">0.12</us-gaap:AccountsPayableInterestBearingInterestRate>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000830"
      unitRef="USD">769000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableInterestBearingInterestRate
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000833"
      unitRef="Pure">1</us-gaap:AccountsPayableInterestBearingInterestRate>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000831"
      unitRef="USD">3853000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableInterestBearingInterestRate
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000835"
      unitRef="Pure">1</us-gaap:AccountsPayableInterestBearingInterestRate>
    <GTBP:ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact000838">&lt;p id="xdx_89C_ecustom--ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock_zRP0PaRVjNGc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
details of the Company&#x2019;s accounts payable to Cytovance were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="display: none"&gt;&lt;span id="xdx_8B6_zMcldOtFeIHd"&gt;Schedule of Accounts Payable to Related Party&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 75%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20250101__20250930_zV7l9V0nwTS6" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20240101__20240930_zZqcGinV4shb" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Nine Months Ending&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;(Unaudited)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;(Unaudited)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AccountsPayableTradeCurrent_iS_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zmDQqzj4sENi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Beginning balance&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,183,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;3,515,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--ProceedsFromRelatedPartyDebt_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zatWKkVN8o2f" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Invoices, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;686,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,365,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--RepaymentsOfRelatedPartyDebt_iN_di_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zkfc1ri0A3gb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Payments in cash&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(962,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,432,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--PaymentsForRepurchaseOfCommonStock_iN_di_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_znsAUxadALma" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Payments in common stock, at fair value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0849"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(810,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--RepaymentsOfPrefundedWarrantsAtFairValue_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zF8Hdx51h8Aj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Payments in pre-funded warrants, at fair value&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(847,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0853"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AccountsPayableTradeCurrent_iE_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zeSPOiiFsmI9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Ending balance&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;60,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;638,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</GTBP:ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="AsOf2024-12-31_custom_CytovanceBiologicsIncMember"
      decimals="0"
      id="Fact000840"
      unitRef="USD">1183000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="AsOf2023-12-31_custom_CytovanceBiologicsIncMember"
      decimals="0"
      id="Fact000841"
      unitRef="USD">3515000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="From2025-01-012025-09-30_custom_CytovanceBiologicsIncMember"
      decimals="0"
      id="Fact000843"
      unitRef="USD">686000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="From2024-01-012024-09-30_custom_CytovanceBiologicsIncMember"
      decimals="0"
      id="Fact000844"
      unitRef="USD">1365000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="From2025-01-012025-09-30_custom_CytovanceBiologicsIncMember"
      decimals="0"
      id="Fact000846"
      unitRef="USD">962000</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="From2024-01-012024-09-30_custom_CytovanceBiologicsIncMember"
      decimals="0"
      id="Fact000847"
      unitRef="USD">3432000</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="From2024-01-012024-09-30_custom_CytovanceBiologicsIncMember"
      decimals="0"
      id="Fact000850"
      unitRef="USD">810000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <GTBP:RepaymentsOfPrefundedWarrantsAtFairValue
      contextRef="From2025-01-012025-09-30_custom_CytovanceBiologicsIncMember"
      decimals="0"
      id="Fact000852"
      unitRef="USD">-847000</GTBP:RepaymentsOfPrefundedWarrantsAtFairValue>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="AsOf2025-09-30_custom_CytovanceBiologicsIncMember"
      decimals="0"
      id="Fact000855"
      unitRef="USD">60000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="AsOf2024-09-30_custom_CytovanceBiologicsIncMember"
      decimals="0"
      id="Fact000856"
      unitRef="USD">638000</us-gaap:AccountsPayableTradeCurrent>
    <GTBP:StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable
      contextRef="From2024-04-012024-04-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000858"
      unitRef="Shares">127597</GTBP:StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable>
    <GTBP:StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable
      contextRef="From2024-06-012024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000860"
      unitRef="Shares">127597</GTBP:StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable>
    <GTBP:StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable
      contextRef="From2024-04-012024-04-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000862"
      unitRef="USD">810000</GTBP:StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable>
    <GTBP:StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable
      contextRef="From2024-06-012024-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000864"
      unitRef="USD">810000</GTBP:StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-03-31_custom_CytovanceBiologicsIncMember"
      decimals="INF"
      id="Fact000866"
      unitRef="Shares">326251</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-03-31_custom_CytovanceBiologicsIncMember"
      decimals="INF"
      id="Fact000868"
      unitRef="USDPShares">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <GTBP:RepaymentsOfPrefundedWarrantsAtFairValue
      contextRef="From2025-03-012025-03-31_custom_CytovanceBiologicsIncMember"
      decimals="0"
      id="Fact000870"
      unitRef="USD">-847000</GTBP:RepaymentsOfPrefundedWarrantsAtFairValue>
    <us-gaap:PaymentsForFees
      contextRef="From2025-03-012025-03-31_custom_LegalServicesFirmMember"
      decimals="-6"
      id="Fact000872"
      unitRef="USD">1000000</us-gaap:PaymentsForFees>
    <us-gaap:RepaymentsOfOtherDebt
      contextRef="From2025-06-012025-06-30_custom_AdvisoryAgreementMember"
      decimals="0"
      id="Fact000874"
      unitRef="USD">100000</us-gaap:RepaymentsOfOtherDebt>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2025-06-30_custom_AdvisoryAgreementMember"
      decimals="0"
      id="Fact000876"
      unitRef="USD">150000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2025-06-012025-06-30_custom_AdvisoryAgreementMember"
      decimals="0"
      id="Fact000878"
      unitRef="USD">537000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction
      contextRef="From2025-06-012025-06-30_custom_AdvisoryAgreementMember"
      id="Fact000880">The Agreement begins on July 1, 2025 and terminates on June 30, 2026. PDPC is considered a related party as its CEO is an individual
who has voting and investment control over an entity whose beneficial ownership exceeded 5% of the issued and outstanding shares of the
Company&#x2019;s common stock.</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <GTBP:WarrantLiabilityTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact000882">&lt;p id="xdx_80C_ecustom--WarrantLiabilityTextBlock_z9XQ8r7o1ui4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
4 &#x2013; &lt;span id="xdx_823_z1Hv2m00lTj2"&gt;Warrant Liability&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2023
Warrants&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 4, 2023, as part of the private placement offering, the Company issued warrants to purchase up to an aggregate of &lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230104__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentyThreeCommonWarrantsMember__srt--RangeAxis__srt--MaximumMember_z0jYKakzILe2" title="Warrants to purchase"&gt;216,667&lt;/span&gt; shares
of the Company&#x2019;s common stock (the &#x201c;2023 Common Warrants&#x201d;), and placement agent warrants to purchase up to &lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230104__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentyThreePlacementAgentsWarrantsMember__srt--RangeAxis__srt--MaximumMember_zkjK6gi1nXR" title="Warrants to purchase"&gt;13,000&lt;/span&gt; shares
of the Company&#x2019;s common stock (the &#x201c;2023 Placement Agents Warrants&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
2023 Common Warrants and the 2023 Placement Agents Warrants (collectively the &#x201c;2023 Warrants&#x201d;), provide for a value calculation
for the warrants using the Black Scholes model in the event of certain fundamental transactions. The fair value calculation provides
for a floor on the volatility amount utilized in the value calculation at &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230104__20230104__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentyThreeWarrantsMember_zbesnlHgVKw2" title="Volatility amount utilized in the value calculation percentage"&gt;100&lt;/span&gt;% or greater. The Company has determined this provision
introduces leverage to the holders that could result in a value that would be greater than the settlement amount of a fixed-for-fixed
option on the Company&#x2019;s own equity shares. Therefore, pursuant to ASC 815, the Company has classified the 2023 Warrants as a liability
in its balance sheet. The classification of the 2023 Warrants, including whether they should be recorded as liability or as equity, is
evaluated at the end of each reporting period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
2023 Warrants were initially recorded at a fair value at $&lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstanding_iI_pn5n6_c20230104__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentyThreeWarrantsMember_zU121x20o7o4" title="Warrant  fair value"&gt;5.8&lt;/span&gt; million at the grant date, and upon the closing of placement, was recorded
as a cost of capital. The fair value of the 2023 Warrants classified as a liability in the Company&#x2019;s unaudited condensed balance
sheets and will be re-measured at the end of every reporting period with the change in value reported in the unaudited condensed statements
of operations until they are either exercised or expired.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hus-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_zNBFfx9SPuOi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
2023 Warrant liability is valued using a Black Scholes Option pricing model with the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B8_zWjZ7Hx5lTx9" style="display: none"&gt;Schedule of Warrant Liability Assumptions&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 75%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023 Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;(Unaudited)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Stock price&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_zLJNysyStj71" style="width: 16%; text-align: right" title="Warrants measurement input"&gt;0.59&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_zGijmKtKrnD" style="width: 16%; text-align: right" title="Warrants measurement input"&gt;3.05&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Risk-free interest rate &lt;b&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fMQ_____zULjtQhhpXck" style="text-align: right" title="Warrants measurement input"&gt;3.61&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fMQ_____zq4NwV2DTbR9" style="text-align: right" title="Warrants measurement input"&gt;4.27&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected volatility &lt;b&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fMg_____zc00RU4JLLt7" style="text-align: right" title="Warrants measurement input"&gt;110&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fMg_____zNZTlpAwVrz" style="text-align: right" title="Warrants measurement input"&gt;114&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected life (in years) &lt;b&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember__srt--RangeAxis__srt--MinimumMember_fMw_____zInI89XGEZB5" title="Expected life (in years)"&gt;2.25&lt;/span&gt; &#x2013; &lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember__srt--RangeAxis__srt--MaximumMember_fMw_____zvxxIyKx9oHk" title="Expected life (in years)"&gt;2.76&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember__srt--RangeAxis__srt--MinimumMember_fMw_____ziFUP3rBV05k" title="Expected life (in years)"&gt;3.0&lt;/span&gt; &#x2013; &lt;span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember__srt--RangeAxis__srt--MaximumMember_fMw_____z1srIpYXvahf" title="Expected life (in years)"&gt;3.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected dividend yield &lt;b&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fNA_____z5JzdFvXs74h" style="text-align: right" title="Warrants measurement input"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0914"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fNA_____zCh0lwsjSzVc" style="text-align: right" title="Warrants measurement input"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0916"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Fair value of warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FairValueAdjustmentOfWarrants_c20250101__20250930__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_znWjiU7lWKzi" style="text-align: right" title="Fair value of warrants"&gt;8,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_z6ZUOUOr0Yle" style="text-align: right" title="Fair value of warrants"&gt;252,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;sup&gt;&#160;&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b id="xdx_F0D_zYErwEVo5Yh2"&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F12_zWAhoOiEQ2p4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Based on rates
established by the Federal Reserve Bank&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b id="xdx_F04_zuzIqXJv6Heg"&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F18_znCoxutDAss8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Historical volatility
of the Company&#x2019;s common stock is used to estimate the future volatility of its common stock&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span id="xdx_F03_z7LK8N3afFF3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F19_zHgePmiMPZt5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Determined by the
remaining contractual life of the derivative instrument&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b id="xdx_F0D_zaBKs5VLDYW9"&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F1A_zabJbDUIuca3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Based on no dividends
paid or expected to be paid&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p id="xdx_8A6_zVTirCa3aaY8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zS1ssbT5Gvm6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
details of warrant liability transactions were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BF_zd2V521KWH91" style="display: none"&gt;Schedule of Warrant Liability Transactions&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 75%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20250101__20250930_znewNSHF8QP9" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20240101__20240930_z831OcIKrEY7" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Nine Months Ending&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;(Unaudited)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;(Unaudited)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--WarrantLiabilityCurrent_iS_zcqzMKyIIuj1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Beginning balance&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;252,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,052,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--IssuanceOfStockAndWarrantsForServicesOrClaims_zLXpDWrQTXu8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Issuance of warrants at fair value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0931"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0932"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_zY8WYsozPh3f" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Change in fair value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(244,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(870,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--ExtinguishmentOfWarrant_zZhKbNjqBTJh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1pt"&gt;Extinguishment&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0937"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0938"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--WarrantLiabilityCurrent_iE_zSyhNnzQCCA8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Ending balance&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;8,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;182,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_z3ojhHHCiXmf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</GTBP:WarrantLiabilityTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-01-04_custom_TwoThousandTwentyThreeCommonWarrantsMember_srt_MaximumMember"
      decimals="INF"
      id="Fact000884"
      unitRef="Shares">216667</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-01-04_custom_TwoThousandTwentyThreePlacementAgentsWarrantsMember_srt_MaximumMember"
      decimals="INF"
      id="Fact000886"
      unitRef="Shares">13000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2023-01-042023-01-04_custom_TwoThousandTwentyThreeWarrantsMember"
      decimals="INF"
      id="Fact000888"
      unitRef="Pure">1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2023-01-04_custom_TwoThousandTwentyThreeWarrantsMember"
      decimals="-5"
      id="Fact000890"
      unitRef="USD">5800000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="From2025-01-012025-09-30_custom_TwoThousandTwentyThreeWarrantsMember"
      id="Fact000892">&lt;p id="xdx_891_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hus-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_zNBFfx9SPuOi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
2023 Warrant liability is valued using a Black Scholes Option pricing model with the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B8_zWjZ7Hx5lTx9" style="display: none"&gt;Schedule of Warrant Liability Assumptions&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 75%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023 Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;(Unaudited)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Stock price&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_zLJNysyStj71" style="width: 16%; text-align: right" title="Warrants measurement input"&gt;0.59&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_zGijmKtKrnD" style="width: 16%; text-align: right" title="Warrants measurement input"&gt;3.05&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Risk-free interest rate &lt;b&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fMQ_____zULjtQhhpXck" style="text-align: right" title="Warrants measurement input"&gt;3.61&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fMQ_____zq4NwV2DTbR9" style="text-align: right" title="Warrants measurement input"&gt;4.27&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected volatility &lt;b&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fMg_____zc00RU4JLLt7" style="text-align: right" title="Warrants measurement input"&gt;110&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fMg_____zNZTlpAwVrz" style="text-align: right" title="Warrants measurement input"&gt;114&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected life (in years) &lt;b&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember__srt--RangeAxis__srt--MinimumMember_fMw_____zInI89XGEZB5" title="Expected life (in years)"&gt;2.25&lt;/span&gt; &#x2013; &lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember__srt--RangeAxis__srt--MaximumMember_fMw_____zvxxIyKx9oHk" title="Expected life (in years)"&gt;2.76&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember__srt--RangeAxis__srt--MinimumMember_fMw_____ziFUP3rBV05k" title="Expected life (in years)"&gt;3.0&lt;/span&gt; &#x2013; &lt;span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember__srt--RangeAxis__srt--MaximumMember_fMw_____z1srIpYXvahf" title="Expected life (in years)"&gt;3.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected dividend yield &lt;b&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fNA_____z5JzdFvXs74h" style="text-align: right" title="Warrants measurement input"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0914"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fNA_____zCh0lwsjSzVc" style="text-align: right" title="Warrants measurement input"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0916"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Fair value of warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FairValueAdjustmentOfWarrants_c20250101__20250930__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_znWjiU7lWKzi" style="text-align: right" title="Fair value of warrants"&gt;8,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_z6ZUOUOr0Yle" style="text-align: right" title="Fair value of warrants"&gt;252,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;sup&gt;&#160;&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b id="xdx_F0D_zYErwEVo5Yh2"&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F12_zWAhoOiEQ2p4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Based on rates
established by the Federal Reserve Bank&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b id="xdx_F04_zuzIqXJv6Heg"&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F18_znCoxutDAss8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Historical volatility
of the Company&#x2019;s common stock is used to estimate the future volatility of its common stock&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span id="xdx_F03_z7LK8N3afFF3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F19_zHgePmiMPZt5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Determined by the
remaining contractual life of the derivative instrument&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b id="xdx_F0D_zaBKs5VLDYW9"&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F1A_zabJbDUIuca3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Based on no dividends
paid or expected to be paid&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2025-09-30_us-gaap_MeasurementInputSharePriceMember_custom_TwoThousandTwentyThreeWarrantsMember"
      decimals="INF"
      id="Fact000894"
      unitRef="USDPShares">0.59</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-31_us-gaap_MeasurementInputSharePriceMember_custom_TwoThousandTwentyThreeWarrantsMember"
      decimals="INF"
      id="Fact000896"
      unitRef="USDPShares">3.05</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2025-09-30_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_TwoThousandTwentyThreeWarrantsMember"
      decimals="INF"
      id="Fact000898"
      unitRef="Pure">3.61</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_TwoThousandTwentyThreeWarrantsMember"
      decimals="INF"
      id="Fact000900"
      unitRef="Pure">4.27</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2025-09-30_us-gaap_MeasurementInputPriceVolatilityMember_custom_TwoThousandTwentyThreeWarrantsMember"
      decimals="INF"
      id="Fact000902"
      unitRef="Pure">110</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_TwoThousandTwentyThreeWarrantsMember"
      decimals="INF"
      id="Fact000904"
      unitRef="Pure">114</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2025-09-30_us-gaap_MeasurementInputExpectedTermMember_custom_TwoThousandTwentyThreeWarrantsMember_srt_MinimumMember"
      id="Fact000906">P2Y3M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2025-09-30_us-gaap_MeasurementInputExpectedTermMember_custom_TwoThousandTwentyThreeWarrantsMember_srt_MaximumMember"
      id="Fact000908">P2Y9M3D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2024-12-31_us-gaap_MeasurementInputExpectedTermMember_custom_TwoThousandTwentyThreeWarrantsMember_srt_MinimumMember"
      id="Fact000910">P3Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2024-12-31_us-gaap_MeasurementInputExpectedTermMember_custom_TwoThousandTwentyThreeWarrantsMember_srt_MaximumMember"
      id="Fact000912">P3Y6M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2025-01-012025-09-30_custom_TwoThousandTwentyThreeWarrantsMember"
      decimals="0"
      id="Fact000918"
      unitRef="USD">8000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-01-012024-12-31_custom_TwoThousandTwentyThreeWarrantsMember"
      decimals="0"
      id="Fact000920"
      unitRef="USD">252000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact000926">&lt;p id="xdx_89B_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zS1ssbT5Gvm6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
details of warrant liability transactions were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BF_zd2V521KWH91" style="display: none"&gt;Schedule of Warrant Liability Transactions&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 75%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20250101__20250930_znewNSHF8QP9" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20240101__20240930_z831OcIKrEY7" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Nine Months Ending&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;(Unaudited)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;(Unaudited)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--WarrantLiabilityCurrent_iS_zcqzMKyIIuj1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Beginning balance&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;252,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,052,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--IssuanceOfStockAndWarrantsForServicesOrClaims_zLXpDWrQTXu8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Issuance of warrants at fair value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0931"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0932"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_zY8WYsozPh3f" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Change in fair value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(244,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(870,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--ExtinguishmentOfWarrant_zZhKbNjqBTJh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1pt"&gt;Extinguishment&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0937"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0938"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--WarrantLiabilityCurrent_iE_zSyhNnzQCCA8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Ending balance&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;8,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;182,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock>
    <GTBP:WarrantLiabilityCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000928"
      unitRef="USD">252000</GTBP:WarrantLiabilityCurrent>
    <GTBP:WarrantLiabilityCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000929"
      unitRef="USD">1052000</GTBP:WarrantLiabilityCurrent>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact000934"
      unitRef="USD">-244000</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact000935"
      unitRef="USD">-870000</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <GTBP:WarrantLiabilityCurrent
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000940"
      unitRef="USD">8000</GTBP:WarrantLiabilityCurrent>
    <GTBP:WarrantLiabilityCurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000941"
      unitRef="USD">182000</GTBP:WarrantLiabilityCurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact000943">&lt;p id="xdx_804_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zM4aRlEgIoDe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
5 &#x2013; &lt;span id="xdx_826_zSs3qfoGQvm9"&gt;Stockholders&#x2019; Equity (Deficit)&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s authorized capital as of September 30, 2025 was &lt;span id="xdx_905_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20250930_zotYYF0QbOD" title="Common stock, shares authorized"&gt;250,000,000&lt;/span&gt; shares of common stock, par value $&lt;span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20250930_z5F4QeLkQ093" title="Common stock, par value"&gt;0.001&lt;/span&gt; per share, and &lt;span id="xdx_90D_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20250930_zbweAxEGc3pa" title="Preferred stock, shares authorized"&gt;15,000,000&lt;/span&gt;
shares of preferred stock, par value $&lt;span id="xdx_908_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20250930_zZvnJTZWc9ra" title="Preferred stock, par value"&gt;0.01&lt;/span&gt; per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Common
Stock&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2025
Private Placement of Equity Facility&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 14, 2025, and as amended on June 10, 2025, the Company entered into a common shares purchase agreement (the &#x201c;Purchase Agreement&#x201d;)
with investors (collectively, the &#x201c;Investors&#x201d;) relating to a committed equity facility (the &#x201c;Facility&#x201d;). Pursuant
to the Purchase Agreement, the Company has the right from time to time at its option to sell to the Investors up to $&lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_pn6n6_c20250514__20250514__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zDVzuO1CXkJ5" title="Warrants to purcahse"&gt;20&lt;/span&gt; million of its
common stock subject to certain conditions and limitations set forth in the Purchase Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Sales
of the shares of common stock to the Investors under the Purchase Agreement, and the timing of any sales, will be determined by the Company
from time to time in its sole discretion and will depend on a variety of factors, including, among other things, market conditions, the
trading price of the common stock and determinations by the Company regarding the use of proceeds from the sale of such shares of common
stock. The net proceeds from any sales under the Purchase Agreement will depend on the frequency with, and prices at, which the shares
of common stock are sold to the Investors.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
purchase price of the shares of common stock that the Company elects to sell to the Investors pursuant to the Purchase Agreement will
be &lt;span id="xdx_90F_ecustom--WeightedAverageVolumePriceOfCommonStockPercentage_pid_dp_uPure_c20250514__20250514__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_z3wAuLvWfJag" title="Weighted average volume price of common stock percentage"&gt;93&lt;/span&gt;% of the volume weighted average price of the shares of common stock during the applicable purchase date on which the Company has
timely delivered written notice to the Investors directing it to purchase shares of common stock under the Purchase Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the execution of the Purchase Agreement, the Company agreed to issue to the Investors pre-funded warrants to purchase
an aggregate of &lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250514__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zj2V9IhH8Vkf" title="Warrants to purcahse"&gt;300,000&lt;/span&gt; shares of common stock as consideration for their irrevocable commitment to purchase the shares of common stock
upon the terms and subject to the satisfaction of the conditions set forth in the Purchase Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2025
Warrant Inducement Transaction&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 26, 2025, the Company received gross proceeds of $&lt;span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_c20250226__20250226_zEs2IHD2nizg" title="Proceeds from private placement"&gt;686,000&lt;/span&gt; before deducting placement agent fees and other offering expenses
of $&lt;span id="xdx_908_eus-gaap--NoninterestExpenseOfferingCost_c20250226__20250226_zADJLQR8FZp2" title="Other offering expenses"&gt;70,000&lt;/span&gt; in relation to a warrant exercise inducement agreement with certain holders of existing warrants. The existing warrants were
exercisable into &lt;span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_iI_c20250226_zhToVOKHakR8" title="Issuance of warrants, exercisable"&gt;302,069&lt;/span&gt; shares of the Company&#x2019;s common stock at $&lt;span id="xdx_908_eus-gaap--SharePrice_iI_c20250226__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z3IzXbvFzyid" title="Share price"&gt;4.35&lt;/span&gt; per share. The holders agreed to exercise these existing
warrants at a reduced exercise price of $&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250226__us-gaap--StatementEquityComponentsAxis__custom--InducementWarrantsMember_zO5DN5VS6rYh" title="Share price"&gt;2.27&lt;/span&gt; per share in exchange for the Company&#x2019;s agreement to issue the holders new warrants
(the &#x201c;Inducement Warrants&#x201d;) exercisable for an aggregate of up to &lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250226__us-gaap--StatementEquityComponentsAxis__custom--InducementWarrantsMember_z7uBOwRJOfCl" title="Issuance of warrants"&gt;604,138&lt;/span&gt; shares of common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Inducement Warrants consist of (i) new Series A Inducement Warrants, representing warrants to purchase up to &lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250226__us-gaap--StatementEquityComponentsAxis__custom--SeriesAInducementWarrantsMember_zf5ihwX5oo5e" title="Issuance of warrants"&gt;302,069&lt;/span&gt; shares of Common
Stock at $&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250226__us-gaap--StatementEquityComponentsAxis__custom--SeriesAInducementWarrantsMember_zmYrpu6rGlp5" title="Exercise price"&gt;2.02&lt;/span&gt; per share exercisable immediately upon issuance with a term of &lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_c20250226__us-gaap--StatementEquityComponentsAxis__custom--SeriesAInducementWarrantsMember_zpqpCetQluIh" title="Warrant term"&gt;five years&lt;/span&gt; from the date of issuance, and (ii) new Series
B Inducement Warrants, representing warrants to purchase up to &lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250226__us-gaap--StatementEquityComponentsAxis__custom--SeriesBInducementWarrantsMember_zivr0O9X0lnf" title="Issuance of warrants"&gt;302,069&lt;/span&gt; shares of common stock at $&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250226__us-gaap--StatementEquityComponentsAxis__custom--SeriesBInducementWarrantsMember_zfzJnpckr2x1" title="Exercise price"&gt;2.02&lt;/span&gt; per share exercisable immediately
upon issuance with a term of &lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20250226__us-gaap--StatementEquityComponentsAxis__custom--SeriesBInducementWarrantsMember_zyrBitJRRTVi" title="Warrant term"&gt;eighteen months&lt;/span&gt; from the date of issuance. In addition, the Company issued warrants to the placement agent
to purchase &lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250226_zSV3RSIy3w45" title="Placement agents"&gt;21,145&lt;/span&gt; shares of common stock at $&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250226_zTnR3WTxnmt1" title="Exercise price"&gt;2.8375&lt;/span&gt; per share exercisable immediately upon issuance with a term of &lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_c20250226_zxqj6rLc5lK4" title="Warrant term"&gt;five years&lt;/span&gt; from the
date of issuance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company determined that under ASC 815, the 2025 inducement and placement agent warrants are considered indexed to the Company&#x2019;s
own stock and eligible for an exception from derivative accounting. Accordingly, the fair value of the 2025 inducement and placement
agent warrants are classified as equity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognized the aggregate effect of the modification of warrants and grant of inducement warrants of $&lt;span id="xdx_90B_eus-gaap--PaymentsOfStockIssuanceCosts_pn5n6_c20250101__20250930_zvIZsfTHl78g" title="Equity issuance cost"&gt;1.1 &lt;/span&gt;million as an equity
issuance cost and the accounting effect is recognized in the Statement of Stockholders&#x2019; Equity (Deficit).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Preferred
Stock&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Series
C Preferred Stock&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of September 30, 2025, there were &lt;span id="xdx_907_eus-gaap--PreferredStockSharesIssued_iI_pid_c20250930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zkTpTyCFB2Fd" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_908_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20250930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_z7RVvDQTJ5ca" title="Preferred stock, shares outstanding"&gt;96,230&lt;/span&gt;&lt;/span&gt; shares of series C preferred stock, par value $&lt;span id="xdx_904_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20250930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zpJbpcyPk0V" title="Preferred stock, par value"&gt;0.01&lt;/span&gt; per share (the &#x201c;Series C Preferred
Stock&#x201d;) issued and outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
a result of numerous reverse stock-splits in previous years and the agreement terms for adjusting the rights of the related shares, the
&lt;span id="xdx_90A_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20250930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zMVJ1oEI7zh8" title="Preferred stock, shares outstanding"&gt;96,230&lt;/span&gt; shares of Series C Preferred Stock are convertible into an infinitesimal amount of common stock, have no voting rights, and in
the event of liquidation, the holders of the Series C Preferred Stock would not participate in any distribution of the assets or surplus
funds of the Company. The holders of Series C Preferred Stock also are not currently entitled to any dividends if and when declared by
the Board. No dividends to holders of the Series C Preferred Stock were declared or unpaid through September 30, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Series
L Convertible Preferred Stock and Warrants&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 12, 2025 (as amended May 21, 2025), the Company entered into a securities purchase agreement (the &#x201c;Securities Purchase
Agreement&#x201d;) with certain purchasers (the &#x201c;Purchasers&#x201d;) providing for the issuance and sale of (i) &lt;span id="xdx_90F_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pp2d_c20250512__20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember_ztx6S0x1T4Kk" title="Issuance of shares"&gt;6,611.11&lt;/span&gt;
shares of the Company&#x2019;s Series L 10% Convertible Preferred Stock (the &#x201c;Series L Convertible Preferred Stock&#x201d;) with
an aggregate stated value of $&lt;span id="xdx_908_ecustom--AggregateStatedValue_c20250512__20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember_z7DyNRduahDi" title="Aggregate stated value"&gt;6,611,111&lt;/span&gt;,
(ii) warrants to purchase up to &lt;span id="xdx_90E_ecustom--ClassOfWarrantsPurchaseUpPercentage_iI_pid_c20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember_zKaSxg7t3qf7" title="Warrants purchase up percentage"&gt;100&lt;/span&gt;%
of the shares of the Company&#x2019;s common stock issuable upon conversion of the shares of Series L Convertible Preferred Stock
(the &#x201c;Common Warrants&#x201d;), and (iii) warrants to purchase up to the number of Greenshoe Conversion Shares (as defined in
the Securities Purchase Agreement) issuable upon exercise of the Greenshoe Right (as defined below) (the &#x201c;Vesting
Warrants&#x201d;, and together with the Common Warrants, the &#x201c;Warrants&#x201d;). The aggregate purchase price of the Series L
Convertible Preferred Stock and Warrants was $&lt;span id="xdx_900_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20250512__20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember_zYHvRursQSS" title="Issuance of shares, value"&gt;5,950,000&lt;/span&gt;,
and net proceeds was $&lt;span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_c20250512__20250512__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_zWaz6954aBbe" title="Proceeds from issuance of preferred stock and warrants, net"&gt;5,441,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the Securities Purchase Agreement, each Purchaser may elect to purchase shares of Series L Convertible Preferred Stock with an aggregate
stated value of up to $&lt;span id="xdx_904_ecustom--AggregateStatedValue_c20250512__20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--GreenshoeRightsMember_zE5QoHpFxzFk" title="Aggregate stated value"&gt;24,018,349&lt;/span&gt; (the &#x201c;Greenshoe Rights&#x201d;) for an aggregate purchase price of $&lt;span id="xdx_90D_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20250512__20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--GreenshoeRightsMember_zjptJeHHx12a" title="Issuance of shares, value"&gt;21,616,514&lt;/span&gt;, subject to adjustments.
Each Purchaser is entitled to exercise its respective Greenshoe Rights in the ratio of such Purchaser&#x2019;s original subscription amount
to the original aggregate subscription amounts of all Purchasers.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 12, 2025, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series L 10% Convertible Preferred
Stock (the &#x201c;Certificate of Designation&#x201d;) with the Secretary of State of the State of Delaware. On May 22, 2025, the Company
increased the shares of Series L Convertible Preferred Stock from &lt;span id="xdx_904_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250522__20250522__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember__srt--RangeAxis__srt--MinimumMember_zpZQME2P54qd" title="Issuance of shares"&gt;28,056&lt;/span&gt; shares to&lt;span id="xdx_905_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250522__20250522__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember__srt--RangeAxis__srt--MaximumMember_zvktF17NJYZ3" title="Issuance of shares"&gt; 30,630&lt;/span&gt; shares.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the Certificate of Designation and subject to certain ownership limitations, the Series L Convertible Preferred Stock may be converted
at any time at the option of the Purchasers into shares of the Company&#x2019;s common stock at an initial conversion price of $&lt;span id="xdx_909_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember_z5PwysY2uhSf" title="Conversion price per share"&gt;2.043&lt;/span&gt;,
subject to certain conditions. In addition, the holders of the Series L Convertible Preferred Stock are entitled to receive cumulative
dividends at the rate of &lt;span id="xdx_909_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_c20250511__20250511__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember_znLwgML2v0L5" title="Percentage of dividend"&gt;10&lt;/span&gt;% per annum until May 11, 2026, increasing to &lt;span id="xdx_903_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_c20250512__20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember_z2WK8sCAKFfj" title="Percentage of dividend"&gt;12&lt;/span&gt;% per annum thereafter. The dividends are payable quarterly
in cash, shares of the Company&#x2019;s common stock, or a combination thereof.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the Securities Purchase Agreement, each Purchaser was issued (i) a Common Warrant and (ii) a Vesting Warrant. An aggregate of &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pp2d_c20250512__20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonWarrantsMember_za6m4cSDSyic" title="Number of shares issued"&gt;3,235,978&lt;/span&gt;
Common Warrants were issued with an initial exercise price of $&lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonWarrantsMember_zxyOdy8sH6g1" title="Exercise price per share"&gt;2.043&lt;/span&gt; per share, are exercisable immediately subject to certain ownership
limitations, and have a term of &lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonWarrantsMember_zAenxlZYBXU9" title="Warrants term"&gt;five years&lt;/span&gt;. An aggregate of &lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pp2d_c20250512__20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLTenPercentConvertiblePreferredStockMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonWarrantsMember_zn3lRSHIIg6j" title="Aggregate number of shares vested"&gt;11,576,406&lt;/span&gt; Vesting Warrants were issued with an initial exercise price of
$&lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--VestingWarrantsMember_zcR0fgUyrS35" title="Exercise price per share"&gt;2.043&lt;/span&gt; per share, are exercisable immediately subject to certain vesting and ownership limitations, and have a term of &lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonWarrantsMember_z3xGkqNl52L1" title="Warrants term"&gt;five years&lt;/span&gt; from
the date that the applicable warrant shares vest.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Preferred Shares and Warrants both have full-ratchet price and anti-dilution protections and are subject to other adjustments, as
further described in the Certificate of Designation or the Warrants, as applicable, subject, solely with respect to adjustments in
connection with the exercise of Greenshoe Rights, a floor price of $&lt;span id="xdx_90A_eus-gaap--DerivativeFloorPrice_iI_pid_uUSDPShares_c20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--GreenshoeRightsMember_zPcYycTzBZZ3" title="Floor price"&gt;0.454&lt;/span&gt;
per share (subject to adjustment for reverse and forward splits, recapitalizations and similar transactions).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company and the Purchasers entered into a registration rights agreement pursuant to which the Company agreed to file a registration statement
with the Securities and Exchange Commission covering the public resale of the common stock issuable upon conversion of the Series L Convertible
Preferred Stock and upon exercise of the Warrants. The Company agreed to file a registration statement within 30 days after the initial
closing and after each closing of the exercise of a Greenshoe Right in accordance with the Securities Purchase Agreement, to become effective
no later than 90 days after filing. If these deadlines are not met,&lt;span id="xdx_904_ecustom--LiableOfLiquidatedDamagePercentageDescription_c20250512__20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zd3819ibNCHa" title="Liable of liquidated damage percentage, description"&gt; the Company will be liable for liquidated damages of 1.5% of the
subscription amount paid by each Purchaser. Further, if the Company fails to pay such liquidated damages within 7 days from the date
payable, the Company will pay interest thereon at the prime rate plus 12% to each holder of the registrable securities.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the Securities Purchase Agreement, the Company agreed to hold a meeting of its stockholders at the earliest practical date after the
execution of the Securities Purchase Agreement for the purpose of obtaining stockholder approval for the issuance, in the aggregate,
of more than &lt;span id="xdx_90E_ecustom--CommonStockSharesOutstandingPercentage_pid_dp_c20250512__20250512__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z5HNrNTGJ4Ei" title="Common stock shares outstanding percentage"&gt;19.99&lt;/span&gt;% of the number of shares of the Company&#x2019;s common stock outstanding on the date of the initial closing (&#x201c;Shareholder
Approval&#x201d;). Shareholder Approval was obtained on July 24, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the three months ended September 30, 2025, Purchasers of the Company&#x2019;s Series L 10% Convertible Preferred Stock elected to
exercise their Greenshoe Rights and purchased &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250701__20250930__us-gaap--StatementClassOfStockAxis__custom--SeriesL10PercentageConvertiblePreferredStockMember_z78FKOCsAIEb" title="Shares issued"&gt;1,222.22&lt;/span&gt;
shares of the Company&#x2019;s Series L 10% Convertible Preferred Stock with a stated value of $&lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pid_c20250701__20250930__us-gaap--StatementClassOfStockAxis__custom--SeriesL10PercentageConvertiblePreferredStockMember_zoTvKkAKtP6g" title="Shares issued value"&gt;1,222,222&lt;/span&gt;
for a purchase price of $&lt;span id="xdx_90B_ecustom--PreferredStockPurchasePrice_c20250701__20250930__us-gaap--StatementClassOfStockAxis__custom--SeriesL10PercentageConvertiblePreferredStockMember_z5BxqfcEo2Kd" title="Purchase price"&gt;1,100,000&lt;/span&gt;.
As a result of the transactions, the conversion price of the Series L 10% Convertible Preferred Stock was decreased from $&lt;span id="xdx_90C_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20250929__us-gaap--StatementClassOfStockAxis__custom--SeriesL10PercentageConvertiblePreferredStockMember_z5p2cekScWQl" title="Exercise price"&gt;2.043&lt;/span&gt;
to $&lt;span id="xdx_902_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20250930__us-gaap--StatementClassOfStockAxis__custom--SeriesL10PercentageConvertiblePreferredStockMember_zqeHfw1J9l0i" title="Exercise price"&gt;0.6421&lt;/span&gt;.
The conversion price adjustment constitutes a Dilutive Issuance (as defined in each of the Common Warrants and Vesting Warrants) and
as a result, the exercise price of the Warrants have been decreased, and the number of warrant shares have been increased, such that
the aggregate exercise price of the Warrants, after taking into account the decrease in the exercise price, shall be equal to the
aggregate exercise price prior to such adjustment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Dividends
to holders of the Series L Convertible Preferred Stock in the amount of $&lt;span id="xdx_901_eus-gaap--PaymentsForRepurchaseOfConvertiblePreferredStock_c20250101__20250930__us-gaap--StatementClassOfStockAxis__custom--SeriesLConvertiblePreferredStockMember_zjV54006XzIk" title="Dividends to holders unpaid"&gt;229,000&lt;/span&gt; were declared and $&lt;span id="xdx_909_eus-gaap--DividendsPayableCurrent_iI_c20250930__us-gaap--StatementClassOfStockAxis__custom--SeriesLConvertiblePreferredStockMember_zR3r37g1Af9e" title="Dividends unpaid"&gt;144,000&lt;/span&gt; was unpaid as of September
30, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Series
L Convertible Preferred Stock initially classified as Mezzanine Equity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
May 2025 private placement of Series L Convertible Preferred Stock and Warrants described above was allocated to mezzanine equity and
additional paid in capital based on the relative fair value of the Series L Convertible Preferred Stock and Warrants at issuance, respectively.
Initially, upon the occurrence of certain triggering events, each holder had the right to require the Company to redeem the Preferred
Shares at a premium, in accordance with and subject to certain conditions as further described in the Certificate of Designation. Accordingly,
the relative fair value of the Series L Convertible Preferred Stock was initially recorded as mezzanine equity. The relative fair value
of the Warrants was recorded in additional paid in capital. The relative fair values and allocation of net proceeds is below:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--ScheduleOfConversionsOfStockTextBlock_zwlEtNrdjBIj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BE_zQD8KHdsgYI3" style="display: none"&gt;Schedule of fair values and allocation of net proceeds&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.85in; border-collapse: collapse; width: 65%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20250501__20250531_zUQwYfvYORY1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Relative Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Percentage&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_hus-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_zFqcvEw9WdC7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Series L Convertible Preferred Stock&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;3,688,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ConvertiblePreferredStockAndWarrantsFairValuePercentage_pid_dp_uPure_c20250501__20250531__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_zlzQG7EOTMcj" style="width: 16%; text-align: right" title="Convertible preferred stock and warrants fair value percentage"&gt;37.7&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_hus-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPCubDqq44Af" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;6,089,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ConvertiblePreferredStockAndWarrantsFairValuePercentage_pid_dp_uPure_c20250501__20250531__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z0cmsSWGOh0g" style="padding-bottom: 1pt; text-align: right" title="Convertible preferred stock and warrants fair value percentage"&gt;62.3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_zhGmkVgz1ka4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;9,777,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ConvertiblePreferredStockAndWarrantsFairValuePercentage_pid_dp_uPure_c20250501__20250531_z4QTbDtFRz6" style="padding-bottom: 2.5pt; text-align: right" title="Convertible preferred stock and warrants fair value percentage"&gt;100.0&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.85in; border-collapse: collapse; width: 65%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20250501__20250531_zSfL5Pa7z8J" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Allocation of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Net Proceeds&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Percentage&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_hus-gaap--StatementClassOfStockAxis__custom--MezzanineEquityMember_z6B8H5k5PQNh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Mezzanine equity&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;2,052,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ConvertiblePreferredStockAndWarrantsNetProceedsPercentage_pid_dp_uPure_c20250501__20250531__us-gaap--StatementClassOfStockAxis__custom--MezzanineEquityMember_zD8Ra4yZrJh9" style="width: 16%; text-align: right" title="Convertible preferred stock and warrants net proceeds percentage"&gt;37.7&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_hus-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zbl8wWapqWZ7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Additional paid in capital&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,389,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ConvertiblePreferredStockAndWarrantsNetProceedsPercentage_pid_dp_uPure_c20250501__20250531__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zjsO5UCWw2jl" style="padding-bottom: 1pt; text-align: right" title="Convertible preferred stock and warrants net proceeds percentage"&gt;62.3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_zIX6QabUbDC6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,441,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ConvertiblePreferredStockAndWarrantsNetProceedsPercentage_pid_dp_uPure_c20250501__20250531_zAnr0VDobY3g" style="padding-bottom: 2.5pt; text-align: right" title="Convertible preferred stock and warrants net proceeds percentage"&gt;100.0&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zqglQf5Ut4De" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
September 2025, all the holders of GT Biopharma, Inc.&#x2019;s Series L 10% Convertible Preferred Stock provided waivers and agreed to
waive the rights to redemption set forth in the Certificate of Designation. Accordingly, as of September 30, 2025 the Preferred Stock
has been reclassified from mezzanine equity to shareholders&#x2019; equity as it is no longer conditionally redeemable upon the occurrence
of certain events that were not solely within the control of the Company,&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000945"
      unitRef="Shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000947"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000949"
      unitRef="Shares">15000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000951"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-05-142025-05-14_custom_PurchaseAgreementMember"
      decimals="-6"
      id="Fact000953"
      unitRef="USD">20000000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <GTBP:WeightedAverageVolumePriceOfCommonStockPercentage
      contextRef="From2025-05-142025-05-14_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact000955"
      unitRef="Pure">0.93</GTBP:WeightedAverageVolumePriceOfCommonStockPercentage>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-05-14_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact000957"
      unitRef="Shares">300000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2025-02-262025-02-26"
      decimals="0"
      id="Fact000959"
      unitRef="USD">686000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:NoninterestExpenseOfferingCost
      contextRef="From2025-02-262025-02-26"
      decimals="0"
      id="Fact000961"
      unitRef="USD">70000</us-gaap:NoninterestExpenseOfferingCost>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber
      contextRef="AsOf2025-02-26"
      decimals="INF"
      id="Fact000963"
      unitRef="Shares">302069</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber>
    <us-gaap:SharePrice
      contextRef="AsOf2025-02-26_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000965"
      unitRef="USDPShares">4.35</us-gaap:SharePrice>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-02-26_custom_InducementWarrantsMember"
      decimals="INF"
      id="Fact000967"
      unitRef="USDPShares">2.27</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-02-26_custom_InducementWarrantsMember"
      decimals="INF"
      id="Fact000969"
      unitRef="Shares">604138</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-02-26_custom_SeriesAInducementWarrantsMember"
      decimals="INF"
      id="Fact000971"
      unitRef="Shares">302069</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-02-26_custom_SeriesAInducementWarrantsMember"
      decimals="INF"
      id="Fact000973"
      unitRef="USDPShares">2.02</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2025-02-26_custom_SeriesAInducementWarrantsMember"
      id="Fact000975">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-02-26_custom_SeriesBInducementWarrantsMember"
      decimals="INF"
      id="Fact000977"
      unitRef="Shares">302069</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-02-26_custom_SeriesBInducementWarrantsMember"
      decimals="INF"
      id="Fact000979"
      unitRef="USDPShares">2.02</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2025-02-26_custom_SeriesBInducementWarrantsMember"
      id="Fact000981">P18M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-02-26"
      decimals="INF"
      id="Fact000983"
      unitRef="Shares">21145</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-02-26"
      decimals="INF"
      id="Fact000985"
      unitRef="USDPShares">2.8375</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="AsOf2025-02-26" id="Fact000987">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2025-01-01to2025-09-30"
      decimals="-5"
      id="Fact000989"
      unitRef="USD">1100000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2025-09-30_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000991"
      unitRef="Shares">96230</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2025-09-30_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000993"
      unitRef="Shares">96230</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2025-09-30_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000995"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2025-09-30_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000997"
      unitRef="Shares">96230</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-05-122025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_SeriesLTenPercentConvertiblePreferredStockMember"
      decimals="2"
      id="Fact000999"
      unitRef="Shares">6611.11</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <GTBP:AggregateStatedValue
      contextRef="From2025-05-122025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_SeriesLTenPercentConvertiblePreferredStockMember"
      decimals="0"
      id="Fact001001"
      unitRef="USD">6611111</GTBP:AggregateStatedValue>
    <GTBP:ClassOfWarrantsPurchaseUpPercentage
      contextRef="AsOf2025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_SeriesLTenPercentConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact001003"
      unitRef="Pure">100</GTBP:ClassOfWarrantsPurchaseUpPercentage>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2025-05-122025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_SeriesLTenPercentConvertiblePreferredStockMember"
      decimals="0"
      id="Fact001005"
      unitRef="USD">5950000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="From2025-05-122025-05-12_custom_SeriesLPreferredStockMember"
      decimals="0"
      id="Fact001007"
      unitRef="USD">5441000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <GTBP:AggregateStatedValue
      contextRef="From2025-05-122025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_GreenshoeRightsMember"
      decimals="0"
      id="Fact001009"
      unitRef="USD">24018349</GTBP:AggregateStatedValue>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2025-05-122025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_GreenshoeRightsMember"
      decimals="0"
      id="Fact001011"
      unitRef="USD">21616514</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-05-222025-05-22_custom_SeriesLTenPercentConvertiblePreferredStockMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001013"
      unitRef="Shares">28056</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-05-222025-05-22_custom_SeriesLTenPercentConvertiblePreferredStockMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001015"
      unitRef="Shares">30630</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="AsOf2025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_SeriesLTenPercentConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact001017"
      unitRef="USDPShares">2.043</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="From2025-05-112025-05-11_custom_SecuritiesPurchaseAgreementMember_custom_SeriesLTenPercentConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact001019"
      unitRef="Pure">0.10</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="From2025-05-122025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_SeriesLTenPercentConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact001021"
      unitRef="Pure">0.12</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2025-05-122025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_SeriesLTenPercentConvertiblePreferredStockMember_custom_CommonWarrantsMember"
      decimals="2"
      id="Fact001023"
      unitRef="Shares">3235978</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_CommonWarrantsMember"
      decimals="INF"
      id="Fact001025"
      unitRef="USDPShares">2.043</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_CommonWarrantsMember"
      id="Fact001027">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2025-05-122025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_SeriesLTenPercentConvertiblePreferredStockMember_custom_CommonWarrantsMember"
      decimals="2"
      id="Fact001029"
      unitRef="Shares">11576406</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_VestingWarrantsMember"
      decimals="INF"
      id="Fact001031"
      unitRef="USDPShares">2.043</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_CommonWarrantsMember"
      id="Fact001033">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:DerivativeFloorPrice
      contextRef="AsOf2025-05-12_custom_SecuritiesPurchaseAgreementMember_custom_GreenshoeRightsMember"
      decimals="INF"
      id="Fact001035"
      unitRef="USDPShares">0.454</us-gaap:DerivativeFloorPrice>
    <GTBP:LiableOfLiquidatedDamagePercentageDescription
      contextRef="From2025-05-122025-05-12_custom_SecuritiesPurchaseAgreementMember"
      id="Fact001037">the Company will be liable for liquidated damages of 1.5% of the
subscription amount paid by each Purchaser. Further, if the Company fails to pay such liquidated damages within 7 days from the date
payable, the Company will pay interest thereon at the prime rate plus 12% to each holder of the registrable securities.</GTBP:LiableOfLiquidatedDamagePercentageDescription>
    <GTBP:CommonStockSharesOutstandingPercentage
      contextRef="From2025-05-122025-05-12_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact001039"
      unitRef="Pure">0.1999</GTBP:CommonStockSharesOutstandingPercentage>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-07-012025-09-30_custom_SeriesL10PercentageConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact001041"
      unitRef="Shares">1222.22</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-07-012025-09-30_custom_SeriesL10PercentageConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact001043"
      unitRef="USD">1222222</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <GTBP:PreferredStockPurchasePrice
      contextRef="From2025-07-012025-09-30_custom_SeriesL10PercentageConvertiblePreferredStockMember"
      decimals="0"
      id="Fact001045"
      unitRef="USD">1100000</GTBP:PreferredStockPurchasePrice>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="AsOf2025-09-29_custom_SeriesL10PercentageConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact001047"
      unitRef="USDPShares">2.043</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="AsOf2025-09-30_custom_SeriesL10PercentageConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact001049"
      unitRef="USDPShares">0.6421</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:PaymentsForRepurchaseOfConvertiblePreferredStock
      contextRef="From2025-01-012025-09-30_custom_SeriesLConvertiblePreferredStockMember16969765"
      decimals="0"
      id="Fact001051"
      unitRef="USD">229000</us-gaap:PaymentsForRepurchaseOfConvertiblePreferredStock>
    <us-gaap:DividendsPayableCurrent
      contextRef="AsOf2025-09-30_custom_SeriesLConvertiblePreferredStockMember"
      decimals="0"
      id="Fact001053"
      unitRef="USD">144000</us-gaap:DividendsPayableCurrent>
    <us-gaap:ScheduleOfConversionsOfStockTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact001055">&lt;p id="xdx_893_eus-gaap--ScheduleOfConversionsOfStockTextBlock_zwlEtNrdjBIj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BE_zQD8KHdsgYI3" style="display: none"&gt;Schedule of fair values and allocation of net proceeds&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.85in; border-collapse: collapse; width: 65%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20250501__20250531_zUQwYfvYORY1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Relative Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Percentage&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_hus-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_zFqcvEw9WdC7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Series L Convertible Preferred Stock&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;3,688,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ConvertiblePreferredStockAndWarrantsFairValuePercentage_pid_dp_uPure_c20250501__20250531__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember_zlzQG7EOTMcj" style="width: 16%; text-align: right" title="Convertible preferred stock and warrants fair value percentage"&gt;37.7&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_hus-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPCubDqq44Af" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;6,089,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ConvertiblePreferredStockAndWarrantsFairValuePercentage_pid_dp_uPure_c20250501__20250531__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z0cmsSWGOh0g" style="padding-bottom: 1pt; text-align: right" title="Convertible preferred stock and warrants fair value percentage"&gt;62.3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_zhGmkVgz1ka4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;9,777,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ConvertiblePreferredStockAndWarrantsFairValuePercentage_pid_dp_uPure_c20250501__20250531_z4QTbDtFRz6" style="padding-bottom: 2.5pt; text-align: right" title="Convertible preferred stock and warrants fair value percentage"&gt;100.0&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.85in; border-collapse: collapse; width: 65%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20250501__20250531_zSfL5Pa7z8J" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Allocation of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Net Proceeds&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Percentage&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_hus-gaap--StatementClassOfStockAxis__custom--MezzanineEquityMember_z6B8H5k5PQNh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Mezzanine equity&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;2,052,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ConvertiblePreferredStockAndWarrantsNetProceedsPercentage_pid_dp_uPure_c20250501__20250531__us-gaap--StatementClassOfStockAxis__custom--MezzanineEquityMember_zD8Ra4yZrJh9" style="width: 16%; text-align: right" title="Convertible preferred stock and warrants net proceeds percentage"&gt;37.7&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_hus-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zbl8wWapqWZ7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Additional paid in capital&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,389,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ConvertiblePreferredStockAndWarrantsNetProceedsPercentage_pid_dp_uPure_c20250501__20250531__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember_zjsO5UCWw2jl" style="padding-bottom: 1pt; text-align: right" title="Convertible preferred stock and warrants net proceeds percentage"&gt;62.3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_zIX6QabUbDC6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,441,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ConvertiblePreferredStockAndWarrantsNetProceedsPercentage_pid_dp_uPure_c20250501__20250531_zAnr0VDobY3g" style="padding-bottom: 2.5pt; text-align: right" title="Convertible preferred stock and warrants net proceeds percentage"&gt;100.0&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfConversionsOfStockTextBlock>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="From2025-05-012025-05-31_custom_SeriesLPreferredStockMember"
      decimals="0"
      id="Fact001057"
      unitRef="USD">3688000</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <GTBP:ConvertiblePreferredStockAndWarrantsFairValuePercentage
      contextRef="From2025-05-012025-05-31_custom_SeriesLPreferredStockMember"
      decimals="INF"
      id="Fact001059"
      unitRef="Pure">0.377</GTBP:ConvertiblePreferredStockAndWarrantsFairValuePercentage>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="From2025-05-012025-05-31_us-gaap_WarrantMember"
      decimals="0"
      id="Fact001061"
      unitRef="USD">6089000</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <GTBP:ConvertiblePreferredStockAndWarrantsFairValuePercentage
      contextRef="From2025-05-012025-05-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001063"
      unitRef="Pure">0.623</GTBP:ConvertiblePreferredStockAndWarrantsFairValuePercentage>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="From2025-05-012025-05-31"
      decimals="0"
      id="Fact001065"
      unitRef="USD">9777000</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <GTBP:ConvertiblePreferredStockAndWarrantsFairValuePercentage
      contextRef="From2025-05-012025-05-31"
      decimals="INF"
      id="Fact001067"
      unitRef="Pure">1.000</GTBP:ConvertiblePreferredStockAndWarrantsFairValuePercentage>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="From2025-05-012025-05-31_custom_MezzanineEquityMember"
      decimals="0"
      id="Fact001069"
      unitRef="USD">2052000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <GTBP:ConvertiblePreferredStockAndWarrantsNetProceedsPercentage
      contextRef="From2025-05-012025-05-31_custom_MezzanineEquityMember"
      decimals="INF"
      id="Fact001071"
      unitRef="Pure">0.377</GTBP:ConvertiblePreferredStockAndWarrantsNetProceedsPercentage>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="From2025-05-012025-05-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact001073"
      unitRef="USD">3389000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <GTBP:ConvertiblePreferredStockAndWarrantsNetProceedsPercentage
      contextRef="From2025-05-012025-05-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="INF"
      id="Fact001075"
      unitRef="Pure">0.623</GTBP:ConvertiblePreferredStockAndWarrantsNetProceedsPercentage>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="From2025-05-012025-05-31"
      decimals="0"
      id="Fact001077"
      unitRef="USD">5441000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <GTBP:ConvertiblePreferredStockAndWarrantsNetProceedsPercentage
      contextRef="From2025-05-012025-05-31"
      decimals="INF"
      id="Fact001079"
      unitRef="Pure">1.000</GTBP:ConvertiblePreferredStockAndWarrantsNetProceedsPercentage>
    <GTBP:CommonStockWarrantsAndOptionsTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact001081">&lt;p id="xdx_809_ecustom--CommonStockWarrantsAndOptionsTextBlock_zNrj7GekWaY" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
6 &#x2013; &lt;span id="xdx_82C_z3h5xfFF7ev5"&gt;Common Stock Warrants and Options&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Common
Stock Warrants&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zojafDrERnad" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock
warrant transactions for the nine months ended September 30, 2025 were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B0_zmIuocYy0Jvj" style="display: none"&gt;Schedule of Warrant Activity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 75%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Nine Months Ended September 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%"&gt;Warrants outstanding at December 31, 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20250101__20250930_zDMi81wrfrC8" style="width: 18%; text-align: right" title="Warrants outstanding, beginning balance"&gt;1,120,429&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20250930_zD5R47lSsiu2" style="width: 18%; text-align: right" title="Weighted average exercise price, beginning balance"&gt;18.85&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20250101__20250930_z0wqIIccBgEc" style="text-align: right" title="Number of warrants, granted"&gt;16,468,308&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice_pid_c20250101__20250930_zmvI925Vzm15" style="text-align: right" title="Weighted average exercise price, granted"&gt;2.04&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Granted pursuant to full-ratchet price and anti-dilution protections&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedPursuantToFullRatchetPriceProtection_pid_c20250101__20250930_z8gbwwRzu8B9" style="text-align: right" title="Number of warrants, granted pursuant to full ratchet price and anti-dilution protections"&gt;32,709,588&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedPursuantToFullRatchetPriceProtectionWeightedAverageExercisePrice_pid_c20250101__20250930_zyRMRaQV3zRl" style="text-align: right" title="Weighted average exercise price, granted pursuant to full ratchet price and anti-dilution protections"&gt;0.64&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Forfeited/cancelled&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20250101__20250930_zCUCfhiXx9zl" style="text-align: right" title="Number of warrants, forfeited/cancelled"&gt;(1,866&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice_pid_c20250101__20250930_zdYoRgK4SmH2" style="text-align: right" title="Weighted average exercise price, forfeited/cancelled"&gt;102.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20250101__20250930_ziKRaAnaZiQ" style="border-bottom: Black 1pt solid; text-align: right" title="Number of warrants, exercised"&gt;(837,069&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice_pid_c20250101__20250930_z9CDiYG0FdPa" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, exercised"&gt;2.11&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Warrants outstanding at September 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20250101__20250930_zQEAWPH7U4u" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants outstanding, ending balance"&gt;49,459,390&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20250930_zBUzbvpGWmhf" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, ending balance"&gt;1.04&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Warrants exercisable at September 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_iI_pid_c20250930_zeOz6m1p7MEa" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants exercisable, ending balance"&gt;13,956,955&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20250930_zRozTTnSJ334" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable, ending balance"&gt;2.04&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zIwQ0dxgDORg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
aggregate intrinsic value of all warrants outstanding and all warrants vested and exercisable as of September 30, 2025 was approximately
$&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20250930_zTb9aWQiLZJl" title="Options outstanding vested intrinsic value"&gt;281,000&lt;/span&gt;, in each case based on the fair value of the Company&#x2019;s common stock on September 30, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the May 2025 Private Placement of Series L Convertible Preferred Stock and Warrants the Company issued an aggregate of &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pp2d_c20250531__20250531__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonWarrantsMember_zCSUyqlm2cHd" title="Aggregate number of shares issued"&gt;3,235,978&lt;/span&gt;
Common Warrants with an initial exercise price of $&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250531__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonWarrantsMember_zDcPfglbFdF6" title="Exercise price per share"&gt;2.043&lt;/span&gt;
per share, they are exercisable, subject to certain ownership limitations, immediately upon issuance and have a term of exercise
equal to five years. An aggregate of &lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pp2d_c20250531__20250531__us-gaap--StatementClassOfStockAxis__custom--SeriesLPreferredStockMember__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonWarrantsMember_zQi7HBcM70jk" title="Aggregate number of shares vested"&gt;11,756,406&lt;/span&gt;
Vesting Warrants were issued with an initial exercise price of $&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250531__us-gaap--ClassOfWarrantOrRightAxis__custom--VestingWarrantsMember_zkFZpB3GJbm5" title="Exercise price per share"&gt;2.043&lt;/span&gt;
per share, they are exercisable subject to certain vesting and ownership limitations, and have a term of exercise equal to five
years from the date that the applicable warrant shares vest. The Common and Vesting Warrants both have full-ratchet price and
anti-dilition protections and are subject to other adjustments, as further described in the Certificate of Designation or the
Warrants, as applicable, subject, solely with respect to adjustments in connection with the exercise of Greenshoe Rights, a floor
price of $&lt;span id="xdx_902_eus-gaap--DerivativeFloorPrice_iI_pid_uUSDPShares_c20250531__us-gaap--StatementEquityComponentsAxis__custom--GreenshoeRightsMember_zHbNpj77xgTk" title="Floor price per share"&gt;0.454&lt;/span&gt;
per share (subject to adjustment for reverse and forward splits, recapitalizations and similar transactions). As of September 30,
2025 pursuant to full-ratchet price and anti-dilution protections the exercise price of the Common and Vesting Warrants has been
reduced to $&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonWarrantsMember_zzpU0TD1JD33" title="Exercise price per share"&gt;0.6421&lt;/span&gt;
and an additional &lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250930__us-gaap--ClassOfWarrantOrRightAxis__custom--CommonWarrantsMember_z2AT9QXbDLAj" title="Class of warrant or right outstanding"&gt;32,709,588&lt;/span&gt;
Common and Vesting Warrants have been issued.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the May 2025 Private Placement of Equity Facility the Company issued pre-funded warrants to purchase an aggregate of &lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250531__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zPdSLkFaatBe" title="Issuance of pre-funded warrants"&gt;300,000&lt;/span&gt; shares
of common stock as consideration for its irrevocable commitment to purchase the shares of common stock upon the terms and subject to
the satisfaction of the conditions set forth in the Purchase Agreement. The pre-funded warrants may be exercise at any time after issuance
and until exercised in full.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
May 2025 the Company issued warrants underlying &lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250531_zS0KkOPMJ4K" title="Number of warrant issued"&gt;24,390&lt;/span&gt; shares of common stock exercisable immediately upon issuance with a term of five
years from the date of issuance at $&lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250531_zTGi2zrQVaF6" title="Exercise price per share"&gt;2.46&lt;/span&gt; per share with a fair value of approximately $&lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstanding_iI_c20250531_zFF0dfWJalwc" title="Fair value of warrant"&gt;44,000&lt;/span&gt; in exchange for the waiver of a variable
rate transaction (&#x201c;VRT&#x201d;). In addition, in May and June 2025, the Company issued &lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250601__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmYKWEzdQW87" title="Number of new shares issued"&gt;&lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250501__20250531__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ze8F9Bicvl9i" title="Number of new shares issued"&gt;50,000&lt;/span&gt;&lt;/span&gt; shares of common stock and warrants
underlying &lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250531__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zrX3ygy0wad2" title="Number of warrant issued"&gt;&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ztbmfnSf0WWl" title="Number of warrant issued"&gt;200,000&lt;/span&gt;&lt;/span&gt; shares of common stock with an aggregate fair value of approximately $&lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20250501__20250531_zvcpnhAqmNdb" title="Number shares issued for service, value"&gt;&lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20250601__20250630_z3Zi4w9DOaDk" title="Number shares issued for service, value"&gt;718,000&lt;/span&gt;&lt;/span&gt; to vendors as compensation for services.
The warrants underlying &lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250531__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5lfFA3HHcl7" title="Number of warrant issued"&gt;200,000&lt;/span&gt; shares of common stock consist of warrants underlying &lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250531__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_z9TgMDXP9eRb" title="Number of warrant issued"&gt;50,000&lt;/span&gt; shares of common stock that are exercisable
immediately upon issuance with a term of five years from the date of issuance at $&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250531__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zeMrACZ3YOPk" title="Exercise price per share"&gt;2.50&lt;/span&gt; per share, and warrants underlying &lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightUnissued_iI_c20250531__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zbQozpLu8xm7" title="Issuance of pre-funded warrants"&gt;150,000&lt;/span&gt; shares
of common stock that are pre-funded warrants exercisable at any time after issuance and until exercised in full.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_ecustom--ScheduleOfWarrantsOustandingAndExercisableTableTextBlock_hus-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zHWlacB2NAk9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Warrants
outstanding as of September 30, 2025 are exercisable as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B4_z7RvbhSWOw3f" style="display: none"&gt;Schedule of Warrants Outstanding and Exercisable&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Warrants Outstanding and Exercisable as of September 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Range of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Remaining Contractual Life (Years)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 22%; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zUT6l6jEKntk" title="Range of exercise price"&gt;0.0001&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_ziHQqR1L4Zu9" style="width: 22%; text-align: right" title="Number of outstanding"&gt;476,251&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 21%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 21%; text-align: right"&gt;&lt;span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zlvanojrrKPb" title="Warrants weighted average exercise price"&gt;0.0001&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zXi70y0pXUBb" title="Range of exercise price"&gt;0.6421&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_ziHdbHHQIde7" style="text-align: right" title="Number of outstanding"&gt;10,296,061&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zSYduWdmwKB4" title="Warrants outstanding, weighted average remaining contractual life (years)"&gt;4.6&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z1BDBE5FhwH4" title="Warrants weighted average exercise price"&gt;0.6421&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zmAGy9fK2cNa" title="Range of exercise price"&gt;0.6421&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_z9wH87jvtpC7" style="text-align: right" title="Number of outstanding"&gt;37,405,912&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zhbZKUXx3eVf" title="Warrants weighted average exercise price"&gt;0.6421&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zUgmU8Um88wi" title="Range of exercise price"&gt;2.02&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_z0cqNmFeX6S2" style="text-align: right" title="Number of outstanding"&gt;369,138&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zgyaDsI6O1ph" title="Warrants outstanding, weighted average remaining contractual life (years)"&gt;2.7&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zfC14Nv9cbnc" title="Warrants weighted average exercise price"&gt;2.02&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zs2RZdjqL7wa" title="Range of exercise price"&gt;2.46&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zEb5IIygSNy7" style="text-align: right" title="Number of outstanding"&gt;24,390&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_z2y1Y41ZnAl1" title="Warrants outstanding, weighted average remaining contractual life (years)"&gt;4.6&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zrbKcHFfFGIk" title="Warrants weighted average exercise price"&gt;2.46&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zeWeRJMU1rSh" title="Range of exercise price"&gt;2.50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zss7EjAJGnd2" style="text-align: right" title="Number of outstanding"&gt;50,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_z6vfFtikprAl" title="Warrants outstanding, weighted average remaining contractual life (years)"&gt;2.6&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_z0QEfBc2ITei" title="Warrants weighted average exercise price"&gt;2.50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zzkSwPZhUuKa" title="Range of exercise price"&gt;2.8375&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zuq6OtqvRWj" style="text-align: right" title="Number of outstanding"&gt;21,145&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zqo2FRONefMi" title="Warrants outstanding, weighted average remaining contractual life (years)"&gt;4.6&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zW5gd8jtwPg6" title="Warrants weighted average exercise price"&gt;2.8375&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zkBpwOf5vpT3" title="Range of exercise price"&gt;4.35&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_z5IfCHLtsme5" style="text-align: right" title="Number of outstanding"&gt;437,931&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zl282ScRvmz" title="Warrants outstanding, weighted average remaining contractual life (years)"&gt;3.6&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zf8NbEcZDPH5" title="Warrants weighted average exercise price"&gt;4.35&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zDJLO9B31ut4" title="Range of exercise price"&gt;5.4375&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zV7sR378lp05" style="text-align: right" title="Number of outstanding"&gt;88,800&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_z50UlTboaJS" title="Warrants outstanding, weighted average remaining contractual life (years)"&gt;3.6&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zYHcMNW7OeBg" title="Warrants weighted average exercise price"&gt;5.4375&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_znnXzdKRhTql" title="Range of exercise price"&gt;30.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zarnJJL9S6O5" style="text-align: right" title="Number of outstanding"&gt;216,666&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zQhwh4r1G8u7" title="Warrants outstanding, weighted average remaining contractual life (years)"&gt;2.8&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zOASU6c886" title="Warrants weighted average exercise price"&gt;30.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeElevenMember_zUbRjEgZB0m7" title="Range of exercise price"&gt;37.50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeElevenMember_zyho79WSLx8b" style="text-align: right" title="Number of outstanding"&gt;13,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeElevenMember_z8J5A8vfjn3b" title="Warrants outstanding, weighted average remaining contractual life (years)"&gt;2.3&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeElevenMember_zucetDw1K5zg" title="Warrants weighted average exercise price"&gt;37.50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwelveMember_zUN460lJhTZ5" title="Range of exercise price"&gt;165.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwelveMember_zLFwzeWGv932" style="text-align: right" title="Number of outstanding"&gt;52,316&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwelveMember_zQ515VieNZ95" title="Warrants outstanding, weighted average remaining contractual life (years)"&gt;0.4&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwelveMember_zULwM9EVitxc" title="Warrants weighted average exercise price"&gt;165.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThirteenMember_zD6FzkOCevq1" title="Range of exercise price"&gt;206.25&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThirteenMember_z6z8QGOxFjF6" style="border-bottom: Black 1pt solid; text-align: right" title="Number of outstanding"&gt;7,780&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThirteenMember_zBtbV2FGmGK2" title="Warrants outstanding, weighted average remaining contractual life (years)"&gt;0.4&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThirteenMember_zf2jmpvYapTk" title="Warrants weighted average exercise price"&gt;206.25&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zr5DMGgWwvi4" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of outstanding"&gt;49,459,390&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zbQ0KpRWj123" title="Warrants outstanding, weighted average remaining contractual life (years)"&gt;4.5&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zFZSoYIVudOd" title="Warrants weighted average exercise price"&gt;1.04&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zHPoc0x7mo3k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Common
Stock Options&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
April 2022 the Company established the 2022 Omnibus Incentive Plan (the &#x201c;Plan&#x201d;). The Plan was approved by our Board and stockholders.
The purpose of the Plan is to grant stock and options to purchase our common stock, and other incentive awards, to our employees, directors,
and key consultants. On July 24, 2025 shareholders voted to increase the maximum number of shares of common stock that may be issued
pursuant to awards granted under the Plan by &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220401__20220430__us-gaap--AwardTypeAxis__custom--OmnibusIncentivePlanMember_z2F9mVB3ZSh8" title="Common stock awards granted"&gt;583,334&lt;/span&gt;. Pursuant to the increase, the maximum number of shares of common stock that may
be issued pursuant to awards granted under the Plan is &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220401__20220430__us-gaap--AwardTypeAxis__custom--OmnibusIncentivePlanMember__srt--RangeAxis__srt--MaximumMember_zuu4XF7xh6o4" title="Common stock awards granted"&gt;750,000&lt;/span&gt;. The shares of our common stock underlying cancelled and forfeited awards
issued under the Plan may again become available for grant under the Plan. As of September 30, 2025, there were &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250930_zGDZ7L3FJ3Ec" title="Stock option outstanding"&gt;597,550&lt;/span&gt; stock options
outstanding and &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20250101__20250930_zedJ8fhwYUF1" title="Rstricted stock granted"&gt;25,935&lt;/span&gt; shares of restricted stock granted in prior years under the Plan, which left &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20250930__us-gaap--AwardTypeAxis__custom--OmnibusIncentivePlanMember_z34bHj57XFP6" title="Available for grant"&gt;126,515&lt;/span&gt; shares available for grant
under the Plan. The following table summarizes stock option transactions for the nine months ended September 30, 2025:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z58qRwcj4efd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BD_zVD5FfCQp6Ol" style="display: none"&gt;Schedule of Options Activity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 75%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Nine Months Ended September, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Options&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%"&gt;Options outstanding at December 31, 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20250101__20250930_zlCpHCqAJDz5" style="width: 18%; text-align: right" title="Number of options outstanding, beginning"&gt;124,600&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20250930_zTb4DgWPqfB1" style="width: 18%; text-align: right" title="Weighted-Average Exercise Price, beginning"&gt;32.69&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20250101__20250930_z4z6r8NWelW5" style="text-align: right" title="Number of options, granted"&gt;525,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250101__20250930_zx5pwK3pMYOi" style="text-align: right" title="Weighted-Average Exercise Price, granted"&gt;1.33&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Forfeited/cancelled&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20250101__20250930_zw8dICJoUuEg" style="text-align: right" title="Number of options, forfeited/cancelled"&gt;(52,050&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20250101__20250930_zzysbtEhWNF1" style="text-align: right" title="Weighted-Average Exercise Price, forfeited/cancelled"&gt;43.08&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20250101__20250930_z3Y07HEMPkHk" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1289"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20250101__20250930_zQVMUgoguQN7" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-Average Exercise Price, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1291"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Options outstanding at September 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20250101__20250930_ztu8a4f904Id" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options outstanding, ending"&gt;597,550&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20250930_ziUdv9555Hrk" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-Average Exercise Price, ending"&gt;4.23&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Options exercisable at September 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20250930_zbVv8HUHubmc" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options outstanding exercisable"&gt;396,439&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20250930_z6ymFUoUBJil" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-Average Exercise Price,exercisable, ending"&gt;5.68&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zWwYbfLCiwnh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
weighted average remaining contractual life of all options outstanding, and all options vested and exercisable as of September 30, 2025
was approximately &lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20250930_zpMaxqfj9EMk" title="Share-based compensation weighted average remaining contractual term"&gt;9.6&lt;/span&gt; years. Furthermore, the aggregate intrinsic value of all options outstanding and all options vested and exercisable
as of September 30, 2025 was $&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20250101__20250930_zdBGXeAA89Gl" title="Options outstanding intrinsic value"&gt;0&lt;/span&gt;, in each case based on the fair value of the Company&#x2019;s common stock on September 30, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
total fair value of options that vested during the nine months ended September 30, 2025 and 2024, was $&lt;span id="xdx_909_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_c20250101__20250930_z2uHj3u5pRah" title="Fair value of vested stock options"&gt;386,000&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_c20240101__20240930_zZFDFXG9r483" title="Fair value of vested stock options"&gt;222,000&lt;/span&gt;, respectively,
and is included in selling, general and administrative expense in the accompanying unaudited condensed statements of operations. As of
September 30, 2025, &lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20250930_zZjKAxYknOm8" title="Stock option, exercisable"&gt;396,439&lt;/span&gt; stock options were vested and exercisable and unvested compensation expense amounted to approximately $&lt;span id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1_c20250101__20250930_zzjFdcqVZVdg" title="Stock option, unvested compensation"&gt;236,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zQxhkOstx6f2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Options
outstanding as of September 30, 2025 are exercisable as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BD_ziaOabyQCHsk" style="display: none"&gt;Schedule of Options Outstanding and Options Exercisable&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Stock Options Exercisable as of September 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Range of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Remaining Contractual Life (Years)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 22%; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zf3an5PIZ5Cf" title="Range of excercise price"&gt;1.33&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_z2rH9xN7Lf5e" style="width: 22%; text-align: right" title="Options outstanding"&gt;337,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 21%; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zIAMyDui7Wk9" title="Options outstanding, weighted average remaining contractual life (years)"&gt;9.9&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 21%; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zEGktHgLOcUa" title="Options outstanding, weighted average exercise price"&gt;1.33&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zKBOZuDHs8C7" title="Range of excercise price"&gt;2.11&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zjGSanyWE235" style="text-align: right" title="Options outstanding"&gt;9,723&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z467DOdJnBM3" title="Options outstanding, weighted average remaining contractual life (years)"&gt;7.7&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z6PAHYRchmTf" title="Options outstanding, weighted average exercise price"&gt;2.11&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zJQF9JaqeCfj" title="Range of excercise price"&gt;10.50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zqa0EH8A9zP4" style="text-align: right" title="Options outstanding"&gt;16,667&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zrGTW5p5sR09" title="Options outstanding, weighted average remaining contractual life (years)"&gt;7.6&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zpvtAqCOUnB7" title="Options outstanding, weighted average exercise price"&gt;10.50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zuNrXfu4ilVh" title="Range of excercise price"&gt;25.50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_z4wZzY6gaPkh" style="text-align: right" title="Options outstanding"&gt;16,667&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zNTlFwlRbljl" title="Options outstanding, weighted average remaining contractual life (years)"&gt;7.3&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_z7cZQdT707Uj" title="Options outstanding, weighted average exercise price"&gt;25.50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zK7rXtkb54Bk" title="Range of excercise price"&gt;74.40&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zErabDuoLU19" style="border-bottom: Black 1pt solid; text-align: right" title="Options outstanding"&gt;15,882&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zGQxVdCMPUPa" title="Options outstanding, weighted average remaining contractual life (years)"&gt;6.8&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zW7MkwNXEat6" title="Options outstanding, weighted average exercise price"&gt;74.40&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250930_z7jQCwmR4Tqe" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding"&gt;396,439&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zFRbcgUZkXRj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

</GTBP:CommonStockWarrantsAndOptionsTextBlock>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact001083">&lt;p id="xdx_89F_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zojafDrERnad" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock
warrant transactions for the nine months ended September 30, 2025 were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B0_zmIuocYy0Jvj" style="display: none"&gt;Schedule of Warrant Activity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 75%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Nine Months Ended September 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%"&gt;Warrants outstanding at December 31, 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20250101__20250930_zDMi81wrfrC8" style="width: 18%; text-align: right" title="Warrants outstanding, beginning balance"&gt;1,120,429&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20250930_zD5R47lSsiu2" style="width: 18%; text-align: right" title="Weighted average exercise price, beginning balance"&gt;18.85&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20250101__20250930_z0wqIIccBgEc" style="text-align: right" title="Number of warrants, granted"&gt;16,468,308&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice_pid_c20250101__20250930_zmvI925Vzm15" style="text-align: right" title="Weighted average exercise price, granted"&gt;2.04&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Granted pursuant to full-ratchet price and anti-dilution protections&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedPursuantToFullRatchetPriceProtection_pid_c20250101__20250930_z8gbwwRzu8B9" style="text-align: right" title="Number of warrants, granted pursuant to full ratchet price and anti-dilution protections"&gt;32,709,588&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedPursuantToFullRatchetPriceProtectionWeightedAverageExercisePrice_pid_c20250101__20250930_zyRMRaQV3zRl" style="text-align: right" title="Weighted average exercise price, granted pursuant to full ratchet price and anti-dilution protections"&gt;0.64&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Forfeited/cancelled&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20250101__20250930_zCUCfhiXx9zl" style="text-align: right" title="Number of warrants, forfeited/cancelled"&gt;(1,866&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice_pid_c20250101__20250930_zdYoRgK4SmH2" style="text-align: right" title="Weighted average exercise price, forfeited/cancelled"&gt;102.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20250101__20250930_ziKRaAnaZiQ" style="border-bottom: Black 1pt solid; text-align: right" title="Number of warrants, exercised"&gt;(837,069&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice_pid_c20250101__20250930_z9CDiYG0FdPa" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, exercised"&gt;2.11&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Warrants outstanding at September 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20250101__20250930_zQEAWPH7U4u" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants outstanding, ending balance"&gt;49,459,390&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20250930_zBUzbvpGWmhf" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, ending balance"&gt;1.04&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Warrants exercisable at September 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_iI_pid_c20250930_zeOz6m1p7MEa" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants exercisable, ending balance"&gt;13,956,955&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20250930_zRozTTnSJ334" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable, ending balance"&gt;2.04&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001085"
      unitRef="Shares">1120429</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001087"
      unitRef="USDPShares">18.85</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2025-01-01to2025-09-30"
      decimals="INF"
      id="Fact001089"
      unitRef="Shares">16468308</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice
      contextRef="From2025-01-01to2025-09-30"
      decimals="INF"
      id="Fact001091"
      unitRef="USDPShares">2.04</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedPursuantToFullRatchetPriceProtection
      contextRef="From2025-01-01to2025-09-30"
      decimals="INF"
      id="Fact001093"
      unitRef="Shares">32709588</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedPursuantToFullRatchetPriceProtection>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedPursuantToFullRatchetPriceProtectionWeightedAverageExercisePrice
      contextRef="From2025-01-01to2025-09-30"
      decimals="INF"
      id="Fact001095"
      unitRef="USDPShares">0.64</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedPursuantToFullRatchetPriceProtectionWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations
      contextRef="From2025-01-01to2025-09-30"
      decimals="INF"
      id="Fact001097"
      unitRef="Shares">1866</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice
      contextRef="From2025-01-01to2025-09-30"
      decimals="INF"
      id="Fact001099"
      unitRef="USDPShares">102.00</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2025-01-01to2025-09-30"
      decimals="INF"
      id="Fact001101"
      unitRef="Shares">837069</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice
      contextRef="From2025-01-01to2025-09-30"
      decimals="INF"
      id="Fact001103"
      unitRef="USDPShares">2.11</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact001105"
      unitRef="Shares">49459390</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact001107"
      unitRef="USDPShares">1.04</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact001109"
      unitRef="Shares">13956955</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact001111"
      unitRef="USDPShares">2.04</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact001113"
      unitRef="USD">281000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2025-05-312025-05-31_custom_SeriesLPreferredStockMember_custom_CommonWarrantsMember"
      decimals="2"
      id="Fact001115"
      unitRef="Shares">3235978</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-05-31_custom_CommonWarrantsMember"
      decimals="INF"
      id="Fact001117"
      unitRef="USDPShares">2.043</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2025-05-312025-05-31_custom_SeriesLPreferredStockMember_custom_CommonWarrantsMember"
      decimals="2"
      id="Fact001119"
      unitRef="Shares">11756406</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-05-31_custom_VestingWarrantsMember"
      decimals="INF"
      id="Fact001121"
      unitRef="USDPShares">2.043</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DerivativeFloorPrice
      contextRef="AsOf2025-05-31_custom_GreenshoeRightsMember"
      decimals="INF"
      id="Fact001123"
      unitRef="USDPShares">0.454</us-gaap:DerivativeFloorPrice>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-09-30_custom_CommonWarrantsMember"
      decimals="INF"
      id="Fact001125"
      unitRef="USDPShares">0.6421</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-09-30_custom_CommonWarrantsMember"
      decimals="INF"
      id="Fact001127"
      unitRef="Shares">32709588</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-05-31_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact001129"
      unitRef="Shares">300000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-05-31"
      decimals="INF"
      id="Fact001131"
      unitRef="Shares">24390</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-05-31"
      decimals="INF"
      id="Fact001133"
      unitRef="USDPShares">2.46</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2025-05-31"
      decimals="0"
      id="Fact001135"
      unitRef="USD">44000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-06-012025-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001137"
      unitRef="Shares">50000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-05-012025-05-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001139"
      unitRef="Shares">50000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-05-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001141"
      unitRef="Shares">200000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001143"
      unitRef="Shares">200000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-05-012025-05-31"
      decimals="0"
      id="Fact001145"
      unitRef="USD">718000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-06-012025-06-30"
      decimals="0"
      id="Fact001147"
      unitRef="USD">718000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-05-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001149"
      unitRef="Shares">200000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-05-31_custom_PrefundedWarrantsMember"
      decimals="INF"
      id="Fact001151"
      unitRef="Shares">50000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-05-31_custom_PrefundedWarrantsMember"
      decimals="INF"
      id="Fact001153"
      unitRef="USDPShares">2.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightUnissued
      contextRef="AsOf2025-05-31_custom_PrefundedWarrantsMember"
      decimals="INF"
      id="Fact001155"
      unitRef="Shares">150000</us-gaap:ClassOfWarrantOrRightUnissued>
    <GTBP:ScheduleOfWarrantsOustandingAndExercisableTableTextBlock
      contextRef="From2025-01-012025-09-30_custom_WarrantsMember"
      id="Fact001157">&lt;p id="xdx_89D_ecustom--ScheduleOfWarrantsOustandingAndExercisableTableTextBlock_hus-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zHWlacB2NAk9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Warrants
outstanding as of September 30, 2025 are exercisable as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B4_z7RvbhSWOw3f" style="display: none"&gt;Schedule of Warrants Outstanding and Exercisable&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Warrants Outstanding and Exercisable as of September 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Range of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Remaining Contractual Life (Years)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 22%; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zUT6l6jEKntk" title="Range of exercise price"&gt;0.0001&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_ziHQqR1L4Zu9" style="width: 22%; text-align: right" title="Number of outstanding"&gt;476,251&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 21%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 21%; text-align: right"&gt;&lt;span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zlvanojrrKPb" title="Warrants weighted average exercise price"&gt;0.0001&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zXi70y0pXUBb" title="Range of exercise price"&gt;0.6421&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_ziHdbHHQIde7" style="text-align: right" title="Number of outstanding"&gt;10,296,061&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zSYduWdmwKB4" title="Warrants outstanding, weighted average remaining contractual life (years)"&gt;4.6&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z1BDBE5FhwH4" title="Warrants weighted average exercise price"&gt;0.6421&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zmAGy9fK2cNa" title="Range of exercise price"&gt;0.6421&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_z9wH87jvtpC7" style="text-align: right" title="Number of outstanding"&gt;37,405,912&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zhbZKUXx3eVf" title="Warrants weighted average exercise price"&gt;0.6421&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zUgmU8Um88wi" title="Range of exercise price"&gt;2.02&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_z0cqNmFeX6S2" style="text-align: right" title="Number of outstanding"&gt;369,138&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zgyaDsI6O1ph" title="Warrants outstanding, weighted average remaining contractual life (years)"&gt;2.7&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zfC14Nv9cbnc" title="Warrants weighted average exercise price"&gt;2.02&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zs2RZdjqL7wa" title="Range of exercise price"&gt;2.46&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zEb5IIygSNy7" style="text-align: right" title="Number of outstanding"&gt;24,390&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_z2y1Y41ZnAl1" title="Warrants outstanding, weighted average remaining contractual life (years)"&gt;4.6&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zrbKcHFfFGIk" title="Warrants weighted average exercise price"&gt;2.46&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zeWeRJMU1rSh" title="Range of exercise price"&gt;2.50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zss7EjAJGnd2" style="text-align: right" title="Number of outstanding"&gt;50,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_z6vfFtikprAl" title="Warrants outstanding, weighted average remaining contractual life (years)"&gt;2.6&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_z0QEfBc2ITei" title="Warrants weighted average exercise price"&gt;2.50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zzkSwPZhUuKa" title="Range of exercise price"&gt;2.8375&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zuq6OtqvRWj" style="text-align: right" title="Number of outstanding"&gt;21,145&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zqo2FRONefMi" title="Warrants outstanding, weighted average remaining contractual life (years)"&gt;4.6&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zW5gd8jtwPg6" title="Warrants weighted average exercise price"&gt;2.8375&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zkBpwOf5vpT3" title="Range of exercise price"&gt;4.35&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_z5IfCHLtsme5" style="text-align: right" title="Number of outstanding"&gt;437,931&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zl282ScRvmz" title="Warrants outstanding, weighted average remaining contractual life (years)"&gt;3.6&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zf8NbEcZDPH5" title="Warrants weighted average exercise price"&gt;4.35&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zDJLO9B31ut4" title="Range of exercise price"&gt;5.4375&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zV7sR378lp05" style="text-align: right" title="Number of outstanding"&gt;88,800&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_z50UlTboaJS" title="Warrants outstanding, weighted average remaining contractual life (years)"&gt;3.6&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zYHcMNW7OeBg" title="Warrants weighted average exercise price"&gt;5.4375&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_znnXzdKRhTql" title="Range of exercise price"&gt;30.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zarnJJL9S6O5" style="text-align: right" title="Number of outstanding"&gt;216,666&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zQhwh4r1G8u7" title="Warrants outstanding, weighted average remaining contractual life (years)"&gt;2.8&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zOASU6c886" title="Warrants weighted average exercise price"&gt;30.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeElevenMember_zUbRjEgZB0m7" title="Range of exercise price"&gt;37.50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeElevenMember_zyho79WSLx8b" style="text-align: right" title="Number of outstanding"&gt;13,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeElevenMember_z8J5A8vfjn3b" title="Warrants outstanding, weighted average remaining contractual life (years)"&gt;2.3&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeElevenMember_zucetDw1K5zg" title="Warrants weighted average exercise price"&gt;37.50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwelveMember_zUN460lJhTZ5" title="Range of exercise price"&gt;165.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwelveMember_zLFwzeWGv932" style="text-align: right" title="Number of outstanding"&gt;52,316&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwelveMember_zQ515VieNZ95" title="Warrants outstanding, weighted average remaining contractual life (years)"&gt;0.4&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwelveMember_zULwM9EVitxc" title="Warrants weighted average exercise price"&gt;165.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThirteenMember_zD6FzkOCevq1" title="Range of exercise price"&gt;206.25&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThirteenMember_z6z8QGOxFjF6" style="border-bottom: Black 1pt solid; text-align: right" title="Number of outstanding"&gt;7,780&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThirteenMember_zBtbV2FGmGK2" title="Warrants outstanding, weighted average remaining contractual life (years)"&gt;0.4&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThirteenMember_zf2jmpvYapTk" title="Warrants weighted average exercise price"&gt;206.25&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zr5DMGgWwvi4" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of outstanding"&gt;49,459,390&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zbQ0KpRWj123" title="Warrants outstanding, weighted average remaining contractual life (years)"&gt;4.5&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20250930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zFZSoYIVudOd" title="Warrants weighted average exercise price"&gt;1.04&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</GTBP:ScheduleOfWarrantsOustandingAndExercisableTableTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_RangeOneMember"
      decimals="INF"
      id="Fact001159"
      unitRef="USDPShares">0.0001</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeOneMember"
      decimals="INF"
      id="Fact001161"
      unitRef="Shares">476251</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeOneMember"
      decimals="INF"
      id="Fact001163"
      unitRef="USDPShares">0.0001</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_RangeTwoMember"
      decimals="INF"
      id="Fact001165"
      unitRef="USDPShares">0.6421</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeTwoMember"
      decimals="INF"
      id="Fact001167"
      unitRef="Shares">10296061</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_RangeTwoMember"
      id="Fact001169">P4Y7M6D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeTwoMember"
      decimals="INF"
      id="Fact001171"
      unitRef="USDPShares">0.6421</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_RangeThreeMember"
      decimals="INF"
      id="Fact001173"
      unitRef="USDPShares">0.6421</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeThreeMember"
      decimals="INF"
      id="Fact001175"
      unitRef="Shares">37405912</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeThreeMember"
      decimals="INF"
      id="Fact001177"
      unitRef="USDPShares">0.6421</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_RangeFourMember"
      decimals="INF"
      id="Fact001179"
      unitRef="USDPShares">2.02</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeFourMember"
      decimals="INF"
      id="Fact001181"
      unitRef="Shares">369138</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_RangeFourMember"
      id="Fact001183">P2Y8M12D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeFourMember"
      decimals="INF"
      id="Fact001185"
      unitRef="USDPShares">2.02</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_RangeFiveMember"
      decimals="INF"
      id="Fact001187"
      unitRef="USDPShares">2.46</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeFiveMember"
      decimals="INF"
      id="Fact001189"
      unitRef="Shares">24390</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_RangeFiveMember"
      id="Fact001191">P4Y7M6D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeFiveMember"
      decimals="INF"
      id="Fact001193"
      unitRef="USDPShares">2.46</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_RangeSixMember"
      decimals="INF"
      id="Fact001195"
      unitRef="USDPShares">2.50</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeSixMember"
      decimals="INF"
      id="Fact001197"
      unitRef="Shares">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_RangeSixMember"
      id="Fact001199">P2Y7M6D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeSixMember"
      decimals="INF"
      id="Fact001201"
      unitRef="USDPShares">2.50</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_RangeSevenMember"
      decimals="INF"
      id="Fact001203"
      unitRef="USDPShares">2.8375</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeSevenMember"
      decimals="INF"
      id="Fact001205"
      unitRef="Shares">21145</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_RangeSevenMember"
      id="Fact001207">P4Y7M6D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeSevenMember"
      decimals="INF"
      id="Fact001209"
      unitRef="USDPShares">2.8375</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_RangeEightMember"
      decimals="INF"
      id="Fact001211"
      unitRef="USDPShares">4.35</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeEightMember"
      decimals="INF"
      id="Fact001213"
      unitRef="Shares">437931</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_RangeEightMember"
      id="Fact001215">P3Y7M6D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeEightMember"
      decimals="INF"
      id="Fact001217"
      unitRef="USDPShares">4.35</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_RangeNineMember"
      decimals="INF"
      id="Fact001219"
      unitRef="USDPShares">5.4375</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeNineMember"
      decimals="INF"
      id="Fact001221"
      unitRef="Shares">88800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_RangeNineMember"
      id="Fact001223">P3Y7M6D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeNineMember"
      decimals="INF"
      id="Fact001225"
      unitRef="USDPShares">5.4375</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_RangeTenMember"
      decimals="INF"
      id="Fact001227"
      unitRef="USDPShares">30.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeTenMember"
      decimals="INF"
      id="Fact001229"
      unitRef="Shares">216666</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_RangeTenMember"
      id="Fact001231">P2Y9M18D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeTenMember"
      decimals="INF"
      id="Fact001233"
      unitRef="USDPShares">30.00</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_RangeElevenMember"
      decimals="INF"
      id="Fact001235"
      unitRef="USDPShares">37.50</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeElevenMember"
      decimals="INF"
      id="Fact001237"
      unitRef="Shares">13000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_RangeElevenMember"
      id="Fact001239">P2Y3M18D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeElevenMember"
      decimals="INF"
      id="Fact001241"
      unitRef="USDPShares">37.50</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_RangeTwelveMember"
      decimals="INF"
      id="Fact001243"
      unitRef="USDPShares">165.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeTwelveMember"
      decimals="INF"
      id="Fact001245"
      unitRef="Shares">52316</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_RangeTwelveMember"
      id="Fact001247">P0Y4M24D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeTwelveMember"
      decimals="INF"
      id="Fact001249"
      unitRef="USDPShares">165.00</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_RangeThirteenMember"
      decimals="INF"
      id="Fact001251"
      unitRef="USDPShares">206.25</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeThirteenMember"
      decimals="INF"
      id="Fact001253"
      unitRef="Shares">7780</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="From2025-01-012025-09-30_us-gaap_WarrantMember_custom_RangeThirteenMember"
      id="Fact001255">P0Y4M24D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-09-30_us-gaap_WarrantMember_custom_RangeThirteenMember"
      decimals="INF"
      id="Fact001257"
      unitRef="USDPShares">206.25</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2025-09-30_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001259"
      unitRef="Shares">49459390</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="From2025-01-012025-09-30_us-gaap_WarrantMember16970921"
      id="Fact001261">P4Y6M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-09-30_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001263"
      unitRef="USDPShares">1.04</GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2022-04-012022-04-30_custom_OmnibusIncentivePlanMember"
      decimals="INF"
      id="Fact001265"
      unitRef="Shares">583334</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2022-04-012022-04-30_custom_OmnibusIncentivePlanMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001267"
      unitRef="Shares">750000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact001269"
      unitRef="Shares">597550</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2025-01-01to2025-09-30"
      decimals="INF"
      id="Fact001271"
      unitRef="Shares">25935</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2025-09-30_custom_OmnibusIncentivePlanMember"
      decimals="INF"
      id="Fact001273"
      unitRef="Shares">126515</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact001275">&lt;p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z58qRwcj4efd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BD_zVD5FfCQp6Ol" style="display: none"&gt;Schedule of Options Activity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 75%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Nine Months Ended September, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Options&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%"&gt;Options outstanding at December 31, 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20250101__20250930_zlCpHCqAJDz5" style="width: 18%; text-align: right" title="Number of options outstanding, beginning"&gt;124,600&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20250930_zTb4DgWPqfB1" style="width: 18%; text-align: right" title="Weighted-Average Exercise Price, beginning"&gt;32.69&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20250101__20250930_z4z6r8NWelW5" style="text-align: right" title="Number of options, granted"&gt;525,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250101__20250930_zx5pwK3pMYOi" style="text-align: right" title="Weighted-Average Exercise Price, granted"&gt;1.33&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Forfeited/cancelled&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20250101__20250930_zw8dICJoUuEg" style="text-align: right" title="Number of options, forfeited/cancelled"&gt;(52,050&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20250101__20250930_zzysbtEhWNF1" style="text-align: right" title="Weighted-Average Exercise Price, forfeited/cancelled"&gt;43.08&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20250101__20250930_z3Y07HEMPkHk" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1289"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20250101__20250930_zQVMUgoguQN7" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-Average Exercise Price, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1291"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Options outstanding at September 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20250101__20250930_ztu8a4f904Id" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options outstanding, ending"&gt;597,550&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20250930_ziUdv9555Hrk" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-Average Exercise Price, ending"&gt;4.23&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Options exercisable at September 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20250930_zbVv8HUHubmc" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options outstanding exercisable"&gt;396,439&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20250930_z6ymFUoUBJil" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-Average Exercise Price,exercisable, ending"&gt;5.68&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001277"
      unitRef="Shares">124600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001279"
      unitRef="USDPShares">32.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2025-01-01to2025-09-30"
      decimals="INF"
      id="Fact001281"
      unitRef="Shares">525000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2025-01-01to2025-09-30"
      decimals="INF"
      id="Fact001283"
      unitRef="USDPShares">1.33</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="From2025-01-01to2025-09-30"
      decimals="INF"
      id="Fact001285"
      unitRef="Shares">52050</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2025-01-01to2025-09-30"
      decimals="INF"
      id="Fact001287"
      unitRef="USDPShares">43.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact001293"
      unitRef="Shares">597550</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact001295"
      unitRef="USDPShares">4.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact001297"
      unitRef="Shares">396439</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact001299"
      unitRef="USDPShares">5.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2025-01-01to2025-09-30" id="Fact001301">P9Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact001303"
      unitRef="USD">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact001305"
      unitRef="USD">386000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2024-01-012024-09-30"
      decimals="0"
      id="Fact001307"
      unitRef="USD">222000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact001309"
      unitRef="Shares">396439</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <GTBP:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1
      contextRef="From2025-01-01to2025-09-30"
      decimals="0"
      id="Fact001311"
      unitRef="USD">236000</GTBP:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonVestedInPeriodFairValue1>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact001313">&lt;p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zQxhkOstx6f2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Options
outstanding as of September 30, 2025 are exercisable as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BD_ziaOabyQCHsk" style="display: none"&gt;Schedule of Options Outstanding and Options Exercisable&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Stock Options Exercisable as of September 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Range of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Remaining Contractual Life (Years)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 22%; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zf3an5PIZ5Cf" title="Range of excercise price"&gt;1.33&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_z2rH9xN7Lf5e" style="width: 22%; text-align: right" title="Options outstanding"&gt;337,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 21%; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zIAMyDui7Wk9" title="Options outstanding, weighted average remaining contractual life (years)"&gt;9.9&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 21%; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zEGktHgLOcUa" title="Options outstanding, weighted average exercise price"&gt;1.33&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zKBOZuDHs8C7" title="Range of excercise price"&gt;2.11&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zjGSanyWE235" style="text-align: right" title="Options outstanding"&gt;9,723&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z467DOdJnBM3" title="Options outstanding, weighted average remaining contractual life (years)"&gt;7.7&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z6PAHYRchmTf" title="Options outstanding, weighted average exercise price"&gt;2.11&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zJQF9JaqeCfj" title="Range of excercise price"&gt;10.50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zqa0EH8A9zP4" style="text-align: right" title="Options outstanding"&gt;16,667&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zrGTW5p5sR09" title="Options outstanding, weighted average remaining contractual life (years)"&gt;7.6&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zpvtAqCOUnB7" title="Options outstanding, weighted average exercise price"&gt;10.50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zuNrXfu4ilVh" title="Range of excercise price"&gt;25.50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_z4wZzY6gaPkh" style="text-align: right" title="Options outstanding"&gt;16,667&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zNTlFwlRbljl" title="Options outstanding, weighted average remaining contractual life (years)"&gt;7.3&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_z7cZQdT707Uj" title="Options outstanding, weighted average exercise price"&gt;25.50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zK7rXtkb54Bk" title="Range of excercise price"&gt;74.40&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zErabDuoLU19" style="border-bottom: Black 1pt solid; text-align: right" title="Options outstanding"&gt;15,882&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zGQxVdCMPUPa" title="Options outstanding, weighted average remaining contractual life (years)"&gt;6.8&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zW7MkwNXEat6" title="Options outstanding, weighted average exercise price"&gt;74.40&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20250930_z7jQCwmR4Tqe" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding"&gt;396,439&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2025-01-012025-09-30_custom_RangeOneMember"
      decimals="INF"
      id="Fact001315"
      unitRef="USDPShares">1.33</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2025-09-30_custom_RangeOneMember"
      decimals="INF"
      id="Fact001317"
      unitRef="Shares">337500</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="From2025-01-012025-09-30_custom_RangeOneMember"
      id="Fact001319">P9Y10M24D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="AsOf2025-09-30_custom_RangeOneMember"
      decimals="INF"
      id="Fact001321"
      unitRef="USDPShares">1.33</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2025-01-012025-09-30_custom_RangeTwoMember"
      decimals="INF"
      id="Fact001323"
      unitRef="USDPShares">2.11</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2025-09-30_custom_RangeTwoMember"
      decimals="INF"
      id="Fact001325"
      unitRef="Shares">9723</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="From2025-01-012025-09-30_custom_RangeTwoMember"
      id="Fact001327">P7Y8M12D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="AsOf2025-09-30_custom_RangeTwoMember"
      decimals="INF"
      id="Fact001329"
      unitRef="USDPShares">2.11</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2025-01-012025-09-30_custom_RangeThreeMember"
      decimals="INF"
      id="Fact001331"
      unitRef="USDPShares">10.50</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2025-09-30_custom_RangeThreeMember"
      decimals="INF"
      id="Fact001333"
      unitRef="Shares">16667</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="From2025-01-012025-09-30_custom_RangeThreeMember"
      id="Fact001335">P7Y7M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="AsOf2025-09-30_custom_RangeThreeMember"
      decimals="INF"
      id="Fact001337"
      unitRef="USDPShares">10.50</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2025-01-012025-09-30_custom_RangeFourMember"
      decimals="INF"
      id="Fact001339"
      unitRef="USDPShares">25.50</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2025-09-30_custom_RangeFourMember"
      decimals="INF"
      id="Fact001341"
      unitRef="Shares">16667</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="From2025-01-012025-09-30_custom_RangeFourMember"
      id="Fact001343">P7Y3M18D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="AsOf2025-09-30_custom_RangeFourMember"
      decimals="INF"
      id="Fact001345"
      unitRef="USDPShares">25.50</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2025-01-012025-09-30_custom_RangeFiveMember"
      decimals="INF"
      id="Fact001347"
      unitRef="USDPShares">74.40</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2025-09-30_custom_RangeFiveMember"
      decimals="INF"
      id="Fact001349"
      unitRef="Shares">15882</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="From2025-01-012025-09-30_custom_RangeFiveMember"
      id="Fact001351">P6Y9M18D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="AsOf2025-09-30_custom_RangeFiveMember"
      decimals="INF"
      id="Fact001353"
      unitRef="USDPShares">74.40</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact001355"
      unitRef="Shares">396439</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact001357">&lt;p id="xdx_80E_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zhurUA49gX87" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
7 &#x2013; &lt;span id="xdx_827_zPH1yKHKxpUb"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.05pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Litigation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is involved in certain legal proceedings that arise from time to time in the ordinary course of our business. Except for income
tax contingencies, we record accruals for contingencies to the extent that our management concludes that the occurrence is probable and
that the related amounts of loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred.
There is no current or pending litigation of any significance with the exception of the matters identified below that have arisen under,
and are being handled in, the normal course of business:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Ohri
Matter&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 22, 2024, the Company filed an AAA Arbitration Demand against Manu Ohri, its former Chief Financial Officer. In the demand, the
Company asserts claims against Mr. Ohri for breach of his fiduciary duties and breach of contract and seeks a declaratory judgment providing
that the Company may characterize Mr. Ohri&#x2019;s termination as &#x201c;for cause&#x201d; under his employment agreement, and that the
Company may revoke the separation agreement entered into between the Company and Mr. Ohri prior to the Company learning of Mr. Ohri&#x2019;s
breaches. In addition to the declaratory judgment, the Company seeks damages arising from Mr. Ohri&#x2019;s violations, and attorneys&#x2019;
fees and any forum and arbitration fees. On September 3, 2024, Mr. Ohri filed both a general denial of the Company&#x2019;s claims against
him and counterclaims for breach of his employment agreement and Separation Agreement. The final hearing date, originally scheduled for
June 10, 2025, has been postponed indefinitely in order to allow the parties to mediate the dispute. At this time, mediation has not
been scheduled. There is a status conference scheduled for December 11, 2025 before the AAA. At this stage in the proceedings the Company
is not able to determine the probability of the outcome of this matter or a range of reasonably expected losses, if any. The Company
believes it has recorded an appropriate accrual for the matter.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;TWF
Global Matter&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 24, 2023, TWF Global, LLC (&#x201c;TWF&#x201d;) filed a Complaint in the California Superior Court for the County of Los Angeles naming
the Company as defendant. The complaint alleges that TWF is the holder of two Convertible Promissory Notes (&#x201c;Notes&#x201d;) and
that the Company did not deliver shares of common stock due on conversion in February 2021. TWF was seeking per diem liquidated damages
based on the terms of alleged Notes. On July 14, 2023, the Company filed a motion to dismiss for improper forum because the terms of
the Notes, as alleged, require disputes to be filed in New York state and federal courts. TWF voluntarily dismissed its complaint before
the California Superior Court of Los Angeles without prejudice. The Company subsequently filed a summons and complaint for interpleader
against TWF and Z-One, LLC before the Supreme Court of the State of New York County of New York, asking the Supreme Court to determine
if the Company&#x2019;s shares of common stock should be registered to TWF or Z-One LLC, as both of these entities have made conflicting
demands for the shares. On February 5, 2024, the Company filed a motion for entry of default against TWF, seeking an order directing
the Company to register the shares of common stock in the name of Z-One, LLC and that the Company be released from all associated liability
and claims. The Court denied the motion without prejudice and agreed to reconsider the motion without further briefing upon the filing
of a supplemental party affidavit. On May 9, 2024, Z-One, LLC filed a motion for summary judgement seeking dismissal of the action, representing
that Z-One, LLC and TWF have settled their dispute over the entitlement to the Company&#x2019;s shares of common stock and there is no
remaining dispute before the Court. On May 21, 2024, the Company filed a supplemental affidavit in support of its motion for entry of
default. On November 14, 2024, the Court held a hearing on the parties&#x2019; motions, at which the Court found that the motion for entry
of default was mooted by the settlement agreement between Z-One, LLC and TWF. The Court ordered that the case be dismissed. On February
17, 2025, Z-One, LLC filed a Summons with Notice in the Supreme Court of the State of New York, County of New York. The Company then
filed a demand that Z-One, LLC serve a complaint, and on June 25, 2025, Z-One, LLC filed a Complaint alleging that it is the holder,
either originally or by assignment, of a Convertible Note in the principal amount of $&lt;span id="xdx_905_eus-gaap--LossContingencyDamagesPaidValue_c20250217__20250217__srt--LitigationCaseAxis__custom--ZOneLLCMember_z5zo3RDdTZk6" title="Principal amount"&gt;150,000&lt;/span&gt;, that the Company breached the Convertible
Note by failing to deliver conversion shares to Z-One, LLC, and that the Company owes it damages in excess of $&lt;span id="xdx_904_eus-gaap--LossContingencyDamagesSoughtValue_c20250217__20250217__srt--LitigationCaseAxis__custom--ZOneLLCMember_zKbHcI6bAt81" title="Damages sought value"&gt;500,000&lt;/span&gt;. On August 26,
2025, the Company filed a motion to dismiss the Complaint in its entirety for lack of standing and failure to state a cause of action.
The Company believes that the claims related to the Notes are without merit, and will continue to vigorously defend against these claims.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Silberfein,
DiPietro, and Werthman Trust Matters&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 8, 2025, Coby Silberfein filed a summons with notice in the State of New York Supreme Court for the County of New York naming the
Company as defendant seeking damages for breach of a securities purchase agreement and convertible note in the principal amount of $&lt;span id="xdx_901_eus-gaap--LossContingencyDamagesPaidValue_c20250708__20250708__srt--LitigationCaseAxis__custom--CobySilberfeinMember_zR3V9lwZs5ag" title="Principal amount"&gt;100,000&lt;/span&gt;.
On July 8, 2025, Justin DiPietro filed a summons with notice in the State of New York Supreme Court for the County of New York naming
the Company as defendant seeking damages for breach of a securities purchase agreement and convertible note in the principal amount of
$&lt;span id="xdx_908_eus-gaap--LossContingencyDamagesPaidValue_c20250708__20250708__srt--LitigationCaseAxis__custom--CobySilberfeinMember_zMLS7M2rrQli" title="Principal amount"&gt;100,000&lt;/span&gt;. On July 9, 2025, Phillip Werthman Trust filed a summons with notice in the State of New York Supreme Court for the County of
New York naming the Company as defendant seeking damages for breach of a securities purchase agreement and convertible note in the principal
amount of $&lt;span id="xdx_901_eus-gaap--LossContingencyDamagesPaidValue_c20250709__20250709__srt--LitigationCaseAxis__custom--CobySilberfeinMember_zfZNVgRWRC23" title="Damages paid"&gt;100,000&lt;/span&gt;. The three summons with notice are identical and allege that the plaintiffs are holders of convertible notes and that
the Company breached the convertible notes by failing to deliver shares of common stock due on conversion in in 2021. Plaintiffs are
seeking specific performance and damages. On August 12, 2025, the Company filed demands that the plaintiffs serve complaints. On September
2, 2025, each plaintiff served a Complaint similar in substance to the summons, except that Plaintiff Silberfein now alleges breach of
a convertible note with a principal amount of $&lt;span id="xdx_906_eus-gaap--LossContingencyDamagesPaidValue_c20250902__20250902__srt--LitigationCaseAxis__custom--CobySilberfeinMember_zU643R2p4TY5" title="Principal amount"&gt;150,000&lt;/span&gt;, rather than $&lt;span id="xdx_909_eus-gaap--LossContingencyDamagesSoughtValue_c20250902__20250902__srt--LitigationCaseAxis__custom--CobySilberfeinMember_zocpXuXyMZ4b" title="Damages sought value"&gt;100,000&lt;/span&gt;. Each plaintiff alleges that the Company breached a convertible
note by failing to deliver conversion shares to the plaintiff holder, and that the Company owes damages in excess of $&lt;span id="xdx_90F_eus-gaap--LossContingencyDamagesSought_c20250902__20250902__srt--LitigationCaseAxis__custom--CobySilberfeinMember_zdBbxEl87YU8" title="Owes damages excess value"&gt;500,000&lt;/span&gt;. The Company
intends to seek dismissal of the complaints. The Company believes that the claims are without merit, and intends to vigorously defend
against these claims.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Significant
Agreements&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Cytovance
Biologics, Inc., a Related Party&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
October 2020, the Company entered into a Master Services Agreement with Cytovance, to perform biologic development and manufacturing
services, and to produce and test compounds used in the Company&#x2019;s potential product candidates. The Company subsequently executed
numerous Statements of Work (&#x201c;SOWs&#x201d;) for the research and development of products for use in clinical trials.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 24, 2022, the Company entered into a Settlement and Investment Agreement with Cytovance that amended existing SOWs and allowed
for future invoices to be settled in in a combination of cash and issuance of the Company&#x2019;s common stock. The Settlement and Investment
Agreement also set Cytovance&#x2019;s beneficial ownership limitation at &lt;span id="xdx_905_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20220824__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--CytovanceBiologicsIncMember_znf6Z4AxyKEf" title="Equity method investment, ownership percentage"&gt;4.9&lt;/span&gt;% of the issued and outstanding shares of the Company&#x2019;s
common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 25, 2024, the Company entered into an Amendment to the Settlement and Investment Agreement with Cytovance that increased Cytovance&#x2019;s
beneficial ownership limitation to &lt;span id="xdx_907_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20240425__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--CytovanceBiologicsIncMember_zohVwgGfZU51" title="Equity method investment, ownership percentage"&gt;9.9&lt;/span&gt;% of the issued and outstanding shares of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 30, 2024, Cytovance became a related party as their beneficial ownership exceeded &lt;span id="xdx_903_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20240630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--CytovanceBiologicsIncMember_zh5CelRi7wJg" title="Equity method investment, ownership percentage"&gt;5&lt;/span&gt;% of the issued and outstanding shares of the
Company&#x2019;s common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the nine months ended September 30, 2025 and 2024, the Company recognized research and development expenses of approximately $&lt;span id="xdx_906_eus-gaap--ProceedsFromRelatedPartyDebt_c20250101__20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zEnuRAjrxg4" title="Research and development expenses"&gt;686,000&lt;/span&gt;
and $&lt;span id="xdx_908_eus-gaap--ProceedsFromRelatedPartyDebt_pn5n6_c20240101__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z6nlxR7lCn65" title="Research and development expenses"&gt;1.4&lt;/span&gt; million, respectively and made cash payments amounting to approximately $&lt;span id="xdx_90A_eus-gaap--RepaymentsOfRelatedPartyDebt_pn6n6_c20250101__20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_z9uaPyKlY69b" title="Cash payments"&gt;1&lt;/span&gt; million and $&lt;span id="xdx_904_eus-gaap--RepaymentsOfRelatedPartyDebt_pn5n6_c20240101__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zi6YarCf6Ir3" title="Cash payments"&gt;3.4&lt;/span&gt; million, respectively to Cytovance.
In addition, during the nine months ended September 30, 2025, the Company issued pre-funded warrants to purchase up to &lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zoZ9qtczA3qe" title="Issuance of pre-funded warrants"&gt;326,251&lt;/span&gt; shares
of common stock exercisable at $&lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_z9vEMOpzkEQh" title="Exercise price"&gt;0.0001&lt;/span&gt; per share to settle accounts payable valued at approximately $&lt;span id="xdx_905_eus-gaap--FairValueAdjustmentOfWarrants_c20250101__20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zXGv2cqMrSik" title="Fair value"&gt;847,000&lt;/span&gt;; and during the nine months
ended September 30, 2024, the Company issued &lt;span id="xdx_90C_ecustom--StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable_pid_c20240101__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zIOHfkM9SfB8" title="Issuance of common stock in settlement of vendor payable, shares"&gt;127,597&lt;/span&gt; shares of common stock to settle accounts payable valued at approximately $&lt;span id="xdx_90F_ecustom--StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable_c20240101__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zgGYE3L0TU4a" title="Issuance of common stock in settlement of vendor payable"&gt;810,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of September 30, 2025, the Company&#x2019;s commitments in relation to unbilled and unaccrued SOWs and any related Change Orders from
Cytovance for services that have not yet been rendered as of September 30, 2025, amounted to approximately $&lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20250101__20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zayxE9SGETo8" title="Stock issued during period, value, issued for services"&gt;273,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;University
of Minnesota&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2023
Sponsored Research Agreement&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 20, 2024, the Company entered into a sponsored research agreement with the Regents of the University of Minnesota (the &#x201c;2023
Sponsored Research Agreement&#x201d;), effective July 1, 2023, and expiring on July 1, 2025. Payments totaling approximately $&lt;span id="xdx_907_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_pn5n6_c20240520__20240520__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeSponsoredResearchAgreementMember_zqvAqnH26Nsa" title="Aggregate research and development expense"&gt;1.7&lt;/span&gt; million
are due over the life of the agreement. The purpose of the agreement is for the Regents of the University of Minnesota to continue work
with the Company with three major goals in mind: (1) support the Company&#x2019;s TriKE&lt;sup&gt;&#xae;&lt;/sup&gt; product development and commercial
GMP manufacturing efforts; (2) TriKE&lt;sup&gt;&#xae;&lt;/sup&gt; pharmacokinetics optimization in humans and investigation of effects of altering
the route of administration; and (3) research and development of TriKE&lt;sup&gt;&#xae;&lt;/sup&gt; platform. The major deliverables proposed are:
(1) creation of IND enabling data for TriKE&lt;sup&gt;&#xae;&lt;/sup&gt; constructs in support of the Company&#x2019;s product development and commercial
GMP manufacturing efforts outside of the University of Minnesota; (2) TriKE&lt;sup&gt;&#xae;&lt;/sup&gt; platform drug delivery changes to allow transition
from intravenous (IV) continuous infusion to alternative drug delivery administration (IV bolus, intraperitoneal [IP], subcutaneous [SQ])
and extended PK in humans and gain an increased understanding of changes in the patient&#x2019;s native NK cell population as a result
of alteration of TriKE&lt;sup&gt;&#xae;&lt;/sup&gt; administration; and (3) research and development of TriKE&lt;sup&gt;&#xae;&lt;/sup&gt; platform combination
with other FDA approved (or soon to be approved) therapeutics and alterations to TriKE&lt;sup&gt;&#xae;&lt;/sup&gt; platform through formation of
immune complexes. Most studies will use TriKE&lt;sup&gt;&#xae;&lt;/sup&gt; DNA/amino acid sequences created by the Company under existing licensing
terms.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 18, 2025, the 2023 Sponsored Research Agreement was amended to expire on December 31, 2025. In addition, payments amounting to $&lt;span id="xdx_904_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20250618__20250618__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeSponsoredResearchAgreementMember_zqvANflg3Obf" title="Payments of research and development"&gt;216,000&lt;/span&gt;
were added bringing the total payments due over the life of the agreement to approximately $&lt;span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_pn5n6_c20250618__20250618__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeSponsoredResearchAgreementMember_z7udLjmFHPwh" title="Aggregate research and development expense"&gt;1.9&lt;/span&gt; million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recorded an expense classified as research and development of approximately $&lt;span id="xdx_900_eus-gaap--ResearchAndDevelopmentExpense_c20250101__20250930__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeSponsoredResearchAgreementMember_zomvjXZuuC4d" title="Research and development expense"&gt;647,000&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20240930__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeSponsoredResearchAgreementMember_z0lEyhPEXhI3" title="Research and development expense"&gt;863,000&lt;/span&gt;, pursuant to the 2023 Sponsored
Research Agreement, for the nine months ended September 30, 2025 and 2024, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of September 30, 2025 the Company&#x2019;s commitments in relation to unbilled and unaccrued amounts from the University of Minnesota
pursuant to the 2023 Sponsored Research Agreement for services that have not yet been rendered as of September 30, 2025, amounted to
approximately $&lt;span id="xdx_90F_eus-gaap--UnbilledReceivablesCurrent_iI_c20250930__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeSponsoredResearchAgreementMember_zd6OojdXTQ94" title="Unbilled and unaccrued amounts"&gt;216,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2016
Exclusive Patent License Agreement&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
July 18, 2016, the Company entered into an exclusive patent license agreement with the Regents of the University of Minnesota (as amended,
the &#x201c;2016 Exclusive Patent License Agreement&#x201d;), to further develop and commercialize cancer therapies using TriKE&lt;sup&gt;&#xae;&lt;/sup&gt;
technology developed by researchers at the University of Minnesota to target NK cells to cancer. Under the terms of the agreement, the
Company receives exclusive rights to conduct research and to develop, make, use, sell, and import TriKE&lt;sup&gt;&#xae;&lt;/sup&gt; technology worldwide
for the treatment of any disease, state, or condition in humans. The Company is responsible for obtaining all permits, licenses, authorizations,
registrations, and regulatory approvals required or granted by any governmental authority anywhere in the world that is responsible for
the regulation of products such as the TriKE&lt;sup&gt;&#xae;&lt;/sup&gt; technology, including without limitation the FDA and the European Agency
for the Evaluation of Medicinal Products in the European Union. The agreement requires an upfront payment of $&lt;span id="xdx_907_ecustom--ProceedsFromUpfrontAmount_iI_c20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zf0pyul1aoWi" title="Proceeds from upfront amount"&gt;200,000&lt;/span&gt;, and license maintenance
fees of $&lt;span id="xdx_903_eus-gaap--CostMaintenance_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__us-gaap--AwardDateAxis__custom--TwoThousandSeventeenThroughTwoThousandTwentyMember_zGjUu5lOWnOl" title="License maintenance fees"&gt;200,000&lt;/span&gt; for years 2017 through 2020, and $&lt;span id="xdx_907_eus-gaap--CostMaintenance_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zx490uHUSach" title="License maintenance fees"&gt;100,000&lt;/span&gt; per year beginning in year 2021 and each year thereafter. The agreement also
includes &lt;span id="xdx_902_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__srt--RangeAxis__srt--MinimumMember_zbdhHp5gUWa9" title="Royalty fee percentage"&gt;4&lt;/span&gt;% royalty fees on the net sales of licensed products, not to exceed &lt;span id="xdx_905_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__srt--RangeAxis__srt--MaximumMember_zUS5s4pLTWbc" title="Royalty fee percentage"&gt;6&lt;/span&gt;% under subsequent license agreements or amendments to
this agreement, and minimum royalty payments due upon the commencement of commercial sales of licensed product is $&lt;span id="xdx_90B_eus-gaap--RoyaltyExpense_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentyTwoMember_zX2S8o3vomq5" title="Annual royalty payments"&gt;250,000&lt;/span&gt; beginning
in 2022, $&lt;span id="xdx_908_eus-gaap--RoyaltyExpense_pn6n6_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentyFiveMember_zngAHCHtDbS3" title="Annual royalty payments"&gt;2&lt;/span&gt; million beginning in 2025, and $&lt;span id="xdx_909_eus-gaap--RoyaltyExpense_pn6n6_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentySevenMember_zBOkncMom0Vk" title="Annual royalty payments"&gt;5&lt;/span&gt; million beginning in 2027 throughout the remainder of the term. The agreement also includes
numerous performance milestone payments including clinical development milestone payments totaling $&lt;span id="xdx_909_ecustom--PerformanceMilestonePayments_pn5n6_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zis3bcFsYVMg" title="Performance milestone payments"&gt;3.1&lt;/span&gt; million, and one-time sales milestone
payments of $&lt;span id="xdx_90A_ecustom--SalesMilestonePayments_pn6n6_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zJEf8dRDGWNe" title="One-time sales milestone payments"&gt;1&lt;/span&gt; million upon reaching $&lt;span id="xdx_904_ecustom--GrossSales_pn6n6_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zEDLAGJ4CYej" title="Sales"&gt;250&lt;/span&gt; million in cumulative gross sales, and $&lt;span id="xdx_90D_ecustom--SalesRevenue_pn6n6_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zkEPcC0bzm59" title="Sales revenue"&gt;5&lt;/span&gt; million upon reaching $&lt;span id="xdx_907_ecustom--CummulativeGrossSales_pn6n6_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zquDabCUEJx7" title="Cumulative gross sales"&gt;500&lt;/span&gt; million in cumulative
gross sales of licensed products.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
May 13, 2024, the Company entered into an amended and restated exclusive patent license agreement with the Regents of the University
of Minnesota. The amendment requires an upfront payment of $&lt;span id="xdx_90C_ecustom--ProceedsFromUpfrontAmount_iI_c20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zmRprPPH7tAb" title="Proceeds from upfront amount"&gt;145,000&lt;/span&gt; and amends the license maintenance fees to $&lt;span id="xdx_901_eus-gaap--CostMaintenance_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentyFiveMember_ztugY6kUm1yf" title="License maintenance fees"&gt;50,000&lt;/span&gt; in 2025, and $&lt;span id="xdx_902_eus-gaap--CostMaintenance_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_z4NvcZnzR9mb" title="License maintenance fees"&gt;100,000&lt;/span&gt;
per year beginning in year 2026 and each year thereafter. The amendment also includes &lt;span id="xdx_908_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__srt--RangeAxis__srt--MinimumMember_zSP0YAHGTUV6" title="Royalty fee percentage"&gt;1&lt;/span&gt;% to &lt;span id="xdx_90C_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__srt--RangeAxis__srt--MaximumMember_zDYpi4vlZVti" title="Royalty fee percentage"&gt;5&lt;/span&gt;% royalty fees on the net sales of licensed
products, not to exceed &lt;span id="xdx_90E_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zSjFYSbWbLj4" title="Royalty fee percentage"&gt;6&lt;/span&gt;% under subsequent license agreements or amendments, and minimum royalty payments due upon the commencement
of commercial sales of licensed product is $&lt;span id="xdx_906_ecustom--RoyaltyExpenseYearOne_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_ziTht2PQwnch" title="Royalty expense year one"&gt;250,000&lt;/span&gt; in year one, $&lt;span id="xdx_903_ecustom--RoyaltyExpenseYearTwoThroughFive_pn6n6_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zSyiVIqkU7Kf" title="Royalty expense years two through five"&gt;2&lt;/span&gt; million in years two through five, and $&lt;span id="xdx_900_ecustom--RoyaltyExpenseYearAfterSix_pn6n6_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_z58oVH3LQ0B" title="Royalty expense year six and thereafter"&gt;5&lt;/span&gt; million in year six throughout
the remainder of the term. The amendment also includes numerous performance milestone payments including clinical development milestone
payments totaling $&lt;span id="xdx_90B_ecustom--PerformanceMilestonePayments_pn5n6_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zPNX5BSyMDY4" title="Performance milestone payments"&gt;3.1&lt;/span&gt; million, and one-time sales milestone, and one-time sales milestone payments of $&lt;span id="xdx_90B_ecustom--SalesMilestonePayments_pn6n6_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zFwGgmt9iHr" title="One-time sales milestone payments"&gt;1&lt;/span&gt; million upon reaching $&lt;span id="xdx_902_ecustom--GrossSales_pn6n6_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_z7FCwVdFrZGl" title="Gross sales"&gt;250&lt;/span&gt;
million in cumulative gross sales, and $&lt;span id="xdx_904_ecustom--SalesRevenue_pn6n6_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zzXVHVZczmR5" title="Sales revenue"&gt;5&lt;/span&gt; million upon reaching $&lt;span id="xdx_90B_ecustom--CummulativeGrossSales_pn6n6_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zOKiZFDtJy" title="Cumulative gross sales"&gt;500&lt;/span&gt; million in cumulative gross sales of licensed products.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recorded an expense classified as research and development of approximately $&lt;span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_c20250101__20250930__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_z5ZW4qbnP2nd" title="Research and development expense"&gt;0&lt;/span&gt; and $&lt;span id="xdx_90C_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20240930__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_ztw8F1oZGO53" title="Research and development expense"&gt;145,000&lt;/span&gt;, pursuant to the 2016 Exclusive Patent
License Agreement, for the nine months ended September 30, 2025 and 2024, respectively&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2021
Exclusive License Agreement&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
March 26, 2021, the Company entered into an exclusive license agreement with the Regents of the University of Minnesota (the &#x201c;2021
Exclusive Patent License Agreement&#x201d;), specific to the B7H3 targeted TriKE&lt;sup&gt;&#xae;&lt;/sup&gt;. The agreement requires an upfront payment
of $&lt;span id="xdx_902_ecustom--UpfrontLicenseFee_pp0p0_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zE7MI2Bgi1oe" title="Upfront license fee"&gt;20,000&lt;/span&gt;, and license maintenance fees of $&lt;span id="xdx_900_eus-gaap--CostMaintenance_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_z8YeHZQGU2S1" title="License maintenance fees"&gt;5,000&lt;/span&gt; per year beginning in year 2022 and each year thereafter. The agreement also includes&lt;span id="xdx_90D_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20210326__20210326__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zvM6SmSQ2MJa" title="Royalty fee percentage"&gt;
2.5&lt;/span&gt;% to &lt;span id="xdx_904_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20210326__20210326__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zD71w4I0FsO2" title="Royalty fee percentage"&gt;5&lt;/span&gt;% royalty fees on the net sales of licensed products, and minimum royalty payments due upon the commencement of commercial sales
of licensed product is $&lt;span id="xdx_90D_ecustom--RoyaltyExpenseYearOneThoughFour_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zJ0wury3GQ4l" title="Royalty expense year one though four"&gt;250,000&lt;/span&gt; in year one though four, and $&lt;span id="xdx_904_ecustom--RoyaltyExpenseYearAfterFive_pn6n6_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_z0M2x9OnoQUi" title="Royalty expense year five and thereafter"&gt;2&lt;/span&gt; million beginning in year five and throughout the remainder of the term.
The agreement also includes numerous performance milestone payments including clinical development milestone payments totaling $&lt;span id="xdx_907_ecustom--PerformanceMilestonePayments_pn5n6_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zPqwCW0BN4C6" title="Performance milestone payments"&gt;3.1&lt;/span&gt; million,
and one-time sales milestone payments of $&lt;span id="xdx_90E_ecustom--SalesMilestonePayments_pn6n6_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_z9QGgGlQiU8i" title="One-time sales milestone payments"&gt;1&lt;/span&gt; million upon reaching $&lt;span id="xdx_905_ecustom--GrossSales_pn6n6_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zeN0wqMTsCLc" title="Gross sales"&gt;250&lt;/span&gt; million in cumulative gross sales, and $&lt;span id="xdx_906_ecustom--SalesRevenue_pn6n6_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_z4JldzGVp4cf" title="Sales revenue"&gt;5&lt;/span&gt; million upon reaching
$&lt;span id="xdx_90D_ecustom--CummulativeGrossSales_pn6n6_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zdfoVX3DJ2i3" title="Cumulative gross sales"&gt;500&lt;/span&gt; million in cumulative gross sales of licensed products. There is no double payment intended; if one of the milestone payments has
been paid under the 2016 restated exclusive patent license agreement no further payment is due for the corresponding milestone.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company did not record any expense classified as research and development, pursuant to the 2021 Exclusive License Agreement, for the
nine months ended September 30, 2025 and 2024, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2024
GTB-3650 Clinical Trial Agreement&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 18, 2024, the Registrant entered into an Investigator Initiated Clinical Trial Agreement (the &#x201c;Agreement&#x201d;) with
the Regents of the University of Minnesota (the &#x201c;University&#x201d;), pursuant to which, the University shall sponsor an Investigational
New Drug (&#x201c;IND&#x201d;) application for IND 165546 GTB-3650 (the &#x201c;Research Program&#x201d;) and shall serve as a sponsor investigator
for a phase 1 clinical trial entitled, &#x201c;GTB-3650 (CD16/IL-15/CD33) Tri-Specific Killer Engager (TriKE) for the Treatment of High
Risk Myelodysplastic Syndromes (MDS), Refractory/Relapsed Acute Myeloid Leukemia (AML), and Minimal Residual Disease in AML,&#x201d; designed
by the University (the &#x201c;Study&#x201d;). The Research Program is being conducted for clinical research use. The budget for the Study,
including without limitations, funding and resources, provides for up to approximately $&lt;span id="xdx_901_eus-gaap--RoyaltyExpense_pn5n6_c20241118__20241118__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember_zJnyRpgd63Ga" title="Annual royalty payments"&gt;2.1&lt;/span&gt; million over the course of three years borne
by the Company. The Study data will be owned by the University, however, the Company may use the Study data subject to any applicable
signed informed consent documents and authorization forms, applicable law and terms of the Agreement. The University and the Company
will each have the right to publish the Study results. The Agreement may be terminated by the Company or the University at any time upon
thirty days&#x2019; written notice to the other party, by the University immediately for health, welfare and safety reasons, or by either
party if the other party materially breaches the Agreement, provided that the breaching party fails to cure such breach within thirty
days.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company did not record any expense classified as research and development, pursuant to the 2024 Clinical Trial Agreement, for the nine
months ended September 30, 2025 and 2024, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of September 30, 2025 the Company&#x2019;s commitments in relation to unbilled and unaccrued amounts from the University of Minnesota
pursuant to the 2024 Clinical Trial Agreement for services that have not yet been rendered as of September 30, 2025, amounted to approximately
$&lt;span id="xdx_900_eus-gaap--UnbilledReceivablesCurrent_iI_pn5n6_c20250930__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember_zcDeSXmGJ9Ad" title="Unbilled and unaccrued amounts"&gt;1.9&lt;/span&gt; million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Contingency
&#x2013; NASDAQ Matters&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 21, 2024, we received a letter (the &#x201c;Notification Letter&#x201d;) from the Nasdaq Listing Qualifications Staff (the &#x201c;Staff&#x201d;)
notifying us that the amount of our stockholders&#x2019; equity had fallen below the $&lt;span id="xdx_908_ecustom--ContigencyMinimumRequired_iI_c20241121_zpaVEXkKVLf8" title="Contigency minimum required"&gt;2,500,000&lt;/span&gt; required minimum for continued listing
set forth in Nasdaq Listing Rule 5550(b)(1) (the &#x201c;Minimum Stockholders&#x2019; Equity Requirement&#x201d;). Nasdaq&#x2019;s determination
was based upon our stockholders&#x2019; equity as reported in our Quarterly Report on Form 10-Q for the period ended September 30, 2024.
The Notification Letter also noted that we did not meet the alternatives of market value of listed securities or net income from continuing
operations, and therefore, we no longer complied with Nasdaq&#x2019;s Listing Rules.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Notification Letter indicated that we had 45 days (i.e., until January 6, 2025) to submit a plan to regain compliance with the Minimum
Stockholders&#x2019; Equity Requirement, noting that if such plan is accepted, the Staff can grant us an extension of up to 180 days from
the date of the Notification Letter to evidence compliance. In determining whether to accept our plan, the Staff will consider such things
as the likelihood that the plan will result in compliance with Nasdaq&#x2019;s continued listing criteria, our past compliance history,
the reasons for our current non-compliance, other corporate events that may occur within the review period, our overall financial condition
and our public disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
submitted a plan of compliance to the Staff on December 31, 2024, outlining our plan to conduct periodic public and private securities
offerings to regain compliance. The Staff also requested additional information regarding our financing plans and financial projection,
which we provided to them. On June 13, 2025, we received a letter from the Staff notifying us that we have regained compliance with the
Minimum Stockholders&#x2019; Equity Requirement set forth in Nasdaq Listing Rule 5550(b)(1). Nasdaq will continue to monitor the Company
to ensure its ongoing compliance with the Minimum Stockholders&#x2019; Equity Requirement, so if at the time of the filing of the Company&#x2019;s
next periodic financial statements the Company does not evidence compliance with the Minimum Stockholders&#x2019; Equity Requirement,
the Company may be subject to delisting.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;If
our common stock is delisted from Nasdaq, our ability to raise capital through public offerings of our securities and to finance our
operations could be adversely affected. We also believe that delisting would likely result in decreased liquidity and/or increased volatility
in our common stock and could harm our business and future prospects. In addition, we believe that, if our common stock is delisted,
our stockholders would likely find it more difficult to obtain accurate quotations as to the price of our common stock and it may be
more difficult for stockholders to buy or sell our common stock at competitive market prices, or at all.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyDamagesPaidValue
      contextRef="From2025-02-172025-02-17_custom_ZOneLLCMember"
      decimals="0"
      id="Fact001359"
      unitRef="USD">150000</us-gaap:LossContingencyDamagesPaidValue>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="From2025-02-172025-02-17_custom_ZOneLLCMember"
      decimals="0"
      id="Fact001361"
      unitRef="USD">500000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:LossContingencyDamagesPaidValue
      contextRef="From2025-07-082025-07-08_custom_CobySilberfeinMember"
      decimals="0"
      id="Fact001363"
      unitRef="USD">100000</us-gaap:LossContingencyDamagesPaidValue>
    <us-gaap:LossContingencyDamagesPaidValue
      contextRef="From2025-07-082025-07-08_custom_CobySilberfeinMember"
      decimals="0"
      id="Fact001365"
      unitRef="USD">100000</us-gaap:LossContingencyDamagesPaidValue>
    <us-gaap:LossContingencyDamagesPaidValue
      contextRef="From2025-07-092025-07-09_custom_CobySilberfeinMember"
      decimals="0"
      id="Fact001367"
      unitRef="USD">100000</us-gaap:LossContingencyDamagesPaidValue>
    <us-gaap:LossContingencyDamagesPaidValue
      contextRef="From2025-09-022025-09-02_custom_CobySilberfeinMember"
      decimals="0"
      id="Fact001369"
      unitRef="USD">150000</us-gaap:LossContingencyDamagesPaidValue>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="From2025-09-022025-09-02_custom_CobySilberfeinMember"
      decimals="0"
      id="Fact001371"
      unitRef="USD">100000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:LossContingencyDamagesSought
      contextRef="From2025-09-022025-09-02_custom_CobySilberfeinMember"
      id="Fact001373">500,000</us-gaap:LossContingencyDamagesSought>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2022-08-24_custom_CytovanceBiologicsIncMember"
      decimals="INF"
      id="Fact001375"
      unitRef="Pure">0.049</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2024-04-25_custom_CytovanceBiologicsIncMember"
      decimals="INF"
      id="Fact001377"
      unitRef="Pure">0.099</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2024-06-30_custom_CytovanceBiologicsIncMember"
      decimals="INF"
      id="Fact001379"
      unitRef="Pure">0.05</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="From2025-01-012025-09-30_custom_CytovanceBiologicsIncMember_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="Fact001381"
      unitRef="USD">686000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="From2024-01-012024-09-30_custom_CytovanceBiologicsIncMember_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-5"
      id="Fact001383"
      unitRef="USD">1400000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="From2025-01-012025-09-30_custom_CytovanceBiologicsIncMember"
      decimals="-6"
      id="Fact001385"
      unitRef="USD">1000000</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="From2024-01-012024-09-30_custom_CytovanceBiologicsIncMember"
      decimals="-5"
      id="Fact001387"
      unitRef="USD">3400000</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-09-30_custom_CytovanceBiologicsIncMember"
      decimals="INF"
      id="Fact001389"
      unitRef="Shares">326251</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-09-30_custom_CytovanceBiologicsIncMember"
      decimals="INF"
      id="Fact001391"
      unitRef="USDPShares">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2025-01-012025-09-30_custom_CytovanceBiologicsIncMember"
      decimals="0"
      id="Fact001393"
      unitRef="USD">847000</us-gaap:FairValueAdjustmentOfWarrants>
    <GTBP:StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable
      contextRef="From2024-01-012024-09-30_custom_CytovanceBiologicsIncMember"
      decimals="INF"
      id="Fact001395"
      unitRef="Shares">127597</GTBP:StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable>
    <GTBP:StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable
      contextRef="From2024-01-012024-09-30_custom_CytovanceBiologicsIncMember"
      decimals="0"
      id="Fact001397"
      unitRef="USD">810000</GTBP:StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-01-012025-09-30_custom_CytovanceBiologicsIncMember"
      decimals="0"
      id="Fact001399"
      unitRef="USD">273000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="From2024-05-202024-05-20_custom_TwoThousandTwentyThreeSponsoredResearchAgreementMember"
      decimals="-5"
      id="Fact001401"
      unitRef="USD">1700000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="From2025-06-182025-06-18_custom_TwoThousandTwentyThreeSponsoredResearchAgreementMember"
      decimals="0"
      id="Fact001403"
      unitRef="USD">216000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="From2025-06-182025-06-18_custom_TwoThousandTwentyThreeSponsoredResearchAgreementMember"
      decimals="-5"
      id="Fact001405"
      unitRef="USD">1900000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-012025-09-30_custom_TwoThousandTwentyThreeSponsoredResearchAgreementMember"
      decimals="0"
      id="Fact001407"
      unitRef="USD">647000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-09-30_custom_TwoThousandTwentyThreeSponsoredResearchAgreementMember"
      decimals="0"
      id="Fact001409"
      unitRef="USD">863000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:UnbilledReceivablesCurrent
      contextRef="AsOf2025-09-30_custom_TwoThousandTwentyThreeSponsoredResearchAgreementMember"
      decimals="0"
      id="Fact001411"
      unitRef="USD">216000</us-gaap:UnbilledReceivablesCurrent>
    <GTBP:ProceedsFromUpfrontAmount
      contextRef="AsOf2016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="0"
      id="Fact001413"
      unitRef="USD">200000</GTBP:ProceedsFromUpfrontAmount>
    <us-gaap:CostMaintenance
      contextRef="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember_custom_TwoThousandSeventeenThroughTwoThousandTwentyMember"
      decimals="0"
      id="Fact001415"
      unitRef="USD">200000</us-gaap:CostMaintenance>
    <us-gaap:CostMaintenance
      contextRef="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="0"
      id="Fact001417"
      unitRef="USD">100000</us-gaap:CostMaintenance>
    <GTBP:RoyaltyFeePercentage
      contextRef="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001419"
      unitRef="Pure">0.04</GTBP:RoyaltyFeePercentage>
    <GTBP:RoyaltyFeePercentage
      contextRef="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001421"
      unitRef="Pure">0.06</GTBP:RoyaltyFeePercentage>
    <us-gaap:RoyaltyExpense
      contextRef="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember_custom_TwoThousandTwentyTwoMember"
      decimals="0"
      id="Fact001423"
      unitRef="USD">250000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember_custom_TwoThousandTwentyFiveMember"
      decimals="-6"
      id="Fact001425"
      unitRef="USD">2000000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember_custom_TwoThousandTwentySevenMember"
      decimals="-6"
      id="Fact001427"
      unitRef="USD">5000000</us-gaap:RoyaltyExpense>
    <GTBP:PerformanceMilestonePayments
      contextRef="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="-5"
      id="Fact001429"
      unitRef="USD">3100000</GTBP:PerformanceMilestonePayments>
    <GTBP:SalesMilestonePayments
      contextRef="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="-6"
      id="Fact001431"
      unitRef="USD">1000000</GTBP:SalesMilestonePayments>
    <GTBP:GrossSales
      contextRef="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="-6"
      id="Fact001433"
      unitRef="USD">250000000</GTBP:GrossSales>
    <GTBP:SalesRevenue
      contextRef="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="-6"
      id="Fact001435"
      unitRef="USD">5000000</GTBP:SalesRevenue>
    <GTBP:CummulativeGrossSales
      contextRef="From2016-07-182016-07-18_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="-6"
      id="Fact001437"
      unitRef="USD">500000000</GTBP:CummulativeGrossSales>
    <GTBP:ProceedsFromUpfrontAmount
      contextRef="AsOf2024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="0"
      id="Fact001439"
      unitRef="USD">145000</GTBP:ProceedsFromUpfrontAmount>
    <us-gaap:CostMaintenance
      contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember_custom_TwoThousandTwentyFiveMember"
      decimals="0"
      id="Fact001441"
      unitRef="USD">50000</us-gaap:CostMaintenance>
    <us-gaap:CostMaintenance
      contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="0"
      id="Fact001443"
      unitRef="USD">100000</us-gaap:CostMaintenance>
    <GTBP:RoyaltyFeePercentage
      contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001445"
      unitRef="Pure">0.01</GTBP:RoyaltyFeePercentage>
    <GTBP:RoyaltyFeePercentage
      contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001447"
      unitRef="Pure">0.05</GTBP:RoyaltyFeePercentage>
    <GTBP:RoyaltyFeePercentage
      contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="INF"
      id="Fact001449"
      unitRef="Pure">0.06</GTBP:RoyaltyFeePercentage>
    <GTBP:RoyaltyExpenseYearOne
      contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="0"
      id="Fact001451"
      unitRef="USD">250000</GTBP:RoyaltyExpenseYearOne>
    <GTBP:RoyaltyExpenseYearTwoThroughFive
      contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="-6"
      id="Fact001453"
      unitRef="USD">2000000</GTBP:RoyaltyExpenseYearTwoThroughFive>
    <GTBP:RoyaltyExpenseYearAfterSix
      contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="-6"
      id="Fact001455"
      unitRef="USD">5000000</GTBP:RoyaltyExpenseYearAfterSix>
    <GTBP:PerformanceMilestonePayments
      contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="-5"
      id="Fact001457"
      unitRef="USD">3100000</GTBP:PerformanceMilestonePayments>
    <GTBP:SalesMilestonePayments
      contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="-6"
      id="Fact001459"
      unitRef="USD">1000000</GTBP:SalesMilestonePayments>
    <GTBP:GrossSales
      contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="-6"
      id="Fact001461"
      unitRef="USD">250000000</GTBP:GrossSales>
    <GTBP:SalesRevenue
      contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="-6"
      id="Fact001463"
      unitRef="USD">5000000</GTBP:SalesRevenue>
    <GTBP:CummulativeGrossSales
      contextRef="From2024-05-132024-05-13_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="-6"
      id="Fact001465"
      unitRef="USD">500000000</GTBP:CummulativeGrossSales>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-012025-09-30_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="0"
      id="Fact001467"
      unitRef="USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-09-30_custom_TwoThousandSixteenPatentLicenseAgreementMember"
      decimals="0"
      id="Fact001469"
      unitRef="USD">145000</us-gaap:ResearchAndDevelopmentExpense>
    <GTBP:UpfrontLicenseFee
      contextRef="From2021-03-262021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember"
      decimals="0"
      id="Fact001471"
      unitRef="USD">20000</GTBP:UpfrontLicenseFee>
    <us-gaap:CostMaintenance
      contextRef="From2021-03-262021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember"
      decimals="0"
      id="Fact001473"
      unitRef="USD">5000</us-gaap:CostMaintenance>
    <GTBP:RoyaltyFeePercentage
      contextRef="From2021-03-262021-03-26_srt_MinimumMember_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember"
      decimals="INF"
      id="Fact001475"
      unitRef="Pure">0.025</GTBP:RoyaltyFeePercentage>
    <GTBP:RoyaltyFeePercentage
      contextRef="From2021-03-262021-03-26_srt_MaximumMember_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember"
      decimals="INF"
      id="Fact001477"
      unitRef="Pure">0.05</GTBP:RoyaltyFeePercentage>
    <GTBP:RoyaltyExpenseYearOneThoughFour
      contextRef="From2021-03-262021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember"
      decimals="0"
      id="Fact001479"
      unitRef="USD">250000</GTBP:RoyaltyExpenseYearOneThoughFour>
    <GTBP:RoyaltyExpenseYearAfterFive
      contextRef="From2021-03-262021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember"
      decimals="-6"
      id="Fact001481"
      unitRef="USD">2000000</GTBP:RoyaltyExpenseYearAfterFive>
    <GTBP:PerformanceMilestonePayments
      contextRef="From2021-03-262021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember"
      decimals="-5"
      id="Fact001483"
      unitRef="USD">3100000</GTBP:PerformanceMilestonePayments>
    <GTBP:SalesMilestonePayments
      contextRef="From2021-03-262021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember"
      decimals="-6"
      id="Fact001485"
      unitRef="USD">1000000</GTBP:SalesMilestonePayments>
    <GTBP:GrossSales
      contextRef="From2021-03-262021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember"
      decimals="-6"
      id="Fact001487"
      unitRef="USD">250000000</GTBP:GrossSales>
    <GTBP:SalesRevenue
      contextRef="From2021-03-262021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember"
      decimals="-6"
      id="Fact001489"
      unitRef="USD">5000000</GTBP:SalesRevenue>
    <GTBP:CummulativeGrossSales
      contextRef="From2021-03-262021-03-26_custom_TwoThousandAndTwentyOnePatentLicenseAgreementMember"
      decimals="-6"
      id="Fact001491"
      unitRef="USD">500000000</GTBP:CummulativeGrossSales>
    <us-gaap:RoyaltyExpense
      contextRef="From2024-11-182024-11-18_custom_TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember"
      decimals="-5"
      id="Fact001493"
      unitRef="USD">2100000</us-gaap:RoyaltyExpense>
    <us-gaap:UnbilledReceivablesCurrent
      contextRef="AsOf2025-09-30_custom_TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember"
      decimals="-5"
      id="Fact001495"
      unitRef="USD">1900000</us-gaap:UnbilledReceivablesCurrent>
    <GTBP:ContigencyMinimumRequired
      contextRef="AsOf2024-11-21"
      decimals="0"
      id="Fact001497"
      unitRef="USD">2500000</GTBP:ContigencyMinimumRequired>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact001499">&lt;p id="xdx_809_eus-gaap--SegmentReportingDisclosureTextBlock_zue1yziCvkia" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
8 &#x2013; &lt;span id="xdx_828_zwO53ogHG65a"&gt;Segment Information&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company operates and manages its business as &lt;span id="xdx_90B_eus-gaap--NumberOfReportableSegments_dc_uSegment_c20250101__20250930_znmpa1ZCCgY" title="Number of reportable segments"&gt;&lt;span id="xdx_901_eus-gaap--NumberOfOperatingSegments_dc_uSegment_c20250101__20250930_zLKiXK4kkIXa" title="Number of operating segments"&gt;one&lt;/span&gt;&lt;/span&gt; reportable and operating as a clinical stage biopharmaceutical company focused on the
development and commercialization of novel immune-oncology products based on our proprietary Tri-specific Killer Engager (TriKE&#xae;),
and Tetra-specific Killer Engager (Dual Targeting TriKE&#xae;) platforms. The measure of segment assets is reported on the balance sheet
as total assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s CODM reviews financial information presented and decides how to allocate resources based on net income (loss). Net income
(loss) is used for evaluating financial performance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Significant
segment expenses include research and development, salaries, insurance, and stock-based compensation. Operating expenses include all
remaining costs necessary to operate our business, which primarily include external professional services and other administrative expenses.
The following table presents the significant segment expenses and other segment items regularly reviewed by our CODM:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zYUjP5kVJlN9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B6_z0MNCmWZBUfc" style="display: none"&gt;Schedule of Segment Information&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20250701__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentsMember_zlHe3GHsSYwk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20240701__20240930__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentsMember_z5gnyLMkjvjk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20250101__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentsMember_z3RPZOqW7rb6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20240101__20240930__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentsMember_zo9Z7Dj7q5Ba" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Three Months Ended&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September 30,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Nine Months Ended&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September 30,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OtherResearchAndDevelopmentExpense_z0188yUA6f1k" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 20%; text-align: left"&gt;Research and development&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;634,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,307,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;2,096,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;3,868,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--SalariesAndWages_zFNlmjpWubMa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Salaries&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;373,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;340,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,006,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,106,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--InsuranceCommissions_zdhHkdntQvxd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Insurance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;54,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;42,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;175,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;194,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--ShareBasedCompensation_zbAxehkzxAn8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Stock-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;379,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1523"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;386,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;222,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OperatingExpenses_z56JyVmBIh79" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Operating expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,942,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,915,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,164,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,211,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--NonoperatingIncomeExpense_zWuKoT7EHPj1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Other income&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(268,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(193,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,504,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,214,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--NetIncomeLoss_zqz2pyh33BXd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Net loss&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,114,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,411,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,323,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;9,387,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zqj5a1ll4YFf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="From2025-01-01to2025-09-30"
      decimals="INF"
      id="Fact001501"
      unitRef="Segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="From2025-01-01to2025-09-30"
      decimals="INF"
      id="Fact001503"
      unitRef="Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact001505">&lt;p id="xdx_898_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zYUjP5kVJlN9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B6_z0MNCmWZBUfc" style="display: none"&gt;Schedule of Segment Information&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20250701__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentsMember_zlHe3GHsSYwk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20240701__20240930__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentsMember_z5gnyLMkjvjk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20250101__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentsMember_z3RPZOqW7rb6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20240101__20240930__us-gaap--StatementBusinessSegmentsAxis__custom--SegmentsMember_zo9Z7Dj7q5Ba" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Three Months Ended&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September 30,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Nine Months Ended&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September 30,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OtherResearchAndDevelopmentExpense_z0188yUA6f1k" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 20%; text-align: left"&gt;Research and development&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;634,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,307,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;2,096,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;3,868,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--SalariesAndWages_zFNlmjpWubMa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Salaries&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;373,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;340,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,006,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,106,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--InsuranceCommissions_zdhHkdntQvxd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Insurance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;54,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;42,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;175,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;194,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--ShareBasedCompensation_zbAxehkzxAn8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Stock-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;379,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1523"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;386,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;222,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OperatingExpenses_z56JyVmBIh79" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Operating expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,942,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,915,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,164,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,211,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--NonoperatingIncomeExpense_zWuKoT7EHPj1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Other income&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(268,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(193,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,504,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,214,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--NetIncomeLoss_zqz2pyh33BXd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Net loss&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,114,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,411,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,323,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;9,387,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="From2025-07-012025-09-30_custom_SegmentsMember"
      decimals="0"
      id="Fact001507"
      unitRef="USD">634000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="From2024-07-012024-09-30_custom_SegmentsMember"
      decimals="0"
      id="Fact001508"
      unitRef="USD">1307000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="From2025-01-012025-09-30_custom_SegmentsMember"
      decimals="0"
      id="Fact001509"
      unitRef="USD">2096000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-09-30_custom_SegmentsMember"
      decimals="0"
      id="Fact001510"
      unitRef="USD">3868000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:SalariesAndWages
      contextRef="From2025-07-012025-09-30_custom_SegmentsMember"
      decimals="0"
      id="Fact001512"
      unitRef="USD">373000</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages
      contextRef="From2024-07-012024-09-30_custom_SegmentsMember"
      decimals="0"
      id="Fact001513"
      unitRef="USD">340000</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages
      contextRef="From2025-01-012025-09-30_custom_SegmentsMember"
      decimals="0"
      id="Fact001514"
      unitRef="USD">1006000</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages
      contextRef="From2024-01-012024-09-30_custom_SegmentsMember"
      decimals="0"
      id="Fact001515"
      unitRef="USD">1106000</us-gaap:SalariesAndWages>
    <us-gaap:InsuranceCommissions
      contextRef="From2025-07-012025-09-30_custom_SegmentsMember"
      decimals="0"
      id="Fact001517"
      unitRef="USD">54000</us-gaap:InsuranceCommissions>
    <us-gaap:InsuranceCommissions
      contextRef="From2024-07-012024-09-30_custom_SegmentsMember"
      decimals="0"
      id="Fact001518"
      unitRef="USD">42000</us-gaap:InsuranceCommissions>
    <us-gaap:InsuranceCommissions
      contextRef="From2025-01-012025-09-30_custom_SegmentsMember"
      decimals="0"
      id="Fact001519"
      unitRef="USD">175000</us-gaap:InsuranceCommissions>
    <us-gaap:InsuranceCommissions
      contextRef="From2024-01-012024-09-30_custom_SegmentsMember"
      decimals="0"
      id="Fact001520"
      unitRef="USD">194000</us-gaap:InsuranceCommissions>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-07-012025-09-30_custom_SegmentsMember"
      decimals="0"
      id="Fact001522"
      unitRef="USD">379000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-01-012025-09-30_custom_SegmentsMember"
      decimals="0"
      id="Fact001524"
      unitRef="USD">386000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-09-30_custom_SegmentsMember"
      decimals="0"
      id="Fact001525"
      unitRef="USD">222000</us-gaap:ShareBasedCompensation>
    <us-gaap:OperatingExpenses
      contextRef="From2025-07-012025-09-30_custom_SegmentsMember"
      decimals="0"
      id="Fact001527"
      unitRef="USD">1942000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2024-07-012024-09-30_custom_SegmentsMember"
      decimals="0"
      id="Fact001528"
      unitRef="USD">1915000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2025-01-012025-09-30_custom_SegmentsMember"
      decimals="0"
      id="Fact001529"
      unitRef="USD">3164000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2024-01-012024-09-30_custom_SegmentsMember"
      decimals="0"
      id="Fact001530"
      unitRef="USD">5211000</us-gaap:OperatingExpenses>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2025-07-012025-09-30_custom_SegmentsMember"
      decimals="0"
      id="Fact001532"
      unitRef="USD">-268000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2024-07-012024-09-30_custom_SegmentsMember"
      decimals="0"
      id="Fact001533"
      unitRef="USD">-193000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2025-01-012025-09-30_custom_SegmentsMember"
      decimals="0"
      id="Fact001534"
      unitRef="USD">-1504000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2024-01-012024-09-30_custom_SegmentsMember"
      decimals="0"
      id="Fact001535"
      unitRef="USD">-1214000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012025-09-30_custom_SegmentsMember"
      decimals="0"
      id="Fact001537"
      unitRef="USD">3114000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012024-09-30_custom_SegmentsMember"
      decimals="0"
      id="Fact001538"
      unitRef="USD">3411000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-09-30_custom_SegmentsMember"
      decimals="0"
      id="Fact001539"
      unitRef="USD">5323000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-09-30_custom_SegmentsMember"
      decimals="0"
      id="Fact001540"
      unitRef="USD">9387000</us-gaap:NetIncomeLoss>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact001542">&lt;p id="xdx_80B_eus-gaap--SubsequentEventsTextBlock_zuFckF18x079" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
9 &#x2013; &lt;span id="xdx_823_zk5l3Imrk4O"&gt;Subsequent Events&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise
of Series L 10% Convertible Preferred Stock Greenshoe Rights&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
October 2025, Purchasers of the Company&#x2019;s Series L 10% Convertible Preferred Stock (the &#x201c;Preferred Stock&#x201d;) elected
to exercise their Greenshoe Rights and purchased &lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20251001__20251031__us-gaap--StatementClassOfStockAxis__custom--SeriesL10PercentageConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zx7wB4P8NCvc" title="Shares issued"&gt;2,055.55&lt;/span&gt; shares of the Company&#x2019;s Preferred Stock with a stated value of $&lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20251001__20251031__us-gaap--StatementClassOfStockAxis__custom--SeriesL10PercentageConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zBm1jURi5wt8" title="Shares issued value"&gt;2,055,556&lt;/span&gt;
for a purchase price of $&lt;span id="xdx_901_ecustom--PreferredStockPurchasePrice_c20251001__20251031__us-gaap--StatementClassOfStockAxis__custom--SeriesL10PercentageConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zsvLfPMdyRsk" title="Purchase price"&gt;1,850,000&lt;/span&gt;. As a result of the transaction the conversion price of the Preferred Stock was decreased from $&lt;span id="xdx_909_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20251030__us-gaap--StatementClassOfStockAxis__custom--SeriesL10PercentageConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zK2xyp1rnce7" title="Exercise price"&gt;0.6421&lt;/span&gt;
to $&lt;span id="xdx_90A_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20251031__us-gaap--StatementClassOfStockAxis__custom--SeriesL10PercentageConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zWYI0C1yjuji" title="Exercise price"&gt;0.5319&lt;/span&gt;. The conversion price adjustment constitutes a dilutive issuance and as a result, the exercise price of the Common Warrants
and Vesting Warrants issued in the Series L 10% Convertible Preferred Stock transaction have been decreased, and the number of warrant
shares have been increased, such that the aggregate exercise price of the warrants, after taking into account the decrease in the exercise
price, shall be equal to the aggregate exercise price prior to such adjustment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Conversion
of Series L 10% Convertible Preferred Stock&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
October 2025, the holders of the Company&#x2019;s Series L Convertible Preferred Stock have converted &lt;span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_c20251031__us-gaap--StatementClassOfStockAxis__custom--SeriesLConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zON0FDn918l7" title="Shares converted"&gt;2,556.48&lt;/span&gt; shares of Series L Convertible
Preferred Stock into &lt;span id="xdx_90A_eus-gaap--CommonStockSharesOutstanding_iI_c20251031__us-gaap--StatementClassOfStockAxis__custom--SeriesLConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z0kVyr8VBbT4" title="Number of shares converted"&gt;4,309,288&lt;/span&gt; shares of common stock.&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-10-012025-10-31_custom_SeriesL10PercentageConvertiblePreferredStockMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001544"
      unitRef="Shares">2055.55</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-10-012025-10-31_custom_SeriesL10PercentageConvertiblePreferredStockMember_us-gaap_SubsequentEventMember"
      decimals="0"
      id="Fact001546"
      unitRef="USD">2055556</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <GTBP:PreferredStockPurchasePrice
      contextRef="From2025-10-012025-10-31_custom_SeriesL10PercentageConvertiblePreferredStockMember_us-gaap_SubsequentEventMember"
      decimals="0"
      id="Fact001548"
      unitRef="USD">1850000</GTBP:PreferredStockPurchasePrice>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="AsOf2025-10-30_custom_SeriesL10PercentageConvertiblePreferredStockMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001550"
      unitRef="USDPShares">0.6421</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="AsOf2025-10-31_custom_SeriesL10PercentageConvertiblePreferredStockMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001552"
      unitRef="USDPShares">0.5319</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2025-10-31_custom_SeriesLConvertiblePreferredStockMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001554"
      unitRef="Shares">2556.48</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-10-31_custom_SeriesLConvertiblePreferredStockMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001556"
      unitRef="Shares">4309288</us-gaap:CommonStockSharesOutstanding>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="From2025-01-01to2025-09-30" id="Fact001557">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="From2025-01-01to2025-09-30" id="Fact001558">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="From2025-01-01to2025-09-30" id="Fact001559">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="From2025-01-01to2025-09-30" id="Fact001560">false</ecd:NonRule10b51ArrTrmntdFlag>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact000772"
          xlink:label="Fact000772"
          xlink:type="locator"/>
        <link:footnote id="Footnote000783" xlink:label="Footnote000783" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Converted into
common stock using a conversion price of $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEFudGktZGlsdXRpdmUgU2VjdXJpdGllcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__"
  id="xdx_904_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20250930_zYB0aw7k7YA3"
  title="Conversion price per share">0.6421</xhtml:span> per share, as of September 30, 2025</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000772"
          xlink:to="Footnote000783"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0773"
          xlink:label="xdx2ixbrl0773"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0773"
          xlink:to="Footnote000783"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000799"
          xlink:label="Fact000799"
          xlink:type="locator"/>
        <link:footnote id="Footnote000836" xlink:label="Footnote000836" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Accounts Payable
to Cytovance, a related party, since Cytovance owns greater than 5% of the Company&#x2019;s issued and outstanding common stock. See Note
7 &#x2013; Commitments and Contingencies, Significant Agreements.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000799"
          xlink:to="Footnote000836"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000800"
          xlink:label="Fact000800"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000800"
          xlink:to="Footnote000836"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000802"
          xlink:label="Fact000802"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000802"
          xlink:to="Footnote000836"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000804"
          xlink:label="Fact000804"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000804"
          xlink:to="Footnote000836"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000898"
          xlink:label="Fact000898"
          xlink:type="locator"/>
        <link:footnote id="Footnote000921" xlink:label="Footnote000921" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Based on rates
established by the Federal Reserve Bank</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000898"
          xlink:to="Footnote000921"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000900"
          xlink:label="Fact000900"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000900"
          xlink:to="Footnote000921"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000902"
          xlink:label="Fact000902"
          xlink:type="locator"/>
        <link:footnote id="Footnote000922" xlink:label="Footnote000922" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Historical volatility
of the Company&#x2019;s common stock is used to estimate the future volatility of its common stock</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000902"
          xlink:to="Footnote000922"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000904"
          xlink:label="Fact000904"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000904"
          xlink:to="Footnote000922"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000906"
          xlink:label="Fact000906"
          xlink:type="locator"/>
        <link:footnote id="Footnote000923" xlink:label="Footnote000923" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Determined by the
remaining contractual life of the derivative instrument</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000906"
          xlink:to="Footnote000923"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000908"
          xlink:label="Fact000908"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000908"
          xlink:to="Footnote000923"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000910"
          xlink:label="Fact000910"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000910"
          xlink:to="Footnote000923"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000912"
          xlink:label="Fact000912"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000912"
          xlink:to="Footnote000923"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0914"
          xlink:label="xdx2ixbrl0914"
          xlink:type="locator"/>
        <link:footnote id="Footnote000924" xlink:label="Footnote000924" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Based on no dividends
paid or expected to be paid</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0914"
          xlink:to="Footnote000924"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0916"
          xlink:label="xdx2ixbrl0916"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0916"
          xlink:to="Footnote000924"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
